Sort code,Jurisdiction,Drug class code,Drug class,Age group,Sex , TPS ($ 000) ,"Proportion 
of TPS (%)","Rate of 
use (%)", Number of active beneficiaries ,Rank
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"1,233,882.07",8.2,0.5,"65,514",1
1,Canada,S01LA,Antineovascularization agents,Total,Total,"774,484.40",5.2,0.6,"80,045",2
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,Total,"638,652.18",4.3,0.1,"12,444",3
1,Canada,L01XE,Protein kinase inhibitors,Total,Total,"566,185.41",3.8,0.1,"15,320",4
1,Canada,L04AA,Selective immunosuppressants,Total,Total,"428,442.41",2.9,0.4,"58,267",5
1,Canada,B01AF,Direct factor Xa inhibitors,Total,Total,"402,180.13",2.7,3.7,"512,312",6
1,Canada,L04AX,Other immunosuppressants,Total,Total,"400,011.15",2.7,0.3,"42,006",7
1,Canada,N05AX,Other antipsychotics,Total,Total,"332,642.24",2.2,2.2,"304,034",8
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"324,088.21",2.2,4.2,"587,098",9
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,Total,"306,978.74",2,26.4,"3,704,811",10
1,Canada,A02BC,Proton pump inhibitors,Total,Total,"254,727.90",1.7,19.6,"2,747,723",11
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"246,029.51",1.6,2.1,"299,151",12
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"245,020.81",1.6,2.3,"319,705",13
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"244,783.22",1.6,2,"283,201",14
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"215,171.79",1.4,2.1,"300,171",15
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"212,218.46",1.4,0.2,"27,439",16
1,Canada,N06AX,Other antidepressants,Total,Total,"208,039.10",1.4,9.7,"1,360,197",17
1,Canada,L04AC,Interleukin inhibitors,Total,Total,"201,112.98",1.3,0.1,"13,809",18
1,Canada,N03AX,Other antiepileptics,Total,Total,"197,957.05",1.3,6.9,"967,662",19
1,Canada,N07BC,Drugs used in opioid dependence,Total,Total,"197,212.16",1.3,0.8,"108,992",20
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"181,800.01",1.2,4,"564,956",21
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"176,247.29",1.2,11,"1,538,280",22
1,Canada,C08CA,Dihydropyridine derivatives,Total,Total,"166,633.12",1.1,12.2,"1,704,642",23
1,Canada,N02AA,Natural opium alkaloids,Total,Total,"165,891.67",1.1,5.6,"786,641",24
1,Canada,R03BB,Anticholinergics,Total,Total,"152,173.31",1,3.4,"481,445",25
1,Canada,N06BA,Centrally acting sympathomimetics,Total,Total,"151,371.61",1,2.3,"328,809",26
1,Canada,C09AA,"ACE inhibitors, plain",Total,Total,"145,400.45",1,13.2,"1,846,540",27
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"132,464.13",0.9,1.4,"189,492",28
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"126,656.99",0.8,8.6,"1,210,401",29
1,Canada,C07AB,"Beta-blocking agents, selective",Total,Total,"115,358.25",0.8,11.4,"1,599,483",30
1,Canada,R03BA,Glucocorticoids,Total,Total,"113,614.71",0.8,6,"842,257",31
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"104,197.55",0.7,0.2,"34,586",32
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"103,375.93",0.7,1.7,"236,935",33
1,Canada,H03AA,Thyroid hormones,Total,Total,"99,842.70",0.7,11.1,"1,559,049",34
1,Canada,L03AA,Colony-stimulating factors,Total,Total,"87,752.16",0.6,0.1,"18,003",35
1,Canada,B03XA,Other antianemic preparations,Total,Total,"87,254.14",0.6,0.1,"17,974",36
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"85,119.84",0.6,2.9,"403,291",37
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"83,428.88",0.6,0,"5,638",38
1,Canada,M05BA,Bisphosphonates,Total,Total,"81,561.23",0.5,3.3,"459,022",39
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"79,169.57",0.5,2,"278,005",40
1,Canada,B01AB,Heparin group,Total,Total,"74,299.50",0.5,0.5,"70,152",41
1,Canada,L02BX,Other hormone antagonists and related agents,Total,Total,"74,004.74",0.5,0,"4,718",42
1,Canada,A10BA,Biguanides,Total,Total,"72,198.32",0.5,8.7,"1,216,175",43
1,Canada,H01CB,Somatostatin and analogues,Total,Total,"71,497.40",0.5,0,"4,700",44
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"70,327.27",0.5,4.9,"690,391",45
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"65,485.14",0.4,12.8,"1,790,869",46
1,Canada,L04AD,Calcineurin inhibitors,Total,Total,"63,134.44",0.4,0.1,"20,356",47
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"62,743.59",0.4,0.2,"30,065",48
1,Canada,N05BA,Benzodiazepine derivatives,Total,Total,"62,642.55",0.4,7.7,"1,080,957",49
1,Canada,S01EE,Prostaglandin analogues,Total,Total,"61,820.65",0.4,2.2,"305,843",50
1,Canada,A11CC,Vitamin D and analogues,Total,Total,"61,148.23",0.4,5.6,"784,815",51
1,Canada,L02BB,Antiandrogens,Total,Total,"60,119.14",0.4,0.1,"17,047",52
1,Canada,S01ED,Beta-blocking agents,Total,Total,"56,677.43",0.4,2.1,"300,668",53
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"56,064.74",0.4,0.9,"126,792",54
1,Canada,C08DB,Benzothiazepine derivatives,Total,Total,"54,987.21",0.4,1.7,"236,538",55
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"53,652.35",0.4,0.2,"27,223",56
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,Total,"52,954.28",0.4,0.6,"91,091",57
1,Canada,N04BA,Dopa and dopa derivatives,Total,Total,"50,768.34",0.3,0.6,"82,419",58
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"50,430.82",0.3,8,"1,123,150",59
1,Canada,A16AB,Enzymes,Total,Total,"50,397.82",0.3,0,103,60
1,Canada,C03CA,"Sulfonamides, plain",Total,Total,"48,023.71",0.3,4.6,"645,295",61
1,Canada,L01XC,Monoclonal antibodies,Total,Total,"47,944.28",0.3,0,"4,324",62
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"43,606.99",0.3,3.1,"436,824",63
1,Canada,C10AX,Other lipid-modifying agents,Total,Total,"42,640.24",0.3,1.9,"259,436",64
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"42,551.01",0.3,2.7,"383,173",65
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"41,902.37",0.3,0.3,"44,859",66
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"41,776.15",0.3,3.2,"447,373",67
1,Canada,L03AB,Interferons,Total,Total,"41,643.53",0.3,0,"2,735",68
1,Canada,A10BB,Sulfonylureas,Total,Total,"41,636.46",0.3,3.4,"476,474",69
1,Canada,N06DA,Anticholinesterases,Total,Total,"41,606.94",0.3,0.9,"130,939",70
1,Canada,N02BA,Salicylic acid and derivatives,Total,Total,"41,304.12",0.3,3.5,"490,296",71
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"40,245.16",0.3,0.2,"25,290",72
1,Canada,J05AX,Other antivirals,Total,Total,"40,097.29",0.3,0.1,"7,451",73
1,Canada,R01AD,Corticosteroids,Total,Total,"40,069.91",0.3,6.8,"949,922",74
1,Canada,C09BA,ACE inhibitors and diuretics,Total,Total,"39,830.71",0.3,2.3,"324,290",75
1,Canada,B01AE,Direct thrombin inhibitors,Total,Total,"39,722.46",0.3,0.3,"44,937",76
1,Canada,N02BE,Anilides,Total,Total,"37,849.68",0.3,7,"981,091",77
1,Canada,N07BA,Drugs used in nicotine dependence,Total,Total,"34,885.93",0.2,1.7,"236,260",78
1,Canada,N03AG,Fatty acid derivatives,Total,Total,"33,746.83",0.2,0.7,"100,221",79
1,Canada,L03AX,Other immunostimulants,Total,Total,"33,726.74",0.2,0,"3,181",80
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"33,236.00",0.2,1.9,"271,409",81
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"32,767.18",0.2,0,"1,518",82
1,Canada,N03AE,Benzodiazepine derivatives,Total,Total,"32,656.38",0.2,2.4,"331,909",83
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"31,637.35",0.2,2.3,"328,701",84
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,Total,"29,715.20",0.2,8.6,"1,200,182",85
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"29,597.75",0.2,0.3,"47,409",86
1,Canada,A04AD,Other antiemetics,Total,Total,"29,079.36",0.2,0.4,"53,240",87
1,Canada,H02AB,Glucocorticoids,Total,Total,"28,719.33",0.2,8.3,"1,165,220",88
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"27,636.98",0.2,3.6,"501,105",89
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,Total,"27,384.91",0.2,3,"427,007",90
1,Canada,L01XX,Other antineoplastic agents,Total,Total,"27,321.07",0.2,0.1,"12,267",91
1,Canada,M01AE,Propionic acid derivatives,Total,Total,"27,162.52",0.2,8.6,"1,206,019",92
1,Canada,C01CA,Adrenergic and dopaminergic agents,Total,Total,"26,505.46",0.2,1.4,"195,525",93
1,Canada,C01DA,Organic nitrates,Total,Total,"26,263.42",0.2,2.5,"347,440",94
1,Canada,J01CA,Penicillins with extended spectrum,Total,Total,"26,183.35",0.2,14.8,"2,071,571",95
1,Canada,J05AE,Protease inhibitors,Total,Total,"25,376.15",0.2,0,"3,752",96
1,Canada,A02BA,H2-receptor antagonists,Total,Total,"24,411.21",0.2,3,"419,654",97
1,Canada,N05AE,Indole derivatives,Total,Total,"24,131.15",0.2,0.1,"19,681",98
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"24,005.00",0.2,3.2,"443,902",99
1,Canada,M04AA,Preparations inhibiting uric acid production,Total,Total,"23,783.87",0.2,2.4,"334,400",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"607,001.13",8.2,0.5,"30,001",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,M,"420,507.25",5.7,0.1,"8,161",2
1,Canada,S01LA,Antineovascularization agents,Total,M,"330,499.82",4.5,0.6,"34,825",3
1,Canada,L01XE,Protein kinase inhibitors,Total,M,"279,438.95",3.8,0.1,"7,514",4
1,Canada,L04AX,Other immunosuppressants,Total,M,"223,688.04",3,0.3,"17,844",5
1,Canada,N05AX,Other antipsychotics,Total,M,"208,704.97",2.8,2.4,"149,674",6
1,Canada,B01AF,Direct factor Xa inhibitors,Total,M,"204,579.76",2.8,4.2,"262,362",7
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"162,589.12",2.2,0.3,"20,938",8
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,M,"155,701.09",2.1,31.8,"1,996,005",9
1,Canada,L04AA,Selective immunosuppressants,Total,M,"148,940.10",2,0.4,"22,615",10
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"140,450.54",1.9,4,"247,915",11
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"140,074.17",1.9,2.6,"163,142",12
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"133,535.30",1.8,2.7,"170,680",13
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"126,741.99",1.7,2.8,"177,386",14
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"124,524.16",1.7,2.5,"153,872",15
1,Canada,N07BC,Drugs used in opioid dependence,Total,M,"114,341.78",1.6,1,"63,506",16
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"105,765.84",1.4,4.2,"261,091",17
1,Canada,A02BC,Proton pump inhibitors,Total,M,"103,598.93",1.4,18.5,"1,161,205",18
1,Canada,L04AC,Interleukin inhibitors,Total,M,"95,204.80",1.3,0.1,"6,101",19
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"94,078.24",1.3,0.5,"29,428",20
1,Canada,N06BA,Centrally acting sympathomimetics,Total,M,"94,027.44",1.3,3.2,"199,138",21
1,Canada,N03AX,Other antiepileptics,Total,M,"84,339.66",1.1,6.2,"388,300",22
1,Canada,N02AA,Natural opium alkaloids,Total,M,"79,982.42",1.1,5.4,"341,262",23
1,Canada,C09AA,"ACE inhibitors, plain",Total,M,"74,777.26",1,16.2,"1,019,136",24
1,Canada,N06AX,Other antidepressants,Total,M,"74,699.54",1,7.8,"490,753",25
1,Canada,L02BX,Other hormone antagonists and related agents,Total,M,**,**,**,**,26
1,Canada,R03BB,Anticholinergics,Total,M,"73,864.93",1,3.7,"230,932",27
1,Canada,C08CA,Dihydropyridine derivatives,Total,M,"73,645.21",1,12.9,"809,420",28
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"67,436.61",0.9,10.5,"658,202",29
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,M,"63,277.43",0.9,8.2,"517,285",30
1,Canada,L02BB,Antiandrogens,Total,M,"60,098.11",0.8,0.3,"17,008",31
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"56,966.58",0.8,2,"125,000",32
1,Canada,C07AB,"Beta-blocking agents, selective",Total,M,"55,184.01",0.8,13.2,"830,922",33
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"50,589.45",0.7,8.3,"522,408",34
1,Canada,R03BA,Glucocorticoids,Total,M,"47,843.45",0.7,5.8,"366,030",35
1,Canada,B03XA,Other antianemic preparations,Total,M,"47,520.39",0.6,0.1,"9,345",36
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"42,541.98",0.6,3.7,"234,583",37
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"40,003.94",0.5,0.3,"20,292",38
1,Canada,L04AD,Calcineurin inhibitors,Total,M,"38,242.50",0.5,0.2,"12,283",39
1,Canada,A10BA,Biguanides,Total,M,"36,393.95",0.5,10.4,"650,981",40
1,Canada,H01CB,Somatostatin and analogues,Total,M,"36,352.12",0.5,0,"2,133",41
1,Canada,B01AB,Heparin group,Total,M,"35,829.31",0.5,0.5,"30,854",42
1,Canada,L03AA,Colony-stimulating factors,Total,M,"34,537.29",0.5,0.1,"7,029",43
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"33,115.78",0.5,4.3,"269,867",44
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"33,041.85",0.4,0,"2,108",45
1,Canada,A16AB,Enzymes,Total,M,"32,378.93",0.4,0,65,46
1,Canada,N04BA,Dopa and dopa derivatives,Total,M,"30,192.78",0.4,0.7,"45,878",47
1,Canada,J05AX,Other antivirals,Total,M,"29,945.40",0.4,0.1,"5,047",48
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"29,666.28",0.4,1,"65,025",49
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"29,397.37",0.4,12.5,"781,892",50
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,M,"27,349.78",0.4,1.5,"93,865",51
1,Canada,S01EE,Prostaglandin analogues,Total,M,"26,293.75",0.4,2.2,"135,633",52
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,M,"25,531.62",0.3,0.6,"40,736",53
1,Canada,S01ED,Beta-blocking agents,Total,M,"25,528.86",0.3,2.2,"140,688",54
1,Canada,H03AA,Thyroid hormones,Total,M,"25,240.40",0.3,6.1,"383,850",55
1,Canada,N05BA,Benzodiazepine derivatives,Total,M,"23,984.92",0.3,5.9,"370,436",56
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"23,691.44",0.3,0.2,"14,083",57
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"22,987.31",0.3,0.2,"9,648",58
1,Canada,C10AX,Other lipid-modifying agents,Total,M,"22,981.12",0.3,2.3,"144,671",59
1,Canada,B01AE,Direct thrombin inhibitors,Total,M,"22,710.41",0.3,0.4,"26,268",60
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"22,532.26",0.3,8.3,"519,120",61
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"22,431.10",0.3,0.4,"23,365",62
1,Canada,C08DB,Benzothiazepine derivatives,Total,M,"22,180.86",0.3,1.6,"99,149",63
1,Canada,A10BB,Sulfonylureas,Total,M,"21,908.02",0.3,4.2,"266,499",64
1,Canada,N02BA,Salicylic acid and derivatives,Total,M,"21,614.13",0.3,4.3,"269,895",65
1,Canada,A11CC,Vitamin D and analogues,Total,M,"20,990.65",0.3,3.8,"235,334",66
1,Canada,C09BA,ACE inhibitors and diuretics,Total,M,"20,630.73",0.3,2.7,"172,150",67
1,Canada,C03CA,"Sulfonamides, plain",Total,M,"20,303.26",0.3,4.7,"291,878",68
1,Canada,J05AE,Protease inhibitors,Total,M,"19,336.42",0.3,0,"2,760",69
1,Canada,N03AG,Fatty acid derivatives,Total,M,"19,117.41",0.3,0.8,"52,964",70
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"18,289.40",0.2,0.3,"16,306",71
1,Canada,N07BA,Drugs used in nicotine dependence,Total,M,"18,047.24",0.2,1.9,"121,521",72
1,Canada,R01AD,Corticosteroids,Total,M,"17,394.76",0.2,6.3,"392,452",73
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"17,175.02",0.2,3.1,"196,170",74
1,Canada,M05BA,Bisphosphonates,Total,M,"16,861.33",0.2,1.3,"84,700",75
1,Canada,G03BA,3-oxoandrosten (4) derivatives,Total,M,"16,676.93",0.2,0.7,"45,866",76
1,Canada,M04AA,Preparations inhibiting uric acid production,Total,M,"15,939.77",0.2,3.9,"244,520",77
1,Canada,N06DA,Anticholinesterases,Total,M,"15,201.55",0.2,0.8,"50,519",78
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"15,174.77",0.2,2.2,"137,602",79
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"14,912.55",0.2,0.4,"23,813",80
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,M,"14,336.90",0.2,8.5,"535,586",81
1,Canada,L01XC,Monoclonal antibodies,Total,M,"14,050.63",0.2,0,"1,347",82
1,Canada,N03AE,Benzodiazepine derivatives,Total,M,"13,996.31",0.2,2,"123,624",83
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"13,649.22",0.2,0.3,"21,886",84
1,Canada,N02BE,Anilides,Total,M,"13,546.68",0.2,6.2,"389,489",85
1,Canada,C01CA,Adrenergic and dopaminergic agents,Total,M,"12,950.57",0.2,1.4,"87,751",86
1,Canada,C01DA,Organic nitrates,Total,M,"12,773.95",0.2,3.1,"194,395",87
1,Canada,H01AC,Somatropin and somatropin agonists,Total,M,"12,739.08",0.2,0,"1,264",88
1,Canada,R07AX,Other respiratory system products,Total,M,"12,506.04",0.2,0,55,89
1,Canada,A09AA,Enzyme preparations,Total,M,"12,407.38",0.2,0.2,"13,272",90
1,Canada,A04AD,Other antiemetics,Total,M,"12,256.32",0.2,0.3,"21,000",91
1,Canada,H02AB,Glucocorticoids,Total,M,"12,141.85",0.2,8.1,"506,855",92
1,Canada,V03AC,Iron-chelating agents,Total,M,"12,114.07",0.2,0,609,93
1,Canada,J01CA,Penicillins with extended spectrum,Total,M,"12,033.94",0.2,15,"941,295",94
1,Canada,M01AE,Propionic acid derivatives,Total,M,"11,852.59",0.2,8.3,"520,520",95
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"11,770.33",0.2,0.7,"41,087",96
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"10,776.63",0.1,0.1,"9,001",97
1,Canada,L01XX,Other antineoplastic agents,Total,M,"10,549.26",0.1,0.1,"5,262",98
1,Canada,N03AF,Carboxamide derivatives,Total,M,"10,504.94",0.1,0.5,"31,603",99
1,Canada,L03AB,Interferons,Total,M,"10,395.84",0.1,0,719,100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"626,867.11",8.2,0.5,"35,512",1
1,Canada,S01LA,Antineovascularization agents,Total,F,"443,961.13",5.8,0.6,"45,217",2
1,Canada,L01XE,Protein kinase inhibitors,Total,F,"286,732.83",3.8,0.1,"7,804",3
1,Canada,L04AA,Selective immunosuppressants,Total,F,"279,486.66",3.7,0.5,"35,644",4
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,F,"217,990.54",2.9,0.1,"4,280",5
1,Canada,B01AF,Direct factor Xa inhibitors,Total,F,"197,555.04",2.6,3.2,"249,889",6
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"183,541.19",2.4,4.4,"339,002",7
1,Canada,L04AX,Other immunosuppressants,Total,F,"176,321.46",2.3,0.3,"24,155",8
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,F,"151,177.48",2,22.1,"1,707,700",9
1,Canada,A02BC,Proton pump inhibitors,Total,F,"151,026.86",2,20.5,"1,585,086",10
1,Canada,N06AX,Other antidepressants,Total,F,"133,270.93",1.8,11.2,"868,876",11
1,Canada,N05AX,Other antipsychotics,Total,F,"123,739.98",1.6,2,"154,202",12
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"121,385.05",1.6,1.9,"145,139",13
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"114,151.48",1.5,2.2,"173,150",14
1,Canada,N03AX,Other antiepileptics,Total,F,"113,537.96",1.5,7.5,"578,968",15
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,F,"112,909.01",1.5,13.2,"1,020,436",16
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"111,398.65",1.5,1.9,"148,870",17
1,Canada,L04AC,Interleukin inhibitors,Total,F,"105,908.18",1.4,0.1,"7,708",18
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"104,480.50",1.4,1.6,"119,793",19
1,Canada,C08CA,Dihydropyridine derivatives,Total,F,"92,924.36",1.2,11.6,"894,617",20
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"88,289.51",1.2,1.6,"122,588",21
1,Canada,N02AA,Natural opium alkaloids,Total,F,"85,891.37",1.1,5.8,"445,178",22
1,Canada,N07BC,Drugs used in opioid dependence,Total,F,"82,812.34",1.1,0.6,"45,418",23
1,Canada,R03BB,Anticholinergics,Total,F,"78,279.73",1,3.2,"250,395",24
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"76,017.43",1,8.9,"687,610",25
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"75,982.18",1,3.9,"303,600",26
1,Canada,H03AA,Thyroid hormones,Total,F,"74,583.55",1,15.2,"1,174,883",27
1,Canada,C09AA,"ACE inhibitors, plain",Total,F,"70,574.45",0.9,10.7,"826,832",28
1,Canada,R03BA,Glucocorticoids,Total,F,"65,694.71",0.9,6.2,"475,290",29
1,Canada,M05BA,Bisphosphonates,Total,F,"64,668.85",0.8,4.8,"374,202",30
1,Canada,C07AB,"Beta-blocking agents, selective",Total,F,"60,144.24",0.8,9.9,"768,124",31
1,Canada,N06BA,Centrally acting sympathomimetics,Total,F,"57,318.38",0.8,1.7,"129,609",32
1,Canada,L03AA,Colony-stimulating factors,Total,F,"53,194.43",0.7,0.1,"10,969",33
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,F,"51,801.67",0.7,2.4,"184,073",34
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"50,387.04",0.7,0,"3,530",35
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"48,424.09",0.6,0.1,"6,367",36
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"46,370.20",0.6,1.4,"111,848",37
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"42,552.36",0.6,2.2,"168,595",38
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"41,835.67",0.5,4.9,"379,171",39
1,Canada,A11CC,Vitamin D and analogues,Total,F,"40,061.45",0.5,7.1,"545,930",40
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"39,742.59",0.5,0.3,"20,413",41
1,Canada,B03XA,Other antianemic preparations,Total,F,"39,733.45",0.5,0.1,"8,627",42
1,Canada,N05BA,Benzodiazepine derivatives,Total,F,"38,644.23",0.5,9.2,"710,273",43
1,Canada,B01AB,Heparin group,Total,F,"38,457.38",0.5,0.5,"39,263",44
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"36,029.94",0.5,13,"1,006,815",45
1,Canada,A10BA,Biguanides,Total,F,"35,775.71",0.5,7.3,"564,709",46
1,Canada,S01EE,Prostaglandin analogues,Total,F,"35,514.17",0.5,2.2,"170,166",47
1,Canada,H01CB,Somatostatin and analogues,Total,F,"35,139.65",0.5,0,"2,566",48
1,Canada,L01XC,Monoclonal antibodies,Total,F,"33,893.65",0.4,0,"2,977",49
1,Canada,C08DB,Benzothiazepine derivatives,Total,F,"32,800.50",0.4,1.8,"137,366",50
1,Canada,L03AB,Interferons,Total,F,"31,247.69",0.4,0,"2,016",51
1,Canada,S01ED,Beta-blocking agents,Total,F,"31,137.15",0.4,2.1,"159,910",52
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"28,418.67",0.4,3.9,"299,003",53
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"27,884.06",0.4,7.8,"603,627",54
1,Canada,C03CA,"Sulfonamides, plain",Total,F,"27,709.26",0.4,4.6,"353,228",55
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"27,614.92",0.4,6.5,"500,828",56
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,F,"27,415.02",0.4,0.7,"50,343",57
1,Canada,N06DA,Anticholinesterases,Total,F,"26,400.53",0.3,1,"80,401",58
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"26,392.13",0.3,0.8,"61,747",59
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"25,451.08",0.3,3.5,"269,471",60
1,Canada,L04AD,Calcineurin inhibitors,Total,F,"24,890.55",0.3,0.1,"8,070",61
1,Canada,L03AX,Other immunostimulants,Total,F,"24,648.49",0.3,0,"2,342",62
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"24,585.49",0.3,3.3,"251,075",63
1,Canada,N02BE,Anilides,Total,F,"24,161.59",0.3,7.6,"585,800",64
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"23,332.25",0.3,0,"1,052",65
1,Canada,R01AD,Corticosteroids,Total,F,"22,651.79",0.3,7.2,"556,984",66
1,Canada,N04BA,Dopa and dopa derivatives,Total,F,"20,571.96",0.3,0.5,"36,526",67
1,Canada,A10BB,Sulfonylureas,Total,F,"19,710.18",0.3,2.7,"209,759",68
1,Canada,N02BA,Salicylic acid and derivatives,Total,F,"19,689.52",0.3,2.9,"220,377",69
1,Canada,C10AX,Other lipid-modifying agents,Total,F,"19,650.90",0.3,1.5,"114,716",70
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"19,464.33",0.3,0.3,"21,482",71
1,Canada,C09BA,ACE inhibitors and diuretics,Total,F,"19,176.33",0.3,2,"151,986",72
1,Canada,N03AE,Benzodiazepine derivatives,Total,F,"18,653.41",0.2,2.7,"208,185",73
1,Canada,A16AB,Enzymes,Total,F,"18,018.89",0.2,0,38,74
1,Canada,G02BA,Intrauterine contraceptives,Total,F,"17,217.18",0.2,1.1,"83,016",75
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,F,"17,199.70",0.2,3.6,"276,970",76
1,Canada,B01AE,Direct thrombin inhibitors,Total,F,"17,009.19",0.2,0.2,"18,665",77
1,Canada,A12AA,Calcium,Total,F,"16,844.97",0.2,2.9,"224,643",78
1,Canada,N07BA,Drugs used in nicotine dependence,Total,F,"16,835.35",0.2,1.5,"114,718",79
1,Canada,A04AD,Other antiemetics,Total,F,"16,815.52",0.2,0.4,"32,230",80
1,Canada,L01XX,Other antineoplastic agents,Total,F,"16,766.05",0.2,0.1,"6,994",81
1,Canada,H02AB,Glucocorticoids,Total,F,"16,561.04",0.2,8.5,"657,660",82
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"16,491.80",0.2,0.1,"11,161",83
1,Canada,L02BG,Aromatase inhibitors,Total,F,"16,290.70",0.2,0.7,"51,956",84
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,F,"15,341.99",0.2,8.6,"663,625",85
1,Canada,M01AE,Propionic acid derivatives,Total,F,"15,258.50",0.2,8.8,"682,983",86
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"14,665.51",0.2,0.3,"23,562",87
1,Canada,N03AG,Fatty acid derivatives,Total,F,"14,613.71",0.2,0.6,"47,193",88
1,Canada,C03AA,"Thiazides, plain",Total,F,"14,586.17",0.2,5.6,"434,896",89
1,Canada,N05AE,Indole derivatives,Total,F,"14,549.45",0.2,0.2,"12,232",90
1,Canada,A02BA,H2-receptor antagonists,Total,F,"14,472.04",0.2,3.3,"257,855",91
1,Canada,J01CA,Penicillins with extended spectrum,Total,F,"14,043.69",0.2,14.6,"1,125,804",92
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"14,039.47",0.2,3.9,"297,736",93
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"13,641.61",0.2,0.1,"6,924",94
1,Canada,C01CA,Adrenergic and dopaminergic agents,Total,F,"13,542.31",0.2,1.4,"107,700",95
1,Canada,C01DA,Organic nitrates,Total,F,"13,483.42",0.2,2,"152,977",96
1,Canada,L01BA,Folic acid analogues,Total,F,"13,013.25",0.2,1,"77,756",97
1,Canada,M03BX,Other centrally acting agents,Total,F,"12,757.46",0.2,3.7,"285,593",98
1,Canada,N02CC,Selective serotonin (5HT1) agonists,Total,F,"12,498.05",0.2,1.2,"92,267",99
1,Canada,A06AB,Contact laxatives,Total,F,"12,175.66",0.2,2.9,"223,803",100
1,Canada,S01LA,Antineovascularization agents,65+,Total,"729,014.29",8.3,1.3,"74,612",1
1,Canada,L01XE,Protein kinase inhibitors,65+,Total,"437,757.15",5,0.2,"11,677",2
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"399,432.82",4.6,0.4,"21,653",3
1,Canada,B01AF,Direct factor Xa inhibitors,65+,Total,"377,365.89",4.3,7.8,"466,638",4
1,Canada,L04AX,Other immunosuppressants,65+,Total,"287,578.02",3.3,0.4,"21,293",5
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,Total,"250,424.21",2.9,49.3,"2,937,161",6
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"242,521.41",2.8,6.6,"395,591",7
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"202,917.63",2.3,4,"239,117",8
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"189,533.58",2.2,3.5,"210,132",9
1,Canada,A02BC,Proton pump inhibitors,65+,Total,"184,103.84",2.1,31.5,"1,878,078",10
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"167,641.97",1.9,3.6,"211,576",11
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"157,199.98",1.8,3.5,"208,877",12
1,Canada,L04AA,Selective immunosuppressants,65+,Total,"154,670.54",1.8,0.5,"28,381",13
1,Canada,C08CA,Dihydropyridine derivatives,65+,Total,"141,673.64",1.6,23.2,"1,379,397",14
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"125,812.09",1.4,3,"180,001",15
1,Canada,R03BB,Anticholinergics,65+,Total,"123,414.24",1.4,6.3,"376,156",16
1,Canada,C09AA,"ACE inhibitors, plain",65+,Total,"114,987.92",1.3,23.4,"1,394,053",17
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"109,884.12",1.3,16.9,"1,006,141",18
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,Total,"108,481.27",1.2,0,"2,084",19
1,Canada,N06AX,Other antidepressants,65+,Total,"102,719.28",1.2,11.4,"679,396",20
1,Canada,C07AB,"Beta-blocking agents, selective",65+,Total,"97,805.88",1.1,22.4,"1,336,551",21
1,Canada,N03AX,Other antiepileptics,65+,Total,"91,742.85",1,9.3,"553,046",22
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"88,285.32",1,0.5,"27,428",23
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"82,629.97",0.9,10.7,"639,557",24
1,Canada,L04AC,Interleukin inhibitors,65+,Total,"80,480.01",0.9,0.1,"5,483",25
1,Canada,H03AA,Thyroid hormones,65+,Total,"75,805.59",0.9,18.6,"1,105,253",26
1,Canada,M05BA,Bisphosphonates,65+,Total,"74,513.14",0.9,7,"418,023",27
1,Canada,N02AA,Natural opium alkaloids,65+,Total,"72,962.61",0.8,7.9,"473,193",28
1,Canada,B03XA,Other antianemic preparations,65+,Total,"71,760.10",0.8,0.2,"14,147",29
1,Canada,L02BX,Other hormone antagonists and related agents,65+,Total,"70,521.94",0.8,0.1,"4,476",30
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"64,835.56",0.7,3.7,"219,435",31
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"64,185.58",0.7,10,"598,250",32
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"61,833.39",0.7,2.3,"134,625",33
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"61,625.93",0.7,5.5,"325,956",34
1,Canada,R03BA,Glucocorticoids,65+,Total,"59,264.05",0.7,5.5,"325,836",35
1,Canada,S01EE,Prostaglandin analogues,65+,Total,"57,845.00",0.7,4.7,"277,076",36
1,Canada,L02BB,Antiandrogens,65+,Total,"56,757.41",0.6,0.3,"16,331",37
1,Canada,S01ED,Beta-blocking agents,65+,Total,"52,484.88",0.6,4.5,"267,491",38
1,Canada,H01CB,Somatostatin and analogues,65+,Total,"51,697.92",0.6,0.1,"3,300",39
1,Canada,L03AA,Colony-stimulating factors,65+,Total,"51,611.35",0.6,0.2,"10,604",40
1,Canada,A10BA,Biguanides,65+,Total,"51,526.35",0.6,14.2,"848,541",41
1,Canada,B01AB,Heparin group,65+,Total,"50,363.67",0.6,0.8,"49,716",42
1,Canada,C08DB,Benzothiazepine derivatives,65+,Total,"49,198.97",0.6,3.4,"203,340",43
1,Canada,N05AX,Other antipsychotics,65+,Total,"48,158.31",0.6,1.7,"102,043",44
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"47,385.68",0.5,1.7,"102,488",45
1,Canada,N04BA,Dopa and dopa derivatives,65+,Total,"46,221.83",0.5,1.2,"73,737",46
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"45,302.76",0.5,0.4,"22,427",47
1,Canada,A11CC,Vitamin D and analogues,65+,Total,"44,686.91",0.5,8.9,"531,695",48
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"42,591.69",0.5,0,"2,774",49
1,Canada,C03CA,"Sulfonamides, plain",65+,Total,"41,932.93",0.5,9.4,"562,479",50
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"41,446.94",0.5,3.6,"214,129",51
1,Canada,N06DA,Anticholinesterases,65+,Total,"40,930.27",0.5,2.2,"128,821",52
1,Canada,B01AE,Direct thrombin inhibitors,65+,Total,"38,267.97",0.4,0.7,"42,885",53
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"36,187.41",0.4,13.3,"793,512",54
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"35,938.64",0.4,6.2,"367,368",55
1,Canada,C10AX,Other lipid-modifying agents,65+,Total,"34,938.18",0.4,3.7,"218,999",56
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,Total,"34,449.49",0.4,0.8,"49,366",57
1,Canada,N02BA,Salicylic acid and derivatives,65+,Total,"34,112.35",0.4,6.7,"401,524",58
1,Canada,N05BA,Benzodiazepine derivatives,65+,Total,"34,088.53",0.4,10.5,"627,113",59
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"33,425.07",0.4,0.3,"16,582",60
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"31,764.87",0.4,4.2,"250,990",61
1,Canada,C09BA,ACE inhibitors and diuretics,65+,Total,"31,691.07",0.4,4.1,"241,946",62
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"31,626.84",0.4,4.2,"252,432",63
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"31,290.11",0.4,0.1,"3,353",64
1,Canada,A10BB,Sulfonylureas,65+,Total,"30,107.90",0.3,5.7,"339,918",65
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"28,359.41",0.3,0.5,"30,559",66
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"26,422.01",0.3,4.5,"268,979",67
1,Canada,N02BE,Anilides,65+,Total,"25,338.67",0.3,9.6,"574,485",68
1,Canada,L01XC,Monoclonal antibodies,65+,Total,"25,205.47",0.3,0,"2,242",69
1,Canada,C01DA,Organic nitrates,65+,Total,"24,022.89",0.3,5,"298,898",70
1,Canada,L04AD,Calcineurin inhibitors,65+,Total,"23,991.76",0.3,0.1,"8,398",71
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"23,596.12",0.3,0.6,"37,283",72
1,Canada,R01AD,Corticosteroids,65+,Total,"23,270.58",0.3,7.9,"473,043",73
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"22,524.15",0.3,3.8,"225,798",74
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"22,275.50",0.3,8.9,"531,590",75
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,Total,"20,792.04",0.2,4.6,"272,112",76
1,Canada,L01XX,Other antineoplastic agents,65+,Total,"19,996.16",0.2,0.2,"9,817",77
1,Canada,H02AB,Glucocorticoids,65+,Total,"18,943.74",0.2,11,"652,749",78
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,Total,"18,783.14",0.2,4.4,"261,654",79
1,Canada,C03AA,"Thiazides, plain",65+,Total,"18,222.07",0.2,9.4,"561,901",80
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"18,149.56",0.2,0,787,81
1,Canada,A12AA,Calcium,65+,Total,"17,766.81",0.2,3.7,"219,034",82
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,Total,"17,748.37",0.2,10.2,"608,040",83
1,Canada,B01AA,Vitamin K antagonists,65+,Total,"16,586.71",0.2,2.8,"165,773",84
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"15,045.77",0.2,0.8,"50,054",85
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"15,022.99",0.2,0.5,"29,418",86
1,Canada,A02BA,H2-receptor antagonists,65+,Total,"14,482.08",0.2,3.9,"230,446",87
1,Canada,A06AB,Contact laxatives,65+,Total,"14,410.82",0.2,5.1,"302,315",88
1,Canada,C03DA,Aldosterone antagonists,65+,Total,"14,073.68",0.2,2.7,"160,177",89
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"13,820.14",0.2,3.8,"226,514",90
1,Canada,L01BA,Folic acid analogues,65+,Total,"13,736.19",0.2,1.3,"75,868",91
1,Canada,L02BG,Aromatase inhibitors,65+,Total,"13,694.62",0.2,0.7,"39,342",92
1,Canada,A06AA,"Softeners, emollients",65+,Total,"13,657.09",0.2,3.5,"211,312",93
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"13,438.65",0.2,0.2,"11,794",94
1,Canada,A06AD,Osmotically acting laxatives,65+,Total,"13,225.09",0.2,4.1,"243,622",95
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,Total,"12,963.45",0.1,1.4,"81,254",96
1,Canada,A07AA,Antibiotics,65+,Total,"12,570.79",0.1,1.3,"79,012",97
1,Canada,S01XA,Other ophthalmologicals,65+,Total,"12,559.32",0.1,1.3,"78,738",98
1,Canada,C07AG,Alpha- and beta-blocking agents,65+,Total,"12,166.30",0.1,0.9,"55,315",99
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"12,139.60",0.1,3,"176,565",100
1,Canada,S01LA,Antineovascularization agents,65+,M,"305,273.64",7.3,1.2,"31,765",1
1,Canada,L01XE,Protein kinase inhibitors,65+,M,"219,469.51",5.3,0.2,"5,850",2
1,Canada,B01AF,Direct factor Xa inhibitors,65+,M,"189,815.69",4.5,8.8,"236,499",3
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"172,579.44",4.1,0.3,"8,729",4
1,Canada,L04AX,Other immunosuppressants,65+,M,"171,678.28",4.1,0.4,"9,792",5
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,M,"125,089.13",3,57.6,"1,553,501",6
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"110,470.91",2.6,4.6,"123,042",7
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"106,707.81",2.6,6.3,"169,119",8
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"103,472.86",2.5,4.6,"123,724",9
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"96,206.53",2.3,4.7,"127,819",10
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"94,615.60",2.3,4.3,"115,484",11
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"88,211.72",2.1,1,"27,397",12
1,Canada,A02BC,Proton pump inhibitors,65+,M,"72,753.71",1.7,29.3,"789,188",13
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,M,"72,648.42",1.7,0.1,"1,395",14
1,Canada,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,15
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"61,717.10",1.5,21.4,"576,457",16
1,Canada,R03BB,Anticholinergics,65+,M,"60,384.97",1.4,6.8,"183,089",17
1,Canada,C08CA,Dihydropyridine derivatives,65+,M,"60,315.32",1.4,23.4,"630,222",18
1,Canada,C09AA,"ACE inhibitors, plain",65+,M,"57,629.47",1.4,28,"754,944",19
1,Canada,L02BB,Antiandrogens,65+,M,"56,741.44",1.4,0.6,"16,310",20
1,Canada,L04AA,Selective immunosuppressants,65+,M,"56,116.51",1.3,0.4,"11,394",21
1,Canada,C07AB,"Beta-blocking agents, selective",65+,M,"44,880.02",1.1,25.2,"678,488",22
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"42,945.75",1,15.8,"425,212",23
1,Canada,B03XA,Other antianemic preparations,65+,M,"39,612.54",0.9,0.3,"7,339",24
1,Canada,N03AX,Other antiepileptics,65+,M,"36,391.84",0.9,8.1,"217,182",25
1,Canada,L04AC,Interleukin inhibitors,65+,M,"36,348.50",0.9,0.1,"2,276",26
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"35,309.46",0.8,2.7,"72,808",27
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"33,628.35",0.8,0.6,"16,637",28
1,Canada,N06AX,Other antidepressants,65+,M,"32,831.67",0.8,8.7,"234,935",29
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"32,503.40",0.8,6.9,"186,704",30
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"31,550.18",0.8,9.3,"251,466",31
1,Canada,N02AA,Natural opium alkaloids,65+,M,"30,861.67",0.7,7.4,"200,369",32
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"27,416.63",0.7,0.1,"2,940",33
1,Canada,N04BA,Dopa and dopa derivatives,65+,M,"27,335.58",0.7,1.5,"41,401",34
1,Canada,H01CB,Somatostatin and analogues,65+,M,"26,499.51",0.6,0.1,"1,516",35
1,Canada,A10BA,Biguanides,65+,M,"26,081.42",0.6,17.1,"461,583",36
1,Canada,B01AB,Heparin group,65+,M,"25,756.95",0.6,0.8,"22,527",37
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,M,"25,535.47",0.6,7.5,"202,476",38
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"25,081.12",0.6,2,"52,931",39
1,Canada,S01EE,Prostaglandin analogues,65+,M,"24,455.80",0.6,4.5,"121,899",40
1,Canada,L03AA,Colony-stimulating factors,65+,M,"23,708.34",0.6,0.2,"4,781",41
1,Canada,R03BA,Glucocorticoids,65+,M,"23,620.85",0.6,4.7,"126,065",42
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,M,"23,447.47",0.6,2.9,"77,683",43
1,Canada,S01ED,Beta-blocking agents,65+,M,"23,315.13",0.6,4.6,"123,249",44
1,Canada,B01AE,Direct thrombin inhibitors,65+,M,"21,706.27",0.5,0.9,"24,836",45
1,Canada,C08DB,Benzothiazepine derivatives,65+,M,"19,365.64",0.5,3.1,"82,636",46
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"19,188.46",0.5,0,"1,209",47
1,Canada,H03AA,Thyroid hormones,65+,M,"18,971.77",0.5,10.6,"286,783",48
1,Canada,N05AX,Other antipsychotics,65+,M,"18,926.48",0.5,1.4,"37,383",49
1,Canada,C10AX,Other lipid-modifying agents,65+,M,"18,737.43",0.4,4.5,"121,332",50
1,Canada,N02BA,Salicylic acid and derivatives,65+,M,"17,375.35",0.4,8.1,"217,960",51
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"17,250.30",0.4,3.2,"87,367",52
1,Canada,C03CA,"Sulfonamides, plain",65+,M,"17,238.82",0.4,9.3,"252,147",53
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"17,020.14",0.4,0.6,"15,173",54
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,M,"16,795.67",0.4,0.8,"22,567",55
1,Canada,C09BA,ACE inhibitors and diuretics,65+,M,"16,176.65",0.4,4.7,"125,484",56
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"16,089.02",0.4,0.6,"16,985",57
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"16,003.23",0.4,12.2,"329,067",58
1,Canada,A10BB,Sulfonylureas,65+,M,"15,875.49",0.4,7.1,"191,296",59
1,Canada,A11CC,Vitamin D and analogues,65+,M,"14,972.50",0.4,6.1,"164,552",60
1,Canada,L04AD,Calcineurin inhibitors,65+,M,"14,907.39",0.4,0.2,"5,239",61
1,Canada,M05BA,Bisphosphonates,65+,M,"14,891.53",0.4,2.8,"75,263",62
1,Canada,N06DA,Anticholinesterases,65+,M,"14,857.06",0.4,1.8,"49,448",63
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"14,513.28",0.3,5.8,"157,070",64
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,M,"13,682.28",0.3,7.1,"192,813",65
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"11,901.89",0.3,0.7,"18,578",66
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"11,554.13",0.3,0.2,"5,222",67
1,Canada,C01DA,Organic nitrates,65+,M,"11,454.55",0.3,6.1,"164,135",68
1,Canada,N05BA,Benzodiazepine derivatives,65+,M,"10,896.45",0.3,7.6,"204,386",69
1,Canada,R01AD,Corticosteroids,65+,M,"10,422.73",0.2,7.4,"199,686",70
1,Canada,G03BA,3-oxoandrosten (4) derivatives,65+,M,"10,108.25",0.2,0.9,"23,378",71
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"9,687.02",0.2,9.2,"246,897",72
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,M,"8,913.92",0.2,10.4,"280,489",73
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"8,832.90",0.2,0.6,"16,981",74
1,Canada,L01XX,Other antineoplastic agents,65+,M,"8,644.10",0.2,0.2,"4,116",75
1,Canada,N02BE,Anilides,65+,M,"8,150.63",0.2,8,"215,458",76
1,Canada,L01XC,Monoclonal antibodies,65+,M,"8,107.40",0.2,0,765,77
1,Canada,B01AA,Vitamin K antagonists,65+,M,"8,106.44",0.2,3.4,"91,141",78
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"8,056.78",0.2,0.2,"6,376",79
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"8,055.47",0.2,1,"27,170",80
1,Canada,H02AB,Glucocorticoids,65+,M,"7,916.34",0.2,10.5,"283,002",81
1,Canada,J05AX,Other antivirals,65+,M,"7,833.43",0.2,0,"1,006",82
1,Canada,C03DA,Aldosterone antagonists,65+,M,"7,623.26",0.2,3,"81,576",83
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,M,"7,515.65",0.2,4.2,"112,276",84
1,Canada,C07AG,Alpha- and beta-blocking agents,65+,M,"6,809.26",0.2,1.2,"32,381",85
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"6,704.88",0.2,2.5,"68,540",86
1,Canada,D05AX,Other antipsoriatics for topical use,65+,M,"6,464.75",0.2,0.9,"24,339",87
1,Canada,C03AA,"Thiazides, plain",65+,M,"6,399.51",0.2,8,"216,302",88
1,Canada,A07AA,Antibiotics,65+,M,"5,899.98",0.1,1.1,"29,702",89
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,M,"5,888.70",0.1,1.4,"38,001",90
1,Canada,A06AB,Contact laxatives,65+,M,"5,884.27",0.1,4.9,"133,017",91
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,"5,836.32",0.1,3.5,"94,403",92
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,"5,485.55",0.1,2.4,"63,435",93
1,Canada,A06AD,Osmotically acting laxatives,65+,M,"5,458.59",0.1,3.8,"103,542",94
1,Canada,A02BA,H2-receptor antagonists,65+,M,"5,423.48",0.1,3.3,"88,909",95
1,Canada,C10AC,Bile acid sequestrants,65+,M,"5,329.78",0.1,0.5,"13,700",96
1,Canada,V03AC,Iron-chelating agents,65+,M,"5,322.86",0.1,0,307,97
1,Canada,N07BC,Drugs used in opioid dependence,65+,M,"5,309.80",0.1,0.2,"5,016",98
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"5,294.20",0.1,0.1,"3,697",99
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,M,"5,168.63",0.1,1.9,"50,495",100
1,Canada,S01LA,Antineovascularization agents,65+,F,"423,723.24",9.3,1.3,"42,845",1
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"226,853.38",5,0.4,"12,924",2
1,Canada,L01XE,Protein kinase inhibitors,65+,F,"218,279.46",4.8,0.2,"5,826",3
1,Canada,B01AF,Direct factor Xa inhibitors,65+,F,"187,517.98",4.1,7.1,"230,099",4
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"135,778.18",3,6.9,"226,409",5
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,F,"125,291.76",2.7,42.4,"1,383,259",6
1,Canada,L04AX,Other immunosuppressants,65+,F,"115,898.85",2.5,0.4,"11,498",7
1,Canada,A02BC,Proton pump inhibitors,65+,F,"111,325.24",2.4,33.4,"1,088,623",8
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"108,774.50",2.4,5.1,"164,800",9
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"99,387.22",2.2,3.5,"115,337",10
1,Canada,L04AA,Selective immunosuppressants,65+,F,"98,553.81",2.2,0.5,"16,986",11
1,Canada,C08CA,Dihydropyridine derivatives,65+,F,"81,329.63",1.8,23,"748,956",12
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"78,978.19",1.7,2.7,"87,005",13
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"73,002.80",1.6,2.9,"96,048",14
1,Canada,N06AX,Other antidepressants,65+,F,"69,879.90",1.5,13.6,"444,398",15
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"66,913.68",1.5,17.8,"580,768",16
1,Canada,R03BB,Anticholinergics,65+,F,"63,018.53",1.4,5.9,"193,027",17
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"60,953.48",1.3,2.5,"81,007",18
1,Canada,M05BA,Bisphosphonates,65+,F,"59,604.30",1.3,10.5,"342,696",19
1,Canada,C09AA,"ACE inhibitors, plain",65+,F,"57,339.90",1.3,19.6,"638,929",20
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,F,"57,085.92",1.3,13.4,"437,022",21
1,Canada,H03AA,Thyroid hormones,65+,F,"56,827.83",1.2,25.1,"818,394",22
1,Canada,N03AX,Other antiepileptics,65+,F,"55,338.30",1.2,10.3,"335,789",23
1,Canada,C07AB,"Beta-blocking agents, selective",65+,F,"52,910.28",1.2,20.2,"657,879",24
1,Canada,L04AC,Interleukin inhibitors,65+,F,"44,131.51",1,0.1,"3,207",25
1,Canada,N02AA,Natural opium alkaloids,65+,F,"42,099.86",0.9,8.4,"272,794",26
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,F,"41,378.71",0.9,4.3,"141,721",27
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,F,"35,832.85",0.8,0,689,28
1,Canada,R03BA,Glucocorticoids,65+,F,"35,635.74",0.8,6.1,"199,735",29
1,Canada,S01EE,Prostaglandin analogues,65+,F,"33,382.49",0.7,4.8,"155,153",30
1,Canada,B03XA,Other antianemic preparations,65+,F,"32,147.56",0.7,0.2,"6,808",31
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"31,690.30",0.7,7.7,"250,448",32
1,Canada,C08DB,Benzothiazepine derivatives,65+,F,"29,831.09",0.7,3.7,"120,692",33
1,Canada,A11CC,Vitamin D and analogues,65+,F,"29,711.58",0.7,11.3,"367,123",34
1,Canada,N05AX,Other antipsychotics,65+,F,"29,228.36",0.6,2,"64,657",35
1,Canada,S01ED,Beta-blocking agents,65+,F,"29,163.48",0.6,4.4,"144,215",36
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"29,110.76",0.6,4.3,"139,198",37
1,Canada,L03AA,Colony-stimulating factors,65+,F,"27,903.01",0.6,0.2,"5,823",38
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"26,516.54",0.6,1.9,"61,798",39
1,Canada,N06DA,Anticholinesterases,65+,F,"26,068.81",0.6,2.4,"79,356",40
1,Canada,A10BA,Biguanides,65+,F,"25,432.83",0.6,11.9,"386,796",41
1,Canada,H01CB,Somatostatin and analogues,65+,F,"25,198.41",0.6,0.1,"1,784",42
1,Canada,C03CA,"Sulfonamides, plain",65+,F,"24,689.08",0.5,9.5,"310,264",43
1,Canada,B01AB,Heparin group,65+,F,"24,606.58",0.5,0.8,"27,188",44
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"24,193.26",0.5,3.9,"126,744",45
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"23,403.23",0.5,0,"1,565",46
1,Canada,N05BA,Benzodiazepine derivatives,65+,F,"23,190.33",0.5,13,"422,690",47
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"22,300.92",0.5,1.5,"49,550",48
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"21,870.94",0.5,0.3,"11,360",49
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"21,417.83",0.5,6.5,"210,241",50
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"21,253.38",0.5,6.7,"218,484",51
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"20,179.11",0.4,14.2,"464,345",52
1,Canada,N04BA,Dopa and dopa derivatives,65+,F,"18,883.85",0.4,1,"32,326",53
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,F,"17,651.91",0.4,0.8,"26,796",54
1,Canada,N02BE,Anilides,65+,F,"17,179.84",0.4,11,"358,812",55
1,Canada,L01XC,Monoclonal antibodies,65+,F,"17,098.06",0.4,0,"1,477",56
1,Canada,N02BA,Salicylic acid and derivatives,65+,F,"16,736.86",0.4,5.6,"183,560",57
1,Canada,B01AE,Direct thrombin inhibitors,65+,F,"16,559.84",0.4,0.6,"18,046",58
1,Canada,C10AX,Other lipid-modifying agents,65+,F,"16,199.43",0.4,3,"97,655",59
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"15,817.89",0.3,4.8,"157,236",60
1,Canada,C09BA,ACE inhibitors and diuretics,65+,F,"15,507.44",0.3,3.6,"116,422",61
1,Canada,A10BB,Sulfonylureas,65+,F,"14,223.57",0.3,4.6,"148,540",62
1,Canada,L02BG,Aromatase inhibitors,65+,F,"13,659.58",0.3,1.2,"39,182",63
1,Canada,A12AA,Calcium,65+,F,"13,591.53",0.3,5.3,"171,403",64
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"13,057.10",0.3,0,546,65
1,Canada,R01AD,Corticosteroids,65+,F,"12,843.97",0.3,8.4,"273,288",66
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"12,586.05",0.3,8.7,"284,625",67
1,Canada,C01DA,Organic nitrates,65+,F,"12,564.30",0.3,4.1,"134,726",68
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"12,269.31",0.3,0.4,"13,572",69
1,Canada,C03AA,"Thiazides, plain",65+,F,"11,819.78",0.3,10.6,"345,535",70
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"11,685.22",0.3,0.6,"18,691",71
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"11,673.55",0.3,0.2,"5,789",72
1,Canada,L01XX,Other antineoplastic agents,65+,F,"11,352.06",0.2,0.2,"5,701",73
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,F,"11,262.45",0.2,4.6,"149,314",74
1,Canada,H02AB,Glucocorticoids,65+,F,"11,025.36",0.2,11.3,"369,689",75
1,Canada,S01XA,Other ophthalmologicals,65+,F,"9,791.86",0.2,1.6,"53,621",76
1,Canada,L04AD,Calcineurin inhibitors,65+,F,"9,084.37",0.2,0.1,"3,159",77
1,Canada,L01BA,Folic acid analogues,65+,F,"9,066.31",0.2,1.5,"49,281",78
1,Canada,A02BA,H2-receptor antagonists,65+,F,"9,056.01",0.2,4.3,"141,499",79
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,F,"8,830.86",0.2,10,"327,477",80
1,Canada,A06AA,"Softeners, emollients",65+,F,"8,526.80",0.2,3.8,"125,118",81
1,Canada,A06AB,Contact laxatives,65+,F,"8,520.69",0.2,5.2,"169,205",82
1,Canada,B01AA,Vitamin K antagonists,65+,F,"8,478.93",0.2,2.3,"74,620",83
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"7,983.22",0.2,4.1,"132,073",84
1,Canada,A06AD,Osmotically acting laxatives,65+,F,"7,764.53",0.2,4.3,"140,045",85
1,Canada,N03AE,Benzodiazepine derivatives,65+,F,"7,128.69",0.2,3,"99,100",86
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,F,"7,107.83",0.2,2.4,"79,281",87
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,F,"7,072.62",0.2,1.3,"43,242",88
1,Canada,N02AB,Phenylpiperidine derivatives,65+,F,"7,000.14",0.2,0.4,"12,468",89
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"6,989.87",0.2,0.7,"22,882",90
1,Canada,A07AA,Antibiotics,65+,F,"6,663.82",0.1,1.5,"49,300",91
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,"6,652.70",0.1,3.5,"113,119",92
1,Canada,N04BC,Dopamine agonists,65+,F,"6,470.20",0.1,1,"31,586",93
1,Canada,C03DA,Aldosterone antagonists,65+,F,"6,449.28",0.1,2.4,"78,588",94
1,Canada,A03FA,Propulsives,65+,F,"6,366.14",0.1,3,"97,881",95
1,Canada,M01AH,Coxibs,65+,F,"6,315.83",0.1,4.1,"132,907",96
1,Canada,A04AD,Other antiemetics,65+,F,"6,286.58",0.1,0.5,"14,787",97
1,Canada,C07AA,"Beta-blocking agents, non-selective",65+,F,"6,245.83",0.1,1.7,"55,233",98
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,"6,181.11",0.1,0.4,"12,427",99
1,Canada,A12BA,Potassium,65+,F,"6,172.66",0.1,2.2,"70,984",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"834,449.24",13.4,0.5,"43,861",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,Total,"530,170.92",8.5,0.1,"10,360",2
1,Canada,N05AX,Other antipsychotics,<65,Total,"284,483.93",4.6,2.5,"201,991",3
1,Canada,L04AA,Selective immunosuppressants,<65,Total,"273,771.86",4.4,0.4,"29,886",4
1,Canada,N07BC,Drugs used in opioid dependence,<65,Total,"189,180.81",3,1.2,"100,396",5
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"180,928.35",2.9,0.3,"24,086",6
1,Canada,N06BA,Centrally acting sympathomimetics,<65,Total,"146,393.97",2.3,3.9,"315,021",7
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"140,353.08",2.3,4.4,"350,827",8
1,Canada,L01XE,Protein kinase inhibitors,<65,Total,"128,428.26",2.1,0,"3,643",9
1,Canada,L04AC,Interleukin inhibitors,<65,Total,"120,632.97",1.9,0.1,"8,326",10
1,Canada,L04AX,Other immunosuppressants,<65,Total,"112,433.13",1.8,0.3,"20,713",11
1,Canada,N03AX,Other antiepileptics,<65,Total,"106,213.93",1.7,5.1,"414,615",12
1,Canada,N06AX,Other antidepressants,<65,Total,"105,319.82",1.7,8.4,"680,801",13
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"93,617.16",1.5,11.2,"898,721",14
1,Canada,N02AA,Natural opium alkaloids,<65,Total,"92,929.06",1.5,3.9,"313,445",15
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"81,566.80",1.3,2.4,"191,507",16
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"77,378.83",1.2,1.3,"108,129",17
1,Canada,A02BC,Proton pump inhibitors,<65,Total,"70,623.90",1.1,10.8,"869,642",18
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"57,971.81",0.9,1.1,"91,294",19
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,Total,"56,554.14",0.9,9.5,"767,646",20
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"55,249.64",0.9,0.9,"73,069",21
1,Canada,R03BA,Glucocorticoids,<65,Total,"54,350.66",0.9,6.4,"516,421",22
1,Canada,S01LA,Antineovascularization agents,<65,Total,"45,470.10",0.7,0.1,"5,433",23
1,Canada,A16AB,Enzymes,<65,Total,"43,684.25",0.7,0,88,24
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"43,111.88",0.7,0.7,"60,034",25
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"41,542.53",0.7,1.3,"102,310",26
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"40,837.19",0.7,0,"2,864",27
1,Canada,L04AD,Calcineurin inhibitors,<65,Total,"39,142.68",0.6,0.1,"11,958",28
1,Canada,L03AA,Colony-stimulating factors,<65,Total,"36,140.81",0.6,0.1,"7,399",29
1,Canada,L03AB,Interferons,<65,Total,"33,706.82",0.5,0,"2,175",30
1,Canada,J05AX,Other antivirals,<65,Total,"31,016.30",0.5,0.1,"6,277",31
1,Canada,C09AA,"ACE inhibitors, plain",<65,Total,"30,412.16",0.5,5.6,"452,485",32
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"29,318.52",0.5,0.2,"13,483",33
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"29,297.73",0.5,12.4,"997,354",34
1,Canada,L03AX,Other immunostimulants,<65,Total,"29,228.10",0.5,0,"2,818",35
1,Canada,R03BB,Anticholinergics,<65,Total,"28,759.07",0.5,1.3,"105,289",36
1,Canada,N05BA,Benzodiazepine derivatives,<65,Total,"28,554.02",0.5,5.6,"453,841",37
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"28,155.25",0.5,7.3,"591,558",38
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"27,625.51",0.4,6.2,"500,993",39
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"26,806.51",0.4,0.2,"13,496",40
1,Canada,N07BA,Drugs used in nicotine dependence,<65,Total,"26,640.86",0.4,2.2,"181,016",41
1,Canada,N03AG,Fatty acid derivatives,<65,Total,"25,873.04",0.4,0.9,"72,998",42
1,Canada,C08CA,Dihydropyridine derivatives,<65,Total,"24,959.35",0.4,4,"325,244",43
1,Canada,B01AF,Direct factor Xa inhibitors,<65,Total,"24,812.79",0.4,0.6,"45,673",44
1,Canada,H03AA,Thyroid hormones,<65,Total,"24,036.94",0.4,5.6,"453,793",45
1,Canada,B01AB,Heparin group,<65,Total,"23,935.84",0.4,0.3,"20,436",46
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"23,493.91",0.4,1,"77,335",47
1,Canada,R07AX,Other respiratory system products,<65,Total,"22,829.35",0.4,0,106,48
1,Canada,L01XC,Monoclonal antibodies,<65,Total,"22,738.81",0.4,0,"2,082",49
1,Canada,N03AE,Benzodiazepine derivatives,<65,Total,"21,870.47",0.4,2.2,"180,023",50
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"21,082.61",0.3,2.6,"211,024",51
1,Canada,A10BA,Biguanides,<65,Total,"20,671.97",0.3,4.6,"367,634",52
1,Canada,J05AE,Protease inhibitors,<65,Total,"20,247.40",0.3,0,"3,092",53
1,Canada,N05AE,Indole derivatives,<65,Total,"20,197.97",0.3,0.2,"16,612",54
1,Canada,H01AC,Somatropin and somatropin agonists,<65,Total,"20,046.76",0.3,0,"2,069",55
1,Canada,H01CB,Somatostatin and analogues,<65,Total,"19,799.48",0.3,0,"1,400",56
1,Canada,J01CA,Penicillins with extended spectrum,<65,Total,"19,635.22",0.3,17.8,"1,437,333",57
1,Canada,M01AE,Propionic acid derivatives,<65,Total,"19,380.80",0.3,10.9,"876,727",58
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,Total,"19,310.99",0.3,1.8,"144,836",59
1,Canada,A04AD,Other antiemetics,<65,Total,"18,663.42",0.3,0.4,"28,874",60
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,Total,"18,504.79",0.3,0.5,"41,725",61
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"17,677.01",0.3,0,119,62
1,Canada,C07AB,"Beta-blocking agents, selective",<65,Total,"17,552.17",0.3,3.3,"262,929",63
1,Canada,G02BA,Intrauterine contraceptives,<65,Total,"17,148.10",0.3,1,"82,804",64
1,Canada,R01AD,Corticosteroids,<65,Total,"16,799.33",0.3,5.9,"476,879",65
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"16,772.75",0.3,2.5,"204,259",66
1,Canada,V06C,Infant formulas,<65,Total,"16,671.02",0.3,0.2,"12,368",67
1,Canada,A11CC,Vitamin D and analogues,<65,Total,"16,461.31",0.3,3.1,"253,120",68
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"15,912.23",0.3,0.1,"7,158",69
1,Canada,B03XA,Other antianemic preparations,<65,Total,"15,494.04",0.2,0,"3,827",70
1,Canada,N03AF,Carboxamide derivatives,<65,Total,"15,093.87",0.2,0.5,"38,286",71
1,Canada,M03BX,Other centrally acting agents,<65,Total,"15,059.53",0.2,4,"318,557",72
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"14,617.62",0.2,0,731,73
1,Canada,V03AC,Iron-chelating agents,<65,Total,"14,361.43",0.2,0,619,74
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"14,334.02",0.2,0.7,"58,570",75
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"13,542.96",0.2,0.2,"14,300",76
1,Canada,C02AC,Imidazoline receptor agonists,<65,Total,"13,337.81",0.2,0.8,"62,503",77
1,Canada,A09AA,Enzyme preparations,<65,Total,"12,924.47",0.2,0.2,"13,283",78
1,Canada,N02BE,Anilides,<65,Total,"12,511.01",0.2,5,"406,606",79
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,Total,"11,966.83",0.2,7.3,"592,142",80
1,Canada,J01FA,Macrolides,<65,Total,"11,877.97",0.2,9,"724,115",81
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"11,865.41",0.2,3.3,"267,337",82
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,Total,"11,695.89",0.2,0,437,83
1,Canada,A10BB,Sulfonylureas,<65,Total,"11,528.57",0.2,1.7,"136,556",84
1,Canada,J01DB,First-generation cephalosporins,<65,Total,"11,518.89",0.2,6.1,"491,063",85
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"11,047.52",0.2,1.1,"89,830",86
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"10,786.13",0.2,1.6,"132,183",87
1,Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,"10,388.05",0.2,1.6,"131,030",88
1,Canada,A02BA,H2-receptor antagonists,<65,Total,"9,929.04",0.2,2.3,"189,206",89
1,Canada,J02AC,Triazole derivatives,<65,Total,"9,825.42",0.2,1.3,"104,976",90
1,Canada,D06AX,Other antibiotics for topical use,<65,Total,"9,797.92",0.2,4.2,"335,643",91
1,Canada,H02AB,Glucocorticoids,<65,Total,"9,775.58",0.2,6.4,"512,469",92
1,Canada,V03AB,Antidotes,<65,Total,"9,254.31",0.1,0.6,"46,871",93
1,Canada,R05CB,Mucolytics,<65,Total,"8,855.62",0.1,0,"1,467",94
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"8,679.05",0.1,0.3,"24,304",95
1,Canada,B03AA,"Iron bivalent, oral preparations",<65,Total,"8,601.77",0.1,2.1,"165,353",96
1,Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"8,601.72",0.1,0.3,"27,379",97
1,Canada,B02AB,Proteinase inhibitors,<65,Total,"8,580.62",0.1,0,85,98
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"8,521.71",0.1,0.1,"8,376",99
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"8,349.59",0.1,0.1,"4,796",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"434,421.69",13.7,0.6,"21,272",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,M,"347,858.84",10.9,0.2,"6,766",2
1,Canada,N05AX,Other antipsychotics,<65,M,"189,778.49",6,3.1,"112,291",3
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"135,172.49",4.3,0.5,"17,998",4
1,Canada,N07BC,Drugs used in opioid dependence,<65,M,"109,031.98",3.4,1.6,"58,490",5
1,Canada,L04AA,Selective immunosuppressants,<65,M,"92,823.59",2.9,0.3,"11,221",6
1,Canada,N06BA,Centrally acting sympathomimetics,<65,M,"91,674.45",2.9,5.4,"192,443",7
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"88,515.54",2.8,4.9,"173,724",8
1,Canada,L01XE,Protein kinase inhibitors,<65,M,"59,969.44",1.9,0,"1,664",9
1,Canada,L04AC,Interleukin inhibitors,<65,M,"58,856.30",1.9,0.1,"3,825",10
1,Canada,L04AX,Other immunosuppressants,<65,M,"52,009.76",1.6,0.2,"8,052",11
1,Canada,N02AA,Natural opium alkaloids,<65,M,"49,120.74",1.5,3.9,"140,893",12
1,Canada,N03AX,Other antiepileptics,<65,M,"47,947.55",1.5,4.8,"171,117",13
1,Canada,N06AX,Other antidepressants,<65,M,"41,867.88",1.3,7.2,"255,818",14
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"38,919.70",1.2,1.5,"55,196",15
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,M,"37,741.96",1.2,8.8,"314,809",16
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"33,742.73",1.1,2.2,"78,796",17
1,Canada,A02BC,Proton pump inhibitors,<65,M,"30,845.22",1,10.4,"372,017",18
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,M,"30,611.84",1,12.4,"442,503",19
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"30,535.46",1,1.4,"49,567",20
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"29,603.26",0.9,1.1,"40,100",21
1,Canada,A16AB,Enzymes,<65,M,"28,875.75",0.9,0,58,22
1,Canada,S01LA,Antineovascularization agents,<65,M,"25,226.19",0.8,0.1,"3,060",23
1,Canada,R03BA,Glucocorticoids,<65,M,"24,222.60",0.8,6.7,"239,965",24
1,Canada,L04AD,Calcineurin inhibitors,<65,M,"23,335.11",0.7,0.2,"7,044",25
1,Canada,J05AX,Other antivirals,<65,M,"22,111.97",0.7,0.1,"4,041",26
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"21,657.12",0.7,1.5,"52,192",27
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"21,051.30",0.7,0.8,"30,148",28
1,Canada,C09AA,"ACE inhibitors, plain",<65,M,"17,147.73",0.5,7.4,"264,191",29
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"15,634.66",0.5,0.2,"7,707",30
1,Canada,N03AG,Fatty acid derivatives,<65,M,"15,482.47",0.5,1.1,"40,973",31
1,Canada,B01AF,Direct factor Xa inhibitors,<65,M,"14,762.62",0.5,0.7,"25,862",32
1,Canada,J05AE,Protease inhibitors,<65,M,"14,665.04",0.5,0.1,"2,164",33
1,Canada,N07BA,Drugs used in nicotine dependence,<65,M,"13,930.87",0.4,2.6,"93,754",34
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"13,853.39",0.4,0,899,35
1,Canada,R03BB,Anticholinergics,<65,M,"13,479.96",0.4,1.3,"47,843",36
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"13,394.14",0.4,12.7,"452,825",37
1,Canada,C08CA,Dihydropyridine derivatives,<65,M,"13,329.89",0.4,5,"179,198",38
1,Canada,N05BA,Benzodiazepine derivatives,<65,M,"13,088.47",0.4,4.6,"166,050",39
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"12,845.24",0.4,7.6,"272,223",40
1,Canada,H01AC,Somatropin and somatropin agonists,<65,M,"12,574.58",0.4,0,"1,218",41
1,Canada,R07AX,Other respiratory system products,<65,M,"12,506.04",0.4,0,55,42
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"11,433.18",0.4,0.1,"4,426",43
1,Canada,L03AA,Colony-stimulating factors,<65,M,"10,828.95",0.3,0.1,"2,248",44
1,Canada,N03AE,Benzodiazepine derivatives,<65,M,"10,339.40",0.3,2,"70,844",45
1,Canada,A10BA,Biguanides,<65,M,"10,312.53",0.3,5.3,"189,398",46
1,Canada,C07AB,"Beta-blocking agents, selective",<65,M,"10,303.94",0.3,4.3,"152,433",47
1,Canada,B01AB,Heparin group,<65,M,"10,072.36",0.3,0.2,"8,327",48
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"10,038.58",0.3,1.3,"47,879",49
1,Canada,H01CB,Somatostatin and analogues,<65,M,"9,852.61",0.3,0,617,50
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,M,"9,740.65",0.3,1.9,"67,608",51
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,"9,431.02",0.3,0,59,52
1,Canada,J01CA,Penicillins with extended spectrum,<65,M,"9,095.74",0.3,18.3,"653,633",53
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,M,"8,735.95",0.3,0.5,"18,169",54
1,Canada,L03AB,Interferons,<65,M,"8,630.88",0.3,0,562,55
1,Canada,C02AC,Imidazoline receptor agonists,<65,M,"8,527.45",0.3,0.9,"31,293",56
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"8,469.85",0.3,1.9,"69,061",57
1,Canada,M01AE,Propionic acid derivatives,<65,M,"8,433.28",0.3,10.4,"372,185",58
1,Canada,N05AE,Indole derivatives,<65,M,"8,287.20",0.3,0.2,"6,448",59
1,Canada,N03AF,Carboxamide derivatives,<65,M,"8,286.64",0.3,0.5,"19,519",60
1,Canada,A04AD,Other antiemetics,<65,M,"8,126.96",0.3,0.3,"11,421",61
1,Canada,V06C,Infant formulas,<65,M,"7,974.58",0.3,0.1,"5,297",62
1,Canada,B03XA,Other antianemic preparations,<65,M,"7,907.85",0.2,0.1,"2,006",63
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"7,643.69",0.2,2.7,"97,196",64
1,Canada,L03AX,Other immunostimulants,<65,M,"7,516.78",0.2,0,728,65
1,Canada,A09AA,Enzyme preparations,<65,M,"7,463.58",0.2,0.2,"5,896",66
1,Canada,R01AD,Corticosteroids,<65,M,"6,972.03",0.2,5.4,"192,766",67
1,Canada,V03AC,Iron-chelating agents,<65,M,"6,791.22",0.2,0,302,68
1,Canada,M03BX,Other centrally acting agents,<65,M,"6,622.59",0.2,3.7,"132,749",69
1,Canada,G03BA,3-oxoandrosten (4) derivatives,<65,M,"6,568.69",0.2,0.6,"22,488",70
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"6,375.59",0.2,0.1,"3,655",71
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"6,342.08",0.2,0.2,"6,380",72
1,Canada,H03AA,Thyroid hormones,<65,M,"6,268.63",0.2,2.7,"97,067",73
1,Canada,A10BB,Sulfonylureas,<65,M,"6,032.54",0.2,2.1,"75,203",74
1,Canada,A11CC,Vitamin D and analogues,<65,M,"6,018.15",0.2,2,"70,782",75
1,Canada,L01XC,Monoclonal antibodies,<65,M,"5,943.23",0.2,0,582,76
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"5,866.51",0.2,0.1,"2,031",77
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"5,719.37",0.2,2.3,"81,744",78
1,Canada,J01DB,First-generation cephalosporins,<65,M,"5,604.65",0.2,6.5,"230,742",79
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"5,482.42",0.2,0.1,"5,304",80
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,M,"5,422.98",0.2,7.1,"255,097",81
1,Canada,N02BE,Anilides,<65,M,"5,396.05",0.2,4.9,"174,031",82
1,Canada,B02AB,Proteinase inhibitors,<65,M,"5,287.59",0.2,0,48,83
1,Canada,J01FA,Macrolides,<65,M,"5,254.91",0.2,8.7,"312,003",84
1,Canada,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"4,914.69",0.2,0,"1,202",85
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"4,816.33",0.2,0.1,"4,905",86
1,Canada,J02AC,Triazole derivatives,<65,M,"4,623.70",0.1,0.3,"11,238",87
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"4,585.16",0.1,0.3,"12,094",88
1,Canada,D06AX,Other antibiotics for topical use,<65,M,"4,575.81",0.1,4.3,"154,993",89
1,Canada,A02BA,H2-receptor antagonists,<65,M,"4,499.00",0.1,2,"72,500",90
1,Canada,R05CB,Mucolytics,<65,M,"4,483.04",0.1,0,737,91
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"4,462.23",0.1,2.3,"82,619",92
1,Canada,C09BA,ACE inhibitors and diuretics,<65,M,"4,454.08",0.1,1.3,"46,666",93
1,Canada,V03AB,Antidotes,<65,M,"4,433.40",0.1,0.6,"21,548",94
1,Canada,N05AF,Thioxanthene derivatives,<65,M,"4,408.48",0.1,0.2,"6,606",95
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,M,"4,366.03",0.1,0,168,96
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"4,341.50",0.1,0,224,97
1,Canada,J01GB,Other aminoglycosides,<65,M,"4,309.83",0.1,0,974,98
1,Canada,C10AX,Other lipid-modifying agents,<65,M,"4,243.69",0.1,0.7,"23,339",99
1,Canada,N02BA,Salicylic acid and derivatives,<65,M,"4,238.78",0.1,1.5,"51,935",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"400,013.72",13.1,0.5,"22,588",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,F,"182,157.69",6,0.1,"3,591",2
1,Canada,L04AA,Selective immunosuppressants,<65,F,"180,932.85",5.9,0.4,"18,658",3
1,Canada,N05AX,Other antipsychotics,<65,F,"94,511.62",3.1,2,"89,545",4
1,Canada,N07BC,Drugs used in opioid dependence,<65,F,"80,092.39",2.6,0.9,"41,840",5
1,Canada,L01XE,Protein kinase inhibitors,<65,F,"68,453.37",2.2,0,"1,978",6
1,Canada,N06AX,Other antidepressants,<65,F,"63,391.02",2.1,9.5,"424,478",7
1,Canada,L04AC,Interleukin inhibitors,<65,F,"61,776.67",2,0.1,"4,501",8
1,Canada,L04AX,Other immunosuppressants,<65,F,"60,422.60",2,0.3,"12,657",9
1,Canada,N03AX,Other antiepileptics,<65,F,"58,199.66",1.9,5.4,"243,179",10
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,F,"55,823.09",1.8,13.1,"583,414",11
1,Canada,N06BA,Centrally acting sympathomimetics,<65,F,"54,693.73",1.8,2.7,"122,516",12
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"51,788.91",1.7,4,"176,856",13
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"47,763.01",1.6,2.5,"112,593",14
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"44,568.32",1.5,0.1,"5,956",15
1,Canada,N02AA,Natural opium alkaloids,<65,F,"43,791.51",1.4,3.9,"172,384",16
1,Canada,A02BC,Proton pump inhibitors,<65,F,"39,701.62",1.3,11.1,"496,463",17
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"38,395.84",1.3,1.2,"52,822",18
1,Canada,R03BA,Glucocorticoids,<65,F,"30,058.97",1,6.2,"275,555",19
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"27,606.37",0.9,11.2,"500,734",20
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"27,336.03",0.9,0.9,"41,581",21
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"26,983.81",0.9,0,"1,965",22
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,F,"25,885.61",0.8,7.3,"324,440",23
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"25,502.31",0.8,0.7,"32,788",24
1,Canada,L03AA,Colony-stimulating factors,<65,F,"25,291.42",0.8,0.1,"5,146",25
1,Canada,L03AB,Interferons,<65,F,"25,075.95",0.8,0,"1,613",26
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"21,997.83",0.7,0.7,"29,802",27
1,Canada,L03AX,Other immunostimulants,<65,F,"21,561.57",0.7,0,"2,089",28
1,Canada,S01LA,Antineovascularization agents,<65,F,"20,237.89",0.7,0.1,"2,372",29
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"19,853.66",0.7,1.1,"50,050",30
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"17,871.65",0.6,0.2,"9,053",31
1,Canada,H03AA,Thyroid hormones,<65,F,"17,755.65",0.6,8,"356,488",32
1,Canada,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,33
1,Canada,L01XC,Monoclonal antibodies,<65,F,"16,795.58",0.6,0,"1,500",34
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"15,850.83",0.5,12.1,"542,470",35
1,Canada,L04AD,Calcineurin inhibitors,<65,F,"15,806.18",0.5,0.1,"4,911",36
1,Canada,N05BA,Benzodiazepine derivatives,<65,F,"15,453.90",0.5,6.4,"287,583",37
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"15,298.01",0.5,7.1,"319,002",38
1,Canada,R03BB,Anticholinergics,<65,F,"15,261.20",0.5,1.3,"57,368",39
1,Canada,A16AB,Enzymes,<65,F,"14,808.50",0.5,0,30,40
1,Canada,B01AB,Heparin group,<65,F,"13,850.80",0.5,0.3,"12,075",41
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"13,441.61",0.4,0.7,"29,397",42
1,Canada,C09AA,"ACE inhibitors, plain",<65,F,"13,234.55",0.4,4.2,"187,903",43
1,Canada,N07BA,Drugs used in nicotine dependence,<65,F,"12,706.66",0.4,2,"87,241",44
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"12,600.78",0.4,3.2,"141,767",45
1,Canada,N05AE,Indole derivatives,<65,F,"11,901.48",0.4,0.2,"10,156",46
1,Canada,C08CA,Dihydropyridine derivatives,<65,F,"11,594.73",0.4,3.3,"145,661",47
1,Canada,N03AE,Benzodiazepine derivatives,<65,F,"11,524.73",0.4,2.4,"109,085",48
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"11,122.30",0.4,0.1,"5,754",49
1,Canada,M01AE,Propionic acid derivatives,<65,F,"10,897.93",0.4,11.2,"502,091",50
1,Canada,A04AD,Other antiemetics,<65,F,"10,528.94",0.3,0.4,"17,443",51
1,Canada,J01CA,Penicillins with extended spectrum,<65,F,"10,435.63",0.3,17.5,"779,345",52
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,F,"10,422.96",0.3,0.9,"42,352",53
1,Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,54
1,Canada,N03AG,Fatty acid derivatives,<65,F,"10,376.51",0.3,0.7,"31,964",55
1,Canada,A11CC,Vitamin D and analogues,<65,F,"10,349.87",0.3,4,"178,807",56
1,Canada,A10BA,Biguanides,<65,F,"10,342.88",0.3,4,"177,913",57
1,Canada,R07AX,Other respiratory system products,<65,F,"10,323.31",0.3,0,51,58
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"10,275.15",0.3,0,506,59
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"10,145.37",0.3,2.9,"128,723",60
1,Canada,B01AF,Direct factor Xa inhibitors,<65,F,"10,037.06",0.3,0.4,"19,790",61
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"10,032.53",0.3,0.1,"5,121",62
1,Canada,H01CB,Somatostatin and analogues,<65,F,"9,941.23",0.3,0,782,63
1,Canada,R01AD,Corticosteroids,<65,F,"9,807.82",0.3,6.4,"283,696",64
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,F,"9,763.11",0.3,0.5,"23,547",65
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,F,"9,557.93",0.3,1.7,"77,156",66
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"9,103.75",0.3,2.4,"106,842",67
1,Canada,J05AX,Other antivirals,<65,F,"8,783.57",0.3,0,"2,216",68
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,F,"8,674.09",0.3,1.7,"73,847",69
1,Canada,M03BX,Other centrally acting agents,<65,F,"8,428.98",0.3,4.2,"185,612",70
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"8,245.99",0.3,0,60,71
1,Canada,V06C,Infant formulas,<65,F,"7,973.05",0.3,0.1,"6,267",72
1,Canada,B03XA,Other antianemic preparations,<65,F,"7,585.89",0.2,0,"1,819",73
1,Canada,V03AC,Iron-chelating agents,<65,F,"7,570.21",0.2,0,317,74
1,Canada,H01AC,Somatropin and somatropin agonists,<65,F,"7,472.17",0.2,0,851,75
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"7,386.77",0.2,4.1,"184,617",76
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,F,"7,329.86",0.2,0,269,77
1,Canada,C07AB,"Beta-blocking agents, selective",<65,F,"7,233.97",0.2,2.5,"110,245",78
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"7,195.02",0.2,0.2,"7,910",79
1,Canada,N02BE,Anilides,<65,F,"6,981.75",0.2,5.1,"226,988",80
1,Canada,N03AF,Carboxamide derivatives,<65,F,"6,801.70",0.2,0.4,"18,742",81
1,Canada,G03AC,Progestogens,<65,F,"6,605.73",0.2,2.4,"106,825",82
1,Canada,J01FA,Macrolides,<65,F,"6,592.38",0.2,9.2,"410,920",83
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,F,"6,511.13",0.2,7.5,"336,148",84
1,Canada,B03AA,"Iron bivalent, oral preparations",<65,F,"5,937.24",0.2,2.9,"127,656",85
1,Canada,J01DB,First-generation cephalosporins,<65,F,"5,843.04",0.2,5.8,"259,310",86
1,Canada,H02AB,Glucocorticoids,<65,F,"5,535.68",0.2,6.4,"287,971",87
1,Canada,J05AE,Protease inhibitors,<65,F,"5,531.75",0.2,0,917,88
1,Canada,A04AA,Serotonin (5HT3) antagonists,<65,F,"5,520.28",0.2,0.4,"19,459",89
1,Canada,A10BB,Sulfonylureas,<65,F,"5,486.60",0.2,1.4,"61,219",90
1,Canada,A09AA,Enzyme preparations,<65,F,"5,458.14",0.2,0.2,"7,384",91
1,Canada,A02BA,H2-receptor antagonists,<65,F,"5,415.94",0.2,2.6,"116,355",92
1,Canada,L01XX,Other antineoplastic agents,<65,F,"5,413.99",0.2,0,"1,293",93
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"5,376.98",0.2,0.2,"8,350",94
1,Canada,J02AC,Triazole derivatives,<65,F,"5,196.04",0.2,2.1,"93,628",95
1,Canada,D06AX,Other antibiotics for topical use,<65,F,"5,164.56",0.2,4,"179,065",96
1,Canada,M05BA,Bisphosphonates,<65,F,"5,064.55",0.2,0.7,"31,506",97
1,Canada,V03AB,Antidotes,<65,F,"4,813.82",0.2,0.6,"25,307",98
1,Canada,C02AC,Imidazoline receptor agonists,<65,F,"4,808.54",0.2,0.7,"31,184",99
1,Canada,N02AB,Phenylpiperidine derivatives,<65,F,"4,683.14",0.2,0.1,"5,998",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"11,623.81",7.6,0.7,749,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,Total,"8,423.99",5.5,0.5,499,2
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,Total,"6,784.32",4.5,2.2,"2,324",3
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,Total,"6,495.01",4.3,0.2,200,4
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,Total,"5,264.24",3.5,0.1,93,5
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,Total,"3,896.61",2.6,37.8,"39,417",6
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,Total,"3,400.03",2.2,37.3,"38,938",7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"3,358.72",2.2,4.9,"5,065",8
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,Total,"3,226.50",2.1,14.4,"15,029",9
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,095.49",2,17.6,"18,348",10
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,Total,"2,999.32",2,0.5,478,11
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,Total,"2,883.98",1.9,0.2,243,12
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"2,860.00",1.9,4.3,"4,445",13
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,Total,"2,859.42",1.9,9.4,"9,833",14
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"2,622.90",1.7,2.5,"2,643",15
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,Total,"2,515.28",1.7,22.4,"23,325",16
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,Total,"2,464.26",1.6,12.8,"13,371",17
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,Total,"2,079.85",1.4,22.3,"23,237",18
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,Total,"1,998.48",1.3,2.5,"2,606",19
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"1,986.97",1.3,5,"5,265",20
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,Total,"1,907.89",1.3,0.2,243,21
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,Total,"1,797.30",1.2,4.8,"5,045",22
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,Total,"1,589.89",1,3.1,"3,198",23
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,Total,"1,554.33",1,6.6,"6,844",24
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,Total,"1,484.77",1,15.9,"16,612",25
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,Total,"1,398.85",0.9,10.5,"10,941",26
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,286.16",0.8,21.1,"22,010",27
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,211.98",0.8,2.8,"2,892",28
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,103.36",0.7,8.6,"8,917",29
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,103.02",0.7,9.7,"10,093",30
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,Total,"1,098.87",0.7,0.4,450,31
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,030.21",0.7,7.7,"8,009",32
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,Total,"1,029.71",0.7,11.8,"12,287",33
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,011.26",0.7,1.3,"1,384",34
2,Newfoundland and Labrador,A10BA,Biguanides,Total,Total,"1,002.22",0.7,14.5,"15,136",35
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,957.06,0.6,0.3,346,36
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,Total,948.12,0.6,1.2,"1,260",37
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,Total,896.57,0.6,5.5,"5,773",38
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,Total,890.68,0.6,2.8,"2,879",39
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,Total,849.09,0.6,8.1,"8,476",40
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,Total,847.86,0.6,0.2,236,41
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,Total,841.93,0.6,5.6,"5,818",42
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,Total,838.56,0.6,10.2,"10,644",43
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,Total,809.16,0.5,0,40,44
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,787.47,0.5,0.1,102,45
2,Newfoundland and Labrador,L03AB,Interferons,Total,Total,786.02,0.5,0,40,46
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,763.2,0.5,6.4,"6,679",47
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,Total,689.11,0.5,13.4,"13,921",48
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,Total,675.67,0.4,0.8,809,49
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,Total,664.57,0.4,1.9,"2,001",50
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,652.06,0.4,4.6,"4,802",51
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,Total,632.77,0.4,9.1,"9,446",52
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,Total,626.29,0.4,1.4,"1,507",53
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,Total,603.33,0.4,3.2,"3,358",54
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,Total,597.98,0.4,0.1,111,55
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,Total,597.1,0.4,2.3,"2,447",56
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,Total,556.66,0.4,14.6,"15,237",57
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,Total,547.21,0.4,1.9,"2,020",58
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,Total,525.94,0.3,4,"4,184",59
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,Total,514.58,0.3,4.1,"4,228",60
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,Total,485.8,0.3,11.1,"11,560",61
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,Total,478.94,0.3,0,38,62
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,476.69,0.3,3.2,"3,353",63
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,Total,467.19,0.3,2.8,"2,957",64
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,Total,444.08,0.3,7.4,"7,735",65
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,Total,421.8,0.3,7.6,"7,893",66
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,Total,416.43,0.3,0,37,67
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,Total,405.16,0.3,17.9,"18,689",68
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,Total,402.04,0.3,4.9,"5,095",69
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,Total,401.61,0.3,9.1,"9,440",70
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,Total,384.78,0.3,3.3,"3,391",71
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,Total,378.15,0.2,1.2,"1,233",72
2,Newfoundland and Labrador,A16AB,Enzymes,Total,Total,**,**,**,*,73
2,Newfoundland and Labrador,J01FA,Macrolides,Total,Total,364.55,0.2,11.2,"11,651",74
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,358.71,0.2,0,16,75
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,**,**,**,**,76
2,Newfoundland and Labrador,A12BA,Potassium,Total,Total,346.8,0.2,3.7,"3,830",77
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,Total,342.24,0.2,6.7,"6,985",78
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,Total,**,**,**,**,79
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,Total,316.61,0.2,0.1,156,80
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,Total,311.42,0.2,0.8,794,81
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,310.84,0.2,2.9,"3,039",82
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,305.91,0.2,8.4,"8,795",83
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,Total,281.01,0.2,1.5,"1,603",84
2,Newfoundland and Labrador,C10AB,Fibrates,Total,Total,268.79,0.2,1.9,"1,977",85
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",Total,Total,266.02,0.2,1.4,"1,446",86
2,Newfoundland and Labrador,A07AA,Antibiotics,Total,Total,264.1,0.2,1.5,"1,541",87
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,Total,Total,262.69,0.2,0.6,656,88
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,Total,258.01,0.2,2.7,"2,836",89
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,Total,249.74,0.2,8.6,"8,955",90
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,Total,249.56,0.2,4.1,"4,248",91
2,Newfoundland and Labrador,R05CB,Mucolytics,Total,Total,248.4,0.2,0,43,92
2,Newfoundland and Labrador,A03FA,Propulsives,Total,Total,245.2,0.2,3.7,"3,886",93
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,243.72,0.2,1.6,"1,689",94
2,Newfoundland and Labrador,A04AD,Other antiemetics,Total,Total,238.56,0.2,0.4,412,95
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,Total,238.47,0.2,0.7,680,96
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,Total,238.1,0.2,0.1,99,97
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,Total,Total,236.01,0.2,1.2,"1,223",98
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,235.97,0.2,2,"2,046",99
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,Total,Total,**,**,**,*,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"5,315.25",7.6,0.7,334,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,M,"4,426.54",6.3,0.5,209,2
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,M,"4,051.84",5.8,3.1,"1,398",3
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,M,"3,744.55",5.3,0.1,67,4
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,M,"3,060.85",4.4,0.2,95,5
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,M,"1,808.20",2.6,40.6,"18,148",6
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,512.27",2.2,5,"2,224",7
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,M,"1,419.53",2,14.6,"6,540",8
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,M,"1,357.36",1.9,34.6,"15,466",9
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,M,"1,351.54",1.9,3.2,"1,452",10
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,242.55",1.8,4.4,"1,956",11
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,241.70",1.8,5.5,"2,478",12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,M,"1,193.91",1.7,8.6,"3,863",13
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,M,"1,191.94",1.7,0.2,101,14
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"1,179.21",1.7,2.7,"1,195",15
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,M,"1,161.37",1.7,25,"11,198",16
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,M,"1,139.42",1.6,0.4,184,17
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,061.38",1.5,13.3,"5,966",18
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,M,"1,014.71",1.4,4.6,"2,045",19
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,M,926.18,1.3,24.1,"10,760",20
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,M,878.82,1.3,0.7,313,21
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,M,857.27,1.2,10.4,"4,635",22
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,M,847.86,1.2,0.5,236,23
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,M,802.62,1.1,4.9,"2,189",24
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,M,768.48,1.1,7.2,"3,232",25
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,M,679.44,1,13.4,"6,004",26
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,M,653.88,0.9,10,"4,494",27
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,608.96,0.9,0.2,77,28
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,M,572.31,0.8,0.1,63,29
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,559.67,0.8,20.1,"8,996",30
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,M,530.92,0.8,12.1,"5,418",31
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,529.82,0.8,8.9,"3,976",32
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,528.74,0.8,2.8,"1,250",33
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,M,521.86,0.7,0.5,217,34
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,M,478.94,0.7,0.1,38,35
2,Newfoundland and Labrador,A10BA,Biguanides,Total,M,455.2,0.6,15.5,"6,924",36
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,M,424.17,0.6,1.3,566,37
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,M,413.43,0.6,5.9,"2,625",38
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,391.25,0.6,1.2,546,39
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,386.08,0.6,8.2,"3,669",40
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,M,369.6,0.5,8.5,"3,793",41
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,M,366.71,0.5,4.9,"2,208",42
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,M,353,0.5,2.5,"1,131",43
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,M,352.44,0.5,1.7,777,44
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,346.8,0.5,6,"2,679",45
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,337.93,0.5,5.8,"2,590",46
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,M,323.01,0.5,0.8,367,47
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,M,322.16,0.5,8.7,"3,897",48
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,M,**,**,**,**,49
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,M,279.29,0.4,12.7,"5,667",50
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,M,273.46,0.4,1.8,801,51
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,M,273.15,0.4,0.1,44,52
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,M,268.08,0.4,5.1,"2,260",53
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,M,249.64,0.4,2.3,"1,019",54
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,M,246.65,0.4,4.8,"2,166",55
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,**,**,**,**,56
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,M,242.28,0.3,6.9,"3,086",57
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,M,239.97,0.3,8.6,"3,847",58
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,M,227.08,0.3,6.1,"2,719",59
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,M,224.46,0.3,13.7,"6,140",60
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,M,208.33,0.3,1.8,790,61
2,Newfoundland and Labrador,L03AB,Interferons,Total,M,205.12,0.3,0,11,62
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,M,202.03,0.3,6.7,"3,007",63
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,M,184.54,0.3,0.2,83,64
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,M,181.34,0.3,1.2,548,65
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,M,179.46,0.3,2.6,"1,174",66
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,M,168.9,0.2,0.9,408,67
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,167.09,0.2,0,5,68
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,M,163.9,0.2,16.1,"7,205",69
2,Newfoundland and Labrador,R07AX,Other respiratory system products,Total,M,**,**,**,*,70
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,M,**,**,**,**,71
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,M,161.23,0.2,9,"4,032",72
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,M,152.81,0.2,6.3,"2,812",73
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,M,151.5,0.2,7.3,"3,254",74
2,Newfoundland and Labrador,J01FA,Macrolides,Total,M,146.02,0.2,9.5,"4,246",75
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,M,144.29,0.2,6.2,"2,778",76
2,Newfoundland and Labrador,R05CB,Mucolytics,Total,M,132.78,0.2,0.1,25,77
2,Newfoundland and Labrador,J05AX,Other antivirals,Total,M,131.95,0.2,0,15,78
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,M,130.68,0.2,1.7,768,79
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,128.09,0.2,7.9,"3,552",80
2,Newfoundland and Labrador,J05AE,Protease inhibitors,Total,M,**,**,**,**,81
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,Total,M,121.36,0.2,1.5,673,82
2,Newfoundland and Labrador,C10AB,Fibrates,Total,M,119.03,0.2,2,875,83
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,117.67,0.2,0.6,248,84
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,M,116.39,0.2,3,"1,346",85
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,Total,M,109.63,0.2,0.3,155,86
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,109.5,0.2,2.4,"1,071",87
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,Total,M,105.31,0.2,8.1,"3,645",88
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,Total,M,103.71,0.1,0.1,26,89
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,103.45,0.1,0.6,279,90
2,Newfoundland and Labrador,A12BA,Potassium,Total,M,103.09,0.1,2.7,"1,194",91
2,Newfoundland and Labrador,A07AA,Antibiotics,Total,M,101.84,0.1,1.1,500,92
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,M,101.72,0.1,1.3,563,93
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,M,99.73,0.1,6.8,"3,063",94
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,M,98.88,0.1,2.7,"1,206",95
2,Newfoundland and Labrador,A04AD,Other antiemetics,Total,M,96.28,0.1,0.4,167,96
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,Total,M,90.04,0.1,4.3,"1,912",97
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",Total,M,89.92,0.1,2.3,"1,014",98
2,Newfoundland and Labrador,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,87.08,0.1,0.1,39,99
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,M,82.9,0.1,0,10,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"6,308.57",7.7,0.7,415,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,F,"3,997.45",4.9,0.5,290,2
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,F,"3,434.15",4.2,0.2,105,3
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,F,"2,732.47",3.3,1.6,926,4
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,087.21",2.5,35.7,"21,257",5
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,F,"2,042.05",2.5,39.4,"23,459",6
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,033.42",2.5,20.8,"12,379",7
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,F,"1,859.89",2.3,0.5,294,8
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,846.45",2.3,4.8,"2,841",9
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,F,"1,806.76",2.2,14.3,"8,487",10
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,F,"1,692.04",2.1,0.2,142,11
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,F,"1,664.27",2,10,"5,968",12
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"1,617.45",2,4.2,"2,489",13
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,F,"1,606.63",2,14.7,"8,733",14
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,F,"1,519.69",1.9,0,26,15
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"1,443.68",1.8,2.4,"1,448",16
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,F,"1,352.57",1.6,20.4,"12,119",17
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,F,"1,335.58",1.6,0.3,180,18
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,F,"1,152.92",1.4,20.9,"12,468",19
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,F,994.68,1.2,4.8,"2,856",20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,F,953.48,1.2,18.8,"11,189",21
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,F,802.3,1,16.1,"9,565",22
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,F,785.51,1,6.1,"3,609",23
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,745.11,0.9,4.7,"2,785",24
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,F,744.59,0.9,10.8,"6,442",25
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,726.43,0.9,21.9,"13,010",26
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,716.43,0.9,10.8,"6,418",27
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,683.27,0.8,9,"5,328",28
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,683.24,0.8,2.8,"1,642",29
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,F,646.93,0.8,1.9,"1,154",30
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,620.01,0.8,1.4,838,31
2,Newfoundland and Labrador,L03AB,Interferons,Total,F,580.9,0.7,0,29,32
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,F,577.01,0.7,0.4,233,33
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,F,575.18,0.7,1.9,"1,153",34
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,573.4,0.7,8.3,"4,940",35
2,Newfoundland and Labrador,A10BA,Biguanides,Total,F,546.57,0.7,13.8,"8,206",36
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,F,537.68,0.7,2.9,"1,748",37
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,F,522.37,0.6,1.2,692,38
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,F,516.4,0.6,11.3,"6,747",39
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,F,**,**,**,**,40
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,F,482.88,0.6,5.3,"3,146",41
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,F,479.41,0.6,7.9,"4,681",42
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,F,475.21,0.6,6.1,"3,609",43
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,F,472.59,0.6,4.4,"2,589",44
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,468.37,0.6,5.6,"3,321",45
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,F,409.79,0.5,13.9,"8,253",46
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,F,392.68,0.5,9.4,"5,597",47
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,F,391.11,0.5,2,"1,200",48
2,Newfoundland and Labrador,A16AB,Enzymes,Total,F,**,**,**,*,49
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,F,352.66,0.4,0.7,442,50
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,F,346.8,0.4,2.4,"1,425",51
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,F,338.61,0.4,2.1,"1,229",52
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,F,337.59,0.4,5,"3,001",53
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,F,333.52,0.4,0,27,54
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,F,332.13,0.4,15.3,"9,095",55
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,F,324.83,0.4,0.1,67,56
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,F,324.39,0.4,12.6,"7,522",57
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,314.1,0.4,3.7,"2,211",58
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,**,**,**,**,59
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,F,287.53,0.4,3,"1,781",60
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,F,279.26,0.3,3.4,"2,017",61
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,F,273.85,0.3,1.2,730,62
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,F,268.96,0.3,8.5,"5,079",63
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,266.02,0.3,2.4,"1,446",64
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,Total,F,**,**,**,**,65
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,F,250.07,0.3,10.4,"6,184",66
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,F,246.27,0.3,3.3,"1,966",67
2,Newfoundland and Labrador,A12BA,Potassium,Total,F,243.71,0.3,4.4,"2,636",68
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,F,242.01,0.3,7.9,"4,726",69
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,F,241.24,0.3,19.3,"11,482",70
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,**,**,**,**,71
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,Total,F,**,**,**,*,72
2,Newfoundland and Labrador,J01FA,Macrolides,Total,F,218.49,0.3,12.4,"7,402",73
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,201.19,0.2,3.3,"1,966",74
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,F,197.91,0.2,7.1,"4,205",75
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,F,196.81,0.2,1.2,685,76
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,191.63,0.2,0,11,77
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,F,179.23,0.2,1.7,"1,039",78
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,178.52,0.2,0,25,79
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,F,178.27,0.2,0.1,60,80
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,177.68,0.2,8.8,"5,240",81
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,F,174.06,0.2,4.9,"2,931",82
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,F,**,**,**,**,83
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,Total,F,170.66,0.2,1.4,856,84
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,Total,F,168.49,0.2,9.3,"5,552",85
2,Newfoundland and Labrador,A03FA,Propulsives,Total,F,164.11,0.2,4.4,"2,609",86
2,Newfoundland and Labrador,A07AA,Antibiotics,Total,F,162.27,0.2,1.7,"1,041",87
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,F,159.76,0.2,3.4,"2,009",88
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,Total,F,**,**,**,**,89
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,F,156.58,0.2,0.8,494,90
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,F,150,0.2,9.9,"5,891",91
2,Newfoundland and Labrador,C10AB,Fibrates,Total,F,149.59,0.2,1.8,"1,101",92
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,148.62,0.2,3,"1,766",93
2,Newfoundland and Labrador,G03AC,Progestogens,Total,F,146.32,0.2,2.2,"1,319",94
2,Newfoundland and Labrador,L01BA,Folic acid analogues,Total,F,143.17,0.2,1.3,767,95
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,F,142.52,0.2,0.6,386,96
2,Newfoundland and Labrador,A04AD,Other antiemetics,Total,F,142.29,0.2,0.4,245,97
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,F,140.96,0.2,2.5,"1,489",98
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,*,99
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,F,132.08,0.2,0.1,73,100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,Total,"5,450.00",7,0.4,230,1
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,Total,"4,966.11",6.4,0.3,144,2
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"3,677.17",4.7,0.4,220,3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,Total,"2,851.05",3.7,55.2,"30,623",4
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,Total,"2,637.59",3.4,22.4,"12,439",5
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,Total,"2,599.41",3.3,0.7,403,6
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,Total,"2,097.56",2.7,46.2,"25,641",7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,945.08",2.5,5.5,"3,073",8
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"1,916.38",2.5,3.5,"1,921",9
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,Total,"1,873.90",2.4,32.3,"17,947",10
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"1,715.97",2.2,5.1,"2,846",11
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,Total,"1,659.48",2.1,34.7,"19,275",12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,Total,"1,544.14",2,8.8,"4,858",13
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,260.83",1.6,15.2,"8,445",14
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,Total,"1,125.84",1.4,9,"5,006",15
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,Total,944.66,1.2,11.2,"6,210",16
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,877.09,1.1,14.8,"8,195",17
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,Total,869.92,1.1,0.1,71,18
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,851.65,1.1,2.1,"1,175",19
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,Total,830.75,1.1,2,"1,085",20
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,807.09,1,0.5,282,21
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,Total,785.05,1,0.4,216,22
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,762.7,1,3.4,"1,901",23
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,Total,**,**,**,**,24
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,Total,707.04,0.9,16.5,"9,167",25
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,Total,702.35,0.9,16.7,"9,295",26
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,663.15,0.8,10.5,"5,803",27
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,Total,655.24,0.8,7.9,"4,386",28
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,646.72,0.8,21.3,"11,807",29
2,Newfoundland and Labrador,A10BA,Biguanides,65+,Total,640.83,0.8,19.7,"10,923",30
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,Total,614.63,0.8,11.6,"6,431",31
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,Total,601.82,0.8,0.2,99,32
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,Total,567.31,0.7,3.1,"1,719",33
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,Total,558.27,0.7,5.3,"2,944",34
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,Total,524.39,0.7,3.9,"2,174",35
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,515.35,0.7,7.3,"4,040",36
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,Total,513.87,0.7,14.3,"7,909",37
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,511.63,0.7,8.3,"4,603",38
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,Total,485.5,0.6,3.2,"1,801",39
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,Total,478.13,0.6,6.6,"3,669",40
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,Total,474.71,0.6,10.4,"5,797",41
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,Total,459.18,0.6,11.7,"6,497",42
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,43
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,Total,**,**,**,**,44
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,Total,422.52,0.5,6.6,"3,655",45
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,Total,421.26,0.5,0.9,502,46
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,411.24,0.5,3.9,"2,178",47
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,Total,384.81,0.5,0.1,71,48
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,Total,379.63,0.5,4,"2,217",49
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,Total,369.21,0.5,18.6,"10,338",50
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,364.09,0.5,8.5,"4,697",51
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,Total,358.01,0.5,5.7,"3,191",52
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,Total,351.45,0.5,0,16,53
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,Total,345.64,0.4,16.5,"9,154",54
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,335.13,0.4,4.5,"2,500",55
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,Total,313.38,0.4,7.5,"4,158",56
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**,**,**,**,57
2,Newfoundland and Labrador,A12BA,Potassium,65+,Total,290.23,0.4,5.8,"3,208",58
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,Total,268.74,0.3,1.2,687,59
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,Total,264.5,0.3,10.3,"5,691",60
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,253.2,0.3,4.5,"2,505",61
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,Total,250.44,0.3,2.2,"1,203",62
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,225.83,0.3,2.8,"1,581",63
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,Total,219.32,0.3,3,"1,685",64
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,Total,218.32,0.3,0.9,526,65
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,Total,213.34,0.3,1.5,822,66
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,Total,210.35,0.3,4.1,"2,272",67
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,Total,207.73,0.3,9.2,"5,107",68
2,Newfoundland and Labrador,J01FA,Macrolides,65+,Total,200.17,0.3,11.2,"6,209",69
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,Total,196.34,0.3,7.5,"4,158",70
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,Total,194.78,0.2,6,"3,335",71
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,Total,180.96,0.2,0.9,483,72
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,Total,173.45,0.2,3.9,"2,160",73
2,Newfoundland and Labrador,C10AB,Fibrates,65+,Total,172.92,0.2,2.5,"1,368",74
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,Total,168.4,0.2,1.5,829,75
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,Total,166.65,0.2,11,"6,117",76
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,Total,159.77,0.2,3.7,"2,080",77
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,158.24,0.2,8.8,"4,905",78
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,Total,155.68,0.2,1.7,919,79
2,Newfoundland and Labrador,A03FA,Propulsives,65+,Total,148.77,0.2,4.5,"2,491",80
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,Total,140.35,0.2,4.4,"2,449",81
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,Total,137.23,0.2,1.7,943,82
2,Newfoundland and Labrador,A07AA,Antibiotics,65+,Total,134.8,0.2,1.8,974,83
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,Total,131.43,0.2,7.5,"4,149",84
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,Total,130.71,0.2,1.2,682,85
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,Total,130.26,0.2,13.7,"7,582",86
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,Total,128.09,0.2,5.1,"2,834",87
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,126.59,0.2,0.7,365,88
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,122.26,0.2,0.6,331,89
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,Total,119.32,0.2,5.9,"3,291",90
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,118.89,0.2,0.1,56,91
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,Total,118.67,0.2,5.5,"3,041",92
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,116.6,0.1,0,9,93
2,Newfoundland and Labrador,M01AH,Coxibs,65+,Total,115.88,0.1,4.1,"2,270",94
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,Total,115.36,0.1,1,529,95
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,65+,Total,113.75,0.1,0.6,349,96
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,Total,112.12,0.1,4.6,"2,543",97
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,Total,109.47,0.1,2.6,"1,421",98
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,107.59,0.1,2.3,"1,261",99
2,Newfoundland and Labrador,S01BA,"Corticosteroids, plain",65+,Total,103.98,0.1,4,"2,210",100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,M,"2,798.68",8.2,0.4,104,1
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,M,"2,100.14",6.1,0.3,65,2
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"1,540.08",4.5,0.4,86,3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,286.66",3.8,59.5,"13,979",4
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,M,"1,108.67",3.2,22.3,"5,231",5
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,M,959.67,2.8,0.7,154,6
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,906.6,2.7,3.9,915,7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,905.66,2.6,5.8,"1,367",8
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,M,839.6,2.5,36.3,"8,531",9
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,M,807.09,2.4,1.2,282,10
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,M,802.95,2.3,43.2,"10,151",11
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,M,785.05,2.3,0.9,216,12
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,M,782.11,2.3,5.4,"1,274",13
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,M,703.09,2.1,37.4,"8,790",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,M,665.99,1.9,8.2,"1,923",15
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,M,589.45,1.7,22.5,"5,292",16
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,M,561.86,1.6,10.3,"2,416",17
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,M,449.7,1.3,0.1,33,18
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,M,368.48,1.1,0.6,139,19
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,M,358.24,1,2.1,483,20
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,M,354.56,1,10.5,"2,475",21
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,335.3,1,3.5,820,22
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,M,324.67,0.9,0.1,25,23
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,322.53,0.9,1.9,455,24
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,M,296.74,0.9,8.4,"1,979",25
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,M,293.73,0.9,8.6,"2,023",26
2,Newfoundland and Labrador,A10BA,Biguanides,65+,M,289.85,0.8,21.8,"5,118",27
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,289.05,0.8,12.3,"2,895",28
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,288.02,0.8,21,"4,936",29
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,270.51,0.8,9.1,"2,144",30
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,*,31
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,M,261.46,0.8,12.3,"2,901",32
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,M,244.95,0.7,5.2,"1,226",33
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,34
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,M,221.91,0.6,2.8,665,35
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,M,218.99,0.6,7.9,"1,858",36
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,M,214.4,0.6,12,"2,821",37
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,M,212.84,0.6,8.2,"1,926",38
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,M,212.21,0.6,3.7,881,39
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,M,197.48,0.6,1,228,40
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,195.13,0.6,3.8,888,41
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,M,189.63,0.6,13.8,"3,239",42
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,M,178.97,0.5,10.4,"2,454",43
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,176.27,0.5,9.1,"2,139",44
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,M,175.83,0.5,2.9,691,45
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,M,171.52,0.5,0.1,30,46
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,M,168.33,0.5,9,"2,116",47
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,M,166.73,0.5,10.1,"2,381",48
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,M,165.22,0.5,0.1,25,49
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,**,**,**,*,50
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,M,152.78,0.4,8.7,"2,038",51
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,M,147.89,0.4,18.2,"4,285",52
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,147.33,0.4,6.3,"1,472",53
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,M,141.76,0.4,1.5,352,54
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,M,129.42,0.4,0,9,55
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,M,120.2,0.4,1.4,339,56
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,M,118.38,0.3,11.2,"2,635",57
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,M,110.49,0.3,13.7,"3,209",58
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,M,**,**,**,**,59
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,60
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,M,96.84,0.3,2,467,61
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,M,89.88,0.3,7.5,"1,767",62
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,85.53,0.3,3.7,870,63
2,Newfoundland and Labrador,A12BA,Potassium,65+,M,83.46,0.2,4.2,983,64
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,M,81.55,0.2,7.8,"1,832",65
2,Newfoundland and Labrador,J01FA,Macrolides,65+,M,81.4,0.2,10,"2,360",66
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,M,80.96,0.2,4.5,"1,054",67
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,M,77.95,0.2,2.1,491,68
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,M,76.12,0.2,2.6,622,69
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,M,75.19,0.2,3.4,790,70
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,M,73.5,0.2,4.2,983,71
2,Newfoundland and Labrador,C10AB,Fibrates,65+,M,71.97,0.2,2.5,586,72
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,68.63,0.2,0.8,187,73
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,M,67.63,0.2,9.3,"2,179",74
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,67.31,0.2,8.8,"2,056",75
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,66.59,0.2,0.8,187,76
2,Newfoundland and Labrador,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,**,77
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,M,62.22,0.2,0.6,134,78
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,M,**,**,**,**,79
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,M,58.14,0.2,5.1,"1,197",80
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,M,57.94,0.2,4.5,"1,068",81
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,65+,M,57.65,0.2,0.7,158,82
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,M,**,**,**,**,83
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,M,54.38,0.2,5.9,"1,378",84
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,M,53.61,0.2,1,246,85
2,Newfoundland and Labrador,C04AD,Purine derivatives,65+,M,50.89,0.1,0.5,118,86
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,M,50.28,0.1,11.9,"2,804",87
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,M,49.16,0.1,2.4,574,88
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,M,48.98,0.1,1.3,313,89
2,Newfoundland and Labrador,A03FA,Propulsives,65+,M,48.39,0.1,3.7,869,90
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,M,47.04,0.1,4.6,"1,071",91
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,65+,M,47.02,0.1,1.4,324,92
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,M,45.87,0.1,3.7,881,93
2,Newfoundland and Labrador,A07AA,Antibiotics,65+,M,45.68,0.1,1.3,312,94
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,M,44.64,0.1,5,"1,166",95
2,Newfoundland and Labrador,C01BD,"Antiarrhythmics, class III",65+,M,44.37,0.1,1.4,337,96
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,65+,M,43.46,0.1,0.8,196,97
2,Newfoundland and Labrador,M01AH,Coxibs,65+,M,43.31,0.1,3.6,852,98
2,Newfoundland and Labrador,M04AC,Preparations with no effect on uric acid metabolism,65+,M,43.25,0.1,3.7,868,99
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,42.59,0.1,1.8,418,100
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,F,"2,865.96",6.5,0.2,79,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,F,"2,651.32",6,0.4,126,2
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"2,137.09",4.9,0.4,134,3
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,F,"1,639.74",3.7,0.8,249,4
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,563.28",3.6,52,"16,633",5
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,F,"1,528.85",3.5,22.5,"7,207",6
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,F,"1,294.09",2.9,48.4,"15,479",7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"1,039.42",2.4,5.3,"1,706",8
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,F,"1,033.26",2.4,29.4,"9,409",9
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"1,009.79",2.3,3.1,"1,006",10
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,F,955.78,2.2,32.8,"10,478",11
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,F,933.85,2.1,4.9,"1,572",12
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,F,906.27,2.1,18.7,"5,970",13
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,F,876.9,2,9.2,"2,933",14
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,F,650.7,1.5,13.1,"4,185",15
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,587.65,1.3,16.6,"5,295",16
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,F,563.63,1.3,8.1,"2,587",17
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,F,553.99,1.3,22.3,"7,127",18
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,F,545.25,1.2,0.1,46,19
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,529.12,1.2,2.3,720,20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,F,487.58,1.1,20.2,"6,469",21
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,F,470.92,1.1,1.9,600,22
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,F,436.59,1,0.2,74,23
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,427.4,1,3.4,"1,081",24
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,F,380.77,0.9,0.5,162,25
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,364.16,0.8,9.8,"3,129",26
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,358.63,0.8,21.5,"6,867",27
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,F,358.24,0.8,7.5,"2,405",28
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,F,353.08,0.8,11,"3,528",29
2,Newfoundland and Labrador,A10BA,Biguanides,65+,F,350.53,0.8,18.1,"5,799",30
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,F,345.4,0.8,3.3,"1,054",31
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,**,**,**,**,32
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,F,324.12,0.7,14.6,"4,668",33
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,F,319.66,0.7,8.9,"2,860",34
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,F,313.33,0.7,5.4,"1,718",35
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,F,311.96,0.7,4,"1,292",36
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,F,309.4,0.7,3.5,"1,109",37
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,F,306.14,0.7,11.5,"3,677",38
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,F,301.63,0.7,5.4,"1,725",39
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,F,292.44,0.7,12.9,"4,116",40
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,F,259.12,0.6,5.7,"1,810",41
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,244.81,0.6,5.9,"1,895",42
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,F,235.05,0.5,18.6,"5,941",43
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,F,223.78,0.5,0.9,274,44
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,F,222.02,0.5,0,7,45
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,F,221.25,0.5,18.9,"6,051",46
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,47
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,216.06,0.5,4,"1,289",48
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,F,213.29,0.5,0.1,41,49
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,F,209.46,0.5,5.4,"1,727",50
2,Newfoundland and Labrador,A12BA,Potassium,65+,F,206.77,0.5,7,"2,225",51
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,187.68,0.4,8,"2,557",52
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,F,**,**,**,*,53
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,167.51,0.4,5.1,"1,633",54
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,F,153.6,0.4,2.3,736,55
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,F,146.08,0.3,9.6,"3,055",56
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,F,143,0.3,3.3,"1,061",57
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,*,58
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,F,136.83,0.3,7.1,"2,266",59
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,F,135.15,0.3,4.6,"1,481",60
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,F,134.41,0.3,5.3,"1,704",61
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,F,126.97,0.3,1,335,62
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,F,126.16,0.3,10.2,"3,274",63
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,F,118.74,0.3,1.1,349,64
2,Newfoundland and Labrador,J01FA,Macrolides,65+,F,118.74,0.3,12,"3,846",65
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,F,111.86,0.3,11.2,"3,593",66
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,F,**,**,**,**,67
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,F,106.63,0.2,1.9,605,68
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,F,106.42,0.2,7.5,"2,389",69
2,Newfoundland and Labrador,C10AB,Fibrates,65+,F,100.79,0.2,2.4,781,70
2,Newfoundland and Labrador,A03FA,Propulsives,65+,F,100.38,0.2,5.1,"1,622",71
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,F,99.01,0.2,12.3,"3,937",72
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,F,94.48,0.2,4.9,"1,568",73
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,F,93.14,0.2,1.5,483,74
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,F,92.5,0.2,3.5,"1,106",75
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,F,92.05,0.2,1.5,484,76
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,90.79,0.2,8.9,"2,846",77
2,Newfoundland and Labrador,A07AA,Antibiotics,65+,F,89.11,0.2,2.1,662,78
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,F,86.16,0.2,3.4,"1,096",79
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,F,79.96,0.2,14.9,"4,776",80
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,F,**,**,**,**,81
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,F,73.97,0.2,5.9,"1,873",82
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,F,73.7,0.2,1.6,511,83
2,Newfoundland and Labrador,M01AH,Coxibs,65+,F,72.47,0.2,4.4,"1,417",84
2,Newfoundland and Labrador,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,71.25,0.2,1.3,412,85
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,F,69.91,0.2,5.1,"1,635",86
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,65+,F,66.98,0.2,0.1,37,87
2,Newfoundland and Labrador,C05AA,Corticosteroids,65+,F,66.47,0.2,3.5,"1,132",88
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,F,65.08,0.1,4.6,"1,472",89
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,64.96,0.1,2.6,842,90
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,F,64.91,0.1,6,"1,911",91
2,Newfoundland and Labrador,S01BA,"Corticosteroids, plain",65+,F,62.9,0.1,4.2,"1,353",92
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,F,61.76,0.1,0.9,283,93
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,F,60.31,0.1,2.6,847,94
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,57.96,0.1,0.6,178,95
2,Newfoundland and Labrador,B01AB,Heparin group,65+,F,**,**,**,**,96
2,Newfoundland and Labrador,D07AA,"Corticosteroids, weak (group I)",65+,F,57.04,0.1,5.6,"1,780",97
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,65+,F,56.09,0.1,0.6,191,98
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,55.66,0.1,0.5,144,99
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,65+,F,53.06,0.1,0.9,285,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"7,946.65",10.7,1.1,529,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,Total,"6,737.69",9.1,4.7,"2,296",2
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,Total,**,**,**,**,3
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,Total,"2,973.99",4,0.6,269,4
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,Total,"2,014.07",2.7,0.4,172,5
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,834.56",2.5,20.3,"9,902",6
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,Total,"1,785.14",2.4,3.7,"1,784",7
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,Total,"1,577.24",2.1,6.5,"3,156",8
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"1,575.73",2.1,6.3,"3,087",9
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,Total,"1,528.90",2.1,0.1,56,10
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,Total,"1,519.60",2.1,14.7,"7,161",11
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,413.65",1.9,4.1,"1,992",12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,Total,"1,315.28",1.8,10.2,"4,975",13
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,Total,"1,306.07",1.8,0.3,144,14
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,Total,"1,302.37",1.8,27.3,"13,295",15
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,Total,"1,239.03",1.7,4.3,"2,101",16
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,144.04",1.5,3.3,"1,599",17
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,045.24",1.4,18,"8,791",18
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,Total,923.88,1.2,10.5,"5,142",19
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,Total,782.42,1.1,15,"7,317",20
2,Newfoundland and Labrador,L03AB,Interferons,<65,Total,**,**,**,**,21
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,739.27,1,8.7,"4,220",22
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,706.51,1,1.5,722,23
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,670.87,0.9,0.2,93,24
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,Total,641.01,0.9,11,"5,376",25
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,Total,639.98,0.9,3.4,"1,675",26
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,639.45,0.9,20.9,"10,203",27
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,Total,631.57,0.9,7.3,"3,546",28
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,Total,588.78,0.8,5.3,"2,589",29
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,518.54,0.7,7,"3,405",30
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,Total,512.54,0.7,2.4,"1,158",31
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,Total,457.72,0.6,0,24,32
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,449.28,0.6,2,991,33
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,Total,428.5,0.6,3.8,"1,838",34
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,Total,424.62,0.6,16.9,"8,230",35
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,Total,420.18,0.6,8.1,"3,959",36
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,Total,399.91,0.5,0.2,75,37
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,Total,**,**,**,**,38
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,Total,379.3,0.5,8.5,"4,146",39
2,Newfoundland and Labrador,A16AB,Enzymes,<65,Total,**,**,**,*,40
2,Newfoundland and Labrador,A10BA,Biguanides,<65,Total,361.39,0.5,8.6,"4,213",41
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,Total,**,**,**,**,42
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,Total,335.12,0.5,0,24,43
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,Total,324.75,0.4,9.1,"4,444",44
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,Total,322.54,0.4,6.4,"3,118",45
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,**,**,**,**,46
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,Total,293.71,0.4,10.4,"5,059",47
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,Total,281.64,0.4,1.5,752,48
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,Total,274.9,0.4,22.8,"11,107",49
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,266.02,0.4,3,"1,446",50
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,Total,257.23,0.3,0.2,107,51
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,Total,254.41,0.3,0.6,307,52
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,Total,247.98,0.3,0.1,36,53
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,Total,247.87,0.3,2.6,"1,272",54
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,Total,241.32,0.3,2.8,"1,386",55
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,235.97,0.3,4.2,"2,046",56
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,<65,Total,**,**,**,*,57
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,Total,234.46,0.3,4.2,"2,045",58
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,225.82,0.3,3.9,"1,897",59
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,Total,223.7,0.3,2.3,"1,141",60
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,Total,213.18,0.3,0.1,40,61
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,Total,193.88,0.3,8.9,"4,333",62
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,Total,**,**,**,**,63
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,Total,187.45,0.3,10,"4,899",64
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,Total,184.61,0.2,1.9,925,65
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,Total,**,**,**,**,66
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,Total,172.19,0.2,0.5,243,67
2,Newfoundland and Labrador,J01FA,Macrolides,<65,Total,164.38,0.2,11.2,"5,442",68
2,Newfoundland and Labrador,R07AX,Other respiratory system products,<65,Total,**,**,**,*,69
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,157.89,0.2,0.4,208,70
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,Total,155.26,0.2,0.9,450,71
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,Total,154.71,0.2,0.1,31,72
2,Newfoundland and Labrador,G03AC,Progestogens,<65,Total,**,**,**,**,73
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,149.96,0.2,0.1,64,74
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,147.67,0.2,8,"3,890",75
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,Total,145.9,0.2,5.8,"2,827",76
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,141.56,0.2,1.7,853,77
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,Total,140.09,0.2,4.9,"2,404",78
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,Total,137.46,0.2,8,"3,881",79
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,136.71,0.2,1.6,762,80
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,81
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,Total,134.42,0.2,1,480,82
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,Total,131.66,0.2,0.4,196,83
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,Total,129.31,0.2,1.2,567,84
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,Total,125.33,0.2,1.4,684,85
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,Total,122.85,0.2,1.2,567,86
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,119.95,0.2,2.5,"1,225",87
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,Total,118.83,0.2,3.1,"1,535",88
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,Total,116.3,0.2,2.4,"1,189",89
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,Total,115.92,0.2,0.4,174,90
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,103.81,0.1,0.3,126,91
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,Total,99.9,0.1,1.8,875,92
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,Total,97.25,0.1,0.6,282,93
2,Newfoundland and Labrador,A03FA,Propulsives,<65,Total,96.43,0.1,2.9,"1,395",94
2,Newfoundland and Labrador,C10AB,Fibrates,<65,Total,95.87,0.1,1.2,609,95
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,Total,95.21,0.1,4,"1,930",96
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,<65,Total,92.06,0.1,1.2,573,97
2,Newfoundland and Labrador,N05AN,Lithium,<65,Total,90.29,0.1,0.7,339,98
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,<65,Total,88.66,0.1,1.9,937,99
2,Newfoundland and Labrador,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,87.35,0.1,0.6,275,100
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,M,**,**,**,**,1
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"3,775.17",10.5,1.2,248,2
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,3
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,M,"1,627.86",4.5,0.5,105,4
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,M,"1,231.35",3.4,5.2,"1,113",5
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"1,046.57",2.9,7.5,"1,590",6
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,M,"1,007.97",2.8,9.5,"2,026",7
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,M,960.71,2.7,0.1,30,8
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,M,867.28,2.4,0.4,76,9
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,M,706.81,2,16.4,"3,491",10
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,606.61,1.7,4,857,11
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,M,563.54,1.6,12.3,"2,612",12
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,M,557.67,1.6,4.5,963,13
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,M,554.41,1.5,25,"5,315",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,M,527.92,1.5,9.1,"1,940",15
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,M,521.42,1.5,19.6,"4,168",16
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,17
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,M,485.43,1.4,11.2,"2,377",18
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,M,460.44,1.3,3.2,682,19
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,M,407.09,1.1,0.2,38,20
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,353.55,1,8.7,"1,837",21
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,M,321.71,0.9,12.6,"2,666",22
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,M,316.52,0.9,12.2,"2,597",23
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,M,310.87,0.9,6.2,"1,309",24
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,M,294.78,0.8,2.9,619,25
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,M,291.52,0.8,6.7,"1,418",26
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,272.62,0.8,1.3,280,27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,271.64,0.8,19.1,"4,060",28
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,M,255.9,0.7,3.1,663,29
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,M,223.04,0.6,9.3,"1,969",30
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,M,206.62,0.6,3.8,816,31
2,Newfoundland and Labrador,L03AB,Interferons,<65,M,**,**,**,**,32
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,199.44,0.6,5.7,"1,206",33
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,193.45,0.5,2,430,34
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,M,186.08,0.5,0,9,35
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,M,179.76,0.5,0.1,30,36
2,Newfoundland and Labrador,A10BA,Biguanides,<65,M,165.35,0.5,8.5,"1,806",37
2,Newfoundland and Labrador,R07AX,Other respiratory system products,<65,M,**,**,**,*,38
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,M,161.68,0.5,0.1,13,39
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,M,160.91,0.4,14.3,"3,032",40
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,M,157.69,0.4,0.3,58,41
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,M,155.42,0.4,7.1,"1,516",42
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,M,153.38,0.4,0.4,78,43
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,M,147.65,0.4,7.7,"1,629",44
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,M,137.88,0.4,1.7,352,45
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,M,**,**,**,**,46
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,M,125.53,0.3,0.7,139,47
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,M,116.69,0.3,3,646,48
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,M,113.62,0.3,20.7,"4,401",49
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,M,**,**,**,**,50
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,M,**,**,**,**,51
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,M,108.14,0.3,4.2,892,52
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,M,103.34,0.3,2.6,552,53
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,M,101.63,0.3,0.1,14,54
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,97.03,0.3,3.6,774,55
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,M,94.66,0.3,7.6,"1,615",56
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,M,94.47,0.3,0.6,131,57
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,M,89.84,0.3,3.3,711,58
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,M,**,**,**,**,59
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,M,76.57,0.2,8.7,"1,855",60
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,M,74.34,0.2,1.6,349,61
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,M,74.3,0.2,3.2,681,62
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,M,71.72,0.2,0.1,31,63
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,M,69.95,0.2,6.7,"1,422",64
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,M,69.91,0.2,0.4,93,65
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,M,68.45,0.2,8,"1,696",66
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,67.42,0.2,2.1,446,67
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,67,0.2,0.4,90,68
2,Newfoundland and Labrador,J01FA,Macrolides,<65,M,64.63,0.2,8.9,"1,886",69
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,M,64.48,0.2,0.4,82,70
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,<65,M,63.31,0.2,3,632,71
2,Newfoundland and Labrador,L02BB,Antiandrogens,<65,M,62.82,0.2,0.1,20,72
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,60.79,0.2,7,"1,496",73
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,M,59.83,0.2,1.6,332,74
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,M,56.15,0.2,0.9,188,75
2,Newfoundland and Labrador,N05AD,Butyrophenone derivatives,<65,M,55.5,0.2,0.6,122,76
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,<65,M,55.24,0.2,1.6,334,77
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,M,54.78,0.2,0.8,180,78
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,M,54.41,0.2,4.8,"1,011",79
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,M,52.74,0.1,1.2,250,80
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,M,52.73,0.1,1.3,277,81
2,Newfoundland and Labrador,N05AA,Phenothiazines with aliphatic side-chain,<65,M,51.97,0.1,0.7,152,82
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,M,51.55,0.1,0.6,136,83
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,51.08,0.1,0.3,61,84
2,Newfoundland and Labrador,N05AN,Lithium,<65,M,50.78,0.1,0.8,169,85
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,M,50.75,0.1,3.9,823,86
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,M,50.3,0.1,2.9,607,87
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,M,**,**,**,**,88
2,Newfoundland and Labrador,C10AB,Fibrates,<65,M,47.06,0.1,1.4,289,89
2,Newfoundland and Labrador,N03AA,Barbiturates and derivatives,<65,M,46.8,0.1,0.6,126,90
2,Newfoundland and Labrador,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,**,91
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,M,43.42,0.1,0,8,92
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,M,43,0.1,4,841,93
2,Newfoundland and Labrador,N04AC,Ethers of tropine or tropine derivatives,<65,M,42.46,0.1,1,216,94
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",<65,M,40.76,0.1,2.1,440,95
2,Newfoundland and Labrador,J01GB,Other aminoglycosides,<65,M,40.61,0.1,0.1,15,96
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,<65,M,37.42,0.1,0.6,138,97
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,36.29,0.1,1.4,301,98
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,<65,M,35.44,0.1,1.4,292,99
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,34.82,0.1,0.4,92,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"4,171.48",10.9,1,281,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,**,2
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,F,"1,346.13",3.5,0.6,164,3
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,F,**,**,**,**,4
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,F,"1,146.79",3,0.3,96,5
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,127.15",3,23.3,"6,409",6
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,F,955.93,2.5,16.5,"4,548",7
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,F,898.98,2.4,0.4,106,8
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,807.03,2.1,4.1,"1,135",9
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,F,787.36,2.1,11,"3,035",10
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,F,747.96,2,29,"7,980",11
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,F,683.6,1.8,3.3,917,12
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,F,681.36,1.8,4.1,"1,138",13
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,F,569.27,1.5,4.1,"1,130",14
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,F,568.19,1.5,0.1,26,15
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,F,553.79,1.5,2.4,671,16
2,Newfoundland and Labrador,L03AB,Interferons,<65,F,**,**,**,**,17
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,529.05,1.4,5.4,"1,496",18
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,F,523.81,1.4,16.8,"4,623",19
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,F,465.9,1.2,17.1,"4,720",20
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,F,438.45,1.2,10,"2,765",21
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,433.89,1.1,1.6,442,22
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,385.72,1,8.7,"2,383",23
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,F,384.07,1,3.7,"1,012",24
2,Newfoundland and Labrador,A16AB,Enzymes,<65,F,**,**,**,*,25
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,367.8,1,22.3,"6,143",26
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,F,340.05,0.9,7.7,"2,128",27
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,F,319.31,0.8,9.8,"2,710",28
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,319.1,0.8,8,"2,199",29
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,F,**,**,**,**,30
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,31
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,F,277.91,0.7,4.6,"1,280",32
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,F,271.64,0.7,0.1,15,33
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,266.02,0.7,5.3,"1,446",34
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,F,263.7,0.7,18.9,"5,198",35
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,255.84,0.7,2,561,36
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,F,248.24,0.7,8.9,"2,437",37
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,38
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,<65,F,**,**,**,*,39
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,F,223.87,0.6,9.6,"2,630",40
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,F,221.87,0.6,3.7,"1,022",41
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,F,220.15,0.6,0.2,45,42
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,F,217.76,0.6,2,539,43
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,F,199.05,0.5,12.5,"3,444",44
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,F,197.13,0.5,7.2,"1,990",45
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,F,196.25,0.5,0.3,71,46
2,Newfoundland and Labrador,A10BA,Biguanides,<65,F,196.03,0.5,8.7,"2,407",47
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,F,177.1,0.5,10.2,"2,815",48
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,F,173.44,0.5,0,11,49
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,F,170.96,0.4,3.1,864,50
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,F,161.28,0.4,24.4,"6,706",51
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,52
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,53
2,Newfoundland and Labrador,G03AC,Progestogens,<65,F,**,**,**,**,54
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,F,144.53,0.4,2.6,720,55
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,F,143.76,0.4,1.5,400,56
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,57
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,**,**,**,**,58
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,F,128.88,0.3,0.6,168,59
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,128.78,0.3,4.1,"1,123",60
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,F,126.33,0.3,4.2,"1,153",61
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,F,124.78,0.3,2.2,593,62
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,F,124.63,0.3,2.7,740,63
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,F,123.91,0.3,10.6,"2,910",64
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,F,**,**,**,**,65
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,F,111.54,0.3,0.1,26,66
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,F,111.29,0.3,0.1,23,67
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,F,110.88,0.3,11.1,"3,044",68
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,F,102.28,0.3,0.5,150,69
2,Newfoundland and Labrador,J01FA,Macrolides,<65,F,99.75,0.3,12.9,"3,556",70
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,F,99.54,0.3,0.2,49,71
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,F,91.49,0.2,6.6,"1,816",72
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,90.89,0.2,0.4,118,73
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,F,89.34,0.2,5.7,"1,581",74
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,86.88,0.2,8.7,"2,394",75
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,83.65,0.2,3.4,924,76
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,F,79.64,0.2,1.1,300,77
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,F,**,**,**,**,78
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,F,78.24,0.2,0.1,33,79
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,F,73.15,0.2,1.4,379,80
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,F,72.6,0.2,1.6,434,81
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,69.29,0.2,1.1,316,82
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,F,69.02,0.2,7.9,"2,185",83
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,F,68.53,0.2,3.4,928,84
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,F,**,**,**,**,85
2,Newfoundland and Labrador,J02AC,Triazole derivatives,<65,F,65.94,0.2,7.1,"1,961",86
2,Newfoundland and Labrador,A03FA,Propulsives,<65,F,63.73,0.2,3.6,987,87
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,F,**,**,**,**,88
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,<65,F,56.63,0.1,7.1,"1,959",89
2,Newfoundland and Labrador,G03XB,Progesterone receptor modulators,<65,F,53.78,0.1,0.5,151,90
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,52.74,0.1,0.2,65,91
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,F,52.21,0.1,4,"1,089",92
2,Newfoundland and Labrador,J01AA,Tetracyclines,<65,F,51.55,0.1,5.2,"1,436",93
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,F,51.44,0.1,0.3,92,94
2,Newfoundland and Labrador,L01BA,Folic acid analogues,<65,F,51.12,0.1,1,283,95
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,<65,F,50.98,0.1,7.1,"1,954",96
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,97
2,Newfoundland and Labrador,C10AB,Fibrates,<65,F,48.8,0.1,1.2,320,98
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,F,48.51,0.1,0.8,218,99
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,<65,F,48.46,0.1,1.4,383,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"4,714.61",13.5,0.7,341,1
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,Total,"1,688.87",4.8,0.4,213,2
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,Total,"1,475.45",4.2,1.8,860,3
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,Total,"1,251.00",3.6,0.2,107,4
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,Total,"1,213.52",3.5,0.2,115,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"1,094.36",3.1,5,"2,444",6
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,Total,"1,053.99",3,0.1,67,7
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,Total,686.86,2,31.4,"15,220",8
3,Prince Edward Island,A16AB,Enzymes,Total,Total,**,**,**,*,9
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,619.19,1.8,4.8,"2,310",10
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,Total,613.22,1.8,26.8,"12,989",11
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,608.77,1.7,2.6,"1,247",12
3,Prince Edward Island,N05AX,Other antipsychotics,Total,Total,580.54,1.7,1.8,854,13
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,Total,575.96,1.6,15.5,"7,541",14
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,Total,541.74,1.5,1.6,791,15
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,519.78,1.5,1.4,698,16
3,Prince Edward Island,R03BB,Anticholinergics,Total,Total,519.49,1.5,5.5,"2,664",17
3,Prince Edward Island,R03BA,Glucocorticoids,Total,Total,513.85,1.5,4.9,"2,378",18
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,Total,478.12,1.4,1.3,655,19
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,Total,450.22,1.3,5.1,"2,490",20
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,425.86,1.2,0.4,172,21
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,Total,425.48,1.2,14.6,"7,061",22
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,Total,414.84,1.2,0.1,28,23
3,Prince Edward Island,N03AX,Other antiepileptics,Total,Total,406.1,1.2,5.9,"2,861",24
3,Prince Edward Island,L02BB,Antiandrogens,Total,Total,393.27,1.1,0.2,96,25
3,Prince Edward Island,N06AX,Other antidepressants,Total,Total,381.96,1.1,10.2,"4,933",26
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,Total,366.53,1,17,"8,254",27
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,340.73,1,11.7,"5,699",28
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,Total,262.73,0.8,16,"7,781",29
3,Prince Edward Island,L03AB,Interferons,Total,Total,243.24,0.7,0,21,30
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,Total,235.59,0.7,7.2,"3,479",31
3,Prince Edward Island,H03AA,Thyroid hormones,Total,Total,235.27,0.7,14.4,"6,978",32
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,Total,234.95,0.7,3.2,"1,529",33
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,212.05,0.6,13.6,"6,619",34
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,Total,186.31,0.5,0,17,35
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,Total,180.25,0.5,0.7,352,36
3,Prince Edward Island,A10BA,Biguanides,Total,Total,178.25,0.5,14.2,"6,902",37
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,Total,173.81,0.5,2.1,"1,007",38
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,173.24,0.5,4.8,"2,344",39
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,171.18,0.5,3.1,"1,525",40
3,Prince Edward Island,L03AX,Other immunostimulants,Total,Total,170.73,0.5,0,19,41
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,162.02,0.5,1.3,627,42
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,160.41,0.5,4.9,"2,367",43
3,Prince Edward Island,R01AD,Corticosteroids,Total,Total,157.11,0.4,11.4,"5,517",44
3,Prince Edward Island,A10BB,Sulfonylureas,Total,Total,154.58,0.4,6.4,"3,118",45
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,144.89,0.4,6.6,"3,208",46
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,Total,144.23,0.4,2.3,"1,138",47
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,Total,140.73,0.4,1.1,522,48
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,Total,139.23,0.4,2.4,"1,179",49
3,Prince Edward Island,C01DA,Organic nitrates,Total,Total,130.94,0.4,2.7,"1,289",50
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,Total,122.35,0.4,5,"2,431",51
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,Total,119.13,0.3,2.4,"1,176",52
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,Total,118.29,0.3,1.9,927,53
3,Prince Edward Island,H02AB,Glucocorticoids,Total,Total,110.73,0.3,12.6,"6,119",54
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,Total,109.99,0.3,1.7,845,55
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,109.73,0.3,5.1,"2,491",56
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,100.07,0.3,0.4,176,57
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,99.06,0.3,0.5,251,58
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,Total,97.94,0.3,1.1,556,59
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,Total,97.84,0.3,2.1,"1,034",60
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,Total,94.99,0.3,1.2,576,61
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,Total,91.9,0.3,0.8,370,62
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,Total,91.39,0.3,6.7,"3,259",63
3,Prince Edward Island,N06DA,Anticholinesterases,Total,Total,85.69,0.2,1.1,524,64
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,Total,84.74,0.2,0,7,65
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,84.7,0.2,3,"1,475",66
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,Total,80.28,0.2,3.3,"1,600",67
3,Prince Edward Island,R07AX,Other respiratory system products,Total,Total,**,**,**,*,68
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,Total,73.8,0.2,7,"3,375",69
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,Total,73.17,0.2,0.1,39,70
3,Prince Edward Island,M05BA,Bisphosphonates,Total,Total,72.62,0.2,3.2,"1,575",71
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,Total,70.84,0.2,9.3,"4,519",72
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,Total,69.7,0.2,0.2,89,73
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,Total,69.32,0.2,0.7,328,74
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,**,**,**,**,75
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,68.56,0.2,2.5,"1,227",76
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,Total,68.37,0.2,6.2,"3,005",77
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,Total,62.74,0.2,14,"6,793",78
3,Prince Edward Island,A09AA,Enzyme preparations,Total,Total,58.35,0.2,0.2,79,79
3,Prince Edward Island,N02BE,Anilides,Total,Total,57.46,0.2,1.8,882,80
3,Prince Edward Island,J01AA,Tetracyclines,Total,Total,57.28,0.2,8.4,"4,057",81
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,55.31,0.2,5.8,"2,832",82
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,55.29,0.2,0.2,120,83
3,Prince Edward Island,L01BA,Folic acid analogues,Total,Total,54.13,0.2,1.1,532,84
3,Prince Edward Island,A06AB,Contact laxatives,Total,Total,53.02,0.2,1.5,709,85
3,Prince Edward Island,D06BB,Antivirals,Total,Total,52.83,0.2,0.8,375,86
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,Total,50.87,0.1,4.5,"2,189",87
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,Total,50.01,0.1,0.6,281,88
3,Prince Edward Island,L01AX,Other alkylating agents,Total,Total,**,**,**,**,89
3,Prince Edward Island,B02BX,Other systemic hemostatics,Total,Total,**,**,**,*,90
3,Prince Edward Island,N03AF,Carboxamide derivatives,Total,Total,46.6,0.1,0.6,314,91
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,46.46,0.1,1.9,901,92
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,46.35,0.1,0.1,67,93
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,Total,45.92,0.1,0.5,220,94
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,Total,45.42,0.1,6.3,"3,078",95
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,45.11,0.1,0.2,112,96
3,Prince Edward Island,N04BC,Dopamine agonists,Total,Total,42.84,0.1,0.6,290,97
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,Total,41.07,0.1,0.7,354,98
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,Total,40.48,0.1,1.2,561,99
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",Total,Total,37.21,0.1,0.4,207,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"2,131.56",12.6,0.7,154,1
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,M,924.88,5.5,0.4,100,2
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,M,**,**,**,**,3
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,M,658.88,3.9,0.2,37,4
3,Prince Edward Island,A16AB,Enzymes,Total,M,**,**,**,*,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,M,585.66,3.5,6.2,"1,375",6
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,M,**,**,**,**,7
3,Prince Edward Island,N05AX,Other antipsychotics,Total,M,419.26,2.5,2.1,468,8
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,M,**,**,**,**,9
3,Prince Edward Island,L02BB,Antiandrogens,Total,M,393.27,2.3,0.4,96,10
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,379.37,2.2,2.8,632,11
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,M,366.61,2.2,37.4,"8,357",12
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,342.53,2,5.8,"1,292",13
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,M,316.62,1.9,1.8,398,14
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,M,282.66,1.7,1.8,400,15
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,M,271.24,1.6,25.4,"5,681",16
3,Prince Edward Island,R03BB,Anticholinergics,Total,M,259.34,1.5,6,"1,340",17
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,223.87,1.3,1.4,313,18
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,M,219.12,1.3,11.9,"2,649",19
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,M,209.93,1.2,4.7,"1,052",20
3,Prince Edward Island,R03BA,Glucocorticoids,Total,M,205.99,1.2,4.2,944,21
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,M,201.43,1.2,15.7,"3,516",22
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,M,186.31,1.1,0.1,17,23
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,M,186.04,1.1,20.2,"4,520",24
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,M,176.84,1,0.1,25,25
3,Prince Edward Island,N03AX,Other antiepileptics,Total,M,168.63,1,5.1,"1,139",26
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,M,166.01,1,0,11,27
3,Prince Edward Island,N06AX,Other antidepressants,Total,M,144.32,0.9,8,"1,790",28
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,142.94,0.8,11.1,"2,486",29
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,M,129.92,0.8,18.5,"4,124",30
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,M,107.51,0.6,10.9,"2,441",31
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,M,106.53,0.6,5.6,"1,247",32
3,Prince Edward Island,A10BA,Biguanides,Total,M,102.1,0.6,17.7,"3,954",33
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,91.23,0.5,12.7,"2,826",34
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,M,91.22,0.5,2.8,617,35
3,Prince Edward Island,A10BB,Sulfonylureas,Total,M,87.5,0.5,8.2,"1,839",36
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,84.08,0.5,1.5,326,37
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,M,80.87,0.5,1.3,285,38
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,76.41,0.5,5.7,"1,277",39
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,M,72.14,0.4,0.6,138,40
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,M,69.83,0.4,1.8,397,41
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,M,68.37,0.4,2.1,458,42
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,67.61,0.4,6.7,"1,497",43
3,Prince Edward Island,R01AD,Corticosteroids,Total,M,65.52,0.4,9.8,"2,182",44
3,Prince Edward Island,C01DA,Organic nitrates,Total,M,64.2,0.4,3,671,45
3,Prince Edward Island,H03AA,Thyroid hormones,Total,M,60.28,0.4,8,"1,797",46
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,58.49,0.3,3.3,747,47
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,M,57.02,0.3,1.5,341,48
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,M,56.92,0.3,2.2,496,49
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,M,52.67,0.3,4.4,987,50
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,M,52.57,0.3,1.7,382,51
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,M,52.4,0.3,2.6,570,52
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,M,52.15,0.3,1.1,246,53
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,50.72,0.3,0.6,131,54
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,47.97,0.3,0.4,80,55
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,M,46.92,0.3,0.8,175,56
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,**,**,**,**,57
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,M,44.63,0.3,4,883,58
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,M,44.51,0.3,1.6,354,59
3,Prince Edward Island,H02AB,Glucocorticoids,Total,M,42.74,0.3,11.9,"2,663",60
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,M,42.6,0.3,0.2,54,61
3,Prince Edward Island,L01AX,Other alkylating agents,Total,M,**,**,**,**,62
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,38.22,0.2,3,677,63
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,M,37.34,0.2,6.4,"1,427",64
3,Prince Edward Island,L03AX,Other immunostimulants,Total,M,36.51,0.2,0,5,65
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,M,35.3,0.2,6.1,"1,370",66
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,M,34.58,0.2,1.5,341,67
3,Prince Edward Island,L03AB,Interferons,Total,M,**,**,**,*,68
3,Prince Edward Island,N06DA,Anticholinesterases,Total,M,32.35,0.2,0.9,203,69
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,M,30.83,0.2,6.3,"1,408",70
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,M,26.99,0.2,0.1,16,71
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,**,**,**,**,72
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,26.56,0.2,1.8,407,73
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,M,26.45,0.2,7.5,"1,685",74
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,26.35,0.2,0.3,74,75
3,Prince Edward Island,N03AF,Carboxamide derivatives,Total,M,26.27,0.2,0.7,154,76
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,M,26.05,0.2,12.9,"2,875",77
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,**,**,**,**,78
3,Prince Edward Island,A09AA,Enzyme preparations,Total,M,24.41,0.1,0.2,40,79
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,23.67,0.1,5.3,"1,189",80
3,Prince Edward Island,J01AA,Tetracyclines,Total,M,22.3,0.1,7.9,"1,760",81
3,Prince Edward Island,D06BB,Antivirals,Total,M,22.17,0.1,0.5,113,82
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,M,**,**,**,**,83
3,Prince Edward Island,J01XX,Other antibacterials,Total,M,20.71,0.1,0,9,84
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,Total,M,20.62,0.1,4.3,951,85
3,Prince Edward Island,C01AA,Digitalis glycosides,Total,M,20.5,0.1,1,216,86
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,M,20.16,0.1,4,892,87
3,Prince Edward Island,N02BE,Anilides,Total,M,19.83,0.1,1.5,328,88
3,Prince Edward Island,A06AB,Contact laxatives,Total,M,19.5,0.1,1.3,282,89
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,M,19.23,0.1,6.4,"1,430",90
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,M,18.82,0.1,0.7,150,91
3,Prince Edward Island,L01BA,Folic acid analogues,Total,M,18.63,0.1,0.9,191,92
3,Prince Edward Island,L01BC,Pyrimidine analogues,Total,M,18.25,0.1,0.8,188,93
3,Prince Edward Island,B01AB,Heparin group,Total,M,17.62,0.1,0.3,63,94
3,Prince Edward Island,A06AD,Osmotically acting laxatives,Total,M,17.5,0.1,0.7,146,95
3,Prince Edward Island,N04BC,Dopamine agonists,Total,M,17.12,0.1,0.4,83,96
3,Prince Edward Island,C03DA,Aldosterone antagonists,Total,M,16.28,0.1,1.9,419,97
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,Total,M,15.98,0.1,2.1,469,98
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,M,15.52,0.1,1,225,99
3,Prince Edward Island,M05BA,Bisphosphonates,Total,M,15.04,0.1,1.1,252,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"2,583.04",14.3,0.7,187,1
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,F,"1,036.68",5.7,0.3,90,2
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,F,763.98,4.2,0.4,113,3
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,F,**,**,**,**,4
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,F,**,**,**,**,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,F,508.7,2.8,4.1,"1,069",6
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,F,395.11,2.2,0.1,30,7
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,F,356.84,2,18.7,"4,892",8
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,F,341.8,1.9,27.9,"7,307",9
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,F,320.09,1.8,26.2,"6,862",10
3,Prince Edward Island,R03BA,Glucocorticoids,Total,F,307.86,1.7,5.5,"1,434",11
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,295.91,1.6,1.5,385,12
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,276.66,1.5,3.9,"1,018",13
3,Prince Edward Island,R03BB,Anticholinergics,Total,F,260.15,1.4,5.1,"1,324",14
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,F,259.08,1.4,1.5,391,15
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,F,248.83,1.4,0.1,17,16
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,F,240.29,1.3,5.5,"1,438",17
3,Prince Edward Island,N06AX,Other antidepressants,Total,F,237.63,1.3,12,"3,143",18
3,Prince Edward Island,N03AX,Other antiepileptics,Total,F,236.47,1.3,6.6,"1,721",19
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,228.49,1.3,2.3,614,20
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,F,224.05,1.2,13.5,"3,545",21
3,Prince Edward Island,L03AB,Interferons,Total,F,**,**,**,**,22
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,197.78,1.1,12.3,"3,213",23
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,F,180.31,1,14.3,"3,733",24
3,Prince Edward Island,H03AA,Thyroid hormones,Total,F,174.98,1,19.8,"5,181",25
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,170.74,0.9,5.8,"1,520",26
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,F,161.5,0.9,1,257,27
3,Prince Edward Island,N05AX,Other antipsychotics,Total,F,161.29,0.9,1.5,386,28
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,F,143.74,0.8,3.5,912,29
3,Prince Edward Island,L03AX,Other immunostimulants,Total,F,134.22,0.7,0.1,14,30
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,F,132.81,0.7,14,"3,657",31
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,F,128.92,0.7,8.5,"2,231",32
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,120.82,0.7,14.5,"3,793",33
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,114.74,0.6,6.1,"1,597",34
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,F,108.1,0.6,0.8,214,35
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,F,103.98,0.6,2.3,610,36
3,Prince Edward Island,R01AD,Corticosteroids,Total,F,91.59,0.5,12.7,"3,335",37
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,F,84.55,0.5,3.2,835,38
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,83.81,0.5,4.2,"1,089",39
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,F,82.31,0.5,2.6,683,40
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,77.94,0.4,1.1,301,41
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,77.28,0.4,6.5,"1,711",42
3,Prince Edward Island,R07AX,Other respiratory system products,Total,F,**,**,**,*,43
3,Prince Edward Island,A10BA,Biguanides,Total,F,76.16,0.4,11.3,"2,948",44
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,F,75.85,0.4,2.6,680,45
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,F,**,**,**,**,46
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,F,69.68,0.4,5.5,"1,444",47
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,69.3,0.4,3.4,901,48
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,F,**,**,**,**,49
3,Prince Edward Island,H02AB,Glucocorticoids,Total,F,67.98,0.4,13.2,"3,456",50
3,Prince Edward Island,A10BB,Sulfonylureas,Total,F,67.08,0.4,4.9,"1,279",51
3,Prince Edward Island,C01DA,Organic nitrates,Total,F,66.74,0.4,2.4,618,52
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,F,65.73,0.4,2.1,545,53
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,F,65.48,0.4,1.9,491,54
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,F,59.87,0.3,0.9,237,55
3,Prince Edward Island,M05BA,Bisphosphonates,Total,F,57.58,0.3,5.1,"1,323",56
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,F,54.05,0.3,7,"1,832",57
3,Prince Edward Island,N06DA,Anticholinesterases,Total,F,53.35,0.3,1.2,321,58
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,52.1,0.3,0.4,96,59
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,48.33,0.3,0.5,120,60
3,Prince Edward Island,B02BX,Other systemic hemostatics,Total,F,**,**,**,*,61
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,46.48,0.3,3,798,62
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,F,46.18,0.3,0.1,23,63
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,F,45.44,0.3,1.8,464,64
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,F,44.98,0.2,0.7,195,65
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,F,44.39,0.2,10.8,"2,834",66
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,F,42.97,0.2,7.5,"1,967",67
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,F,42.84,0.2,1.3,330,68
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,41.99,0.2,3.1,820,69
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,F,40.92,0.2,0.8,215,70
3,Prince Edward Island,N02BE,Anilides,Total,F,37.63,0.2,2.1,554,71
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,F,36.69,0.2,15,"3,918",72
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,F,35.77,0.2,0.8,200,73
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,F,35.65,0.2,2.7,717,74
3,Prince Edward Island,L01BA,Folic acid analogues,Total,F,35.51,0.2,1.3,341,75
3,Prince Edward Island,J01AA,Tetracyclines,Total,F,34.98,0.2,8.8,"2,297",76
3,Prince Edward Island,A09AA,Enzyme preparations,Total,F,33.94,0.2,0.1,39,77
3,Prince Edward Island,A06AB,Contact laxatives,Total,F,33.52,0.2,1.6,427,78
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,F,33.07,0.2,6.2,"1,635",79
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,31.65,0.2,6.3,"1,643",80
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,**,81
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,F,30.71,0.2,5,"1,297",82
3,Prince Edward Island,D06BB,Antivirals,Total,F,30.66,0.2,1,262,83
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",Total,F,30.07,0.2,0.6,164,84
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,30.07,0.2,1,269,85
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,**,**,**,**,86
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,F,27.1,0.2,0.1,35,87
3,Prince Edward Island,J01XE,Nitrofuran derivatives,Total,F,27.06,0.1,7.7,"2,024",88
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,F,26.19,0.1,6.3,"1,648",89
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,Total,F,26.03,0.1,0.7,187,90
3,Prince Edward Island,N04BC,Dopamine agonists,Total,F,25.72,0.1,0.8,207,91
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,F,**,**,**,**,92
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,F,24.96,0.1,1.3,336,93
3,Prince Edward Island,A03FA,Propulsives,Total,F,24.78,0.1,2.8,742,94
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,F,**,**,**,**,95
3,Prince Edward Island,A07AA,Antibiotics,Total,F,24.42,0.1,1.4,363,96
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,Total,F,22.77,0.1,0.5,127,97
3,Prince Edward Island,G03AC,Progestogens,Total,F,**,**,**,**,98
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,F,22.25,0.1,0.8,204,99
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,**,**,**,**,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"1,484.42",8,0.4,101,1
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,Total,"1,161.99",6.3,0.4,120,2
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,Total,973.84,5.3,0.3,85,3
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,Total,728.65,3.9,0.2,55,4
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,Total,649.16,3.5,0.2,47,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,573.46,3.1,4.3,"1,244",6
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,Total,543.99,2.9,44.8,"12,843",7
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,Total,506.15,2.7,2.6,740,8
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,440.96,2.4,2.1,604,9
3,Prince Edward Island,R03BB,Anticholinergics,65+,Total,425.19,2.3,7.9,"2,269",10
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,380.2,2.1,0.5,155,11
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,Total,379.07,2.1,33.2,"9,519",12
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,Total,360.34,1.9,21.2,"6,071",13
3,Prince Edward Island,L02BB,Antiandrogens,65+,Total,**,**,**,**,14
3,Prince Edward Island,R03BA,Glucocorticoids,65+,Total,288.86,1.6,4.9,"1,395",15
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,283.85,1.5,3.5,"1,011",16
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,283.46,1.5,16.9,"4,853",17
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,Total,280.39,1.5,23.5,"6,731",18
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,Total,228.98,1.2,5.2,"1,479",19
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,Total,214.92,1.2,23.5,"6,748",20
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,Total,191.26,1,13.7,"3,939",21
3,Prince Edward Island,H03AA,Thyroid hormones,65+,Total,173.38,0.9,22.3,"6,399",22
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,Total,156.31,0.8,3.2,911,23
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,24
3,Prince Edward Island,N03AX,Other antiepileptics,65+,Total,151.23,0.8,6,"1,716",25
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,146.36,0.8,4.6,"1,315",26
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,Total,136.05,0.7,0,8,27
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,Total,131.91,0.7,3.9,"1,133",28
3,Prince Edward Island,N06AX,Other antidepressants,65+,Total,128.64,0.7,9.4,"2,689",29
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,Total,120.07,0.6,6.7,"1,936",30
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,Total,118.23,0.6,0.9,265,31
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,115.86,0.6,6.8,"1,961",32
3,Prince Edward Island,C01DA,Organic nitrates,65+,Total,115.05,0.6,4,"1,135",33
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,107.74,0.6,15,"4,295",34
3,Prince Edward Island,R01AD,Corticosteroids,65+,Total,99.87,0.5,13.2,"3,784",35
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,98.57,0.5,5.7,"1,648",36
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,97.3,0.5,7.9,"2,279",37
3,Prince Edward Island,A10BA,Biguanides,65+,Total,95.52,0.5,14.2,"4,076",38
3,Prince Edward Island,A10BB,Sulfonylureas,65+,Total,95.42,0.5,6.7,"1,925",39
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,93.61,0.5,1.3,374,40
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,Total,89.89,0.5,3.3,947,41
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,89.52,0.5,0.8,230,42
3,Prince Edward Island,H02AB,Glucocorticoids,65+,Total,86.61,0.5,16.7,"4,787",43
3,Prince Edward Island,L03AB,Interferons,65+,Total,84.62,0.5,0,5,44
3,Prince Edward Island,N06DA,Anticholinesterases,65+,Total,84.1,0.5,1.8,517,45
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,Total,81.5,0.4,2.2,636,46
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,80.73,0.4,1,288,47
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,Total,**,**,**,**,48
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,78.61,0.4,0.5,143,49
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,Total,76.75,0.4,8.9,"2,560",50
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,Total,76.23,0.4,1.6,469,51
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,Total,75.59,0.4,2.8,811,52
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,Total,72.67,0.4,10,"2,855",53
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,71.95,0.4,4.3,"1,247",54
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,Total,**,**,**,**,55
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,Total,66.14,0.4,4.9,"1,420",56
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,Total,**,**,**,**,57
3,Prince Edward Island,N05AX,Other antipsychotics,65+,Total,64.98,0.4,1.2,336,58
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,63.89,0.3,8.8,"2,511",59
3,Prince Edward Island,M05BA,Bisphosphonates,65+,Total,58.85,0.3,5,"1,448",60
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,Total,57.93,0.3,0.9,270,61
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,Total,56.88,0.3,13.1,"3,772",62
3,Prince Edward Island,A09AA,Enzyme preparations,65+,Total,54.96,0.3,0.3,72,63
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,Total,**,**,**,*,64
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,Total,45.53,0.2,7.9,"2,263",65
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,Total,45.44,0.2,7.1,"2,026",66
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,**,**,**,**,67
3,Prince Edward Island,D06BB,Antivirals,65+,Total,38.59,0.2,1.1,312,68
3,Prince Edward Island,N02BE,Anilides,65+,Total,36.99,0.2,2.1,601,69
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,35.93,0.2,2.8,796,70
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,Total,**,**,**,**,71
3,Prince Edward Island,N04BC,Dopamine agonists,65+,Total,34.25,0.2,0.8,241,72
3,Prince Edward Island,L01BA,Folic acid analogues,65+,Total,34.09,0.2,1.4,389,73
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,**,**,**,**,74
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,Total,**,**,**,**,75
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,Total,32.51,0.2,0.6,167,76
3,Prince Edward Island,J01AA,Tetracyclines,65+,Total,32.07,0.2,9.6,"2,748",77
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,**,**,**,**,78
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,30.93,0.2,6.2,"1,789",79
3,Prince Edward Island,B01AB,Heparin group,65+,Total,30.15,0.2,0.5,155,80
3,Prince Edward Island,L03AX,Other immunostimulants,65+,Total,**,**,**,*,81
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,Total,29.05,0.2,5.5,"1,591",82
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,Total,**,**,**,**,83
3,Prince Edward Island,A06AB,Contact laxatives,65+,Total,26.75,0.1,1.5,442,84
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,26.7,0.1,0.2,66,85
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,Total,25.79,0.1,4.2,"1,212",86
3,Prince Edward Island,M01AH,Coxibs,65+,Total,24.26,0.1,3,859,87
3,Prince Edward Island,L01BC,Pyrimidine analogues,65+,Total,23.57,0.1,1.1,329,88
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,Total,23.13,0.1,0.1,20,89
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",65+,Total,23.02,0.1,0.4,128,90
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,Total,22.56,0.1,12.2,"3,505",91
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,Total,22.21,0.1,1.6,467,92
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**,**,**,*,93
3,Prince Edward Island,A07AA,Antibiotics,65+,Total,21.78,0.1,1.4,414,94
3,Prince Edward Island,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,Total,**,**,**,**,95
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,Total,21.15,0.1,2.2,639,96
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,Total,21.01,0.1,0.9,271,97
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,Total,20.85,0.1,1.9,557,98
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,Total,20.34,0.1,1.7,494,99
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,Total,20.04,0.1,1.8,521,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,741.07,8.6,0.3,45,1
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,M,671.17,7.8,0.4,58,2
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,M,427.94,5,0.2,27,3
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,M,380.2,4.4,1.2,155,4
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,M,**,**,**,**,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,M,319.62,3.7,5.3,699,6
3,Prince Edward Island,L02BB,Antiandrogens,65+,M,297.96,3.5,0.7,88,7
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,M,284.98,3.3,53.2,"7,005",8
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,M,**,**,**,**,9
3,Prince Edward Island,R03BB,Anticholinergics,65+,M,213.36,2.5,8.8,"1,161",10
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,191.18,2.2,2.1,275,11
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,M,165.67,1.9,22.4,"2,942",12
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,M,158.64,1.8,31.6,"4,155",13
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,152.74,1.8,4.3,567,14
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,15
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,M,136.56,1.6,27.4,"3,609",16
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,116.62,1.4,15.8,"2,083",17
3,Prince Edward Island,R03BA,Glucocorticoids,65+,M,110.15,1.3,4.1,534,18
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,M,102.2,1.2,26.7,"3,520",19
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,M,**,**,**,**,20
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,M,**,**,**,**,21
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,M,66.19,0.8,10.2,"1,340",22
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,M,**,**,**,**,23
3,Prince Edward Island,N03AX,Other antiepileptics,65+,M,60.93,0.7,5.1,677,24
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,M,**,**,**,*,25
3,Prince Edward Island,C01DA,Organic nitrates,65+,M,55.54,0.6,4.4,581,26
3,Prince Edward Island,A10BA,Biguanides,65+,M,55.04,0.6,17.8,"2,346",27
3,Prince Edward Island,A10BB,Sulfonylureas,65+,M,54.58,0.6,8.6,"1,128",28
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,M,51.82,0.6,3.6,471,29
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,M,49.86,0.6,0.1,12,30
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,48.97,0.6,1.6,205,31
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,48.3,0.6,7.8,"1,030",32
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,M,47.89,0.6,6.2,813,33
3,Prince Edward Island,N06AX,Other antidepressants,65+,M,46.85,0.5,7.4,980,34
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,46.07,0.5,14,"1,847",35
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**,**,**,**,36
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,M,45.94,0.5,0.8,103,37
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,45.71,0.5,1,135,38
3,Prince Edward Island,H03AA,Thyroid hormones,65+,M,42.55,0.5,12.5,"1,647",39
3,Prince Edward Island,R01AD,Corticosteroids,65+,M,**,**,**,**,40
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,M,**,**,**,**,41
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,M,40.81,0.5,3.4,448,42
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,43
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,M,**,**,**,**,44
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,M,**,**,**,**,45
3,Prince Edward Island,N05AX,Other antipsychotics,65+,M,**,**,**,**,46
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,**,**,**,**,47
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,M,35.08,0.4,5.8,765,48
3,Prince Edward Island,H02AB,Glucocorticoids,65+,M,33.52,0.4,16.1,"2,116",49
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,32.45,0.4,9.2,"1,216",50
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,31.58,0.4,4.3,564,51
3,Prince Edward Island,N06DA,Anticholinesterases,65+,M,**,**,**,**,52
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,30.71,0.4,3.8,500,53
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,M,29.73,0.3,2,261,54
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,M,28.59,0.3,9.4,"1,238",55
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,M,28.41,0.3,6.6,873,56
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,M,**,**,**,**,57
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,M,**,**,**,**,58
3,Prince Edward Island,A09AA,Enzyme preparations,65+,M,**,**,**,**,59
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,M,23.43,0.3,8.1,"1,061",60
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,M,20.01,0.2,10.5,"1,378",61
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,**,**,**,**,62
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,M,**,**,**,**,63
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,M,**,**,**,**,64
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,M,**,**,**,**,65
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,15.95,0.2,2.2,291,66
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,**,**,**,**,67
3,Prince Edward Island,D06BB,Antivirals,65+,M,15.8,0.2,0.7,98,68
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,M,15.43,0.2,0.6,83,69
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,M,**,**,**,**,70
3,Prince Edward Island,N04BC,Dopamine agonists,65+,M,**,**,**,**,71
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,14.15,0.2,0.3,42,72
3,Prince Edward Island,L01BC,Pyrimidine analogues,65+,M,**,**,**,**,73
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,13.48,0.2,6,785,74
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,M,13.26,0.2,5.4,711,75
3,Prince Edward Island,L01AX,Other alkylating agents,65+,M,**,**,**,*,76
3,Prince Edward Island,B01AB,Heparin group,65+,M,**,**,**,**,77
3,Prince Edward Island,J01AA,Tetracyclines,65+,M,12.93,0.2,9.4,"1,243",78
3,Prince Edward Island,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,**,**,**,**,79
3,Prince Edward Island,L01BA,Folic acid analogues,65+,M,11.82,0.1,1.1,141,80
3,Prince Edward Island,N02BE,Anilides,65+,M,11.18,0.1,1.5,194,81
3,Prince Edward Island,M05BA,Bisphosphonates,65+,M,**,**,**,**,82
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,M,10.81,0.1,2.5,325,83
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,M,10.32,0.1,0.1,9,84
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,M,10.17,0.1,2.6,338,85
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,M,9.8,0.1,11.8,"1,548",86
3,Prince Edward Island,M01AH,Coxibs,65+,M,9.23,0.1,2.6,348,87
3,Prince Edward Island,C02CA,Alpha-adrenoreceptor antagonists,65+,M,9.11,0.1,0.5,64,88
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,M,**,**,**,**,89
3,Prince Edward Island,A06AB,Contact laxatives,65+,M,8.89,0.1,1.2,164,90
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,M,**,**,**,**,91
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,M,**,**,**,**,92
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,M,8.12,0.1,1.5,191,93
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,M,**,**,**,**,94
3,Prince Edward Island,C10AB,Fibrates,65+,M,**,**,**,**,95
3,Prince Edward Island,A07AA,Antibiotics,65+,M,**,**,**,**,96
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,M,7.64,0.1,1.6,209,97
3,Prince Edward Island,A06AD,Osmotically acting laxatives,65+,M,7.45,0.1,0.5,70,98
3,Prince Edward Island,S01AE,Fluoroquinolones,65+,M,**,**,**,**,99
3,Prince Edward Island,D06AX,Other antibiotics for topical use,65+,M,**,**,**,**,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,743.34,7.5,0.4,56,1
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,F,678.78,6.9,0.3,43,2
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,F,**,**,**,**,3
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,F,490.83,5,0.4,62,4
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,F,258.84,2.6,37.6,"5,837",5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,F,253.84,2.6,3.5,545,6
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,249.78,2.5,2.1,329,7
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,F,**,**,**,**,8
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,F,221.23,2.2,0.1,20,9
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,F,220.24,2.2,34.5,"5,363",10
3,Prince Edward Island,R03BB,Anticholinergics,65+,F,211.83,2.1,7.1,"1,108",11
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,F,194.67,2,20.2,"3,129",12
3,Prince Edward Island,R03BA,Glucocorticoids,65+,F,178.71,1.8,5.5,861,13
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,166.84,1.7,17.8,"2,770",14
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,146.36,1.5,8.5,"1,315",15
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,F,143.64,1.5,20.1,"3,121",16
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,F,**,**,**,**,17
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,131.11,1.3,2.9,444,18
3,Prince Edward Island,H03AA,Thyroid hormones,65+,F,130.83,1.3,30.6,"4,752",19
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,F,125.07,1.3,16.7,"2,599",20
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,F,112.72,1.1,20.8,"3,228",21
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,F,**,**,**,**,22
3,Prince Edward Island,N03AX,Other antiepileptics,65+,F,89.3,0.9,6.7,"1,038",23
3,Prince Edward Island,L03AB,Interferons,65+,F,**,**,**,*,24
3,Prince Edward Island,N06AX,Other antidepressants,65+,F,81.79,0.8,11,"1,709",25
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,F,80.09,0.8,4.3,662,26
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,F,**,**,**,**,27
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,F,72.29,0.7,1,162,28
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,F,72.18,0.7,7.2,"1,123",29
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,67.86,0.7,7.4,"1,148",30
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,67.37,0.7,6,930,31
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,F,**,**,**,**,32
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,61.67,0.6,15.8,"2,448",33
3,Prince Edward Island,C01DA,Organic nitrates,65+,F,59.51,0.6,3.6,554,34
3,Prince Edward Island,R01AD,Corticosteroids,65+,F,**,**,**,**,35
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,36
3,Prince Edward Island,H02AB,Glucocorticoids,65+,F,53.09,0.5,17.2,"2,671",37
3,Prince Edward Island,N06DA,Anticholinesterases,65+,F,**,**,**,**,38
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,F,51.77,0.5,2.4,375,39
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,F,48.21,0.5,10.9,"1,686",40
3,Prince Edward Island,M05BA,Bisphosphonates,65+,F,**,**,**,**,41
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,F,**,**,**,*,42
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,44.64,0.5,1.1,169,43
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,F,44.08,0.4,10.4,"1,617",44
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**,**,**,**,45
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,**,**,**,**,46
3,Prince Edward Island,A10BB,Sulfonylureas,65+,F,40.84,0.4,5.1,797,47
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,F,**,**,**,**,48
3,Prince Edward Island,A10BA,Biguanides,65+,F,40.48,0.4,11.1,"1,730",49
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,40.37,0.4,4.4,683,50
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,F,**,**,**,**,51
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,F,36.87,0.4,15.4,"2,394",52
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,F,34.77,0.4,2.3,363,53
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,F,**,**,**,**,54
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,34.11,0.3,1,152,55
3,Prince Edward Island,A09AA,Enzyme preparations,65+,F,**,**,**,**,56
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,31.45,0.3,8.3,"1,295",57
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,F,31.06,0.3,4.2,655,58
3,Prince Edward Island,L03AX,Other immunostimulants,65+,F,**,**,**,*,59
3,Prince Edward Island,N05AX,Other antipsychotics,65+,F,**,**,**,**,60
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,F,**,**,**,**,61
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,F,**,**,**,**,62
3,Prince Edward Island,N02BE,Anilides,65+,F,25.8,0.3,2.6,407,63
3,Prince Edward Island,D06BB,Antivirals,65+,F,22.79,0.2,1.4,214,64
3,Prince Edward Island,L01BA,Folic acid analogues,65+,F,22.27,0.2,1.6,248,65
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,*,66
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,F,22.09,0.2,7.7,"1,202",67
3,Prince Edward Island,N04BC,Dopamine agonists,65+,F,**,**,**,**,68
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,19.98,0.2,3.3,505,69
3,Prince Edward Island,J01AA,Tetracyclines,65+,F,19.14,0.2,9.7,"1,505",70
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,F,**,**,**,**,71
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,F,**,**,**,**,72
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",65+,F,18.03,0.2,0.7,101,73
3,Prince Edward Island,A06AB,Contact laxatives,65+,F,17.86,0.2,1.8,278,74
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,17.46,0.2,6.5,"1,004",75
3,Prince Edward Island,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,76
3,Prince Edward Island,B01AB,Heparin group,65+,F,**,**,**,**,77
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,F,17.08,0.2,0.5,84,78
3,Prince Edward Island,J01XE,Nitrofuran derivatives,65+,F,**,**,**,**,79
3,Prince Edward Island,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,80
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,F,15.79,0.2,5.7,880,81
3,Prince Edward Island,L01XC,Monoclonal antibodies,65+,F,**,**,**,*,82
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,**,**,**,**,83
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,**,**,**,**,84
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,F,**,**,**,**,85
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,15.09,0.2,0.8,117,86
3,Prince Edward Island,M01AH,Coxibs,65+,F,15.02,0.2,3.3,511,87
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,F,**,**,**,**,88
3,Prince Edward Island,A07AA,Antibiotics,65+,F,**,**,**,**,89
3,Prince Edward Island,A03FA,Propulsives,65+,F,13.99,0.1,3.4,534,90
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,F,12.81,0.1,0.1,11,91
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,F,12.76,0.1,12.6,"1,957",92
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,12.55,0.1,0.2,24,93
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,F,12.39,0.1,2,312,94
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,F,12.22,0.1,2,303,95
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,F,**,**,**,**,96
3,Prince Edward Island,J01DD,Third-generation cephalosporins,65+,F,11.32,0.1,2.5,383,97
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,F,**,**,**,**,98
3,Prince Edward Island,S01AE,Fluoroquinolones,65+,F,**,**,**,**,99
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,F,10.98,0.1,1.9,301,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"3,230.19",19.6,1.2,240,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,Total,**,**,**,**,2
3,Prince Edward Island,A16AB,Enzymes,<65,Total,**,**,**,*,3
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,528.04,3.2,4.8,959,4
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,Total,526.87,3.2,0.5,93,5
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,520.9,3.2,6,"1,200",6
3,Prince Edward Island,N05AX,Other antipsychotics,<65,Total,515.57,3.1,2.6,518,7
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,Total,484.87,2.9,0.3,60,8
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,Total,475.38,2.9,3.2,637,9
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,Total,404.82,2.5,0.1,20,10
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,Total,384.7,2.3,18.2,"3,602",11
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,335.34,2,6.5,"1,299",12
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,Total,330.15,2,2.8,554,13
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,Total,278.79,1.7,0.1,20,14
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,Total,277.16,1.7,0.1,22,15
3,Prince Edward Island,N03AX,Other antiepileptics,<65,Total,254.88,1.5,5.8,"1,145",16
3,Prince Edward Island,N06AX,Other antidepressants,<65,Total,253.32,1.5,11.3,"2,244",17
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,Total,234.15,1.4,17.5,"3,470",18
3,Prince Edward Island,R03BA,Glucocorticoids,<65,Total,225,1.4,5,983,19
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,Total,158.84,1,4.6,919,20
3,Prince Edward Island,L03AB,Interferons,<65,Total,158.62,1,0.1,16,21
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,Total,142.87,0.9,12,"2,377",22
3,Prince Edward Island,L03AX,Other immunostimulants,<65,Total,**,**,**,**,23
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,Total,123.89,0.8,3.2,644,24
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,Total,108.22,0.7,1.8,355,25
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,104.31,0.6,11.7,"2,324",26
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,Total,98.25,0.6,2,406,27
3,Prince Edward Island,L02BB,Antiandrogens,<65,Total,**,**,**,**,28
3,Prince Edward Island,R03BB,Anticholinergics,<65,Total,94.29,0.6,2,395,29
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,Total,89.49,0.5,2.4,480,30
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,Total,86.14,0.5,7.7,"1,523",31
3,Prince Edward Island,A10BA,Biguanides,<65,Total,82.73,0.5,14.2,"2,826",32
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,80.99,0.5,3.5,697,33
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,78.82,0.5,0.5,94,34
3,Prince Edward Island,R07AX,Other respiratory system products,<65,Total,**,**,**,*,35
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,74.67,0.5,3.5,696,36
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,69.3,0.4,4.5,901,37
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,Total,**,**,**,**,38
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,68.42,0.4,1.3,253,39
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,Total,65.14,0.4,5,990,40
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,Total,62.02,0.4,0.4,87,41
3,Prince Edward Island,H03AA,Thyroid hormones,<65,Total,61.88,0.4,2.9,579,42
3,Prince Edward Island,A10BB,Sulfonylureas,<65,Total,59.16,0.4,6,"1,193",43
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,57.27,0.3,4.3,846,44
3,Prince Edward Island,R01AD,Corticosteroids,<65,Total,57.24,0.3,8.7,"1,733",45
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,Total,**,**,**,**,46
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,Total,50.04,0.3,0.1,19,47
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,Total,47.81,0.3,5.2,"1,033",48
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,45.65,0.3,0.1,17,49
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,Total,44.76,0.3,9,"1,784",50
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,44.55,0.3,2,406,51
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,Total,40.18,0.2,16.6,"3,288",52
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,Total,37.25,0.2,1,197,53
3,Prince Edward Island,L01AX,Other alkylating agents,<65,Total,**,**,**,**,54
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,Total,35.59,0.2,0.3,51,55
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,<65,Total,**,**,**,*,56
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,Total,32.99,0.2,0.9,184,57
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,Total,32.93,0.2,0.8,161,58
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,32.63,0.2,2.2,431,59
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,Total,31.44,0.2,5.7,"1,135",60
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,30.07,0.2,1.4,269,61
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,Total,29.24,0.2,1.2,229,62
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,Total,28.49,0.2,1.1,209,63
3,Prince Edward Island,A06AB,Contact laxatives,<65,Total,26.27,0.2,1.3,267,64
3,Prince Edward Island,J01AA,Tetracyclines,<65,Total,25.21,0.2,6.6,"1,309",65
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,24.82,0.2,1.1,210,66
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,24.38,0.1,5.3,"1,043",67
3,Prince Edward Island,H02AB,Glucocorticoids,<65,Total,24.12,0.1,6.7,"1,332",68
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,**,**,**,**,69
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,Total,22.84,0.1,3.7,742,70
3,Prince Edward Island,G03AC,Progestogens,<65,Total,**,**,**,**,71
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,Total,22.26,0.1,1.1,223,72
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,Total,22.03,0.1,0.8,162,73
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,Total,21.84,0.1,1.1,211,74
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,Total,21.71,0.1,0.4,87,75
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,21.46,0.1,0.2,33,76
3,Prince Edward Island,N02BE,Anilides,<65,Total,20.47,0.1,1.4,281,77
3,Prince Edward Island,L01BA,Folic acid analogues,<65,Total,20.05,0.1,0.7,143,78
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,**,**,**,**,79
3,Prince Edward Island,J01FA,Macrolides,<65,Total,19.76,0.1,3.7,739,80
3,Prince Edward Island,J01XX,Other antibacterials,<65,Total,**,**,**,*,81
3,Prince Edward Island,G02BA,Intrauterine contraceptives,<65,Total,18.95,0.1,0.3,51,82
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,Total,18.72,0.1,2,404,83
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,Total,**,**,**,**,84
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,18.4,0.1,0.2,46,85
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,Total,18.27,0.1,0.5,94,86
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,Total,17.49,0.1,0.5,96,87
3,Prince Edward Island,A03FA,Propulsives,<65,Total,16.44,0.1,1.6,317,88
3,Prince Edward Island,C01DA,Organic nitrates,<65,Total,15.89,0.1,0.8,154,89
3,Prince Edward Island,N05AD,Butyrophenone derivatives,<65,Total,15.03,0.1,0.3,58,90
3,Prince Edward Island,J02AC,Triazole derivatives,<65,Total,14.3,0.1,0.1,11,91
3,Prince Edward Island,D06BB,Antivirals,<65,Total,14.24,0.1,0.3,63,92
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",<65,Total,14.19,0.1,0.4,79,93
3,Prince Edward Island,D06AX,Other antibiotics for topical use,<65,Total,14.15,0.1,2.1,423,94
3,Prince Edward Island,B01AA,Vitamin K antagonists,<65,Total,14.14,0.1,0.9,180,95
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,Total,13.96,0.1,3.8,747,96
3,Prince Edward Island,N05BE,Azaspirodecanedione derivatives,<65,Total,**,**,**,**,97
3,Prince Edward Island,M05BA,Bisphosphonates,<65,Total,13.78,0.1,0.6,127,98
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,**,**,**,**,99
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,<65,Total,13.26,0.1,0.4,88,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"1,390.49",16.8,1.2,109,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,M,**,**,**,**,2
3,Prince Edward Island,A16AB,Enzymes,<65,M,**,**,**,*,3
3,Prince Edward Island,N05AX,Other antipsychotics,<65,M,**,**,**,**,4
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,333.66,4,5.4,497,5
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,M,**,**,**,**,6
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,M,266.04,3.2,7.4,676,7
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,M,253.71,3.1,0.5,42,8
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,M,230.95,2.8,0.1,10,9
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,189.79,2.3,7.9,725,10
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,M,**,**,**,**,11
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,M,162.04,2,2.6,239,12
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,M,152.92,1.8,14.3,"1,309",13
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,M,126.97,1.5,0.1,13,14
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,M,112.59,1.4,16.6,"1,526",15
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,M,**,**,**,**,16
3,Prince Edward Island,N03AX,Other antiepileptics,<65,M,107.7,1.3,5,462,17
3,Prince Edward Island,N06AX,Other antidepressants,<65,M,97.48,1.2,8.8,810,18
3,Prince Edward Island,R03BA,Glucocorticoids,<65,M,95.85,1.2,4.5,410,19
3,Prince Edward Island,L02BB,Antiandrogens,<65,M,95.31,1.2,0.1,8,20
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,M,81.63,1,14.7,"1,352",21
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,M,78.12,0.9,4.1,374,22
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,M,65.43,0.8,2.2,202,23
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,M,60.25,0.7,2.9,267,24
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,M,**,**,**,**,25
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,M,49.48,0.6,9.9,911,26
3,Prince Edward Island,A10BA,Biguanides,<65,M,47.05,0.6,17.5,"1,608",27
3,Prince Edward Island,R03BB,Anticholinergics,<65,M,45.98,0.6,2,179,28
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,45.16,0.5,10.7,979,29
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,M,44.92,0.5,1.9,173,30
3,Prince Edward Island,L03AX,Other immunostimulants,<65,M,**,**,**,**,31
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,M,35.75,0.4,6.3,574,32
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,35.16,0.4,3.1,281,33
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,35.12,0.4,1.3,121,34
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,<65,M,**,**,**,*,35
3,Prince Edward Island,A10BB,Sulfonylureas,<65,M,32.92,0.4,7.8,711,36
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,32.69,0.4,0.4,38,37
3,Prince Edward Island,L03AB,Interferons,<65,M,**,**,**,*,38
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,28.11,0.3,2.7,247,39
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,27.79,0.3,2.7,247,40
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,M,27.72,0.3,6.6,604,41
3,Prince Edward Island,L01AX,Other alkylating agents,<65,M,**,**,**,*,42
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,26.33,0.3,4.4,403,43
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,M,26.2,0.3,0.4,35,44
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,M,**,**,**,**,45
3,Prince Edward Island,R01AD,Corticosteroids,<65,M,**,**,**,**,46
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,M,**,**,**,**,47
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,M,21.13,0.3,0.1,7,48
3,Prince Edward Island,J01XX,Other antibacterials,<65,M,**,**,**,*,49
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,M,**,**,**,**,50
3,Prince Edward Island,H03AA,Thyroid hormones,<65,M,17.73,0.2,1.6,150,51
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,M,17.58,0.2,7.6,697,52
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,M,16.67,0.2,0.1,7,53
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,M,16.25,0.2,14.5,"1,327",54
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,M,**,**,**,**,55
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,M,14.78,0.2,1,93,56
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,M,14.73,0.2,0.8,75,57
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,M,**,**,**,**,58
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,**,**,**,**,59
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,12.2,0.1,0.3,32,60
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,M,11.87,0.1,3.4,309,61
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,<65,M,**,**,**,**,62
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,M,11.59,0.1,1.3,122,63
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,**,**,**,**,64
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,M,**,**,**,**,65
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,M,10.71,0.1,0.6,58,66
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,10.61,0.1,1.3,116,67
3,Prince Edward Island,A06AB,Contact laxatives,<65,M,10.61,0.1,1.3,118,68
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,10.19,0.1,4.4,404,69
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,M,**,**,**,*,70
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,M,10.05,0.1,0.8,76,71
3,Prince Edward Island,B01AA,Vitamin K antagonists,<65,M,9.55,0.1,1.3,118,72
3,Prince Edward Island,J01AA,Tetracyclines,<65,M,9.37,0.1,5.6,517,73
3,Prince Edward Island,H02AB,Glucocorticoids,<65,M,9.23,0.1,6,547,74
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,M,8.75,0.1,2.1,189,75
3,Prince Edward Island,C01DA,Organic nitrates,<65,M,8.66,0.1,1,90,76
3,Prince Edward Island,N02BE,Anilides,<65,M,8.65,0.1,1.5,134,77
3,Prince Edward Island,N05AD,Butyrophenone derivatives,<65,M,**,**,**,**,78
3,Prince Edward Island,H01BA,Vasopressin and analogues,<65,M,**,**,**,**,79
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,M,**,**,**,**,80
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,<65,M,**,**,**,**,81
3,Prince Edward Island,G03HA,"Antiandrogens, plain",<65,M,**,**,**,**,82
3,Prince Edward Island,N03AB,Hydantoin derivatives,<65,M,**,**,**,**,83
3,Prince Edward Island,J01FA,Macrolides,<65,M,7.77,0.1,3.3,307,84
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,M,**,**,**,**,85
3,Prince Edward Island,L01BA,Folic acid analogues,<65,M,6.81,0.1,0.5,50,86
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,**,**,**,**,87
3,Prince Edward Island,N04AC,Ethers of tropine or tropine derivatives,<65,M,**,**,**,**,88
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,6.65,0.1,1.2,113,89
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,M,**,**,**,**,90
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,M,6.44,0.1,3.3,307,91
3,Prince Edward Island,N05BE,Azaspirodecanedione derivatives,<65,M,**,**,**,**,92
3,Prince Edward Island,D06BB,Antivirals,<65,M,6.37,0.1,0.2,15,93
3,Prince Edward Island,G03BA,3-oxoandrosten (4) derivatives,<65,M,**,**,**,**,94
3,Prince Edward Island,C03DA,Aldosterone antagonists,<65,M,6.11,0.1,0.9,81,95
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,<65,M,**,**,**,**,96
3,Prince Edward Island,A03FA,Propulsives,<65,M,5.66,0.1,1.2,109,97
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,<65,M,**,**,**,**,98
3,Prince Edward Island,N07BB,Drugs used in alcohol dependence,<65,M,**,**,**,**,99
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,<65,M,5.17,0.1,1.6,144,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"1,839.70",22.5,1.2,131,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,**,2
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,F,357.9,4.4,0.4,47,3
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,F,273.16,3.3,0.5,51,4
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,F,254.86,3.1,4.9,524,5
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,F,231.77,2.8,21.5,"2,293",6
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,194.38,2.4,4.3,462,7
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,F,173.88,2.1,0.1,10,8
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,F,**,**,**,**,9
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,F,168.11,2.1,3,315,10
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,F,**,**,**,**,11
3,Prince Edward Island,N06AX,Other antidepressants,<65,F,155.84,1.9,13.4,"1,434",12
3,Prince Edward Island,N03AX,Other antiepileptics,<65,F,147.17,1.8,6.4,683,13
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,145.56,1.8,5.4,574,14
3,Prince Edward Island,N05AX,Other antipsychotics,<65,F,**,**,**,**,15
3,Prince Edward Island,R03BA,Glucocorticoids,<65,F,129.15,1.6,5.4,573,16
3,Prince Edward Island,L03AB,Interferons,<65,F,**,**,**,**,17
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,F,121.56,1.5,18.2,"1,944",18
3,Prince Edward Island,L03AX,Other immunostimulants,<65,F,**,**,**,**,19
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,F,**,**,**,**,20
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,F,80.72,1,5.1,545,21
3,Prince Edward Island,R07AX,Other respiratory system products,<65,F,**,**,**,*,22
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,69.3,0.8,8.4,901,23
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,F,63.64,0.8,3.5,377,24
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,F,61.24,0.7,9.6,"1,025",25
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,59.14,0.7,12.6,"1,345",26
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,F,**,**,**,*,27
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,F,53.33,0.7,2.2,233,28
3,Prince Edward Island,R03BB,Anticholinergics,<65,F,48.32,0.6,2,216,29
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,46.88,0.6,4.2,449,30
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,46.13,0.6,0.5,56,31
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,45.83,0.6,3.9,416,32
3,Prince Edward Island,H03AA,Thyroid hormones,<65,F,44.15,0.5,4,429,33
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,F,42.79,0.5,1.4,153,34
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,F,**,**,**,**,35
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,F,36.66,0.4,5.7,612,36
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,F,35.81,0.4,0.5,52,37
3,Prince Edward Island,A10BA,Biguanides,<65,F,35.67,0.4,11.4,"1,218",38
3,Prince Edward Island,R01AD,Corticosteroids,<65,F,**,**,**,**,39
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,F,33.37,0.4,0.1,12,40
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,33.3,0.4,1.2,132,41
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,30.94,0.4,4.2,443,42
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,F,**,**,**,**,43
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,30.07,0.4,2.5,269,44
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,F,29.38,0.4,3.9,416,45
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,F,27.18,0.3,10.2,"1,087",46
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,F,26.54,0.3,1.3,139,47
3,Prince Edward Island,A10BB,Sulfonylureas,<65,F,26.25,0.3,4.5,482,48
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,F,24.52,0.3,0.1,10,49
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,24.38,0.3,1.9,205,50
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,F,23.93,0.3,18.4,"1,961",51
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,F,**,**,**,**,52
3,Prince Edward Island,G03AC,Progestogens,<65,F,**,**,**,**,53
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,22.02,0.3,3,315,54
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,F,20.1,0.2,4,429,55
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,F,19.26,0.2,1.7,177,56
3,Prince Edward Island,G02BA,Intrauterine contraceptives,<65,F,18.95,0.2,0.5,51,57
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,F,18.26,0.2,1,109,58
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,F,**,**,**,**,59
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,16.44,0.2,1.5,159,60
3,Prince Edward Island,J01AA,Tetracyclines,<65,F,15.84,0.2,7.4,792,61
3,Prince Edward Island,A06AB,Contact laxatives,<65,F,15.66,0.2,1.4,149,62
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,F,**,**,**,**,63
3,Prince Edward Island,H02AB,Glucocorticoids,<65,F,14.89,0.2,7.4,785,64
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,14.19,0.2,6,639,65
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,F,13.71,0.2,1.1,116,66
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,F,**,**,**,**,67
3,Prince Edward Island,L01BA,Folic acid analogues,<65,F,13.24,0.2,0.9,93,68
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,**,**,**,**,69
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",<65,F,12.05,0.1,0.6,63,70
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,F,**,**,**,**,71
3,Prince Edward Island,J01FA,Macrolides,<65,F,11.98,0.1,4.1,432,72
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,F,11.98,0.1,0.8,86,73
3,Prince Edward Island,N02BE,Anilides,<65,F,11.83,0.1,1.4,147,74
3,Prince Edward Island,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,75
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,F,10.97,0.1,4.1,433,76
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,<65,F,10.94,0.1,0.7,70,77
3,Prince Edward Island,A03FA,Propulsives,<65,F,10.79,0.1,2,208,78
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,F,**,**,**,**,79
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,F,10.67,0.1,0.9,101,80
3,Prince Edward Island,J01XE,Nitrofuran derivatives,<65,F,**,**,**,**,81
3,Prince Edward Island,A07AA,Antibiotics,<65,F,**,**,**,**,82
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,F,9.97,0.1,2,215,83
3,Prince Edward Island,J02AC,Triazole derivatives,<65,F,**,**,**,**,84
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,<65,F,**,**,**,**,85
3,Prince Edward Island,M05BA,Bisphosphonates,<65,F,**,**,**,**,86
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,F,**,**,**,**,87
3,Prince Edward Island,L01AX,Other alkylating agents,<65,F,**,**,**,*,88
3,Prince Edward Island,D06AX,Other antibiotics for topical use,<65,F,**,**,**,**,89
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,F,**,**,**,**,90
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,*,91
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,**,**,**,**,92
3,Prince Edward Island,N05AE,Indole derivatives,<65,F,**,**,**,**,93
3,Prince Edward Island,B03AA,"Iron bivalent, oral preparations",<65,F,7.98,0.1,0.7,78,94
3,Prince Edward Island,D06BB,Antivirals,<65,F,7.87,0.1,0.5,48,95
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,F,7.52,0.1,4.1,440,96
3,Prince Edward Island,D10BA,Retinoids for treatment of acne,<65,F,**,**,**,**,97
3,Prince Edward Island,N05BE,Azaspirodecanedione derivatives,<65,F,**,**,**,**,98
3,Prince Edward Island,C01DA,Organic nitrates,<65,F,7.23,0.1,0.6,64,99
3,Prince Edward Island,C02CA,Alpha-adrenoreceptor antagonists,<65,F,7.23,0.1,0.4,45,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"25,529.98",11.1,1,"1,552",1
4,Nova Scotia,L04AX,Other immunosuppressants,Total,Total,"13,794.54",6,0.5,839,2
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,Total,"12,336.10",5.4,0.2,369,3
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,Total,"7,997.53",3.5,0.5,756,4
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"6,901.17",3,0.1,139,5
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"6,591.30",2.9,44.9,"70,729",6
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"5,604.86",2.4,4.5,"7,021",7
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,Total,"5,211.30",2.3,36.8,"57,895",8
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"5,183.02",2.3,4.2,"6,551",9
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,Total,"3,927.85",1.7,19.6,"30,796",10
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,Total,"3,853.58",1.7,0.2,264,11
4,Nova Scotia,R03BB,Anticholinergics,Total,Total,"3,460.35",1.5,8.3,"13,040",12
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,Total,"3,377.57",1.5,22.5,"35,336",13
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,Total,"3,305.36",1.4,2.9,"4,523",14
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,149.48",1.4,16,"25,242",15
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,Total,"3,138.20",1.4,23.4,"36,879",16
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"2,914.00",1.3,0.6,900,17
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,881.23",1.3,3.6,"5,666",18
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,Total,"2,830.48",1.2,7.9,"12,363",19
4,Nova Scotia,H03AA,Thyroid hormones,Total,Total,"2,685.78",1.2,21.6,"34,072",20
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,Total,Total,"2,599.44",1.1,0.1,162,21
4,Nova Scotia,N06AX,Other antidepressants,Total,Total,"2,560.85",1.1,12.5,"19,740",22
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"2,542.87",1.1,14.4,"22,656",23
4,Nova Scotia,R03BA,Glucocorticoids,Total,Total,"2,380.35",1,6.3,"9,977",24
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"2,290.66",1,3,"4,757",25
4,Nova Scotia,R07AX,Other respiratory system products,Total,Total,"1,925.33",0.8,0,6,26
4,Nova Scotia,N03AX,Other antiepileptics,Total,Total,"1,841.75",0.8,5.3,"8,313",27
4,Nova Scotia,L02BB,Antiandrogens,Total,Total,"1,819.36",0.8,0.3,500,28
4,Nova Scotia,A10BA,Biguanides,Total,Total,"1,602.30",0.7,15.5,"24,365",29
4,Nova Scotia,N05AX,Other antipsychotics,Total,Total,"1,602.09",0.7,1.8,"2,856",30
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,542.38",0.7,16.6,"26,097",31
4,Nova Scotia,B01AB,Heparin group,Total,Total,"1,460.17",0.6,0.9,"1,466",32
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,Total,"1,405.64",0.6,0.7,"1,170",33
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,Total,"1,351.51",0.6,3.6,"5,669",34
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,Total,"1,340.77",0.6,0.1,107,35
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,314.36",0.6,7.4,"11,695",36
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,Total,"1,261.09",0.5,10.9,"17,216",37
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,260.04",0.5,3.8,"6,034",38
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"1,246.31",0.5,3.6,"5,730",39
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,182.18",0.5,5,"7,900",40
4,Nova Scotia,A10BB,Sulfonylureas,Total,Total,"1,170.40",0.5,8,"12,553",41
4,Nova Scotia,S01ED,Beta-blocking agents,Total,Total,"1,161.95",0.5,3.3,"5,133",42
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,Total,"1,161.06",0.5,10.4,"16,351",43
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,Total,"1,149.54",0.5,5.3,"8,359",44
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,125.58",0.5,0.9,"1,487",45
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,Total,"1,104.44",0.5,2.9,"4,574",46
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,080.00",0.5,4.2,"6,666",47
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,"1,040.77",0.5,9.1,"14,260",48
4,Nova Scotia,C01DA,Organic nitrates,Total,Total,"1,017.03",0.4,6.1,"9,528",49
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"1,015.66",0.4,6.6,"10,385",50
4,Nova Scotia,M05BA,Bisphosphonates,Total,Total,"1,015.57",0.4,5.6,"8,799",51
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,975.66,0.4,5.8,"9,092",52
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,963.43,0.4,0.2,358,53
4,Nova Scotia,L01XX,Other antineoplastic agents,Total,Total,935.26,0.4,0.2,267,54
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,Total,931.13,0.4,0.1,80,55
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,Total,928.76,0.4,8.2,"12,899",56
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,Total,899.89,0.4,7.8,"12,250",57
4,Nova Scotia,H02AB,Glucocorticoids,Total,Total,884.29,0.4,13.3,"20,928",58
4,Nova Scotia,C03AA,"Thiazides, plain",Total,Total,845.28,0.4,12.2,"19,164",59
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,Total,822.45,0.4,1.1,"1,710",60
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,Total,818.61,0.4,5,"7,894",61
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,777.54,0.3,0.5,793,62
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,766.1,0.3,0,70,63
4,Nova Scotia,A16AB,Enzymes,Total,Total,**,**,**,*,64
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,729.06,0.3,5.8,"9,061",65
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,663.94,0.3,1.4,"2,258",66
4,Nova Scotia,B03XA,Other antianemic preparations,Total,Total,654.51,0.3,0,32,67
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,Total,639.69,0.3,4.8,"7,537",68
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,639.12,0.3,0.6,989,69
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,Total,633.54,0.3,1.4,"2,207",70
4,Nova Scotia,A12BA,Potassium,Total,Total,620.73,0.3,3.8,"5,971",71
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,Total,601.68,0.3,3.8,"5,982",72
4,Nova Scotia,N06DA,Anticholinesterases,Total,Total,587.27,0.3,1.6,"2,553",73
4,Nova Scotia,R01AD,Corticosteroids,Total,Total,566.52,0.2,7,"11,065",74
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,Total,553.33,0.2,0.9,"1,353",75
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,Total,548.64,0.2,0.4,559,76
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,Total,548.02,0.2,1.9,"3,067",77
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,547.81,0.2,2.4,"3,750",78
4,Nova Scotia,S01XA,Other ophthalmologicals,Total,Total,543.21,0.2,4.7,"7,343",79
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,492.23,0.2,0,30,80
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,Total,490.64,0.2,8.1,"12,780",81
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,Total,469.07,0.2,4.2,"6,628",82
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,Total,Total,446.18,0.2,0.2,251,83
4,Nova Scotia,A04AD,Other antiemetics,Total,Total,429.67,0.2,0.6,905,84
4,Nova Scotia,A03FA,Propulsives,Total,Total,412.3,0.2,3.7,"5,897",85
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,410.51,0.2,0.5,781,86
4,Nova Scotia,L01AX,Other alkylating agents,Total,Total,409.18,0.2,0,70,87
4,Nova Scotia,L02BG,Aromatase inhibitors,Total,Total,407.27,0.2,0.7,"1,170",88
4,Nova Scotia,L01BA,Folic acid analogues,Total,Total,392.38,0.2,1.4,"2,177",89
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,388.83,0.2,0.5,721,90
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,383.07,0.2,0.2,351,91
4,Nova Scotia,C03DA,Aldosterone antagonists,Total,Total,371.73,0.2,2.6,"4,073",92
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,Total,369.73,0.2,2.5,"3,954",93
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,Total,363.62,0.2,4.5,"7,141",94
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,360.78,0.2,2.9,"4,614",95
4,Nova Scotia,J01AA,Tetracyclines,Total,Total,360.59,0.2,8.9,"14,060",96
4,Nova Scotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,354.33,0.2,0.2,331,97
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,Total,Total,353.91,0.2,1.3,"2,088",98
4,Nova Scotia,B03AC,"Iron, parenteral preparations",Total,Total,350.63,0.2,0.3,480,99
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,Total,332.87,0.1,5.3,"8,265",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"11,182.44",10.2,1,660,1
4,Nova Scotia,L04AX,Other immunosuppressants,Total,M,"8,318.46",7.6,0.6,380,2
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,M,"6,240.87",5.7,0.3,183,3
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,M,"5,323.60",4.9,0.2,107,4
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,M,"3,313.74",3,52.8,"35,781",5
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"3,064.79",2.8,5.4,"3,659",6
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"2,810.15",2.6,1.3,859,7
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,Total,M,"2,599.44",2.4,0.2,162,8
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,351.39",2.1,4.3,"2,895",9
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,M,"2,196.15",2,0.3,212,10
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,M,"2,058.40",1.9,34.3,"23,267",11
4,Nova Scotia,L02BB,Antiandrogens,Total,M,"1,819.36",1.7,0.7,500,12
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,M,"1,795.22",1.6,0.2,107,13
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,M,"1,754.30",1.6,20.4,"13,843",14
4,Nova Scotia,R03BB,Anticholinergics,Total,M,"1,683.69",1.5,9,"6,096",15
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,M,"1,676.04",1.5,3.4,"2,274",16
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,M,"1,667.88",1.5,26.5,"17,942",17
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,582.18",1.4,4.3,"2,887",18
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,M,"1,465.79",1.3,26.6,"18,010",19
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,M,"1,282.16",1.2,7.5,"5,112",20
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"1,162.33",1.1,3.4,"2,336",21
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,028.82",0.9,11.7,"7,907",22
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,987.35,0.9,13.4,"9,104",23
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,973.56,0.9,14.7,"9,938",24
4,Nova Scotia,R07AX,Other respiratory system products,Total,M,**,**,**,*,25
4,Nova Scotia,R03BA,Glucocorticoids,Total,M,919.89,0.8,5.5,"3,700",26
4,Nova Scotia,N06AX,Other antidepressants,Total,M,854.24,0.8,9.7,"6,597",27
4,Nova Scotia,A10BA,Biguanides,Total,M,849.96,0.8,19.1,"12,930",28
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,M,840.74,0.8,1.1,719,29
4,Nova Scotia,N03AX,Other antiepileptics,Total,M,780.89,0.7,4.7,"3,207",30
4,Nova Scotia,N05AX,Other antipsychotics,Total,M,779.55,0.7,1.7,"1,173",31
4,Nova Scotia,B01AB,Heparin group,Total,M,700.82,0.6,1,680,32
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,672,0.6,15.4,"10,451",33
4,Nova Scotia,H03AA,Thyroid hormones,Total,M,659.02,0.6,12.5,"8,475",34
4,Nova Scotia,A10BB,Sulfonylureas,Total,M,613.17,0.6,9.9,"6,707",35
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,M,585.56,0.5,6.1,"4,155",36
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,560.96,0.5,6.2,"4,224",37
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,M,554.41,0.5,0.1,49,38
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,**,**,**,**,39
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,M,523.4,0.5,0.9,633,40
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,520.89,0.5,3.4,"2,301",41
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,M,519.91,0.5,1.4,925,42
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,M,509.47,0.5,3.3,"2,264",43
4,Nova Scotia,C01DA,Organic nitrates,Total,M,495.18,0.5,7.6,"5,118",44
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,M,483.87,0.4,10.4,"7,053",45
4,Nova Scotia,S01ED,Beta-blocking agents,Total,M,464.51,0.4,3.2,"2,183",46
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,M,449.7,0.4,8.2,"5,550",47
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,M,441.52,0.4,2.7,"1,811",48
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,M,435.24,0.4,6.3,"4,281",49
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,435.17,0.4,5.6,"3,777",50
4,Nova Scotia,L01XX,Other antineoplastic agents,Total,M,422.96,0.4,0.2,105,51
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,412.67,0.4,0.6,423,52
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,406.63,0.4,8.5,"5,731",53
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,M,397.87,0.4,7.2,"4,879",54
4,Nova Scotia,H02AB,Glucocorticoids,Total,M,388.26,0.4,13.1,"8,878",55
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,377.42,0.3,5.4,"3,632",56
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,362.48,0.3,0.2,121,57
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,M,357.06,0.3,1.9,"1,295",58
4,Nova Scotia,B03XA,Other antianemic preparations,Total,M,352.23,0.3,0,16,59
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,M,339.52,0.3,6.9,"4,667",60
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,335.72,0.3,1.6,"1,074",61
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,M,327.38,0.3,6.5,"4,430",62
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,325.36,0.3,0.7,485,63
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,M,320.01,0.3,1.1,775,64
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,317.79,0.3,5.9,"3,985",65
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,M,315.39,0.3,2.4,"1,647",66
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,Total,M,306.09,0.3,2.6,"1,768",67
4,Nova Scotia,C03AA,"Thiazides, plain",Total,M,294.58,0.3,10.1,"6,864",68
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,294.47,0.3,0.8,567,69
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,M,289.07,0.3,0,23,70
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,M,288.56,0.3,0.4,302,71
4,Nova Scotia,L01AX,Other alkylating agents,Total,M,261.92,0.2,0.1,42,72
4,Nova Scotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,258.9,0.2,0.4,250,73
4,Nova Scotia,R01AD,Corticosteroids,Total,M,253.14,0.2,6.6,"4,498",74
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,M,233.22,0.2,8.2,"5,567",75
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,M,232.49,0.2,1.9,"1,301",76
4,Nova Scotia,N06DA,Anticholinesterases,Total,M,226.16,0.2,1.4,950,77
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,225.77,0.2,0.6,418,78
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,M,224.6,0.2,3.2,"2,139",79
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,224.55,0.2,0,19,80
4,Nova Scotia,A12BA,Potassium,Total,M,206.22,0.2,3,"2,019",81
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,204.32,0.2,0.1,63,82
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,M,197.58,0.2,3.1,"2,119",83
4,Nova Scotia,C03DA,Aldosterone antagonists,Total,M,195.37,0.2,3.1,"2,084",84
4,Nova Scotia,B03AC,"Iron, parenteral preparations",Total,M,191.44,0.2,0.4,250,85
4,Nova Scotia,A04AD,Other antiemetics,Total,M,180.22,0.2,0.5,362,86
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,M,173.22,0.2,3.6,"2,442",87
4,Nova Scotia,J01AA,Tetracyclines,Total,M,165.42,0.2,8.7,"5,905",88
4,Nova Scotia,N05CD,Benzodiazepine derivatives,Total,M,156.19,0.1,1.4,957,89
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,M,156.16,0.1,4.3,"2,898",90
4,Nova Scotia,C01AA,Digitalis glycosides,Total,M,149.19,0.1,1.5,988,91
4,Nova Scotia,S01XA,Other ophthalmologicals,Total,M,149.07,0.1,3.3,"2,267",92
4,Nova Scotia,M05BA,Bisphosphonates,Total,M,147.01,0.1,1.9,"1,284",93
4,Nova Scotia,A07AA,Antibiotics,Total,M,146.49,0.1,1.3,869,94
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,146.12,0.1,2.2,"1,491",95
4,Nova Scotia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,144.5,0.1,0.2,147,96
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,M,141.81,0.1,5,"3,379",97
4,Nova Scotia,M03BX,Other centrally acting agents,Total,M,132.71,0.1,3.1,"2,116",98
4,Nova Scotia,A03FA,Propulsives,Total,M,132.02,0.1,3.1,"2,085",99
4,Nova Scotia,A09AA,Enzyme preparations,Total,M,130.37,0.1,0.3,179,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"14,347.54",12,1,892,1
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,F,"6,095.23",5.1,0.2,186,2
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,F,"5,801.38",4.8,0.6,544,3
4,Nova Scotia,L04AX,Other immunosuppressants,Total,F,"5,476.08",4.6,0.5,459,4
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,F,"3,277.56",2.7,39,"34,948",5
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,F,"3,152.90",2.6,38.6,"34,628",6
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"2,831.63",2.4,4.1,"3,656",7
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"2,540.06",2.1,3.8,"3,362",8
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,F,"2,173.55",1.8,18.9,"16,953",9
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,120.67",1.8,19.3,"17,335",10
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,F,"2,058.36",1.7,0.2,157,11
4,Nova Scotia,H03AA,Thyroid hormones,Total,F,"2,026.75",1.7,28.6,"25,597",12
4,Nova Scotia,R03BB,Anticholinergics,Total,F,"1,776.66",1.5,7.7,"6,944",13
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,F,"1,709.70",1.4,19.4,"17,394",14
4,Nova Scotia,N06AX,Other antidepressants,Total,F,"1,706.61",1.4,14.7,"13,143",15
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,F,"1,672.40",1.4,21.1,"18,869",16
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,F,"1,629.32",1.4,2.5,"2,249",17
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,F,"1,577.57",1.3,0,32,18
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,555.52",1.3,15.1,"13,552",19
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,F,"1,548.32",1.3,8.1,"7,251",20
4,Nova Scotia,R03BA,Glucocorticoids,Total,F,"1,460.46",1.2,7,"6,277",21
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,299.04",1.1,3.1,"2,779",22
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,128.33",0.9,2.7,"2,421",23
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,076.00",0.9,7.4,"6,641",24
4,Nova Scotia,N03AX,Other antiepileptics,Total,F,"1,060.86",0.9,5.7,"5,106",25
4,Nova Scotia,R07AX,Other respiratory system products,Total,F,**,**,**,*,26
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,F,944.64,0.8,4.9,"4,387",27
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,879.19,0.7,8.8,"7,918",28
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,870.38,0.7,17.5,"15,646",29
4,Nova Scotia,M05BA,Bisphosphonates,Total,F,868.56,0.7,8.4,"7,515",30
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,F,842.04,0.7,3.8,"3,405",31
4,Nova Scotia,N05AX,Other antipsychotics,Total,F,822.54,0.7,1.9,"1,683",32
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,F,811.39,0.7,13,"11,666",33
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,F,786.36,0.7,0.1,58,34
4,Nova Scotia,B01AB,Heparin group,Total,F,759.36,0.6,0.9,786,35
4,Nova Scotia,A10BA,Biguanides,Total,F,752.34,0.6,12.8,"11,435",36
4,Nova Scotia,A16AB,Enzymes,Total,F,**,**,**,*,37
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,725.42,0.6,3.8,"3,429",38
4,Nova Scotia,S01ED,Beta-blocking agents,Total,F,697.44,0.6,3.3,"2,950",39
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,F,677.18,0.6,10.4,"9,298",40
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,F,662.92,0.6,3.1,"2,763",41
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,F,642.06,0.5,0.1,57,42
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,634.14,0.5,9.5,"8,529",43
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,621.22,0.5,4.1,"3,676",44
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,F,602.19,0.5,1,854,45
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,600.95,0.5,0.3,237,46
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,598.24,0.5,6.1,"5,460",47
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,F,589.24,0.5,9.2,"8,232",48
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,F,572.51,0.5,8.7,"7,820",49
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,F,564.9,0.5,0.5,451,50
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,F,563.99,0.5,4.7,"4,204",51
4,Nova Scotia,A10BB,Sulfonylureas,Total,F,557.23,0.5,6.5,"5,846",52
4,Nova Scotia,C03AA,"Thiazides, plain",Total,F,550.71,0.5,13.7,"12,300",53
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,541.55,0.5,0.1,51,54
4,Nova Scotia,C01DA,Organic nitrates,Total,F,521.85,0.4,4.9,"4,410",55
4,Nova Scotia,L01XX,Other antineoplastic agents,Total,F,512.31,0.4,0.2,162,56
4,Nova Scotia,H02AB,Glucocorticoids,Total,F,496.04,0.4,13.4,"12,050",57
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,**,58
4,Nova Scotia,A12BA,Potassium,Total,F,414.5,0.3,4.4,"3,952",59
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,411.27,0.3,5.7,"5,076",60
4,Nova Scotia,L02BG,Aromatase inhibitors,Total,F,403.55,0.3,1.3,"1,159",61
4,Nova Scotia,S01XA,Other ophthalmologicals,Total,F,394.14,0.3,5.7,"5,076",62
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,F,383.37,0.3,4,"3,613",63
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,F,377.08,0.3,4.3,"3,843",64
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,364.86,0.3,0.4,370,65
4,Nova Scotia,N06DA,Anticholinesterases,Total,F,361.11,0.3,1.8,"1,603",66
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,Total,F,354.42,0.3,0.2,210,67
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,328.22,0.3,1.3,"1,184",68
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,F,315.53,0.3,2,"1,766",69
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,313.77,0.3,0.6,504,70
4,Nova Scotia,R01AD,Corticosteroids,Total,F,313.38,0.3,7.3,"6,567",71
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,F,302.54,0.3,0.9,785,72
4,Nova Scotia,B03XA,Other antianemic preparations,Total,F,302.29,0.3,0,16,73
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,F,295.85,0.2,4.7,"4,186",74
4,Nova Scotia,A05AA,Bile acids and derivatives,Total,F,286.03,0.2,0.2,180,75
4,Nova Scotia,A03FA,Propulsives,Total,F,280.28,0.2,4.3,"3,812",76
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,F,276.47,0.2,1,912,77
4,Nova Scotia,L01BA,Folic acid analogues,Total,F,272.05,0.2,1.7,"1,497",78
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,F,260.08,0.2,0.3,257,79
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,F,257.42,0.2,8,"7,213",80
4,Nova Scotia,A04AD,Other antiemetics,Total,F,249.45,0.2,0.6,543,81
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,F,241.83,0.2,3,"2,658",82
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,F,233.31,0.2,0.6,578,83
4,Nova Scotia,J01XE,Nitrofuran derivatives,Total,F,219.14,0.2,8.5,"7,610",84
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,214.66,0.2,3.5,"3,123",85
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,F,207.46,0.2,4.7,"4,243",86
4,Nova Scotia,M01AH,Coxibs,Total,F,205.49,0.2,3.4,"3,024",87
4,Nova Scotia,M03BX,Other centrally acting agents,Total,F,196.45,0.2,3.7,"3,317",88
4,Nova Scotia,J01AA,Tetracyclines,Total,F,195.17,0.2,9.1,"8,155",89
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,F,191.06,0.2,5.5,"4,886",90
4,Nova Scotia,A07AA,Antibiotics,Total,F,181.42,0.2,1.8,"1,617",91
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,Total,F,178.75,0.1,0.3,288,92
4,Nova Scotia,A09AA,Enzyme preparations,Total,F,178.14,0.1,0.2,205,93
4,Nova Scotia,C03DA,Aldosterone antagonists,Total,F,176.36,0.1,2.2,"1,989",94
4,Nova Scotia,J01DB,First-generation cephalosporins,Total,F,174.95,0.1,8.5,"7,661",95
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,F,172.14,0.1,2,"1,835",96
4,Nova Scotia,N04BC,Dopamine agonists,Total,F,172.07,0.1,1.1,997,97
4,Nova Scotia,J01CA,Penicillins with extended spectrum,Total,F,168.75,0.1,11.7,"10,458",98
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,163.06,0.1,0.3,303,99
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,159.95,0.1,6.1,"5,476",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"12,808.20",7.1,0.5,690,1
4,Nova Scotia,L04AX,Other immunosuppressants,65+,Total,"10,567.35",5.8,0.4,523,2
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,Total,"10,083.52",5.6,0.2,297,3
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"6,307.97",3.5,49.7,"65,071",4
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"4,931.52",2.7,4.5,"5,832",5
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,892.47",2.7,4.6,"6,011",6
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,Total,"4,840.43",2.7,39.4,"51,585",7
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,Total,"3,867.36",2.1,0.3,421,8
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,Total,"3,781.32",2.1,21.9,"28,696",9
4,Nova Scotia,R03BB,Anticholinergics,65+,Total,"3,272.09",1.8,9.1,"11,972",10
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,Total,"3,219.63",1.8,3.3,"4,323",11
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,Total,"3,218.10",1.8,24.5,"32,095",12
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,Total,"3,019.77",1.7,26.1,"34,237",13
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"2,723.11",1.5,0.6,829,14
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"2,692.79",1.5,15.4,"20,119",15
4,Nova Scotia,H03AA,Thyroid hormones,65+,Total,"2,549.69",1.4,23.6,"30,978",16
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,65+,Total,"2,519.00",1.4,0.1,156,17
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"2,462.84",1.4,16.1,"21,128",18
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,453.23",1.4,3.5,"4,544",19
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,Total,"2,399.97",1.3,0.1,152,20
4,Nova Scotia,R03BA,Glucocorticoids,65+,Total,"2,166.47",1.2,6.5,"8,505",21
4,Nova Scotia,N06AX,Other antidepressants,65+,Total,"2,157.58",1.2,12.1,"15,904",22
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,Total,"2,108.68",1.2,7.9,"10,337",23
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"2,029.17",1.1,3.1,"4,064",24
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,Total,"1,796.64",1,0,36,25
4,Nova Scotia,L02BB,Antiandrogens,65+,Total,"1,722.62",1,0.4,488,26
4,Nova Scotia,A10BA,Biguanides,65+,Total,"1,486.29",0.8,16.3,"21,359",27
4,Nova Scotia,N03AX,Other antiepileptics,65+,Total,"1,421.03",0.8,4.9,"6,480",28
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"1,387.72",0.8,16.8,"22,020",29
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,Total,"1,336.02",0.7,4.2,"5,533",30
4,Nova Scotia,B01AB,Heparin group,65+,Total,"1,183.17",0.7,0.9,"1,217",31
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,172.43",0.6,4.2,"5,459",32
4,Nova Scotia,S01ED,Beta-blocking agents,65+,Total,"1,147.67",0.6,3.8,"5,005",33
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,133.66",0.6,7.4,"9,710",34
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,Total,"1,131.01",0.6,0.1,83,35
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,Total,"1,111.96",0.6,11.6,"15,209",36
4,Nova Scotia,A10BB,Sulfonylureas,65+,Total,"1,103.45",0.6,8.5,"11,173",37
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,Total,"1,086.93",0.6,5.7,"7,527",38
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,Total,"1,080.88",0.6,3.3,"4,353",39
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,Total,"1,071.70",0.6,11.1,"14,585",40
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,049.43",0.6,5.6,"7,360",41
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"1,035.17",0.6,10.8,"14,148",42
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"1,021.02",0.6,4.6,"5,984",43
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,Total,"1,006.65",0.6,0.9,"1,222",44
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,004.53",0.6,3.3,"4,320",45
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,994.71,0.5,7.6,"9,955",46
4,Nova Scotia,M05BA,Bisphosphonates,65+,Total,993.03,0.5,6.5,"8,510",47
4,Nova Scotia,C01DA,Organic nitrates,65+,Total,992.7,0.5,6.9,"9,008",48
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,939.78,0.5,6.5,"8,457",49
4,Nova Scotia,N05AX,Other antipsychotics,65+,Total,871.28,0.5,1.6,"2,125",50
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,Total,858.63,0.5,8.8,"11,510",51
4,Nova Scotia,C03AA,"Thiazides, plain",65+,Total,810.35,0.4,13.6,"17,756",52
4,Nova Scotia,H02AB,Glucocorticoids,65+,Total,792.23,0.4,13.8,"18,102",53
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,Total,786.66,0.4,5.7,"7,440",54
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,Total,783.57,0.4,8,"10,491",55
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,Total,783.15,0.4,1.2,"1,624",56
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,757.67,0.4,0.6,765,57
4,Nova Scotia,L01XX,Other antineoplastic agents,65+,Total,732.59,0.4,0.2,249,58
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,Total,693.83,0.4,0,57,59
4,Nova Scotia,B03XA,Other antianemic preparations,65+,Total,**,**,**,**,60
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,**,**,**,**,61
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,627.61,0.3,1.6,"2,063",62
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,Total,620.62,0.3,5.4,"7,110",63
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,618.22,0.3,5.8,"7,636",64
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,602.6,0.3,0.7,909,65
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,Total,587.1,0.3,1.5,"1,942",66
4,Nova Scotia,A12BA,Potassium,65+,Total,586.08,0.3,4.2,"5,540",67
4,Nova Scotia,N06DA,Anticholinesterases,65+,Total,580.8,0.3,1.9,"2,533",68
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,576.72,0.3,0,44,69
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,Total,542.23,0.3,0.4,548,70
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,541.91,0.3,2.8,"3,676",71
4,Nova Scotia,R01AD,Corticosteroids,65+,Total,527.95,0.3,7.6,"9,929",72
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,Total,525.19,0.3,5.4,"7,089",73
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,Total,511.05,0.3,2,"2,668",74
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,Total,455.47,0.3,8.7,"11,333",75
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,Total,431.28,0.2,4.5,"5,949",76
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,Total,425.95,0.2,3.4,"4,419",77
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,425.24,0.2,0,20,78
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,65+,Total,397.89,0.2,0.2,210,79
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,382.38,0.2,0.5,708,80
4,Nova Scotia,L02BG,Aromatase inhibitors,65+,Total,381.64,0.2,0.8,"1,034",81
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,372.64,0.2,0.3,346,82
4,Nova Scotia,A03FA,Propulsives,65+,Total,354.68,0.2,3.8,"5,038",83
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,Total,351.87,0.2,5.2,"6,780",84
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,Total,349.96,0.2,2.8,"3,702",85
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,Total,346.74,0.2,2.8,"3,606",86
4,Nova Scotia,L01BA,Folic acid analogues,65+,Total,343.85,0.2,1.3,"1,757",87
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,65+,Total,339.1,0.2,1.5,"1,916",88
4,Nova Scotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,331.54,0.2,0.2,301,89
4,Nova Scotia,J01AA,Tetracyclines,65+,Total,328.71,0.2,9.4,"12,321",90
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,328.07,0.2,0.5,626,91
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,310.93,0.2,2.9,"3,841",92
4,Nova Scotia,A04AD,Other antiemetics,65+,Total,306.49,0.2,0.5,678,93
4,Nova Scotia,B03AC,"Iron, parenteral preparations",65+,Total,299.73,0.2,0.3,389,94
4,Nova Scotia,C01AA,Digitalis glycosides,65+,Total,295.35,0.2,1.5,"1,909",95
4,Nova Scotia,M01AH,Coxibs,65+,Total,292.26,0.2,3.2,"4,206",96
4,Nova Scotia,A09AA,Enzyme preparations,65+,Total,278.8,0.2,0.2,316,97
4,Nova Scotia,N05CD,Benzodiazepine derivatives,65+,Total,276.41,0.2,1.7,"2,165",98
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,Total,274.82,0.2,4.8,"6,275",99
4,Nova Scotia,N04BC,Dopamine agonists,65+,Total,273.62,0.2,1,"1,365",100
4,Nova Scotia,L04AX,Other immunosuppressants,65+,M,"6,696.42",7.7,0.5,257,1
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"5,115.80",5.9,0.5,265,2
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,M,"5,110.09",5.9,0.3,147,3
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,M,"3,166.22",3.7,58.1,"32,913",4
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"2,754.85",3.2,5.5,"3,096",5
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"2,723.11",3.1,1.5,829,6
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,65+,M,"2,519.00",2.9,0.3,156,7
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,222.19",2.6,4.7,"2,664",8
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,M,"1,910.22",2.2,36.7,"20,804",9
4,Nova Scotia,L02BB,Antiandrogens,65+,M,"1,722.62",2,0.9,488,10
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,M,"1,675.87",1.9,22.5,"12,771",11
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,M,"1,624.91",1.9,3.8,"2,171",12
4,Nova Scotia,R03BB,Anticholinergics,65+,M,"1,596.85",1.8,9.9,"5,624",13
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,M,"1,583.73",1.8,28.7,"16,244",14
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,409.00",1.6,0,28,15
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,M,"1,399.39",1.6,29.3,"16,596",16
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,360.78",1.6,4.1,"2,347",17
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,M,"1,170.45",1.3,0.2,133,18
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,M,"1,127.89",1.3,0.1,64,19
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"1,040.24",1.2,3.5,"2,009",20
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,954.65,1.1,16.9,"9,566",21
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,949.28,1.1,14.9,"8,463",22
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,M,941.98,1.1,7.5,"4,221",23
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,M,863.65,1,11.1,"6,286",24
4,Nova Scotia,R03BA,Glucocorticoids,65+,M,843.87,1,5.6,"3,158",25
4,Nova Scotia,A10BA,Biguanides,65+,M,792.84,0.9,20.3,"11,494",26
4,Nova Scotia,N06AX,Other antidepressants,65+,M,709.77,0.8,9.4,"5,352",27
4,Nova Scotia,H03AA,Thyroid hormones,65+,M,628.6,0.7,13.8,"7,820",28
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,609.99,0.7,15.7,"8,870",29
4,Nova Scotia,N03AX,Other antiepileptics,65+,M,601.55,0.7,4.4,"2,518",30
4,Nova Scotia,B01AB,Heparin group,65+,M,582.29,0.7,1,567,31
4,Nova Scotia,A10BB,Sulfonylureas,65+,M,580.93,0.7,10.6,"6,029",32
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,M,553.19,0.6,6.6,"3,738",33
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,34
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,533.28,0.6,6.9,"3,894",35
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,M,502.86,0.6,3.9,"2,207",36
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,M,499.83,0.6,1.5,876,37
4,Nova Scotia,C01DA,Organic nitrates,65+,M,482.55,0.6,8.5,"4,826",38
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,M,475.62,0.5,0.9,528,39
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,M,475.54,0.5,0.1,36,40
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,M,461.93,0.5,11.6,"6,549",41
4,Nova Scotia,S01ED,Beta-blocking agents,65+,M,458.27,0.5,3.8,"2,126",42
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,M,429.24,0.5,3,"1,710",43
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,M,415.23,0.5,7.1,"4,014",44
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,406.82,0.5,3,"1,683",45
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,404.45,0.5,10.1,"5,698",46
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,403.39,0.5,0.7,412,47
4,Nova Scotia,L01XX,Other antineoplastic agents,65+,M,395.82,0.5,0.2,100,48
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,M,383.79,0.4,8.1,"4,565",49
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,M,373.2,0.4,8.2,"4,669",50
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,368.04,0.4,5.5,"3,143",51
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,363.1,0.4,6,"3,380",52
4,Nova Scotia,B03XA,Other antianemic preparations,65+,M,**,**,**,**,53
4,Nova Scotia,H02AB,Glucocorticoids,65+,M,348.29,0.4,13.7,"7,775",54
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,M,332.51,0.4,2,"1,155",55
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**,**,**,**,56
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,M,312.85,0.4,7.4,"4,169",57
4,Nova Scotia,N05AX,Other antipsychotics,65+,M,311.48,0.4,1.3,754,58
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,308.93,0.4,0.8,449,59
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,65+,M,296.96,0.3,2.9,"1,670",60
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,M,295.32,0.3,2.7,"1,507",61
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,M,**,**,**,**,62
4,Nova Scotia,C03AA,"Thiazides, plain",65+,M,279.36,0.3,11.2,"6,337",63
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,M,279.21,0.3,6.7,"3,782",64
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,276.63,0.3,0.9,521,65
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,273.38,0.3,6,"3,418",66
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,**,**,**,**,67
4,Nova Scotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,**,68
4,Nova Scotia,R01AD,Corticosteroids,65+,M,**,**,**,**,69
4,Nova Scotia,N06DA,Anticholinesterases,65+,M,**,**,**,**,70
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,M,219.98,0.3,0,18,71
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,M,219.48,0.3,8.9,"5,030",72
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,M,217.8,0.3,2,"1,143",73
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,**,**,**,**,74
4,Nova Scotia,A12BA,Potassium,65+,M,195.08,0.2,3.3,"1,858",75
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,**,76
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,M,186.7,0.2,3.5,"1,980",77
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,185.11,0.2,0.6,364,78
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,M,182.72,0.2,3.2,"1,831",79
4,Nova Scotia,B03AC,"Iron, parenteral preparations",65+,M,167.68,0.2,0.4,202,80
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,M,160.31,0.2,3.9,"2,213",81
4,Nova Scotia,J01AA,Tetracyclines,65+,M,153.52,0.2,9.3,"5,256",82
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,M,150.39,0.2,4.9,"2,761",83
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,M,144.81,0.2,2.8,"1,569",84
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,M,142.96,0.2,3.8,"2,175",85
4,Nova Scotia,C01AA,Digitalis glycosides,65+,M,**,**,**,**,86
4,Nova Scotia,M05BA,Bisphosphonates,65+,M,140.28,0.2,2.1,"1,209",87
4,Nova Scotia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,**,**,**,**,88
4,Nova Scotia,N05CD,Benzodiazepine derivatives,65+,M,136.49,0.2,1.5,835,89
4,Nova Scotia,A04AD,Other antiemetics,65+,M,128.25,0.1,0.5,274,90
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,125.88,0.1,2.3,"1,297",91
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,M,121.9,0.1,4.7,"2,679",92
4,Nova Scotia,A07AA,Antibiotics,65+,M,120.23,0.1,1.3,728,93
4,Nova Scotia,C10AB,Fibrates,65+,M,119.13,0.1,1.4,816,94
4,Nova Scotia,N07BC,Drugs used in opioid dependence,65+,M,**,**,**,**,95
4,Nova Scotia,N04BC,Dopamine agonists,65+,M,117.45,0.1,0.9,500,96
4,Nova Scotia,A03FA,Propulsives,65+,M,116.77,0.1,3.2,"1,811",97
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,115.73,0.1,6.3,"3,547",98
4,Nova Scotia,A09AA,Enzyme preparations,65+,M,112.2,0.1,0.2,140,99
4,Nova Scotia,G03BA,3-oxoandrosten (4) derivatives,65+,M,111.62,0.1,0.7,404,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"7,692.40",8.2,0.6,425,1
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,F,"4,973.44",5.3,0.2,150,2
4,Nova Scotia,L04AX,Other immunosuppressants,65+,F,"3,870.93",4.1,0.4,266,3
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,F,"3,141.75",3.3,43.2,"32,158",4
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,F,"2,930.22",3.1,41.4,"30,781",5
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,F,"2,696.91",2.9,0.4,288,6
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,670.29",2.8,4.5,"3,347",7
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"2,176.67",2.3,3.7,"2,736",8
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,F,"2,105.45",2.2,21.4,"15,925",9
4,Nova Scotia,H03AA,Thyroid hormones,65+,F,"1,921.09",2,31.1,"23,158",10
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,829.13",1.9,18.6,"13,833",11
4,Nova Scotia,R03BB,Anticholinergics,65+,F,"1,675.25",1.8,8.5,"6,348",12
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,F,"1,634.37",1.7,21.3,"15,851",13
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,F,"1,620.39",1.7,23.7,"17,641",14
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,F,"1,594.72",1.7,2.9,"2,152",15
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"1,513.55",1.6,17,"12,665",16
4,Nova Scotia,N06AX,Other antidepressants,65+,F,"1,447.81",1.5,14.2,"10,552",17
4,Nova Scotia,R03BA,Glucocorticoids,65+,F,"1,322.60",1.4,7.2,"5,347",18
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,F,"1,272.08",1.3,0.1,88,19
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,F,"1,166.70",1.2,8.2,"6,116",20
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"1,092.45",1.2,3,"2,197",21
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"1,020.16",1.1,8,"5,978",22
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,988.92,1,2.8,"2,055",23
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,F,877.11,0.9,5.3,"3,952",24
4,Nova Scotia,M05BA,Bisphosphonates,65+,F,852.75,0.9,9.8,"7,301",25
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,F,833.15,0.9,4.5,"3,326",26
4,Nova Scotia,N03AX,Other antiepileptics,65+,F,819.48,0.9,5.3,"3,962",27
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,777.73,0.8,17.7,"13,150",28
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,765.62,0.8,8.8,"6,567",29
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,F,698.5,0.7,13.3,"9,916",30
4,Nova Scotia,A10BA,Biguanides,65+,F,693.45,0.7,13.3,"9,865",31
4,Nova Scotia,S01ED,Beta-blocking agents,65+,F,689.4,0.7,3.9,"2,879",32
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,F,655.47,0.7,0.1,47,33
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,F,651.64,0.7,3.6,"2,643",34
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,F,650.02,0.7,11.6,"8,660",35
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,630.72,0.7,11.4,"8,450",36
4,Nova Scotia,B01AB,Heparin group,65+,F,600.88,0.6,0.9,650,37
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,597.71,0.6,3.5,"2,637",38
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,576.68,0.6,6.8,"5,077",39
4,Nova Scotia,N05AX,Other antipsychotics,65+,F,559.81,0.6,1.8,"1,371",40
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,F,545.78,0.6,9.9,"7,341",41
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,F,533.75,0.6,5.1,"3,789",42
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,F,531.03,0.6,0.9,694,43
4,Nova Scotia,C03AA,"Thiazides, plain",65+,F,530.99,0.6,15.4,"11,419",44
4,Nova Scotia,A10BB,Sulfonylureas,65+,F,522.52,0.6,6.9,"5,144",45
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,516.14,0.5,4.7,"3,466",46
4,Nova Scotia,C01DA,Organic nitrates,65+,F,510.15,0.5,5.6,"4,182",47
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,F,504.35,0.5,9,"6,709",48
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,F,473.85,0.5,0.1,39,49
4,Nova Scotia,H02AB,Glucocorticoids,65+,F,443.93,0.5,13.9,"10,327",50
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,**,51
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,**,52
4,Nova Scotia,A12BA,Potassium,65+,F,391.01,0.4,5,"3,682",53
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,F,387.64,0.4,0,8,54
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,**,**,**,**,55
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,F,382.23,0.4,6.6,"4,914",56
4,Nova Scotia,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,57
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,F,371.44,0.4,4.6,"3,426",58
4,Nova Scotia,N06DA,Anticholinesterases,65+,F,**,**,**,**,59
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,354.28,0.4,0.5,353,60
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,344.84,0.4,5.7,"4,218",61
4,Nova Scotia,L01XX,Other antineoplastic agents,65+,F,336.76,0.4,0.2,149,62
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,63
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**,**,**,**,64
4,Nova Scotia,B03XA,Other antianemic preparations,65+,F,**,**,**,**,65
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,293.67,0.3,0.6,460,66
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,F,293.25,0.3,2.1,"1,525",67
4,Nova Scotia,R01AD,Corticosteroids,65+,F,**,**,**,**,68
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,F,283.31,0.3,1,748,69
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,F,281.14,0.3,3.8,"2,850",70
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,F,270.97,0.3,5,"3,736",71
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,F,**,**,**,**,72
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,F,254.58,0.3,1.1,787,73
4,Nova Scotia,L01BA,Folic acid analogues,65+,F,238.28,0.3,1.6,"1,199",74
4,Nova Scotia,A03FA,Propulsives,65+,F,237.91,0.3,4.3,"3,227",75
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,F,236.83,0.3,3.4,"2,545",76
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,F,235.99,0.3,8.5,"6,303",77
4,Nova Scotia,J01XE,Nitrofuran derivatives,65+,F,203.25,0.2,9,"6,684",78
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,F,201.48,0.2,5.4,"4,019",79
4,Nova Scotia,M01AH,Coxibs,65+,F,185.88,0.2,3.6,"2,658",80
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,185.05,0.2,3.4,"2,544",81
4,Nova Scotia,A04AD,Other antiemetics,65+,F,178.24,0.2,0.5,404,82
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,83
4,Nova Scotia,J01AA,Tetracyclines,65+,F,175.19,0.2,9.5,"7,065",84
4,Nova Scotia,A09AA,Enzyme preparations,65+,F,166.6,0.2,0.2,176,85
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,F,164.02,0.2,2.4,"1,775",86
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,F,163.25,0.2,2.3,"1,722",87
4,Nova Scotia,J01DB,First-generation cephalosporins,65+,F,157.19,0.2,9,"6,692",88
4,Nova Scotia,N04BC,Dopamine agonists,65+,F,156.17,0.2,1.2,865,89
4,Nova Scotia,C01AA,Digitalis glycosides,65+,F,**,**,**,**,90
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,F,152.92,0.2,4.8,"3,596",91
4,Nova Scotia,A07AA,Antibiotics,65+,F,152.31,0.2,1.8,"1,372",92
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,142.96,0.2,0.4,262,93
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,142.69,0.2,6.2,"4,590",94
4,Nova Scotia,J01CA,Penicillins with extended spectrum,65+,F,142.23,0.2,11.2,"8,317",95
4,Nova Scotia,N05CD,Benzodiazepine derivatives,65+,F,139.91,0.1,1.8,"1,330",96
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,65+,F,137.08,0.1,2,"1,512",97
4,Nova Scotia,S01EC,Carbonic anhydrase inhibitors,65+,F,135.23,0.1,0.9,644,98
4,Nova Scotia,B03AC,"Iron, parenteral preparations",65+,F,132.05,0.1,0.3,187,99
4,Nova Scotia,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,F,127.08,0.1,2.9,"2,169",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"12,721.78",26.1,3.3,862,1
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"5,104.53",10.5,0.4,103,2
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,Total,"4,130.17",8.5,1.3,335,3
4,Nova Scotia,L04AX,Other immunosuppressants,<65,Total,"3,227.18",6.6,1.2,316,4
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,Total,"2,252.58",4.6,0.3,72,5
4,Nova Scotia,R07AX,Other respiratory system products,<65,Total,"1,925.33",4,0,6,6
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,Total,"1,453.61",3,0.4,112,7
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,Total,"1,216.64",2.5,3.6,955,8
4,Nova Scotia,A16AB,Enzymes,<65,Total,**,**,**,*,9
4,Nova Scotia,N05AX,Other antipsychotics,<65,Total,730.8,1.5,2.8,731,10
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,Total,721.8,1.5,7.7,"2,026",11
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,673.34,1.4,4.5,"1,189",12
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,Total,476.14,1,4.3,"1,134",13
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,456.7,0.9,19.4,"5,123",14
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,428,0.9,4.3,"1,122",15
4,Nova Scotia,N03AX,Other antiepileptics,<65,Total,420.71,0.9,6.9,"1,833",16
4,Nova Scotia,N06AX,Other antidepressants,<65,Total,403.27,0.8,14.5,"3,836",17
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,Total,370.86,0.8,23.9,"6,310",18
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,**,**,**,**,19
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,290.55,0.6,2,540,20
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,Total,283.33,0.6,21.4,"5,658",21
4,Nova Scotia,B01AB,Heparin group,<65,Total,277.01,0.6,0.9,249,22
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,261.49,0.5,2.6,693,23
4,Nova Scotia,L01AX,Other alkylating agents,<65,Total,257.51,0.5,0.1,38,24
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,241.78,0.5,5.3,"1,410",25
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,Total,237.31,0.5,0.1,23,26
4,Nova Scotia,R03BA,Glucocorticoids,<65,Total,213.89,0.4,5.6,"1,472",27
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,Total,209.76,0.4,0.1,24,28
4,Nova Scotia,L01XX,Other antineoplastic agents,<65,Total,202.68,0.4,0.1,18,29
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,190.88,0.4,0.3,71,30
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,189.39,0.4,0.1,26,31
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,Total,189.39,0.4,10,"2,631",32
4,Nova Scotia,A05AA,Bile acids and derivatives,<65,Total,188.29,0.4,0.1,34,33
4,Nova Scotia,R03BB,Anticholinergics,<65,Total,188.26,0.4,4,"1,068",34
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,180.7,0.4,7.5,"1,985",35
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,Total,175.74,0.4,5.9,"1,563",36
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,Total,159.47,0.3,12.3,"3,241",37
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,154.67,0.3,15.5,"4,077",38
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,Total,146.53,0.3,8,"2,100",39
4,Nova Scotia,H03AA,Thyroid hormones,<65,Total,136.09,0.3,11.7,"3,094",40
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,132.75,0.3,2,540,41
4,Nova Scotia,A04AD,Other antiemetics,<65,Total,123.18,0.3,0.9,227,42
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,Total,118.94,0.2,1,265,43
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,Total,118.43,0.2,10,"2,642",44
4,Nova Scotia,M03BX,Other centrally acting agents,<65,Total,117.79,0.2,5.4,"1,419",45
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,Total,116.32,0.2,6.7,"1,759",46
4,Nova Scotia,A10BA,Biguanides,<65,Total,116.01,0.2,11.4,"3,006",47
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,110.84,0.2,5.4,"1,425",48
4,Nova Scotia,A16AA,Amino acids and derivatives,<65,Total,108.16,0.2,0,8,49
4,Nova Scotia,L02BB,Antiandrogens,<65,Total,96.74,0.2,0,12,50
4,Nova Scotia,H02AB,Glucocorticoids,<65,Total,92.07,0.2,10.7,"2,826",51
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,Total,87.61,0.2,2.2,575,52
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,Total,85.73,0.2,0.8,200,53
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,<65,Total,80.44,0.2,0,6,54
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,80.03,0.2,5.8,"1,528",55
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,Total,75.17,0.2,0.3,77,56
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,Total,71.09,0.1,1.4,374,57
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,Total,70.13,0.1,5.3,"1,389",58
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,66.99,0.1,0,10,59
4,Nova Scotia,A10BB,Sulfonylureas,<65,Total,66.95,0.1,5.2,"1,380",60
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,Total,62.61,0.1,3.2,832,61
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,60.75,0.1,0.4,95,62
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,58.99,0.1,2.6,682,63
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,Total,58.05,0.1,7.5,"1,990",64
4,Nova Scotia,A03FA,Propulsives,<65,Total,57.62,0.1,3.3,859,65
4,Nova Scotia,A07AA,Antibiotics,<65,Total,55.37,0.1,1.5,386,66
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,Total,52.38,0.1,0.3,89,67
4,Nova Scotia,B03AC,"Iron, parenteral preparations",<65,Total,50.9,0.1,0.3,91,68
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,49.85,0.1,2.9,773,69
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,Total,49.1,0.1,4.3,"1,142",70
4,Nova Scotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,48.57,0.1,3.4,901,71
4,Nova Scotia,L01BA,Folic acid analogues,<65,Total,48.54,0.1,1.6,420,72
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,<65,Total,48.28,0.1,0.2,41,73
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,Total,47.68,0.1,0.8,212,74
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,Total,46.44,0.1,1,265,75
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,Total,46.03,0.1,1.1,279,76
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,Total,44.1,0.1,13.1,"3,457",77
4,Nova Scotia,N04BA,Dopa and dopa derivatives,<65,Total,39.3,0.1,0.3,86,78
4,Nova Scotia,N05CD,Benzodiazepine derivatives,<65,Total,38.85,0.1,1,277,79
4,Nova Scotia,R01AD,Corticosteroids,<65,Total,38.57,0.1,4.3,"1,136",80
4,Nova Scotia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,38.12,0.1,0.7,183,81
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,Total,37.79,0.1,2.6,679,82
4,Nova Scotia,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,37.14,0.1,1.7,441,83
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,Total,36.96,0.1,1.5,399,84
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,36.53,0.1,0.3,80,85
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,36.33,0.1,0.7,195,86
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,35.88,0.1,2.4,635,87
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,Total,35.17,0.1,5.5,"1,447",88
4,Nova Scotia,C03AA,"Thiazides, plain",<65,Total,34.93,0.1,5.3,"1,408",89
4,Nova Scotia,A12BA,Potassium,<65,Total,34.64,0.1,1.6,431,90
4,Nova Scotia,G02BA,Intrauterine contraceptives,<65,Total,33.45,0.1,0.6,150,91
4,Nova Scotia,B01AA,Vitamin K antagonists,<65,Total,31.95,0.1,1.7,454,92
4,Nova Scotia,J01AA,Tetracyclines,<65,Total,31.88,0.1,6.6,"1,739",93
4,Nova Scotia,N05AE,Indole derivatives,<65,Total,31.6,0.1,0.1,31,94
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,Total,31.59,0.1,6.3,"1,658",95
4,Nova Scotia,B02BX,Other systemic hemostatics,<65,Total,**,**,**,*,96
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,30.31,0.1,5.4,"1,419",97
4,Nova Scotia,A09AA,Enzyme preparations,<65,Total,29.71,0.1,0.3,68,98
4,Nova Scotia,R05DA,Opium alkaloids and derivatives,<65,Total,28.86,0.1,0.6,146,99
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,28.13,0.1,0.3,73,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"6,066.64",26.4,3.6,395,1
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,M,"3,914.60",17,0.7,79,2
4,Nova Scotia,L04AX,Other immunosuppressants,<65,M,"1,622.04",7,1.1,123,3
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,M,"1,130.78",4.9,0.3,36,4
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,M,"1,025.69",4.5,0.7,79,5
4,Nova Scotia,R07AX,Other respiratory system products,<65,M,**,**,**,*,6
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,M,**,**,**,**,7
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,M,667.34,2.9,0.4,43,8
4,Nova Scotia,N05AX,Other antipsychotics,<65,M,468.08,2,3.8,419,9
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,M,340.18,1.5,8,891,10
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,309.94,1.3,5.1,563,11
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,M,278.99,1.2,6,666,12
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,221.4,1,4.9,540,13
4,Nova Scotia,N03AX,Other antiepileptics,<65,M,179.34,0.8,6.2,689,14
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,M,165.16,0.7,14.6,"1,621",15
4,Nova Scotia,L01AX,Other alkylating agents,<65,M,164.9,0.7,0.2,25,16
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,M,148.18,0.6,22.1,"2,463",17
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,M,147.51,0.6,25.8,"2,868",18
4,Nova Scotia,N06AX,Other antidepressants,<65,M,144.47,0.6,11.2,"1,245",19
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,129.21,0.6,2.1,231,20
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,122.08,0.5,2.9,327,21
4,Nova Scotia,B01AB,Heparin group,<65,M,118.53,0.5,1,113,22
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,114.07,0.5,5.6,618,23
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,24
4,Nova Scotia,L02BB,Antiandrogens,<65,M,96.74,0.4,0.1,12,25
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,M,87.04,0.4,0.3,30,26
4,Nova Scotia,R03BB,Anticholinergics,<65,M,86.85,0.4,4.2,472,27
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,M,84.14,0.4,15.3,"1,698",28
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,<65,M,80.44,0.3,0.1,6,29
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,M,79.79,0.3,5.1,570,30
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,M,78.87,0.3,0.1,13,31
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,M,78.42,0.3,9.6,"1,072",32
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,M,76.49,0.3,7.9,881,33
4,Nova Scotia,R03BA,Glucocorticoids,<65,M,76.03,0.3,4.9,542,34
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,M,69.09,0.3,0,5,35
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,67.13,0.3,5.7,634,36
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,M,66.41,0.3,12.7,"1,414",37
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,62.01,0.3,14.2,"1,581",38
4,Nova Scotia,A10BA,Biguanides,<65,M,57.12,0.2,12.9,"1,436",39
4,Nova Scotia,A04AD,Other antiemetics,<65,M,51.96,0.2,0.8,88,40
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,M,51.12,0.2,0.9,103,41
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,M,48.16,0.2,5.8,648,42
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,M,47.78,0.2,0.9,105,43
4,Nova Scotia,M03BX,Other centrally acting agents,<65,M,46.75,0.2,4.2,470,44
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,44.41,0.2,5.1,567,45
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,M,42.7,0.2,0.4,39,46
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,M,41.88,0.2,1.7,194,47
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,40.66,0.2,0.5,54,48
4,Nova Scotia,H02AB,Glucocorticoids,<65,M,39.96,0.2,9.9,"1,103",49
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,38.07,0.2,5.8,641,50
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,M,32.37,0.1,3.7,417,51
4,Nova Scotia,A10BB,Sulfonylureas,<65,M,32.24,0.1,6.1,678,52
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,*,53
4,Nova Scotia,B02BX,Other systemic hemostatics,<65,M,**,**,**,*,54
4,Nova Scotia,H03AA,Thyroid hormones,<65,M,30.42,0.1,5.9,655,55
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,27.68,0.1,3,330,56
4,Nova Scotia,L01XX,Other antineoplastic agents,<65,M,27.13,0.1,0,5,57
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,M,26.67,0.1,4.5,498,58
4,Nova Scotia,A07AA,Antibiotics,<65,M,26.26,0.1,1.3,141,59
4,Nova Scotia,A16AB,Enzymes,<65,M,**,**,**,*,60
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,M,24.55,0.1,1.3,140,61
4,Nova Scotia,B03AC,"Iron, parenteral preparations",<65,M,23.75,0.1,0.4,48,62
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,M,21.94,0.1,4.5,504,63
4,Nova Scotia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,21.38,0.1,0.8,92,64
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,M,21.26,0.1,0.3,38,65
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,20.24,0.1,1.7,194,66
4,Nova Scotia,N04BA,Dopa and dopa derivatives,<65,M,20.08,0.1,0.4,49,67
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,M,20.07,0.1,1.3,140,68
4,Nova Scotia,B01AA,Vitamin K antagonists,<65,M,20.01,0.1,2.4,267,69
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,M,19.91,0.1,6.3,700,70
4,Nova Scotia,N03AB,Hydantoin derivatives,<65,M,19.83,0.1,0.9,97,71
4,Nova Scotia,N05CD,Benzodiazepine derivatives,<65,M,19.7,0.1,1.1,122,72
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,18.9,0.1,3.3,372,73
4,Nova Scotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,**,**,**,**,74
4,Nova Scotia,A09AA,Enzyme preparations,<65,M,18.17,0.1,0.4,39,75
4,Nova Scotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,17.85,0.1,0.4,46,76
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,M,17.58,0.1,11.8,"1,316",77
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,**,**,**,**,78
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,16.43,0.1,0.3,36,79
4,Nova Scotia,G03BA,3-oxoandrosten (4) derivatives,<65,M,15.8,0.1,1,108,80
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,M,15.78,0.1,0.8,89,81
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,M,15.69,0.1,1.1,123,82
4,Nova Scotia,A03FA,Propulsives,<65,M,15.25,0.1,2.5,274,83
4,Nova Scotia,C03AA,"Thiazides, plain",<65,M,15.21,0.1,4.7,527,84
4,Nova Scotia,L01BA,Folic acid analogues,<65,M,14.76,0.1,1.1,122,85
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,M,14.69,0.1,1.4,158,86
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,14.32,0.1,2.3,252,87
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,<65,M,14.07,0.1,2.8,314,88
4,Nova Scotia,N05AE,Indole derivatives,<65,M,14.03,0.1,0.1,11,89
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,M,13.83,0.1,6.2,689,90
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,M,13.74,0.1,4.8,537,91
4,Nova Scotia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,13.64,0.1,0.1,12,92
4,Nova Scotia,R01AD,Corticosteroids,<65,M,**,**,**,**,93
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,13.05,0.1,4.8,533,94
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,M,12.91,0.1,2.1,229,95
4,Nova Scotia,C03DA,Aldosterone antagonists,<65,M,12.66,0.1,2.3,253,96
4,Nova Scotia,C01DA,Organic nitrates,<65,M,12.63,0.1,2.6,292,97
4,Nova Scotia,C08DB,Benzothiazepine derivatives,<65,M,12.28,0.1,0.9,101,98
4,Nova Scotia,J01AA,Tetracyclines,<65,M,11.91,0.1,5.8,649,99
4,Nova Scotia,C02AC,Imidazoline receptor agonists,<65,M,**,**,**,**,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"6,655.15",25.9,3.1,467,1
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,F,"3,104.48",12.1,1.7,256,2
4,Nova Scotia,L04AX,Other immunosuppressants,<65,F,"1,605.14",6.2,1.3,193,3
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,F,"1,189.93",4.6,0.2,24,4
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,F,"1,121.79",4.4,0.2,36,5
4,Nova Scotia,R07AX,Other respiratory system products,<65,F,**,**,**,*,6
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,F,786.28,3.1,0.5,69,7
4,Nova Scotia,A16AB,Enzymes,<65,F,**,**,**,*,8
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,**,9
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,F,381.62,1.5,7.4,"1,135",10
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,363.39,1.4,4.1,626,11
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,F,291.53,1.1,22.9,"3,502",12
4,Nova Scotia,N05AX,Other antipsychotics,<65,F,262.73,1,2,312,13
4,Nova Scotia,N06AX,Other antidepressants,<65,F,258.8,1,17,"2,591",14
4,Nova Scotia,N03AX,Other antiepileptics,<65,F,241.37,0.9,7.5,"1,144",15
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,F,222.68,0.9,25.2,"3,847",16
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,206.59,0.8,3.8,582,17
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,18
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,F,197.15,0.8,3.1,468,19
4,Nova Scotia,A05AA,Bile acids and derivatives,<65,F,**,**,**,**,20
4,Nova Scotia,L01XX,Other antineoplastic agents,<65,F,175.54,0.7,0.1,13,21
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,F,168.22,0.7,0.1,18,22
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,161.34,0.6,2,309,23
4,Nova Scotia,B01AB,Heparin group,<65,F,158.48,0.6,0.9,136,24
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,25
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,139.41,0.5,2.4,366,26
4,Nova Scotia,R03BA,Glucocorticoids,<65,F,137.86,0.5,6.1,930,27
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,F,135.81,0.5,18.3,"2,790",28
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,F,130.89,0.5,0.1,11,29
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,127.71,0.5,5.2,792,30
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,113.57,0.4,8.9,"1,351",31
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,F,112.89,0.4,11.5,"1,750",32
4,Nova Scotia,A16AA,Amino acids and derivatives,<65,F,**,**,**,**,33
4,Nova Scotia,H03AA,Thyroid hormones,<65,F,105.67,0.4,16,"2,439",34
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,105.08,0.4,1.4,210,35
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,103.85,0.4,0.3,41,36
4,Nova Scotia,R03BB,Anticholinergics,<65,F,101.41,0.4,3.9,596,37
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,F,95.94,0.4,6.5,993,38
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,92.66,0.4,16.4,"2,496",39
4,Nova Scotia,L01AX,Other alkylating agents,<65,F,92.61,0.4,0.1,13,40
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,F,75.33,0.3,10.1,"1,543",41
4,Nova Scotia,A04AD,Other antiemetics,<65,F,71.22,0.3,0.9,139,42
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,F,71.16,0.3,1,160,43
4,Nova Scotia,M03BX,Other centrally acting agents,<65,F,71.04,0.3,6.2,949,44
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,F,68.16,0.3,7.3,"1,111",45
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,F,68.1,0.3,6.7,"1,028",46
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,F,67.53,0.3,2.9,435,47
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,66.43,0.3,5.6,858,48
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,49
4,Nova Scotia,A10BA,Biguanides,<65,F,58.89,0.2,10.3,"1,570",50
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,55.84,0.2,4.3,663,51
4,Nova Scotia,H02AB,Glucocorticoids,<65,F,52.1,0.2,11.3,"1,723",52
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,F,52.02,0.2,8,"1,228",53
4,Nova Scotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,48.57,0.2,5.9,901,54
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,F,43.46,0.2,5.8,891,55
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,<65,F,**,**,**,**,56
4,Nova Scotia,A03FA,Propulsives,<65,F,42.37,0.2,3.8,585,57
4,Nova Scotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,41.96,0.2,5.8,887,58
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,F,38.14,0.1,8.5,"1,290",59
4,Nova Scotia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,37.14,0.1,2.9,441,60
4,Nova Scotia,A10BB,Sulfonylureas,<65,F,34.71,0.1,4.6,702,61
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,F,34.6,0.1,0.6,97,62
4,Nova Scotia,L01BA,Folic acid analogues,<65,F,33.77,0.1,2,298,63
4,Nova Scotia,G02BA,Intrauterine contraceptives,<65,F,33.45,0.1,1,150,64
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,F,32.48,0.1,0.2,38,65
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,F,31.9,0.1,0.8,123,66
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,F,31.12,0.1,0.3,51,67
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,F,30.34,0.1,1,156,68
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,F,30.24,0.1,2.7,415,69
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,29.61,0.1,3.8,579,70
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,F,29.21,0.1,1.2,180,71
4,Nova Scotia,A07AA,Antibiotics,<65,F,29.11,0.1,1.6,245,72
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,F,27.16,0.1,4.2,638,73
4,Nova Scotia,B03AC,"Iron, parenteral preparations",<65,F,27.15,0.1,0.3,43,74
4,Nova Scotia,L03AX,Other immunostimulants,<65,F,**,**,**,*,75
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,F,26.52,0.1,14,"2,141",76
4,Nova Scotia,R01AD,Corticosteroids,<65,F,**,**,**,**,77
4,Nova Scotia,G03AC,Progestogens,<65,F,**,**,**,**,78
4,Nova Scotia,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,79
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,F,24.88,0.1,2.9,450,80
4,Nova Scotia,A12BA,Potassium,<65,F,23.5,0.1,1.8,270,81
4,Nova Scotia,N02CC,Selective serotonin (5HT1) agonists,<65,F,23.24,0.1,1.5,235,82
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,F,22.28,0.1,1.6,241,83
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,F,21.89,0.1,0.8,125,84
4,Nova Scotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,F,21.56,0.1,2.5,383,85
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,F,21.42,0.1,6,910,86
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,20.1,0.1,0.3,41,87
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,20.09,0.1,0.3,44,88
4,Nova Scotia,J01AA,Tetracyclines,<65,F,19.98,0.1,7.1,"1,090",89
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,**,**,**,**,90
4,Nova Scotia,C03AA,"Thiazides, plain",<65,F,19.72,0.1,5.8,881,91
4,Nova Scotia,M01AH,Coxibs,<65,F,19.61,0.1,2.4,366,92
4,Nova Scotia,N04BA,Dopa and dopa derivatives,<65,F,19.23,0.1,0.2,37,93
4,Nova Scotia,N05CD,Benzodiazepine derivatives,<65,F,19.16,0.1,1,155,94
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,F,17.76,0.1,6.3,969,95
4,Nova Scotia,J02AC,Triazole derivatives,<65,F,17.68,0.1,3.7,571,96
4,Nova Scotia,R05DA,Opium alkaloids and derivatives,<65,F,17.65,0.1,0.6,94,97
4,Nova Scotia,N05AE,Indole derivatives,<65,F,17.57,0.1,0.1,20,98
4,Nova Scotia,N07BA,Drugs used in nicotine dependence,<65,F,**,**,**,**,99
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,17.26,0.1,5.8,886,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"24,124.63",9.1,1,"1,274",1
5,New Brunswick,S01LA,Antineovascularization agents,Total,Total,"13,705.80",5.2,1.1,"1,428",2
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,Total,"11,950.54",4.5,0.2,320,3
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,Total,"11,597.45",4.4,0.2,224,4
5,New Brunswick,L04AX,Other immunosuppressants,Total,Total,"11,033.54",4.2,0.6,742,5
5,New Brunswick,L04AA,Selective immunosuppressants,Total,Total,"9,030.81",3.4,0.8,"1,047",6
5,New Brunswick,N05AX,Other antipsychotics,Total,Total,"7,458.90",2.8,5,"6,438",7
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,Total,"7,216.42",2.7,2,"2,620",8
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,403.41",2.4,5.6,"7,233",9
5,New Brunswick,A02BC,Proton pump inhibitors,Total,Total,"5,571.06",2.1,39.6,"50,703",10
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"5,154.91",2,4.9,"6,218",11
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"5,144.02",1.9,9.3,"11,963",12
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,Total,"4,812.57",1.8,4.6,"5,939",13
5,New Brunswick,L04AC,Interleukin inhibitors,Total,Total,"4,584.67",1.7,0.2,269,14
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,355.37",1.6,39.6,"50,754",15
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,277.13",1.6,19.6,"25,132",16
5,New Brunswick,N06AX,Other antidepressants,Total,Total,"3,986.61",1.5,14.1,"18,062",17
5,New Brunswick,N02AA,Natural opium alkaloids,Total,Total,"3,799.72",1.4,9.1,"11,673",18
5,New Brunswick,N03AX,Other antiepileptics,Total,Total,"3,526.10",1.3,12.6,"16,089",19
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"3,397.29",1.3,3,"3,870",20
5,New Brunswick,R03BB,Anticholinergics,Total,Total,"3,386.34",1.3,8.8,"11,279",21
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,Total,"3,378.64",1.3,9.7,"12,440",22
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"3,220.68",1.2,0.2,308,23
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,Total,"3,212.22",1.2,17.5,"22,458",24
5,New Brunswick,R03BA,Glucocorticoids,Total,Total,"3,159.20",1.2,9.9,"12,698",25
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,Total,"2,575.60",1,21.9,"28,092",26
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,565.47",1,3.4,"4,336",27
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,Total,"2,326.79",0.9,13.9,"17,772",28
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,Total,"2,283.28",0.9,18.5,"23,684",29
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"2,046.46",0.8,5.5,"7,038",30
5,New Brunswick,B03XA,Other antianemic preparations,Total,Total,"2,018.88",0.8,0.3,356,31
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"1,932.23",0.7,0.4,565,32
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,Total,"1,806.01",0.7,2.3,"2,908",33
5,New Brunswick,L02BB,Antiandrogens,Total,Total,"1,742.92",0.7,0.2,266,34
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,Total,"1,730.17",0.7,19.6,"25,107",35
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,684.43",0.6,3.7,"4,768",36
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,Total,"1,664.62",0.6,0.1,81,37
5,New Brunswick,H03AA,Thyroid hormones,Total,Total,"1,636.18",0.6,18,"23,069",38
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,Total,"1,608.67",0.6,5.8,"7,423",39
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,577.47",0.6,10.6,"13,624",40
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,Total,"1,549.40",0.6,0.4,510,41
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,Total,"1,480.38",0.6,4.1,"5,228",42
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,465.94",0.6,1.3,"1,607",43
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"1,430.27",0.5,1.4,"1,780",44
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,331.20",0.5,20.5,"26,249",45
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,**,**,**,*,46
5,New Brunswick,L03AA,Colony-stimulating factors,Total,Total,"1,282.36",0.5,0.2,204,47
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,Total,"1,270.29",0.5,6,"7,658",48
5,New Brunswick,H01CB,Somatostatin and analogues,Total,Total,"1,239.60",0.5,0.1,66,49
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,211.36",0.5,1.1,"1,392",50
5,New Brunswick,L03AB,Interferons,Total,Total,"1,182.96",0.4,0.1,79,51
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,005.71",0.4,9,"11,561",52
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,980.6,0.4,5.6,"7,224",53
5,New Brunswick,A10BA,Biguanides,Total,Total,977.59,0.4,14.2,"18,139",54
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,969.43,0.4,1.7,"2,143",55
5,New Brunswick,R07AX,Other respiratory system products,Total,Total,**,**,**,*,56
5,New Brunswick,B01AB,Heparin group,Total,Total,956.52,0.4,0.5,690,57
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,943.73,0.4,0.3,412,58
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,925.08,0.4,0.1,72,59
5,New Brunswick,A04AD,Other antiemetics,Total,Total,918.26,0.3,1,"1,296",60
5,New Brunswick,S01ED,Beta-blocking agents,Total,Total,846.1,0.3,2.8,"3,584",61
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,842.65,0.3,7.4,"9,459",62
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,839.4,0.3,0.9,"1,133",63
5,New Brunswick,S01EE,Prostaglandin analogues,Total,Total,816.45,0.3,2.4,"3,104",64
5,New Brunswick,N03AG,Fatty acid derivatives,Total,Total,803.55,0.3,1.8,"2,340",65
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,Total,778.29,0.3,9.7,"12,417",66
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,759.35,0.3,3.4,"4,317",67
5,New Brunswick,M05BA,Bisphosphonates,Total,Total,758.44,0.3,5.1,"6,509",68
5,New Brunswick,R01AD,Corticosteroids,Total,Total,724.15,0.3,11.6,"14,841",69
5,New Brunswick,A09AA,Enzyme preparations,Total,Total,681.04,0.3,0.3,350,70
5,New Brunswick,J05AX,Other antivirals,Total,Total,680.33,0.3,0.1,81,71
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,Total,677.32,0.3,3.1,"3,988",72
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,Total,629.11,0.2,1.1,"1,470",73
5,New Brunswick,C01DA,Organic nitrates,Total,Total,628.61,0.2,5.2,"6,674",74
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,619.01,0.2,0.8,"1,010",75
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,Total,603.85,0.2,0.5,610,76
5,New Brunswick,A10BB,Sulfonylureas,Total,Total,601.72,0.2,6,"7,634",77
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,Total,571.42,0.2,1.1,"1,415",78
5,New Brunswick,A02BA,H2-receptor antagonists,Total,Total,544.86,0.2,4.9,"6,283",79
5,New Brunswick,M03BX,Other centrally acting agents,Total,Total,543.94,0.2,5.3,"6,811",80
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,494.81,0.2,3,"3,892",81
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,Total,491.54,0.2,3,"3,835",82
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,Total,479.66,0.2,1.4,"1,736",83
5,New Brunswick,M01AE,Propionic acid derivatives,Total,Total,474.2,0.2,7.3,"9,376",84
5,New Brunswick,M01AH,Coxibs,Total,Total,467.96,0.2,5,"6,432",85
5,New Brunswick,J05AE,Protease inhibitors,Total,Total,454.42,0.2,0,63,86
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,453.63,0.2,0.2,199,87
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,447.92,0.2,0.3,340,88
5,New Brunswick,L03AX,Other immunostimulants,Total,Total,443.19,0.2,0,43,89
5,New Brunswick,B01AA,Vitamin K antagonists,Total,Total,422.27,0.2,4.2,"5,425",90
5,New Brunswick,H02AB,Glucocorticoids,Total,Total,419.43,0.2,11.6,"14,808",91
5,New Brunswick,N06DA,Anticholinesterases,Total,Total,416.05,0.2,1.5,"1,973",92
5,New Brunswick,L01BA,Folic acid analogues,Total,Total,389.16,0.1,1.4,"1,820",93
5,New Brunswick,A12BA,Potassium,Total,Total,386.44,0.1,3.6,"4,578",94
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,371.27,0.1,2.2,"2,826",95
5,New Brunswick,N05AE,Indole derivatives,Total,Total,370.4,0.1,0.2,306,96
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,Total,365.42,0.1,3.1,"3,960",97
5,New Brunswick,N03AF,Carboxamide derivatives,Total,Total,360.93,0.1,1.1,"1,362",98
5,New Brunswick,A03FA,Propulsives,Total,Total,347.26,0.1,3.8,"4,879",99
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),Total,Total,342.63,0.1,1.3,"1,650",100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"10,996.80",8.5,1,574,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,M,"8,119.62",6.3,0.3,157,2
5,New Brunswick,L04AX,Other immunosuppressants,Total,M,"6,518.85",5,0.6,322,3
5,New Brunswick,S01LA,Antineovascularization agents,Total,M,"6,031.21",4.7,1.1,621,4
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,M,"5,991.03",4.6,0.3,151,5
5,New Brunswick,N05AX,Other antipsychotics,Total,M,"4,966.51",3.8,5.9,"3,342",6
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,M,"4,179.85",3.2,2.7,"1,542",7
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,015.04",2.3,10,"5,606",8
5,New Brunswick,L04AA,Selective immunosuppressants,Total,M,"2,961.52",2.3,0.8,460,9
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,802.58",2.2,5.4,"3,057",10
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"2,612.75",2,0.4,245,11
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"2,557.39",2,5.5,"3,084",12
5,New Brunswick,L04AC,Interleukin inhibitors,Total,M,"2,501.21",1.9,0.2,139,13
5,New Brunswick,A02BC,Proton pump inhibitors,Total,M,"2,253.04",1.7,36.9,"20,709",14
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,M,"2,242.96",1.7,4.9,"2,741",15
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,141.34",1.7,45,"25,291",16
5,New Brunswick,N02AA,Natural opium alkaloids,Total,M,"2,000.55",1.5,8.8,"4,948",17
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,M,"1,792.12",1.4,8.5,"4,764",18
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"1,784.48",1.4,0.9,514,19
5,New Brunswick,L02BB,Antiandrogens,Total,M,"1,742.92",1.3,0.5,266,20
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,M,"1,664.62",1.3,0.1,81,21
5,New Brunswick,R03BB,Anticholinergics,Total,M,"1,622.92",1.3,9.4,"5,259",22
5,New Brunswick,N06AX,Other antidepressants,Total,M,"1,607.88",1.2,11.6,"6,522",23
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"1,593.70",1.2,3.3,"1,851",24
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,584.29",1.2,15.3,"8,583",25
5,New Brunswick,N03AX,Other antiepileptics,Total,M,"1,496.99",1.2,11.3,"6,332",26
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,M,"1,395.90",1.1,17.5,"9,809",27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,281.43",1,3.8,"2,110",28
5,New Brunswick,R03BA,Glucocorticoids,Total,M,"1,243.44",1,8.6,"4,828",29
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,M,"1,223.51",0.9,24.6,"13,841",30
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,M,"1,143.61",0.9,3,"1,713",31
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,M,"1,075.82",0.8,12.8,"7,165",32
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,M,999.95,0.8,0.6,321,33
5,New Brunswick,B03XA,Other antianemic preparations,Total,M,938.17,0.7,0.3,158,34
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,M,900.59,0.7,14.5,"8,145",35
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,804.05,0.6,1.6,879,36
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,801.76,0.6,1.8,"1,021",37
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,M,796.52,0.6,21.3,"11,951",38
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,M,778.68,0.6,15.9,"8,934",39
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,M,765.52,0.6,5.1,"2,843",40
5,New Brunswick,H01CB,Somatostatin and analogues,Total,M,749.73,0.6,0.1,39,41
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,657.4,0.5,0.5,292,42
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,650.94,0.5,6.5,"3,644",43
5,New Brunswick,R07AX,Other respiratory system products,Total,M,**,**,**,*,44
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,M,613.05,0.5,6.6,"3,708",45
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,M,587.47,0.5,3.8,"2,111",46
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,570.05,0.4,18.8,"10,582",47
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,568.35,0.4,9.1,"5,124",48
5,New Brunswick,J05AX,Other antivirals,Total,M,539.85,0.4,0.1,58,49
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,M,502.35,0.4,1,572,50
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,M,501.41,0.4,2.5,"1,379",51
5,New Brunswick,A10BA,Biguanides,Total,M,475.65,0.4,16.4,"9,192",52
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,**,**,**,*,53
5,New Brunswick,B01AB,Heparin group,Total,M,468.68,0.4,0.5,283,54
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,464.18,0.4,1.8,"1,032",55
5,New Brunswick,L03AA,Colony-stimulating factors,Total,M,463.48,0.4,0.1,64,56
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,455.64,0.4,9.2,"5,148",57
5,New Brunswick,N03AG,Fatty acid derivatives,Total,M,438.22,0.3,2.2,"1,212",58
5,New Brunswick,J05AE,Protease inhibitors,Total,M,**,**,**,**,59
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,403.68,0.3,0.9,523,60
5,New Brunswick,H03AA,Thyroid hormones,Total,M,390.91,0.3,10.2,"5,737",61
5,New Brunswick,A09AA,Enzyme preparations,Total,M,373.39,0.3,0.3,156,62
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,369.59,0.3,5,"2,814",63
5,New Brunswick,A04AD,Other antiemetics,Total,M,353.06,0.3,0.9,506,64
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,342.22,0.3,1,554,65
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,341.13,0.3,4,"2,252",66
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,M,337.72,0.3,3.5,"1,952",67
5,New Brunswick,S01ED,Beta-blocking agents,Total,M,327.86,0.3,2.6,"1,473",68
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,M,318.81,0.2,0.6,329,69
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,M,311.53,0.2,1.3,712,70
5,New Brunswick,A10BB,Sulfonylureas,Total,M,304.16,0.2,7,"3,941",71
5,New Brunswick,S01EE,Prostaglandin analogues,Total,M,301.58,0.2,2.2,"1,214",72
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,M,295.44,0.2,8.8,"4,948",73
5,New Brunswick,C01DA,Organic nitrates,Total,M,284.62,0.2,6.2,"3,480",74
5,New Brunswick,R01AD,Corticosteroids,Total,M,283.56,0.2,9.6,"5,412",75
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,Total,M,273.29,0.2,0.1,73,76
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,M,272.73,0.2,1.1,591,77
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,M,269.36,0.2,1.8,"1,014",78
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,244.31,0.2,0,18,79
5,New Brunswick,H01AC,Somatropin and somatropin agonists,Total,M,233.71,0.2,0,16,80
5,New Brunswick,A02BA,H2-receptor antagonists,Total,M,226.96,0.2,4.4,"2,453",81
5,New Brunswick,M03BX,Other centrally acting agents,Total,M,226.53,0.2,4.7,"2,639",82
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,M,202.75,0.2,3.7,"2,102",83
5,New Brunswick,B01AA,Vitamin K antagonists,Total,M,200.13,0.2,4.9,"2,758",84
5,New Brunswick,M01AE,Propionic acid derivatives,Total,M,198.57,0.2,6.7,"3,776",85
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,M,194.16,0.1,2.7,"1,509",86
5,New Brunswick,N03AF,Carboxamide derivatives,Total,M,191.79,0.1,1.2,655,87
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,Total,M,190.34,0.1,5.1,"2,851",88
5,New Brunswick,M01AH,Coxibs,Total,M,187.54,0.1,4.4,"2,444",89
5,New Brunswick,L01AX,Other alkylating agents,Total,M,186.44,0.1,0,19,90
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,180.3,0.1,2.6,"1,447",91
5,New Brunswick,L03AB,Interferons,Total,M,174.95,0.1,0,14,92
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,169.49,0.1,0.1,73,93
5,New Brunswick,H02AB,Glucocorticoids,Total,M,167.13,0.1,10.6,"5,970",94
5,New Brunswick,N05AE,Indole derivatives,Total,M,152.21,0.1,0.2,125,95
5,New Brunswick,L01BA,Folic acid analogues,Total,M,147.93,0.1,1.2,690,96
5,New Brunswick,N06DA,Anticholinesterases,Total,M,146.79,0.1,1.3,718,97
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,Total,M,144.75,0.1,0.4,239,98
5,New Brunswick,J01GB,Other aminoglycosides,Total,M,142.85,0.1,0.1,38,99
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",Total,M,142.24,0.1,6.6,"3,680",100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"13,127.83",9.8,1,700,1
5,New Brunswick,S01LA,Antineovascularization agents,Total,F,"7,674.59",5.7,1.1,807,2
5,New Brunswick,L04AA,Selective immunosuppressants,Total,F,"6,069.29",4.5,0.8,587,3
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,F,"5,959.51",4.4,0.2,169,4
5,New Brunswick,L04AX,Other immunosuppressants,Total,F,"4,514.70",3.4,0.6,420,5
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,600.83",2.7,5.8,"4,176",6
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,F,"3,477.83",2.6,0.1,67,7
5,New Brunswick,A02BC,Proton pump inhibitors,Total,F,"3,317.96",2.5,41.7,"29,993",8
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,F,"3,036.57",2.3,1.5,"1,078",9
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,692.78",2,23,"16,548",10
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"2,597.52",1.9,4.4,"3,134",11
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,F,"2,569.61",1.9,4.4,"3,198",12
5,New Brunswick,N05AX,Other antipsychotics,Total,F,"2,492.39",1.9,4.3,"3,096",13
5,New Brunswick,N06AX,Other antidepressants,Total,F,"2,378.74",1.8,16,"11,540",14
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,213.97",1.6,35.4,"25,462",15
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,128.98",1.6,8.8,"6,357",16
5,New Brunswick,L04AC,Interleukin inhibitors,Total,F,"2,083.46",1.5,0.2,130,17
5,New Brunswick,N03AX,Other antiepileptics,Total,F,"2,029.11",1.5,13.6,"9,757",18
5,New Brunswick,R03BA,Glucocorticoids,Total,F,"1,915.75",1.4,10.9,"7,870",19
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,F,"1,816.32",1.3,17.6,"12,649",20
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"1,803.59",1.3,2.8,"2,019",21
5,New Brunswick,N02AA,Natural opium alkaloids,Total,F,"1,799.17",1.3,9.3,"6,725",22
5,New Brunswick,R03BB,Anticholinergics,Total,F,"1,763.42",1.3,8.4,"6,020",23
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,F,"1,586.52",1.2,10.7,"7,676",24
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,395.52",1,4.7,"3,394",25
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,F,"1,382.69",1,21.6,"15,539",26
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,F,"1,352.09",1,19.8,"14,251",27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,284.04",1,3.1,"2,226",28
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,F,"1,250.98",0.9,14.7,"10,607",29
5,New Brunswick,H03AA,Thyroid hormones,Total,F,"1,245.24",0.9,24.1,"17,331",30
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,183.02",0.9,4.7,"3,389",31
5,New Brunswick,B03XA,Other antianemic preparations,Total,F,"1,080.70",0.8,0.3,198,32
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,009.12",0.7,11.8,"8,500",33
5,New Brunswick,L03AB,Interferons,Total,F,"1,008.01",0.7,0.1,65,34
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,F,933.65,0.7,18.3,"13,156",35
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,F,891.01,0.7,4.3,"3,115",36
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,F,843.15,0.6,6.4,"4,580",37
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,**,**,**,*,38
5,New Brunswick,L03AA,Colony-stimulating factors,Total,F,818.89,0.6,0.2,140,39
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,761.14,0.6,21.8,"15,667",40
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,746.17,0.6,5.9,"4,255",41
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,F,709.01,0.5,1.1,820,42
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,680.77,0.5,0.1,54,43
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,F,662.4,0.5,1.7,"1,195",44
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,661.89,0.5,1,728,45
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,F,657.24,0.5,5.5,"3,950",46
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,639.27,0.5,6.9,"4,971",47
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,628.51,0.5,1.1,759,48
5,New Brunswick,M05BA,Bisphosphonates,Total,F,628.42,0.5,7.5,"5,390",49
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,607.93,0.5,0.1,63,50
5,New Brunswick,A04AD,Other antiemetics,Total,F,565.19,0.4,1.1,790,51
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,550,0.4,8.9,"6,412",52
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,F,549.44,0.4,0.3,189,53
5,New Brunswick,S01ED,Beta-blocking agents,Total,F,518.24,0.4,2.9,"2,111",54
5,New Brunswick,S01EE,Prostaglandin analogues,Total,F,514.86,0.4,2.6,"1,890",55
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,505.25,0.4,1.5,"1,111",56
5,New Brunswick,A10BA,Biguanides,Total,F,501.94,0.4,12.4,"8,947",57
5,New Brunswick,H01CB,Somatostatin and analogues,Total,F,489.87,0.4,0,27,58
5,New Brunswick,B01AB,Heparin group,Total,F,487.84,0.4,0.6,407,59
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,F,482.85,0.4,10.4,"7,469",60
5,New Brunswick,R01AD,Corticosteroids,Total,F,440.6,0.3,13.1,"9,429",61
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,435.72,0.3,0.8,610,62
5,New Brunswick,N03AG,Fatty acid derivatives,Total,F,365.33,0.3,1.6,"1,128",63
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,F,356.38,0.3,1.2,879,64
5,New Brunswick,C01DA,Organic nitrates,Total,F,343.99,0.3,4.4,"3,194",65
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,F,339.6,0.3,2.8,"2,036",66
5,New Brunswick,L02BG,Aromatase inhibitors,Total,F,329.98,0.2,1.2,861,67
5,New Brunswick,R07AX,Other respiratory system products,Total,F,**,**,**,*,68
5,New Brunswick,L03AX,Other immunostimulants,Total,F,318.72,0.2,0,32,69
5,New Brunswick,A02BA,H2-receptor antagonists,Total,F,317.91,0.2,5.3,"3,830",70
5,New Brunswick,M03BX,Other centrally acting agents,Total,F,317.41,0.2,5.8,"4,172",71
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,314.51,0.2,3.4,"2,445",72
5,New Brunswick,A09AA,Enzyme preparations,Total,F,307.65,0.2,0.3,194,73
5,New Brunswick,A10BB,Sulfonylureas,Total,F,297.56,0.2,5.1,"3,693",74
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,F,297.37,0.2,3.2,"2,326",75
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,**,76
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,286.33,0.2,0.2,120,77
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,F,285.04,0.2,0.4,281,78
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,284.14,0.2,0.2,126,79
5,New Brunswick,M01AH,Coxibs,Total,F,280.42,0.2,5.5,"3,988",80
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,276.79,0.2,0.6,456,81
5,New Brunswick,M01AE,Propionic acid derivatives,Total,F,275.63,0.2,7.8,"5,600",82
5,New Brunswick,N06DA,Anticholinesterases,Total,F,269.26,0.2,1.7,"1,255",83
5,New Brunswick,A12BA,Potassium,Total,F,264.06,0.2,4.4,"3,150",84
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,F,259.89,0.2,1,703,85
5,New Brunswick,B02BX,Other systemic hemostatics,Total,F,**,**,**,**,86
5,New Brunswick,H02AB,Glucocorticoids,Total,F,252.29,0.2,12.3,"8,837",87
5,New Brunswick,L01BA,Folic acid analogues,Total,F,241.23,0.2,1.6,"1,130",88
5,New Brunswick,G03XB,Progesterone receptor modulators,Total,F,**,**,**,**,89
5,New Brunswick,B01AA,Vitamin K antagonists,Total,F,222.14,0.2,3.7,"2,667",90
5,New Brunswick,A03FA,Propulsives,Total,F,221.58,0.2,4.5,"3,209",91
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),Total,F,218.94,0.2,1.5,"1,051",92
5,New Brunswick,N05AE,Indole derivatives,Total,F,218.19,0.2,0.3,181,93
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",Total,F,213.95,0.2,5,"3,586",94
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,Total,F,213.32,0.2,0.1,85,95
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,F,210.3,0.2,1,722,96
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,210.05,0.2,3.2,"2,322",97
5,New Brunswick,L01XC,Monoclonal antibodies,Total,F,**,**,**,**,98
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",Total,F,191.6,0.1,1.7,"1,199",99
5,New Brunswick,C03AA,"Thiazides, plain",Total,F,188.79,0.1,8.2,"5,885",100
5,New Brunswick,S01LA,Antineovascularization agents,65+,Total,"12,661.23",9,1.6,"1,306",1
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,Total,"8,807.75",6.3,0.3,232,2
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"8,265.85",5.9,0.5,452,3
5,New Brunswick,L04AX,Other immunosuppressants,65+,Total,"8,034.60",5.7,0.5,393,4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,898.19",3.5,6.7,"5,495",5
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,Total,"4,450.80",3.2,6.6,"5,405",6
5,New Brunswick,A02BC,Proton pump inhibitors,65+,Total,"3,786.04",2.7,46.1,"37,977",7
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,338.13",2.4,51.3,"42,255",8
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"3,287.99",2.3,5.2,"4,300",9
5,New Brunswick,L04AA,Selective immunosuppressants,65+,Total,"2,884.42",2.1,0.5,424,10
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"2,727.98",1.9,3.8,"3,097",11
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,Total,"2,727.84",1.9,23.8,"19,601",12
5,New Brunswick,R03BB,Anticholinergics,65+,Total,"2,644.56",1.9,10.6,"8,692",13
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,Total,"1,974.93",1.4,28.1,"23,173",14
5,New Brunswick,R03BA,Glucocorticoids,65+,Total,"1,905.73",1.4,9.1,"7,512",15
5,New Brunswick,B03XA,Other antianemic preparations,65+,Total,"1,807.83",1.3,0.4,303,16
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,757.65",1.2,17.8,"14,645",17
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,Total,"1,695.41",1.2,10.8,"8,893",18
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"1,659.39",1.2,0.6,479,19
5,New Brunswick,L04AC,Interleukin inhibitors,65+,Total,"1,634.09",1.2,0.1,97,20
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,21
5,New Brunswick,N02AA,Natural opium alkaloids,65+,Total,"1,528.82",1.1,9.7,"8,012",22
5,New Brunswick,L02BB,Antiandrogens,65+,Total,"1,525.71",1.1,0.3,248,23
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,524.43",1.1,3.4,"2,813",24
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,Total,"1,379.13",1,26.4,"21,717",25
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,347.44",1,14.5,"11,922",26
5,New Brunswick,N06AX,Other antidepressants,65+,Total,"1,338.44",1,11.8,"9,746",27
5,New Brunswick,N03AX,Other antiepileptics,65+,Total,"1,307.53",0.9,12,"9,860",28
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,Total,"1,304.29",0.9,5.7,"4,659",29
5,New Brunswick,H03AA,Thyroid hormones,65+,Total,"1,169.55",0.8,23,"18,973",30
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,146.62",0.8,4.3,"3,571",31
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,115.80",0.8,1.5,"1,223",32
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,Total,"1,078.99",0.8,19.4,"15,939",33
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,018.77",0.7,6.1,"4,987",34
5,New Brunswick,H01CB,Somatostatin and analogues,65+,Total,**,**,**,**,35
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,Total,992.73,0.7,7.5,"6,179",36
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,Total,975.46,0.7,0,18,37
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,967.46,0.7,1.5,"1,219",38
5,New Brunswick,N05AX,Other antipsychotics,65+,Total,958.99,0.7,3.2,"2,596",39
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,900.8,0.6,7.6,"6,251",40
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,Total,850.89,0.6,1.2,963,41
5,New Brunswick,L03AA,Colony-stimulating factors,65+,Total,849.14,0.6,0.2,133,42
5,New Brunswick,S01ED,Beta-blocking agents,65+,Total,783.42,0.6,4,"3,324",43
5,New Brunswick,S01EE,Prostaglandin analogues,65+,Total,763.21,0.5,3.5,"2,899",44
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,762.71,0.5,0.4,328,45
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,754.59,0.5,20.2,"16,664",46
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,Total,741.97,0.5,14,"11,531",47
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,727.02,0.5,10.3,"8,457",48
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,697.11,0.5,2,"1,611",49
5,New Brunswick,M05BA,Bisphosphonates,65+,Total,677.03,0.5,7.2,"5,905",50
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,670.58,0.5,1.1,935,51
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,Total,609.47,0.4,12.8,"10,531",52
5,New Brunswick,B01AB,Heparin group,65+,Total,596.95,0.4,0.6,486,53
5,New Brunswick,A10BA,Biguanides,65+,Total,595.86,0.4,16.7,"13,774",54
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,Total,582.51,0.4,0.7,589,55
5,New Brunswick,C01DA,Organic nitrates,65+,Total,578.75,0.4,7.2,"5,947",56
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,559.63,0.4,4,"3,306",57
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,515.74,0.4,1,827,58
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,Total,507.26,0.4,1.6,"1,284",59
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,Total,505.64,0.4,0.2,184,60
5,New Brunswick,R01AD,Corticosteroids,65+,Total,478.87,0.3,12.2,"10,060",61
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,426.46,0.3,4.1,"3,413",62
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,420.49,0.3,5.3,"4,394",63
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,415.32,0.3,0.4,317,64
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,413,0.3,7.7,"6,349",65
5,New Brunswick,A10BB,Sulfonylureas,65+,Total,411.25,0.3,7.1,"5,816",66
5,New Brunswick,N06DA,Anticholinesterases,65+,Total,405.88,0.3,2.3,"1,935",67
5,New Brunswick,A04AD,Other antiemetics,65+,Total,380.11,0.3,0.8,699,68
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,372.75,0.3,0,37,69
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,370.2,0.3,0,26,70
5,New Brunswick,B01AA,Vitamin K antagonists,65+,Total,365.31,0.3,6,"4,910",71
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,Total,360.34,0.3,1.7,"1,379",72
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,350.88,0.2,3.3,"2,686",73
5,New Brunswick,A12BA,Potassium,65+,Total,316.86,0.2,4.8,"3,959",74
5,New Brunswick,L03AB,Interferons,65+,Total,303.65,0.2,0,21,75
5,New Brunswick,A02BA,H2-receptor antagonists,65+,Total,293.29,0.2,5.1,"4,241",76
5,New Brunswick,M01AH,Coxibs,65+,Total,292.27,0.2,5.8,"4,782",77
5,New Brunswick,L02BG,Aromatase inhibitors,65+,Total,283.78,0.2,0.9,733,78
5,New Brunswick,B02BX,Other systemic hemostatics,65+,Total,**,**,**,**,79
5,New Brunswick,H02AB,Glucocorticoids,65+,Total,281.66,0.2,12.7,"10,464",80
5,New Brunswick,L01BA,Folic acid analogues,65+,Total,280.03,0.2,1.6,"1,317",81
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,Total,270.94,0.2,4.2,"3,423",82
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,Total,270.43,0.2,3.2,"2,617",83
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,Total,258.21,0.2,4.8,"3,912",84
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,Total,253.23,0.2,3.8,"3,105",85
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,Total,236.8,0.2,1.5,"1,197",86
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,Total,233.66,0.2,5.4,"4,472",87
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,Total,223.27,0.2,1.8,"1,442",88
5,New Brunswick,C10AC,Bile acid sequestrants,65+,Total,213.05,0.2,0.9,710,89
5,New Brunswick,A03FA,Propulsives,65+,Total,208.64,0.1,4.3,"3,500",90
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,Total,208.47,0.1,7.4,"6,094",91
5,New Brunswick,N04BC,Dopamine agonists,65+,Total,207.23,0.1,1.2,986,92
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,206.62,0.1,6.2,"5,067",93
5,New Brunswick,D01AC,Imidazole and triazole derivatives,65+,Total,202.36,0.1,3.7,"3,060",94
5,New Brunswick,J05AX,Other antivirals,65+,Total,**,**,**,**,95
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,Total,199.92,0.1,5.6,"4,598",96
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,Total,198.35,0.1,0.8,681,97
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,195.7,0.1,2.9,"2,359",98
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,195.46,0.1,0,10,99
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,**,**,**,**,100
5,New Brunswick,S01LA,Antineovascularization agents,65+,M,"5,576.15",8.4,1.6,557,1
5,New Brunswick,L04AX,Other immunosuppressants,65+,M,"5,169.39",7.8,0.5,190,2
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,M,"4,506.42",6.8,0.3,115,3
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"3,450.02",5.2,0.5,182,4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,177.00",3.3,6.8,"2,386",5
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,M,"2,038.00",3.1,7,"2,466",6
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"1,708.17",2.6,6.2,"2,162",7
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,8
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,M,"1,632.32",2.5,0.2,76,9
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,611.42",2.4,59.6,"20,917",10
5,New Brunswick,L02BB,Antiandrogens,65+,M,"1,525.71",2.3,0.7,248,11
5,New Brunswick,A02BC,Proton pump inhibitors,65+,M,"1,440.79",2.2,43.4,"15,210",12
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"1,310.68",2,4.3,"1,513",13
5,New Brunswick,R03BB,Anticholinergics,65+,M,"1,251.71",1.9,11.6,"4,062",14
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,M,"1,143.95",1.7,23.7,"8,325",15
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,M,892.36,1.3,32,"11,223",16
5,New Brunswick,L04AC,Interleukin inhibitors,65+,M,845.74,1.3,0.1,48,17
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,M,837.18,1.3,9.5,"3,347",18
5,New Brunswick,L04AA,Selective immunosuppressants,65+,M,833.07,1.3,0.6,201,19
5,New Brunswick,B03XA,Other antianemic preparations,65+,M,818.02,1.2,0.4,130,20
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,795.78,1.2,4,"1,392",21
5,New Brunswick,R03BA,Glucocorticoids,65+,M,734.93,1.1,7.9,"2,782",22
5,New Brunswick,N02AA,Natural opium alkaloids,65+,M,678.14,1,9.3,"3,278",23
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,M,673.41,1,22.9,"8,045",24
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,630.6,1,2,693,25
5,New Brunswick,H01CB,Somatostatin and analogues,65+,M,617.02,0.9,0.1,30,26
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,M,612.7,0.9,0,12,27
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,M,596.16,0.9,28.8,"10,103",28
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,569.65,0.9,2.1,738,29
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,M,547.29,0.8,13.1,"4,578",30
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,529.51,0.8,0.7,231,31
5,New Brunswick,N03AX,Other antiepileptics,65+,M,508.35,0.8,10.7,"3,739",32
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,M,508.28,0.8,5.3,"1,847",33
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,M,471.07,0.7,8.4,"2,953",34
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,467.95,0.7,12.5,"4,388",35
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,455.08,0.7,5.6,"1,952",36
5,New Brunswick,N06AX,Other antidepressants,65+,M,440.75,0.7,9.2,"3,240",37
5,New Brunswick,N05AX,Other antipsychotics,65+,M,423.95,0.6,2.8,997,38
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,420.14,0.6,9.1,"3,184",39
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,M,357.29,0.5,14.4,"5,055",40
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,M,354.29,0.5,0.4,125,41
5,New Brunswick,L03AA,Colony-stimulating factors,65+,M,350.81,0.5,0.1,45,42
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,349.55,0.5,7.6,"2,679",43
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,M,347.31,0.5,1.1,390,44
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,339.39,0.5,2.2,786,45
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,46
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,333.42,0.5,1.3,445,47
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,M,323.41,0.5,2.9,"1,022",48
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,318.61,0.5,19.2,"6,731",49
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,M,303.75,0.5,0.9,315,50
5,New Brunswick,B01AB,Heparin group,65+,M,300.02,0.5,0.6,213,51
5,New Brunswick,S01ED,Beta-blocking agents,65+,M,297.86,0.4,3.8,"1,347",52
5,New Brunswick,A10BA,Biguanides,65+,M,286.22,0.4,20.3,"7,131",53
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,281.44,0.4,1.3,448,54
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,M,279.88,0.4,12.5,"4,397",55
5,New Brunswick,S01EE,Prostaglandin analogues,65+,M,278.83,0.4,3.2,"1,126",56
5,New Brunswick,H03AA,Thyroid hormones,65+,M,276.94,0.4,13.4,"4,697",57
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,M,272.22,0.4,1.9,651,58
5,New Brunswick,C01DA,Organic nitrates,65+,M,257.14,0.4,8.7,"3,061",59
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,M,250.07,0.4,0.2,65,60
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,M,222.17,0.3,11.8,"4,135",61
5,New Brunswick,A10BB,Sulfonylureas,65+,M,203.36,0.3,8.7,"3,034",62
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,M,200.96,0.3,2.3,811,63
5,New Brunswick,R01AD,Corticosteroids,65+,M,193.43,0.3,10.8,"3,784",64
5,New Brunswick,J05AX,Other antivirals,65+,M,**,**,**,**,65
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,182.81,0.3,8.1,"2,854",66
5,New Brunswick,B01AA,Vitamin K antagonists,65+,M,169.53,0.3,7.1,"2,484",67
5,New Brunswick,A04AD,Other antiemetics,65+,M,161.01,0.2,0.8,290,68
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,M,153.96,0.2,7,"2,465",69
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,153.04,0.2,3.6,"1,260",70
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,M,150.68,0.2,5.2,"1,816",71
5,New Brunswick,N06DA,Anticholinesterases,65+,M,142.88,0.2,2,699,72
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,140.21,0.2,0,8,73
5,New Brunswick,L01AX,Other alkylating agents,65+,M,**,**,**,**,74
5,New Brunswick,A02BA,H2-receptor antagonists,65+,M,112.38,0.2,4.6,"1,621",75
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,M,110.59,0.2,2.1,719,76
5,New Brunswick,H02AB,Glucocorticoids,65+,M,110.09,0.2,12.2,"4,263",77
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,109.97,0.2,3.6,"1,261",78
5,New Brunswick,L01BA,Folic acid analogues,65+,M,109.04,0.2,1.4,500,79
5,New Brunswick,M01AH,Coxibs,65+,M,104.28,0.2,5.1,"1,797",80
5,New Brunswick,M05BA,Bisphosphonates,65+,M,102.79,0.2,2.6,918,81
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,M,101.52,0.2,2.8,983,82
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,M,99.78,0.2,7.8,"2,744",83
5,New Brunswick,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,97.7,0.1,0.8,287,84
5,New Brunswick,C03DA,Aldosterone antagonists,65+,M,96.42,0.1,3.7,"1,282",85
5,New Brunswick,A12BA,Potassium,65+,M,95.03,0.1,3.4,"1,199",86
5,New Brunswick,C10AC,Bile acid sequestrants,65+,M,94.59,0.1,0.7,231,87
5,New Brunswick,A09AA,Enzyme preparations,65+,M,92.38,0.1,0.2,72,88
5,New Brunswick,N07BC,Drugs used in opioid dependence,65+,M,89.61,0.1,0.1,41,89
5,New Brunswick,N03AG,Fatty acid derivatives,65+,M,88.41,0.1,0.8,291,90
5,New Brunswick,N04BC,Dopamine agonists,65+,M,87.2,0.1,1,345,91
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,M,84.16,0.1,1.2,429,92
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,M,83.83,0.1,2.9,"1,026",93
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,M,81.35,0.1,4.7,"1,662",94
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,80.81,0.1,2.4,829,95
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,78.05,0.1,5.3,"1,863",96
5,New Brunswick,L01XC,Monoclonal antibodies,65+,M,**,**,**,**,97
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,M,76.6,0.1,5.3,"1,855",98
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,M,71.86,0.1,0.7,243,99
5,New Brunswick,D01AC,Imidazole and triazole derivatives,65+,M,71.69,0.1,3.1,"1,093",100
5,New Brunswick,S01LA,Antineovascularization agents,65+,F,"7,085.08",9.5,1.6,749,1
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"4,815.83",6.5,0.6,270,2
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,F,"4,301.32",5.8,0.2,117,3
5,New Brunswick,L04AX,Other immunosuppressants,65+,F,"2,865.21",3.9,0.4,203,4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,721.19",3.7,6.6,"3,109",5
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,F,"2,412.80",3.2,6.2,"2,939",6
5,New Brunswick,A02BC,Proton pump inhibitors,65+,F,"2,345.25",3.2,48.2,"22,767",7
5,New Brunswick,L04AA,Selective immunosuppressants,65+,F,"2,051.35",2.8,0.5,223,8
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,726.72",2.3,45.1,"21,338",9
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,F,"1,583.89",2.1,23.8,"11,276",10
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,579.82",2.1,4.5,"2,138",11
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"1,417.30",1.9,3.4,"1,584",12
5,New Brunswick,R03BB,Anticholinergics,65+,F,"1,392.85",1.9,9.8,"4,630",13
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,210.36",1.6,21.3,"10,067",14
5,New Brunswick,R03BA,Glucocorticoids,65+,F,"1,170.80",1.6,10,"4,730",15
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,F,"1,082.58",1.5,25.3,"11,950",16
5,New Brunswick,B03XA,Other antianemic preparations,65+,F,989.8,1.3,0.4,173,17
5,New Brunswick,N06AX,Other antidepressants,65+,F,897.69,1.2,13.8,"6,506",18
5,New Brunswick,H03AA,Thyroid hormones,65+,F,892.62,1.2,30.2,"14,276",19
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,879.49,1.2,15.9,"7,534",20
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,F,858.23,1.2,11.7,"5,546",21
5,New Brunswick,N02AA,Natural opium alkaloids,65+,F,850.68,1.1,10,"4,734",22
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,F,823.21,1.1,5.4,"2,549",23
5,New Brunswick,N03AX,Other antiepileptics,65+,F,799.18,1.1,12.9,"6,121",24
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,F,796.01,1.1,5.9,"2,812",25
5,New Brunswick,L04AC,Interleukin inhibitors,65+,F,788.35,1.1,0.1,49,26
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,F,782.97,1.1,24.6,"11,614",27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,728.65,1,3,"1,421",28
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,F,721.7,1,23,"10,884",29
5,New Brunswick,M05BA,Bisphosphonates,65+,F,574.24,0.8,10.5,"4,987",30
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,563.69,0.8,6.4,"3,035",31
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,556.8,0.7,7,"3,288",32
5,New Brunswick,N05AX,Other antipsychotics,65+,F,535.03,0.7,3.4,"1,599",33
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,F,521.67,0.7,6.8,"3,226",34
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,F,503.58,0.7,1.2,573,35
5,New Brunswick,L03AA,Colony-stimulating factors,65+,F,498.33,0.7,0.2,88,36
5,New Brunswick,S01ED,Beta-blocking agents,65+,F,485.56,0.7,4.2,"1,977",37
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,485.19,0.7,1.1,530,38
5,New Brunswick,S01EE,Prostaglandin analogues,65+,F,484.38,0.7,3.8,"1,773",39
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,480.66,0.6,6.5,"3,067",40
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,F,462.1,0.6,15.1,"7,134",41
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,435.98,0.6,21,"9,933",42
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,397.82,0.5,1,481,43
5,New Brunswick,H01CB,Somatostatin and analogues,65+,F,397.28,0.5,0,21,44
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,F,387.3,0.5,13.5,"6,396",45
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,F,362.76,0.5,0,6,46
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,357.72,0.5,1.7,825,47
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,337.16,0.5,1,490,48
5,New Brunswick,C01DA,Organic nitrates,65+,F,321.62,0.4,6.1,"2,886",49
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,310.52,0.4,6.6,"3,133",50
5,New Brunswick,A10BA,Biguanides,65+,F,309.64,0.4,14.1,"6,643",51
5,New Brunswick,B01AB,Heparin group,65+,F,296.93,0.4,0.6,273,52
5,New Brunswick,R01AD,Corticosteroids,65+,F,285.44,0.4,13.3,"6,276",53
5,New Brunswick,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,54
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,F,278.75,0.4,0.6,274,55
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,273.42,0.4,4.6,"2,153",56
5,New Brunswick,L03AB,Interferons,65+,F,**,**,**,**,57
5,New Brunswick,N06DA,Anticholinesterases,65+,F,262.99,0.4,2.6,"1,236",58
5,New Brunswick,B02BX,Other systemic hemostatics,65+,F,**,**,**,**,59
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,F,235.04,0.3,1.3,633,60
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,234.3,0.3,0.8,379,61
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,233.19,0.3,0.2,97,62
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,230.19,0.3,7.4,"3,495",63
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,229.99,0.3,0,18,64
5,New Brunswick,A12BA,Potassium,65+,F,221.83,0.3,5.8,"2,760",65
5,New Brunswick,A04AD,Other antiemetics,65+,F,219.11,0.3,0.9,409,66
5,New Brunswick,A10BB,Sulfonylureas,65+,F,207.89,0.3,5.9,"2,782",67
5,New Brunswick,B01AA,Vitamin K antagonists,65+,F,195.79,0.3,5.1,"2,426",68
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,**,69
5,New Brunswick,M01AH,Coxibs,65+,F,187.99,0.3,6.3,"2,985",70
5,New Brunswick,A02BA,H2-receptor antagonists,65+,F,180.9,0.2,5.5,"2,620",71
5,New Brunswick,H02AB,Glucocorticoids,65+,F,171.57,0.2,13.1,"6,201",72
5,New Brunswick,L01BA,Folic acid analogues,65+,F,171,0.2,1.7,817,73
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,F,169.4,0.2,4.4,"2,079",74
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,F,168.92,0.2,3.5,"1,634",75
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,F,165.25,0.2,0.5,252,76
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,F,159.38,0.2,1.2,568,77
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,**,78
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,F,152.63,0.2,1.6,768,79
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,F,152.31,0.2,5.9,"2,810",80
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,F,151.35,0.2,0.1,59,81
5,New Brunswick,A03FA,Propulsives,65+,F,141.71,0.2,4.9,"2,307",82
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,83
5,New Brunswick,D01AC,Imidazole and triazole derivatives,65+,F,130.66,0.2,4.2,"1,967",84
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,128.57,0.2,6.8,"3,204",85
5,New Brunswick,N02AB,Phenylpiperidine derivatives,65+,F,127.29,0.2,0.4,167,86
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,F,126.5,0.2,0.9,438,87
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",65+,F,125.15,0.2,1.8,834,88
5,New Brunswick,C03AA,"Thiazides, plain",65+,F,124.41,0.2,10.4,"4,934",89
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,F,123.32,0.2,5.8,"2,743",90
5,New Brunswick,L02AB,Progestogens,65+,F,121,0.2,0.2,96,91
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,F,120.26,0.2,3.4,"1,607",92
5,New Brunswick,N04BC,Dopamine agonists,65+,F,120.03,0.2,1.4,641,93
5,New Brunswick,C10AC,Bile acid sequestrants,65+,F,118.46,0.2,1,479,94
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,114.88,0.2,3.2,"1,530",95
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,F,112.68,0.2,1.5,723,96
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,F,108.68,0.1,7.1,"3,350",97
5,New Brunswick,A07AA,Antibiotics,65+,F,107.15,0.1,1.8,848,98
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,F,104.24,0.1,3.1,"1,447",99
5,New Brunswick,J01DC,Second-generation cephalosporins,65+,F,101.65,0.1,6.1,"2,898",100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"15,858.78",12.8,1.8,822,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,Total,"10,621.99",8.6,0.4,206,2
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,Total,"7,097.02",5.8,5.6,"2,562",3
5,New Brunswick,N05AX,Other antipsychotics,<65,Total,"6,499.91",5.3,8.4,"3,842",4
5,New Brunswick,L04AA,Selective immunosuppressants,<65,Total,"6,146.39",5,1.4,623,5
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"4,125.25",3.3,15.2,"6,976",6
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,Total,"3,142.79",2.5,0.2,88,7
5,New Brunswick,L04AX,Other immunosuppressants,<65,Total,"2,998.95",2.4,0.8,349,8
5,New Brunswick,L04AC,Interleukin inhibitors,<65,Total,"2,950.58",2.4,0.4,172,9
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"2,847.93",2.3,0.6,271,10
5,New Brunswick,N06AX,Other antidepressants,<65,Total,"2,648.17",2.1,18.2,"8,316",11
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,519.42",2,22.9,"10,486",12
5,New Brunswick,N02AA,Natural opium alkaloids,<65,Total,"2,270.90",1.8,8,"3,661",13
5,New Brunswick,N03AX,Other antiepileptics,<65,Total,"2,218.58",1.8,13.6,"6,229",14
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,866.92",1.5,4.2,"1,918",15
5,New Brunswick,A02BC,Proton pump inhibitors,<65,Total,"1,784.96",1.4,27.8,"12,725",16
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,Total,"1,749.34",1.4,6,"2,731",17
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,Total,"1,683.23",1.4,7.7,"3,547",18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,Total,"1,584.82",1.3,13.6,"6,241",19
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,505.23",1.2,3.8,"1,738",20
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,Total,"1,355.44",1.1,9.4,"4,318",21
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,**,**,**,*,22
5,New Brunswick,R03BA,Glucocorticoids,<65,Total,"1,253.46",1,11.3,"5,186",23
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,Total,"1,204.29",1,16.9,"7,745",24
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"1,145.66",0.9,1.7,787,25
5,New Brunswick,S01LA,Antineovascularization agents,<65,Total,"1,044.57",0.8,0.3,122,26
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,Total,"1,043.76",0.8,0.7,326,27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,041.05",0.8,3.3,"1,523",28
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,017.18",0.8,18.5,"8,498",29
5,New Brunswick,R07AX,Other respiratory system products,<65,Total,**,**,**,*,30
5,New Brunswick,L03AB,Interferons,<65,Total,879.31,0.7,0.1,58,31
5,New Brunswick,R03BB,Anticholinergics,<65,Total,741.78,0.6,5.6,"2,587",32
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,669.3,0.5,1.7,773,33
5,New Brunswick,N03AG,Fatty acid derivatives,<65,Total,623.08,0.5,3.6,"1,668",34
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,Total,600.67,0.5,10.7,"4,919",35
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,592.64,0.5,11.4,"5,211",36
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,576.61,0.5,20.9,"9,585",37
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,Total,568.98,0.5,2.2,"1,000",38
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,559.91,0.5,6.2,"2,829",39
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,554.88,0.4,0.1,46,40
5,New Brunswick,A04AD,Other antiemetics,<65,Total,538.14,0.4,1.3,597,41
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,Total,537.81,0.4,2.6,"1,197",42
5,New Brunswick,A09AA,Enzyme preparations,<65,Total,508.97,0.4,0.4,169,43
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,Total,484.38,0.4,6.2,"2,857",44
5,New Brunswick,J05AX,Other antivirals,<65,Total,**,**,**,**,45
5,New Brunswick,H03AA,Thyroid hormones,<65,Total,466.6,0.4,8.9,"4,095",46
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,462.81,0.4,1.2,561,47
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,Total,454.05,0.4,5.6,"2,546",48
5,New Brunswick,L03AA,Colony-stimulating factors,<65,Total,433.22,0.4,0.2,71,49
5,New Brunswick,M03BX,Other centrally acting agents,<65,Total,396.9,0.3,8.1,"3,700",50
5,New Brunswick,J05AE,Protease inhibitors,<65,Total,390.92,0.3,0.1,53,51
5,New Brunswick,A10BA,Biguanides,<65,Total,381.73,0.3,9.5,"4,365",52
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,Total,361.78,0.3,1.2,534,53
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,Total,360.47,0.3,0.9,429,54
5,New Brunswick,B01AB,Heparin group,<65,Total,359.57,0.3,0.4,204,55
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,Total,351.04,0.3,7.4,"3,390",56
5,New Brunswick,M01AE,Propionic acid derivatives,<65,Total,350.97,0.3,12.3,"5,641",57
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,350.14,0.3,0.8,384,58
5,New Brunswick,L03AX,Other immunostimulants,<65,Total,342.3,0.3,0.1,36,59
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,Total,329.4,0.3,0.1,26,60
5,New Brunswick,N05AE,Indole derivatives,<65,Total,304.19,0.2,0.6,253,61
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,Total,277.55,0.2,3.2,"1,479",62
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,272.84,0.2,0.2,86,63
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,272.32,0.2,1.2,532,64
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,Total,266.17,0.2,0.9,431,65
5,New Brunswick,J01GB,Other aminoglycosides,<65,Total,264.12,0.2,0.1,45,66
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,**,**,**,**,67
5,New Brunswick,R05CB,Mucolytics,<65,Total,255.75,0.2,0.1,33,68
5,New Brunswick,N03AF,Carboxamide derivatives,<65,Total,254.61,0.2,1.6,738,69
5,New Brunswick,A02BA,H2-receptor antagonists,<65,Total,251.58,0.2,4.5,"2,042",70
5,New Brunswick,R01AD,Corticosteroids,<65,Total,245.29,0.2,10.4,"4,781",71
5,New Brunswick,G03XB,Progesterone receptor modulators,<65,Total,235.87,0.2,1.5,681,72
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,230.03,0.2,3.7,"1,702",73
5,New Brunswick,H01CB,Somatostatin and analogues,<65,Total,**,**,**,**,74
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,Total,221.1,0.2,2.7,"1,218",75
5,New Brunswick,L02BB,Antiandrogens,<65,Total,217.21,0.2,0,18,76
5,New Brunswick,B03XA,Other antianemic preparations,<65,Total,211.05,0.2,0.1,53,77
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,199.72,0.2,2.2,"1,011",78
5,New Brunswick,A10BB,Sulfonylureas,<65,Total,190.47,0.2,4,"1,818",79
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,181.02,0.1,0.2,84,80
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,81
5,New Brunswick,M01AH,Coxibs,<65,Total,175.69,0.1,3.6,"1,650",82
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,174.7,0.1,3.2,"1,463",83
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,Total,174.19,0.1,1.2,567,84
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,Total,168.82,0.1,4.1,"1,886",85
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,168.82,0.1,0.4,198,86
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,Total,161.49,0.1,0.9,421,87
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,Total,155.72,0.1,14.9,"6,816",88
5,New Brunswick,L01XC,Monoclonal antibodies,<65,Total,**,**,**,**,89
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,146.31,0.1,0,11,90
5,New Brunswick,G03AC,Progestogens,<65,Total,**,**,**,**,91
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,140.05,0.1,2.3,"1,074",92
5,New Brunswick,A03FA,Propulsives,<65,Total,138.62,0.1,3,"1,379",93
5,New Brunswick,H02AB,Glucocorticoids,<65,Total,137.76,0.1,9.5,"4,343",94
5,New Brunswick,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,137.57,0.1,1.5,672,95
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,Total,132.92,0.1,0.5,219,96
5,New Brunswick,L01AX,Other alkylating agents,<65,Total,131.84,0.1,0,11,97
5,New Brunswick,C01CA,Adrenergic and dopaminergic agents,<65,Total,129.74,0.1,1.5,665,98
5,New Brunswick,J02AC,Triazole derivatives,<65,Total,123.45,0.1,2.5,"1,156",99
5,New Brunswick,N07BB,Drugs used in alcohol dependence,<65,Total,120.69,0.1,0.3,153,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"7,546.78",11.9,1.9,392,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,M,"7,506.92",11.9,0.7,145,2
5,New Brunswick,N05AX,Other antipsychotics,<65,M,"4,542.56",7.2,11.1,"2,345",3
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,M,"4,090.24",6.5,7.1,"1,501",4
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"2,559.96",4,17.3,"3,654",5
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,6
5,New Brunswick,L04AA,Selective immunosuppressants,<65,M,"2,128.45",3.4,1.2,259,7
5,New Brunswick,L04AC,Interleukin inhibitors,<65,M,"1,655.47",2.6,0.4,91,8
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,M,"1,484.61",2.3,0.2,36,9
5,New Brunswick,L04AX,Other immunosuppressants,<65,M,"1,349.46",2.1,0.6,132,10
5,New Brunswick,N02AA,Natural opium alkaloids,<65,M,"1,322.41",2.1,7.9,"1,670",11
5,New Brunswick,N06AX,Other antidepressants,<65,M,"1,167.12",1.8,15.6,"3,282",12
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,M,"1,124.33",1.8,7.8,"1,646",13
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,037.01",1.6,19,"4,005",14
5,New Brunswick,N03AX,Other antiepileptics,<65,M,988.64,1.6,12.3,"2,593",15
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,M,954.94,1.5,6.7,"1,417",16
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,M,849.22,1.3,4.4,922,17
5,New Brunswick,A02BC,Proton pump inhibitors,<65,M,812.25,1.3,26.1,"5,499",18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,M,795.94,1.3,13.1,"2,768",19
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,M,681.7,1.1,8.6,"1,817",20
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,M,645.67,1,0.9,196,21
5,New Brunswick,R07AX,Other respiratory system products,<65,M,**,**,**,*,22
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,625.59,1,3.2,671,23
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,M,543.3,0.9,14.6,"3,090",24
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,M,529.93,0.8,20.7,"4,374",25
5,New Brunswick,R03BA,Glucocorticoids,<65,M,508.51,0.8,9.7,"2,046",26
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,485.65,0.8,3.4,718,27
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,**,**,**,*,28
5,New Brunswick,S01LA,Antineovascularization agents,<65,M,455.06,0.7,0.3,64,29
5,New Brunswick,R03BB,Anticholinergics,<65,M,371.21,0.6,5.7,"1,197",30
5,New Brunswick,N03AG,Fatty acid derivatives,<65,M,349.81,0.6,4.4,921,31
5,New Brunswick,J05AX,Other antivirals,<65,M,**,**,**,**,32
5,New Brunswick,J05AE,Protease inhibitors,<65,M,346.75,0.5,0.2,46,33
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,M,331.16,0.5,12.4,"2,618",34
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,283.02,0.4,1.6,338,35
5,New Brunswick,A09AA,Enzyme preparations,<65,M,281.01,0.4,0.4,84,36
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,272.83,0.4,10.9,"2,294",37
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,M,260.82,0.4,2.3,491,38
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,M,251.95,0.4,7,"1,484",39
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,251.45,0.4,18.3,"3,851",40
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,M,233.71,0.4,0.1,16,41
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,232.11,0.4,1.3,283,42
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,231.16,0.4,4.7,991,43
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,230.8,0.4,2.2,460,44
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,M,227.14,0.4,5.8,"1,233",45
5,New Brunswick,L02BB,Antiandrogens,<65,M,217.21,0.3,0.1,18,46
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,M,204.96,0.3,1.3,275,47
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,M,200.36,0.3,8.8,"1,848",48
5,New Brunswick,A04AD,Other antiemetics,<65,M,192.06,0.3,1,216,49
5,New Brunswick,A10BA,Biguanides,<65,M,189.43,0.3,9.8,"2,061",50
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,M,178,0.3,1.7,357,51
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,173.45,0.3,0.9,186,52
5,New Brunswick,B01AB,Heparin group,<65,M,168.66,0.3,0.3,70,53
5,New Brunswick,M03BX,Other centrally acting agents,<65,M,165.43,0.3,6.6,"1,401",54
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,M,155.04,0.2,0.9,182,55
5,New Brunswick,N03AF,Carboxamide derivatives,<65,M,145.43,0.2,1.9,399,56
5,New Brunswick,L03AB,Interferons,<65,M,**,**,**,**,57
5,New Brunswick,M01AE,Propionic acid derivatives,<65,M,143.34,0.2,10.4,"2,194",58
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,M,141.98,0.2,3.6,755,59
5,New Brunswick,H01CB,Somatostatin and analogues,<65,M,132.71,0.2,0,9,60
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,61
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,127.89,0.2,0.3,61,62
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**,**,**,**,63
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,M,125.53,0.2,0.8,166,64
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,124.79,0.2,1.2,246,65
5,New Brunswick,J01GB,Other aminoglycosides,<65,M,124.24,0.2,0.1,24,66
5,New Brunswick,N05AE,Indole derivatives,<65,M,121.37,0.2,0.5,103,67
5,New Brunswick,B03XA,Other antianemic preparations,<65,M,120.15,0.2,0.1,28,68
5,New Brunswick,A02BA,H2-receptor antagonists,<65,M,114.57,0.2,3.9,832,69
5,New Brunswick,H03AA,Thyroid hormones,<65,M,113.98,0.2,4.9,"1,040",70
5,New Brunswick,L03AA,Colony-stimulating factors,<65,M,112.67,0.2,0.1,19,71
5,New Brunswick,R05CB,Mucolytics,<65,M,**,**,**,**,72
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,<65,M,105.27,0.2,4.2,889,73
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,104.09,0.2,0,10,74
5,New Brunswick,A10BB,Sulfonylureas,<65,M,100.8,0.2,4.3,907,75
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,100.4,0.2,3.5,736,76
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,M,94.33,0.1,0.7,147,77
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,M,92.64,0.1,2.5,526,78
5,New Brunswick,R01AD,Corticosteroids,<65,M,90.13,0.1,7.7,"1,628",79
5,New Brunswick,M01AH,Coxibs,<65,M,83.26,0.1,3.1,647,80
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,M,79.19,0.1,1.3,264,81
5,New Brunswick,N07BB,Drugs used in alcohol dependence,<65,M,74.99,0.1,0.4,89,82
5,New Brunswick,N05AD,Butyrophenone derivatives,<65,M,74.13,0.1,0.9,200,83
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,M,73.27,0.1,3.9,813,84
5,New Brunswick,L03AX,Other immunostimulants,<65,M,**,**,**,**,85
5,New Brunswick,L01AX,Other alkylating agents,<65,M,**,**,**,**,86
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,70.26,0.1,0.4,78,87
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,M,69.2,0.1,13.7,"2,893",88
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,<65,M,68.4,0.1,1,203,89
5,New Brunswick,V03AC,Iron-chelating agents,<65,M,**,**,**,*,90
5,New Brunswick,N05AA,Phenothiazines with aliphatic side-chain,<65,M,67.62,0.1,0.9,189,91
5,New Brunswick,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,**,92
5,New Brunswick,N04AC,Ethers of tropine or tropine derivatives,<65,M,64.57,0.1,2.1,451,93
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,60.78,0.1,0.5,106,94
5,New Brunswick,N03AB,Hydantoin derivatives,<65,M,60.61,0.1,1.4,289,95
5,New Brunswick,A03FA,Propulsives,<65,M,58.75,0.1,2.3,477,96
5,New Brunswick,H02AB,Glucocorticoids,<65,M,57.04,0.1,8.1,"1,707",97
5,New Brunswick,A07AA,Antibiotics,<65,M,56.34,0.1,1,216,98
5,New Brunswick,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,M,**,**,**,**,99
5,New Brunswick,N05AN,Lithium,<65,M,52.38,0.1,1.3,264,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"8,312.00",13.8,1.7,430,1
5,New Brunswick,L04AA,Selective immunosuppressants,<65,F,"4,017.94",6.7,1.5,364,2
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,F,"3,115.07",5.2,0.2,61,3
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,F,"3,006.78",5,4.3,"1,061",4
5,New Brunswick,N05AX,Other antipsychotics,<65,F,"1,957.36",3.3,6.1,"1,497",5
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,F,"1,658.19",2.8,0.2,52,6
5,New Brunswick,L04AX,Other immunosuppressants,<65,F,"1,649.49",2.7,0.9,217,7
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,565.29",2.6,13.4,"3,322",8
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,482.41",2.5,26.2,"6,481",9
5,New Brunswick,N06AX,Other antidepressants,<65,F,"1,481.05",2.5,20.4,"5,034",10
5,New Brunswick,L04AC,Interleukin inhibitors,<65,F,"1,295.11",2.2,0.3,81,11
5,New Brunswick,N03AX,Other antiepileptics,<65,F,"1,229.93",2,14.7,"3,636",12
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,017.70",1.7,4,996,13
5,New Brunswick,A02BC,Proton pump inhibitors,<65,F,972.71,1.6,29.2,"7,226",14
5,New Brunswick,N02AA,Natural opium alkaloids,<65,F,948.49,1.6,8.1,"1,991",15
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,914.86,1.5,1.3,327,16
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,879.64,1.5,4.3,"1,067",17
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,**,**,**,*,18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,F,788.88,1.3,14.1,"3,473",19
5,New Brunswick,R03BA,Glucocorticoids,<65,F,744.95,1.2,12.7,"3,140",20
5,New Brunswick,L03AB,Interferons,<65,F,**,**,**,**,21
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,F,728.29,1.2,8.6,"2,130",22
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,F,673.75,1.1,10.1,"2,501",23
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,F,660.99,1.1,18.8,"4,655",24
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,F,625.01,1,4.4,"1,085",25
5,New Brunswick,S01LA,Antineovascularization agents,<65,F,589.51,1,0.2,58,26
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,555.39,0.9,3.3,805,28
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,F,487.25,0.8,16.7,"4,124",29
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,450.78,0.7,0.1,36,30
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,F,398.09,0.7,0.5,130,31
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,386.29,0.6,1.8,435,32
5,New Brunswick,R03BB,Anticholinergics,<65,F,370.57,0.6,5.6,"1,390",33
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,F,359.81,0.6,3.4,840,34
5,New Brunswick,H03AA,Thyroid hormones,<65,F,352.63,0.6,12.4,"3,055",35
5,New Brunswick,A04AD,Other antiemetics,<65,F,346.08,0.6,1.5,381,36
5,New Brunswick,R07AX,Other respiratory system products,<65,F,**,**,**,*,37
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,328.75,0.5,7.4,"1,838",38
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,325.16,0.5,23.2,"5,734",39
5,New Brunswick,L03AA,Colony-stimulating factors,<65,F,320.55,0.5,0.2,52,40
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,319.81,0.5,11.8,"2,917",41
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,F,308.16,0.5,2.1,509,42
5,New Brunswick,N03AG,Fatty acid derivatives,<65,F,273.27,0.5,3,747,43
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,F,269.52,0.4,9.3,"2,301",44
5,New Brunswick,L03AX,Other immunostimulants,<65,F,**,**,**,**,45
5,New Brunswick,G03XB,Progesterone receptor modulators,<65,F,**,**,**,**,46
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,F,232.43,0.4,5.6,"1,373",47
5,New Brunswick,M03BX,Other centrally acting agents,<65,F,231.47,0.4,9.3,"2,299",48
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,230.7,0.4,1.1,278,49
5,New Brunswick,A09AA,Enzyme preparations,<65,F,227.96,0.4,0.3,85,50
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,F,226.92,0.4,5.3,"1,313",51
5,New Brunswick,M01AE,Propionic acid derivatives,<65,F,207.63,0.3,13.9,"3,447",52
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,F,205.43,0.3,1,247,53
5,New Brunswick,A10BA,Biguanides,<65,F,192.3,0.3,9.3,"2,304",54
5,New Brunswick,B01AB,Heparin group,<65,F,190.91,0.3,0.5,134,55
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,189.37,0.3,3.9,967,56
5,New Brunswick,N05AE,Indole derivatives,<65,F,182.82,0.3,0.6,150,57
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,176.69,0.3,0.8,198,58
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,173.29,0.3,5.9,"1,450",59
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,60
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,F,156.82,0.3,1,259,61
5,New Brunswick,R01AD,Corticosteroids,<65,F,155.16,0.3,12.8,"3,153",62
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,63
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,F,150.67,0.3,6.2,"1,542",64
5,New Brunswick,R05CB,Mucolytics,<65,F,**,**,**,**,65
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,147.53,0.2,1.2,286,66
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,67
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,F,140.64,0.2,1.1,265,68
5,New Brunswick,G03AC,Progestogens,<65,F,**,**,**,**,69
5,New Brunswick,J01GB,Other aminoglycosides,<65,F,139.88,0.2,0.1,21,70
5,New Brunswick,A02BA,H2-receptor antagonists,<65,F,137,0.2,4.9,"1,210",71
5,New Brunswick,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,136.51,0.2,2.7,664,72
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,F,135.58,0.2,2.9,724,73
5,New Brunswick,J05AX,Other antivirals,<65,F,**,**,**,**,74
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,129.63,0.2,3.9,966,75
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,76
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,F,128.46,0.2,2.8,692,77
5,New Brunswick,N03AF,Carboxamide derivatives,<65,F,109.18,0.2,1.4,339,78
5,New Brunswick,L01XC,Monoclonal antibodies,<65,F,**,**,**,**,79
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,98.56,0.2,0.5,120,80
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,81
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,F,95.69,0.2,0,10,82
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,F,95.55,0.2,4.3,"1,073",83
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,95.17,0.2,3.2,792,84
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,F,95,0.2,1.2,303,85
5,New Brunswick,J02AC,Triazole derivatives,<65,F,93.49,0.2,4.1,"1,012",86
5,New Brunswick,H01CB,Somatostatin and analogues,<65,F,92.59,0.2,0,6,87
5,New Brunswick,M01AH,Coxibs,<65,F,92.44,0.2,4.1,"1,003",88
5,New Brunswick,B03XA,Other antianemic preparations,<65,F,90.9,0.2,0.1,25,89
5,New Brunswick,A10BB,Sulfonylureas,<65,F,89.67,0.1,3.7,911,90
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,F,86.52,0.1,15.9,"3,923",91
5,New Brunswick,C01CA,Adrenergic and dopaminergic agents,<65,F,80.8,0.1,1.7,417,92
5,New Brunswick,H02AB,Glucocorticoids,<65,F,80.73,0.1,10.7,"2,636",93
5,New Brunswick,A03FA,Propulsives,<65,F,79.87,0.1,3.6,902,94
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,<65,F,**,**,**,**,95
5,New Brunswick,N02CC,Selective serotonin (5HT1) agonists,<65,F,70.24,0.1,1.6,386,96
5,New Brunswick,L01BA,Folic acid analogues,<65,F,70.23,0.1,1.3,313,97
5,New Brunswick,A05AA,Bile acids and derivatives,<65,F,69.08,0.1,0.2,40,98
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",<65,F,66.45,0.1,1.5,365,99
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),<65,F,66.3,0.1,1.1,283,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"275,155.63",6.7,0.5,"13,905",1
6,Quebec,S01LA,Antineovascularization agents,Total,Total,"219,490.12",5.4,0.7,"21,237",2
6,Quebec,L01XE,Protein kinase inhibitors,Total,Total,"187,997.70",4.6,0.2,"5,009",3
6,Quebec,L04AA,Selective immunosuppressants,Total,Total,"118,011.27",2.9,0.5,"13,706",4
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,Total,"108,457.54",2.7,5,"147,429",5
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,Total,"107,738.98",2.6,32.7,"966,097",6
6,Quebec,A02BC,Proton pump inhibitors,Total,Total,"92,949.98",2.3,29.1,"857,620",7
6,Quebec,L04AX,Other immunosuppressants,Total,Total,"88,499.73",2.2,0.3,"7,518",8
6,Quebec,N05AX,Other antipsychotics,Total,Total,"83,244.70",2,2.7,"80,329",9
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"78,167.82",1.9,4.8,"142,055",10
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"70,865.45",1.7,6.2,"181,898",11
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,Total,"64,767.68",1.6,0,"1,335",12
6,Quebec,N03AX,Other antiepileptics,Total,Total,"61,191.51",1.5,8.6,"254,495",13
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"60,938.89",1.5,0.3,"9,250",14
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"55,951.70",1.4,2.7,"80,886",15
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"55,487.55",1.4,2.8,"81,765",16
6,Quebec,C08CA,Dihydropyridine derivatives,Total,Total,"55,368.10",1.4,15.6,"460,217",17
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,Total,"53,583.58",1.3,3.4,"98,975",18
6,Quebec,N06AX,Other antidepressants,Total,Total,"51,034.37",1.2,11.5,"339,394",19
6,Quebec,A11CC,Vitamin D and analogues,Total,Total,"49,583.61",1.2,22.7,"671,469",20
6,Quebec,R03BB,Anticholinergics,Total,Total,"49,387.97",1.2,4.8,"142,242",21
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"48,000.53",1.2,2.5,"72,812",22
6,Quebec,L04AC,Interleukin inhibitors,Total,Total,"45,244.03",1.1,0.1,"2,901",23
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,Total,"43,370.94",1.1,13.9,"410,705",24
6,Quebec,N02BA,Salicylic acid and derivatives,Total,Total,"41,093.65",1,16.4,"485,102",25
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"40,966.68",1,10.7,"314,527",26
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"38,993.30",1,1.9,"57,001",27
6,Quebec,C09AA,"ACE inhibitors, plain",Total,Total,"38,892.82",1,11.9,"351,499",28
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"38,104.81",0.9,11.2,"331,830",29
6,Quebec,B03XA,Other antianemic preparations,Total,Total,"38,060.34",0.9,0.3,"9,019",30
6,Quebec,H03AA,Thyroid hormones,Total,Total,"37,049.14",0.9,14.1,"416,909",31
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"34,891.60",0.9,1.5,"45,586",32
6,Quebec,N02AA,Natural opium alkaloids,Total,Total,"34,348.20",0.8,10,"294,112",33
6,Quebec,R03BA,Glucocorticoids,Total,Total,"34,304.21",0.8,8.1,"238,798",34
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"33,750.32",0.8,0.4,"11,770",35
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"31,336.55",0.8,11.1,"326,406",36
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"29,147.17",0.7,0.1,"2,072",37
6,Quebec,L03AA,Colony-stimulating factors,Total,Total,"27,997.81",0.7,0.2,"5,749",38
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"27,616.28",0.7,0.6,"18,119",39
6,Quebec,A10BA,Biguanides,Total,Total,"26,674.72",0.7,9.9,"293,297",40
6,Quebec,N05BA,Benzodiazepine derivatives,Total,Total,"26,625.30",0.7,12.1,"357,973",41
6,Quebec,B01AB,Heparin group,Total,Total,"24,096.63",0.6,1,"28,570",42
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"22,996.86",0.6,12.7,"374,773",43
6,Quebec,L02BB,Antiandrogens,Total,Total,"22,868.19",0.6,0.2,"5,842",44
6,Quebec,H01CB,Somatostatin and analogues,Total,Total,"21,998.23",0.5,0.1,"1,723",45
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"21,810.88",0.5,1.6,"47,333",46
6,Quebec,M05BA,Bisphosphonates,Total,Total,"21,235.80",0.5,5.3,"155,286",47
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"20,851.09",0.5,3.3,"97,407",48
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,Total,"20,669.00",0.5,0.1,"1,580",49
6,Quebec,N02BE,Anilides,Total,Total,"20,616.11",0.5,14.2,"419,426",50
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"20,543.72",0.5,2.6,"75,960",51
6,Quebec,A12AA,Calcium,Total,Total,"20,417.54",0.5,8.7,"256,293",52
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"20,130.04",0.5,6.2,"181,685",53
6,Quebec,C03CA,"Sulfonamides, plain",Total,Total,"18,145.41",0.4,4.8,"140,321",54
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"17,663.15",0.4,0.3,"8,696",55
6,Quebec,L04AD,Calcineurin inhibitors,Total,Total,"16,805.61",0.4,0.2,"5,546",56
6,Quebec,A16AB,Enzymes,Total,Total,"16,673.83",0.4,0,20,57
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"16,224.35",0.4,1.1,"31,968",58
6,Quebec,J05AX,Other antivirals,Total,Total,"16,107.75",0.4,0.1,"2,972",59
6,Quebec,N06DA,Anticholinesterases,Total,Total,"16,104.82",0.4,1.4,"41,054",60
6,Quebec,S01ED,Beta-blocking agents,Total,Total,"15,515.32",0.4,2.8,"81,189",61
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"15,496.64",0.4,5.3,"157,503",62
6,Quebec,S01EE,Prostaglandin analogues,Total,Total,"15,319.36",0.4,2.6,"75,499",63
6,Quebec,A10BB,Sulfonylureas,Total,Total,"15,279.62",0.4,4.5,"133,651",64
6,Quebec,C08DB,Benzothiazepine derivatives,Total,Total,"15,260.32",0.4,2.1,"63,320",65
6,Quebec,C10AX,Other lipid-modifying agents,Total,Total,"14,899.44",0.4,2.7,"80,618",66
6,Quebec,R01AD,Corticosteroids,Total,Total,"13,479.37",0.3,10.5,"311,195",67
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,"13,059.72",0.3,4.4,"129,645",68
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,Total,"12,942.07",0.3,0.7,"19,725",69
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"12,617.17",0.3,0.2,"5,610",70
6,Quebec,A06AA,"Softeners, emollients",Total,Total,"12,557.93",0.3,4.6,"135,307",71
6,Quebec,V06C,Infant formulas,Total,Total,"12,273.30",0.3,0.3,"9,602",72
6,Quebec,N04BA,Dopa and dopa derivatives,Total,Total,"12,198.30",0.3,0.5,"15,868",73
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"12,186.78",0.3,3.1,"92,523",74
6,Quebec,L01XX,Other antineoplastic agents,Total,Total,"11,876.61",0.3,0.2,"4,581",75
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"11,683.92",0.3,4.6,"135,715",76
6,Quebec,S01XA,Other ophthalmologicals,Total,Total,"11,630.56",0.3,1.2,"36,581",77
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,Total,"11,433.94",0.3,2.6,"77,926",78
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"11,206.17",0.3,0.4,"10,856",79
6,Quebec,L01XC,Monoclonal antibodies,Total,Total,"10,910.74",0.3,0,"1,000",80
6,Quebec,N03AE,Benzodiazepine derivatives,Total,Total,"10,385.68",0.3,3.7,"110,615",81
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"10,325.83",0.3,3.4,"101,536",82
6,Quebec,N07BC,Drugs used in opioid dependence,Total,Total,"10,311.30",0.3,0.3,"7,617",83
6,Quebec,C01DA,Organic nitrates,Total,Total,"10,140.19",0.2,3.6,"106,511",84
6,Quebec,L03AB,Interferons,Total,Total,"9,847.03",0.2,0,761,85
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,Total,"9,788.13",0.2,2.4,"70,188",86
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,Total,"9,711.78",0.2,4.8,"142,839",87
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"9,494.26",0.2,0,380,88
6,Quebec,B01AE,Direct thrombin inhibitors,Total,Total,"9,128.85",0.2,0.4,"11,749",89
6,Quebec,N03AG,Fatty acid derivatives,Total,Total,"8,799.43",0.2,0.8,"24,916",90
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"8,741.33",0.2,1.1,"33,732",91
6,Quebec,J05AE,Protease inhibitors,Total,Total,"8,429.31",0.2,0,"1,267",92
6,Quebec,C03AA,"Thiazides, plain",Total,Total,"8,154.13",0.2,4.7,"137,854",93
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"7,827.93",0.2,3.6,"107,133",94
6,Quebec,M04AA,Preparations inhibiting uric acid production,Total,Total,"7,813.00",0.2,2.4,"71,275",95
6,Quebec,C02AC,Imidazoline receptor agonists,Total,Total,"7,778.47",0.2,0.8,"23,572",96
6,Quebec,R07AX,Other respiratory system products,Total,Total,"7,718.44",0.2,0,42,97
6,Quebec,A06AD,Osmotically acting laxatives,Total,Total,"7,616.56",0.2,4.7,"140,121",98
6,Quebec,A06AB,Contact laxatives,Total,Total,"7,587.03",0.2,2.7,"78,528",99
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"7,543.85",0.2,1.3,"39,490",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"136,453.55",6.9,0.5,"6,376",1
6,Quebec,S01LA,Antineovascularization agents,Total,M,"91,205.13",4.6,0.7,"8,985",2
6,Quebec,L01XE,Protein kinase inhibitors,Total,M,"84,678.59",4.3,0.2,"2,254",3
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,M,"55,502.83",2.8,5.9,"76,360",4
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,M,"55,276.48",2.8,40.6,"521,517",5
6,Quebec,N05AX,Other antipsychotics,Total,M,"53,737.79",2.7,3,"38,640",6
6,Quebec,L04AX,Other immunosuppressants,Total,M,"50,083.90",2.5,0.3,"3,381",7
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"49,413.71",2.5,0.6,"7,523",8
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,M,"43,386.91",2.2,0.1,890,9
6,Quebec,L04AA,Selective immunosuppressants,Total,M,"43,020.10",2.2,0.4,"5,696",10
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"42,361.30",2.1,6.5,"84,010",11
6,Quebec,A02BC,Proton pump inhibitors,Total,M,"38,355.60",1.9,28.3,"363,161",12
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"33,490.81",1.7,4.6,"58,687",13
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"33,166.03",1.7,3.8,"48,656",14
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,M,"31,995.57",1.6,4.2,"54,485",15
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"30,810.52",1.6,0.8,"10,114",16
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"28,811.70",1.5,3.4,"44,247",17
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"28,433.74",1.4,3.4,"43,009",18
6,Quebec,N03AX,Other antiepileptics,Total,M,"25,409.45",1.3,7.9,"101,628",19
6,Quebec,C08CA,Dihydropyridine derivatives,Total,M,"24,874.54",1.3,17,"218,037",20
6,Quebec,R03BB,Anticholinergics,Total,M,"23,380.57",1.2,5.3,"67,424",21
6,Quebec,L02BB,Antiandrogens,Total,M,"22,863.76",1.2,0.5,"5,829",22
6,Quebec,N02BA,Salicylic acid and derivatives,Total,M,"21,514.33",1.1,20.8,"267,242",23
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,M,"21,193.33",1.1,16.3,"209,051",24
6,Quebec,C09AA,"ACE inhibitors, plain",Total,M,"20,951.90",1.1,15.4,"197,856",25
6,Quebec,B03XA,Other antianemic preparations,Total,M,"20,946.23",1.1,0.4,"4,875",26
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,M,**,**,**,**,27
6,Quebec,L04AC,Interleukin inhibitors,Total,M,"20,533.55",1,0.1,"1,241",28
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"20,050.28",1,2,"25,178",29
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"19,206.97",1,13.5,"173,439",30
6,Quebec,N06AX,Other antidepressants,Total,M,"17,621.34",0.9,9.3,"119,480",31
6,Quebec,N02AA,Natural opium alkaloids,Total,M,"16,292.39",0.8,10.2,"131,085",32
6,Quebec,A11CC,Vitamin D and analogues,Total,M,"16,184.57",0.8,15.2,"195,717",33
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"15,541.48",0.8,11.4,"146,360",34
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"15,038.59",0.8,0.8,"9,832",35
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,M,"14,076.27",0.7,8,"103,082",36
6,Quebec,R03BA,Glucocorticoids,Total,M,"14,012.36",0.7,7.4,"94,477",37
6,Quebec,A10BA,Biguanides,Total,M,"13,864.45",0.7,12.5,"159,958",38
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"13,440.39",0.7,0.5,"6,586",39
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"12,783.13",0.6,2,"25,936",40
6,Quebec,J05AX,Other antivirals,Total,M,"12,477.24",0.6,0.2,"2,192",41
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"12,137.03",0.6,7.2,"91,975",42
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"12,111.18",0.6,0.1,836,43
6,Quebec,L03AA,Colony-stimulating factors,Total,M,"11,993.37",0.6,0.2,"2,370",44
6,Quebec,B01AB,Heparin group,Total,M,"11,694.40",0.6,1,"12,720",45
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"11,221.74",0.6,4.4,"57,017",46
6,Quebec,H01CB,Somatostatin and analogues,Total,M,"10,925.76",0.6,0.1,774,47
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"10,357.90",0.5,12.2,"156,978",48
6,Quebec,L04AD,Calcineurin inhibitors,Total,M,"10,243.95",0.5,0.3,"3,374",49
6,Quebec,H03AA,Thyroid hormones,Total,M,"10,038.27",0.5,8.4,"107,924",50
6,Quebec,N05BA,Benzodiazepine derivatives,Total,M,"9,763.82",0.5,9.7,"124,366",51
6,Quebec,A16AB,Enzymes,Total,M,"9,395.17",0.5,0,12,52
6,Quebec,A10BB,Sulfonylureas,Total,M,"8,409.75",0.4,6,"77,317",53
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"8,247.58",0.4,1.3,"16,078",54
6,Quebec,C03CA,"Sulfonamides, plain",Total,M,"8,241.00",0.4,5,"64,353",55
6,Quebec,C10AX,Other lipid-modifying agents,Total,M,"8,150.50",0.4,3.6,"45,671",56
6,Quebec,N04BA,Dopa and dopa derivatives,Total,M,"7,258.25",0.4,0.7,"8,915",57
6,Quebec,N02BE,Anilides,Total,M,"7,190.65",0.4,12.9,"165,592",58
6,Quebec,S01ED,Beta-blocking agents,Total,M,"6,940.48",0.4,2.9,"37,632",59
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,M,"6,844.30",0.3,2.1,"27,066",60
6,Quebec,J05AE,Protease inhibitors,Total,M,"6,811.58",0.3,0.1,"1,005",61
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"6,793.86",0.3,0.5,"6,438",62
6,Quebec,N07BC,Drugs used in opioid dependence,Total,M,"6,491.29",0.3,0.3,"4,477",63
6,Quebec,S01EE,Prostaglandin analogues,Total,M,"6,444.87",0.3,2.6,"33,231",64
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"6,435.68",0.3,5.4,"69,925",65
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,M,"6,317.47",0.3,0.7,"9,055",66
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,M,"6,123.77",0.3,4.6,"58,809",67
6,Quebec,V06C,Infant formulas,Total,M,"6,104.19",0.3,0.3,"4,423",68
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,Total,M,"6,079.00",0.3,1.1,"13,993",69
6,Quebec,C08DB,Benzothiazepine derivatives,Total,M,"6,015.27",0.3,2,"25,768",70
6,Quebec,N06DA,Anticholinesterases,Total,M,"5,873.57",0.3,1.2,"15,190",71
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,M,"5,750.82",0.3,3,"38,756",72
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"5,725.12",0.3,0.2,"2,952",73
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,"5,616.83",0.3,4.4,"56,125",74
6,Quebec,R01AD,Corticosteroids,Total,M,"5,600.88",0.3,9.5,"122,269",75
6,Quebec,C02AC,Imidazoline receptor agonists,Total,M,"5,342.92",0.3,0.8,"9,756",76
6,Quebec,M04AA,Preparations inhibiting uric acid production,Total,M,"5,309.44",0.3,4,"51,550",77
6,Quebec,B01AE,Direct thrombin inhibitors,Total,M,"5,270.34",0.3,0.5,"6,982",78
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,M,"5,230.71",0.3,3,"38,337",79
6,Quebec,C01DA,Organic nitrates,Total,M,"5,082.82",0.3,4.7,"60,172",80
6,Quebec,M05BA,Bisphosphonates,Total,M,"4,992.48",0.3,2.5,"32,072",81
6,Quebec,A12AA,Calcium,Total,M,"4,902.23",0.2,4.2,"53,762",82
6,Quebec,N03AG,Fatty acid derivatives,Total,M,"4,839.53",0.2,1,"12,954",83
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"4,828.60",0.2,1.4,"18,274",84
6,Quebec,A06AA,"Softeners, emollients",Total,M,"4,803.13",0.2,3.9,"50,128",85
6,Quebec,L01XX,Other antineoplastic agents,Total,M,"4,650.93",0.2,0.1,"1,912",86
6,Quebec,N03AE,Benzodiazepine derivatives,Total,M,"4,245.05",0.2,3.1,"40,140",87
6,Quebec,J01DH,Carbapenems,Total,M,"3,913.76",0.2,0.2,"2,166",88
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,M,"3,890.87",0.2,4,"51,920",89
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"3,806.79",0.2,0.1,"1,532",90
6,Quebec,R07AX,Other respiratory system products,Total,M,"3,664.08",0.2,0,19,91
6,Quebec,L01XC,Monoclonal antibodies,Total,M,"3,619.79",0.2,0,354,92
6,Quebec,B02BX,Other systemic hemostatics,Total,M,"3,534.62",0.2,0,91,93
6,Quebec,C03DA,Aldosterone antagonists,Total,M,"3,411.76",0.2,1.9,"24,250",94
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"3,314.71",0.2,2.3,"29,966",95
6,Quebec,D07AC,"Corticosteroids, potent (group III)",Total,M,"3,299.60",0.2,7.4,"95,501",96
6,Quebec,H02AB,Glucocorticoids,Total,M,"3,165.22",0.2,7.8,"100,443",97
6,Quebec,A06AD,Osmotically acting laxatives,Total,M,"3,137.17",0.2,4.3,"54,818",98
6,Quebec,V03AC,Iron-chelating agents,Total,M,"3,106.80",0.2,0,140,99
6,Quebec,L01BC,Pyrimidine analogues,Total,M,"3,065.06",0.2,0.7,"9,188",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"138,702.08",6.6,0.5,"7,529",1
6,Quebec,S01LA,Antineovascularization agents,Total,F,"128,284.99",6.1,0.7,"12,252",2
6,Quebec,L01XE,Protein kinase inhibitors,Total,F,"103,319.11",4.9,0.2,"2,755",3
6,Quebec,L04AA,Selective immunosuppressants,Total,F,"74,991.18",3.5,0.5,"8,010",4
6,Quebec,A02BC,Proton pump inhibitors,Total,F,"54,594.38",2.6,29.6,"494,459",5
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,F,"52,954.71",2.5,4.3,"71,069",6
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,F,"52,462.50",2.5,26.7,"444,580",7
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"44,677.01",2.1,5,"83,368",8
6,Quebec,L04AX,Other immunosuppressants,Total,F,"38,415.83",1.8,0.2,"4,137",9
6,Quebec,N03AX,Other antiepileptics,Total,F,"35,782.06",1.7,9.2,"152,867",10
6,Quebec,N06AX,Other antidepressants,Total,F,"33,413.04",1.6,13.2,"219,914",11
6,Quebec,A11CC,Vitamin D and analogues,Total,F,"33,399.04",1.6,28.5,"475,752",12
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"33,268.19",1.6,3.2,"54,049",13
6,Quebec,C08CA,Dihydropyridine derivatives,Total,F,"30,493.56",1.4,14.5,"242,180",14
6,Quebec,N05AX,Other antipsychotics,Total,F,"29,506.91",1.4,2.5,"41,689",15
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"28,504.15",1.3,5.9,"97,888",16
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"27,053.80",1.3,2.3,"38,756",17
6,Quebec,H03AA,Thyroid hormones,Total,F,"27,010.87",1.3,18.5,"308,985",18
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,F,"26,890.41",1.3,12.7,"211,445",19
6,Quebec,R03BB,Anticholinergics,Total,F,"26,007.40",1.2,4.5,"74,818",20
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"25,212.78",1.2,16,"267,597",21
6,Quebec,L04AC,Interleukin inhibitors,Total,F,"24,710.48",1.2,0.1,"1,660",22
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"22,785.67",1.1,1.9,"32,230",23
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"22,563.34",1.1,11.1,"185,470",24
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,F,"22,177.61",1,12.1,"201,654",25
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,F,"21,588.01",1,2.7,"44,490",26
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,F,"21,380.78",1,0,445,27
6,Quebec,R03BA,Glucocorticoids,Total,F,"20,291.85",1,8.7,"144,321",28
6,Quebec,N02BA,Salicylic acid and derivatives,Total,F,"19,579.32",0.9,13.1,"217,860",29
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"19,188.82",0.9,1.7,"28,565",30
6,Quebec,N02AA,Natural opium alkaloids,Total,F,"18,055.81",0.9,9.8,"163,027",31
6,Quebec,C09AA,"ACE inhibitors, plain",Total,F,"17,940.92",0.8,9.2,"153,643",32
6,Quebec,B03XA,Other antianemic preparations,Total,F,"17,114.11",0.8,0.2,"4,144",33
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"17,035.99",0.8,0.1,"1,236",34
6,Quebec,N05BA,Benzodiazepine derivatives,Total,F,"16,861.47",0.8,14,"233,607",35
6,Quebec,M05BA,Bisphosphonates,Total,F,"16,243.33",0.8,7.4,"123,214",36
6,Quebec,L03AA,Colony-stimulating factors,Total,F,"16,004.44",0.8,0.2,"3,379",37
6,Quebec,A12AA,Calcium,Total,F,"15,515.31",0.7,12.1,"202,531",38
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"14,841.32",0.7,1.2,"20,408",39
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,F,"13,699.42",0.6,2.9,"48,894",40
6,Quebec,N02BE,Anilides,Total,F,"13,425.46",0.6,15.2,"253,834",41
6,Quebec,A10BA,Biguanides,Total,F,"12,810.27",0.6,8,"133,339",42
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"12,638.96",0.6,13.1,"217,795",43
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"12,577.69",0.6,0.5,"8,287",44
6,Quebec,B01AB,Heparin group,Total,F,"12,402.23",0.6,1,"15,850",45
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"11,543.59",0.5,8.1,"135,098",46
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"11,525.19",0.5,0.1,"1,727",47
6,Quebec,H01CB,Somatostatin and analogues,Total,F,"11,072.47",0.5,0.1,949,48
6,Quebec,N06DA,Anticholinesterases,Total,F,"10,231.25",0.5,1.6,"25,864",49
6,Quebec,C03CA,"Sulfonamides, plain",Total,F,"9,904.41",0.5,4.6,"75,968",50
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"9,629.35",0.5,2.4,"40,390",51
6,Quebec,S01XA,Other ophthalmologicals,Total,F,"9,300.50",0.4,1.6,"26,225",52
6,Quebec,C08DB,Benzothiazepine derivatives,Total,F,"9,245.05",0.4,2.3,"37,552",53
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"9,060.96",0.4,5.3,"87,578",54
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"9,027.75",0.4,1.3,"21,397",55
6,Quebec,S01EE,Prostaglandin analogues,Total,F,"8,874.49",0.4,2.5,"42,268",56
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"8,810.39",0.4,0.2,"4,078",57
6,Quebec,S01ED,Beta-blocking agents,Total,F,"8,574.83",0.4,2.6,"43,557",58
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"7,976.77",0.4,1,"15,890",59
6,Quebec,R01AD,Corticosteroids,Total,F,"7,878.49",0.4,11.3,"188,926",60
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"7,825.02",0.4,6.4,"107,112",61
6,Quebec,A06AA,"Softeners, emollients",Total,F,"7,754.80",0.4,5.1,"85,179",62
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,"7,442.88",0.4,4.4,"73,520",63
6,Quebec,L01XC,Monoclonal antibodies,Total,F,"7,290.96",0.3,0,646,64
6,Quebec,A16AB,Enzymes,Total,F,"7,278.65",0.3,0,8,65
6,Quebec,L03AB,Interferons,Total,F,"7,241.73",0.3,0,536,66
6,Quebec,L01XX,Other antineoplastic agents,Total,F,"7,225.69",0.3,0.2,"2,669",67
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"7,011.12",0.3,4.3,"71,570",68
6,Quebec,A10BB,Sulfonylureas,Total,F,"6,869.86",0.3,3.4,"56,334",69
6,Quebec,C10AX,Other lipid-modifying agents,Total,F,"6,748.94",0.3,2.1,"34,947",70
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,F,"6,624.60",0.3,0.6,"10,670",71
6,Quebec,L04AD,Calcineurin inhibitors,Total,F,"6,561.66",0.3,0.1,"2,172",72
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"6,486.27",0.3,0,248,73
6,Quebec,V06C,Infant formulas,Total,F,"6,169.11",0.3,0.3,"5,179",74
6,Quebec,N03AE,Benzodiazepine derivatives,Total,F,"6,140.63",0.3,4.2,"70,475",75
6,Quebec,L02BG,Aromatase inhibitors,Total,F,"5,829.69",0.3,1.3,"21,277",76
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,F,"5,820.91",0.3,5.5,"90,919",77
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,Total,F,"5,737.27",0.3,2,"32,799",78
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,F,"5,683.12",0.3,2.3,"39,170",79
6,Quebec,L03AX,Other immunostimulants,Total,F,"5,305.11",0.3,0,482,80
6,Quebec,C03AA,"Thiazides, plain",Total,F,"5,089.65",0.2,5,"83,658",81
6,Quebec,C01DA,Organic nitrates,Total,F,"5,057.37",0.2,2.8,"46,339",82
6,Quebec,N04BA,Dopa and dopa derivatives,Total,F,"4,940.05",0.2,0.4,"6,953",83
6,Quebec,A06AB,Contact laxatives,Total,F,"4,593.64",0.2,2.9,"47,853",84
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,F,"4,557.42",0.2,1.9,"31,851",85
6,Quebec,N02AB,Phenylpiperidine derivatives,Total,F,"4,520.18",0.2,0.5,"8,902",86
6,Quebec,A06AD,Osmotically acting laxatives,Total,F,"4,479.39",0.2,5.1,"85,303",87
6,Quebec,L01BA,Folic acid analogues,Total,F,"4,428.78",0.2,1.1,"19,135",88
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,"4,412.31",0.2,0.3,"4,418",89
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"4,322.54",0.2,5,"83,350",90
6,Quebec,H02AB,Glucocorticoids,Total,F,"4,311.97",0.2,8.3,"139,008",91
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"4,222.77",0.2,0.1,"2,110",92
6,Quebec,G02BA,Intrauterine contraceptives,Total,F,**,**,**,**,93
6,Quebec,R07AX,Other respiratory system products,Total,F,"4,054.36",0.2,0,23,94
6,Quebec,N03AG,Fatty acid derivatives,Total,F,"3,959.90",0.2,0.7,"11,962",95
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"3,912.72",0.2,0.9,"15,458",96
6,Quebec,A12BA,Potassium,Total,F,"3,862.14",0.2,2,"32,998",97
6,Quebec,B01AE,Direct thrombin inhibitors,Total,F,"3,858.52",0.2,0.3,"4,767",98
6,Quebec,H05AA,Parathyroid hormones and analogues,Total,F,"3,850.31",0.2,0,634,99
6,Quebec,N07BC,Drugs used in opioid dependence,Total,F,"3,820.01",0.2,0.2,"3,140",100
6,Quebec,S01LA,Antineovascularization agents,65+,Total,"205,432.90",7.9,1.4,"19,814",1
6,Quebec,L01XE,Protein kinase inhibitors,65+,Total,"148,221.84",5.7,0.3,"3,877",2
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"113,059.16",4.4,0.4,"5,946",3
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,Total,"98,897.23",3.8,9.2,"131,055",4
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,Total,"85,966.87",3.3,52.7,"754,762",5
6,Quebec,L04AX,Other immunosuppressants,65+,Total,"69,359.62",2.7,0.3,"4,178",6
6,Quebec,A02BC,Proton pump inhibitors,65+,Total,"68,046.48",2.6,40.4,"578,483",7
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"54,696.70",2.1,6.5,"92,407",8
6,Quebec,C08CA,Dihydropyridine derivatives,65+,Total,"46,367.29",1.8,26,"372,216",9
6,Quebec,L04AA,Selective immunosuppressants,65+,Total,"45,996.27",1.8,0.5,"6,794",10
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"44,610.31",1.7,4.5,"64,233",11
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"40,157.55",1.5,3.9,"56,367",12
6,Quebec,R03BB,Anticholinergics,65+,Total,"38,468.40",1.5,7.7,"110,067",13
6,Quebec,A11CC,Vitamin D and analogues,65+,Total,"38,099.70",1.5,33.7,"481,649",14
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,Total,"36,823.20",1.4,24,"343,695",15
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"35,510.08",1.4,3.6,"52,118",16
6,Quebec,N02BA,Salicylic acid and derivatives,65+,Total,"33,987.14",1.3,27.8,"398,139",17
6,Quebec,N03AX,Other antiepileptics,65+,Total,"33,358.97",1.3,11.2,"159,672",18
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"31,779.47",1.2,3.3,"47,519",19
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"31,627.43",1.2,18.6,"265,721",20
6,Quebec,B03XA,Other antianemic preparations,65+,Total,"31,084.25",1.2,0.5,"7,369",21
6,Quebec,C09AA,"ACE inhibitors, plain",65+,Total,"30,340.56",1.2,18.6,"266,923",22
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,**,**,**,**,23
6,Quebec,H03AA,Thyroid hormones,65+,Total,"28,418.81",1.1,21.1,"302,695",24
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"26,268.67",1,18.7,"268,000",25
6,Quebec,N06AX,Other antidepressants,65+,Total,"26,162.93",1,11.9,"170,218",26
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"23,804.11",0.9,2.2,"31,252",27
6,Quebec,L02BB,Antiandrogens,65+,Total,"21,910.33",0.8,0.4,"5,557",28
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"21,628.88",0.8,10.9,"155,363",29
6,Quebec,A10BA,Biguanides,65+,Total,"19,742.41",0.8,14.9,"212,777",30
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,Total,"19,537.13",0.8,0.1,"1,493",31
6,Quebec,L04AC,Interleukin inhibitors,65+,Total,"19,331.07",0.7,0.1,"1,342",32
6,Quebec,R03BA,Glucocorticoids,65+,Total,"19,072.42",0.7,8.3,"118,181",33
6,Quebec,L03AA,Colony-stimulating factors,65+,Total,"18,993.61",0.7,0.3,"3,927",34
6,Quebec,M05BA,Bisphosphonates,65+,Total,"18,596.63",0.7,9.6,"137,026",35
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"17,879.60",0.7,11,"157,387",36
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"17,861.38",0.7,0.8,"11,349",37
6,Quebec,N05BA,Benzodiazepine derivatives,65+,Total,"17,771.96",0.7,17.4,"248,847",38
6,Quebec,A12AA,Calcium,65+,Total,"16,957.06",0.7,14.5,"207,135",39
6,Quebec,B01AB,Heparin group,65+,Total,"16,708.81",0.6,1.4,"20,107",40
6,Quebec,N02AA,Natural opium alkaloids,65+,Total,"16,503.89",0.6,11.9,"170,309",41
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"16,284.36",0.6,4.2,"60,003",42
6,Quebec,H01CB,Somatostatin and analogues,65+,Total,"16,249.40",0.6,0.1,"1,298",43
6,Quebec,C03CA,"Sulfonamides, plain",65+,Total,"16,068.15",0.6,8.7,"124,534",44
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"15,943.85",0.6,5.7,"82,015",45
6,Quebec,N06DA,Anticholinesterases,65+,Total,"15,903.20",0.6,2.8,"40,542",46
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"15,819.06",0.6,5,"71,794",47
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"15,512.49",0.6,0.1,"1,190",48
6,Quebec,N02BE,Anilides,65+,Total,"15,211.46",0.6,19.2,"274,812",49
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"14,709.47",0.6,14.1,"202,092",50
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"14,103.06",0.5,0.5,"6,903",51
6,Quebec,S01ED,Beta-blocking agents,65+,Total,"13,978.35",0.5,5,"71,890",52
6,Quebec,S01EE,Prostaglandin analogues,65+,Total,"13,933.29",0.5,4.7,"67,760",53
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"13,884.47",0.5,2.1,"29,979",54
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"13,374.39",0.5,1.8,"26,287",55
6,Quebec,C08DB,Benzothiazepine derivatives,65+,Total,"13,133.73",0.5,3.8,"53,942",56
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"12,901.58",0.5,8.9,"127,813",57
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,Total,"12,694.88",0.5,0,253,58
6,Quebec,N05AX,Other antipsychotics,65+,Total,"12,195.50",0.5,2.1,"30,017",59
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"12,114.48",0.5,0.1,"1,456",60
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"11,387.31",0.4,5.8,"83,569",61
6,Quebec,C10AX,Other lipid-modifying agents,65+,Total,"11,374.89",0.4,4.4,"63,398",62
6,Quebec,A10BB,Sulfonylureas,65+,Total,"11,372.25",0.4,6.7,"95,903",63
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"11,180.42",0.4,7.7,"109,752",64
6,Quebec,N04BA,Dopa and dopa derivatives,65+,Total,"10,556.31",0.4,1,"14,435",65
6,Quebec,S01XA,Other ophthalmologicals,65+,Total,"9,676.47",0.4,2.1,"29,519",66
6,Quebec,C01DA,Organic nitrates,65+,Total,"9,221.12",0.4,6.4,"92,040",67
6,Quebec,A06AA,"Softeners, emollients",65+,Total,"8,955.80",0.3,7.1,"101,161",68
6,Quebec,L01XX,Other antineoplastic agents,65+,Total,"8,868.02",0.3,0.3,"3,737",69
6,Quebec,B01AE,Direct thrombin inhibitors,65+,Total,"8,627.95",0.3,0.8,"11,060",70
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,Total,"8,011.92",0.3,0.8,"11,535",71
6,Quebec,R01AD,Corticosteroids,65+,Total,"7,840.71",0.3,11.4,"163,356",72
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,Total,"7,698.09",0.3,6.7,"96,012",73
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"7,570.31",0.3,0.6,"8,572",74
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,Total,"7,343.32",0.3,3.6,"51,595",75
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"7,104.65",0.3,5.8,"83,226",76
6,Quebec,L01XC,Monoclonal antibodies,65+,Total,"6,823.68",0.3,0,657,77
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,Total,"6,771.57",0.3,4.2,"60,218",78
6,Quebec,L04AD,Calcineurin inhibitors,65+,Total,"6,761.86",0.3,0.2,"2,505",79
6,Quebec,C03AA,"Thiazides, plain",65+,Total,"6,661.78",0.3,7.7,"110,827",80
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"6,172.68",0.2,0.2,"3,020",81
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"6,076.00",0.2,1.6,"23,205",82
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"5,640.06",0.2,3.8,"53,995",83
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"5,488.21",0.2,0,210,84
6,Quebec,A06AB,Contact laxatives,65+,Total,"5,330.65",0.2,4.1,"59,224",85
6,Quebec,A12BA,Potassium,65+,Total,"5,301.11",0.2,3.2,"45,712",86
6,Quebec,A06AD,Osmotically acting laxatives,65+,Total,"5,286.28",0.2,7.1,"101,040",87
6,Quebec,H02AB,Glucocorticoids,65+,Total,"5,180.30",0.2,10.5,"149,867",88
6,Quebec,B01AA,Vitamin K antagonists,65+,Total,"5,030.70",0.2,2.4,"33,684",89
6,Quebec,L01BA,Folic acid analogues,65+,Total,"4,889.73",0.2,1.5,"20,897",90
6,Quebec,C03DA,Aldosterone antagonists,65+,Total,"4,675.37",0.2,2.6,"36,604",91
6,Quebec,L02BG,Aromatase inhibitors,65+,Total,"4,670.86",0.2,1.1,"15,236",92
6,Quebec,N03AE,Benzodiazepine derivatives,65+,Total,"4,547.33",0.2,4,"57,124",93
6,Quebec,J05AX,Other antivirals,65+,Total,"4,456.56",0.2,0,591,94
6,Quebec,B02BX,Other systemic hemostatics,65+,Total,"4,291.72",0.2,0,122,95
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,Total,"4,210.50",0.2,9.2,"131,867",96
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,Total,"4,165.09",0.2,0.7,"9,409",97
6,Quebec,H05AA,Parathyroid hormones and analogues,65+,Total,"3,955.51",0.2,0,639,98
6,Quebec,C07AA,"Beta-blocking agents, non-selective",65+,Total,"3,914.62",0.2,2,"28,486",99
6,Quebec,S01EC,Carbonic anhydrase inhibitors,65+,Total,"3,864.99",0.1,1.6,"22,347",100
6,Quebec,S01LA,Antineovascularization agents,65+,M,"83,376.18",6.8,1.3,"8,196",1
6,Quebec,L01XE,Protein kinase inhibitors,65+,M,"68,023.71",5.6,0.3,"1,792",2
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"51,733.68",4.2,0.4,"2,498",3
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,M,"49,702.42",4.1,10.5,"66,857",4
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,M,"43,278.07",3.6,62.8,"401,104",5
6,Quebec,L04AX,Other immunosuppressants,65+,M,"40,290.44",3.3,0.3,"2,014",6
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"29,049.41",2.4,1.5,"9,529",7
6,Quebec,A02BC,Proton pump inhibitors,65+,M,"27,454.30",2.3,38.4,"244,875",8
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"23,988.81",2,5.3,"34,132",9
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"23,818.51",2,6.1,"38,795",10
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"22,655.76",1.9,5.2,"33,514",11
6,Quebec,L02BB,Antiandrogens,65+,M,**,**,**,**,12
6,Quebec,C08CA,Dihydropyridine derivatives,65+,M,"19,933.00",1.6,26.6,"169,730",13
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"19,582.81",1.6,4.6,"29,617",14
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,15
6,Quebec,L04AA,Selective immunosuppressants,65+,M,"18,915.47",1.6,0.5,"2,959",16
6,Quebec,R03BB,Anticholinergics,65+,M,"18,506.00",1.5,8.3,"53,236",17
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,M,"17,322.96",1.4,26.8,"170,930",18
6,Quebec,N02BA,Salicylic acid and derivatives,65+,M,"17,318.99",1.4,33.9,"216,312",19
6,Quebec,B03XA,Other antianemic preparations,65+,M,"17,145.97",1.4,0.6,"3,943",20
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"17,091.56",1.4,23.7,"151,512",21
6,Quebec,C09AA,"ACE inhibitors, plain",65+,M,"15,864.90",1.3,23.1,"147,351",22
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"13,852.48",1.1,2.7,"17,416",23
6,Quebec,N03AX,Other antiepileptics,65+,M,"12,912.65",1.1,9.7,"61,615",24
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"12,452.81",1,17.9,"113,969",25
6,Quebec,A11CC,Vitamin D and analogues,65+,M,"12,210.85",1,22.7,"145,221",26
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"11,362.65",0.9,13,"83,279",27
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"10,682.22",0.9,0.8,"5,210",28
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"10,623.49",0.9,0.2,"1,287",29
6,Quebec,A10BA,Biguanides,65+,M,"10,270.77",0.8,18.3,"117,141",30
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"10,193.93",0.8,1,"6,458",31
6,Quebec,L03AA,Colony-stimulating factors,65+,M,"8,984.00",0.7,0.3,"1,792",32
6,Quebec,B01AB,Heparin group,65+,M,"8,638.96",0.7,1.5,"9,303",33
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,M,"8,627.62",0.7,0,171,34
6,Quebec,L04AC,Interleukin inhibitors,65+,M,"8,309.06",0.7,0.1,536,35
6,Quebec,N06AX,Other antidepressants,65+,M,"8,271.86",0.7,8.9,"56,896",36
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"8,257.51",0.7,2.6,"16,645",37
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"8,199.04",0.7,7.3,"46,858",38
6,Quebec,H01CB,Somatostatin and analogues,65+,M,"7,974.25",0.7,0.1,583,39
6,Quebec,H03AA,Thyroid hormones,65+,M,"7,594.17",0.6,12.8,"81,778",40
6,Quebec,R03BA,Glucocorticoids,65+,M,"7,583.17",0.6,7,"44,800",41
6,Quebec,C03CA,"Sulfonamides, plain",65+,M,"7,129.11",0.6,8.8,"56,151",42
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"7,057.15",0.6,0.1,545,43
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"6,902.07",0.6,2.1,"13,465",44
6,Quebec,N02AA,Natural opium alkaloids,65+,M,"6,892.65",0.6,11.8,"75,445",45
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"6,613.30",0.5,13,"83,286",46
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"6,432.41",0.5,4.5,"28,555",47
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,M,"6,367.91",0.5,7.3,"46,852",48
6,Quebec,A10BB,Sulfonylureas,65+,M,"6,216.94",0.5,8.7,"55,321",49
6,Quebec,S01ED,Beta-blocking agents,65+,M,"6,159.29",0.5,5.2,"32,945",50
6,Quebec,C10AX,Other lipid-modifying agents,65+,M,"6,139.24",0.5,5.6,"35,491",51
6,Quebec,N04BA,Dopa and dopa derivatives,65+,M,"6,136.96",0.5,1.3,"8,118",52
6,Quebec,S01EE,Prostaglandin analogues,65+,M,"5,808.64",0.5,4.6,"29,608",53
6,Quebec,N06DA,Anticholinesterases,65+,M,"5,786.32",0.5,2.3,"14,961",54
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,M,"5,672.10",0.5,3.5,"22,442",55
6,Quebec,N05BA,Benzodiazepine derivatives,65+,M,"5,668.02",0.5,12.8,"81,689",56
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"5,266.49",0.4,0.4,"2,667",57
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"5,189.00",0.4,8.6,"55,042",58
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,M,"5,141.09",0.4,7.9,"50,317",59
6,Quebec,C08DB,Benzothiazepine derivatives,65+,M,"5,021.96",0.4,3.4,"21,404",60
6,Quebec,B01AE,Direct thrombin inhibitors,65+,M,"4,912.39",0.4,1,"6,491",61
6,Quebec,N02BE,Anilides,65+,M,"4,868.38",0.4,16.2,"103,737",62
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,"4,825.41",0.4,7.6,"48,724",63
6,Quebec,N05AX,Other antipsychotics,65+,M,"4,802.05",0.4,1.7,"10,584",64
6,Quebec,C01DA,Organic nitrates,65+,M,"4,545.30",0.4,8,"51,192",65
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"4,538.81",0.4,0.8,"5,042",66
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,M,"4,489.55",0.4,6.7,"42,503",67
6,Quebec,M05BA,Bisphosphonates,65+,M,"4,237.74",0.3,4.4,"27,920",68
6,Quebec,L04AD,Calcineurin inhibitors,65+,M,"4,197.16",0.3,0.2,"1,550",69
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,M,"4,029.89",0.3,0.9,"5,504",70
6,Quebec,A12AA,Calcium,65+,M,"3,974.02",0.3,7,"44,780",71
6,Quebec,L01XX,Other antineoplastic agents,65+,M,"3,939.17",0.3,0.2,"1,540",72
6,Quebec,J05AX,Other antivirals,65+,M,"3,842.21",0.3,0.1,509,73
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,M,"3,799.33",0.3,4.3,"27,377",74
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,65+,M,"3,533.82",0.3,1.2,"7,594",75
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"3,377.92",0.3,2,"12,894",76
6,Quebec,R01AD,Corticosteroids,65+,M,"3,348.68",0.3,10.3,"66,038",77
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,M,"3,204.83",0.3,6.6,"41,931",78
6,Quebec,A06AA,"Softeners, emollients",65+,M,"3,204.60",0.3,5.8,"37,343",79
6,Quebec,C03DA,Aldosterone antagonists,65+,M,"2,652.46",0.2,3,"18,997",80
6,Quebec,L01XC,Monoclonal antibodies,65+,M,"2,405.95",0.2,0,243,81
6,Quebec,C03AA,"Thiazides, plain",65+,M,"2,394.92",0.2,6.6,"42,251",82
6,Quebec,L01BC,Pyrimidine analogues,65+,M,"2,376.05",0.2,1.3,"8,197",83
6,Quebec,B01AA,Vitamin K antagonists,65+,M,"2,350.90",0.2,2.8,"17,597",84
6,Quebec,B02BX,Other systemic hemostatics,65+,M,"2,234.09",0.2,0,62,85
6,Quebec,J01DH,Carbapenems,65+,M,"2,216.44",0.2,0.2,"1,252",86
6,Quebec,H02AB,Glucocorticoids,65+,M,"2,192.45",0.2,10,"63,984",87
6,Quebec,A06AD,Osmotically acting laxatives,65+,M,"2,118.69",0.2,6.3,"39,930",88
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,M,"2,080.76",0.2,9.3,"59,674",89
6,Quebec,A06AB,Contact laxatives,65+,M,"1,972.35",0.2,3.6,"22,771",90
6,Quebec,J05AE,Protease inhibitors,65+,M,"1,951.45",0.2,0,267,91
6,Quebec,V03AC,Iron-chelating agents,65+,M,"1,937.08",0.2,0,90,92
6,Quebec,A12BA,Potassium,65+,M,"1,913.97",0.2,2.7,"17,320",93
6,Quebec,S01XA,Other ophthalmologicals,65+,M,"1,842.67",0.2,1.3,"8,207",94
6,Quebec,S01EC,Carbonic anhydrase inhibitors,65+,M,"1,747.79",0.1,1.6,"10,305",95
6,Quebec,L01BA,Folic acid analogues,65+,M,"1,733.89",0.1,1.2,"7,589",96
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"1,687.32",0.1,0.1,790,97
6,Quebec,B03AC,"Iron, parenteral preparations",65+,M,"1,611.82",0.1,0.5,"3,377",98
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"1,610.79",0.1,2.4,"15,531",99
6,Quebec,N07BA,Drugs used in nicotine dependence,65+,M,"1,606.01",0.1,1.8,"11,453",100
6,Quebec,S01LA,Antineovascularization agents,65+,F,"122,056.72",8.9,1.5,"11,618",1
6,Quebec,L01XE,Protein kinase inhibitors,65+,F,"80,198.13",5.8,0.3,"2,085",2
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"61,325.48",4.5,0.4,"3,448",3
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,F,"49,194.81",3.6,8.1,"64,198",4
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,F,"42,688.80",3.1,44.6,"353,658",5
6,Quebec,A02BC,Proton pump inhibitors,65+,F,"40,592.18",2.9,42.1,"333,608",6
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"30,878.20",2.2,6.8,"53,612",7
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"30,243.59",2.2,6.2,"49,451",8
6,Quebec,L04AX,Other immunosuppressants,65+,F,"29,069.18",2.1,0.3,"2,164",9
6,Quebec,L04AA,Selective immunosuppressants,65+,F,"27,080.80",2,0.5,"3,835",10
6,Quebec,C08CA,Dihydropyridine derivatives,65+,F,"26,434.29",1.9,25.5,"202,486",11
6,Quebec,A11CC,Vitamin D and analogues,65+,F,"25,888.86",1.9,42.4,"336,428",12
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"21,954.54",1.6,3.9,"30,719",13
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"21,127.58",1.5,27.5,"217,683",14
6,Quebec,H03AA,Thyroid hormones,65+,F,"20,824.65",1.5,27.9,"220,917",15
6,Quebec,N03AX,Other antiepileptics,65+,F,"20,446.32",1.5,12.4,"98,057",16
6,Quebec,R03BB,Anticholinergics,65+,F,"19,962.40",1.4,7.2,"56,831",17
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,F,"19,500.25",1.4,21.8,"172,765",18
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"19,174.63",1.4,19.1,"151,752",19
6,Quebec,N06AX,Other antidepressants,65+,F,"17,891.07",1.3,14.3,"113,322",20
6,Quebec,N02BA,Salicylic acid and derivatives,65+,F,"16,668.15",1.2,22.9,"181,827",21
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"16,168.74",1.2,2.8,"22,235",22
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,F,"15,260.97",1.1,13.7,"108,511",23
6,Quebec,C09AA,"ACE inhibitors, plain",65+,F,"14,475.66",1.1,15.1,"119,572",24
6,Quebec,M05BA,Bisphosphonates,65+,F,"14,358.89",1,13.8,"109,106",25
6,Quebec,B03XA,Other antianemic preparations,65+,F,"13,938.27",1,0.4,"3,426",26
6,Quebec,A12AA,Calcium,65+,F,"12,983.05",0.9,20.5,"162,355",27
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"12,196.66",0.9,2.3,"17,902",28
6,Quebec,N05BA,Benzodiazepine derivatives,65+,F,"12,103.94",0.9,21.1,"167,158",29
6,Quebec,R03BA,Glucocorticoids,65+,F,"11,489.25",0.8,9.3,"73,381",30
6,Quebec,L04AC,Interleukin inhibitors,65+,F,"11,022.01",0.8,0.1,806,31
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,F,"10,612.27",0.8,4.7,"37,561",32
6,Quebec,N02BE,Anilides,65+,F,"10,343.08",0.8,21.6,"171,075",33
6,Quebec,N06DA,Anticholinesterases,65+,F,"10,116.88",0.7,3.2,"25,581",34
6,Quebec,L03AA,Colony-stimulating factors,65+,F,"10,009.61",0.7,0.3,"2,135",35
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"9,951.64",0.7,1.7,"13,836",36
6,Quebec,N02AA,Natural opium alkaloids,65+,F,"9,611.24",0.7,12,"94,864",37
6,Quebec,A10BA,Biguanides,65+,F,"9,471.63",0.7,12.1,"95,636",38
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"9,386.65",0.7,5.5,"43,239",39
6,Quebec,C03CA,"Sulfonamides, plain",65+,F,"8,939.04",0.6,8.6,"68,383",40
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"8,455.34",0.6,0.1,645,41
6,Quebec,H01CB,Somatostatin and analogues,65+,F,"8,275.15",0.6,0.1,715,42
6,Quebec,S01EE,Prostaglandin analogues,65+,F,"8,124.65",0.6,4.8,"38,152",43
6,Quebec,C08DB,Benzothiazepine derivatives,65+,F,"8,111.78",0.6,4.1,"32,538",44
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"8,096.18",0.6,15,"118,806",45
6,Quebec,B01AB,Heparin group,65+,F,"8,069.85",0.6,1.4,"10,804",46
6,Quebec,S01XA,Other ophthalmologicals,65+,F,"7,833.80",0.6,2.7,"21,312",47
6,Quebec,S01ED,Beta-blocking agents,65+,F,"7,819.06",0.6,4.9,"38,945",48
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"7,744.81",0.6,4.4,"35,157",49
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"7,712.59",0.6,9.2,"72,771",50
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"7,667.45",0.6,0.6,"4,891",51
6,Quebec,N05AX,Other antipsychotics,65+,F,"7,393.45",0.5,2.5,"19,433",52
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"7,096.01",0.5,10.5,"83,171",53
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"6,472.32",0.5,1.6,"12,822",54
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"6,355.01",0.5,7.7,"61,028",55
6,Quebec,A06AA,"Softeners, emollients",65+,F,"5,751.20",0.4,8.1,"63,818",56
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"5,626.96",0.4,1.7,"13,334",57
6,Quebec,C10AX,Other lipid-modifying agents,65+,F,"5,235.65",0.4,3.5,"27,907",58
6,Quebec,A10BB,Sulfonylureas,65+,F,"5,155.31",0.4,5.1,"40,582",59
6,Quebec,L01XX,Other antineoplastic agents,65+,F,"4,928.85",0.4,0.3,"2,197",60
6,Quebec,C01DA,Organic nitrates,65+,F,"4,675.82",0.3,5.2,"40,848",61
6,Quebec,L02BG,Aromatase inhibitors,65+,F,"4,654.43",0.3,1.9,"15,163",62
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,F,"4,493.26",0.3,6.8,"54,081",63
6,Quebec,R01AD,Corticosteroids,65+,F,"4,492.02",0.3,12.3,"97,318",64
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"4,485.36",0.3,0.3,"2,230",65
6,Quebec,N04BA,Dopa and dopa derivatives,65+,F,"4,419.36",0.3,0.8,"6,317",66
6,Quebec,L01XC,Monoclonal antibodies,65+,F,"4,417.73",0.3,0.1,414,67
6,Quebec,C03AA,"Thiazides, plain",65+,F,"4,266.87",0.3,8.7,"68,576",68
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,F,"4,067.26",0.3,0,82,69
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"4,029.26",0.3,4.9,"38,464",70
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"3,985.89",0.3,0,141,71
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,F,"3,982.03",0.3,0.8,"6,031",72
6,Quebec,B01AE,Direct thrombin inhibitors,65+,F,"3,715.55",0.3,0.6,"4,569",73
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,F,"3,543.99",0.3,3.1,"24,218",74
6,Quebec,H05AA,Parathyroid hormones and analogues,65+,F,"3,520.71",0.3,0.1,570,75
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"3,420.84",0.2,0.2,"1,693",76
6,Quebec,A12BA,Potassium,65+,F,"3,387.14",0.2,3.6,"28,392",77
6,Quebec,A06AB,Contact laxatives,65+,F,"3,358.30",0.2,4.6,"36,453",78
6,Quebec,A06AD,Osmotically acting laxatives,65+,F,"3,167.59",0.2,7.7,"61,110",79
6,Quebec,L01BA,Folic acid analogues,65+,F,"3,155.84",0.2,1.7,"13,308",80
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,"3,031.51",0.2,0.4,"3,530",81
6,Quebec,N03AE,Benzodiazepine derivatives,65+,F,"3,002.19",0.2,4.7,"37,519",82
6,Quebec,H02AB,Glucocorticoids,65+,F,"2,987.85",0.2,10.8,"85,883",83
6,Quebec,L02BA,Anti-estrogens,65+,F,"2,939.22",0.2,0.6,"4,564",84
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,F,"2,806.28",0.2,0.8,"6,145",85
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"2,698.09",0.2,1.3,"10,311",86
6,Quebec,B01AA,Vitamin K antagonists,65+,F,"2,679.80",0.2,2,"16,087",87
6,Quebec,L04AD,Calcineurin inhibitors,65+,F,"2,564.71",0.2,0.1,955,88
6,Quebec,C07AA,"Beta-blocking agents, non-selective",65+,F,"2,327.04",0.2,2.1,"16,945",89
6,Quebec,A03FA,Propulsives,65+,F,"2,316.53",0.2,3.6,"28,210",90
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,F,"2,282.02",0.2,2.2,"17,715",91
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,F,"2,129.75",0.2,9.1,"72,193",92
6,Quebec,S01EC,Carbonic anhydrase inhibitors,65+,F,"2,117.20",0.2,1.5,"12,042",93
6,Quebec,L03AB,Interferons,65+,F,"2,082.89",0.2,0,160,94
6,Quebec,B02BX,Other systemic hemostatics,65+,F,"2,057.63",0.1,0,60,95
6,Quebec,M01AH,Coxibs,65+,F,"2,030.28",0.1,7.8,"61,559",96
6,Quebec,C03DA,Aldosterone antagonists,65+,F,"2,022.91",0.1,2.2,"17,607",97
6,Quebec,A07AA,Antibiotics,65+,F,"1,994.97",0.1,1.6,"12,548",98
6,Quebec,N04BC,Dopamine agonists,65+,F,"1,947.06",0.1,1.3,"10,606",99
6,Quebec,R03DC,Leukotriene receptor antagonists,65+,F,"1,908.91",0.1,1.3,"10,636",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"162,096.48",10.9,0.5,"7,959",1
6,Quebec,L04AA,Selective immunosuppressants,<65,Total,"72,015.01",4.8,0.5,"6,912",2
6,Quebec,N05AX,Other antipsychotics,<65,Total,"71,049.20",4.8,3.3,"50,312",3
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"55,046.38",3.7,7.2,"110,104",4
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,Total,"52,415.44",3.5,6.3,"95,437",5
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,Total,"52,072.81",3.5,0.1,"1,082",6
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"48,824.41",3.3,0.5,"7,794",7
6,Quebec,L01XE,Protein kinase inhibitors,<65,Total,"39,775.86",2.7,0.1,"1,132",8
6,Quebec,N03AX,Other antiepileptics,<65,Total,"27,832.54",1.9,6.2,"94,823",9
6,Quebec,L04AC,Interleukin inhibitors,<65,Total,"25,912.96",1.7,0.1,"1,559",10
6,Quebec,A02BC,Proton pump inhibitors,<65,Total,"24,903.51",1.7,18.4,"279,137",11
6,Quebec,N06AX,Other antidepressants,<65,Total,"24,871.44",1.7,11.1,"169,176",12
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"23,471.12",1.6,3.3,"49,648",13
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,Total,"21,772.11",1.5,13.9,"211,335",14
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"19,337.80",1.3,10.5,"159,164",15
6,Quebec,L04AX,Other immunosuppressants,<65,Total,"19,140.11",1.3,0.2,"3,340",16
6,Quebec,N02AA,Natural opium alkaloids,<65,Total,"17,844.31",1.2,8.1,"123,803",17
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"16,221.06",1.1,1.7,"25,293",18
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"15,794.15",1.1,1.6,"24,519",19
6,Quebec,A16AB,Enzymes,<65,Total,**,**,**,**,20
6,Quebec,R03BA,Glucocorticoids,<65,Total,"15,231.78",1,7.9,"120,617",21
6,Quebec,S01LA,Antineovascularization agents,<65,Total,"14,057.22",0.9,0.1,"1,423",22
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"13,634.68",0.9,0.1,882,23
6,Quebec,J05AX,Other antivirals,<65,Total,"11,651.20",0.8,0.2,"2,381",24
6,Quebec,A11CC,Vitamin D and analogues,<65,Total,"11,483.91",0.8,12.5,"189,820",25
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"11,087.49",0.7,0.9,"14,334",26
6,Quebec,R03BB,Anticholinergics,<65,Total,"10,919.56",0.7,2.1,"32,175",27
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"10,877.24",0.7,1.2,"17,532",28
6,Quebec,V06C,Infant formulas,<65,Total,"10,180.53",0.7,0.5,"8,010",29
6,Quebec,L04AD,Calcineurin inhibitors,<65,Total,"10,043.74",0.7,0.2,"3,041",30
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"9,754.90",0.7,0.4,"6,770",31
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,Total,"9,560.32",0.6,1.1,"16,374",32
6,Quebec,N07BC,Drugs used in opioid dependence,<65,Total,"9,351.42",0.6,0.4,"5,798",33
6,Quebec,L03AA,Colony-stimulating factors,<65,Total,"9,004.20",0.6,0.1,"1,822",34
6,Quebec,C08CA,Dihydropyridine derivatives,<65,Total,"9,000.81",0.6,5.8,"88,001",35
6,Quebec,N05BA,Benzodiazepine derivatives,<65,Total,"8,853.33",0.6,7.2,"109,126",36
6,Quebec,H03AA,Thyroid hormones,<65,Total,"8,630.33",0.6,7.5,"114,214",37
6,Quebec,C09AA,"ACE inhibitors, plain",<65,Total,"8,552.25",0.6,5.6,"84,576",38
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"8,287.39",0.6,11.4,"172,681",39
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,Total,"8,061.24",0.5,3.6,"54,321",40
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"7,926.41",0.5,1.1,"17,354",41
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"7,823.44",0.5,7,"107,102",42
6,Quebec,R07AX,Other respiratory system products,<65,Total,"7,718.44",0.5,0,42,43
6,Quebec,B01AB,Heparin group,<65,Total,"7,387.81",0.5,0.6,"8,463",44
6,Quebec,N02BA,Salicylic acid and derivatives,<65,Total,"7,106.51",0.5,5.7,"86,963",45
6,Quebec,B03XA,Other antianemic preparations,<65,Total,"6,976.09",0.5,0.1,"1,650",46
6,Quebec,A10BA,Biguanides,<65,Total,"6,932.31",0.5,5.3,"80,520",47
6,Quebec,L03AB,Interferons,<65,Total,"6,915.41",0.5,0,507,48
6,Quebec,C02AC,Imidazoline receptor agonists,<65,Total,"6,698.05",0.4,0.8,"11,866",49
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,Total,"6,547.74",0.4,4.4,"67,010",50
6,Quebec,N03AG,Fatty acid derivatives,<65,Total,"6,524.58",0.4,1.2,"17,538",51
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"6,477.38",0.4,4.3,"66,109",52
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"6,444.49",0.4,0.2,"2,590",53
6,Quebec,J05AE,Protease inhibitors,<65,Total,"6,241.70",0.4,0.1,969,54
6,Quebec,N03AE,Benzodiazepine derivatives,<65,Total,"5,838.36",0.4,3.5,"53,491",55
6,Quebec,H01CB,Somatostatin and analogues,<65,Total,"5,748.83",0.4,0,425,56
6,Quebec,L03AX,Other immunostimulants,<65,Total,"5,649.58",0.4,0,527,57
6,Quebec,R01AD,Corticosteroids,<65,Total,"5,638.67",0.4,9.7,"147,839",58
6,Quebec,N02BE,Anilides,<65,Total,"5,404.65",0.4,9.5,"144,614",59
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"5,211.36",0.3,1.9,"29,228",60
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,Total,"5,067.88",0.3,3.8,"58,406",61
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,Total,"4,930.15",0.3,0.5,"8,190",62
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"4,907.24",0.3,1,"15,392",63
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"4,685.78",0.3,3.1,"47,541",64
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,**,**,**,**,65
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"4,579.27",0.3,3.5,"52,489",66
6,Quebec,M01AE,Propionic acid derivatives,<65,Total,"4,345.01",0.3,15.8,"240,387",67
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"4,259.36",0.3,1,"15,957",68
6,Quebec,N05AE,Indole derivatives,<65,Total,"4,232.45",0.3,0.2,"3,413",69
6,Quebec,L01XC,Monoclonal antibodies,<65,Total,"4,087.07",0.3,0,343,70
6,Quebec,G02BA,Intrauterine contraceptives,<65,Total,**,**,**,**,71
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"4,006.04",0.3,0,170,72
6,Quebec,A10BB,Sulfonylureas,<65,Total,"3,907.36",0.3,2.5,"37,748",73
6,Quebec,M03BX,Other centrally acting agents,<65,Total,"3,786.98",0.3,5.9,"89,082",74
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"3,643.51",0.2,4.3,"64,675",75
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"3,635.85",0.2,0.2,"2,284",76
6,Quebec,A06AA,"Softeners, emollients",<65,Total,"3,602.13",0.2,2.2,"34,146",77
6,Quebec,N03AF,Carboxamide derivatives,<65,Total,"3,566.29",0.2,0.5,"8,261",78
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"3,560.09",0.2,0.1,"1,793",79
6,Quebec,C10AX,Other lipid-modifying agents,<65,Total,"3,524.55",0.2,1.1,"17,220",80
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,Total,"3,483.22",0.2,0.3,"4,883",81
6,Quebec,A12AA,Calcium,<65,Total,"3,460.48",0.2,3.2,"49,158",82
6,Quebec,A16AA,Amino acids and derivatives,<65,Total,"3,459.40",0.2,0,204,83
6,Quebec,J01FA,Macrolides,<65,Total,"3,207.47",0.2,10,"151,307",84
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,Total,"3,171.16",0.2,1.5,"22,431",85
6,Quebec,G03GA,Gonadotropins,<65,Total,**,**,**,**,86
6,Quebec,J01CA,Penicillins with extended spectrum,<65,Total,"3,125.41",0.2,10.3,"156,258",87
6,Quebec,A04AD,Other antiemetics,<65,Total,"3,083.63",0.2,0.4,"5,842",88
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"3,067.91",0.2,0.3,"4,378",89
6,Quebec,L01XX,Other antineoplastic agents,<65,Total,"3,008.60",0.2,0.1,844,90
6,Quebec,J02AC,Triazole derivatives,<65,Total,"2,902.09",0.2,2.7,"41,275",91
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,Total,"2,896.55",0.2,0.3,"4,406",92
6,Quebec,J01DH,Carbapenems,<65,Total,"2,882.15",0.2,0.1,"1,642",93
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"2,849.96",0.2,0.4,"5,681",94
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,Total,"2,695.95",0.2,5.8,"87,624",95
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"2,665.32",0.2,0.7,"10,527",96
6,Quebec,M05BA,Bisphosphonates,<65,Total,"2,639.17",0.2,1.2,"18,260",97
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,<65,Total,"2,621.77",0.2,0.5,"7,022",98
6,Quebec,A09AA,Enzyme preparations,<65,Total,"2,618.22",0.2,0.2,"3,507",99
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,"2,595.05",0.2,2,"29,690",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"84,719.87",11.2,0.6,"3,878",1
6,Quebec,N05AX,Other antipsychotics,<65,M,"48,935.74",6.5,4.3,"28,056",2
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"38,790.22",5.1,1,"6,236",3
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"35,928.89",4.8,8.6,"55,455",4
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,M,"34,759.29",4.6,0.1,719,5
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,M,"31,440.59",4.2,8.2,"52,780",6
6,Quebec,L04AA,Selective immunosuppressants,<65,M,"24,104.63",3.2,0.4,"2,737",7
6,Quebec,L01XE,Protein kinase inhibitors,<65,M,"16,654.88",2.2,0.1,462,8
6,Quebec,N03AX,Other antiepileptics,<65,M,"12,496.80",1.7,6.2,"40,013",9
6,Quebec,L04AC,Interleukin inhibitors,<65,M,"12,224.49",1.6,0.1,705,10
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,M,"11,998.40",1.6,18.7,"120,413",11
6,Quebec,A02BC,Proton pump inhibitors,<65,M,"10,901.31",1.4,18.3,"118,286",12
6,Quebec,L04AX,Other immunosuppressants,<65,M,"9,793.45",1.3,0.2,"1,367",13
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"9,672.30",1.3,3.1,"19,892",14
6,Quebec,N02AA,Natural opium alkaloids,<65,M,"9,399.74",1.2,8.6,"55,640",15
6,Quebec,N06AX,Other antidepressants,<65,M,"9,349.48",1.2,9.7,"62,584",16
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"9,228.89",1.2,2.3,"14,630",17
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"9,177.22",1.2,2.3,"14,524",18
6,Quebec,A16AB,Enzymes,<65,M,**,**,**,**,19
6,Quebec,J05AX,Other antivirals,<65,M,"8,635.03",1.1,0.3,"1,683",20
6,Quebec,S01LA,Antineovascularization agents,<65,M,"7,828.95",1,0.1,789,21
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,M,"7,708.37",1,8.7,"56,230",22
6,Quebec,R03BA,Glucocorticoids,<65,M,"6,429.19",0.9,7.7,"49,677",23
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"6,197.80",0.8,1.2,"7,762",24
6,Quebec,L04AD,Calcineurin inhibitors,<65,M,"6,046.79",0.8,0.3,"1,824",25
6,Quebec,N07BC,Drugs used in opioid dependence,<65,M,"5,918.66",0.8,0.5,"3,521",26
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,M,"5,800.42",0.8,1.5,"9,503",27
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"5,777.98",0.8,1.5,"9,495",28
6,Quebec,C09AA,"ACE inhibitors, plain",<65,M,"5,087.00",0.7,7.8,"50,505",29
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"5,054.03",0.7,0,291,30
6,Quebec,C02AC,Imidazoline receptor agonists,<65,M,"5,019.19",0.7,1,"6,696",31
6,Quebec,C08CA,Dihydropyridine derivatives,<65,M,"4,941.54",0.7,7.5,"48,307",32
6,Quebec,R03BB,Anticholinergics,<65,M,"4,874.57",0.6,2.2,"14,188",33
6,Quebec,J05AE,Protease inhibitors,<65,M,"4,860.13",0.6,0.1,738,34
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"4,844.66",0.6,0.5,"3,374",35
6,Quebec,V06C,Infant formulas,<65,M,"4,764.42",0.6,0.5,"3,430",36
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"4,525.62",0.6,1.4,"9,291",37
6,Quebec,N02BA,Salicylic acid and derivatives,<65,M,"4,195.35",0.6,7.9,"50,930",38
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,M,"4,144.81",0.5,4.2,"27,303",39
6,Quebec,N05BA,Benzodiazepine derivatives,<65,M,"4,095.80",0.5,6.6,"42,677",40
6,Quebec,A11CC,Vitamin D and analogues,<65,M,"3,973.73",0.5,7.8,"50,496",41
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,M,"3,870.38",0.5,5.9,"38,121",42
6,Quebec,N03AG,Fatty acid derivatives,<65,M,"3,853.42",0.5,1.5,"9,850",43
6,Quebec,B03XA,Other antianemic preparations,<65,M,"3,800.26",0.5,0.1,932,44
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"3,744.60",0.5,11.4,"73,692",45
6,Quebec,R07AX,Other respiratory system products,<65,M,"3,664.08",0.5,0,19,46
6,Quebec,A10BA,Biguanides,<65,M,"3,593.67",0.5,6.6,"42,817",47
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"3,088.67",0.4,5,"32,391",48
6,Quebec,B01AB,Heparin group,<65,M,"3,055.43",0.4,0.5,"3,417",49
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"3,022.71",0.4,1.6,"10,159",50
6,Quebec,L03AA,Colony-stimulating factors,<65,M,"3,009.38",0.4,0.1,578,51
6,Quebec,H01CB,Somatostatin and analogues,<65,M,"2,951.51",0.4,0,191,52
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"2,758.16",0.4,0.2,"1,376",53
6,Quebec,N03AE,Benzodiazepine derivatives,<65,M,"2,699.91",0.4,3.2,"20,535",54
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,<65,M,"2,545.17",0.3,1,"6,399",55
6,Quebec,H03AA,Thyroid hormones,<65,M,"2,444.11",0.3,4.1,"26,146",56
6,Quebec,N02BE,Anilides,<65,M,"2,322.27",0.3,9.6,"61,855",57
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,M,"2,287.58",0.3,0.6,"3,551",58
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"2,255.05",0.3,0.2,"1,396",59
6,Quebec,R01AD,Corticosteroids,<65,M,"2,252.20",0.3,8.7,"56,231",60
6,Quebec,A10BB,Sulfonylureas,<65,M,"2,192.82",0.3,3.4,"21,996",61
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"2,119.46",0.3,0.1,742,62
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"2,115.41",0.3,3.4,"21,927",63
6,Quebec,C10AX,Other lipid-modifying agents,<65,M,"2,011.25",0.3,1.6,"10,180",64
6,Quebec,N05AE,Indole derivatives,<65,M,"1,962.92",0.3,0.2,"1,490",65
6,Quebec,N03AF,Carboxamide derivatives,<65,M,"1,881.28",0.2,0.7,"4,393",66
6,Quebec,A16AA,Amino acids and derivatives,<65,M,"1,773.45",0.2,0,116,67
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"1,761.10",0.2,0.1,585,68
6,Quebec,L03AB,Interferons,<65,M,"1,756.57",0.2,0,131,69
6,Quebec,M01AE,Propionic acid derivatives,<65,M,"1,739.38",0.2,15.2,"97,966",70
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,703.92",0.2,2.2,"14,435",71
6,Quebec,J01DH,Carbapenems,<65,M,"1,697.32",0.2,0.1,914,72
6,Quebec,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"1,665.67",0.2,0.1,402,73
6,Quebec,A06AA,"Softeners, emollients",<65,M,"1,598.53",0.2,2,"12,785",74
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"1,590.24",0.2,0.3,"1,942",75
6,Quebec,M03BX,Other centrally acting agents,<65,M,"1,572.97",0.2,5.5,"35,186",76
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"1,505.66",0.2,0,63,77
6,Quebec,J01CA,Penicillins with extended spectrum,<65,M,"1,493.83",0.2,10.6,"68,451",78
6,Quebec,A09AA,Enzyme preparations,<65,M,"1,487.71",0.2,0.2,"1,439",79
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,M,"1,466.46",0.2,1.4,"9,334",80
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,"1,450.68",0.2,0.8,"5,380",81
6,Quebec,J01FA,Macrolides,<65,M,"1,440.85",0.2,10.2,"66,012",82
6,Quebec,L03AX,Other immunostimulants,<65,M,"1,436.29",0.2,0,136,83
6,Quebec,C09BA,ACE inhibitors and diuretics,<65,M,"1,431.38",0.2,1.7,"10,960",84
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"1,414.44",0.2,0.1,955,85
6,Quebec,J02AC,Triazole derivatives,<65,M,"1,408.61",0.2,0.6,"3,926",86
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"1,345.50",0.2,0.4,"2,613",87
6,Quebec,B02BX,Other systemic hemostatics,<65,M,"1,300.53",0.2,0,29,88
6,Quebec,A04AD,Other antiemetics,<65,M,"1,253.46",0.2,0.3,"2,203",89
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,M,"1,250.85",0.2,0.8,"4,850",90
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,"1,246.68",0.2,2.3,"14,883",91
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,M,"1,218.84",0.2,5.6,"35,827",92
6,Quebec,L01XC,Monoclonal antibodies,<65,M,"1,213.84",0.2,0,111,93
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,M,"1,182.65",0.2,0.3,"1,649",94
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,172.21",0.2,0.7,"4,624",95
6,Quebec,R05CB,Mucolytics,<65,M,"1,171.47",0.2,0,265,96
6,Quebec,V03AC,Iron-chelating agents,<65,M,"1,169.72",0.2,0,50,97
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"1,168.52",0.2,2.7,"17,368",98
6,Quebec,J01GB,Other aminoglycosides,<65,M,"1,153.26",0.2,0.1,337,99
6,Quebec,B02AB,Proteinase inhibitors,<65,M,**,**,**,**,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"77,376.60",10.5,0.5,"4,081",1
6,Quebec,L04AA,Selective immunosuppressants,<65,F,"47,910.38",6.5,0.5,"4,175",2
6,Quebec,L01XE,Protein kinase inhibitors,<65,F,"23,120.98",3.1,0.1,670,3
6,Quebec,N05AX,Other antipsychotics,<65,F,"22,113.46",3,2.5,"22,256",4
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,F,"20,974.85",2.8,4.9,"42,657",5
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"19,117.49",2.6,6.2,"54,649",6
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,F,"17,313.52",2.3,0,363,7
6,Quebec,N06AX,Other antidepressants,<65,F,"15,521.96",2.1,12.2,"106,592",8
6,Quebec,N03AX,Other antiepileptics,<65,F,"15,335.75",2.1,6.3,"54,810",9
6,Quebec,A02BC,Proton pump inhibitors,<65,F,"14,002.20",1.9,18.4,"160,851",10
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"13,798.81",1.9,3.4,"29,756",11
6,Quebec,L04AC,Interleukin inhibitors,<65,F,"13,688.47",1.9,0.1,854,12
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,F,"11,629.43",1.6,11.8,"102,934",13
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"10,034.20",1.4,0.2,"1,558",14
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,F,"9,773.70",1.3,10.4,"90,922",15
6,Quebec,L04AX,Other immunosuppressants,<65,F,"9,346.66",1.3,0.2,"1,973",16
6,Quebec,R03BA,Glucocorticoids,<65,F,"8,802.60",1.2,8.1,"70,940",17
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"8,580.65",1.2,0.1,591,18
6,Quebec,N02AA,Natural opium alkaloids,<65,F,"8,444.57",1.1,7.8,"68,163",19
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"7,822.66",1.1,12.2,"107,091",20
6,Quebec,A11CC,Vitamin D and analogues,<65,F,"7,510.18",1,15.9,"139,324",21
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"6,992.16",0.9,1.2,"10,663",22
6,Quebec,A16AB,Enzymes,<65,F,**,**,**,**,23
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"6,616.93",0.9,1.1,"9,995",24
6,Quebec,S01LA,Antineovascularization agents,<65,F,"6,228.28",0.8,0.1,634,25
6,Quebec,H03AA,Thyroid hormones,<65,F,"6,186.22",0.8,10.1,"88,068",26
6,Quebec,R03BB,Anticholinergics,<65,F,"6,045.00",0.8,2.1,"17,987",27
6,Quebec,L03AA,Colony-stimulating factors,<65,F,"5,994.82",0.8,0.1,"1,244",28
6,Quebec,V06C,Infant formulas,<65,F,"5,416.11",0.7,0.5,"4,580",29
6,Quebec,L03AB,Interferons,<65,F,"5,158.84",0.7,0,376,30
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"5,099.26",0.7,0.9,"8,037",31
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"4,910.25",0.7,0.4,"3,396",32
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"4,889.68",0.7,0.8,"6,572",33
6,Quebec,N05BA,Benzodiazepine derivatives,<65,F,"4,757.53",0.6,7.6,"66,449",34
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"4,542.79",0.6,11.3,"98,989",35
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"4,447.58",0.6,5.9,"51,927",36
6,Quebec,B01AB,Heparin group,<65,F,"4,332.38",0.6,0.6,"5,046",37
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"4,325.02",0.6,0.2,"1,848",38
6,Quebec,L03AX,Other immunostimulants,<65,F,"4,213.29",0.6,0,391,39
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,F,"4,085.20",0.6,5.7,"49,914",40
6,Quebec,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,41
6,Quebec,C08CA,Dihydropyridine derivatives,<65,F,"4,059.27",0.6,4.5,"39,694",42
6,Quebec,R07AX,Other respiratory system products,<65,F,"4,054.36",0.5,0,23,43
6,Quebec,L04AD,Calcineurin inhibitors,<65,F,"3,996.95",0.5,0.1,"1,217",44
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,F,"3,960.51",0.5,2.8,"24,378",45
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,F,"3,916.43",0.5,3.1,"27,018",46
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,F,"3,759.90",0.5,0.8,"6,871",47
6,Quebec,C09AA,"ACE inhibitors, plain",<65,F,"3,465.26",0.5,3.9,"34,071",48
6,Quebec,N07BC,Drugs used in opioid dependence,<65,F,"3,432.76",0.5,0.3,"2,277",49
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"3,400.79",0.5,0.9,"8,063",50
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"3,388.71",0.5,3.9,"33,718",51
6,Quebec,R01AD,Corticosteroids,<65,F,"3,386.47",0.5,10.5,"91,608",52
6,Quebec,A10BA,Biguanides,<65,F,"3,338.64",0.5,4.3,"37,703",53
6,Quebec,B03XA,Other antianemic preparations,<65,F,"3,175.83",0.4,0.1,718,54
6,Quebec,N03AE,Benzodiazepine derivatives,<65,F,"3,138.44",0.4,3.8,"32,956",55
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,F,"3,087.15",0.4,1.3,"11,333",56
6,Quebec,G03GA,Gonadotropins,<65,F,**,**,**,**,57
6,Quebec,N02BE,Anilides,<65,F,"3,082.38",0.4,9.5,"82,759",58
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"3,024.59",0.4,0.5,"4,598",59
6,Quebec,J05AX,Other antivirals,<65,F,"3,016.16",0.4,0.1,698,60
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"2,981.86",0.4,3.8,"33,106",61
6,Quebec,N02BA,Salicylic acid and derivatives,<65,F,"2,911.16",0.4,4.1,"36,033",62
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"2,908.50",0.4,0.2,"1,643",63
6,Quebec,L01XC,Monoclonal antibodies,<65,F,"2,873.23",0.4,0,232,64
6,Quebec,H01CB,Somatostatin and analogues,<65,F,"2,797.32",0.4,0,234,65
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,F,"2,677.36",0.4,3.3,"28,889",66
6,Quebec,N03AG,Fatty acid derivatives,<65,F,"2,671.16",0.4,0.9,"7,688",67
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,F,"2,642.57",0.4,0.5,"4,639",68
6,Quebec,M01AE,Propionic acid derivatives,<65,F,"2,605.62",0.4,16.3,"142,421",69
6,Quebec,A12AA,Calcium,<65,F,"2,532.27",0.3,4.6,"40,176",70
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,500.38",0.3,0,107,71
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"2,474.99",0.3,5.4,"47,307",72
6,Quebec,L01XX,Other antineoplastic agents,<65,F,"2,296.84",0.3,0.1,472,73
6,Quebec,N05AE,Indole derivatives,<65,F,"2,269.53",0.3,0.2,"1,923",74
6,Quebec,M03BX,Other centrally acting agents,<65,F,"2,214.00",0.3,6.2,"53,896",75
6,Quebec,A06AA,"Softeners, emollients",<65,F,"2,003.60",0.3,2.4,"21,361",76
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,884.54",0.3,0.6,"5,233",77
6,Quebec,M05BA,Bisphosphonates,<65,F,"1,884.44",0.3,1.6,"14,108",78
6,Quebec,A04AD,Other antiemetics,<65,F,"1,830.17",0.2,0.4,"3,639",79
6,Quebec,J01FA,Macrolides,<65,F,"1,766.61",0.2,9.7,"85,295",80
6,Quebec,A10BB,Sulfonylureas,<65,F,"1,714.55",0.2,1.8,"15,752",81
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,F,"1,713.89",0.2,0.3,"2,757",82
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,F,"1,704.70",0.2,1.5,"13,097",83
6,Quebec,G03DA,Pregnen (4) derivatives,<65,F,"1,699.69",0.2,2.6,"22,910",84
6,Quebec,A16AA,Amino acids and derivatives,<65,F,"1,685.94",0.2,0,88,85
6,Quebec,N03AF,Carboxamide derivatives,<65,F,"1,685.01",0.2,0.4,"3,868",86
6,Quebec,C02AC,Imidazoline receptor agonists,<65,F,"1,678.86",0.2,0.6,"5,170",87
6,Quebec,J01CA,Penicillins with extended spectrum,<65,F,"1,631.59",0.2,10,"87,807",88
6,Quebec,G03AC,Progestogens,<65,F,"1,578.55",0.2,2.9,"25,220",89
6,Quebec,N07XX,Other nervous system drugs,<65,F,"1,532.14",0.2,0,368,90
6,Quebec,C10AX,Other lipid-modifying agents,<65,F,"1,513.29",0.2,0.8,"7,040",91
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,"1,504.46",0.2,0.4,"3,068",92
6,Quebec,J02AC,Triazole derivatives,<65,F,"1,493.48",0.2,4.3,"37,349",93
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"1,477.67",0.2,0.3,"2,436",94
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,F,"1,477.11",0.2,5.9,"51,797",95
6,Quebec,S01XA,Other ophthalmologicals,<65,F,"1,466.70",0.2,0.6,"4,913",96
6,Quebec,J05AE,Protease inhibitors,<65,F,"1,381.58",0.2,0,231,97
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,"1,380.80",0.2,0.1,888,98
6,Quebec,V03AC,Iron-chelating agents,<65,F,"1,375.78",0.2,0,48,99
6,Quebec,R03DC,Leukotriene receptor antagonists,<65,F,"1,374.58",0.2,1.2,"10,425",100
7,Ontario,S01LA,Antineovascularization agents,Total,Total,"511,846.02",7.7,1.1,"51,122",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"340,751.74",5.2,0.4,"18,433",2
7,Ontario,L01XE,Protein kinase inhibitors,Total,Total,"307,968.95",4.7,0.2,"7,905",3
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,Total,"261,074.13",3.9,0.1,"4,902",4
7,Ontario,L04AX,Other immunosuppressants,Total,Total,"218,862.12",3.3,0.3,"15,430",5
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,Total,"211,252.80",3.2,5,"236,587",6
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"163,327.88",2.5,3.5,"166,624",7
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"162,319.61",2.5,5.8,"275,526",8
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"150,452.81",2.3,3.3,"159,195",9
7,Ontario,N05AX,Other antipsychotics,Total,Total,"149,138.74",2.3,2.7,"128,608",10
7,Ontario,L04AA,Selective immunosuppressants,Total,Total,"140,254.18",2.1,0.5,"23,876",11
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"132,898.58",2,3.4,"161,551",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"131,708.68",2,3.2,"150,561",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,Total,"119,465.24",1.8,29.8,"1,422,081",14
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"116,734.69",1.8,0.3,"12,966",15
7,Ontario,N06AX,Other antidepressants,Total,Total,"96,771.42",1.5,10.1,"480,655",16
7,Ontario,A02BC,Proton pump inhibitors,Total,Total,"94,583.87",1.4,20.6,"984,106",17
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"86,136.37",1.3,2.6,"121,695",18
7,Ontario,N07BC,Drugs used in opioid dependence,Total,Total,"84,352.92",1.3,0.9,"44,613",19
7,Ontario,N03AX,Other antiepileptics,Total,Total,"81,339.03",1.2,7.3,"350,102",20
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"75,788.20",1.1,10.7,"508,009",21
7,Ontario,N02AA,Natural opium alkaloids,Total,Total,"68,558.34",1,5.3,"250,596",22
7,Ontario,L04AC,Interleukin inhibitors,Total,Total,"66,102.40",1,0.1,"4,514",23
7,Ontario,R03BB,Anticholinergics,Total,Total,"64,289.70",1,3.6,"172,337",24
7,Ontario,C08CA,Dihydropyridine derivatives,Total,Total,"63,050.75",1,13.1,"624,417",25
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"61,652.67",0.9,0.4,"19,277",26
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,Total,"58,011.48",0.9,2.8,"133,948",27
7,Ontario,C09AA,"ACE inhibitors, plain",Total,Total,"57,985.06",0.9,14.1,"674,424",28
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"56,333.77",0.9,10.4,"495,701",29
7,Ontario,M05BA,Bisphosphonates,Total,Total,"48,752.69",0.7,4.2,"199,393",30
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"47,100.51",0.7,1.8,"86,482",31
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"46,486.80",0.7,3.6,"169,876",32
7,Ontario,L03AA,Colony-stimulating factors,Total,Total,"46,124.26",0.7,0.2,"8,697",33
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,Total,"45,630.75",0.7,0.1,"2,712",34
7,Ontario,R03BA,Glucocorticoids,Total,Total,"45,156.31",0.7,6.4,"304,555",35
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"43,912.93",0.7,2.6,"125,319",36
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"38,289.27",0.6,3.2,"150,519",37
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,Total,"37,228.43",0.6,12.4,"592,952",38
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"36,766.99",0.6,0.5,"23,203",39
7,Ontario,L04AD,Calcineurin inhibitors,Total,Total,"36,151.10",0.5,0.2,"10,842",40
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"35,889.94",0.5,5.4,"255,880",41
7,Ontario,S01EE,Prostaglandin analogues,Total,Total,"34,082.68",0.5,2.7,"130,035",42
7,Ontario,H01CB,Somatostatin and analogues,Total,Total,"33,863.33",0.5,0,"1,989",43
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"32,893.46",0.5,0,"2,160",44
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"32,641.25",0.5,0.3,"12,209",45
7,Ontario,H03AA,Thyroid hormones,Total,Total,"29,802.18",0.5,9.8,"468,720",46
7,Ontario,L02BB,Antiandrogens,Total,Total,"29,031.59",0.4,0.2,"8,752",47
7,Ontario,S01ED,Beta-blocking agents,Total,Total,"28,430.81",0.4,2.6,"122,334",48
7,Ontario,B03XA,Other antianemic preparations,Total,Total,"27,813.02",0.4,0.1,"3,580",49
7,Ontario,B01AB,Heparin group,Total,Total,"27,748.58",0.4,0.4,"17,369",50
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"26,899.61",0.4,1.1,"50,774",51
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"26,884.80",0.4,0.3,"12,776",52
7,Ontario,N04BA,Dopa and dopa derivatives,Total,Total,"26,395.65",0.4,0.7,"33,866",53
7,Ontario,C08DB,Benzothiazepine derivatives,Total,Total,"26,110.55",0.4,1.9,"91,384",54
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"25,278.64",0.4,9.3,"444,028",55
7,Ontario,C10AX,Other lipid-modifying agents,Total,Total,"24,005.51",0.4,2.9,"139,415",56
7,Ontario,A16AB,Enzymes,Total,Total,"22,763.19",0.3,0,47,57
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"22,679.33",0.3,14.3,"682,244",58
7,Ontario,B01AE,Direct thrombin inhibitors,Total,Total,"22,002.11",0.3,0.5,"22,475",59
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,Total,"21,271.64",0.3,0.6,"27,044",60
7,Ontario,A10BA,Biguanides,Total,Total,"20,353.70",0.3,8.1,"386,753",61
7,Ontario,N06DA,Anticholinesterases,Total,Total,"19,977.98",0.3,1.3,"64,375",62
7,Ontario,R01AD,Corticosteroids,Total,Total,"18,999.70",0.3,7,"334,629",63
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,Total,"18,357.64",0.3,2.6,"125,149",64
7,Ontario,N05BA,Benzodiazepine derivatives,Total,Total,"17,697.96",0.3,6.1,"291,783",65
7,Ontario,J05AX,Other antivirals,Total,Total,"17,569.99",0.3,0.1,"2,937",66
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"17,517.08",0.3,0.5,"22,797",67
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"17,338.15",0.3,2.8,"133,262",68
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"16,652.59",0.3,2,"96,917",69
7,Ontario,A04AD,Other antiemetics,Total,Total,"16,051.23",0.2,0.5,"24,960",70
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,Total,"15,925.33",0.2,1.6,"74,319",71
7,Ontario,C03CA,"Sulfonamides, plain",Total,Total,"15,885.98",0.2,5.3,"254,301",72
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"15,829.61",0.2,3.1,"148,111",73
7,Ontario,N05AE,Indole derivatives,Total,Total,"15,002.55",0.2,0.3,"12,101",74
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"14,709.15",0.2,2.4,"113,872",75
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,Total,"14,405.92",0.2,9.5,"453,610",76
7,Ontario,J01CA,Penicillins with extended spectrum,Total,Total,"13,885.63",0.2,17.2,"821,144",77
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"13,773.01",0.2,3.6,"170,120",78
7,Ontario,N03AG,Fatty acid derivatives,Total,Total,"13,696.67",0.2,0.8,"37,530",79
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,Total,"13,580.03",0.2,0,"1,294",80
7,Ontario,L03AB,Interferons,Total,Total,"12,926.67",0.2,0,745,81
7,Ontario,A10BB,Sulfonylureas,Total,Total,"12,833.02",0.2,3.4,"162,913",82
7,Ontario,L01XX,Other antineoplastic agents,Total,Total,"12,537.21",0.2,0.1,"6,090",83
7,Ontario,N02BE,Anilides,Total,Total,"12,491.26",0.2,8.2,"389,305",84
7,Ontario,L01XC,Monoclonal antibodies,Total,Total,"12,172.02",0.2,0,975,85
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"11,947.92",0.2,0,550,86
7,Ontario,D06AX,Other antibiotics for topical use,Total,Total,"11,798.20",0.2,6.2,"294,195",87
7,Ontario,A06AB,Contact laxatives,Total,Total,"11,729.07",0.2,5.9,"281,169",88
7,Ontario,N03AE,Benzodiazepine derivatives,Total,Total,"11,705.69",0.2,2.3,"108,342",89
7,Ontario,H02AB,Glucocorticoids,Total,Total,"11,454.57",0.2,8.3,"396,216",90
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"11,453.64",0.2,0,33,91
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"11,276.26",0.2,0.5,"21,872",92
7,Ontario,V03AC,Iron-chelating agents,Total,Total,"11,053.35",0.2,0,474,93
7,Ontario,J05AE,Protease inhibitors,Total,Total,"10,981.55",0.2,0,"1,519",94
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,Total,"10,849.40",0.2,0.7,"33,457",95
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,Total,"10,816.47",0.2,3.8,"180,312",96
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,Total,"10,480.01",0.2,0.8,"38,357",97
7,Ontario,A02BA,H2-receptor antagonists,Total,Total,"9,958.10",0.2,3.3,"157,327",98
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"9,362.36",0.1,1.7,"82,219",99
7,Ontario,J01FA,Macrolides,Total,Total,"8,933.18",0.1,8.6,"412,379",100
7,Ontario,S01LA,Antineovascularization agents,Total,M,"220,917.06",6.7,1,"22,533",1
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,M,"169,808.37",5.1,0.1,"3,178",2
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"165,968.10",5,0.4,"8,396",3
7,Ontario,L01XE,Protein kinase inhibitors,Total,M,"156,063.84",4.7,0.2,"3,916",4
7,Ontario,L04AX,Other immunosuppressants,Total,M,"127,538.23",3.8,0.3,"6,752",5
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,M,"108,130.65",3.3,5.5,"120,369",6
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"93,086.36",2.8,4.4,"94,774",7
7,Ontario,N05AX,Other antipsychotics,Total,M,"92,504.55",2.8,2.9,"63,009",8
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"90,187.32",2.7,0.5,"10,076",9
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"78,624.63",2.4,4.4,"94,851",10
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"76,425.59",2.3,3.8,"81,488",11
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"72,149.99",2.2,3.7,"80,512",12
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"70,836.21",2.1,5.3,"116,005",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,M,"60,175.30",1.8,34.1,"741,516",14
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"56,427.35",1.7,0.8,"17,006",15
7,Ontario,N07BC,Drugs used in opioid dependence,Total,M,"48,681.62",1.5,1.2,"25,792",16
7,Ontario,L04AA,Selective immunosuppressants,Total,M,"47,985.22",1.4,0.5,"9,974",17
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,M,"45,626.97",1.4,0.1,"2,711",18
7,Ontario,A02BC,Proton pump inhibitors,Total,M,"38,124.47",1.1,19.1,"415,367",19
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,M,"37,260.14",1.1,4,"87,054",20
7,Ontario,N03AX,Other antiepileptics,Total,M,"35,275.17",1.1,6.5,"141,536",21
7,Ontario,N06AX,Other antidepressants,Total,M,"34,690.85",1,8.2,"177,155",22
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"34,488.60",1,11.2,"243,528",23
7,Ontario,R03BB,Anticholinergics,Total,M,"31,872.05",1,3.9,"83,833",24
7,Ontario,N02AA,Natural opium alkaloids,Total,M,"31,597.77",1,4.8,"105,185",25
7,Ontario,L04AC,Interleukin inhibitors,Total,M,"31,413.21",0.9,0.1,"1,990",26
7,Ontario,C09AA,"ACE inhibitors, plain",Total,M,"29,484.55",0.9,16.8,"365,712",27
7,Ontario,L02BB,Antiandrogens,Total,M,"29,017.40",0.9,0.4,"8,729",28
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,M,"27,755.85",0.8,8.2,"177,158",29
7,Ontario,C08CA,Dihydropyridine derivatives,Total,M,"27,567.36",0.8,13.2,"285,958",30
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"25,963.33",0.8,2.1,"45,430",31
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"24,919.98",0.8,3.7,"79,663",32
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"22,759.79",0.7,9.8,"212,713",33
7,Ontario,L04AD,Calcineurin inhibitors,Total,M,"22,022.11",0.7,0.3,"6,660",34
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"21,639.64",0.7,0.6,"12,967",35
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"19,758.28",0.6,0.4,"9,312",36
7,Ontario,R03BA,Glucocorticoids,Total,M,"19,699.29",0.6,6.5,"141,149",37
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"19,258.45",0.6,4.1,"89,293",38
7,Ontario,L03AA,Colony-stimulating factors,Total,M,"18,560.99",0.6,0.2,"3,565",39
7,Ontario,H01CB,Somatostatin and analogues,Total,M,"17,160.45",0.5,0,896,40
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,M,"17,142.09",0.5,13.9,"302,851",41
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,M,"16,429.36",0.5,2.1,"45,626",42
7,Ontario,A16AB,Enzymes,Total,M,"15,984.81",0.5,0,31,43
7,Ontario,N04BA,Dopa and dopa derivatives,Total,M,"15,792.59",0.5,0.9,"18,968",44
7,Ontario,B03XA,Other antianemic preparations,Total,M,"15,112.41",0.5,0.1,"1,624",45
7,Ontario,S01EE,Prostaglandin analogues,Total,M,"14,926.75",0.4,2.7,"57,840",46
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"14,714.37",0.4,1.2,"26,952",47
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"14,695.05",0.4,5.2,"113,726",48
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"13,765.78",0.4,0.2,"4,579",49
7,Ontario,J05AX,Other antivirals,Total,M,"13,590.39",0.4,0.1,"2,082",50
7,Ontario,B01AB,Heparin group,Total,M,"13,444.16",0.4,0.4,"7,821",51
7,Ontario,S01ED,Beta-blocking agents,Total,M,"13,155.36",0.4,2.6,"57,011",52
7,Ontario,C10AX,Other lipid-modifying agents,Total,M,"12,816.59",0.4,3.5,"77,040",53
7,Ontario,B01AE,Direct thrombin inhibitors,Total,M,"12,752.73",0.4,0.6,"13,208",54
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"12,018.26",0.4,0,752,55
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"11,471.36",0.3,9.3,"201,311",56
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"10,815.61",0.3,0.6,"12,163",57
7,Ontario,C08DB,Benzothiazepine derivatives,Total,M,"10,670.93",0.3,1.7,"37,570",58
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,M,"10,606.14",0.3,0.6,"12,174",59
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"10,446.82",0.3,14.1,"306,677",60
7,Ontario,M05BA,Bisphosphonates,Total,M,"10,036.65",0.3,1.7,"37,849",61
7,Ontario,A10BA,Biguanides,Total,M,"10,031.12",0.3,9.3,"201,726",62
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,M,"9,440.84",0.3,3,"64,441",63
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"8,984.31",0.3,0.5,"11,318",64
7,Ontario,J05AE,Protease inhibitors,Total,M,"8,972.04",0.3,0.1,"1,190",65
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,M,"8,744.30",0.3,0,771,66
7,Ontario,R01AD,Corticosteroids,Total,M,"8,708.15",0.3,6.8,"147,057",67
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,Total,M,"8,688.17",0.3,0.9,"19,015",68
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,M,"8,166.37",0.2,1.7,"36,293",69
7,Ontario,N03AG,Fatty acid derivatives,Total,M,"7,818.04",0.2,0.9,"20,085",70
7,Ontario,N06DA,Anticholinesterases,Total,M,"7,390.93",0.2,1.2,"25,348",71
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,M,"7,165.00",0.2,9.6,"209,534",72
7,Ontario,N05BA,Benzodiazepine derivatives,Total,M,"7,146.20",0.2,4.7,"102,706",73
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,"7,114.02",0.2,0,21,74
7,Ontario,H03AA,Thyroid hormones,Total,M,"7,113.58",0.2,5.3,"115,800",75
7,Ontario,A04AD,Other antiemetics,Total,M,"7,017.11",0.2,0.5,"10,164",76
7,Ontario,A10BB,Sulfonylureas,Total,M,"6,699.53",0.2,4.1,"90,050",77
7,Ontario,J01CA,Penicillins with extended spectrum,Total,M,"6,604.50",0.2,17.6,"381,442",78
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"6,566.24",0.2,2.9,"63,729",79
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"6,285.11",0.2,2,"43,671",80
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,M,"6,254.34",0.2,0.8,"17,654",81
7,Ontario,C03CA,"Sulfonamides, plain",Total,M,"6,154.54",0.2,5.2,"113,673",82
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"5,996.63",0.2,0.5,"11,325",83
7,Ontario,M04AA,Preparations inhibiting uric acid production,Total,M,"5,988.98",0.2,3.9,"84,492",84
7,Ontario,N05AE,Indole derivatives,Total,M,"5,860.79",0.2,0.2,"4,519",85
7,Ontario,V03AC,Iron-chelating agents,Total,M,"5,807.31",0.2,0,244,86
7,Ontario,D06AX,Other antibiotics for topical use,Total,M,"5,492.82",0.2,6.3,"135,933",87
7,Ontario,N03AE,Benzodiazepine derivatives,Total,M,"5,257.56",0.2,1.9,"41,707",88
7,Ontario,A06AB,Contact laxatives,Total,M,"5,124.60",0.2,5.9,"127,325",89
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"5,052.25",0.2,0.2,"3,780",90
7,Ontario,H02AB,Glucocorticoids,Total,M,"4,859.66",0.1,8,"173,516",91
7,Ontario,L01XX,Other antineoplastic agents,Total,M,"4,807.11",0.1,0.1,"2,706",92
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,M,"4,709.69",0.1,0.7,"15,758",93
7,Ontario,A07AA,Antibiotics,Total,M,"4,602.85",0.1,1.1,"22,873",94
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,"4,517.00",0.1,1.4,"29,372",95
7,Ontario,N02BE,Anilides,Total,M,"4,492.17",0.1,7.1,"154,870",96
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,"4,429.11",0.1,0,"1,059",97
7,Ontario,N03AF,Carboxamide derivatives,Total,M,"4,398.43",0.1,0.5,"11,110",98
7,Ontario,A09AA,Enzyme preparations,Total,M,"4,376.19",0.1,0.2,"3,871",99
7,Ontario,R07AX,Other respiratory system products,Total,M,"4,347.64",0.1,0,19,100
7,Ontario,S01LA,Antineovascularization agents,Total,F,"290,905.51",8.8,1.1,"28,586",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"174,769.81",5.3,0.4,"10,036",2
7,Ontario,L01XE,Protein kinase inhibitors,Total,F,"151,891.47",4.6,0.2,"3,987",3
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,F,"103,078.40",3.1,4.5,"116,159",4
7,Ontario,L04AA,Selective immunosuppressants,Total,F,"92,253.50",2.8,0.5,"13,895",5
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"91,387.18",2.8,6.1,"159,341",6
7,Ontario,L04AX,Other immunosuppressants,Total,F,"91,322.24",2.8,0.3,"8,671",7
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,F,"91,111.37",2.8,0.1,"1,721",8
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"75,297.51",2.3,4.2,"109,496",9
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"73,906.92",2.2,3,"77,567",10
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"70,012.96",2.1,2.8,"71,584",11
7,Ontario,N06AX,Other antidepressants,Total,F,"62,012.30",1.9,11.7,"302,936",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"59,471.83",1.8,2.7,"69,894",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,F,"59,191.19",1.8,26.2,"679,473",14
7,Ontario,N05AX,Other antipsychotics,Total,F,"56,436.90",1.7,2.5,"65,441",15
7,Ontario,A02BC,Proton pump inhibitors,Total,F,"56,382.21",1.7,21.9,"567,572",16
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"54,133.65",1.6,2.6,"66,503",17
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,F,"47,972.26",1.5,12.7,"330,296",18
7,Ontario,N03AX,Other antiepileptics,Total,F,"45,992.53",1.4,8,"208,216",19
7,Ontario,M05BA,Bisphosphonates,Total,F,"38,685.05",1.2,6.2,"161,426",20
7,Ontario,N02AA,Natural opium alkaloids,Total,F,"36,944.48",1.1,5.6,"145,279",21
7,Ontario,N07BC,Drugs used in opioid dependence,Total,F,"35,613.27",1.1,0.7,"18,753",22
7,Ontario,C08CA,Dihydropyridine derivatives,Total,F,"35,421.31",1.1,13,"337,862",23
7,Ontario,L04AC,Interleukin inhibitors,Total,F,"34,689.19",1.1,0.1,"2,524",24
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"33,524.38",1,10.9,"282,611",25
7,Ontario,R03BB,Anticholinergics,Total,F,"32,390.76",1,3.4,"88,416",26
7,Ontario,C09AA,"ACE inhibitors, plain",Total,F,"28,453.68",0.9,11.9,"308,156",27
7,Ontario,L03AA,Colony-stimulating factors,Total,F,"27,545.97",0.8,0.2,"5,130",28
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,F,"27,465.55",0.8,3.1,"79,630",29
7,Ontario,R03BA,Glucocorticoids,Total,F,"25,419.07",0.8,6.3,"163,154",30
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"25,346.04",0.8,0.1,"2,761",31
7,Ontario,H03AA,Thyroid hormones,Total,F,"22,671.27",0.7,13.6,"352,630",32
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"21,515.89",0.7,3.5,"89,951",33
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"21,098.03",0.6,1.6,"40,965",34
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"20,875.20",0.6,0.1,"1,408",35
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,F,"20,725.55",0.6,1.8,"46,832",36
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,F,"20,057.10",0.6,11.2,"289,673",37
7,Ontario,S01EE,Prostaglandin analogues,Total,F,"19,143.48",0.6,2.8,"72,153",38
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"19,005.60",0.6,2.4,"61,118",39
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"18,861.78",0.6,0.3,"7,626",40
7,Ontario,H01CB,Somatostatin and analogues,Total,F,"16,702.88",0.5,0,"1,093",41
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"16,410.10",0.5,3.7,"95,744",42
7,Ontario,C08DB,Benzothiazepine derivatives,Total,F,"15,435.67",0.5,2.1,"53,793",43
7,Ontario,S01ED,Beta-blocking agents,Total,F,"15,265.60",0.5,2.5,"65,275",44
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"15,081.08",0.5,0.4,"10,210",45
7,Ontario,B01AB,Heparin group,Total,F,"14,300.97",0.4,0.4,"9,540",46
7,Ontario,L04AD,Calcineurin inhibitors,Total,F,"14,127.61",0.4,0.2,"4,179",47
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"13,792.99",0.4,9.3,"242,317",48
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"13,760.42",0.4,6.6,"169,983",49
7,Ontario,B03XA,Other antianemic preparations,Total,F,"12,700.60",0.4,0.1,"1,956",50
7,Ontario,N06DA,Anticholinesterases,Total,F,"12,582.20",0.4,1.5,"39,008",51
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"12,213.67",0.4,14.5,"375,032",52
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"12,179.25",0.4,0.9,"23,808",53
7,Ontario,C10AX,Other lipid-modifying agents,Total,F,"11,180.80",0.3,2.4,"62,327",54
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"11,039.83",0.3,3.4,"89,375",55
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,F,"10,657.85",0.3,0.6,"14,858",56
7,Ontario,N04BA,Dopa and dopa derivatives,Total,F,"10,599.45",0.3,0.6,"14,883",57
7,Ontario,N05BA,Benzodiazepine derivatives,Total,F,"10,540.24",0.3,7.3,"188,857",58
7,Ontario,A10BA,Biguanides,Total,F,"10,294.37",0.3,7.1,"184,548",59
7,Ontario,R01AD,Corticosteroids,Total,F,"10,268.80",0.3,7.2,"187,112",60
7,Ontario,C03CA,"Sulfonamides, plain",Total,F,"9,723.30",0.3,5.4,"140,503",61
7,Ontario,L03AB,Interferons,Total,F,"9,624.85",0.3,0,545,62
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"9,247.89",0.3,3.3,"84,256",63
7,Ontario,B01AE,Direct thrombin inhibitors,Total,F,"9,246.52",0.3,0.4,"9,263",64
7,Ontario,N05AE,Indole derivatives,Total,F,"9,132.47",0.3,0.3,"7,574",65
7,Ontario,A04AD,Other antiemetics,Total,F,"9,026.60",0.3,0.6,"14,786",66
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,F,"8,893.41",0.3,2.3,"60,556",67
7,Ontario,L01XC,Monoclonal antibodies,Total,F,"8,529.25",0.3,0,676,68
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"8,513.08",0.3,0.4,"11,445",69
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"8,496.42",0.3,0,383,70
7,Ontario,N02BE,Anilides,Total,F,"7,975.90",0.2,9,"233,556",71
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,F,"7,755.04",0.2,1.5,"38,002",72
7,Ontario,L01XX,Other antineoplastic agents,Total,F,"7,724.34",0.2,0.1,"3,373",73
7,Ontario,G02BA,Intrauterine contraceptives,Total,F,"7,708.13",0.2,0.8,"20,196",74
7,Ontario,L02BG,Aromatase inhibitors,Total,F,"7,642.22",0.2,0.8,"21,482",75
7,Ontario,J01CA,Penicillins with extended spectrum,Total,F,"7,264.38",0.2,16.9,"438,746",76
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,F,"7,223.02",0.2,9.4,"243,598",77
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"7,119.72",0.2,0.1,"3,457",78
7,Ontario,A16AB,Enzymes,Total,F,"6,778.38",0.2,0,16,79
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,F,"6,754.60",0.2,4.3,"111,648",80
7,Ontario,A06AB,Contact laxatives,Total,F,"6,592.69",0.2,5.9,"153,591",81
7,Ontario,H02AB,Glucocorticoids,Total,F,"6,588.91",0.2,8.6,"222,496",82
7,Ontario,N03AE,Benzodiazepine derivatives,Total,F,"6,441.69",0.2,2.6,"66,538",83
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,"6,415.27",0.2,2.2,"55,734",84
7,Ontario,D06AX,Other antibiotics for topical use,Total,F,"6,294.49",0.2,6.1,"158,011",85
7,Ontario,L03AX,Other immunostimulants,Total,F,"6,175.17",0.2,0,579,86
7,Ontario,A10BB,Sulfonylureas,Total,F,"6,115.31",0.2,2.8,"72,649",87
7,Ontario,A02BA,H2-receptor antagonists,Total,F,"5,947.45",0.2,3.6,"94,517",88
7,Ontario,N03AG,Fatty acid derivatives,Total,F,"5,866.68",0.2,0.7,"17,396",89
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,F,"5,763.54",0.2,0.9,"22,570",90
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"5,272.70",0.2,0.4,"10,535",91
7,Ontario,V03AC,Iron-chelating agents,Total,F,"5,246.04",0.2,0,230,92
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,F,"5,200.72",0.2,0.1,"2,262",93
7,Ontario,M01AE,Propionic acid derivatives,Total,F,"5,097.78",0.2,7,"181,845",94
7,Ontario,A06AD,Osmotically acting laxatives,Total,F,"4,992.60",0.2,3.3,"86,162",95
7,Ontario,J01FA,Macrolides,Total,F,"4,890.81",0.1,9,"233,427",96
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"4,836.69",0.1,2,"52,789",97
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,F,"4,835.73",0.1,0,523,98
7,Ontario,V06,General nutrients,Total,F,"4,751.81",0.1,0,154,99
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,F,"4,585.41",0.1,0.6,"15,777",100
7,Ontario,S01LA,Antineovascularization agents,65+,Total,"485,956.68",11.4,2,"48,280",1
7,Ontario,L01XE,Protein kinase inhibitors,65+,Total,"239,783.90",5.6,0.3,"6,079",2
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,Total,"202,544.82",4.8,9.3,"223,400",3
7,Ontario,L04AX,Other immunosuppressants,65+,Total,"169,098.81",4,0.4,"9,898",4
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"132,703.41",3.1,5.5,"131,825",5
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"130,335.61",3.1,5.6,"135,846",6
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"129,831.72",3,0.3,"6,996",7
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"125,898.66",3,8.3,"201,025",8
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"104,920.10",2.5,5.2,"125,336",9
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,Total,"103,519.24",2.4,52.4,"1,263,628",10
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"96,498.52",2.3,4.6,"110,102",11
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"83,764.52",2,4.9,"118,185",12
7,Ontario,A02BC,Proton pump inhibitors,65+,Total,"72,110.23",1.7,31.5,"759,041",13
7,Ontario,L04AA,Selective immunosuppressants,65+,Total,"63,504.05",1.5,0.6,"14,103",14
7,Ontario,C08CA,Dihydropyridine derivatives,65+,Total,"56,483.71",1.3,23.3,"562,275",15
7,Ontario,R03BB,Anticholinergics,65+,Total,"53,511.05",1.3,5.9,"141,498",16
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"53,267.36",1.2,0.7,"15,920",17
7,Ontario,N06AX,Other antidepressants,65+,Total,"51,952.46",1.2,12,"289,217",18
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"51,353.77",1.2,18.7,"451,492",19
7,Ontario,C09AA,"ACE inhibitors, plain",65+,Total,"49,948.09",1.2,24.5,"591,440",20
7,Ontario,M05BA,Bisphosphonates,65+,Total,"45,614.10",1.1,7.8,"187,103",21
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,Total,"43,762.60",1,0.1,"2,593",22
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,Total,"39,527.52",0.9,0,731,23
7,Ontario,N03AX,Other antiepileptics,65+,Total,"39,177.75",0.9,9.3,"224,054",24
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"38,193.60",0.9,10.5,"253,596",25
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"37,799.19",0.9,4.4,"105,649",26
7,Ontario,L04AC,Interleukin inhibitors,65+,Total,"35,258.42",0.8,0.1,"2,291",27
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"33,776.23",0.8,9.9,"238,680",28
7,Ontario,N02AA,Natural opium alkaloids,65+,Total,"33,292.54",0.8,7.5,"180,860",29
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,Total,"32,784.98",0.8,22.2,"535,240",30
7,Ontario,S01EE,Prostaglandin analogues,65+,Total,"32,622.83",0.8,5.2,"124,296",31
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"29,951.82",0.7,5.6,"135,774",32
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"29,850.31",0.7,2.3,"54,763",33
7,Ontario,L02BB,Antiandrogens,65+,Total,"27,598.96",0.6,0.4,"8,528",34
7,Ontario,S01ED,Beta-blocking agents,65+,Total,"27,016.23",0.6,4.8,"115,601",35
7,Ontario,B03XA,Other antianemic preparations,65+,Total,"25,803.86",0.6,0.1,"3,151",36
7,Ontario,L03AA,Colony-stimulating factors,65+,Total,"25,772.38",0.6,0.2,"5,063",37
7,Ontario,H01CB,Somatostatin and analogues,65+,Total,"25,051.03",0.6,0.1,"1,372",38
7,Ontario,N04BA,Dopa and dopa derivatives,65+,Total,"24,847.01",0.6,1.3,"31,644",39
7,Ontario,C08DB,Benzothiazepine derivatives,65+,Total,"24,300.71",0.6,3.5,"84,577",40
7,Ontario,H03AA,Thyroid hormones,65+,Total,"24,178.71",0.6,16.2,"391,824",41
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"24,040.44",0.6,0.5,"11,300",42
7,Ontario,R03BA,Glucocorticoids,65+,Total,"23,348.02",0.5,4.8,"115,360",43
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"23,304.96",0.5,1.8,"43,507",44
7,Ontario,N05AX,Other antipsychotics,65+,Total,"23,098.00",0.5,1.8,"42,677",45
7,Ontario,B01AE,Direct thrombin inhibitors,65+,Total,"21,535.93",0.5,0.9,"21,907",46
7,Ontario,C10AX,Other lipid-modifying agents,65+,Total,"20,826.03",0.5,5.2,"125,582",47
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"19,857.38",0.5,0.3,"8,152",48
7,Ontario,N06DA,Anticholinesterases,65+,Total,"19,617.83",0.5,2.6,"63,362",49
7,Ontario,B01AB,Heparin group,65+,Total,"18,861.96",0.4,0.5,"13,034",50
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"18,270.61",0.4,0,"1,077",51
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"17,376.30",0.4,0.1,"1,689",52
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,Total,"16,178.95",0.4,0.8,"19,488",53
7,Ontario,A10BA,Biguanides,65+,Total,"15,912.14",0.4,13.2,"318,024",54
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,Total,"15,829.37",0.4,4.5,"109,188",55
7,Ontario,L04AD,Calcineurin inhibitors,65+,Total,"14,872.80",0.3,0.2,"4,802",56
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"14,712.78",0.3,0.8,"19,351",57
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"14,673.25",0.3,3.5,"84,290",58
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"14,420.02",0.3,5.6,"135,390",59
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"14,307.58",0.3,4.6,"110,936",60
7,Ontario,C03CA,"Sulfonamides, plain",65+,Total,"14,204.51",0.3,9.5,"229,603",61
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"13,302.27",0.3,2.9,"70,306",62
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"12,402.25",0.3,11.9,"287,412",63
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"12,069.73",0.3,0.5,"11,008",64
7,Ontario,R01AD,Corticosteroids,65+,Total,"11,459.99",0.3,8,"192,305",65
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"11,362.78",0.3,13.7,"329,935",66
7,Ontario,A10BB,Sulfonylureas,65+,Total,"10,285.46",0.2,5.6,"134,555",67
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"9,297.74",0.2,3.4,"83,131",68
7,Ontario,L01XX,Other antineoplastic agents,65+,Total,"9,282.00",0.2,0.2,"4,891",69
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,Total,"9,075.46",0.2,11.5,"277,404",70
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"8,924.72",0.2,0.7,"16,648",71
7,Ontario,N02BE,Anilides,65+,Total,"8,758.33",0.2,11.2,"269,581",72
7,Ontario,N05BA,Benzodiazepine derivatives,65+,Total,"8,446.11",0.2,8.2,"197,702",73
7,Ontario,A06AB,Contact laxatives,65+,Total,"8,351.89",0.2,9.3,"225,036",74
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,Total,"7,976.62",0.2,4.5,"108,860",75
7,Ontario,H02AB,Glucocorticoids,65+,Total,"7,839.40",0.2,11.1,"266,925",76
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"7,774.62",0.2,0,320,77
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,Total,"7,757.08",0.2,5.1,"123,123",78
7,Ontario,L01XC,Monoclonal antibodies,65+,Total,"7,646.75",0.2,0,581,79
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,Total,"7,359.52",0.2,1,"23,723",80
7,Ontario,C01DA,Organic nitrates,65+,Total,"7,229.44",0.2,4.5,"108,709",81
7,Ontario,L02BG,Aromatase inhibitors,65+,Total,"6,968.03",0.2,0.8,"19,005",82
7,Ontario,A06AD,Osmotically acting laxatives,65+,Total,"6,825.96",0.2,5.1,"123,250",83
7,Ontario,A02BA,H2-receptor antagonists,65+,Total,"6,690.52",0.2,4.3,"102,962",84
7,Ontario,C10AC,Bile acid sequestrants,65+,Total,"6,454.54",0.2,0.7,"16,692",85
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,Total,"6,383.51",0.1,1.4,"33,685",86
7,Ontario,D06AX,Other antibiotics for topical use,65+,Total,"6,292.70",0.1,6.6,"160,309",87
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,Total,"6,079.40",0.1,0.8,"18,643",88
7,Ontario,N04BC,Dopamine agonists,65+,Total,"5,994.60",0.1,0.9,"21,621",89
7,Ontario,A07AA,Antibiotics,65+,Total,"5,969.12",0.1,1.3,"32,564",90
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,Total,"5,714.05",0.1,0.4,"10,751",91
7,Ontario,A04AD,Other antiemetics,65+,Total,"5,572.73",0.1,0.5,"11,616",92
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"5,561.82",0.1,2.1,"51,839",93
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,Total,"5,224.72",0.1,0.9,"21,869",94
7,Ontario,B01AA,Vitamin K antagonists,65+,Total,"5,219.18",0.1,2.2,"53,608",95
7,Ontario,C03DA,Aldosterone antagonists,65+,Total,"5,218.37",0.1,2.4,"58,725",96
7,Ontario,C03AA,"Thiazides, plain",65+,Total,"5,067.73",0.1,9,"217,822",97
7,Ontario,C07AG,Alpha- and beta-blocking agents,65+,Total,"4,898.54",0.1,0.9,"20,532",98
7,Ontario,J01MA,Fluoroquinolones,65+,Total,"4,810.15",0.1,9.4,"226,811",99
7,Ontario,L01BA,Folic acid analogues,65+,Total,"4,800.17",0.1,1.1,"26,001",100
7,Ontario,S01LA,Antineovascularization agents,65+,M,"206,405.96",9.9,1.9,"20,934",1
7,Ontario,L01XE,Protein kinase inhibitors,65+,M,"123,528.64",5.9,0.3,"3,070",2
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,M,"103,060.68",5,10.4,"113,173",3
7,Ontario,L04AX,Other immunosuppressants,65+,M,"102,014.12",4.9,0.4,"4,586",4
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"76,893.47",3.7,7,"76,201",5
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"66,682.31",3.2,6.4,"70,090",6
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"64,064.51",3.1,7,"75,948",7
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"55,568.03",2.7,7.8,"85,374",8
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"54,321.76",2.6,5.5,"59,844",9
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"53,227.30",2.6,1.5,"15,905",10
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"52,630.13",2.5,0.2,"2,657",11
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,M,"51,631.57",2.5,60.1,"656,830",12
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,M,"43,758.83",2.1,0.2,"2,592",13
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"32,540.98",1.6,20.9,"228,490",14
7,Ontario,A02BC,Proton pump inhibitors,65+,M,"28,157.48",1.4,29.1,"318,451",15
7,Ontario,L02BB,Antiandrogens,65+,M,"27,586.65",1.3,0.8,"8,513",16
7,Ontario,R03BB,Anticholinergics,65+,M,"26,637.20",1.3,6.4,"69,414",17
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,M,"25,421.84",1.2,0,472,18
7,Ontario,C09AA,"ACE inhibitors, plain",65+,M,"24,948.19",1.2,29.2,"318,904",19
7,Ontario,C08CA,Dihydropyridine derivatives,65+,M,"24,173.79",1.2,23.2,"253,932",20
7,Ontario,L04AA,Selective immunosuppressants,65+,M,"22,371.42",1.1,0.5,"5,886",21
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"20,466.48",1,17.6,"192,387",22
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"17,610.31",0.8,0.8,"8,206",23
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"16,883.34",0.8,2.7,"29,122",24
7,Ontario,N06AX,Other antidepressants,65+,M,"16,583.92",0.8,9.2,"100,884",25
7,Ontario,L04AC,Interleukin inhibitors,65+,M,"16,470.05",0.8,0.1,988,26
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"16,266.82",0.8,7.3,"79,666",27
7,Ontario,N03AX,Other antiepileptics,65+,M,"15,835.86",0.8,8.1,"88,324",28
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"15,247.74",0.7,0.1,"1,480",29
7,Ontario,N04BA,Dopa and dopa derivatives,65+,M,"14,845.21",0.7,1.6,"17,842",30
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,M,"14,778.44",0.7,3.6,"39,836",31
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,M,"14,572.53",0.7,24.7,"269,946",32
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"14,296.78",0.7,10.1,"110,823",33
7,Ontario,S01EE,Prostaglandin analogues,65+,M,"14,230.05",0.7,5,"55,115",34
7,Ontario,B03XA,Other antianemic preparations,65+,M,"14,155.75",0.7,0.1,"1,421",35
7,Ontario,N02AA,Natural opium alkaloids,65+,M,"13,492.73",0.6,6.8,"74,360",36
7,Ontario,H01CB,Somatostatin and analogues,65+,M,"13,001.22",0.6,0.1,636,37
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"12,700.82",0.6,2.1,"23,055",38
7,Ontario,B01AE,Direct thrombin inhibitors,65+,M,"12,438.49",0.6,1.2,"12,828",39
7,Ontario,S01ED,Beta-blocking agents,65+,M,"12,362.05",0.6,4.9,"53,498",40
7,Ontario,L03AA,Colony-stimulating factors,65+,M,"12,234.12",0.6,0.2,"2,362",41
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,M,"12,105.04",0.6,7.5,"82,250",42
7,Ontario,C10AX,Other lipid-modifying agents,65+,M,"11,131.29",0.5,6.4,"69,394",43
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"10,184.61",0.5,1.1,"11,474",44
7,Ontario,C08DB,Benzothiazepine derivatives,65+,M,"9,783.58",0.5,3.1,"34,289",45
7,Ontario,B01AB,Heparin group,65+,M,"9,673.69",0.5,0.5,"5,939",46
7,Ontario,L04AD,Calcineurin inhibitors,65+,M,"9,235.40",0.4,0.3,"3,048",47
7,Ontario,R03BA,Glucocorticoids,65+,M,"9,220.63",0.4,4.1,"44,516",48
7,Ontario,M05BA,Bisphosphonates,65+,M,"9,105.15",0.4,3.2,"34,473",49
7,Ontario,N05AX,Other antipsychotics,65+,M,"8,893.65",0.4,1.4,"15,502",50
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,M,"8,084.53",0.4,5.1,"55,934",51
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,M,"8,033.08",0.4,0.8,"8,854",52
7,Ontario,A10BA,Biguanides,65+,M,"7,865.79",0.4,15.5,"169,233",53
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"7,764.24",0.4,0,430,54
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"7,617.89",0.4,0.3,"2,787",55
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"7,511.54",0.4,0.9,"9,530",56
7,Ontario,N06DA,Anticholinesterases,65+,M,"7,199.58",0.3,2.3,"24,826",57
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"7,188.39",0.3,0.5,"5,954",58
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"5,931.59",0.3,5.3,"58,075",59
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,M,"5,711.40",0.3,1,"10,710",60
7,Ontario,H03AA,Thyroid hormones,65+,M,"5,576.02",0.3,8.8,"96,622",61
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"5,449.14",0.3,12.1,"131,948",62
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,M,"5,414.25",0.3,7.1,"78,001",63
7,Ontario,A10BB,Sulfonylureas,65+,M,"5,391.23",0.3,6.9,"75,189",64
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"5,353.52",0.3,2.6,"28,518",65
7,Ontario,R01AD,Corticosteroids,65+,M,"5,353.13",0.3,7.7,"84,474",66
7,Ontario,C03CA,"Sulfonamides, plain",65+,M,"5,322.41",0.3,9.3,"101,740",67
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"5,030.28",0.2,0.8,"9,157",68
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"4,974.48",0.2,12.5,"136,046",69
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,M,"4,660.10",0.2,11.8,"129,220",70
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,M,"4,364.47",0.2,1.2,"12,850",71
7,Ontario,L01XX,Other antineoplastic agents,65+,M,"3,790.53",0.2,0.2,"2,112",72
7,Ontario,A06AB,Contact laxatives,65+,M,"3,600.82",0.2,9.4,"102,925",73
7,Ontario,J05AX,Other antivirals,65+,M,"3,527.44",0.2,0,439,74
7,Ontario,C01DA,Organic nitrates,65+,M,"3,423.35",0.2,5.4,"59,063",75
7,Ontario,C10AC,Bile acid sequestrants,65+,M,"3,214.49",0.2,0.6,"6,034",76
7,Ontario,H02AB,Glucocorticoids,65+,M,"3,196.73",0.2,10.4,"113,829",77
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,M,"3,075.17",0.1,4.8,"52,901",78
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,M,"2,992.91",0.1,1.4,"15,843",79
7,Ontario,A07AA,Antibiotics,65+,M,"2,955.14",0.1,1.2,"12,820",80
7,Ontario,C03DA,Aldosterone antagonists,65+,M,"2,874.81",0.1,2.7,"29,512",81
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"2,866.69",0.1,0.2,"1,799",82
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"2,853.64",0.1,2.4,"25,709",83
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,M,"2,853.30",0.1,1.1,"12,177",84
7,Ontario,D06AX,Other antibiotics for topical use,65+,M,"2,849.19",0.1,6.6,"71,942",85
7,Ontario,N02BE,Anilides,65+,M,"2,810.45",0.1,9.2,"100,941",86
7,Ontario,A06AD,Osmotically acting laxatives,65+,M,"2,793.53",0.1,5,"54,961",87
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,M,"2,775.97",0.1,0.7,"7,378",88
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,"2,748.41",0.1,1.8,"19,374",89
7,Ontario,N04BC,Dopamine agonists,65+,M,"2,722.83",0.1,0.8,"8,406",90
7,Ontario,C07AG,Alpha- and beta-blocking agents,65+,M,"2,699.64",0.1,1.1,"11,939",91
7,Ontario,N05BA,Benzodiazepine derivatives,65+,M,"2,657.26",0.1,5.9,"64,425",92
7,Ontario,B01AA,Vitamin K antagonists,65+,M,"2,567.23",0.1,2.7,"29,463",93
7,Ontario,A02BA,H2-receptor antagonists,65+,M,"2,558.41",0.1,3.7,"40,040",94
7,Ontario,C10AB,Fibrates,65+,M,"2,483.42",0.1,1.3,"13,844",95
7,Ontario,J05AE,Protease inhibitors,65+,M,"2,455.17",0.1,0,290,96
7,Ontario,L01XC,Monoclonal antibodies,65+,M,"2,389.01",0.1,0,184,97
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,"2,299.09",0.1,0,98,98
7,Ontario,J01MA,Fluoroquinolones,65+,M,"2,272.25",0.1,9.4,"103,202",99
7,Ontario,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"2,270.15",0.1,0.5,"5,679",100
7,Ontario,S01LA,Antineovascularization agents,65+,F,"279,533.30",12.8,2.1,"27,344",1
7,Ontario,L01XE,Protein kinase inhibitors,65+,F,"116,247.08",5.3,0.2,"3,008",2
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,F,"99,453.51",4.6,8.4,"110,189",3
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"77,201.59",3.5,0.3,"4,339",4
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"73,562.46",3.4,8.1,"106,683",5
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"70,295.21",3.2,8.8,"115,588",6
7,Ontario,L04AX,Other immunosuppressants,65+,F,"67,083.81",3.1,0.4,"5,309",7
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"63,595.75",2.9,5,"65,700",8
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"55,725.46",2.6,4.2,"55,539",9
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,F,"51,845.61",2.4,46,"606,409",10
7,Ontario,A02BC,Proton pump inhibitors,65+,F,"43,928.57",2,33.4,"440,335",11
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"42,153.19",1.9,3.8,"50,214",12
7,Ontario,L04AA,Selective immunosuppressants,65+,F,"41,132.41",1.9,0.6,"8,216",13
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"40,815.63",1.9,3.7,"49,337",14
7,Ontario,M05BA,Bisphosphonates,65+,F,"36,491.66",1.7,11.6,"152,567",15
7,Ontario,N06AX,Other antidepressants,65+,F,"35,361.05",1.6,14.3,"188,273",16
7,Ontario,C08CA,Dihydropyridine derivatives,65+,F,"32,281.31",1.5,23.3,"308,125",17
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"30,863.00",1.4,19.6,"258,949",18
7,Ontario,R03BB,Anticholinergics,65+,F,"26,863.46",1.2,5.5,"72,047",19
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,F,"26,079.98",1.2,13,"171,287",20
7,Ontario,C09AA,"ACE inhibitors, plain",65+,F,"24,982.57",1.1,20.6,"272,364",21
7,Ontario,N03AX,Other antiepileptics,65+,F,"23,330.19",1.1,10.3,"135,656",22
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,F,"23,011.43",1.1,5,"65,783",23
7,Ontario,N02AA,Natural opium alkaloids,65+,F,"19,798.74",0.9,8.1,"106,470",24
7,Ontario,L04AC,Interleukin inhibitors,65+,F,"18,788.37",0.9,0.1,"1,303",25
7,Ontario,H03AA,Thyroid hormones,65+,F,"18,596.96",0.9,22.4,"295,128",26
7,Ontario,S01EE,Prostaglandin analogues,65+,F,"18,386.35",0.8,5.2,"69,158",27
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,F,"18,197.48",0.8,20.1,"265,117",28
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"14,659.46",0.7,6.4,"84,204",29
7,Ontario,S01ED,Beta-blocking agents,65+,F,"14,648.12",0.7,4.7,"62,077",30
7,Ontario,C08DB,Benzothiazepine derivatives,65+,F,"14,514.88",0.7,3.8,"50,276",31
7,Ontario,N05AX,Other antipsychotics,65+,F,"14,200.87",0.7,2.1,"27,172",32
7,Ontario,R03BA,Glucocorticoids,65+,F,"14,121.16",0.6,5.4,"70,810",33
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,F,"14,105.68",0.6,0,259,34
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"13,673.44",0.6,4.2,"56,056",35
7,Ontario,L03AA,Colony-stimulating factors,65+,F,"13,538.26",0.6,0.2,"2,701",36
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"12,959.57",0.6,1.9,"25,622",37
7,Ontario,N06DA,Anticholinesterases,65+,F,"12,413.86",0.6,2.9,"38,519",38
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"12,239.49",0.6,0.4,"5,365",39
7,Ontario,H01CB,Somatostatin and analogues,65+,F,"12,049.81",0.6,0.1,736,40
7,Ontario,B03XA,Other antianemic preparations,65+,F,"11,648.11",0.5,0.1,"1,730",41
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"10,600.51",0.5,1.5,"20,445",42
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"10,506.36",0.5,0,647,43
7,Ontario,N04BA,Dopa and dopa derivatives,65+,F,"9,999.41",0.5,1,"13,792",44
7,Ontario,C10AX,Other lipid-modifying agents,65+,F,"9,693.53",0.4,4.3,"56,177",45
7,Ontario,B01AB,Heparin group,65+,F,"9,188.13",0.4,0.5,"7,094",46
7,Ontario,B01AE,Direct thrombin inhibitors,65+,F,"9,095.58",0.4,0.7,"9,076",47
7,Ontario,C03CA,"Sulfonamides, plain",65+,F,"8,877.19",0.4,9.7,"127,797",48
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"8,481.06",0.4,5.9,"77,260",49
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,F,"8,143.96",0.4,0.8,"10,631",50
7,Ontario,A10BA,Biguanides,65+,F,"8,034.71",0.4,11.3,"148,635",51
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"7,946.33",0.4,3.2,"41,772",52
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,F,"7,738.11",0.4,4,"53,216",53
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"7,192.22",0.3,0.7,"9,807",54
7,Ontario,L02BG,Aromatase inhibitors,65+,F,"6,957.11",0.3,1.4,"18,943",55
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"6,950.82",0.3,11.8,"155,397",56
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"6,442.86",0.3,4.3,"57,402",57
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"6,429.26",0.3,0.2,"3,093",58
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"6,383.30",0.3,14.7,"193,793",59
7,Ontario,R01AD,Corticosteroids,65+,F,"6,103.00",0.3,8.2,"107,763",60
7,Ontario,N02BE,Anilides,65+,F,"5,939.68",0.3,12.8,"168,425",61
7,Ontario,N05BA,Benzodiazepine derivatives,65+,F,"5,787.61",0.3,10.1,"133,246",62
7,Ontario,L04AD,Calcineurin inhibitors,65+,F,"5,637.40",0.3,0.1,"1,754",63
7,Ontario,L01XX,Other antineoplastic agents,65+,F,"5,491.47",0.3,0.2,"2,779",64
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"5,475.53",0.3,0,222,65
7,Ontario,L01XC,Monoclonal antibodies,65+,F,"5,257.74",0.2,0,397,66
7,Ontario,A10BB,Sulfonylureas,65+,F,"4,885.47",0.2,4.5,"59,286",67
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,F,"4,868.96",0.2,0.4,"5,043",68
7,Ontario,A06AB,Contact laxatives,65+,F,"4,745.20",0.2,9.2,"122,018",69
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,F,"4,676.87",0.2,5.3,"70,158",70
7,Ontario,H02AB,Glucocorticoids,65+,F,"4,640.71",0.2,11.6,"153,041",71
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,F,"4,411.82",0.2,11.2,"148,112",72
7,Ontario,A02BA,H2-receptor antagonists,65+,F,"4,129.53",0.2,4.8,"62,884",73
7,Ontario,A06AD,Osmotically acting laxatives,65+,F,"4,030.46",0.2,5.2,"68,254",74
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"3,893.36",0.2,0.6,"7,489",75
7,Ontario,C01DA,Organic nitrates,65+,F,"3,802.07",0.2,3.8,"49,610",76
7,Ontario,D06AX,Other antibiotics for topical use,65+,F,"3,441.80",0.2,6.7,"88,322",77
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,F,"3,388.48",0.2,1.4,"17,831",78
7,Ontario,C03AA,"Thiazides, plain",65+,F,"3,351.22",0.2,10.3,"135,518",79
7,Ontario,A04AD,Other antiemetics,65+,F,"3,311.77",0.2,0.5,"7,002",80
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,F,"3,303.26",0.2,0.9,"11,264",81
7,Ontario,N04BC,Dopamine agonists,65+,F,"3,270.41",0.2,1,"13,209",82
7,Ontario,C10AC,Bile acid sequestrants,65+,F,"3,240.05",0.1,0.8,"10,658",83
7,Ontario,L01BA,Folic acid analogues,65+,F,"3,195.96",0.1,1.3,"17,244",84
7,Ontario,M01AH,Coxibs,65+,F,"3,049.22",0.1,3.8,"50,375",85
7,Ontario,A07AA,Antibiotics,65+,F,"3,007.00",0.1,1.5,"19,734",86
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,F,"2,993.79",0.1,0.8,"10,870",87
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,"2,812.09",0.1,2.5,"32,455",88
7,Ontario,A06AA,"Softeners, emollients",65+,F,"2,747.26",0.1,4.6,"60,800",89
7,Ontario,B01AA,Vitamin K antagonists,65+,F,"2,650.83",0.1,1.8,"24,135",90
7,Ontario,A16AB,Enzymes,65+,F,**,**,**,**,91
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,F,"2,560.43",0.1,2.3,"30,841",92
7,Ontario,J01XE,Nitrofuran derivatives,65+,F,"2,550.38",0.1,8.9,"118,089",93
7,Ontario,J01MA,Fluoroquinolones,65+,F,"2,536.95",0.1,9.4,"123,582",94
7,Ontario,C03BA,"Sulfonamides, plain",65+,F,"2,501.57",0.1,4.3,"56,285",95
7,Ontario,N02AB,Phenylpiperidine derivatives,65+,F,"2,446.92",0.1,0.2,"3,091",96
7,Ontario,S01BA,"Corticosteroids, plain",65+,F,"2,438.74",0.1,5.1,"67,822",97
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,F,"2,370.32",0.1,0.7,"9,689",98
7,Ontario,C03DA,Aldosterone antagonists,65+,F,"2,342.43",0.1,2.2,"29,200",99
7,Ontario,A04AA,Serotonin (5HT3) antagonists,65+,F,"2,198.70",0.1,0.7,"9,574",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,Total,"221,546.62",9.4,0.2,"4,171",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"210,920.02",9,0.5,"11,437",2
7,Ontario,N05AX,Other antipsychotics,<65,Total,"126,040.74",5.4,3.6,"85,931",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"99,358.39",4.2,0.5,"11,277",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,Total,"81,239.99",3.5,1.8,"41,914",5
7,Ontario,L04AA,Selective immunosuppressants,<65,Total,"76,750.13",3.3,0.4,"9,773",6
7,Ontario,L01XE,Protein kinase inhibitors,<65,Total,"68,185.04",2.9,0.1,"1,826",7
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,Total,"55,686.10",2.4,5.4,"128,264",8
7,Ontario,L04AX,Other immunosuppressants,<65,Total,"49,763.31",2.1,0.2,"5,532",9
7,Ontario,N06AX,Other antidepressants,<65,Total,"44,818.96",1.9,8.1,"191,438",10
7,Ontario,N03AX,Other antiepileptics,<65,Total,"42,161.28",1.8,5.3,"126,048",11
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"37,594.60",1.6,10.8,"254,413",12
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"36,420.95",1.5,3.2,"74,501",13
7,Ontario,N02AA,Natural opium alkaloids,<65,Total,"35,265.79",1.5,3,"69,736",14
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"35,210.16",1.5,1.7,"40,459",15
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"33,184.52",1.4,4.2,"99,570",16
7,Ontario,L04AC,Interleukin inhibitors,<65,Total,"30,843.98",1.3,0.1,"2,223",17
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"30,624.48",1.3,1.5,"34,799",18
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"27,978.48",1.2,1.5,"36,215",19
7,Ontario,S01LA,Antineovascularization agents,<65,Total,"25,889.34",1.1,0.1,"2,842",20
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"24,697.27",1,0.5,"12,195",21
7,Ontario,A02BC,Proton pump inhibitors,<65,Total,"22,473.64",1,9.6,"225,065",22
7,Ontario,R03BA,Glucocorticoids,<65,Total,"21,808.29",0.9,8,"189,195",23
7,Ontario,L04AD,Calcineurin inhibitors,<65,Total,"21,278.30",0.9,0.3,"6,040",24
7,Ontario,L03AA,Colony-stimulating factors,<65,Total,"20,351.87",0.9,0.2,"3,634",25
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"20,117.20",0.9,1,"23,349",26
7,Ontario,A16AB,Enzymes,<65,Total,"18,498.06",0.8,0,39,27
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"17,250.21",0.7,1.3,"31,719",28
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,Total,"15,946.00",0.7,6.7,"158,453",29
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"14,622.85",0.6,0,"1,083",30
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"13,769.92",0.6,7.2,"170,086",31
7,Ontario,J05AX,Other antivirals,<65,Total,"13,529.97",0.6,0.1,"2,432",32
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,Total,"13,510.36",0.6,0.1,"1,276",33
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"12,876.39",0.5,6.6,"156,616",34
7,Ontario,N05AE,Indole derivatives,<65,Total,"12,847.84",0.5,0.4,"10,503",35
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"12,783.87",0.5,0.2,"4,057",36
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,Total,"12,120.18",0.5,2.3,"53,170",37
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"11,453.64",0.5,0,33,38
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"11,316.55",0.5,15,"352,309",39
7,Ontario,J01CA,Penicillins with extended spectrum,<65,Total,"10,804.59",0.5,21.4,"503,244",40
7,Ontario,R03BB,Anticholinergics,<65,Total,"10,778.65",0.5,1.3,"30,839",41
7,Ontario,L03AB,Interferons,<65,Total,"10,517.84",0.4,0,601,42
7,Ontario,A04AD,Other antiemetics,<65,Total,"10,478.50",0.4,0.6,"13,344",43
7,Ontario,N03AG,Fatty acid derivatives,<65,Total,"10,462.13",0.4,1.1,"26,880",44
7,Ontario,N05BA,Benzodiazepine derivatives,<65,Total,"9,251.84",0.4,4,"94,081",45
7,Ontario,B01AB,Heparin group,<65,Total,"8,886.62",0.4,0.2,"4,335",46
7,Ontario,H01CB,Somatostatin and analogues,<65,Total,"8,812.30",0.4,0,617,47
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,Total,"8,707.97",0.4,0.6,"13,187",48
7,Ontario,N03AE,Benzodiazepine derivatives,<65,Total,"8,442.22",0.4,2.4,"55,458",49
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"8,385.31",0.4,0.1,"3,357",50
7,Ontario,J05AE,Protease inhibitors,<65,Total,"8,361.81",0.4,0.1,"1,204",51
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"8,337.46",0.4,0.6,"14,745",52
7,Ontario,V03AC,Iron-chelating agents,<65,Total,"8,302.83",0.4,0,340,53
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"8,040.42",0.3,2.1,"50,131",54
7,Ontario,C09AA,"ACE inhibitors, plain",<65,Total,"8,036.97",0.3,3.5,"82,984",55
7,Ontario,R07AX,Other respiratory system products,<65,Total,"7,841.76",0.3,0,35,56
7,Ontario,G02BA,Intrauterine contraceptives,<65,Total,"7,681.79",0.3,0.9,"20,127",57
7,Ontario,R01AD,Corticosteroids,<65,Total,"7,539.71",0.3,6,"142,324",58
7,Ontario,L03AX,Other immunostimulants,<65,Total,"7,518.25",0.3,0,710,59
7,Ontario,C08CA,Dihydropyridine derivatives,<65,Total,"6,567.03",0.3,2.6,"62,142",60
7,Ontario,V03AB,Antidotes,<65,Total,"6,546.87",0.3,1.4,"33,854",61
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,"6,419.19",0.3,2.4,"55,761",62
7,Ontario,N03AF,Carboxamide derivatives,<65,Total,"6,222.72",0.3,0.5,"12,779",63
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"6,113.73",0.3,0.8,"19,670",64
7,Ontario,V06,General nutrients,<65,Total,"6,071.77",0.3,0,195,65
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,Total,"5,784.85",0.2,0,46,66
7,Ontario,M01AE,Propionic acid derivatives,<65,Total,"5,657.21",0.2,8,"189,090",67
7,Ontario,H03AA,Thyroid hormones,<65,Total,"5,623.47",0.2,3.3,"76,896",68
7,Ontario,D06AX,Other antibiotics for topical use,<65,Total,"5,505.50",0.2,5.7,"133,886",69
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,Total,"5,330.46",0.2,7.5,"176,206",70
7,Ontario,J01FA,Macrolides,<65,Total,"5,313.72",0.2,9,"212,864",71
7,Ontario,M03BX,Other centrally acting agents,<65,Total,"5,205.73",0.2,2.1,"49,519",72
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,Total,"5,092.69",0.2,0.3,"7,556",73
7,Ontario,V06C,Infant formulas,<65,Total,"5,024.07",0.2,0.1,"2,958",74
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"4,980.00",0.2,1.9,"44,209",75
7,Ontario,L01XC,Monoclonal antibodies,<65,Total,"4,525.27",0.2,0,394,76
7,Ontario,J01DB,First-generation cephalosporins,<65,Total,"4,484.50",0.2,5.2,"123,702",77
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,Total,"4,443.44",0.2,2.4,"57,712",78
7,Ontario,A10BA,Biguanides,<65,Total,"4,441.56",0.2,2.9,"68,729",79
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"4,400.60",0.2,0.8,"19,714",80
7,Ontario,A09AA,Enzyme preparations,<65,Total,"4,236.34",0.2,0.1,"2,903",81
7,Ontario,D10AF,Antiinfectives for treatment of acne,<65,Total,"4,223.33",0.2,2.4,"55,972",82
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"4,173.30",0.2,0,230,83
7,Ontario,J02AC,Triazole derivatives,<65,Total,"4,014.30",0.2,1,"24,314",84
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"3,800.55",0.2,1.3,"30,380",85
7,Ontario,N02BE,Anilides,<65,Total,"3,732.93",0.2,5.1,"119,724",86
7,Ontario,H02AB,Glucocorticoids,<65,Total,"3,615.17",0.2,5.5,"129,291",87
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"3,594.65",0.2,0.3,"7,267",88
7,Ontario,D10BA,Retinoids for treatment of acne,<65,Total,"3,578.80",0.2,0.5,"12,454",89
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,Total,"3,489.88",0.1,0.4,"9,734",90
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"3,398.28",0.1,0.1,"3,091",91
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,"3,392.48",0.1,0,852,92
7,Ontario,J01GB,Other aminoglycosides,<65,Total,"3,380.28",0.1,0,700,93
7,Ontario,A06AB,Contact laxatives,<65,Total,"3,377.18",0.1,2.4,"56,133",94
7,Ontario,A02BA,H2-receptor antagonists,<65,Total,"3,267.58",0.1,2.3,"54,365",95
7,Ontario,L01XX,Other antineoplastic agents,<65,Total,"3,255.21",0.1,0.1,"1,199",96
7,Ontario,C10AX,Other lipid-modifying agents,<65,Total,"3,179.48",0.1,0.6,"13,833",97
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,Total,"3,154.88",0.1,0.4,"9,658",98
7,Ontario,M05BA,Bisphosphonates,<65,Total,"3,138.60",0.1,0.5,"12,290",99
7,Ontario,N02AB,Phenylpiperidine derivatives,<65,Total,"3,110.82",0.1,0.1,"2,484",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,M,"144,386.53",11.7,0.3,"2,706",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"113,337.97",9.2,0.5,"5,739",2
7,Ontario,N05AX,Other antipsychotics,<65,M,"83,610.90",6.8,4.4,"47,507",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"74,939.57",6.1,0.8,"8,596",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,M,"46,552.06",3.8,2.2,"24,130",5
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,M,"36,146.31",2.9,7.8,"84,210",6
7,Ontario,L01XE,Protein kinase inhibitors,<65,M,"32,535.20",2.6,0.1,846,7
7,Ontario,L04AA,Selective immunosuppressants,<65,M,"25,613.80",2.1,0.4,"4,088",8
7,Ontario,L04AX,Other immunosuppressants,<65,M,"25,524.11",2.1,0.2,"2,166",9
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"19,566.46",1.6,4.7,"51,145",10
7,Ontario,N03AX,Other antiepileptics,<65,M,"19,439.31",1.6,4.9,"53,212",11
7,Ontario,N06AX,Other antidepressants,<65,M,"18,106.92",1.5,7.1,"76,271",12
7,Ontario,N02AA,Natural opium alkaloids,<65,M,"18,105.05",1.5,2.9,"30,825",13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"17,828.24",1.4,1.9,"20,668",14
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"16,192.90",1.3,1.7,"18,573",15
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,M,"15,650.81",1.3,8.8,"94,908",16
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"15,268.18",1.2,2.8,"30,631",17
7,Ontario,L04AC,Interleukin inhibitors,<65,M,"14,943.16",1.2,0.1,"1,002",18
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"14,560.13",1.2,1.8,"18,903",19
7,Ontario,S01LA,Antineovascularization agents,<65,M,"14,511.10",1.2,0.1,"1,599",20
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"14,451.25",1.2,0.6,"7,013",21
7,Ontario,A16AB,Enzymes,<65,M,**,**,**,**,22
7,Ontario,L04AD,Calcineurin inhibitors,<65,M,"12,786.71",1,0.3,"3,612",23
7,Ontario,R03BA,Glucocorticoids,<65,M,"10,478.65",0.8,9,"96,633",24
7,Ontario,J05AX,Other antivirals,<65,M,"10,062.95",0.8,0.2,"1,643",25
7,Ontario,A02BC,Proton pump inhibitors,<65,M,"9,966.99",0.8,9,"96,916",26
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"9,743.28",0.8,1.1,"11,398",27
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"9,079.99",0.7,1.5,"16,308",28
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,29
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,M,"8,543.73",0.7,7.8,"84,686",30
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,"7,114.02",0.6,0,21,31
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,M,"6,524.33",0.5,2.6,"27,870",32
7,Ontario,J05AE,Protease inhibitors,<65,M,"6,516.87",0.5,0.1,900,33
7,Ontario,L03AA,Colony-stimulating factors,<65,M,"6,326.87",0.5,0.1,"1,203",34
7,Ontario,N03AG,Fatty acid derivatives,<65,M,"6,295.61",0.5,1.4,"15,389",35
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"6,147.89",0.5,0.2,"1,792",36
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"6,022.22",0.5,6.4,"69,363",37
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"5,472.34",0.4,15.8,"170,631",38
7,Ontario,R03BB,Anticholinergics,<65,M,"5,234.85",0.4,1.3,"14,419",39
7,Ontario,J01CA,Penicillins with extended spectrum,<65,M,"5,213.20",0.4,21.9,"236,815",40
7,Ontario,N05AE,Indole derivatives,<65,M,"5,156.39",0.4,0.4,"3,995",41
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,M,"5,069.96",0.4,0.7,"7,196",42
7,Ontario,A04AD,Other antiemetics,<65,M,"4,756.16",0.4,0.5,"5,550",43
7,Ontario,C09AA,"ACE inhibitors, plain",<65,M,"4,536.36",0.4,4.3,"46,808",44
7,Ontario,N05BA,Benzodiazepine derivatives,<65,M,"4,488.95",0.4,3.5,"38,281",45
7,Ontario,R07AX,Other respiratory system products,<65,M,"4,347.64",0.4,0,19,46
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"4,254.02",0.3,0,322,47
7,Ontario,H01CB,Somatostatin and analogues,<65,M,"4,159.23",0.3,0,260,48
7,Ontario,N03AE,Benzodiazepine derivatives,<65,M,"4,150.74",0.3,2.1,"23,187",49
7,Ontario,V03AC,Iron-chelating agents,<65,M,"3,857.81",0.3,0,157,50
7,Ontario,B01AB,Heparin group,<65,M,"3,770.47",0.3,0.2,"1,882",51
7,Ontario,N03AF,Carboxamide derivatives,<65,M,"3,485.68",0.3,0.6,"6,706",52
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"3,431.47",0.3,1.7,"17,962",53
7,Ontario,C08CA,Dihydropyridine derivatives,<65,M,"3,393.56",0.3,3,"32,026",54
7,Ontario,R01AD,Corticosteroids,<65,M,"3,355.02",0.3,5.8,"62,583",55
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"3,200.06",0.3,0.1,"1,101",56
7,Ontario,V03AB,Antidotes,<65,M,"3,176.17",0.3,1.4,"15,378",57
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"2,991.63",0.2,0.9,"9,627",58
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,M,"2,976.77",0.2,0.8,"8,305",59
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"2,889.62",0.2,0.1,702,60
7,Ontario,V06C,Infant formulas,<65,M,**,**,**,**,61
7,Ontario,L03AB,Interferons,<65,M,"2,774.18",0.2,0,165,62
7,Ontario,D06AX,Other antibiotics for topical use,<65,M,"2,643.63",0.2,5.9,"63,991",63
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,M,"2,573.07",0.2,0.3,"3,320",64
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,M,"2,569.55",0.2,3,"32,905",65
7,Ontario,V06,General nutrients,<65,M,"2,506.71",0.2,0,81,66
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,M,"2,504.90",0.2,7.4,"80,314",67
7,Ontario,J01FA,Macrolides,<65,M,"2,485.38",0.2,8.8,"95,381",68
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,**,69
7,Ontario,A09AA,Enzyme preparations,<65,M,"2,386.08",0.2,0.1,"1,463",70
7,Ontario,M01AE,Propionic acid derivatives,<65,M,"2,358.68",0.2,7.3,"78,504",71
7,Ontario,M03BX,Other centrally acting agents,<65,M,"2,343.82",0.2,1.9,"20,425",72
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"2,293.31",0.2,1.9,"20,326",73
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"2,185.57",0.2,0.2,"1,981",74
7,Ontario,J01DB,First-generation cephalosporins,<65,M,"2,169.77",0.2,5.4,"58,023",75
7,Ontario,A10BA,Biguanides,<65,M,"2,165.34",0.2,3,"32,493",76
7,Ontario,L03AX,Other immunostimulants,<65,M,"2,163.44",0.2,0,197,77
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"2,147.97",0.2,0.1,"1,106",78
7,Ontario,J02AC,Triazole derivatives,<65,M,"2,029.04",0.2,0.2,"2,571",79
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"2,013.55",0.2,0.4,"3,897",80
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"1,947.62",0.2,1.4,"15,038",81
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"1,933.72",0.2,0.8,"8,380",82
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,M,"1,889.87",0.2,0.4,"4,804",83
7,Ontario,L02BX,Other hormone antagonists and related agents,<65,M,"1,868.15",0.2,0,119,84
7,Ontario,J01GB,Other aminoglycosides,<65,M,"1,851.98",0.1,0,366,85
7,Ontario,N05AF,Thioxanthene derivatives,<65,M,"1,823.61",0.1,0.2,"2,413",86
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"1,768.58",0.1,0.9,"9,998",87
7,Ontario,C10AX,Other lipid-modifying agents,<65,M,"1,685.30",0.1,0.7,"7,646",88
7,Ontario,N02BE,Anilides,<65,M,"1,681.72",0.1,5,"53,929",89
7,Ontario,H02AB,Glucocorticoids,<65,M,"1,662.92",0.1,5.5,"59,687",90
7,Ontario,D10BA,Retinoids for treatment of acne,<65,M,"1,660.58",0.1,0.5,"5,711",91
7,Ontario,D10AF,Antiinfectives for treatment of acne,<65,M,"1,656.54",0.1,1.9,"20,801",92
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,650.92",0.1,0.5,"5,790",93
7,Ontario,A07AA,Antibiotics,<65,M,"1,647.72",0.1,0.9,"10,053",94
7,Ontario,L01AX,Other alkylating agents,<65,M,"1,587.27",0.1,0,205,95
7,Ontario,H03AA,Thyroid hormones,<65,M,"1,537.56",0.1,1.8,"19,178",96
7,Ontario,A06AB,Contact laxatives,<65,M,"1,523.78",0.1,2.3,"24,400",97
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,"1,472.76",0.1,0.2,"1,788",98
7,Ontario,A02BA,H2-receptor antagonists,<65,M,"1,441.85",0.1,2.1,"22,541",99
7,Ontario,L02BB,Antiandrogens,<65,M,"1,430.75",0.1,0,216,100
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"97,568.22",8.8,0.4,"5,697",1
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,F,"77,005.70",6.9,0.1,"1,462",2
7,Ontario,L04AA,Selective immunosuppressants,<65,F,"51,121.10",4.6,0.4,"5,679",3
7,Ontario,N05AX,Other antipsychotics,<65,F,"42,236.03",3.8,3,"38,269",4
7,Ontario,L01XE,Protein kinase inhibitors,<65,F,"35,644.39",3.2,0.1,979,5
7,Ontario,N07BC,Drugs used in opioid dependence,<65,F,"34,631.48",3.1,1.4,"17,718",6
7,Ontario,N06AX,Other antidepressants,<65,F,"26,651.25",2.4,9,"114,663",7
7,Ontario,L04AX,Other immunosuppressants,<65,F,"24,238.43",2.2,0.3,"3,362",8
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"23,235.19",2.1,0.2,"2,554",9
7,Ontario,N03AX,Other antiepileptics,<65,F,"22,662.34",2,5.7,"72,560",10
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,F,"21,892.28",2,12.5,"159,009",11
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"21,091.96",1.9,3.4,"43,753",12
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,F,"19,514.00",1.8,3.5,"43,992",13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"17,318.64",1.6,1.5,"19,680",14
7,Ontario,N02AA,Natural opium alkaloids,<65,F,"17,145.73",1.5,3,"38,809",15
7,Ontario,L04AC,Interleukin inhibitors,<65,F,"15,900.82",1.4,0.1,"1,221",16
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"14,287.51",1.3,1.3,"16,045",17
7,Ontario,L03AA,Colony-stimulating factors,<65,F,"14,007.71",1.3,0.2,"2,429",18
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"13,757.32",1.2,13.4,"169,949",19
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"13,569.56",1.2,3.8,"48,179",20
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"13,318.02",1.2,1.3,"17,166",21
7,Ontario,A02BC,Proton pump inhibitors,<65,F,"12,453.64",1.1,10,"127,237",22
7,Ontario,S01LA,Antineovascularization agents,<65,F,"11,372.22",1,0.1,"1,242",23
7,Ontario,R03BA,Glucocorticoids,<65,F,"11,297.91",1,7.3,"92,344",24
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"10,368.83",0.9,0.1,761,25
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"10,311.17",0.9,0.9,"11,867",26
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"10,212.12",0.9,0.4,"5,167",27
7,Ontario,L04AD,Calcineurin inhibitors,<65,F,"8,490.21",0.8,0.2,"2,425",28
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"8,138.46",0.7,1.2,"15,343",29
7,Ontario,L03AB,Interferons,<65,F,"7,743.66",0.7,0,436,30
7,Ontario,N05AE,Indole derivatives,<65,F,"7,682.16",0.7,0.5,"6,500",31
7,Ontario,G02BA,Intrauterine contraceptives,<65,F,"7,666.65",0.7,1.6,"20,089",32
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,F,"7,345.58",0.7,5.7,"73,064",33
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"6,842.17",0.6,6.8,"86,920",34
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"6,622.29",0.6,0.2,"2,261",35
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"6,414.79",0.6,4.4,"55,728",36
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"5,830.37",0.5,14.2,"181,239",37
7,Ontario,A04AD,Other antiemetics,<65,F,"5,714.83",0.5,0.6,"7,784",38
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,F,"5,592.11",0.5,2,"25,278",39
7,Ontario,J01CA,Penicillins with extended spectrum,<65,F,"5,576.47",0.5,20.9,"265,585",40
7,Ontario,R03BB,Anticholinergics,<65,F,"5,527.30",0.5,1.3,"16,369",41
7,Ontario,L03AX,Other immunostimulants,<65,F,"5,354.82",0.5,0,513,42
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"5,332.16",0.5,0.4,"5,062",43
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"5,172.06",0.5,0.2,"2,250",44
7,Ontario,B01AB,Heparin group,<65,F,"5,112.84",0.5,0.2,"2,446",45
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,46
7,Ontario,N05BA,Benzodiazepine derivatives,<65,F,"4,752.62",0.4,4.4,"55,611",47
7,Ontario,H01CB,Somatostatin and analogues,<65,F,"4,653.07",0.4,0,357,48
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"4,596.96",0.4,2.5,"31,973",49
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,F,"4,454.12",0.4,1.1,"13,847",50
7,Ontario,V03AC,Iron-chelating agents,<65,F,"4,445.02",0.4,0,183,51
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"4,339.63",0.4,0,12,52
7,Ontario,N03AE,Benzodiazepine derivatives,<65,F,"4,285.34",0.4,2.5,"32,179",53
7,Ontario,A16AB,Enzymes,<65,F,**,**,**,**,54
7,Ontario,R01AD,Corticosteroids,<65,F,"4,165.80",0.4,6.2,"79,349",55
7,Ontario,N03AG,Fatty acid derivatives,<65,F,"4,156.21",0.4,0.9,"11,445",56
7,Ontario,H03AA,Thyroid hormones,<65,F,"4,074.30",0.4,4.5,"57,502",57
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,F,"3,624.90",0.3,0.5,"5,970",58
7,Ontario,V06,General nutrients,<65,F,"3,565.06",0.3,0,114,59
7,Ontario,R07AX,Other respiratory system products,<65,F,"3,494.12",0.3,0,16,60
7,Ontario,C09AA,"ACE inhibitors, plain",<65,F,"3,471.11",0.3,2.8,"35,792",61
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,62
7,Ontario,V03AB,Antidotes,<65,F,"3,363.60",0.3,1.5,"18,460",63
7,Ontario,J05AX,Other antivirals,<65,F,"3,346.25",0.3,0.1,769,64
7,Ontario,M01AE,Propionic acid derivatives,<65,F,"3,280.43",0.3,8.6,"109,807",65
7,Ontario,L01XC,Monoclonal antibodies,<65,F,"3,271.52",0.3,0,279,66
7,Ontario,C08CA,Dihydropyridine derivatives,<65,F,"3,140.00",0.3,2.3,"29,737",67
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"3,020.89",0.3,0,161,68
7,Ontario,M03BX,Other centrally acting agents,<65,F,"2,854.15",0.3,2.3,"28,900",69
7,Ontario,D06AX,Other antibiotics for topical use,<65,F,"2,852.69",0.3,5.5,"69,689",70
7,Ontario,J01FA,Macrolides,<65,F,"2,818.24",0.3,9.2,"117,114",71
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,F,"2,811.20",0.3,7.5,"95,486",72
7,Ontario,N03AF,Carboxamide derivatives,<65,F,"2,732.32",0.2,0.5,"6,051",73
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"2,661.38",0.2,1.9,"23,662",74
7,Ontario,D10AF,Antiinfectives for treatment of acne,<65,F,"2,558.47",0.2,2.8,"35,060",75
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,F,"2,513.89",0.2,0.3,"4,227",76
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"2,460.28",0.2,0.9,"11,306",77
7,Ontario,G03XB,Progesterone receptor modulators,<65,F,**,**,**,**,78
7,Ontario,J01DB,First-generation cephalosporins,<65,F,"2,310.20",0.2,5.1,"65,508",79
7,Ontario,A10BA,Biguanides,<65,F,"2,259.66",0.2,2.8,"35,913",80
7,Ontario,V06C,Infant formulas,<65,F,**,**,**,**,81
7,Ontario,L01XX,Other antineoplastic agents,<65,F,"2,232.87",0.2,0,594,82
7,Ontario,M05BA,Bisphosphonates,<65,F,"2,193.39",0.2,0.7,"8,859",83
7,Ontario,G03AC,Progestogens,<65,F,"2,157.40",0.2,1.9,"23,688",84
7,Ontario,B03AA,"Iron bivalent, oral preparations",<65,F,"2,077.73",0.2,3.3,"41,490",85
7,Ontario,N02BE,Anilides,<65,F,"2,036.22",0.2,5.1,"65,131",86
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"2,024.59",0.2,1.6,"20,334",87
7,Ontario,J02AC,Triazole derivatives,<65,F,"1,984.25",0.2,1.7,"21,696",88
7,Ontario,H02AB,Glucocorticoids,<65,F,"1,948.20",0.2,5.5,"69,455",89
7,Ontario,D10BA,Retinoids for treatment of acne,<65,F,"1,916.96",0.2,0.5,"6,736",90
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,F,"1,859.62",0.2,1.9,"24,556",91
7,Ontario,A09AA,Enzyme preparations,<65,F,"1,847.97",0.2,0.1,"1,439",92
7,Ontario,A06AB,Contact laxatives,<65,F,"1,847.49",0.2,2.5,"31,573",93
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,F,"1,840.49",0.2,0.4,"5,141",94
7,Ontario,A02BA,H2-receptor antagonists,<65,F,"1,817.92",0.2,2.5,"31,633",95
7,Ontario,J05AE,Protease inhibitors,<65,F,"1,794.33",0.2,0,293,96
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"1,750.64",0.2,0.9,"11,540",97
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"1,735.05",0.2,0.2,"2,813",98
7,Ontario,N02AB,Phenylpiperidine derivatives,<65,F,"1,704.64",0.2,0.1,"1,393",99
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,F,"1,591.62",0.1,0.4,"4,907",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"69,056.38",19.1,0.4,"3,283",1
8,Manitoba,L01XE,Protein kinase inhibitors,Total,Total,"24,003.97",6.6,0.1,788,2
8,Manitoba,L04AX,Other immunosuppressants,Total,Total,"19,963.59",5.5,0.3,"2,484",3
8,Manitoba,L04AA,Selective immunosuppressants,Total,Total,"15,030.45",4.2,0.3,"2,328",4
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,Total,"12,375.47",3.4,0,252,5
8,Manitoba,L04AC,Interleukin inhibitors,Total,Total,"9,536.63",2.6,0.1,732,6
8,Manitoba,N05AX,Other antipsychotics,Total,Total,"6,937.04",1.9,1.5,"12,509",7
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,576.34",1.8,4,"34,030",8
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"6,377.83",1.8,2.4,"20,595",9
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"6,287.70",1.7,0.1,"1,098",10
8,Manitoba,N06AX,Other antidepressants,Total,Total,"5,431.86",1.5,7.6,"64,527",11
8,Manitoba,A02BC,Proton pump inhibitors,Total,Total,"5,102.41",1.4,16.7,"141,236",12
8,Manitoba,N02AA,Natural opium alkaloids,Total,Total,"4,718.58",1.3,2.1,"17,357",13
8,Manitoba,N03AX,Other antiepileptics,Total,Total,"4,715.13",1.3,5.2,"43,515",14
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,Total,"4,676.98",1.3,1.7,"14,489",15
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,353.21",1.2,10.7,"90,690",16
8,Manitoba,L03AB,Interferons,Total,Total,"4,347.02",1.2,0,281,17
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,159.84",1.1,17.5,"147,947",18
8,Manitoba,H01CB,Somatostatin and analogues,Total,Total,"4,026.29",1.1,0,171,19
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,Total,"3,715.14",1,2.2,"18,281",20
8,Manitoba,A16AB,Enzymes,Total,Total,"3,526.07",1,0,8,21
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"3,114.39",0.9,1.2,"10,190",22
8,Manitoba,L02BB,Antiandrogens,Total,Total,"2,794.85",0.8,0.1,"1,168",23
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,Total,"2,767.82",0.8,9.2,"77,700",24
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,Total,"2,753.44",0.8,10.1,"85,652",25
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,Total,"2,500.12",0.7,0,100,26
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,Total,"2,451.78",0.7,0.3,"2,183",27
8,Manitoba,L04AD,Calcineurin inhibitors,Total,Total,"2,438.98",0.7,0.1,848,28
8,Manitoba,L03AX,Other immunostimulants,Total,Total,"2,377.92",0.7,0,290,29
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,371.20",0.7,1.2,"10,530",30
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"2,348.58",0.6,12,"101,015",31
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"2,254.07",0.6,0,180,32
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,Total,"2,215.63",0.6,7.7,"65,389",33
8,Manitoba,B02AB,Proteinase inhibitors,Total,Total,"2,147.89",0.6,0,19,34
8,Manitoba,H03AA,Thyroid hormones,Total,Total,"2,040.91",0.6,9.9,"83,554",35
8,Manitoba,L01XC,Monoclonal antibodies,Total,Total,"2,035.71",0.6,0,205,36
8,Manitoba,R03BB,Anticholinergics,Total,Total,"1,984.57",0.5,1.8,"14,975",37
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"1,879.16",0.5,0.6,"4,766",38
8,Manitoba,A10BA,Biguanides,Total,Total,"1,823.72",0.5,7.8,"66,195",39
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,Total,"1,819.92",0.5,6.3,"53,304",40
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"1,719.84",0.5,0.8,"7,034",41
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,717.74",0.5,0.8,"7,143",42
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,683.49",0.5,2.2,"18,933",43
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"1,646.31",0.5,0,168,44
8,Manitoba,J05AE,Protease inhibitors,Total,Total,"1,612.25",0.4,0,302,45
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,Total,"1,492.14",0.4,5.4,"45,745",46
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,428.66",0.4,1.5,"12,249",47
8,Manitoba,L02BG,Aromatase inhibitors,Total,Total,"1,428.60",0.4,0.6,"5,228",48
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,424.83",0.4,6.5,"54,907",49
8,Manitoba,L01XX,Other antineoplastic agents,Total,Total,"1,412.69",0.4,0.1,747,50
8,Manitoba,B01AB,Heparin group,Total,Total,"1,412.38",0.4,0.2,"1,718",51
8,Manitoba,R03BA,Glucocorticoids,Total,Total,"1,406.64",0.4,3.5,"29,226",52
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,402.58",0.4,3,"25,008",53
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,374.90",0.4,11.3,"95,450",54
8,Manitoba,A04AD,Other antiemetics,Total,Total,"1,341.70",0.4,0.3,"2,565",55
8,Manitoba,C03CA,"Sulfonamides, plain",Total,Total,"1,333.17",0.4,3.7,"30,859",56
8,Manitoba,A10BB,Sulfonylureas,Total,Total,"1,268.22",0.4,3.9,"32,592",57
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,221.14",0.3,0.9,"7,337",58
8,Manitoba,J05AX,Other antivirals,Total,Total,"1,211.69",0.3,0,345,59
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,Total,"1,211.27",0.3,2.1,"17,372",60
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,**,**,**,*,61
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,114.65",0.3,0.6,"5,254",62
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"1,097.31",0.3,0.2,"1,291",63
8,Manitoba,N03AG,Fatty acid derivatives,Total,Total,983.94,0.3,0.5,"3,898",64
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,981.9,0.3,0.4,"3,158",65
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,816.37,0.2,3.1,"26,385",66
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,Total,811.99,0.2,0.5,"3,804",67
8,Manitoba,H02AB,Glucocorticoids,Total,Total,811.72,0.2,6.8,"57,677",68
8,Manitoba,S01EE,Prostaglandin analogues,Total,Total,730.52,0.2,1.6,"13,182",69
8,Manitoba,N03AF,Carboxamide derivatives,Total,Total,725.82,0.2,0.4,"3,263",70
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,Total,706.71,0.2,1,"8,590",71
8,Manitoba,R01AD,Corticosteroids,Total,Total,674.06,0.2,8.5,"72,201",72
8,Manitoba,N02BE,Anilides,Total,Total,671.97,0.2,1.9,"15,947",73
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,657.39,0.2,0.4,"3,332",74
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,Total,648.43,0.2,0,96,75
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,Total,644.2,0.2,0.1,"1,191",76
8,Manitoba,M03BX,Other centrally acting agents,Total,Total,630.53,0.2,3.2,"26,902",77
8,Manitoba,A16AX,Various alimentary tract and metabolism products,Total,Total,627.69,0.2,0,10,78
8,Manitoba,S01ED,Beta-blocking agents,Total,Total,620.02,0.2,1.3,"11,357",79
8,Manitoba,L01AX,Other alkylating agents,Total,Total,614.88,0.2,0,85,80
8,Manitoba,A16AA,Amino acids and derivatives,Total,Total,608.81,0.2,0,102,81
8,Manitoba,N05AE,Indole derivatives,Total,Total,604.73,0.2,0.1,649,82
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,Total,599.65,0.2,0.6,"4,764",83
8,Manitoba,A02BA,H2-receptor antagonists,Total,Total,591.2,0.2,2.5,"21,286",84
8,Manitoba,M01AE,Propionic acid derivatives,Total,Total,570.29,0.2,7.7,"65,297",85
8,Manitoba,C03AA,"Thiazides, plain",Total,Total,553.46,0.2,4.8,"40,200",86
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,Total,551.01,0.2,3.5,"29,142",87
8,Manitoba,B01AA,Vitamin K antagonists,Total,Total,535.71,0.1,1.1,"8,922",88
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,Total,533.01,0.1,0.2,"1,270",89
8,Manitoba,A09AA,Enzyme preparations,Total,Total,532.94,0.1,0.1,"1,062",90
8,Manitoba,M04AA,Preparations inhibiting uric acid production,Total,Total,510.34,0.1,2.2,"18,762",91
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,Total,504.11,0.1,2,"17,113",92
8,Manitoba,A12BA,Potassium,Total,Total,483.79,0.1,1.2,"10,178",93
8,Manitoba,R07AX,Other respiratory system products,Total,Total,**,**,**,*,94
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",Total,Total,481.35,0.1,8.2,"69,070",95
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",Total,Total,462.88,0.1,1,"8,722",96
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,461,0.1,2.8,"23,635",97
8,Manitoba,A05AA,Bile acids and derivatives,Total,Total,456.09,0.1,0.1,759,98
8,Manitoba,C10AB,Fibrates,Total,Total,452.73,0.1,0.7,"6,121",99
8,Manitoba,C01DA,Organic nitrates,Total,Total,448.5,0.1,1.3,"10,922",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"32,628.35",18.7,0.4,"1,465",1
8,Manitoba,L01XE,Protein kinase inhibitors,Total,M,"12,990.69",7.5,0.1,434,2
8,Manitoba,L04AX,Other immunosuppressants,Total,M,"9,848.84",5.6,0.3,"1,021",3
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,M,"8,635.15",5,0,177,4
8,Manitoba,L04AA,Selective immunosuppressants,Total,M,"5,343.27",3.1,0.2,927,5
8,Manitoba,L04AC,Interleukin inhibitors,Total,M,"4,707.07",2.7,0.1,351,6
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"4,362.97",2.5,0.2,730,7
8,Manitoba,N05AX,Other antipsychotics,Total,M,"4,234.64",2.4,1.6,"6,057",8
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,975.24",2.3,2.5,"9,622",9
8,Manitoba,A16AB,Enzymes,Total,M,**,**,**,**,10
8,Manitoba,L02BB,Antiandrogens,Total,M,**,**,**,**,11
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,665.65",1.5,3.9,"14,826",12
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,M,"2,500.12",1.4,0,100,13
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,M,"2,356.63",1.4,3,"11,467",14
8,Manitoba,N02AA,Natural opium alkaloids,Total,M,"2,304.02",1.3,1.9,"7,296",15
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,057.09",1.2,21.8,"83,621",16
8,Manitoba,N06AX,Other antidepressants,Total,M,"2,031.75",1.2,5.9,"22,499",17
8,Manitoba,A02BC,Proton pump inhibitors,Total,M,"2,017.57",1.2,16.1,"61,483",18
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,M,"2,014.27",1.2,1.9,"7,280",19
8,Manitoba,H01CB,Somatostatin and analogues,Total,M,"1,951.95",1.1,0,71,20
8,Manitoba,N03AX,Other antiepileptics,Total,M,"1,920.75",1.1,4.5,"17,269",21
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,679.44",1,7.8,"29,873",22
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,616.66",0.9,1.4,"5,426",23
8,Manitoba,L04AD,Calcineurin inhibitors,Total,M,"1,552.99",0.9,0.1,534,24
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,M,"1,368.76",0.8,12.6,"48,430",25
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,M,"1,364.29",0.8,0.3,"1,202",26
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,290.88",0.7,1.4,"5,517",27
8,Manitoba,B02AB,Proteinase inhibitors,Total,M,**,**,**,**,28
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,M,"1,204.09",0.7,10.1,"38,710",29
8,Manitoba,J05AE,Protease inhibitors,Total,M,"1,151.06",0.7,0.1,197,30
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,M,"1,077.22",0.6,9.3,"35,677",31
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,056.71",0.6,12.4,"47,626",32
8,Manitoba,L03AB,Interferons,Total,M,954.5,0.5,0,65,33
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,918.11,0.5,1.1,"4,126",34
8,Manitoba,A10BA,Biguanides,Total,M,907.1,0.5,9.5,"36,357",35
8,Manitoba,R03BB,Anticholinergics,Total,M,900.17,0.5,1.8,"7,035",36
8,Manitoba,J05AX,Other antivirals,Total,M,899.02,0.5,0.1,195,37
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,896.45,0.5,0.7,"2,520",38
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,M,792.34,0.5,4.7,"17,861",39
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,M,765.85,0.4,6.5,"24,978",40
8,Manitoba,L03AX,Other immunostimulants,Total,M,737.04,0.4,0,78,41
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,721.99,0.4,0,63,42
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,668.2,0.4,2.9,"11,054",43
8,Manitoba,A10BB,Sulfonylureas,Total,M,653.01,0.4,4.9,"18,915",44
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,649.23,0.4,0,62,45
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,644.58,0.4,1,"3,948",46
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,M,599.37,0.3,4.4,"16,830",47
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,598.79,0.3,11.2,"42,780",48
8,Manitoba,R03BA,Glucocorticoids,Total,M,578.43,0.3,3.6,"13,784",49
8,Manitoba,N03AG,Fatty acid derivatives,Total,M,575.57,0.3,0.5,"2,095",50
8,Manitoba,B01AB,Heparin group,Total,M,563.63,0.3,0.2,708,51
8,Manitoba,H03AA,Thyroid hormones,Total,M,554.73,0.3,5.2,"19,832",52
8,Manitoba,C03CA,"Sulfonamides, plain",Total,M,550.07,0.3,3.6,"13,777",53
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,549.22,0.3,6.6,"25,289",54
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,546.43,0.3,2.1,"7,929",55
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,M,538.41,0.3,0.6,"2,452",56
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,M,506.62,0.3,1.7,"6,472",57
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,M,486.66,0.3,0.6,"2,331",58
8,Manitoba,L01XX,Other antineoplastic agents,Total,M,484.94,0.3,0.1,296,59
8,Manitoba,A04AD,Other antiemetics,Total,M,481.08,0.3,0.2,865,60
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,475.75,0.3,0.4,"1,641",61
8,Manitoba,L01XC,Monoclonal antibodies,Total,M,463.37,0.3,0,50,62
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,M,452.64,0.3,0.5,"2,039",63
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,423.1,0.2,2.9,"11,103",64
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,422.24,0.2,0.1,392,65
8,Manitoba,N03AF,Carboxamide derivatives,Total,M,407.13,0.2,0.4,"1,596",66
8,Manitoba,L01AX,Other alkylating agents,Total,M,394.57,0.2,0,51,67
8,Manitoba,H02AB,Glucocorticoids,Total,M,378.43,0.2,6.8,"26,114",68
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,M,378.33,0.2,0,58,69
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,M,355.99,0.2,0.8,"3,227",70
8,Manitoba,R07AX,Other respiratory system products,Total,M,**,**,**,*,71
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,304.34,0.2,0.4,"1,540",72
8,Manitoba,M03BX,Other centrally acting agents,Total,M,298.49,0.2,3.1,"11,957",73
8,Manitoba,A09AA,Enzyme preparations,Total,M,293.99,0.2,0.1,473,74
8,Manitoba,M04AA,Preparations inhibiting uric acid production,Total,M,292.18,0.2,3.6,"13,825",75
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,M,280.39,0.2,0.5,"1,840",76
8,Manitoba,R01AD,Corticosteroids,Total,M,280.35,0.2,7.9,"30,150",77
8,Manitoba,B01AA,Vitamin K antagonists,Total,M,270.16,0.2,1.4,"5,287",78
8,Manitoba,S01EE,Prostaglandin analogues,Total,M,267.81,0.2,1.5,"5,718",79
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,M,264.71,0.2,1,"3,821",80
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,M,257.66,0.1,0.2,689,81
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,M,256.14,0.1,0.1,440,82
8,Manitoba,C10AB,Fibrates,Total,M,255.66,0.1,1,"3,880",83
8,Manitoba,N02BE,Anilides,Total,M,252.06,0.1,1.6,"6,121",84
8,Manitoba,A02BA,H2-receptor antagonists,Total,M,247.68,0.1,2.2,"8,363",85
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,M,239.36,0.1,2.5,"9,620",86
8,Manitoba,M01AE,Propionic acid derivatives,Total,M,234.45,0.1,7.4,"28,421",87
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,233.96,0.1,0.1,220,88
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,M,233.93,0.1,4.2,"16,186",89
8,Manitoba,N05AE,Indole derivatives,Total,M,233.52,0.1,0.1,234,90
8,Manitoba,S01ED,Beta-blocking agents,Total,M,233.07,0.1,1.3,"5,146",91
8,Manitoba,C03AA,"Thiazides, plain",Total,M,225.58,0.1,4.4,"16,899",92
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,215.35,0.1,0.2,763,93
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",Total,M,211.91,0.1,7.9,"30,148",94
8,Manitoba,A16AA,Amino acids and derivatives,Total,M,204.66,0.1,0,51,95
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,203.11,0.1,0,59,96
8,Manitoba,C01DA,Organic nitrates,Total,M,203.04,0.1,1.7,"6,385",97
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,196.05,0.1,2,"7,688",98
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",Total,M,189.87,0.1,0.9,"3,349",99
8,Manitoba,R05CB,Mucolytics,Total,M,178.13,0.1,0,24,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"36,428.03",19.4,0.4,"1,818",1
8,Manitoba,L01XE,Protein kinase inhibitors,Total,F,"11,013.28",5.9,0.1,354,2
8,Manitoba,L04AX,Other immunosuppressants,Total,F,"10,114.75",5.4,0.3,"1,463",3
8,Manitoba,L04AA,Selective immunosuppressants,Total,F,"9,687.18",5.2,0.3,"1,401",4
8,Manitoba,L04AC,Interleukin inhibitors,Total,F,"4,829.56",2.6,0.1,381,5
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,910.69",2.1,4.2,"19,204",6
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,F,"3,740.32",2,0,75,7
8,Manitoba,N06AX,Other antidepressants,Total,F,"3,400.11",1.8,9.1,"42,028",8
8,Manitoba,L03AB,Interferons,Total,F,"3,392.52",1.8,0,216,9
8,Manitoba,A02BC,Proton pump inhibitors,Total,F,"3,084.84",1.6,17.3,"79,753",10
8,Manitoba,N03AX,Other antiepileptics,Total,F,"2,794.38",1.5,5.7,"26,246",11
8,Manitoba,N05AX,Other antipsychotics,Total,F,"2,702.41",1.4,1.4,"6,452",12
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,673.77",1.4,13.2,"60,817",13
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,F,"2,662.72",1.4,1.6,"7,209",14
8,Manitoba,N02AA,Natural opium alkaloids,Total,F,"2,414.56",1.3,2.2,"10,061",15
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,402.59",1.3,2.4,"10,973",16
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,102.75",1.1,13.9,"64,326",17
8,Manitoba,H01CB,Somatostatin and analogues,Total,F,"2,074.34",1.1,0,100,18
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"1,924.73",1,0.1,368,19
8,Manitoba,L03AX,Other immunostimulants,Total,F,"1,640.87",0.9,0,212,20
8,Manitoba,L01XC,Monoclonal antibodies,Total,F,"1,572.34",0.8,0,155,21
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,F,"1,563.73",0.8,8.4,"38,990",22
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"1,532.08",0.8,0,117,23
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"1,497.73",0.8,1,"4,764",24
8,Manitoba,H03AA,Thyroid hormones,Total,F,"1,486.18",0.8,13.8,"63,722",25
8,Manitoba,L02BG,Aromatase inhibitors,Total,F,"1,426.33",0.8,1.1,"5,158",26
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,F,"1,384.68",0.7,8.1,"37,222",27
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,F,"1,358.51",0.7,1.5,"6,814",28
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"1,291.86",0.7,11.6,"53,389",29
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,**,**,**,*,30
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,179.33",0.6,1,"4,691",31
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,F,"1,138.41",0.6,6.4,"29,712",32
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,F,"1,087.49",0.6,0.2,981,33
8,Manitoba,R03BB,Anticholinergics,Total,F,"1,084.41",0.6,1.7,"7,940",34
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,080.32",0.6,1.1,"5,013",35
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,072.66",0.6,2,"9,022",36
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,F,"1,027.59",0.5,7.7,"35,443",37
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,015.29",0.5,1.7,"7,879",38
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,997.08,0.5,0,106,39
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,982.71,0.5,0.5,"2,246",40
8,Manitoba,L01XX,Other antineoplastic agents,Total,F,927.76,0.5,0.1,451,41
8,Manitoba,A10BA,Biguanides,Total,F,916.62,0.5,6.5,"29,838",42
8,Manitoba,B02AB,Proteinase inhibitors,Total,F,**,**,**,**,43
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,F,892.77,0.5,6.3,"28,915",44
8,Manitoba,L04AD,Calcineurin inhibitors,Total,F,885.99,0.5,0.1,314,45
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,875.6,0.5,6.4,"29,618",46
8,Manitoba,A04AD,Other antiemetics,Total,F,860.62,0.5,0.4,"1,700",47
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,856.15,0.5,3.7,"17,079",48
8,Manitoba,B01AB,Heparin group,Total,F,848.76,0.5,0.2,"1,010",49
8,Manitoba,R03BA,Glucocorticoids,Total,F,828.21,0.4,3.3,"15,442",50
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,801.73,0.4,0.6,"2,908",51
8,Manitoba,C03CA,"Sulfonamides, plain",Total,F,783.1,0.4,3.7,"17,082",52
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,776.1,0.4,11.4,"52,670",53
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,F,704.65,0.4,2.4,"10,900",54
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,675.07,0.4,0.2,899,55
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,F,627.99,0.3,0.6,"2,923",56
8,Manitoba,A10BB,Sulfonylureas,Total,F,615.21,0.3,3,"13,677",57
8,Manitoba,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,**,58
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,576.56,0.3,0.7,"3,389",59
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,506.16,0.3,0.3,"1,517",60
8,Manitoba,A16AB,Enzymes,Total,F,**,**,**,*,61
8,Manitoba,S01EE,Prostaglandin analogues,Total,F,462.71,0.2,1.6,"7,464",62
8,Manitoba,J05AE,Protease inhibitors,Total,F,461.18,0.2,0,105,63
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,F,442,0.2,1,"4,769",64
8,Manitoba,H02AB,Glucocorticoids,Total,F,433.29,0.2,6.8,"31,563",65
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,420.65,0.2,7.8,"35,924",66
8,Manitoba,N02BE,Anilides,Total,F,419.9,0.2,2.1,"9,826",67
8,Manitoba,N03AG,Fatty acid derivatives,Total,F,408.38,0.2,0.4,"1,803",68
8,Manitoba,A16AA,Amino acids and derivatives,Total,F,404.14,0.2,0,51,69
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,402.45,0.2,3.7,"16,855",70
8,Manitoba,R01AD,Corticosteroids,Total,F,393.71,0.2,9.1,"42,051",71
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,F,388.06,0.2,0.2,751,72
8,Manitoba,S01ED,Beta-blocking agents,Total,F,386.96,0.2,1.3,"6,211",73
8,Manitoba,A05AA,Bile acids and derivatives,Total,F,380.5,0.2,0.1,612,74
8,Manitoba,N05AE,Indole derivatives,Total,F,371.21,0.2,0.1,415,75
8,Manitoba,M05BA,Bisphosphonates,Total,F,368.56,0.2,1.4,"6,436",76
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,F,359.36,0.2,0.4,"1,765",77
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,Total,F,356.95,0.2,1.8,"8,154",78
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,353.05,0.2,0.4,"1,792",79
8,Manitoba,A02BA,H2-receptor antagonists,Total,F,343.52,0.2,2.8,"12,923",80
8,Manitoba,M01AE,Propionic acid derivatives,Total,F,335.84,0.2,8,"36,876",81
8,Manitoba,M03BX,Other centrally acting agents,Total,F,332.04,0.2,3.2,"14,945",82
8,Manitoba,C03AA,"Thiazides, plain",Total,F,327.88,0.2,5,"23,301",83
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,F,319.26,0.2,0.6,"2,924",84
8,Manitoba,N03AF,Carboxamide derivatives,Total,F,318.69,0.2,0.4,"1,667",85
8,Manitoba,A12BA,Potassium,Total,F,317.35,0.2,1.4,"6,435",86
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,F,317.09,0.2,2.8,"12,956",87
8,Manitoba,J05AX,Other antivirals,Total,F,312.67,0.2,0,150,88
8,Manitoba,A03FA,Propulsives,Total,F,282.97,0.2,2.1,"9,507",89
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,F,275.35,0.1,0.1,581,90
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",Total,F,273.01,0.1,1.2,"5,373",91
8,Manitoba,L01BA,Folic acid analogues,Total,F,271.46,0.1,0.8,"3,525",92
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,F,270.09,0.1,0,38,93
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",Total,F,269.44,0.1,8.4,"38,922",94
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,267.24,0.1,2.8,"12,824",95
8,Manitoba,B01AA,Vitamin K antagonists,Total,F,265.55,0.1,0.8,"3,635",96
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,264.94,0.1,3.5,"15,947",97
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,F,264.75,0.1,1.6,"7,493",98
8,Manitoba,G02BA,Intrauterine contraceptives,Total,F,**,**,**,**,99
8,Manitoba,R03DC,Leukotriene receptor antagonists,Total,F,255.34,0.1,1.5,"6,819",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"15,074.63",11.2,0.4,758,1
8,Manitoba,L01XE,Protein kinase inhibitors,65+,Total,"14,338.10",10.6,0.2,485,2
8,Manitoba,L04AX,Other immunosuppressants,65+,Total,"11,571.32",8.6,0.4,792,3
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,Total,"4,037.97",3,5.8,"11,711",4
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"3,701.23",2.7,6.2,"12,539",5
8,Manitoba,L04AA,Selective immunosuppressants,65+,Total,"2,965.97",2.2,0.4,723,6
8,Manitoba,A02BC,Proton pump inhibitors,65+,Total,"2,671.25",2,29.6,"59,880",7
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,Total,"2,645.79",2,42.3,"85,590",8
8,Manitoba,H01CB,Somatostatin and analogues,65+,Total,"2,495.42",1.8,0,100,9
8,Manitoba,L02BB,Antiandrogens,65+,Total,"2,371.02",1.8,0.5,"1,053",10
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,Total,"2,270.13",1.7,0,91,11
8,Manitoba,L04AC,Interleukin inhibitors,65+,Total,"2,191.44",1.6,0.1,168,12
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,Total,"1,931.36",1.4,22.8,"46,183",13
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,Total,"1,813.01",1.3,0,36,14
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,Total,"1,733.30",1.3,23.1,"46,847",15
8,Manitoba,N06AX,Other antidepressants,65+,Total,"1,726.67",1.3,9.2,"18,562",16
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,Total,"1,613.93",1.2,22,"44,616",17
8,Manitoba,N02AA,Natural opium alkaloids,65+,Total,"1,579.44",1.2,4.5,"9,124",18
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"1,474.15",1.1,2,"4,147",19
8,Manitoba,R03BB,Anticholinergics,65+,Total,"1,425.97",1.1,4.8,"9,779",20
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"1,401.74",1,0.1,103,21
8,Manitoba,N03AX,Other antiepileptics,65+,Total,"1,368.46",1,8.5,"17,143",22
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,201.44",0.9,10.2,"20,633",23
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,157.34",0.9,6.9,"13,883",24
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"1,134.19",0.8,1.3,"2,655",25
8,Manitoba,H03AA,Thyroid hormones,65+,Total,"1,126.02",0.8,19.8,"40,024",26
8,Manitoba,B02AB,Proteinase inhibitors,65+,Total,**,**,**,**,27
8,Manitoba,C03CA,"Sulfonamides, plain",65+,Total,"1,043.05",0.8,12,"24,307",28
8,Manitoba,A16AB,Enzymes,65+,Total,**,**,**,*,29
8,Manitoba,A10BA,Biguanides,65+,Total,984.87,0.7,15.7,"31,717",30
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,984.83,0.7,15.5,"31,411",31
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,959.76,0.7,2.7,"5,433",32
8,Manitoba,L02BG,Aromatase inhibitors,65+,Total,942.03,0.7,1.1,"2,132",33
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,923.46,0.7,1.9,"3,897",34
8,Manitoba,L01XC,Monoclonal antibodies,65+,Total,880.46,0.7,0,85,35
8,Manitoba,N05AX,Other antipsychotics,65+,Total,880.38,0.7,1.5,"3,114",36
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,830.18,0.6,1.5,"2,972",37
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,Total,830.15,0.6,3.6,"7,296",38
8,Manitoba,L01XX,Other antineoplastic agents,65+,Total,829.57,0.6,0.3,545,39
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,737.01,0.5,12.9,"26,118",40
8,Manitoba,A10BB,Sulfonylureas,65+,Total,734.76,0.5,8.2,"16,575",41
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,678,0.5,1.8,"3,732",42
8,Manitoba,B01AB,Heparin group,65+,Total,652.18,0.5,0.5,"1,002",43
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,Total,649.77,0.5,9.8,"19,810",44
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,646.67,0.5,9.5,"19,145",45
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,Total,637.67,0.5,1,"2,022",46
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,635.57,0.5,11.2,"22,771",47
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,627.34,0.5,1,"1,961",48
8,Manitoba,S01EE,Prostaglandin analogues,65+,Total,623.05,0.5,5.1,"10,414",49
8,Manitoba,L04AD,Calcineurin inhibitors,65+,Total,575.65,0.4,0.1,239,50
8,Manitoba,L03AB,Interferons,65+,Total,564.67,0.4,0,34,51
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,Total,546.38,0.4,3,"6,065",52
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,Total,539.58,0.4,1.5,"3,026",53
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,537.09,0.4,1.3,"2,591",54
8,Manitoba,S01ED,Beta-blocking agents,65+,Total,525.66,0.4,4.4,"8,814",55
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,Total,516.75,0.4,8.6,"17,316",56
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,492.79,0.4,4.3,"8,706",57
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,Total,481.37,0.4,0.6,"1,117",58
8,Manitoba,R03BA,Glucocorticoids,65+,Total,447.34,0.3,2.4,"4,817",59
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,Total,444.97,0.3,0.9,"1,761",60
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,428.89,0.3,0.2,460,61
8,Manitoba,H02AB,Glucocorticoids,65+,Total,406.84,0.3,7.9,"15,968",62
8,Manitoba,B01AA,Vitamin K antagonists,65+,Total,398.96,0.3,3.3,"6,612",63
8,Manitoba,C01DA,Organic nitrates,65+,Total,384.36,0.3,3.9,"7,983",64
8,Manitoba,A12BA,Potassium,65+,Total,381.86,0.3,3.9,"7,816",65
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,376.16,0.3,4.4,"8,911",66
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,Total,368.14,0.3,5.5,"11,081",67
8,Manitoba,A04AD,Other antiemetics,65+,Total,357.07,0.3,0.5,962,68
8,Manitoba,M05BA,Bisphosphonates,65+,Total,356.53,0.3,3.1,"6,258",69
8,Manitoba,C03AA,"Thiazides, plain",65+,Total,348.55,0.3,11.6,"23,475",70
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,323.14,0.2,0,49,71
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,299.19,0.2,0,28,72
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,285.69,0.2,6.9,"14,012",73
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,Total,283.46,0.2,0.3,682,74
8,Manitoba,N06DA,Anticholinesterases,65+,Total,280.86,0.2,1.4,"2,795",75
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,Total,277.54,0.2,3.9,"7,806",76
8,Manitoba,C01AA,Digitalis glycosides,65+,Total,277.43,0.2,1.6,"3,293",77
8,Manitoba,R01AD,Corticosteroids,65+,Total,269.28,0.2,8.1,"16,303",78
8,Manitoba,N02BE,Anilides,65+,Total,264.83,0.2,3.2,"6,437",79
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,Total,263.32,0.2,2.2,"4,456",80
8,Manitoba,A02BA,H2-receptor antagonists,65+,Total,245.9,0.2,3.7,"7,437",81
8,Manitoba,C03DA,Aldosterone antagonists,65+,Total,238.05,0.2,2.4,"4,863",82
8,Manitoba,A07AA,Antibiotics,65+,Total,226.3,0.2,1.1,"2,147",83
8,Manitoba,A03FA,Propulsives,65+,Total,226.1,0.2,2.5,"4,968",84
8,Manitoba,M01AH,Coxibs,65+,Total,221.74,0.2,3.3,"6,732",85
8,Manitoba,L01AX,Other alkylating agents,65+,Total,221.04,0.2,0,34,86
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,Total,219.54,0.2,1.8,"3,552",87
8,Manitoba,C10AB,Fibrates,65+,Total,216.49,0.2,1.3,"2,687",88
8,Manitoba,J01MA,Fluoroquinolones,65+,Total,212.41,0.2,10.5,"21,213",89
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,Total,204.54,0.2,9.5,"19,141",90
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,200.52,0.1,0.4,829,91
8,Manitoba,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,196.13,0.1,0.5,939,92
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,Total,193.41,0.1,4,"8,123",93
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,Total,184.63,0.1,0.9,"1,768",94
8,Manitoba,L01BA,Folic acid analogues,65+,Total,181.33,0.1,1.1,"2,246",95
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,178.11,0.1,0.1,163,96
8,Manitoba,J05AE,Protease inhibitors,65+,Total,172.46,0.1,0,21,97
8,Manitoba,N03AG,Fatty acid derivatives,65+,Total,170.39,0.1,0.3,702,98
8,Manitoba,N04BC,Dopamine agonists,65+,Total,166.8,0.1,0.8,"1,647",99
8,Manitoba,L02AB,Progestogens,65+,Total,165.29,0.1,0.1,188,100
8,Manitoba,L01XE,Protein kinase inhibitors,65+,M,"8,052.10",12.8,0.3,269,1
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"6,570.88",10.5,0.3,297,2
8,Manitoba,L04AX,Other immunosuppressants,65+,M,"5,998.48",9.5,0.4,346,3
8,Manitoba,L02BB,Antiandrogens,65+,M,**,**,**,**,4
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,M,"2,270.13",3.6,0.1,91,5
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,M,"1,658.15",2.6,6.3,"5,708",6
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"1,459.69",2.3,5.8,"5,274",7
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,308.05",2.1,0,26,8
8,Manitoba,H01CB,Somatostatin and analogues,65+,M,"1,265.42",2,0,43,9
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,205.75",1.9,49.6,"45,293",10
8,Manitoba,L04AA,Selective immunosuppressants,65+,M,"1,015.15",1.6,0.3,285,11
8,Manitoba,A16AB,Enzymes,65+,M,**,**,**,*,12
8,Manitoba,A02BC,Proton pump inhibitors,65+,M,954.18,1.5,26.9,"24,596",13
8,Manitoba,L04AC,Interleukin inhibitors,65+,M,866.45,1.4,0.1,62,14
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,M,790.16,1.3,27.4,"24,979",15
8,Manitoba,B02AB,Proteinase inhibitors,65+,M,**,**,**,**,16
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,M,747.99,1.2,2.4,"2,227",17
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,M,736.26,1.2,22.9,"20,910",18
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,M,712.69,1.1,25.3,"23,076",19
8,Manitoba,R03BB,Anticholinergics,65+,M,617.7,1,5,"4,576",20
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,M,605.43,1,20.3,"18,503",21
8,Manitoba,N02AA,Natural opium alkaloids,65+,M,596.91,0.9,3.8,"3,476",22
8,Manitoba,N06AX,Other antidepressants,65+,M,569.85,0.9,7,"6,357",23
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,511.07,0.8,1.5,"1,359",24
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,494.27,0.8,2.3,"2,101",25
8,Manitoba,N03AX,Other antiepileptics,65+,M,486.34,0.8,7.3,"6,644",26
8,Manitoba,A10BA,Biguanides,65+,M,472.76,0.8,19.2,"17,499",27
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,467.82,0.7,0,36,28
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,433.82,0.7,1.9,"1,755",29
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,430.81,0.7,2.4,"2,226",30
8,Manitoba,C03CA,"Sulfonamides, plain",65+,M,420.01,0.7,11.7,"10,705",31
8,Manitoba,L04AD,Calcineurin inhibitors,65+,M,391.1,0.6,0.2,162,32
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,386.8,0.6,8.2,"7,508",33
8,Manitoba,L01XX,Other antineoplastic agents,65+,M,382.22,0.6,0.2,209,34
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,375.89,0.6,9.8,"8,903",35
8,Manitoba,A10BB,Sulfonylureas,65+,M,366.28,0.6,10.5,"9,539",36
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,M,366.08,0.6,6.9,"6,268",37
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,357.47,0.6,2.3,"2,113",38
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,333.02,0.5,14.3,"13,088",39
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,311.27,0.5,13.4,"12,213",40
8,Manitoba,N05AX,Other antipsychotics,65+,M,311.04,0.5,1.2,"1,137",41
8,Manitoba,B01AB,Heparin group,65+,M,299.45,0.5,0.4,409,42
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,M,286.53,0.5,1.8,"1,637",43
8,Manitoba,H03AA,Thyroid hormones,65+,M,281.88,0.4,11.6,"10,545",44
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,279.09,0.4,1.1,989,45
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,266.62,0.4,10.1,"9,241",46
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,259.1,0.4,0,40,47
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,242.82,0.4,1.3,"1,168",48
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,M,238.06,0.4,7.8,"7,092",49
8,Manitoba,L01XC,Monoclonal antibodies,65+,M,221.7,0.4,0,26,50
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,M,218.94,0.3,0.6,577,51
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,M,211.07,0.3,0.9,793,52
8,Manitoba,S01EE,Prostaglandin analogues,65+,M,207.86,0.3,4.8,"4,369",53
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,M,205.35,0.3,2.3,"2,100",54
8,Manitoba,H02AB,Glucocorticoids,65+,M,201.16,0.3,7.9,"7,208",55
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,M,192.95,0.3,8.1,"7,353",56
8,Manitoba,B01AA,Vitamin K antagonists,65+,M,191.3,0.3,4.2,"3,841",57
8,Manitoba,S01ED,Beta-blocking agents,65+,M,181.4,0.3,4.2,"3,791",58
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,M,180.41,0.3,2.7,"2,488",59
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,M,177.26,0.3,5.9,"5,427",60
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,M,169.19,0.3,0.8,759,61
8,Manitoba,C01DA,Organic nitrates,65+,M,164.82,0.3,4.8,"4,379",62
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,151.67,0.2,2.9,"2,618",63
8,Manitoba,R03BA,Glucocorticoids,65+,M,148.18,0.2,2,"1,833",64
8,Manitoba,J05AE,Protease inhibitors,65+,M,**,**,**,**,65
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,140.22,0.2,0.1,129,66
8,Manitoba,J05AX,Other antivirals,65+,M,**,**,**,**,67
8,Manitoba,A12BA,Potassium,65+,M,125.42,0.2,3.1,"2,787",68
8,Manitoba,C03AA,"Thiazides, plain",65+,M,123.58,0.2,10.1,"9,237",69
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,121.52,0.2,0.1,120,70
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,M,116.11,0.2,4.5,"4,062",71
8,Manitoba,C01AA,Digitalis glycosides,65+,M,114.82,0.2,1.7,"1,540",72
8,Manitoba,L01AX,Other alkylating agents,65+,M,112.84,0.2,0,21,73
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,111.61,0.2,0.5,477,74
8,Manitoba,C03DA,Aldosterone antagonists,65+,M,108,0.2,2.6,"2,418",75
8,Manitoba,R01AD,Corticosteroids,65+,M,106.64,0.2,7.3,"6,647",76
8,Manitoba,A04AD,Other antiemetics,65+,M,103.45,0.2,0.4,321,77
8,Manitoba,C10AB,Fibrates,65+,M,102.41,0.2,1.6,"1,434",78
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,100.93,0.2,0,7,79
8,Manitoba,N06DA,Anticholinesterases,65+,M,100.22,0.2,1.2,"1,135",80
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,M,99.96,0.2,0.2,228,81
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,99.41,0.2,6.7,"6,084",82
8,Manitoba,A02BA,H2-receptor antagonists,65+,M,96.1,0.2,3.3,"3,038",83
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,M,93.95,0.1,1.7,"1,544",84
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,M,90.58,0.1,9.3,"8,486",85
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,M,87.08,0.1,1,953,86
8,Manitoba,J01MA,Fluoroquinolones,65+,M,85.73,0.1,9.5,"8,690",87
8,Manitoba,A07AA,Antibiotics,65+,M,83.25,0.1,0.8,703,88
8,Manitoba,L03AX,Other immunostimulants,65+,M,81.55,0.1,0,7,89
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,M,79.8,0.1,1.6,"1,453",90
8,Manitoba,N03AG,Fatty acid derivatives,65+,M,78.11,0.1,0.3,308,91
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,M,77.2,0.1,4.7,"4,301",92
8,Manitoba,A03FA,Propulsives,65+,M,75.7,0.1,2,"1,810",93
8,Manitoba,N02BE,Anilides,65+,M,73.54,0.1,2.1,"1,913",94
8,Manitoba,L03AB,Interferons,65+,M,72.29,0.1,0,6,95
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,M,**,**,**,**,96
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,64.92,0.1,2,"1,831",97
8,Manitoba,A09AA,Enzyme preparations,65+,M,64.81,0.1,0.2,192,98
8,Manitoba,M01AH,Coxibs,65+,M,64.16,0.1,2.6,"2,391",99
8,Manitoba,N04BC,Dopamine agonists,65+,M,61.03,0.1,0.7,622,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"8,503.75",11.8,0.4,461,1
8,Manitoba,L01XE,Protein kinase inhibitors,65+,F,"6,286.00",8.7,0.2,216,2
8,Manitoba,L04AX,Other immunosuppressants,65+,F,"5,572.85",7.7,0.4,446,3
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,F,"2,379.82",3.3,5.4,"6,003",4
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,241.54",3.1,6.5,"7,265",5
8,Manitoba,L04AA,Selective immunosuppressants,65+,F,"1,950.82",2.7,0.4,438,6
8,Manitoba,A02BC,Proton pump inhibitors,65+,F,"1,717.07",2.4,31.7,"35,284",7
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,440.04",2,36.3,"40,297",8
8,Manitoba,L04AC,Interleukin inhibitors,65+,F,"1,324.99",1.8,0.1,106,9
8,Manitoba,H01CB,Somatostatin and analogues,65+,F,"1,230.00",1.7,0.1,57,10
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,F,"1,195.10",1.7,22.7,"25,273",11
8,Manitoba,N06AX,Other antidepressants,65+,F,"1,156.82",1.6,11,"12,205",12
8,Manitoba,N02AA,Natural opium alkaloids,65+,F,982.54,1.4,5.1,"5,648",13
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,F,943.14,1.3,19.7,"21,868",14
8,Manitoba,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,15
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,933.92,1.3,0.1,67,16
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,F,901.24,1.3,19.4,"21,540",17
8,Manitoba,N03AX,Other antiepileptics,65+,F,882.12,1.2,9.4,"10,499",18
8,Manitoba,H03AA,Thyroid hormones,65+,F,844.14,1.2,26.5,"29,479",19
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,F,835.35,1.2,12.9,"14,365",20
8,Manitoba,R03BB,Anticholinergics,65+,F,808.28,1.1,4.7,"5,203",21
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,770.54,1.1,5.7,"6,375",22
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,F,726.16,1,1.7,"1,920",23
8,Manitoba,L01XC,Monoclonal antibodies,65+,F,658.76,0.9,0.1,59,24
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,651.81,0.9,16.5,"18,323",25
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,F,624.81,0.9,4.7,"5,196",26
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,623.12,0.9,1.2,"1,296",27
8,Manitoba,C03CA,"Sulfonamides, plain",65+,F,623.04,0.9,12.2,"13,602",28
8,Manitoba,N05AX,Other antipsychotics,65+,F,569.34,0.8,1.8,"1,977",29
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,528.95,0.7,2.9,"3,207",30
8,Manitoba,A10BA,Biguanides,65+,F,512.11,0.7,12.8,"14,218",31
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,F,504.96,0.7,0,10,32
8,Manitoba,L03AB,Interferons,65+,F,492.38,0.7,0,28,33
8,Manitoba,L01XX,Other antineoplastic agents,65+,F,447.35,0.6,0.3,336,34
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,429.19,0.6,1.6,"1,796",35
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,F,426.6,0.6,1.1,"1,229",36
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,425.73,0.6,12.5,"13,905",37
8,Manitoba,S01EE,Prostaglandin analogues,65+,F,415.19,0.6,5.4,"6,045",38
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,F,411.71,0.6,11.4,"12,718",39
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,396.36,0.5,1.1,"1,217",40
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,368.95,0.5,12.2,"13,530",41
8,Manitoba,A10BB,Sulfonylureas,65+,F,368.48,0.5,6.3,"7,036",42
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,F,365.97,0.5,3.2,"3,577",43
8,Manitoba,B01AB,Heparin group,65+,F,352.73,0.5,0.5,593,44
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,348.25,0.5,0.9,972,45
8,Manitoba,S01ED,Beta-blocking agents,65+,F,344.26,0.5,4.5,"5,023",46
8,Manitoba,B02AB,Proteinase inhibitors,65+,F,**,**,**,*,47
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,341.12,0.5,5.5,"6,088",48
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,F,339.49,0.5,10.7,"11,889",49
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,320.53,0.4,1.5,"1,619",50
8,Manitoba,M05BA,Bisphosphonates,65+,F,312.24,0.4,5,"5,610",51
8,Manitoba,R03BA,Glucocorticoids,65+,F,299.16,0.4,2.7,"2,984",52
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,294.26,0.4,1.3,"1,423",53
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,288.67,0.4,0.3,331,54
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,F,275.78,0.4,0.9,"1,002",55
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,F,262.43,0.4,0.5,540,56
8,Manitoba,A12BA,Potassium,65+,F,256.44,0.4,4.5,"5,029",57
8,Manitoba,A04AD,Other antiemetics,65+,F,253.62,0.4,0.6,641,58
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,F,253.06,0.4,1.2,"1,389",59
8,Manitoba,C03AA,"Thiazides, plain",65+,F,224.98,0.3,12.8,"14,238",60
8,Manitoba,C01DA,Organic nitrates,65+,F,219.55,0.3,3.2,"3,604",61
8,Manitoba,B01AA,Vitamin K antagonists,65+,F,207.66,0.3,2.5,"2,771",62
8,Manitoba,H02AB,Glucocorticoids,65+,F,205.68,0.3,7.9,"8,760",63
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,198.26,0.3,0,21,64
8,Manitoba,N02BE,Anilides,65+,F,191.29,0.3,4.1,"4,524",65
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,186.28,0.3,7.1,"7,928",66
8,Manitoba,L04AD,Calcineurin inhibitors,65+,F,184.55,0.3,0.1,77,67
8,Manitoba,M05BX,Other drugs affecting bone structure and mineralization,65+,F,183.63,0.3,0.8,905,68
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,F,183.5,0.3,0.4,454,69
8,Manitoba,N06DA,Anticholinesterases,65+,F,180.63,0.3,1.5,"1,660",70
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,F,175.18,0.2,3.4,"3,728",71
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,F,169.37,0.2,2.6,"2,912",72
8,Manitoba,R01AD,Corticosteroids,65+,F,162.64,0.2,8.7,"9,656",73
8,Manitoba,C01AA,Digitalis glycosides,65+,F,162.62,0.2,1.6,"1,753",74
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,F,161.44,0.2,3.4,"3,744",75
8,Manitoba,M01AH,Coxibs,65+,F,157.58,0.2,3.9,"4,341",76
8,Manitoba,L02AB,Progestogens,65+,F,153.91,0.2,0.1,156,77
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,152.58,0.2,5.4,"5,988",78
8,Manitoba,A03FA,Propulsives,65+,F,150.4,0.2,2.8,"3,158",79
8,Manitoba,A02BA,H2-receptor antagonists,65+,F,149.81,0.2,4,"4,399",80
8,Manitoba,A07AA,Antibiotics,65+,F,143.05,0.2,1.3,"1,444",81
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,F,139.73,0.2,1.9,"2,099",82
8,Manitoba,L01BA,Folic acid analogues,65+,F,133.39,0.2,1.4,"1,542",83
8,Manitoba,C03DA,Aldosterone antagonists,65+,F,130.05,0.2,2.2,"2,445",84
8,Manitoba,J01MA,Fluoroquinolones,65+,F,126.68,0.2,11.3,"12,523",85
8,Manitoba,N07CA,Antivertigo preparations,65+,F,117.68,0.2,3.6,"3,947",86
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,F,116.21,0.2,3.4,"3,822",87
8,Manitoba,C10AB,Fibrates,65+,F,114.08,0.2,1.1,"1,253",88
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,F,113.96,0.2,9.6,"10,655",89
8,Manitoba,L01AX,Other alkylating agents,65+,F,108.19,0.2,0,13,90
8,Manitoba,R03DC,Leukotriene receptor antagonists,65+,F,105.84,0.1,1.3,"1,462",91
8,Manitoba,N04BC,Dopamine agonists,65+,F,105.77,0.1,0.9,"1,025",92
8,Manitoba,B03XA,Other antianemic preparations,65+,F,**,**,**,**,93
8,Manitoba,A05AA,Bile acids and derivatives,65+,F,104.51,0.1,0.2,221,94
8,Manitoba,S01EC,Carbonic anhydrase inhibitors,65+,F,100.39,0.1,1.6,"1,734",95
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,F,97.55,0.1,0.7,815,96
8,Manitoba,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,F,94.74,0.1,1.3,"1,450",97
8,Manitoba,N03AG,Fatty acid derivatives,65+,F,92.28,0.1,0.4,394,98
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,88.91,0.1,0.3,352,99
8,Manitoba,J01XE,Nitrofuran derivatives,65+,F,84.07,0.1,8.7,"9,653",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"53,981.75",23.8,0.4,"2,525",1
8,Manitoba,L04AA,Selective immunosuppressants,<65,Total,"12,064.48",5.3,0.2,"1,605",2
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,Total,"10,562.45",4.7,0,216,3
8,Manitoba,L01XE,Protein kinase inhibitors,<65,Total,"9,665.87",4.3,0,303,4
8,Manitoba,L04AX,Other immunosuppressants,<65,Total,"8,392.27",3.7,0.3,"1,692",5
8,Manitoba,L04AC,Interleukin inhibitors,<65,Total,"7,345.19",3.2,0.1,564,6
8,Manitoba,N05AX,Other antipsychotics,<65,Total,"6,056.66",2.7,1.5,"9,395",7
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"5,964.56",2.6,0.2,"1,049",8
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"5,418.07",2.4,2.4,"15,162",9
8,Manitoba,L03AB,Interferons,<65,Total,"3,782.35",1.7,0,247,10
8,Manitoba,N06AX,Other antidepressants,<65,Total,"3,705.20",1.6,7.2,"45,965",11
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,Total,"3,653.17",1.6,2.8,"17,918",12
8,Manitoba,N03AX,Other antiepileptics,<65,Total,"3,346.67",1.5,4.1,"26,372",13
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"3,151.77",1.4,10.9,"70,057",14
8,Manitoba,N02AA,Natural opium alkaloids,<65,Total,"3,139.14",1.4,1.3,"8,233",15
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"2,875.12",1.3,3.3,"21,491",16
8,Manitoba,A16AB,Enzymes,<65,Total,**,**,**,**,17
8,Manitoba,A02BC,Proton pump inhibitors,<65,Total,"2,431.15",1.1,12.7,"81,356",18
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,Total,"2,343.35",1,0.3,"2,033",19
8,Manitoba,L03AX,Other immunostimulants,<65,Total,"2,216.79",1,0,273,20
8,Manitoba,L04AD,Calcineurin inhibitors,<65,Total,"1,863.33",0.8,0.1,609,21
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,640.24",0.7,0.9,"6,043",22
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"1,611.57",0.7,11.7,"74,897",23
8,Manitoba,H01CB,Somatostatin and analogues,<65,Total,"1,530.87",0.7,0,71,24
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,514.05",0.7,9.7,"62,357",25
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,447.74",0.6,1,"6,633",26
8,Manitoba,J05AE,Protease inhibitors,<65,Total,"1,439.79",0.6,0,281,27
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,347.12",0.6,0,140,28
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,Total,"1,303.18",0.6,5.6,"35,988",29
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,**,**,**,*,30
8,Manitoba,L01XC,Monoclonal antibodies,<65,Total,"1,155.26",0.5,0,120,31
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,Total,"1,080.07",0.5,0.8,"5,121",32
8,Manitoba,J05AX,Other antivirals,<65,Total,"1,059.98",0.5,0.1,322,33
8,Manitoba,B02AB,Proteinase inhibitors,<65,Total,**,**,**,**,34
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,Total,"1,020.14",0.4,6,"38,805",35
8,Manitoba,A04AD,Other antiemetics,<65,Total,984.62,0.4,0.2,"1,603",36
8,Manitoba,R03BA,Glucocorticoids,<65,Total,959.3,0.4,3.8,"24,409",37
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,Total,947.94,0.4,2,"12,916",38
8,Manitoba,H03AA,Thyroid hormones,<65,Total,914.89,0.4,6.8,"43,530",39
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,909.79,0.4,2.5,"16,302",40
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,889.66,0.4,0.6,"4,062",41
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,852.33,0.4,0,77,42
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,Total,842.37,0.4,4,"25,935",43
8,Manitoba,A10BA,Biguanides,<65,Total,838.85,0.4,5.4,"34,478",44
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,Total,836.46,0.4,4.9,"31,517",45
8,Manitoba,N03AG,Fatty acid derivatives,<65,Total,813.56,0.4,0.5,"3,196",46
8,Manitoba,B01AB,Heparin group,<65,Total,760.21,0.3,0.1,716,47
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,744.96,0.3,0.3,"2,111",48
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,739.33,0.3,11.3,"72,679",49
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,Total,669.68,0.3,0.5,"3,493",50
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,668.42,0.3,0.1,831,51
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,Total,639.02,0.3,0.4,"2,778",52
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,**,53
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,Total,627.69,0.3,0,10,54
8,Manitoba,N03AF,Carboxamide derivatives,<65,Total,608.56,0.3,0.4,"2,255",55
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,Total,601.69,0.3,3.2,"20,773",56
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,Total,598.5,0.3,0.8,"4,953",57
8,Manitoba,A16AA,Amino acids and derivatives,<65,Total,**,**,**,**,58
8,Manitoba,L01XX,Other antineoplastic agents,<65,Total,583.12,0.3,0,202,59
8,Manitoba,R03BB,Anticholinergics,<65,Total,558.6,0.2,0.8,"5,196",60
8,Manitoba,N05AE,Indole derivatives,<65,Total,557.65,0.2,0.1,591,61
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,543.14,0.2,0.6,"3,605",62
8,Manitoba,A10BB,Sulfonylureas,<65,Total,533.46,0.2,2.5,"16,017",63
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,526.15,0.2,0.8,"5,050",64
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,Total,523.66,0.2,0.6,"3,682",65
8,Manitoba,M03BX,Other centrally acting agents,<65,Total,500.23,0.2,3.4,"21,977",66
8,Manitoba,L02BG,Aromatase inhibitors,<65,Total,486.57,0.2,0.5,"3,096",67
8,Manitoba,R07AX,Other respiratory system products,<65,Total,**,**,**,*,68
8,Manitoba,M01AE,Propionic acid derivatives,<65,Total,467.6,0.2,9,"57,635",69
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,440,0.2,3.7,"23,496",70
8,Manitoba,L02BB,Antiandrogens,<65,Total,423.83,0.2,0,115,71
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,**,**,**,**,72
8,Manitoba,N02BE,Anilides,<65,Total,407.14,0.2,1.5,"9,510",73
8,Manitoba,H02AB,Glucocorticoids,<65,Total,404.88,0.2,6.5,"41,709",74
8,Manitoba,R01AD,Corticosteroids,<65,Total,404.78,0.2,8.7,"55,898",75
8,Manitoba,A09AA,Enzyme preparations,<65,Total,394.15,0.2,0.1,638,76
8,Manitoba,L01AX,Other alkylating agents,<65,Total,393.84,0.2,0,51,77
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,Total,367.73,0.2,1.4,"8,916",78
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,Total,360.74,0.2,0.1,509,79
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,Total,357.6,0.2,3.3,"21,019",80
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,354.56,0.2,0.2,"1,197",81
8,Manitoba,A02BA,H2-receptor antagonists,<65,Total,345.29,0.2,2.2,"13,849",82
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,Total,344,0.2,19.8,"126,990",83
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,328.68,0.1,2.9,"18,545",84
8,Manitoba,J01DB,First-generation cephalosporins,<65,Total,313.09,0.1,7.3,"47,007",85
8,Manitoba,A05AA,Bile acids and derivatives,<65,Total,295.2,0.1,0.1,482,86
8,Manitoba,C03CA,"Sulfonamides, plain",<65,Total,290.12,0.1,1,"6,552",87
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,Total,282.95,0.1,1.9,"11,939",88
8,Manitoba,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,280.09,0.1,0.3,"1,831",89
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,Total,276.82,0.1,7.8,"49,929",90
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,274.95,0.1,1.7,"11,157",91
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,Total,272.41,0.1,0.1,778,92
8,Manitoba,R05CB,Mucolytics,<65,Total,**,**,**,**,93
8,Manitoba,G02BA,Intrauterine contraceptives,<65,Total,257.02,0.1,1,"6,136",94
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,Total,**,**,**,**,95
8,Manitoba,J02AC,Triazole derivatives,<65,Total,249.68,0.1,1.2,"7,617",96
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,Total,245.21,0.1,1.5,"9,693",97
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",<65,Total,243.34,0.1,0.8,"5,170",98
8,Manitoba,J01FA,Macrolides,<65,Total,240.16,0.1,10.7,"68,698",99
8,Manitoba,C10AB,Fibrates,<65,Total,236.24,0.1,0.5,"3,434",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"26,057.47",23.4,0.4,"1,168",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,M,"7,327.09",6.6,0.1,151,2
8,Manitoba,L01XE,Protein kinase inhibitors,<65,M,"4,938.58",4.4,0.1,165,3
8,Manitoba,L04AA,Selective immunosuppressants,<65,M,"4,328.12",3.9,0.2,642,4
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"4,103.87",3.7,0.2,690,5
8,Manitoba,N05AX,Other antipsychotics,<65,M,"3,923.59",3.5,1.7,"4,920",6
8,Manitoba,L04AX,Other immunosuppressants,<65,M,"3,850.37",3.5,0.2,675,7
8,Manitoba,L04AC,Interleukin inhibitors,<65,M,"3,840.63",3.4,0.1,289,8
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"3,544.44",3.2,2.5,"7,396",9
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,M,"2,319.36",2.1,3.9,"11,294",10
8,Manitoba,A16AB,Enzymes,<65,M,**,**,**,*,11
8,Manitoba,N02AA,Natural opium alkaloids,<65,M,"1,707.12",1.5,1.3,"3,820",12
8,Manitoba,N06AX,Other antidepressants,<65,M,"1,461.91",1.3,5.5,"16,142",13
8,Manitoba,N03AX,Other antiepileptics,<65,M,"1,434.41",1.3,3.6,"10,625",14
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,M,"1,315.60",1.2,0.4,"1,128",15
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,313.35",1.2,8.1,"23,605",16
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,205.96",1.1,3.3,"9,552",17
8,Manitoba,L04AD,Calcineurin inhibitors,<65,M,"1,161.88",1,0.1,372,18
8,Manitoba,A02BC,Proton pump inhibitors,<65,M,"1,063.39",1,12.6,"36,887",19
8,Manitoba,J05AE,Protease inhibitors,<65,M,**,**,**,**,20
8,Manitoba,L03AB,Interferons,<65,M,882.21,0.8,0,59,21
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,M,868.67,0.8,1.1,"3,199",22
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,M,851.34,0.8,13.1,"38,328",23
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,796.61,0.7,1.2,"3,416",24
8,Manitoba,J05AX,Other antivirals,<65,M,**,**,**,**,25
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,745.44,0.7,12.1,"35,413",26
8,Manitoba,H01CB,Somatostatin and analogues,<65,M,686.53,0.6,0,28,27
8,Manitoba,L03AX,Other immunostimulants,<65,M,655.49,0.6,0,71,28
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,M,615.08,0.6,4.3,"12,434",29
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,M,578.59,0.5,8,"23,451",30
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,548.3,0.5,0,55,31
8,Manitoba,B02AB,Proteinase inhibitors,<65,M,**,**,**,*,32
8,Manitoba,N03AG,Fatty acid derivatives,<65,M,497.46,0.4,0.6,"1,787",33
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,484.29,0.4,0.8,"2,371",34
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,M,467.83,0.4,6.1,"17,800",35
8,Manitoba,A10BA,Biguanides,<65,M,434.35,0.4,6.5,"18,858",36
8,Manitoba,R03BA,Glucocorticoids,<65,M,430.25,0.4,4.1,"11,951",37
8,Manitoba,L02BB,Antiandrogens,<65,M,**,**,**,**,38
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,M,412.67,0.4,1.7,"4,928",39
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,394.75,0.4,1.8,"5,311",40
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,385.37,0.3,0.4,"1,161",41
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,42
8,Manitoba,A04AD,Other antiemetics,<65,M,377.63,0.3,0.2,544,43
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,M,364.53,0.3,4.3,"12,601",44
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,M,361.31,0.3,3.3,"9,738",45
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,M,356.12,0.3,0.5,"1,572",46
8,Manitoba,N03AF,Carboxamide derivatives,<65,M,355.9,0.3,0.4,"1,144",47
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,332.18,0.3,11.5,"33,539",48
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,M,327.35,0.3,0.6,"1,659",49
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,M,317.47,0.3,0.5,"1,572",50
8,Manitoba,R07AX,Other respiratory system products,<65,M,**,**,**,*,51
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,287.11,0.3,0.6,"1,835",52
8,Manitoba,A10BB,Sulfonylureas,<65,M,286.73,0.3,3.2,"9,376",53
8,Manitoba,R03BB,Anticholinergics,<65,M,282.47,0.3,0.8,"2,459",54
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,282.03,0.3,0.1,263,55
8,Manitoba,L01AX,Other alkylating agents,<65,M,281.73,0.3,0,30,56
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,281.39,0.3,1.2,"3,546",57
8,Manitoba,H03AA,Thyroid hormones,<65,M,272.85,0.2,3.2,"9,287",58
8,Manitoba,B01AB,Heparin group,<65,M,264.18,0.2,0.1,299,59
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,M,261.34,0.2,0.5,"1,532",60
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,254.17,0.2,0,27,61
8,Manitoba,M03BX,Other centrally acting agents,<65,M,241.87,0.2,3.4,"9,881",62
8,Manitoba,L01XC,Monoclonal antibodies,<65,M,241.67,0.2,0,24,63
8,Manitoba,L02BX,Other hormone antagonists and related agents,<65,M,229.99,0.2,0,9,64
8,Manitoba,A09AA,Enzyme preparations,<65,M,229.18,0.2,0.1,281,65
8,Manitoba,N05AE,Indole derivatives,<65,M,217.8,0.2,0.1,214,66
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,216.2,0.2,4.2,"12,201",67
8,Manitoba,A16AA,Amino acids and derivatives,<65,M,**,**,**,**,68
8,Manitoba,M01AE,Propionic acid derivatives,<65,M,198.79,0.2,8.5,"24,946",69
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,196.65,0.2,0.2,652,70
8,Manitoba,N02BE,Anilides,<65,M,178.52,0.2,1.4,"4,208",71
8,Manitoba,H02AB,Glucocorticoids,<65,M,177.27,0.2,6.5,"18,906",72
8,Manitoba,R01AD,Corticosteroids,<65,M,173.71,0.2,8.1,"23,503",73
8,Manitoba,H01AX,Other anterior pituitary lobe hormones and analogues,<65,M,**,**,**,*,74
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,M,166.11,0.1,0.1,402,75
8,Manitoba,R05CB,Mucolytics,<65,M,**,**,**,**,76
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,<65,M,160.42,0.1,2.2,"6,475",77
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,M,156.73,0.1,4.1,"11,885",78
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,M,156.18,0.1,0.1,212,79
8,Manitoba,C10AB,Fibrates,<65,M,153.25,0.1,0.8,"2,446",80
8,Manitoba,A02BA,H2-receptor antagonists,<65,M,151.58,0.1,1.8,"5,325",81
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,M,150.65,0.1,0.4,"1,127",82
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,M,148.36,0.1,19.6,"57,243",83
8,Manitoba,J01DB,First-generation cephalosporins,<65,M,139.73,0.1,7.4,"21,454",84
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,**,85
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,131.13,0.1,2,"5,857",86
8,Manitoba,C03CA,"Sulfonamides, plain",<65,M,130.05,0.1,1.1,"3,072",87
8,Manitoba,N05CD,Benzodiazepine derivatives,<65,M,125.65,0.1,0.5,"1,398",88
8,Manitoba,N05AA,Phenothiazines with aliphatic side-chain,<65,M,125.52,0.1,0.1,437,89
8,Manitoba,J01GB,Other aminoglycosides,<65,M,124.64,0.1,0,21,90
8,Manitoba,C09BA,ACE inhibitors and diuretics,<65,M,123.26,0.1,1.9,"5,558",91
8,Manitoba,A06AA,"Softeners, emollients",<65,M,123.03,0.1,0.2,622,92
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,M,121.33,0.1,7.4,"21,662",93
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,M,119.18,0.1,1.9,"5,475",94
8,Manitoba,J02AC,Triazole derivatives,<65,M,115.88,0.1,0.4,"1,078",95
8,Manitoba,N03AB,Hydantoin derivatives,<65,M,113.95,0.1,0.4,"1,078",96
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,113.53,0.1,0.1,225,97
8,Manitoba,N04AC,Ethers of tropine or tropine derivatives,<65,M,113.42,0.1,0.2,497,98
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,112.44,0.1,0,100,99
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",<65,M,110.07,0.1,0.6,"1,896",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"27,924.28",24.2,0.4,"1,357",1
8,Manitoba,L04AA,Selective immunosuppressants,<65,F,"7,736.36",6.7,0.3,963,2
8,Manitoba,L01XE,Protein kinase inhibitors,<65,F,"4,727.28",4.1,0,138,3
8,Manitoba,L04AX,Other immunosuppressants,<65,F,"4,541.90",3.9,0.3,"1,017",4
8,Manitoba,L04AC,Interleukin inhibitors,<65,F,"3,504.56",3,0.1,275,5
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,F,"3,235.36",2.8,0,65,6
8,Manitoba,L03AB,Interferons,<65,F,"2,900.13",2.5,0.1,188,7
8,Manitoba,N06AX,Other antidepressants,<65,F,"2,243.29",1.9,8.5,"29,823",8
8,Manitoba,N05AX,Other antipsychotics,<65,F,"2,133.07",1.8,1.3,"4,475",9
8,Manitoba,N03AX,Other antiepileptics,<65,F,"1,912.27",1.7,4.5,"15,747",10
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,873.64",1.6,2.2,"7,766",11
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"1,860.69",1.6,0.1,359,12
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,838.42",1.6,13.3,"46,452",13
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,669.15",1.4,3.4,"11,939",14
8,Manitoba,L03AX,Other immunostimulants,<65,F,"1,561.30",1.4,0.1,202,15
8,Manitoba,N02AA,Natural opium alkaloids,<65,F,"1,432.02",1.2,1.3,"4,413",16
8,Manitoba,A02BC,Proton pump inhibitors,<65,F,"1,367.76",1.2,12.7,"44,469",17
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,F,"1,333.81",1.2,1.9,"6,624",18
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,**,**,**,*,19
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,F,"1,027.75",0.9,0.3,905,20
8,Manitoba,L01XC,Monoclonal antibodies,<65,F,913.58,0.8,0,96,21
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,866.13,0.7,11.3,"39,484",22
8,Manitoba,H01CB,Somatostatin and analogues,<65,F,844.34,0.7,0,43,23
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,798.82,0.7,0,85,24
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,F,771.57,0.7,0.8,"2,844",25
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,F,752.73,0.7,1,"3,462",26
8,Manitoba,L04AD,Calcineurin inhibitors,<65,F,701.45,0.6,0.1,237,27
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,F,688.1,0.6,6.7,"23,554",28
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,F,662.71,0.6,6.9,"24,029",29
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,651.13,0.6,0.9,"3,217",30
8,Manitoba,H03AA,Thyroid hormones,<65,F,642.04,0.6,9.8,"34,243",31
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,32
8,Manitoba,A04AD,Other antiemetics,<65,F,607,0.5,0.3,"1,059",33
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,598.16,0.5,0,50,34
8,Manitoba,B02AB,Proteinase inhibitors,<65,F,**,**,**,**,35
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,F,535.28,0.5,2.3,"7,988",36
8,Manitoba,R03BA,Glucocorticoids,<65,F,529.05,0.5,3.6,"12,458",37
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,515.04,0.4,3.1,"10,991",38
8,Manitoba,A16AB,Enzymes,<65,F,**,**,**,*,39
8,Manitoba,B01AB,Heparin group,<65,F,496.03,0.4,0.1,417,40
8,Manitoba,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,41
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,F,481.06,0.4,4.6,"16,197",42
8,Manitoba,L01XX,Other antineoplastic agents,<65,F,480.41,0.4,0,115,43
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,F,447.85,0.4,1.1,"3,826",44
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,F,441.54,0.4,4.4,"15,354",45
8,Manitoba,J05AE,Protease inhibitors,<65,F,**,**,**,**,46
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,420.49,0.4,10.3,"35,919",47
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,407.15,0.4,11.2,"39,140",48
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,405.36,0.4,0.5,"1,691",49
8,Manitoba,A10BA,Biguanides,<65,F,404.5,0.4,4.5,"15,620",50
8,Manitoba,A16AA,Amino acids and derivatives,<65,F,**,**,**,**,51
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,386.39,0.3,0.2,568,52
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,F,368.63,0.3,3.9,"13,717",53
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,359.59,0.3,0.3,950,54
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,F,352.21,0.3,0.5,"1,921",55
8,Manitoba,N05AE,Indole derivatives,<65,F,339.84,0.3,0.1,377,56
8,Manitoba,N03AG,Fatty acid derivatives,<65,F,316.1,0.3,0.4,"1,409",57
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,F,297.11,0.3,2.1,"7,357",58
8,Manitoba,J05AX,Other antivirals,<65,F,**,**,**,**,59
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,F,282.9,0.2,0.3,"1,206",60
8,Manitoba,R03BB,Anticholinergics,<65,F,276.13,0.2,0.8,"2,737",61
8,Manitoba,A05AA,Bile acids and derivatives,<65,F,275.99,0.2,0.1,391,62
8,Manitoba,M01AE,Propionic acid derivatives,<65,F,268.81,0.2,9.3,"32,689",63
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,F,262.32,0.2,0.6,"2,150",64
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,65
8,Manitoba,M03BX,Other centrally acting agents,<65,F,258.36,0.2,3.5,"12,096",66
8,Manitoba,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,67
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,256.03,0.2,0.5,"1,770",68
8,Manitoba,N03AF,Carboxamide derivatives,<65,F,252.66,0.2,0.3,"1,111",69
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,249.87,0.2,3.1,"10,867",70
8,Manitoba,A10BB,Sulfonylureas,<65,F,246.73,0.2,1.9,"6,641",71
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,244.76,0.2,0.4,"1,504",72
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,F,237.16,0.2,2.3,"8,172",73
8,Manitoba,R01AD,Corticosteroids,<65,F,231.07,0.2,9.2,"32,395",74
8,Manitoba,N02BE,Anilides,<65,F,228.62,0.2,1.5,"5,302",75
8,Manitoba,H02AB,Glucocorticoids,<65,F,227.6,0.2,6.5,"22,803",76
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,223.79,0.2,3.2,"11,295",77
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,F,**,**,**,**,78
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,F,204.56,0.2,0.1,297,79
8,Manitoba,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,80
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,F,200.87,0.2,2.6,"9,134",81
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,197.55,0.2,3.6,"12,688",82
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,F,195.64,0.2,19.9,"69,747",83
8,Manitoba,A02BA,H2-receptor antagonists,<65,F,193.71,0.2,2.4,"8,524",84
8,Manitoba,C02CA,Alpha-adrenoreceptor antagonists,<65,F,186.36,0.2,0.3,"1,107",85
8,Manitoba,J01DB,First-generation cephalosporins,<65,F,173.36,0.2,7.3,"25,553",86
8,Manitoba,R07AX,Other respiratory system products,<65,F,**,**,**,*,87
8,Manitoba,A09AA,Enzyme preparations,<65,F,164.97,0.1,0.1,357,88
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,F,163.77,0.1,1.8,"6,464",89
8,Manitoba,C03CA,"Sulfonamides, plain",<65,F,160.07,0.1,1,"3,480",90
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,157.91,0.1,0.2,545,91
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,F,155.48,0.1,8.1,"28,267",92
8,Manitoba,G03AC,Progestogens,<65,F,**,**,**,**,93
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,F,149.5,0.1,1.5,"5,357",94
8,Manitoba,J01FA,Macrolides,<65,F,144.26,0.1,11.3,"39,655",95
8,Manitoba,L01BA,Folic acid analogues,<65,F,138.07,0.1,0.6,"1,983",96
8,Manitoba,J02AC,Triazole derivatives,<65,F,133.8,0.1,1.9,"6,539",97
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",<65,F,133.28,0.1,0.9,"3,274",98
8,Manitoba,A03FA,Propulsives,<65,F,132.57,0.1,1.8,"6,349",99
8,Manitoba,G03DA,Pregnen (4) derivatives,<65,F,122.8,0.1,1.7,"6,026",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"81,457.72",19.6,0.4,"3,496",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,Total,"25,624.83",6.2,0.1,549,2
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,Total,"21,689.80",5.2,0.4,"2,748",3
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,Total,"16,375.44",3.9,0.1,919,4
9,Saskatchewan,N05AX,Other antipsychotics,Total,Total,"9,049.00",2.2,1.4,"10,728",5
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,Total,"9,022.15",2.2,1.7,"13,093",6
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"8,853.14",2.1,0.2,"1,345",7
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,Total,"8,836.91",2.1,2,"15,662",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"8,601.67",2.1,2.1,"16,495",9
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"7,018.26",1.7,1.7,"13,058",10
9,Saskatchewan,L04AX,Other immunosuppressants,Total,Total,"6,813.90",1.6,0.3,"2,311",11
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,Total,"6,364.23",1.5,5.6,"43,303",12
9,Saskatchewan,S01LA,Antineovascularization agents,Total,Total,"6,072.88",1.5,0.5,"3,554",13
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"5,263.39",1.3,2.9,"22,553",14
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,Total,"5,160.58",1.2,16.2,"126,108",15
9,Saskatchewan,N03AX,Other antiepileptics,Total,Total,"5,014.36",1.2,5.3,"41,410",16
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,877.25",1.2,16.1,"125,527",17
9,Saskatchewan,B03XA,Other antianemic preparations,Total,Total,"4,666.47",1.1,0.1,"1,166",18
9,Saskatchewan,N06AX,Other antidepressants,Total,Total,"4,077.44",1,7.9,"61,248",19
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"4,031.51",1,1.6,"12,183",20
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,Total,"3,842.90",0.9,7.2,"56,214",21
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,798.56",0.9,10.3,"80,077",22
9,Saskatchewan,R03BA,Glucocorticoids,Total,Total,"3,423.12",0.8,5.4,"42,199",23
9,Saskatchewan,R03BB,Anticholinergics,Total,Total,"3,295.65",0.8,1.7,"13,599",24
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"3,084.75",0.7,0.6,"4,811",25
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,Total,"2,954.29",0.7,9.7,"75,651",26
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"2,923.33",0.7,0.9,"6,696",27
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,Total,"2,904.64",0.7,0.1,799,28
9,Saskatchewan,L03AB,Interferons,Total,Total,"2,783.30",0.7,0,190,29
9,Saskatchewan,L03AX,Other immunostimulants,Total,Total,"2,427.35",0.6,0,224,30
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"2,416.41",0.6,6.9,"53,758",31
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,Total,"2,354.88",0.6,7.2,"55,853",32
9,Saskatchewan,B01AB,Heparin group,Total,Total,"2,304.65",0.6,0.2,"1,268",33
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"2,247.42",0.5,0,199,34
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"2,235.89",0.5,1.4,"10,744",35
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,Total,"2,212.10",0.5,0.4,"2,742",36
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,Total,"2,009.90",0.5,0,224,37
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,906.00",0.5,0.6,"4,389",38
9,Saskatchewan,H03AA,Thyroid hormones,Total,Total,"1,627.27",0.4,9,"70,070",39
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,610.55",0.4,1.3,"10,502",40
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,604.49",0.4,1.7,"13,401",41
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,Total,"1,542.17",0.4,3.5,"27,030",42
9,Saskatchewan,A10BA,Biguanides,Total,Total,"1,495.97",0.4,7,"54,639",43
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"1,471.26",0.4,3.9,"30,061",44
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,444.55",0.3,3.3,"26,055",45
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,415.68",0.3,0.3,"2,144",46
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,Total,"1,369.03",0.3,0,16,47
9,Saskatchewan,J05AX,Other antivirals,Total,Total,"1,284.03",0.3,0,315,48
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,241.93",0.3,10.7,"83,474",49
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,Total,"1,223.13",0.3,3.7,"28,521",50
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"1,182.48",0.3,0,54,51
9,Saskatchewan,S01ED,Beta-blocking agents,Total,Total,"1,166.03",0.3,1,"7,856",52
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,Total,"1,163.22",0.3,7.9,"61,382",53
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,Total,"1,108.93",0.3,0.9,"7,383",54
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"1,005.27",0.2,0.1,"1,055",55
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,994.85,0.2,0.2,"1,706",56
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,Total,991.35,0.2,0.2,"1,232",57
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,Total,973.42,0.2,0.1,729,58
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,952.16,0.2,3.2,"25,030",59
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,939.9,0.2,0.2,"1,744",60
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,Total,928.7,0.2,1.2,"9,723",61
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,Total,912.52,0.2,0.6,"4,283",62
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,891.99,0.2,2,"15,861",63
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,Total,846.4,0.2,0.8,"6,288",64
9,Saskatchewan,A09AA,Enzyme preparations,Total,Total,841.18,0.2,0.1,984,65
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,839.37,0.2,0.1,542,66
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,Total,831.43,0.2,0.4,"2,726",67
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,Total,778.25,0.2,0.1,865,68
9,Saskatchewan,R05CB,Mucolytics,Total,Total,776.57,0.2,0,98,69
9,Saskatchewan,H02AB,Glucocorticoids,Total,Total,743.71,0.2,8.2,"63,619",70
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,Total,736.92,0.2,0.7,"5,474",71
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,728.88,0.2,3.7,"28,940",72
9,Saskatchewan,A10BB,Sulfonylureas,Total,Total,728.32,0.2,2.6,"20,078",73
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,Total,717.29,0.2,3.3,"25,849",74
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,Total,704.79,0.2,1.3,"9,927",75
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,Total,702.56,0.2,0.7,"5,675",76
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,Total,682.92,0.2,17,"132,023",77
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,Total,681.62,0.2,3.2,"25,123",78
9,Saskatchewan,A16AB,Enzymes,Total,Total,681.4,0.2,0,7,79
9,Saskatchewan,L01XE,Protein kinase inhibitors,Total,Total,667.38,0.2,0,31,80
9,Saskatchewan,C01DA,Organic nitrates,Total,Total,656.42,0.2,1.3,"10,108",81
9,Saskatchewan,M03BX,Other centrally acting agents,Total,Total,639.37,0.2,1.8,"13,881",82
9,Saskatchewan,M05BA,Bisphosphonates,Total,Total,632.3,0.2,0.8,"6,481",83
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,622.33,0.1,4.9,"37,923",84
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,Total,620.73,0.1,8.3,"64,539",85
9,Saskatchewan,J05AE,Protease inhibitors,Total,Total,620.03,0.1,0,114,86
9,Saskatchewan,R01AD,Corticosteroids,Total,Total,612.38,0.1,7.9,"61,666",87
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,Total,611.59,0.1,0,37,88
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,Total,609.82,0.1,1.4,"10,664",89
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,Total,604.96,0.1,2.1,"16,063",90
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,Total,596.78,0.1,0.2,"1,206",91
9,Saskatchewan,A12BA,Potassium,Total,Total,596.26,0.1,1.6,"12,226",92
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,Total,585.91,0.1,1.5,"11,778",93
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,Total,573.66,0.1,3.4,"26,531",94
9,Saskatchewan,J02AC,Triazole derivatives,Total,Total,572.36,0.1,1.4,"10,895",95
9,Saskatchewan,L01BA,Folic acid analogues,Total,Total,565.49,0.1,0.7,"5,138",96
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,Total,553.85,0.1,0.4,"2,727",97
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,Total,540.67,0.1,0,47,98
9,Saskatchewan,J01FA,Macrolides,Total,Total,523.02,0.1,9.4,"73,509",99
9,Saskatchewan,R07AX,Other respiratory system products,Total,Total,**,**,**,*,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"39,719.22",19,0.4,"1,560",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,M,"19,396.65",9.3,0.1,417,2
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,M,"8,767.32",4.2,0.3,"1,166",3
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,M,"7,834.90",3.8,0.1,432,4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"6,542.51",3.1,0.3,"1,006",5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,M,"5,959.15",2.9,2.7,"9,870",6
9,Saskatchewan,N05AX,Other antipsychotics,Total,M,"5,705.61",2.7,1.6,"5,656",7
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"4,935.48",2.4,2.6,"9,368",8
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,M,"4,351.51",2.1,1.8,"6,472",9
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,107.22",1.5,2.8,"9,991",10
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"3,083.89",1.5,1.6,"5,842",11
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,M,"3,071.07",1.5,5.4,"19,339",12
9,Saskatchewan,B03XA,Other antianemic preparations,Total,M,"2,707.08",1.3,0.2,674,13
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,505.07",1.2,20.1,"72,333",14
9,Saskatchewan,S01LA,Antineovascularization agents,Total,M,"2,389.19",1.1,0.4,"1,509",15
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,368.78",1.1,1.9,"6,772",16
9,Saskatchewan,L04AX,Other immunosuppressants,Total,M,"2,267.50",1.1,0.3,978,17
9,Saskatchewan,N03AX,Other antiepileptics,Total,M,"2,214.74",1.1,4.6,"16,685",18
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,M,"2,144.96",1,15.7,"56,589",19
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,M,"1,769.38",0.8,0.1,500,20
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,M,"1,758.43",0.8,8,"28,629",21
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"1,744.26",0.8,1.2,"4,217",22
9,Saskatchewan,R03BA,Glucocorticoids,Total,M,"1,672.48",0.8,5.7,"20,425",23
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"1,624.86",0.8,0.7,"2,687",24
9,Saskatchewan,R03BB,Anticholinergics,Total,M,"1,595.29",0.8,1.8,"6,550",25
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,M,"1,491.87",0.7,12,"43,073",26
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,436.75",0.7,7.4,"26,519",27
9,Saskatchewan,N06AX,Other antidepressants,Total,M,"1,427.45",0.7,6.1,"22,003",28
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,M,"1,204.96",0.6,0.4,"1,573",29
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"1,143.24",0.5,1.4,"5,144",30
9,Saskatchewan,B01AB,Heparin group,Total,M,"1,123.51",0.5,0.1,522,31
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,M,"1,113.81",0.5,8.2,"29,642",32
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,965.48,0.5,7.1,"25,412",33
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,M,964.09,0.5,0.6,"2,063",34
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,935.43,0.4,2.2,"8,035",35
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,M,934.53,0.4,6.6,"23,903",36
9,Saskatchewan,J05AX,Other antivirals,Total,M,843.46,0.4,0.1,187,37
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,M,834.59,0.4,0,94,38
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,M,822.84,0.4,4.3,"15,638",39
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,814.09,0.4,0.4,"1,286",40
9,Saskatchewan,A10BA,Biguanides,Total,M,778.78,0.4,8.5,"30,750",41
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,716.51,0.3,0,59,42
9,Saskatchewan,A16AB,Enzymes,Total,M,**,**,**,**,43
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,655.2,0.3,0.3,"1,035",44
9,Saskatchewan,L03AB,Interferons,Total,M,647.51,0.3,0,47,45
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,639.69,0.3,0.1,403,46
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,594.69,0.3,4.1,"14,674",47
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,586.97,0.3,11,"39,568",48
9,Saskatchewan,A09AA,Enzyme preparations,Total,M,573.12,0.3,0.1,510,49
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,M,561.24,0.3,0,166,50
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,M,557.77,0.3,8.1,"29,284",51
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,M,532.51,0.3,0.6,"2,305",52
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,M,528.77,0.3,3.6,"12,886",53
9,Saskatchewan,R07AX,Other respiratory system products,Total,M,**,**,**,*,54
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,M,500.56,0.2,1.2,"4,312",55
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,M,485.62,0.2,0.4,"1,489",56
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,483.73,0.2,2.2,"8,016",57
9,Saskatchewan,S01ED,Beta-blocking agents,Total,M,464.84,0.2,1,"3,536",58
9,Saskatchewan,L03AX,Other immunostimulants,Total,M,462.46,0.2,0,45,59
9,Saskatchewan,R05CB,Mucolytics,Total,M,459.93,0.2,0,58,60
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,459.68,0.2,2.3,"8,197",61
9,Saskatchewan,J05AE,Protease inhibitors,Total,M,428.83,0.2,0,73,62
9,Saskatchewan,H03AA,Thyroid hormones,Total,M,426.81,0.2,4.6,"16,585",63
9,Saskatchewan,L01XE,Protein kinase inhibitors,Total,M,424.64,0.2,0,20,64
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,M,422.44,0.2,0.8,"2,965",65
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,M,408.23,0.2,0.9,"3,104",66
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,M,407.16,0.2,0.1,477,67
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,M,401.18,0.2,0.8,"2,729",68
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,M,399.54,0.2,0,34,69
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,M,394.98,0.2,3.5,"12,434",70
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,M,393.3,0.2,0,20,71
9,Saskatchewan,A10BB,Sulfonylureas,Total,M,386.25,0.2,3.4,"12,146",72
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,M,385.05,0.2,0.1,450,73
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,M,380.12,0.2,0.7,"2,551",74
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,376.6,0.2,0,19,75
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,M,372.28,0.2,0,9,76
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,345.86,0.2,0.1,292,77
9,Saskatchewan,H02AB,Glucocorticoids,Total,M,337.74,0.2,8.1,"29,147",78
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,M,336.91,0.2,0.8,"2,730",79
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,330.9,0.2,2.6,"9,386",80
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,M,324.95,0.2,17,"61,114",81
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,M,311.38,0.1,1.7,"6,047",82
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,M,309.86,0.1,0.1,515,83
9,Saskatchewan,N05AF,Thioxanthene derivatives,Total,M,308.91,0.1,0.2,634,84
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,M,298.65,0.1,8.4,"30,362",85
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,M,296.98,0.1,1.1,"4,044",86
9,Saskatchewan,C01DA,Organic nitrates,Total,M,294.26,0.1,1.6,"5,760",87
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,M,291.32,0.1,2.6,"9,191",88
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,M,290.53,0.1,2.7,"9,614",89
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,Total,M,288.8,0.1,0.7,"2,562",90
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,M,286.21,0.1,1.5,"5,399",91
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,M,283.33,0.1,0.4,"1,327",92
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,283.17,0.1,0.3,"1,103",93
9,Saskatchewan,J01DF,Monobactams,Total,M,278.39,0.1,0,17,94
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,M,273.58,0.1,4.1,"14,736",95
9,Saskatchewan,M03BX,Other centrally acting agents,Total,M,268.61,0.1,1.7,"6,262",96
9,Saskatchewan,R01AD,Corticosteroids,Total,M,265.65,0.1,7.2,"25,912",97
9,Saskatchewan,A06AD,Osmotically acting laxatives,Total,M,264.94,0.1,0.7,"2,361",98
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,255.94,0.1,4.9,"17,550",99
9,Saskatchewan,N02BE,Anilides,Total,M,254.97,0.1,1.9,"6,804",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"41,738.49",20.1,0.5,"1,936",1
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,F,"12,922.48",6.2,0.4,"1,582",2
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,F,"8,540.54",4.1,0.1,487,3
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,F,"6,228.17",3,0,132,4
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,F,"4,670.63",2.3,1.6,"6,621",5
9,Saskatchewan,L04AX,Other immunosuppressants,Total,F,"4,546.40",2.2,0.3,"1,333",6
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,934.37",1.9,1.7,"7,216",7
9,Saskatchewan,S01LA,Antineovascularization agents,Total,F,"3,683.69",1.8,0.5,"2,045",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"3,666.20",1.8,1.7,"7,127",9
9,Saskatchewan,N05AX,Other antipsychotics,Total,F,"3,343.39",1.6,1.2,"5,072",10
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,F,"3,293.16",1.6,5.7,"23,964",11
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,F,"3,015.62",1.5,16.6,"69,519",12
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,F,"2,877.76",1.4,1.4,"5,792",13
9,Saskatchewan,N03AX,Other antiepileptics,Total,F,"2,799.62",1.4,5.9,"24,725",14
9,Saskatchewan,N06AX,Other antidepressants,Total,F,"2,650.00",1.3,9.4,"39,245",15
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,372.17",1.1,12.7,"53,194",16
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,361.81",1.1,12.8,"53,558",17
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"2,310.63",1.1,0.1,339,18
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,156.16",1,3,"12,562",19
9,Saskatchewan,L03AB,Interferons,Total,F,"2,135.79",1,0,143,20
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,F,"2,084.48",1,6.6,"27,585",21
9,Saskatchewan,L03AX,Other immunostimulants,Total,F,"1,964.89",0.9,0,179,22
9,Saskatchewan,B03XA,Other antianemic preparations,Total,F,"1,959.39",0.9,0.1,492,23
9,Saskatchewan,R03BA,Glucocorticoids,Total,F,"1,750.65",0.8,5.2,"21,774",24
9,Saskatchewan,R03BB,Anticholinergics,Total,F,"1,700.36",0.8,1.7,"7,049",25
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,662.73",0.8,1.3,"5,411",26
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,530.90",0.7,0,140,27
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,F,"1,462.41",0.7,7.8,"32,578",28
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"1,459.90",0.7,0.5,"2,124",29
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,450.93",0.7,6.8,"28,346",30
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,F,"1,241.07",0.6,6.3,"26,211",31
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,209.37",0.6,1.9,"7,773",32
9,Saskatchewan,H03AA,Thyroid hormones,Total,F,"1,200.46",0.6,12.8,"53,485",33
9,Saskatchewan,B01AB,Heparin group,Total,F,"1,181.14",0.6,0.2,746,34
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"1,179.07",0.6,0.6,"2,479",35
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,F,"1,175.31",0.6,0,130,36
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,F,"1,135.26",0.5,0.1,299,37
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"1,092.65",0.5,1.3,"5,600",38
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,F,"1,007.14",0.5,0.3,"1,169",39
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,F,996.75,0.5,0,7,40
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,960.81,0.5,4.3,"18,039",41
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,F,941.91,0.5,0.6,"2,326",42
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,Total,F,881.26,0.4,0.4,"1,627",43
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,878.39,0.4,3.8,"15,726",44
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,876.57,0.4,3.7,"15,387",45
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,805.87,0.4,0,35,46
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,F,719.32,0.3,2.7,"11,392",47
9,Saskatchewan,A10BA,Biguanides,Total,F,717.19,0.3,5.7,"23,889",48
9,Saskatchewan,S01ED,Beta-blocking agents,Total,F,701.2,0.3,1,"4,320",49
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,F,700.71,0.3,1,"4,279",50
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,F,694.36,0.3,3.7,"15,635",51
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,669.06,0.3,1.3,"5,366",52
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,659.41,0.3,0.2,763,53
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,654.96,0.3,10.5,"43,906",54
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,F,606.3,0.3,0.2,782,55
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,F,605.45,0.3,7.7,"32,098",56
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,601.58,0.3,0.2,858,57
9,Saskatchewan,M05BA,Bisphosphonates,Total,F,531.47,0.3,1.4,"5,676",58
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,F,509.49,0.2,0.8,"3,558",59
9,Saskatchewan,J05AX,Other antivirals,Total,F,440.57,0.2,0,128,60
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,F,428.14,0.2,1.3,"5,411",61
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,**,**,**,**,62
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,F,425.97,0.2,4,"16,658",63
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,F,412.18,0.2,0.1,563,64
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,F,407.81,0.2,1.4,"5,883",65
9,Saskatchewan,H02AB,Glucocorticoids,Total,F,405.97,0.2,8.2,"34,472",66
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,397.98,0.2,4.7,"19,554",67
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,F,391.1,0.2,3.7,"15,509",68
9,Saskatchewan,A12BA,Potassium,Total,F,388.96,0.2,1.8,"7,644",69
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,F,380.01,0.2,0.5,"1,978",70
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,F,371.09,0.2,0.1,388,71
9,Saskatchewan,M03BX,Other centrally acting agents,Total,F,370.76,0.2,1.8,"7,619",72
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,366.39,0.2,4.9,"20,373",73
9,Saskatchewan,L01BA,Folic acid analogues,Total,F,362.56,0.2,0.8,"3,172",74
9,Saskatchewan,C01DA,Organic nitrates,Total,F,362.16,0.2,1,"4,348",75
9,Saskatchewan,J02AC,Triazole derivatives,Total,F,360.95,0.2,2.2,"9,225",76
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,F,357.97,0.2,16.9,"70,909",77
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,F,356.8,0.2,0.7,"2,923",78
9,Saskatchewan,R01AD,Corticosteroids,Total,F,346.74,0.2,8.5,"35,754",79
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,F,345.81,0.2,0.3,"1,237",80
9,Saskatchewan,A10BB,Sulfonylureas,Total,F,342.07,0.2,1.9,"7,932",81
9,Saskatchewan,B02BX,Other systemic hemostatics,Total,F,**,**,**,**,82
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,339.65,0.2,0.2,671,83
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,F,322.08,0.2,8.2,"34,177",84
9,Saskatchewan,R05CB,Mucolytics,Total,F,316.65,0.2,0,40,85
9,Saskatchewan,G02BA,Intrauterine contraceptives,Total,F,308.81,0.1,1.4,"6,051",86
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,F,300.08,0.1,2.8,"11,795",87
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,F,299.69,0.1,1.5,"6,379",88
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,F,298.44,0.1,1.1,"4,617",89
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,F,286.92,0.1,0.2,691,90
9,Saskatchewan,J01FA,Macrolides,Total,F,281.11,0.1,9.9,"41,287",91
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,F,280.12,0.1,0.6,"2,710",92
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,Total,F,275.86,0.1,0,160,93
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,F,270.52,0.1,0.3,"1,400",94
9,Saskatchewan,A09AA,Enzyme preparations,Total,F,268.06,0.1,0.1,474,95
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,Total,F,254.88,0.1,2.4,"10,019",96
9,Saskatchewan,M01AH,Coxibs,Total,F,254.55,0.1,1.9,"8,093",97
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",Total,F,250.69,0.1,6,"24,933",98
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,249.47,0.1,5.6,"23,463",99
9,Saskatchewan,C03AA,"Thiazides, plain",Total,F,246.74,0.1,4.5,"18,796",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"18,304.75",11.8,0.5,870,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,Total,"8,431.42",5.4,6.3,"11,176",2
9,Saskatchewan,S01LA,Antineovascularization agents,65+,Total,"5,643.71",3.6,1.7,"3,025",3
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"5,261.20",3.4,4.6,"8,227",4
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"5,224.69",3.4,4.2,"7,463",5
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,Total,"4,929.89",3.2,0.5,865,6
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,405.04",2.2,40.4,"71,960",7
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,Total,"3,084.95",2,30.5,"54,344",8
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,Total,"3,057.84",2,20.1,"35,767",9
9,Saskatchewan,B03XA,Other antianemic preparations,65+,Total,"2,765.15",1.8,0.4,718,10
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,Total,"2,746.54",1.8,0.1,180,11
9,Saskatchewan,R03BB,Anticholinergics,65+,Total,"2,715.82",1.7,5.3,"9,363",12
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,Total,"2,591.04",1.7,8.5,"15,126",13
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"2,414.49",1.6,1.7,"3,003",14
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,Total,"2,120.92",1.4,0,45,15
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,057.46",1.3,3,"5,415",16
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,Total,"2,030.10",1.3,23.6,"41,971",17
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"1,921.50",1.2,1.8,"3,143",18
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,891.18",1.2,18,"32,052",19
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"1,853.92",1.2,4.1,"7,228",20
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,Total,"1,840.12",1.2,21.9,"38,930",21
9,Saskatchewan,N03AX,Other antiepileptics,65+,Total,"1,721.37",1.1,9,"16,029",22
9,Saskatchewan,N06AX,Other antidepressants,65+,Total,"1,631.64",1,9.7,"17,314",23
9,Saskatchewan,R03BA,Glucocorticoids,65+,Total,"1,544.58",1,4.9,"8,715",24
9,Saskatchewan,B01AB,Heparin group,65+,Total,"1,478.95",0.9,0.4,766,25
9,Saskatchewan,N05AX,Other antipsychotics,65+,Total,"1,308.31",0.8,1.9,"3,305",26
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,254.02",0.8,9.9,"17,629",27
9,Saskatchewan,L04AX,Other immunosuppressants,65+,Total,"1,200.13",0.8,0.3,565,28
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"1,157.23",0.7,10,"17,809",29
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,154.22",0.7,3.6,"6,455",30
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,Total,"1,096.89",0.7,7.4,"13,168",31
9,Saskatchewan,H03AA,Thyroid hormones,65+,Total,"1,082.79",0.7,19.5,"34,766",32
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,055.49",0.7,0.7,"1,254",33
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,054.45",0.7,5,"8,854",34
9,Saskatchewan,S01ED,Beta-blocking agents,65+,Total,"1,045.89",0.7,3.4,"6,110",35
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,Total,"1,028.32",0.7,3.3,"5,864",36
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,Total,"1,012.30",0.7,0.7,"1,299",37
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,Total,999.6,0.6,12.6,"22,492",38
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,946.54,0.6,3.6,"6,498",39
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,Total,932.72,0.6,0.1,99,40
9,Saskatchewan,A10BA,Biguanides,65+,Total,914.13,0.6,15.5,"27,603",41
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,889.5,0.6,0.9,"1,515",42
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,794.58,0.5,9.9,"17,704",43
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,Total,749.1,0.5,1.3,"2,258",44
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,Total,739.49,0.5,0.4,771,45
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,703.61,0.5,4.8,"8,541",46
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,Total,703.42,0.5,2.5,"4,427",47
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,667.86,0.4,0,65,48
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,652.57,0.4,0.2,349,49
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,644.68,0.4,3.6,"6,493",50
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,Total,604.75,0.4,0.1,203,51
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,Total,587.58,0.4,0.4,791,52
9,Saskatchewan,L01XE,Protein kinase inhibitors,65+,Total,**,**,**,**,53
9,Saskatchewan,C01DA,Organic nitrates,65+,Total,581.32,0.4,4.2,"7,493",54
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,65+,Total,**,**,**,*,55
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,570.54,0.4,10.8,"19,274",56
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,541.85,0.3,0.7,"1,186",57
9,Saskatchewan,M05BA,Bisphosphonates,65+,Total,537.48,0.3,3.1,"5,524",58
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,516.33,0.3,0,36,59
9,Saskatchewan,L03AB,Interferons,65+,Total,491.71,0.3,0,30,60
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,Total,490.12,0.3,4.7,"8,327",61
9,Saskatchewan,A12BA,Potassium,65+,Total,487.44,0.3,5.3,"9,405",62
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,Total,479.59,0.3,1.7,"3,058",63
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,Total,467.4,0.3,5.3,"9,529",64
9,Saskatchewan,A10BB,Sulfonylureas,65+,Total,453.47,0.3,5.9,"10,488",65
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,Total,439.34,0.3,2.4,"4,281",66
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,430.36,0.3,0.2,322,67
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,Total,424.57,0.3,4.2,"7,464",68
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,418.92,0.3,3.5,"6,274",69
9,Saskatchewan,H02AB,Glucocorticoids,65+,Total,359.63,0.2,10.4,"18,547",70
9,Saskatchewan,C01AA,Digitalis glycosides,65+,Total,346.35,0.2,1.9,"3,445",71
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,Total,341.16,0.2,5,"8,865",72
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,Total,334.12,0.2,0,18,73
9,Saskatchewan,L03AX,Other immunostimulants,65+,Total,330.65,0.2,0,25,74
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,Total,321.8,0.2,0.3,567,75
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,317.64,0.2,0.6,"1,044",76
9,Saskatchewan,R01AD,Corticosteroids,65+,Total,296.11,0.2,8.1,"14,465",77
9,Saskatchewan,B02BX,Other systemic hemostatics,65+,Total,291.63,0.2,0,5,78
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,Total,290.84,0.2,2.8,"4,944",79
9,Saskatchewan,L01BA,Folic acid analogues,65+,Total,290.1,0.2,1.2,"2,139",80
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,286.95,0.2,3.1,"5,489",81
9,Saskatchewan,C03AA,"Thiazides, plain",65+,Total,284.52,0.2,10.6,"18,904",82
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,279.97,0.2,6.2,"10,993",83
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,Total,276.55,0.2,4.2,"7,487",84
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,Total,272.61,0.2,4.8,"8,601",85
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,Total,270.32,0.2,0.8,"1,390",86
9,Saskatchewan,N04BC,Dopamine agonists,65+,Total,264.52,0.2,1.1,"1,876",87
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,259.99,0.2,0,14,88
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,Total,259.48,0.2,3.4,"6,110",89
9,Saskatchewan,M01AH,Coxibs,65+,Total,238.51,0.2,3.5,"6,280",90
9,Saskatchewan,C10AB,Fibrates,65+,Total,232.06,0.1,1.3,"2,299",91
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,Total,229.35,0.1,0.6,"1,113",92
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,227.48,0.1,0.3,482,93
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,Total,221.03,0.1,0.7,"1,308",94
9,Saskatchewan,A07AA,Antibiotics,65+,Total,214.33,0.1,1.2,"2,173",95
9,Saskatchewan,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,Total,207.99,0.1,0.5,934,96
9,Saskatchewan,A03FA,Propulsives,65+,Total,205.92,0.1,2.8,"4,973",97
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,Total,205.01,0.1,6.6,"11,706",98
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,Total,196.64,0.1,0.9,"1,650",99
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,Total,193.4,0.1,2.7,"4,793",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"7,370.65",10.3,0.4,339,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,M,"3,991.77",5.6,6.6,"5,380",2
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,114.12",4.4,5.8,"4,745",3
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,295.50",3.2,4.1,"3,347",4
9,Saskatchewan,S01LA,Antineovascularization agents,65+,M,"2,122.91",3,1.4,"1,173",5
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,M,"1,829.52",2.6,0.4,360,6
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,690.82",2.4,47.6,"38,923",7
9,Saskatchewan,B03XA,Other antianemic preparations,65+,M,"1,637.27",2.3,0.5,419,8
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,587.79",2.2,0,35,9
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,M,"1,305.50",1.8,20,"16,330",10
9,Saskatchewan,R03BB,Anticholinergics,65+,M,"1,301.16",1.8,5.6,"4,616",11
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"1,280.44",1.8,2,"1,661",12
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,M,"1,266.04",1.8,0.1,73,13
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,265.60",1.8,3.8,"3,097",14
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"1,215.47",1.7,2.5,"2,040",15
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,M,"1,184.56",1.7,28.6,"23,413",16
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,M,"1,183.49",1.7,7.8,"6,344",17
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,M,964.48,1.3,27.6,"22,613",18
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,936.74,1.3,4.3,"3,491",19
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,M,815,1.1,23.9,"19,569",20
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,M,783.86,1.1,21.3,"17,414",21
9,Saskatchewan,L04AX,Other immunosuppressants,65+,M,744.08,1,0.3,272,22
9,Saskatchewan,B01AB,Heparin group,65+,M,716.11,1,0.4,326,23
9,Saskatchewan,N03AX,Other antiepileptics,65+,M,712.34,1,8,"6,527",24
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,708.38,1,16.9,"13,816",25
9,Saskatchewan,R03BA,Glucocorticoids,65+,M,654.38,0.9,4.6,"3,788",26
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,630.97,0.9,0.9,774,27
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,617.5,0.9,6.2,"5,064",28
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,579.69,0.8,0.1,58,29
9,Saskatchewan,N05AX,Other antipsychotics,65+,M,572.73,0.8,1.6,"1,299",30
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,M,565.71,0.8,8.7,"7,154",31
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,519.19,0.7,0.3,267,32
9,Saskatchewan,N06AX,Other antidepressants,65+,M,516.99,0.7,7.4,"6,047",33
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,M,511.33,0.7,0.8,638,34
9,Saskatchewan,A10BA,Biguanides,65+,M,480.99,0.7,19.4,"15,879",35
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,443.08,0.6,9.6,"7,815",36
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,M,436,0.6,1.5,"1,249",37
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,M,435.72,0.6,0.1,47,38
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,M,418.6,0.6,12.4,"10,105",39
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,418.05,0.6,7.6,"6,244",40
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,408.9,0.6,3.2,"2,643",41
9,Saskatchewan,S01ED,Beta-blocking agents,65+,M,397.58,0.6,3.1,"2,547",42
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,M,393.12,0.6,0.2,131,43
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,M,389.7,0.5,6.8,"5,573",44
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,M,381.88,0.5,0.5,407,45
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,M,371.71,0.5,2.8,"2,328",46
9,Saskatchewan,L01XE,Protein kinase inhibitors,65+,M,**,**,**,**,47
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,349.09,0.5,0.9,699,48
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,M,287.55,0.4,8.1,"6,625",49
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,M,279.14,0.4,2.3,"1,895",50
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,M,275.95,0.4,2.1,"1,730",51
9,Saskatchewan,H03AA,Thyroid hormones,65+,M,270.99,0.4,11.1,"9,098",52
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,261.47,0.4,10.5,"8,582",53
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,M,260.29,0.4,2.2,"1,775",54
9,Saskatchewan,C01DA,Organic nitrates,65+,M,248.35,0.3,4.9,"4,020",55
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,M,244.27,0.3,5.6,"4,570",56
9,Saskatchewan,A10BB,Sulfonylureas,65+,M,241.57,0.3,7.6,"6,253",57
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,214.36,0.3,0,13,58
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,M,211.84,0.3,0,10,59
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,M,206.46,0.3,4.5,"3,719",60
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,206.27,0.3,3.2,"2,594",61
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,189.97,0.3,0.7,588,62
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,M,176.81,0.2,2.3,"1,878",63
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,M,173.65,0.2,0.3,255,64
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,M,168.71,0.2,0.4,292,65
9,Saskatchewan,A12BA,Potassium,65+,M,162.6,0.2,4.2,"3,435",66
9,Saskatchewan,H02AB,Glucocorticoids,65+,M,154.78,0.2,10.4,"8,498",67
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,M,153.34,0.2,0.9,739,68
9,Saskatchewan,C01AA,Digitalis glycosides,65+,M,147.81,0.2,2,"1,602",69
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,M,146.79,0.2,3.4,"2,764",70
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,142.08,0.2,2.4,"1,987",71
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,M,134.25,0.2,4.3,"3,523",72
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,131.31,0.2,0.3,263,73
9,Saskatchewan,R01AD,Corticosteroids,65+,M,129.62,0.2,7.7,"6,274",74
9,Saskatchewan,C10AB,Fibrates,65+,M,129.4,0.2,1.6,"1,277",75
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,M,123.41,0.2,4.9,"4,029",76
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,123.35,0.2,0.1,87,77
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,M,118.09,0.2,0.8,618,78
9,Saskatchewan,V03AC,Iron-chelating agents,65+,M,**,**,**,**,79
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,115.83,0.2,0,5,80
9,Saskatchewan,A09AA,Enzyme preparations,65+,M,115.29,0.2,0.2,190,81
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,M,111.93,0.2,3.3,"2,709",82
9,Saskatchewan,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,M,111.35,0.2,0.7,535,83
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,109.89,0.2,6,"4,906",84
9,Saskatchewan,N04BC,Dopamine agonists,65+,M,107.8,0.2,0.9,731,85
9,Saskatchewan,A07AA,Antibiotics,65+,M,103.96,0.1,1,812,86
9,Saskatchewan,L01BA,Folic acid analogues,65+,M,102.78,0.1,1,809,87
9,Saskatchewan,C03AA,"Thiazides, plain",65+,M,101.08,0.1,9,"7,339",88
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,M,99.69,0.1,6.6,"5,380",89
9,Saskatchewan,J02AC,Triazole derivatives,65+,M,98.9,0.1,0.6,508,90
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,M,95.69,0.1,0.5,407,91
9,Saskatchewan,A06AD,Osmotically acting laxatives,65+,M,95.11,0.1,1.2,941,92
9,Saskatchewan,G03BA,3-oxoandrosten (4) derivatives,65+,M,90.54,0.1,0.8,664,93
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,M,87.73,0.1,3.4,"2,807",94
9,Saskatchewan,A06AB,Contact laxatives,65+,M,83.65,0.1,1,856,95
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,M,82.65,0.1,2.7,"2,220",96
9,Saskatchewan,J01AA,Tetracyclines,65+,M,79.16,0.1,6.1,"5,029",97
9,Saskatchewan,M01AH,Coxibs,65+,M,78.91,0.1,2.9,"2,350",98
9,Saskatchewan,N03AG,Fatty acid derivatives,65+,M,77.62,0.1,0.4,364,99
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,M,76.17,0.1,0.8,692,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"10,934.10",13,0.6,531,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,F,"4,439.65",5.3,6,"5,796",2
9,Saskatchewan,S01LA,Antineovascularization agents,65+,F,"3,520.80",4.2,1.9,"1,852",3
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,F,"3,100.37",3.7,0.5,505,4
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,929.19",3.5,4.3,"4,116",5
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"2,147.08",2.5,3.6,"3,482",6
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,F,"1,900.39",2.3,32.1,"30,931",7
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,F,"1,752.34",2.1,20.2,"19,437",8
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,714.22",2,34.3,"33,037",9
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,F,"1,480.50",1.8,0.1,107,10
9,Saskatchewan,R03BB,Anticholinergics,65+,F,"1,414.66",1.7,4.9,"4,747",11
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,F,"1,407.55",1.7,9.1,"8,782",12
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"1,182.80",1.4,18.9,"18,236",13
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"1,134.05",1.3,1.4,"1,342",14
9,Saskatchewan,B03XA,Other antianemic preparations,65+,F,"1,127.87",1.3,0.3,299,15
9,Saskatchewan,N06AX,Other antidepressants,65+,F,"1,114.65",1.3,11.7,"11,267",16
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,F,"1,065.61",1.3,20.1,"19,358",17
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,F,"1,025.13",1.2,20.1,"19,361",18
9,Saskatchewan,N03AX,Other antiepileptics,65+,F,"1,009.03",1.2,9.9,"9,502",19
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,917.18,1.1,3.9,"3,737",20
9,Saskatchewan,R03BA,Glucocorticoids,65+,F,890.2,1.1,5.1,"4,927",21
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,F,878.27,1,4.9,"4,725",22
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,F,864.32,1,12.5,"12,056",23
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,F,841.88,1,1.5,"1,425",24
9,Saskatchewan,H03AA,Thyroid hormones,65+,F,811.8,1,26.7,"25,668",25
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,791.86,0.9,2.4,"2,318",26
9,Saskatchewan,B01AB,Heparin group,65+,F,762.84,0.9,0.5,440,27
9,Saskatchewan,N05AX,Other antipsychotics,65+,F,735.58,0.9,2.1,"2,006",28
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,714.15,0.8,10.4,"9,994",29
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,706.03,0.8,1.1,"1,103",30
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,F,656.61,0.8,3.7,"3,536",31
9,Saskatchewan,S01ED,Beta-blocking agents,65+,F,648.31,0.8,3.7,"3,563",32
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,643.25,0.8,6.7,"6,481",33
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,F,581,0.7,12.9,"12,387",34
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,65+,F,**,**,**,*,35
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,537.64,0.6,4,"3,855",36
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,F,533.13,0.6,0,10,37
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,F,531.19,0.6,6.2,"6,014",38
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,F,500.97,0.6,0.7,661,39
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,497.34,0.6,6.2,"5,947",40
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,F,496.99,0.6,0.1,52,41
9,Saskatchewan,M05BA,Bisphosphonates,65+,F,465.83,0.6,5.1,"4,908",42
9,Saskatchewan,L04AX,Other immunosuppressants,65+,F,456.04,0.5,0.3,293,43
9,Saskatchewan,L03AB,Interferons,65+,F,**,**,**,**,44
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,F,443.13,0.5,2.8,"2,652",45
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,436.95,0.5,3.9,"3,790",46
9,Saskatchewan,A10BA,Biguanides,65+,F,433.14,0.5,12.2,"11,724",47
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,424.52,0.5,0.5,480,48
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,F,413.92,0.5,0.6,536,49
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,F,357.61,0.4,0.4,364,50
9,Saskatchewan,C01DA,Organic nitrates,65+,F,332.96,0.4,3.6,"3,473",51
9,Saskatchewan,A12BA,Potassium,65+,F,324.84,0.4,6.2,"5,970",52
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,F,313.1,0.4,1,"1,009",53
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,309.07,0.4,11.1,"10,692",54
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,307,0.4,0.2,235,55
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,301.98,0.4,0,23,56
9,Saskatchewan,L03AX,Other immunostimulants,65+,F,264.1,0.3,0,19,57
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,F,262.54,0.3,2.5,"2,403",58
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,F,245.85,0.3,3.9,"3,757",59
9,Saskatchewan,B02BX,Other systemic hemostatics,65+,F,**,**,**,*,60
9,Saskatchewan,L01XE,Protein kinase inhibitors,65+,F,**,**,**,**,61
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,F,218.11,0.3,3.9,"3,745",62
9,Saskatchewan,A10BB,Sulfonylureas,65+,F,211.89,0.3,4.4,"4,235",63
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,F,211.63,0.3,0.1,72,64
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,F,206.92,0.2,5.5,"5,342",65
9,Saskatchewan,H02AB,Glucocorticoids,65+,F,204.85,0.2,10.4,"10,049",66
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,F,200.45,0.2,1.2,"1,163",67
9,Saskatchewan,C01AA,Digitalis glycosides,65+,F,198.54,0.2,1.9,"1,843",68
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,192.77,0.2,0.5,487,69
9,Saskatchewan,L01BA,Folic acid analogues,65+,F,187.33,0.2,1.4,"1,330",70
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,F,184.88,0.2,6,"5,794",71
9,Saskatchewan,C03AA,"Thiazides, plain",65+,F,183.44,0.2,12,"11,565",72
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,F,179.85,0.2,3,"2,904",73
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,170.08,0.2,6.3,"6,087",74
9,Saskatchewan,R01AD,Corticosteroids,65+,F,166.49,0.2,8.5,"8,191",75
9,Saskatchewan,M01AH,Coxibs,65+,F,159.6,0.2,4.1,"3,930",76
9,Saskatchewan,N04BC,Dopamine agonists,65+,F,156.72,0.2,1.2,"1,145",77
9,Saskatchewan,A05AA,Bile acids and derivatives,65+,F,154,0.2,0.2,219,78
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,F,153.14,0.2,3.6,"3,458",79
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,F,153.1,0.2,0.3,275,80
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,F,147.55,0.2,3.5,"3,401",81
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,144.87,0.2,3.6,"3,502",82
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,144.16,0.2,0,9,83
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,F,144.05,0.2,2.3,"2,180",84
9,Saskatchewan,A03FA,Propulsives,65+,F,133.9,0.2,3.2,"3,041",85
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,F,133.66,0.2,0.7,706,86
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,133.38,0.2,0.1,82,87
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,127.67,0.2,0.5,456,88
9,Saskatchewan,J01XE,Nitrofuran derivatives,65+,F,127.6,0.2,10.4,"9,996",89
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,F,122.28,0.1,0,8,90
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,F,120.47,0.1,1,958,91
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,F,116.99,0.1,0.7,651,92
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,F,110.75,0.1,2.7,"2,573",93
9,Saskatchewan,A07AA,Antibiotics,65+,F,110.37,0.1,1.4,"1,361",94
9,Saskatchewan,M03BX,Other centrally acting agents,65+,F,105.7,0.1,1.7,"1,679",95
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,F,105.32,0.1,6.6,"6,326",96
9,Saskatchewan,C08DA,Phenylalkylamine derivatives,65+,F,104.94,0.1,0.6,575,97
9,Saskatchewan,N07CA,Antivertigo preparations,65+,F,103.4,0.1,3.4,"3,292",98
9,Saskatchewan,A06AB,Contact laxatives,65+,F,103.07,0.1,1,975,99
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,F,102.94,0.1,0.7,690,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"63,152.96",24.3,0.4,"2,626",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,Total,"23,503.90",9,0.1,504,2
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,Total,"16,759.91",6.4,0.3,"1,883",3
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,Total,"13,628.90",5.2,0.1,739,4
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,Total,"8,733.86",3.4,2.6,"15,364",5
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"8,185.28",3.1,0.2,"1,280",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,Total,"7,740.69",3,1.2,"7,423",7
9,Saskatchewan,L04AX,Other immunosuppressants,<65,Total,"5,613.77",2.2,0.3,"1,746",8
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"4,316.85",1.7,2.7,"16,055",9
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,Total,"3,773.19",1.4,4.7,"28,177",10
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"3,340.48",1.3,1.4,"8,268",11
9,Saskatchewan,N03AX,Other antiepileptics,<65,Total,"3,292.99",1.3,4.2,"25,381",12
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,544.54",1,10.4,"62,448",13
9,Saskatchewan,N06AX,Other antidepressants,<65,Total,"2,445.80",0.9,7.3,"43,934",14
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,Total,"2,299.89",0.9,0.1,596,15
9,Saskatchewan,L03AB,Interferons,<65,Total,"2,291.59",0.9,0,160,16
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,Total,"2,100.08",0.8,0.4,"2,379",17
9,Saskatchewan,L03AX,Other immunostimulants,<65,Total,"2,096.71",0.8,0,199,18
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,Total,"2,075.63",0.8,11.9,"71,764",19
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,974.05",0.8,1.1,"6,768",20
9,Saskatchewan,B03XA,Other antianemic preparations,<65,Total,"1,901.32",0.7,0.1,448,21
9,Saskatchewan,R03BA,Glucocorticoids,<65,Total,"1,878.55",0.7,5.6,"33,484",22
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,793.57",0.7,0.9,"5,595",23
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,731.08",0.7,0,163,24
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,472.21",0.6,8.9,"53,567",25
9,Saskatchewan,J05AX,Other antivirals,<65,Total,"1,190.65",0.5,0,299,26
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,Total,"1,077.18",0.4,0,125,27
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,Total,"1,026.48",0.4,7.7,"46,254",28
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"1,001.83",0.4,0.6,"3,553",29
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,Total,924.19,0.4,5.6,"33,680",30
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,922.48,0.4,0,40,31
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,Total,893.7,0.3,0.5,"3,090",32
9,Saskatchewan,B01AB,Heparin group,<65,Total,825.7,0.3,0.1,502,33
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,Total,808.17,0.3,1.4,"8,564",34
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,**,35
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,Total,786.08,0.3,0.1,450,36
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,Total,785.07,0.3,3.4,"20,447",37
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,Total,753.79,0.3,0.6,"3,509",38
9,Saskatchewan,R05CB,Mucolytics,<65,Total,742.47,0.3,0,75,39
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,740.94,0.3,2.9,"17,514",40
9,Saskatchewan,A16AB,Enzymes,<65,Total,681.4,0.3,0,7,41
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,671.39,0.3,10.7,"64,200",42
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,670.26,0.3,0.3,"1,808",43
9,Saskatchewan,A09AA,Enzyme preparations,<65,Total,655.98,0.3,0.1,611,44
9,Saskatchewan,J05AE,Protease inhibitors,<65,Total,**,**,**,**,45
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,Total,591.82,0.2,19.1,"114,985",46
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,Total,590.73,0.2,0.3,"1,917",47
9,Saskatchewan,A10BA,Biguanides,<65,Total,581.83,0.2,4.5,"27,036",48
9,Saskatchewan,R03BB,Anticholinergics,<65,Total,579.83,0.2,0.7,"4,236",49
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,574.92,0.2,0.1,733,50
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,550.04,0.2,0.8,"4,547",51
9,Saskatchewan,H03AA,Thyroid hormones,<65,Total,544.48,0.2,5.9,"35,304",52
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,Total,540.67,0.2,0,47,53
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,525.23,0.2,3.6,"21,706",54
9,Saskatchewan,R07AX,Other respiratory system products,<65,Total,**,**,**,*,55
9,Saskatchewan,J01DF,Monobactams,<65,Total,518.83,0.2,0,32,56
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,Total,515.89,0.2,0.7,"4,166",57
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,Total,514.76,0.2,2.8,"16,923",58
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,Total,509.21,0.2,9.4,"56,319",59
9,Saskatchewan,M03BX,Other centrally acting agents,<65,Total,467.36,0.2,1.8,"10,943",60
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,Total,456.34,0.2,0.7,"4,047",61
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,453,0.2,0.1,520,62
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,Total,445.27,0.2,2.3,"13,862",63
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,Total,444.68,0.2,2.9,"17,248",64
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,441.93,0.2,3.9,"23,451",65
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,Total,438.56,0.2,0.3,"1,906",66
9,Saskatchewan,S01LA,Antineovascularization agents,<65,Total,429.17,0.2,0.1,529,67
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,427.02,0.2,5.8,"34,968",68
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,Total,417.84,0.2,0.1,872,69
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,Total,403.77,0.2,0.1,441,70
9,Saskatchewan,J02AC,Triazole derivatives,<65,Total,390.96,0.2,1.5,"8,731",71
9,Saskatchewan,H02AB,Glucocorticoids,<65,Total,384.08,0.1,7.5,"45,072",72
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,381.96,0.1,0.6,"3,516",73
9,Saskatchewan,J01FA,Macrolides,<65,Total,380.01,0.1,10,"60,068",74
9,Saskatchewan,N02BE,Anilides,<65,Total,362.81,0.1,1.7,"10,250",75
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,360.19,0.1,0.1,890,76
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,342.35,0.1,4.5,"26,930",77
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,Total,340.46,0.1,2.7,"16,258",78
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,340,0.1,5.5,"33,122",79
9,Saskatchewan,J01GB,Other aminoglycosides,<65,Total,330.19,0.1,0,65,80
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,Total,321.91,0.1,0.5,"3,102",81
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,316.5,0.1,0,167,82
9,Saskatchewan,R01AD,Corticosteroids,<65,Total,316.28,0.1,7.9,"47,201",83
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,314.03,0.1,2,"12,252",84
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,Total,**,**,**,**,85
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,Total,305.81,0.1,1.1,"6,649",86
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,Total,297.11,0.1,3.2,"19,044",87
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,Total,294.81,0.1,0.6,"3,608",88
9,Saskatchewan,V06,General nutrients,<65,Total,**,**,**,**,89
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,Total,287.63,0.1,3.4,"20,711",90
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,Total,283.33,0.1,3,"18,100",91
9,Saskatchewan,A16AA,Amino acids and derivatives,<65,Total,**,**,**,**,92
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,Total,277.47,0.1,0,19,93
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,Total,276.7,0.1,5.4,"32,209",94
9,Saskatchewan,L01BA,Folic acid analogues,<65,Total,275.39,0.1,0.5,"2,999",95
9,Saskatchewan,B03AC,"Iron, parenteral preparations",<65,Total,274.98,0.1,0.1,639,96
9,Saskatchewan,A10BB,Sulfonylureas,<65,Total,274.85,0.1,1.6,"9,590",97
9,Saskatchewan,A06AB,Contact laxatives,<65,Total,266.65,0.1,0.4,"2,190",98
9,Saskatchewan,G03AC,Progestogens,<65,Total,266.07,0.1,1.4,"8,470",99
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,Total,265.45,0.1,0.9,"5,646",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"32,348.57",23.6,0.4,"1,221",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,M,"17,808.86",13,0.1,382,2
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,M,"6,937.80",5.1,0.3,806,3
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,M,"6,568.85",4.8,0.1,359,4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"5,962.82",4.3,0.3,948,5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,M,"5,911.32",4.3,3.5,"9,718",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,M,"5,132.88",3.7,1.6,"4,357",7
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"2,698.32",2,2.6,"7,348",8
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,M,"1,887.58",1.4,4.7,"12,995",9
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"1,821.36",1.3,1.7,"4,623",10
9,Saskatchewan,L04AX,Other immunosuppressants,<65,M,"1,523.42",1.1,0.3,706,11
9,Saskatchewan,N03AX,Other antiepileptics,<65,M,"1,502.40",1.1,3.7,"10,158",12
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,M,"1,376.26",1,0.1,369,13
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,M,"1,136.19",0.8,0.5,"1,388",14
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,103.18",0.8,1.3,"3,675",15
9,Saskatchewan,B03XA,Other antianemic preparations,<65,M,"1,069.81",0.8,0.1,255,16
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,047.05",0.8,7.5,"20,946",17
9,Saskatchewan,R03BA,Glucocorticoids,<65,M,"1,018.10",0.7,6,"16,637",18
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,M,960.4,0.7,11.9,"33,176",19
9,Saskatchewan,N06AX,Other antidepressants,<65,M,910.46,0.7,5.7,"15,956",20
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,M,814.26,0.6,12,"33,410",21
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,788.39,0.6,0.9,"2,495",22
9,Saskatchewan,J05AX,Other antivirals,<65,M,**,**,**,**,23
9,Saskatchewan,A16AB,Enzymes,<65,M,**,**,**,**,24
9,Saskatchewan,L03AB,Interferons,<65,M,**,**,**,**,25
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,528.79,0.4,0.8,"2,177",26
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,M,527.9,0.4,0,106,27
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,M,527.39,0.4,7.4,"20,460",28
9,Saskatchewan,R07AX,Other respiratory system products,<65,M,**,**,**,*,29
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,502.15,0.4,0,46,30
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,M,500.19,0.4,7.9,"22,040",31
9,Saskatchewan,A09AA,Enzyme preparations,<65,M,457.84,0.3,0.1,320,32
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,M,454.89,0.3,0.7,"1,941",33
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,M,452.92,0.3,4.4,"12,299",34
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,M,452.76,0.3,0.5,"1,425",35
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,M,446.16,0.3,1.4,"3,846",36
9,Saskatchewan,R05CB,Mucolytics,<65,M,439.81,0.3,0,48,37
9,Saskatchewan,B01AB,Heparin group,<65,M,407.41,0.3,0.1,196,38
9,Saskatchewan,J05AE,Protease inhibitors,<65,M,**,**,**,**,39
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,M,399.54,0.3,0,34,40
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,M,398.87,0.3,0,47,41
9,Saskatchewan,L03AX,Other immunostimulants,<65,M,395.91,0.3,0,39,42
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,**,43
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,M,359.75,0.3,0.4,"1,092",44
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,344.41,0.3,0.4,"1,026",45
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,325.5,0.2,11.1,"30,986",46
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,317.94,0.2,1.1,"2,971",47
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,306.11,0.2,0.1,336,48
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,M,298.82,0.2,3.6,"10,073",49
9,Saskatchewan,A10BA,Biguanides,<65,M,297.79,0.2,5.3,"14,871",50
9,Saskatchewan,R03BB,Anticholinergics,<65,M,294.13,0.2,0.7,"1,934",51
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,M,285.98,0.2,19.1,"53,270",52
9,Saskatchewan,J01DF,Monobactams,<65,M,278.39,0.2,0,17,53
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,277.46,0.2,1.9,"5,422",54
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,M,270.55,0.2,0.2,553,55
9,Saskatchewan,S01LA,Antineovascularization agents,<65,M,266.28,0.2,0.1,336,56
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,M,262.03,0.2,0.7,"1,933",57
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,260.77,0.2,0,14,58
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,M,257.14,0.2,3,"8,484",59
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,257.1,0.2,4.2,"11,596",60
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,M,250.83,0.2,9.5,"26,458",61
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,M,232.59,0.2,0.3,966,62
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,222.51,0.2,0.1,205,63
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,M,211.39,0.2,0.1,195,64
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,206.5,0.2,0.6,"1,653",65
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,M,203.59,0.1,2.3,"6,384",66
9,Saskatchewan,M03BX,Other centrally acting agents,<65,M,202.3,0.1,1.8,"5,003",67
9,Saskatchewan,N02BE,Anilides,<65,M,200.07,0.1,2.2,"6,034",68
9,Saskatchewan,J01GB,Other aminoglycosides,<65,M,199.16,0.1,0,36,69
9,Saskatchewan,A16AA,Amino acids and derivatives,<65,M,**,**,**,**,70
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,188.81,0.1,2.7,"7,399",71
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,M,185.43,0.1,0.7,"1,895",72
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,183.13,0.1,0.2,512,73
9,Saskatchewan,H02AB,Glucocorticoids,<65,M,182.96,0.1,7.4,"20,649",74
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,M,181.46,0.1,0,10,75
9,Saskatchewan,J01FA,Macrolides,<65,M,180.12,0.1,9.5,"26,404",76
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,M,169.83,0.1,0.5,"1,420",77
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,166.84,0.1,5.4,"15,073",78
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,M,156.28,0.1,2.2,"6,091",79
9,Saskatchewan,H03AA,Thyroid hormones,<65,M,155.82,0.1,2.7,"7,487",80
9,Saskatchewan,D09AA,Medicated dressings with antiinfectives,<65,M,**,**,**,**,81
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,153.36,0.1,0,103,82
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,151.61,0.1,2.5,"6,859",83
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,<65,M,150.66,0.1,2.3,"6,489",84
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,M,150.17,0.1,3.8,"10,707",85
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,M,146.13,0.1,0.9,"2,626",86
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,146.05,0.1,4.5,"12,644",87
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,M,145.81,0.1,3.6,"9,921",88
9,Saskatchewan,A06AB,Contact laxatives,<65,M,145.51,0.1,0.4,"1,134",89
9,Saskatchewan,A10BB,Sulfonylureas,<65,M,144.67,0.1,2.1,"5,893",90
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,<65,M,143.3,0.1,0.4,"1,070",91
9,Saskatchewan,B03AC,"Iron, parenteral preparations",<65,M,141.15,0.1,0.1,223,92
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,M,138.21,0.1,3,"8,260",93
9,Saskatchewan,R01AD,Corticosteroids,<65,M,136.03,0.1,7.1,"19,638",94
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,<65,M,135.47,0.1,0.7,"1,823",95
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,M,131.33,0.1,4.9,"13,602",96
9,Saskatchewan,V06,General nutrients,<65,M,**,**,**,**,97
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,M,125.23,0.1,0.4,999,98
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,120.5,0.1,0,136,99
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,M,120.18,0.1,0.8,"2,166",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"30,804.39",25.1,0.4,"1,405",1
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,F,"9,822.11",8,0.3,"1,077",2
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,F,"7,060.05",5.7,0.1,380,3
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,F,"5,695.04",4.6,0,122,4
9,Saskatchewan,L04AX,Other immunosuppressants,<65,F,"4,090.35",3.3,0.3,"1,040",5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,F,"2,822.54",2.3,1.8,"5,646",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,F,"2,607.81",2.1,1,"3,066",7
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"2,222.47",1.8,0.1,332,8
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,F,"1,885.61",1.5,4.7,"15,182",9
9,Saskatchewan,N03AX,Other antiepileptics,<65,F,"1,790.59",1.5,4.7,"15,223",10
9,Saskatchewan,L03AX,Other immunostimulants,<65,F,"1,700.79",1.4,0,160,11
9,Saskatchewan,L03AB,Interferons,<65,F,**,**,**,**,12
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,618.52",1.3,2.7,"8,707",13
9,Saskatchewan,N06AX,Other antidepressants,<65,F,"1,535.34",1.2,8.7,"27,978",14
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,519.12",1.2,1.1,"3,645",15
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,497.49",1.2,12.9,"41,502",16
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"1,228.93",1,0,117,17
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,F,"1,115.23",0.9,12,"38,588",18
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,005.18",0.8,1,"3,100",19
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,F,963.9,0.8,0.3,991,20
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,F,923.63,0.8,0.1,227,21
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,870.87,0.7,1,"3,093",22
9,Saskatchewan,R03BA,Glucocorticoids,<65,F,860.45,0.7,5.2,"16,847",23
9,Saskatchewan,B03XA,Other antianemic preparations,<65,F,831.51,0.7,0.1,193,24
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,F,678.31,0.6,0,78,25
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,661.71,0.5,0,26,26
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,F,657.95,0.5,6.3,"20,157",27
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,F,526.29,0.4,7.5,"24,214",28
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,473.04,0.4,0.4,"1,376",29
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,463.48,0.4,3.8,"12,092",30
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,F,440.94,0.4,0.5,"1,665",31
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,32
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,33
9,Saskatchewan,J05AX,Other antivirals,<65,F,**,**,**,**,34
9,Saskatchewan,B01AB,Heparin group,<65,F,418.29,0.3,0.1,306,35
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,F,396.8,0.3,4.1,"13,220",36
9,Saskatchewan,H03AA,Thyroid hormones,<65,F,388.66,0.3,8.6,"27,817",37
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,F,362,0.3,1.5,"4,718",38
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,352.41,0.3,0.2,528,39
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,345.89,0.3,10.3,"33,214",40
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,F,332.14,0.3,2.5,"8,148",41
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,F,331.1,0.3,0.9,"3,048",42
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,325.85,0.3,0.2,782,43
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,F,307.66,0.3,1.9,"6,046",44
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,F,305.83,0.2,19.1,"61,715",45
9,Saskatchewan,R05CB,Mucolytics,<65,F,302.66,0.2,0,27,46
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,F,298.89,0.2,0.5,"1,568",47
9,Saskatchewan,R03BB,Anticholinergics,<65,F,285.7,0.2,0.7,"2,302",48
9,Saskatchewan,A10BA,Biguanides,<65,F,284.05,0.2,3.8,"12,165",49
9,Saskatchewan,J02AC,Triazole derivatives,<65,F,278.45,0.2,2.3,"7,569",50
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,F,275.86,0.2,0,160,51
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,268.13,0.2,3.1,"10,110",52
9,Saskatchewan,M03BX,Other centrally acting agents,<65,F,265.06,0.2,1.8,"5,940",53
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,F,258.38,0.2,9.3,"29,861",54
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,F,258.18,0.2,0.1,344,55
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,F,253.86,0.2,0.7,"2,233",56
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,253.11,0.2,5,"16,052",57
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,F,241.09,0.2,3.4,"10,864",58
9,Saskatchewan,J01DF,Monobactams,<65,F,240.44,0.2,0,15,59
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,235.14,0.2,2.9,"9,245",60
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,232.1,0.2,0.5,"1,576",61
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,F,230.99,0.2,0.3,825,62
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,F,215.94,0.2,2.1,"6,850",63
9,Saskatchewan,G03AC,Progestogens,<65,F,**,**,**,**,64
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,F,205.96,0.2,0.3,940,65
9,Saskatchewan,H02AB,Glucocorticoids,<65,F,201.12,0.2,7.6,"24,423",66
9,Saskatchewan,J01FA,Macrolides,<65,F,199.89,0.2,10.4,"33,664",67
9,Saskatchewan,A09AA,Enzyme preparations,<65,F,198.14,0.2,0.1,291,68
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,196.3,0.2,4.4,"14,286",69
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,F,192.38,0.2,0.1,246,70
9,Saskatchewan,J05AE,Protease inhibitors,<65,F,**,**,**,**,71
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,F,188.14,0.2,1.7,"5,378",72
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,F,184.18,0.1,3.2,"10,167",73
9,Saskatchewan,R01AD,Corticosteroids,<65,F,180.25,0.1,8.6,"27,563",74
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,177.06,0.1,0.1,378,75
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,175.46,0.1,0.6,"1,863",76
9,Saskatchewan,L01BA,Folic acid analogues,<65,F,175.24,0.1,0.6,"1,842",77
9,Saskatchewan,G03XB,Progesterone receptor modulators,<65,F,174.72,0.1,0.2,607,78
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,173.16,0.1,5.6,"18,049",79
9,Saskatchewan,R06AA,Aminoalkyl ethers,<65,F,173.06,0.1,1.8,"5,956",80
9,Saskatchewan,D10AD,Retinoids for topical use in acne,<65,F,169.9,0.1,1.6,"5,142",81
9,Saskatchewan,S01LA,Antineovascularization agents,<65,F,162.9,0.1,0.1,193,82
9,Saskatchewan,N02BE,Anilides,<65,F,162.74,0.1,1.3,"4,216",83
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,F,162.42,0.1,1.7,"5,393",84
9,Saskatchewan,V06,General nutrients,<65,F,**,**,**,**,85
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,F,159.68,0.1,1.2,"4,023",86
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,F,152.08,0.1,0.5,"1,682",87
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,F,147.29,0.1,0.1,319,88
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,F,146.94,0.1,2.6,"8,337",89
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,146.88,0.1,0.1,184,90
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,F,145.37,0.1,5.8,"18,607",91
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,F,145.27,0.1,1.1,"3,480",92
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,F,145.12,0.1,3.1,"9,840",93
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,F,141.83,0.1,3.3,"10,790",94
9,Saskatchewan,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,95
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,F,141.13,0.1,0,13,96
9,Saskatchewan,B03AC,"Iron, parenteral preparations",<65,F,133.82,0.1,0.1,416,97
9,Saskatchewan,J01GB,Other aminoglycosides,<65,F,131.03,0.1,0,29,98
9,Saskatchewan,A10BB,Sulfonylureas,<65,F,130.18,0.1,1.1,"3,697",99
9,Saskatchewan,A04AA,Serotonin (5HT3) antagonists,<65,F,129.87,0.1,0,129,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"176,671.56",18.9,1.3,"8,353",1
10,Alberta,L04AA,Selective immunosuppressants,Total,Total,"45,006.63",4.8,0.6,"3,771",2
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,Total,"35,253.18",3.8,0.1,686,3
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,Total,"34,452.94",3.7,6.4,"41,337",4
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"29,397.40",3.1,6.3,"40,740",5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"23,590.09",2.5,4.4,"28,591",6
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,Total,"23,143.78",2.5,42.4,"273,454",7
10,Alberta,L04AC,Interleukin inhibitors,Total,Total,"22,868.47",2.4,0.2,"1,550",8
10,Alberta,A02BC,Proton pump inhibitors,Total,Total,"17,363.63",1.9,30.2,"194,470",9
10,Alberta,L04AX,Other immunosuppressants,Total,Total,"16,844.48",1.8,0.6,"3,966",10
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"15,797.25",1.7,3.3,"21,227",11
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"14,038.88",1.5,2.6,"16,537",12
10,Alberta,S01LA,Antineovascularization agents,Total,Total,"13,880.81",1.5,0.2,"1,410",13
10,Alberta,R03BB,Anticholinergics,Total,Total,"13,518.67",1.4,6.2,"39,689",14
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"12,752.21",1.4,17.8,"114,984",15
10,Alberta,C09AA,"ACE inhibitors, plain",Total,Total,"12,655.45",1.4,21.6,"139,314",16
10,Alberta,C08CA,Dihydropyridine derivatives,Total,Total,"12,250.10",1.3,18.7,"120,469",17
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"12,146.65",1.3,2.1,"13,655",18
10,Alberta,N06AX,Other antidepressants,Total,Total,"11,349.97",1.2,11.9,"76,545",19
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"11,044.04",1.2,0.1,611,20
10,Alberta,N02AA,Natural opium alkaloids,Total,Total,"10,925.78",1.2,3.9,"25,429",21
10,Alberta,H03AA,Thyroid hormones,Total,Total,"10,030.13",1.1,21.1,"136,307",22
10,Alberta,B03XA,Other antianemic preparations,Total,Total,"9,273.06",1,0.4,"2,299",23
10,Alberta,B01AB,Heparin group,Total,Total,"9,166.93",1,1.2,"7,844",24
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,Total,"8,436.43",0.9,18.2,"117,302",25
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"8,260.13",0.9,10.9,"70,269",26
10,Alberta,L03AX,Other immunostimulants,Total,Total,"8,153.23",0.9,0.1,657,27
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,Total,"7,900.95",0.8,14.7,"94,680",28
10,Alberta,N03AX,Other antiepileptics,Total,Total,"7,877.10",0.8,9.1,"58,379",29
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"7,582.86",0.8,6.1,"39,645",30
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"7,480.12",0.8,0.7,"4,259",31
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"7,257.64",0.8,2.4,"15,767",32
10,Alberta,H01CB,Somatostatin and analogues,Total,Total,"6,699.14",0.7,0.1,358,33
10,Alberta,M05BA,Bisphosphonates,Total,Total,"5,842.11",0.6,8.1,"52,130",34
10,Alberta,L03AB,Interferons,Total,Total,"5,710.05",0.6,0.1,345,35
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"5,522.83",0.6,3.4,"22,051",36
10,Alberta,L01XE,Protein kinase inhibitors,Total,Total,"5,447.84",0.6,0,251,37
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,326.59",0.6,3.8,"24,761",38
10,Alberta,A10BA,Biguanides,Total,Total,"5,132.67",0.5,14.2,"91,331",39
10,Alberta,R03BA,Glucocorticoids,Total,Total,"5,125.59",0.5,4.3,"27,521",40
10,Alberta,L03AA,Colony-stimulating factors,Total,Total,"5,082.02",0.5,0.1,844,41
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,Total,"5,010.62",0.5,0.9,"5,839",42
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"5,004.17",0.5,9.6,"61,644",43
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"4,804.32",0.5,7.2,"46,665",44
10,Alberta,C08DB,Benzothiazepine derivatives,Total,Total,"4,708.99",0.5,2.6,"16,970",45
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"4,159.91",0.4,1.2,"7,776",46
10,Alberta,L01XC,Monoclonal antibodies,Total,Total,"4,067.92",0.4,0,319,47
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,Total,"4,063.30",0.4,10.7,"68,840",48
10,Alberta,N04BA,Dopa and dopa derivatives,Total,Total,"4,017.85",0.4,1,"6,417",49
10,Alberta,N05AX,Other antipsychotics,Total,Total,"3,993.13",0.4,1.1,"7,227",50
10,Alberta,S01ED,Beta-blocking agents,Total,Total,"3,986.17",0.4,2.9,"18,692",51
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,Total,"3,861.61",0.4,4.3,"27,607",52
10,Alberta,B01AE,Direct thrombin inhibitors,Total,Total,"3,817.96",0.4,0.6,"4,051",53
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"3,682.81",0.4,11.1,"71,394",54
10,Alberta,S01EE,Prostaglandin analogues,Total,Total,"3,605.84",0.4,3.4,"21,642",55
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,Total,"3,601.47",0.4,2,"13,152",56
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"3,066.52",0.3,0.2,"1,377",57
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"3,019.68",0.3,11.7,"75,727",58
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"3,011.62",0.3,2.8,"18,212",59
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,Total,"2,903.47",0.3,0.7,"4,771",60
10,Alberta,C03CA,"Sulfonamides, plain",Total,Total,"2,891.27",0.3,7.7,"49,850",61
10,Alberta,R07AX,Other respiratory system products,Total,Total,"2,854.39",0.3,0,13,62
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"2,801.25",0.3,3.8,"24,810",63
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"2,788.08",0.3,0,10,64
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"2,615.70",0.3,0.6,"4,113",65
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"2,349.91",0.3,3.5,"22,701",66
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,Total,"2,168.58",0.2,4.2,"27,386",67
10,Alberta,C01DA,Organic nitrates,Total,Total,"2,148.20",0.2,4.1,"26,399",68
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,Total,"2,139.06",0.2,1.7,"10,980",69
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"2,093.97",0.2,0.2,"1,281",70
10,Alberta,L01BA,Folic acid analogues,Total,Total,"2,067.15",0.2,1.6,"10,386",71
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,Total,"2,057.41",0.2,6.9,"44,417",72
10,Alberta,A10BB,Sulfonylureas,Total,Total,"2,057.36",0.2,4.4,"28,229",73
10,Alberta,A09AA,Enzyme preparations,Total,Total,"2,047.70",0.2,0.3,"2,077",74
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,040.53",0.2,4.1,"26,230",75
10,Alberta,H02AB,Glucocorticoids,Total,Total,"2,020.34",0.2,10.5,"67,563",76
10,Alberta,C03AA,"Thiazides, plain",Total,Total,"1,929.26",0.2,7.9,"51,110",77
10,Alberta,A16AB,Enzymes,Total,Total,"1,872.36",0.2,0,9,78
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,Total,"1,848.01",0.2,9.2,"59,216",79
10,Alberta,N07BC,Drugs used in opioid dependence,Total,Total,"1,786.03",0.2,0.3,"1,748",80
10,Alberta,A07AA,Antibiotics,Total,Total,"1,755.32",0.2,1.4,"9,001",81
10,Alberta,N05BA,Benzodiazepine derivatives,Total,Total,"1,700.37",0.2,6.5,"41,667",82
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"1,647.02",0.2,0.4,"2,779",83
10,Alberta,B01AA,Vitamin K antagonists,Total,Total,"1,640.95",0.2,2.5,"16,289",84
10,Alberta,G03DA,Pregnen (4) derivatives,Total,Total,"1,617.71",0.2,0.8,"5,322",85
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"1,608.79",0.2,0.8,"5,314",86
10,Alberta,V03AC,Iron-chelating agents,Total,Total,"1,592.35",0.2,0,110,87
10,Alberta,C03DA,Aldosterone antagonists,Total,Total,"1,556.79",0.2,2.8,"18,123",88
10,Alberta,N06DA,Anticholinesterases,Total,Total,"1,552.40",0.2,1,"6,427",89
10,Alberta,R01AD,Corticosteroids,Total,Total,"1,532.34",0.2,7,"45,232",90
10,Alberta,A04AD,Other antiemetics,Total,Total,"1,521.12",0.2,0.4,"2,736",91
10,Alberta,J01MA,Fluoroquinolones,Total,Total,"1,388.58",0.1,9,"57,872",92
10,Alberta,J01CA,Penicillins with extended spectrum,Total,Total,"1,367.24",0.1,12.3,"79,401",93
10,Alberta,C10AX,Other lipid-modifying agents,Total,Total,"1,363.66",0.1,1.7,"10,730",94
10,Alberta,J01FA,Macrolides,Total,Total,"1,348.39",0.1,8.4,"54,213",95
10,Alberta,D05AX,Other antipsoriatics for topical use,Total,Total,"1,257.55",0.1,0.9,"5,762",96
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,198.79",0.1,0.3,"1,857",97
10,Alberta,A12BA,Potassium,Total,Total,"1,170.11",0.1,2.7,"17,552",98
10,Alberta,M01AE,Propionic acid derivatives,Total,Total,"1,141.57",0.1,5.7,"36,767",99
10,Alberta,P01BA,Aminoquinolines,Total,Total,"1,030.79",0.1,1.3,"8,663",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"92,890.14",20.8,1.4,"4,033",1
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,M,"23,121.20",5.2,0.2,447,2
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,M,"18,294.90",4.1,7.5,"21,534",3
10,Alberta,L04AA,Selective immunosuppressants,Total,M,"15,435.92",3.5,0.4,"1,179",4
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"13,990.17",3.1,5.7,"16,206",5
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"13,251.22",3,6.3,"17,943",6
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,M,"12,442.71",2.8,51.5,"147,146",7
10,Alberta,L04AC,Interleukin inhibitors,Total,M,"11,674.38",2.6,0.3,743,8
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"9,682.00",2.2,4.5,"12,914",9
10,Alberta,L04AX,Other immunosuppressants,Total,M,"8,208.87",1.8,0.6,"1,634",10
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"7,622.97",1.7,3.1,"8,896",11
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"7,201.04",1.6,2.8,"8,010",12
10,Alberta,A02BC,Proton pump inhibitors,Total,M,"7,144.74",1.6,28.8,"82,327",13
10,Alberta,R03BB,Anticholinergics,Total,M,"6,719.00",1.5,6.8,"19,348",14
10,Alberta,C09AA,"ACE inhibitors, plain",Total,M,"6,676.26",1.5,26.5,"75,669",15
10,Alberta,C08CA,Dihydropyridine derivatives,Total,M,"5,618.22",1.3,19.6,"56,055",16
10,Alberta,S01LA,Antineovascularization agents,Total,M,"5,492.48",1.2,0.2,583,17
10,Alberta,B03XA,Other antianemic preparations,Total,M,"5,428.95",1.2,0.5,"1,338",18
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"5,214.24",1.2,17.1,"48,840",19
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"5,075.44",1.1,0.1,255,20
10,Alberta,N02AA,Natural opium alkaloids,Total,M,"4,923.52",1.1,3.6,"10,381",21
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"4,920.24",1.1,21,"60,033",22
10,Alberta,B01AB,Heparin group,Total,M,"4,496.59",1,1.2,"3,290",23
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"4,400.72",1,3.1,"8,796",24
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,M,"4,341.88",1,22.1,"63,148",25
10,Alberta,L01XE,Protein kinase inhibitors,Total,M,"3,874.21",0.9,0.1,176,26
10,Alberta,H01CB,Somatostatin and analogues,Total,M,"3,839.63",0.9,0.1,186,27
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"3,498.26",0.8,5.4,"15,403",28
10,Alberta,N06AX,Other antidepressants,Total,M,"3,439.83",0.8,8.8,"25,065",29
10,Alberta,N03AX,Other antiepileptics,Total,M,"3,058.03",0.7,7.9,"22,515",30
10,Alberta,A10BA,Biguanides,Total,M,"2,784.48",0.6,17.5,"49,949",31
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"2,754.82",0.6,8.5,"24,176",32
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,M,"2,742.80",0.6,12,"34,157",33
10,Alberta,H03AA,Thyroid hormones,Total,M,"2,559.95",0.6,13,"37,025",34
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,M,"2,536.27",0.6,7.7,"21,865",35
10,Alberta,N04BA,Dopa and dopa derivatives,Total,M,"2,459.41",0.6,1.3,"3,657",36
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,M,"2,415.72",0.5,0.9,"2,608",37
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"2,316.89",0.5,0.4,"1,055",38
10,Alberta,B01AE,Direct thrombin inhibitors,Total,M,"2,262.93",0.5,0.8,"2,423",39
10,Alberta,L03AX,Other immunostimulants,Total,M,"2,224.20",0.5,0.1,182,40
10,Alberta,R03BA,Glucocorticoids,Total,M,"2,187.66",0.5,4,"11,294",41
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"2,149.94",0.5,1.4,"3,959",42
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,M,"2,059.69",0.5,5.1,"14,594",43
10,Alberta,C08DB,Benzothiazepine derivatives,Total,M,"2,047.17",0.5,2.5,"7,222",44
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"2,030.98",0.5,7,"20,129",45
10,Alberta,R07AX,Other respiratory system products,Total,M,"1,920.76",0.4,0,8,46
10,Alberta,S01ED,Beta-blocking agents,Total,M,"1,843.40",0.4,3.1,"8,819",47
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,**,**,**,**,48
10,Alberta,N05AX,Other antipsychotics,Total,M,"1,758.68",0.4,1,"2,767",49
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,M,"1,660.97",0.4,2.3,"6,583",50
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,577.09",0.4,11.4,"32,478",51
10,Alberta,S01EE,Prostaglandin analogues,Total,M,"1,559.69",0.3,3.3,"9,491",52
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,M,"1,544.05",0.3,6.9,"19,737",53
10,Alberta,L03AB,Interferons,Total,M,"1,523.44",0.3,0,87,54
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"1,508.66",0.3,0.3,957,55
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,M,"1,456.02",0.3,8.7,"24,843",56
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,M,"1,417.07",0.3,0.8,"2,263",57
10,Alberta,L03AA,Colony-stimulating factors,Total,M,"1,406.15",0.3,0.1,290,58
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,368.44",0.3,2.5,"7,138",59
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"1,334.49",0.3,10.9,"31,129",60
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"1,311.73",0.3,0.3,808,61
10,Alberta,C03CA,"Sulfonamides, plain",Total,M,"1,277.54",0.3,8,"22,860",62
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,M,"1,254.82",0.3,2.3,"6,463",63
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,M,"1,195.32",0.3,1.5,"4,428",64
10,Alberta,A10BB,Sulfonylureas,Total,M,"1,185.29",0.3,5.7,"16,349",65
10,Alberta,C01DA,Organic nitrates,Total,M,"1,106.43",0.2,5.3,"15,189",66
10,Alberta,L01XC,Monoclonal antibodies,Total,M,"1,075.00",0.2,0,85,67
10,Alberta,A09AA,Enzyme preparations,Total,M,"1,030.35",0.2,0.3,900,68
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,M,992.85,0.2,7.8,"22,176",69
10,Alberta,N07BC,Drugs used in opioid dependence,Total,M,966.41,0.2,0.3,888,70
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,M,906.73,0.2,9.3,"26,526",71
10,Alberta,A07AA,Antibiotics,Total,M,898.69,0.2,1.1,"3,277",72
10,Alberta,H02AB,Glucocorticoids,Total,M,892.81,0.2,10.3,"29,431",73
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,882.27,0.2,0.5,"1,435",74
10,Alberta,B01AA,Vitamin K antagonists,Total,M,865.15,0.2,3.2,"9,006",75
10,Alberta,V03AC,Iron-chelating agents,Total,M,861.22,0.2,0,64,76
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,846.27,0.2,3,"8,626",77
10,Alberta,A16AB,Enzymes,Total,M,**,**,**,**,78
10,Alberta,C03DA,Aldosterone antagonists,Total,M,833.4,0.2,3.2,"9,131",79
10,Alberta,M05BA,Bisphosphonates,Total,M,785.34,0.2,2.5,"7,063",80
10,Alberta,C10AX,Other lipid-modifying agents,Total,M,776.16,0.2,2.2,"6,194",81
10,Alberta,D05AX,Other antipsoriatics for topical use,Total,M,721.47,0.2,1,"2,972",82
10,Alberta,L01BA,Folic acid analogues,Total,M,714.95,0.2,1.3,"3,622",83
10,Alberta,C03AA,"Thiazides, plain",Total,M,710.63,0.2,6.8,"19,516",84
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,679.35,0.2,0.3,991,85
10,Alberta,R01AD,Corticosteroids,Total,M,674.42,0.2,6.5,"18,663",86
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,635.03,0.1,2.3,"6,521",87
10,Alberta,J01CA,Penicillins with extended spectrum,Total,M,609.56,0.1,12.3,"35,221",88
10,Alberta,J01MA,Fluoroquinolones,Total,M,609.43,0.1,8.7,"24,988",89
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,Total,M,580.1,0.1,1.1,"3,264",90
10,Alberta,N06DA,Anticholinesterases,Total,M,565.37,0.1,0.9,"2,433",91
10,Alberta,J01FA,Macrolides,Total,M,561.04,0.1,7.7,"22,042",92
10,Alberta,C10AB,Fibrates,Total,M,554.8,0.1,1.5,"4,200",93
10,Alberta,A04AD,Other antiemetics,Total,M,553.97,0.1,0.3,979,94
10,Alberta,N05BA,Benzodiazepine derivatives,Total,M,522.82,0.1,4.4,"12,601",95
10,Alberta,M01AE,Propionic acid derivatives,Total,M,495.64,0.1,5.5,"15,805",96
10,Alberta,J02AC,Triazole derivatives,Total,M,493.91,0.1,0.8,"2,206",97
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,486.6,0.1,0.5,"1,293",98
10,Alberta,A16AA,Amino acids and derivatives,Total,M,**,**,**,*,99
10,Alberta,J01DB,First-generation cephalosporins,Total,M,480.69,0.1,7.8,"22,228",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"83,781.42",17.2,1.2,"4,320",1
10,Alberta,L04AA,Selective immunosuppressants,Total,F,"29,570.72",6.1,0.7,"2,592",2
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,F,"16,158.04",3.3,5.5,"19,803",3
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"16,146.18",3.3,6.4,"22,797",4
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,F,"12,131.98",2.5,0.1,239,5
10,Alberta,L04AC,Interleukin inhibitors,Total,F,"11,194.09",2.3,0.2,807,6
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,F,"10,701.07",2.2,35.2,"126,308",7
10,Alberta,A02BC,Proton pump inhibitors,Total,F,"10,218.89",2.1,31.2,"112,143",8
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"9,599.92",2,3.5,"12,385",9
10,Alberta,L04AX,Other immunosuppressants,Total,F,"8,635.61",1.8,0.6,"2,332",10
10,Alberta,S01LA,Antineovascularization agents,Total,F,"8,388.33",1.7,0.2,827,11
10,Alberta,N06AX,Other antidepressants,Total,F,"7,910.14",1.6,14.3,"51,480",12
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"7,538.96",1.5,11,"39,388",13
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"7,537.97",1.5,18.4,"66,144",14
10,Alberta,H03AA,Thyroid hormones,Total,F,"7,470.18",1.5,27.7,"99,282",15
10,Alberta,R03BB,Anticholinergics,Total,F,"6,799.67",1.4,5.7,"20,341",16
10,Alberta,C08CA,Dihydropyridine derivatives,Total,F,"6,631.88",1.4,17.9,"64,414",17
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"6,415.91",1.3,2.1,"7,641",18
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"6,115.25",1.3,2.3,"8,313",19
10,Alberta,N02AA,Natural opium alkaloids,Total,F,"6,002.26",1.2,4.2,"15,048",20
10,Alberta,C09AA,"ACE inhibitors, plain",Total,F,"5,979.20",1.2,17.7,"63,645",21
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"5,971.46",1.2,0.9,"3,302",22
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"5,968.60",1.2,0.1,356,23
10,Alberta,L03AX,Other immunostimulants,Total,F,"5,929.04",1.2,0.1,475,24
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,F,"5,723.86",1.2,13.5,"48,404",25
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,F,"5,158.15",1.1,16.9,"60,523",26
10,Alberta,M05BA,Bisphosphonates,Total,F,"5,056.77",1,12.6,"45,067",27
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"4,945.61",1,1.6,"5,645",28
10,Alberta,N03AX,Other antiepileptics,Total,F,"4,819.07",1,10,"35,864",29
10,Alberta,B01AB,Heparin group,Total,F,"4,670.34",1,1.3,"4,554",30
10,Alberta,L03AB,Interferons,Total,F,"4,186.61",0.9,0.1,258,31
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,F,"4,094.55",0.8,15.1,"54,154",32
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,F,"3,861.86",0.8,4.3,"15,468",33
10,Alberta,B03XA,Other antianemic preparations,Total,F,"3,844.11",0.8,0.3,961,34
10,Alberta,L03AA,Colony-stimulating factors,Total,F,"3,675.86",0.8,0.2,554,35
10,Alberta,L01XC,Monoclonal antibodies,Total,F,"2,992.92",0.6,0.1,234,36
10,Alberta,R03BA,Glucocorticoids,Total,F,"2,937.92",0.6,4.5,"16,227",37
10,Alberta,H01CB,Somatostatin and analogues,Total,F,"2,859.51",0.6,0,172,38
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,856.92",0.6,1.9,"6,971",39
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"2,773.33",0.6,7.4,"26,536",40
10,Alberta,C08DB,Benzothiazepine derivatives,Total,F,"2,661.82",0.5,2.7,"9,748",41
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,F,"2,607.28",0.5,12.3,"43,997",42
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,F,"2,594.90",0.5,0.9,"3,231",43
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,F,"2,406.14",0.5,2.4,"8,724",44
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"2,383.97",0.5,1,"3,745",45
10,Alberta,A10BA,Biguanides,Total,F,"2,348.18",0.5,11.5,"41,382",46
10,Alberta,N05AX,Other antipsychotics,Total,F,"2,234.45",0.5,1.2,"4,460",47
10,Alberta,S01ED,Beta-blocking agents,Total,F,"2,142.77",0.4,2.8,"9,873",48
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"2,105.72",0.4,10.8,"38,916",49
10,Alberta,S01EE,Prostaglandin analogues,Total,F,"2,046.15",0.4,3.4,"12,151",50
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"2,009.97",0.4,1.1,"3,817",51
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,828.34",0.4,2.6,"9,358",52
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,F,"1,801.91",0.4,3.6,"13,013",53
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"1,714.87",0.4,4.5,"16,180",54
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"1,685.19",0.3,12.4,"44,598",55
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"1,643.18",0.3,3.1,"11,074",56
10,Alberta,C03CA,"Sulfonamides, plain",Total,F,"1,613.73",0.3,7.5,"26,990",57
10,Alberta,G03DA,Pregnen (4) derivatives,Total,F,"1,601.56",0.3,1.5,"5,257",58
10,Alberta,L01XE,Protein kinase inhibitors,Total,F,"1,573.63",0.3,0,75,59
10,Alberta,N04BA,Dopa and dopa derivatives,Total,F,"1,558.44",0.3,0.8,"2,760",60
10,Alberta,B01AE,Direct thrombin inhibitors,Total,F,"1,555.03",0.3,0.5,"1,628",61
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,F,"1,486.40",0.3,0.7,"2,508",62
10,Alberta,L01BA,Folic acid analogues,Total,F,"1,352.21",0.3,1.9,"6,764",63
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,349.04",0.3,1.3,"4,550",64
10,Alberta,C03AA,"Thiazides, plain",Total,F,"1,218.63",0.3,8.8,"31,594",65
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,194.26",0.2,4.9,"17,604",66
10,Alberta,N05BA,Benzodiazepine derivatives,Total,F,"1,177.56",0.2,8.1,"29,066",67
10,Alberta,H02AB,Glucocorticoids,Total,F,"1,127.52",0.2,10.6,"38,131",68
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,F,"1,064.57",0.2,6.2,"22,241",69
10,Alberta,C01DA,Organic nitrates,Total,F,"1,041.77",0.2,3.1,"11,210",70
10,Alberta,A16AB,Enzymes,Total,F,**,**,**,*,71
10,Alberta,A09AA,Enzyme preparations,Total,F,"1,017.35",0.2,0.3,"1,177",72
10,Alberta,N06DA,Anticholinesterases,Total,F,987.03,0.2,1.1,"3,994",73
10,Alberta,A04AD,Other antiemetics,Total,F,967.15,0.2,0.5,"1,757",74
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,**,**,**,*,75
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,F,941.28,0.2,9.1,"32,690",76
10,Alberta,R07AX,Other respiratory system products,Total,F,933.63,0.2,0,5,77
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,F,884.23,0.2,1.3,"4,517",78
10,Alberta,A10BB,Sulfonylureas,Total,F,872.07,0.2,3.3,"11,880",79
10,Alberta,R01AD,Corticosteroids,Total,F,857.92,0.2,7.4,"26,569",80
10,Alberta,A07AA,Antibiotics,Total,F,856.62,0.2,1.6,"5,724",81
10,Alberta,N07BC,Drugs used in opioid dependence,Total,F,819.63,0.2,0.2,860,82
10,Alberta,J01FA,Macrolides,Total,F,787.34,0.2,9,"32,171",83
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,782.25,0.2,0.1,473,84
10,Alberta,J01MA,Fluoroquinolones,Total,F,779.14,0.2,9.2,"32,884",85
10,Alberta,B01AA,Vitamin K antagonists,Total,F,775.8,0.2,2,"7,283",86
10,Alberta,A12BA,Potassium,Total,F,773.09,0.2,3.2,"11,419",87
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,764.75,0.2,0.4,"1,344",88
10,Alberta,J01CA,Penicillins with extended spectrum,Total,F,757.67,0.2,12.3,"44,179",89
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,749.63,0.2,0.1,322,90
10,Alberta,P01BA,Aminoquinolines,Total,F,733.75,0.2,1.7,"6,251",91
10,Alberta,V03AC,Iron-chelating agents,Total,F,731.14,0.2,0,46,92
10,Alberta,C03DA,Aldosterone antagonists,Total,F,723.39,0.1,2.5,"8,992",93
10,Alberta,A16AX,Various alimentary tract and metabolism products,Total,F,700.84,0.1,0,6,94
10,Alberta,A05AA,Bile acids and derivatives,Total,F,677.67,0.1,0.3,"1,019",95
10,Alberta,N05AE,Indole derivatives,Total,F,657.63,0.1,0.2,554,96
10,Alberta,M01AE,Propionic acid derivatives,Total,F,645.93,0.1,5.8,"20,962",97
10,Alberta,J01XE,Nitrofuran derivatives,Total,F,644.59,0.1,7.3,"26,187",98
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,F,624.53,0.1,2.1,"7,649",99
10,Alberta,N02AB,Phenylpiperidine derivatives,Total,F,593.56,0.1,0.3,906,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"49,139.17",8,0.5,"2,422",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,Total,"33,410.39",5.4,7.4,"39,660",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"26,344.92",4.3,6.6,"35,677",3
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,Total,"21,356.49",3.5,46.1,"247,951",4
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"19,338.41",3.1,4.4,"23,850",5
10,Alberta,A02BC,Proton pump inhibitors,65+,Total,"15,560.32",2.5,31.6,"169,929",6
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,Total,"14,221.08",2.3,0.1,275,7
10,Alberta,S01LA,Antineovascularization agents,65+,Total,"13,600.99",2.2,0.3,"1,375",8
10,Alberta,L04AA,Selective immunosuppressants,65+,Total,"13,396.67",2.2,0.4,"1,894",9
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"13,228.79",2.2,3.3,"17,615",10
10,Alberta,R03BB,Anticholinergics,65+,Total,"12,775.43",2.1,6.9,"37,010",11
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"12,673.86",2.1,2.8,"14,789",12
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"11,768.96",1.9,19.5,"104,651",13
10,Alberta,C09AA,"ACE inhibitors, plain",65+,Total,"11,684.55",1.9,23.5,"126,505",14
10,Alberta,C08CA,Dihydropyridine derivatives,65+,Total,"11,421.74",1.9,20.7,"111,009",15
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"10,323.40",1.7,2.1,"11,446",16
10,Alberta,N06AX,Other antidepressants,65+,Total,"8,969.59",1.5,11.5,"61,718",17
10,Alberta,H03AA,Thyroid hormones,65+,Total,"8,800.77",1.4,22.3,"119,703",18
10,Alberta,L04AC,Interleukin inhibitors,65+,Total,"8,482.53",1.4,0.1,576,19
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,Total,"8,002.11",1.3,20.4,"109,738",20
10,Alberta,B03XA,Other antianemic preparations,65+,Total,"7,746.78",1.3,0.4,"1,922",21
10,Alberta,N02AA,Natural opium alkaloids,65+,Total,"7,490.94",1.2,3.9,"21,210",22
10,Alberta,B01AB,Heparin group,65+,Total,"7,404.74",1.2,1.3,"6,775",23
10,Alberta,L04AX,Other immunosuppressants,65+,Total,"7,312.68",1.2,0.4,"2,216",24
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,Total,"7,194.79",1.2,15.6,"83,994",25
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"6,669.10",1.1,10.4,"55,693",26
10,Alberta,N03AX,Other antiepileptics,65+,Total,"6,188.93",1,9.1,"48,903",27
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"6,149.14",1,5.9,"31,859",28
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"5,743.64",0.9,0.1,300,29
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"5,634.97",0.9,2.3,"12,471",30
10,Alberta,M05BA,Bisphosphonates,65+,Total,"5,469.94",0.9,9.1,"48,788",31
10,Alberta,L01XE,Protein kinase inhibitors,65+,Total,"5,140.42",0.8,0,233,32
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"5,058.08",0.8,3.7,"20,022",33
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"4,954.84",0.8,4.3,"23,257",34
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"4,854.43",0.8,11,"59,051",35
10,Alberta,H01CB,Somatostatin and analogues,65+,Total,"4,832.00",0.8,0,253,36
10,Alberta,A10BA,Biguanides,65+,Total,"4,661.78",0.8,15.1,"81,183",37
10,Alberta,C08DB,Benzothiazepine derivatives,65+,Total,"4,404.25",0.7,2.9,"15,766",38
10,Alberta,R03BA,Glucocorticoids,65+,Total,"4,375.08",0.7,4.2,"22,414",39
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"4,342.31",0.7,7.8,"41,832",40
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"3,966.28",0.6,1.4,"7,358",41
10,Alberta,S01ED,Beta-blocking agents,65+,Total,"3,843.64",0.6,3.3,"17,879",42
10,Alberta,N04BA,Dopa and dopa derivatives,65+,Total,"3,836.39",0.6,1.1,"6,121",43
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"3,773.75",0.6,0.4,"2,354",44
10,Alberta,B01AE,Direct thrombin inhibitors,65+,Total,"3,690.04",0.6,0.7,"3,890",45
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,Total,"3,642.94",0.6,0.8,"4,168",46
10,Alberta,L03AA,Colony-stimulating factors,65+,Total,"3,626.45",0.6,0.1,621,47
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,Total,"3,562.54",0.6,11.1,"59,605",48
10,Alberta,S01EE,Prostaglandin analogues,65+,Total,"3,464.74",0.6,3.8,"20,652",49
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,Total,"3,435.18",0.6,4.5,"24,302",50
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"3,097.18",0.5,11.2,"60,238",51
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"2,820.26",0.5,0.2,"1,262",52
10,Alberta,C03CA,"Sulfonamides, plain",65+,Total,"2,787.56",0.5,8.8,"47,154",53
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"2,727.99",0.4,4.4,"23,902",54
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,Total,"2,624.95",0.4,1.9,"10,200",55
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,599.06",0.4,11.8,"63,185",56
10,Alberta,L01XC,Monoclonal antibodies,65+,Total,"2,575.73",0.4,0,199,57
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"2,529.25",0.4,0.7,"3,971",58
10,Alberta,N05AX,Other antipsychotics,65+,Total,"2,484.08",0.4,1,"5,383",59
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"2,112.48",0.3,2.6,"14,145",60
10,Alberta,C01DA,Organic nitrates,65+,Total,"2,082.47",0.3,4.7,"25,063",61
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,Total,"2,036.76",0.3,4.7,"25,373",62
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,Total,"1,954.95",0.3,1.9,"10,019",63
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,867.33",0.3,3.4,"18,295",64
10,Alberta,A10BB,Sulfonylureas,65+,Total,"1,857.11",0.3,4.7,"25,096",65
10,Alberta,C03AA,"Thiazides, plain",65+,Total,"1,783.87",0.3,8.6,"46,443",66
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,Total,"1,705.41",0.3,6.7,"36,115",67
10,Alberta,H02AB,Glucocorticoids,65+,Total,"1,674.08",0.3,10.5,"56,289",68
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,638.44",0.3,9.6,"51,383",69
10,Alberta,L01BA,Folic acid analogues,65+,Total,"1,608.10",0.3,1.5,"7,796",70
10,Alberta,B01AA,Vitamin K antagonists,65+,Total,"1,562.65",0.3,2.9,"15,434",71
10,Alberta,N06DA,Anticholinesterases,65+,Total,"1,545.15",0.3,1.2,"6,392",72
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"1,520.92",0.2,3.8,"20,340",73
10,Alberta,C03DA,Aldosterone antagonists,65+,Total,"1,414.41",0.2,3.1,"16,416",74
10,Alberta,A07AA,Antibiotics,65+,Total,"1,414.08",0.2,1.4,"7,623",75
10,Alberta,N05BA,Benzodiazepine derivatives,65+,Total,"1,402.19",0.2,6.3,"33,844",76
10,Alberta,A09AA,Enzyme preparations,65+,Total,"1,366.28",0.2,0.3,"1,655",77
10,Alberta,R01AD,Corticosteroids,65+,Total,"1,312.73",0.2,7,"37,702",78
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"1,285.00",0.2,0.4,"2,130",79
10,Alberta,J01MA,Fluoroquinolones,65+,Total,"1,161.13",0.2,9.5,"50,986",80
10,Alberta,C10AX,Other lipid-modifying agents,65+,Total,"1,143.74",0.2,1.8,"9,856",81
10,Alberta,J01CA,Penicillins with extended spectrum,65+,Total,"1,125.89",0.2,12.1,"64,957",82
10,Alberta,A12BA,Potassium,65+,Total,"1,105.67",0.2,3,"16,289",83
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"1,104.90",0.2,0.3,"1,722",84
10,Alberta,J01FA,Macrolides,65+,Total,"1,097.90",0.2,8.1,"43,728",85
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"1,075.97",0.2,0.1,644,86
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,Total,"1,028.82",0.2,0.9,"4,739",87
10,Alberta,A04AD,Other antiemetics,65+,Total,"1,011.61",0.2,0.4,"2,006",88
10,Alberta,G03DA,Pregnen (4) derivatives,65+,Total,992.59,0.2,0.6,"3,214",89
10,Alberta,C03BA,"Sulfonamides, plain",65+,Total,919.97,0.1,3.2,"17,087",90
10,Alberta,N07BC,Drugs used in opioid dependence,65+,Total,**,**,**,**,91
10,Alberta,M01AE,Propionic acid derivatives,65+,Total,905.13,0.1,5.4,"28,763",92
10,Alberta,C10AB,Fibrates,65+,Total,884.96,0.1,1.2,"6,533",93
10,Alberta,L03AX,Other immunostimulants,65+,Total,867.5,0.1,0,57,94
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,Total,866.9,0.1,0.5,"2,474",95
10,Alberta,J01DB,First-generation cephalosporins,65+,Total,853.65,0.1,7.6,"40,709",96
10,Alberta,S01BA,"Corticosteroids, plain",65+,Total,844.7,0.1,4.1,"21,920",97
10,Alberta,P01BA,Aminoquinolines,65+,Total,820.35,0.1,1.2,"6,696",98
10,Alberta,L03AB,Interferons,65+,Total,809.97,0.1,0,41,99
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,Total,808.29,0.1,1,"5,458",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"22,578.45",7.6,0.4,"1,040",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,M,"17,738.47",6,8.3,"20,737",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"12,149.27",4.1,6.5,"16,169",3
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"11,690.57",3.9,5.5,"13,812",4
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,M,"11,647.92",3.9,54.6,"136,125",5
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,M,"9,324.68",3.1,0.1,180,6
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"8,369.79",2.8,4.4,"11,090",7
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"7,004.80",2.4,3.3,"8,125",8
10,Alberta,A02BC,Proton pump inhibitors,65+,M,"6,557.98",2.2,29.9,"74,478",9
10,Alberta,R03BB,Anticholinergics,65+,M,"6,435.94",2.2,7.4,"18,376",10
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"6,296.24",2.1,2.8,"6,934",11
10,Alberta,C09AA,"ACE inhibitors, plain",65+,M,"6,228.00",2.1,28,"69,843",12
10,Alberta,S01LA,Antineovascularization agents,65+,M,"5,323.89",1.8,0.2,563,13
10,Alberta,C08CA,Dihydropyridine derivatives,65+,M,"5,246.69",1.8,20.9,"52,000",14
10,Alberta,L04AA,Selective immunosuppressants,65+,M,"5,206.10",1.8,0.3,648,15
10,Alberta,L04AX,Other immunosuppressants,65+,M,"5,019.76",1.7,0.4,964,16
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"4,880.97",1.6,18.2,"45,343",17
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"4,781.11",1.6,23.2,"57,766",18
10,Alberta,B03XA,Other antianemic preparations,65+,M,"4,687.04",1.6,0.5,"1,138",19
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,M,"4,117.84",1.4,23.9,"59,484",20
10,Alberta,L04AC,Interleukin inhibitors,65+,M,"4,048.88",1.4,0.1,258,21
10,Alberta,B01AB,Heparin group,65+,M,"3,823.82",1.3,1.2,"2,925",22
10,Alberta,L01XE,Protein kinase inhibitors,65+,M,**,**,**,**,23
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"3,475.96",1.2,2.9,"7,117",24
10,Alberta,N02AA,Natural opium alkaloids,65+,M,"3,403.96",1.1,3.5,"8,834",25
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"3,243.32",1.1,5.8,"14,499",26
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"2,989.11",1,0.1,152,27
10,Alberta,N06AX,Other antidepressants,65+,M,"2,853.02",1,8.5,"21,280",28
10,Alberta,H01CB,Somatostatin and analogues,65+,M,"2,780.28",0.9,0.1,130,29
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"2,690.76",0.9,9.4,"23,408",30
10,Alberta,A10BA,Biguanides,65+,M,"2,580.00",0.9,18.3,"45,683",31
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,M,"2,575.33",0.9,12.7,"31,555",32
10,Alberta,N03AX,Other antiepileptics,65+,M,"2,543.95",0.9,7.9,"19,764",33
10,Alberta,H03AA,Thyroid hormones,65+,M,"2,386.98",0.8,13.9,"34,542",34
10,Alberta,N04BA,Dopa and dopa derivatives,65+,M,"2,361.49",0.8,1.4,"3,522",35
10,Alberta,B01AE,Direct thrombin inhibitors,65+,M,"2,184.05",0.7,0.9,"2,324",36
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"2,145.67",0.7,0.4,970,37
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,111.69",0.7,7.2,"18,027",38
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"2,074.27",0.7,1.5,"3,794",39
10,Alberta,C08DB,Benzothiazepine derivatives,65+,M,"1,912.11",0.6,2.7,"6,728",40
10,Alberta,R03BA,Glucocorticoids,65+,M,"1,911.67",0.6,3.8,"9,551",41
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"1,872.95",0.6,7.4,"18,478",42
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,M,"1,869.70",0.6,5.3,"13,137",43
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,M,"1,815.24",0.6,0.8,"1,931",44
10,Alberta,S01ED,Beta-blocking agents,65+,M,"1,786.31",0.6,3.4,"8,510",45
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,M,"1,589.44",0.5,2.5,"6,250",46
10,Alberta,S01EE,Prostaglandin analogues,65+,M,"1,517.81",0.5,3.7,"9,193",47
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,M,"1,448.54",0.5,7.3,"18,320",48
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"1,379.73",0.5,11.5,"28,775",49
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,M,"1,310.93",0.4,9,"22,403",50
10,Alberta,C03CA,"Sulfonamides, plain",65+,M,"1,232.62",0.4,8.7,"21,801",51
10,Alberta,L03AA,Colony-stimulating factors,65+,M,"1,205.03",0.4,0.1,252,52
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,182.36",0.4,10.8,"26,943",53
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,M,"1,152.92",0.4,2.4,"5,936",54
10,Alberta,A10BB,Sulfonylureas,65+,M,"1,090.17",0.4,6,"14,856",55
10,Alberta,C01DA,Organic nitrates,65+,M,"1,068.28",0.4,5.8,"14,465",56
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"1,053.35",0.4,0.3,706,57
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,M,962.62,0.3,1.5,"3,675",58
10,Alberta,N05AX,Other antipsychotics,65+,M,935.43,0.3,0.8,"1,977",59
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,905.91,0.3,2.3,"5,766",60
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,M,871.05,0.3,7.8,"19,354",61
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,M,840.69,0.3,9.7,"24,240",62
10,Alberta,B01AA,Vitamin K antagonists,65+,M,828.14,0.3,3.4,"8,595",63
10,Alberta,C03DA,Aldosterone antagonists,65+,M,768.52,0.3,3.4,"8,468",64
10,Alberta,H02AB,Glucocorticoids,65+,M,765.34,0.3,10.3,"25,669",65
10,Alberta,M05BA,Bisphosphonates,65+,M,760.83,0.3,2.7,"6,794",66
10,Alberta,L01XC,Monoclonal antibodies,65+,M,748.46,0.3,0,58,67
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,727.72,0.2,0.5,"1,170",68
10,Alberta,A07AA,Antibiotics,65+,M,723.97,0.2,1.2,"2,887",69
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,674.06,0.2,3,"7,404",70
10,Alberta,C03AA,"Thiazides, plain",65+,M,667.46,0.2,7.3,"18,171",71
10,Alberta,A09AA,Enzyme preparations,65+,M,666.87,0.2,0.3,712,72
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,661.26,0.2,0.2,408,73
10,Alberta,C10AX,Other lipid-modifying agents,65+,M,659.61,0.2,2.3,"5,728",74
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,635.58,0.2,0.4,927,75
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,M,610.92,0.2,1,"2,575",76
10,Alberta,R01AD,Corticosteroids,65+,M,609.16,0.2,6.6,"16,540",77
10,Alberta,L01BA,Folic acid analogues,65+,M,574.58,0.2,1.1,"2,812",78
10,Alberta,N06DA,Anticholinesterases,65+,M,561.31,0.2,1,"2,418",79
10,Alberta,J01MA,Fluoroquinolones,65+,M,556.9,0.2,9.3,"23,093",80
10,Alberta,J01CA,Penicillins with extended spectrum,65+,M,531.23,0.2,12.3,"30,566",81
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,522.58,0.2,2.2,"5,560",82
10,Alberta,V03AC,Iron-chelating agents,65+,M,522.47,0.2,0,47,83
10,Alberta,N07BC,Drugs used in opioid dependence,65+,M,494.01,0.2,0.2,501,84
10,Alberta,J01FA,Macrolides,65+,M,485.25,0.2,7.6,"18,984",85
10,Alberta,C10AB,Fibrates,65+,M,482.99,0.2,1.4,"3,607",86
10,Alberta,N05BA,Benzodiazepine derivatives,65+,M,437.58,0.1,4.3,"10,697",87
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,65+,M,437.47,0.1,1,"2,546",88
10,Alberta,J01DB,First-generation cephalosporins,65+,M,425.93,0.1,8,"19,863",89
10,Alberta,A10BX,"Other blood glucose–lowering drugs, excluding insulins",65+,M,420.76,0.1,1.5,"3,864",90
10,Alberta,M01AE,Propionic acid derivatives,65+,M,420.69,0.1,5.4,"13,367",91
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,415.06,0.1,0.4,"1,109",92
10,Alberta,C03BA,"Sulfonamides, plain",65+,M,406.41,0.1,3.1,"7,758",93
10,Alberta,J02AC,Triazole derivatives,65+,M,403.93,0.1,0.8,"1,875",94
10,Alberta,A04AD,Other antiemetics,65+,M,394.07,0.1,0.3,778,95
10,Alberta,M04AC,Preparations with no effect on uric acid metabolism,65+,M,392.14,0.1,3.9,"9,741",96
10,Alberta,C10AC,Bile acid sequestrants,65+,M,383.61,0.1,0.4,"1,102",97
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,M,379.23,0.1,1.1,"2,653",98
10,Alberta,A12BA,Potassium,65+,M,377.94,0.1,2.3,"5,791",99
10,Alberta,D01AC,Imidazole and triazole derivatives,65+,M,377.65,0.1,2.8,"6,941",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"26,560.72",8.3,0.5,"1,382",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,F,"15,671.92",4.9,6.6,"18,923",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"14,195.64",4.5,6.8,"19,508",3
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,F,"9,708.57",3.1,38.8,"111,826",4
10,Alberta,A02BC,Proton pump inhibitors,65+,F,"9,002.34",2.8,33.1,"95,451",5
10,Alberta,S01LA,Antineovascularization agents,65+,F,"8,277.10",2.6,0.3,812,6
10,Alberta,L04AA,Selective immunosuppressants,65+,F,"8,190.57",2.6,0.4,"1,246",7
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"7,647.84",2.4,3.5,"10,038",8
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"6,887.99",2.2,20.6,"59,308",9
10,Alberta,H03AA,Thyroid hormones,65+,F,"6,413.79",2,29.6,"85,161",10
10,Alberta,R03BB,Anticholinergics,65+,F,"6,339.48",2,6.5,"18,634",11
10,Alberta,C08CA,Dihydropyridine derivatives,65+,F,"6,175.04",1.9,20.5,"59,009",12
10,Alberta,N06AX,Other antidepressants,65+,F,"6,116.57",1.9,14,"40,438",13
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"6,114.32",1.9,11,"31,656",14
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"5,669.06",1.8,2.3,"6,664",15
10,Alberta,C09AA,"ACE inhibitors, plain",65+,F,"5,456.55",1.7,19.7,"56,662",16
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,F,"4,896.40",1.5,0,95,17
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"4,858.99",1.5,2.3,"6,525",18
10,Alberta,M05BA,Bisphosphonates,65+,F,"4,709.11",1.5,14.6,"41,994",19
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,F,"4,619.47",1.5,18.2,"52,439",20
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,F,"4,557.40",1.4,13.1,"37,666",21
10,Alberta,L04AC,Interleukin inhibitors,65+,F,"4,433.65",1.4,0.1,318,22
10,Alberta,N02AA,Natural opium alkaloids,65+,F,"4,086.98",1.3,4.3,"12,376",23
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"4,027.16",1.3,1.6,"4,512",24
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,F,"3,884.28",1.2,17.4,"50,254",25
10,Alberta,N03AX,Other antiepileptics,65+,F,"3,644.99",1.1,10.1,"29,139",26
10,Alberta,B01AB,Heparin group,65+,F,"3,580.92",1.1,1.3,"3,850",27
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,F,"3,468.63",1.1,4.8,"13,772",28
10,Alberta,B03XA,Other antianemic preparations,65+,F,"3,059.74",1,0.3,784,29
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"2,754.54",0.9,0.1,148,30
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"2,720.39",0.9,0.6,"1,648",31
10,Alberta,C08DB,Benzothiazepine derivatives,65+,F,"2,492.14",0.8,3.1,"9,038",32
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"2,469.36",0.8,8.1,"23,354",33
10,Alberta,R03BA,Glucocorticoids,65+,F,"2,463.41",0.8,4.5,"12,863",34
10,Alberta,L03AA,Colony-stimulating factors,65+,F,"2,421.42",0.8,0.1,369,35
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"2,301.07",0.7,1.3,"3,609",36
10,Alberta,L04AX,Other immunosuppressants,65+,F,"2,292.92",0.7,0.4,"1,252",37
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,F,"2,251.61",0.7,12.9,"37,202",38
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"2,159.01",0.7,1.9,"5,354",39
10,Alberta,A10BA,Biguanides,65+,F,"2,081.78",0.7,12.3,"35,500",40
10,Alberta,S01ED,Beta-blocking agents,65+,F,"2,057.34",0.6,3.3,"9,369",41
10,Alberta,H01CB,Somatostatin and analogues,65+,F,"2,051.72",0.6,0,123,42
10,Alberta,S01EE,Prostaglandin analogues,65+,F,"1,946.93",0.6,4,"11,459",43
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"1,892.01",0.6,1.2,"3,564",44
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,827.70",0.6,0.8,"2,237",45
10,Alberta,L01XC,Monoclonal antibodies,65+,F,"1,827.27",0.6,0,141,46
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,717.45",0.5,10.9,"31,463",47
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,711.52",0.5,3,"8,758",48
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,F,"1,662.32",0.5,2.3,"6,525",49
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,F,"1,565.48",0.5,3.9,"11,165",50
10,Alberta,C03CA,"Sulfonamides, plain",65+,F,"1,554.94",0.5,8.8,"25,353",51
10,Alberta,N05AX,Other antipsychotics,65+,F,"1,548.65",0.5,1.2,"3,406",52
10,Alberta,B01AE,Direct thrombin inhibitors,65+,F,"1,505.99",0.5,0.5,"1,566",53
10,Alberta,N04BA,Dopa and dopa derivatives,65+,F,"1,474.90",0.5,0.9,"2,599",54
10,Alberta,L01XE,Protein kinase inhibitors,65+,F,**,**,**,**,55
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,416.70",0.4,12.6,"36,242",56
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,344.74",0.4,4.4,"12,735",57
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"1,206.57",0.4,2.9,"8,379",58
10,Alberta,C03AA,"Thiazides, plain",65+,F,"1,116.41",0.4,9.8,"28,272",59
10,Alberta,L01BA,Folic acid analogues,65+,F,"1,033.51",0.3,1.7,"4,984",60
10,Alberta,C01DA,Organic nitrates,65+,F,"1,014.19",0.3,3.7,"10,598",61
10,Alberta,N06DA,Anticholinesterases,65+,F,983.84,0.3,1.4,"3,974",62
10,Alberta,G03DA,Pregnen (4) derivatives,65+,F,980.19,0.3,1.1,"3,165",63
10,Alberta,N05BA,Benzodiazepine derivatives,65+,F,964.62,0.3,8,"23,147",64
10,Alberta,H02AB,Glucocorticoids,65+,F,908.73,0.3,10.6,"30,619",65
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,846.86,0.3,4.5,"12,936",66
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,F,834.36,0.3,5.8,"16,761",67
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,F,802.03,0.3,1.4,"4,083",68
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,F,797.74,0.3,9.4,"27,143",69
10,Alberta,A10BB,Sulfonylureas,65+,F,766.94,0.2,3.6,"10,240",70
10,Alberta,B01AA,Vitamin K antagonists,65+,F,734.5,0.2,2.4,"6,839",71
10,Alberta,A12BA,Potassium,65+,F,727.73,0.2,3.6,"10,498",72
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,F,717.19,0.2,0.7,"2,051",73
10,Alberta,R01AD,Corticosteroids,65+,F,703.57,0.2,7.3,"21,162",74
10,Alberta,A09AA,Enzyme preparations,65+,F,699.41,0.2,0.3,943,75
10,Alberta,A07AA,Antibiotics,65+,F,690.11,0.2,1.6,"4,736",76
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,674.6,0.2,0.1,292,77
10,Alberta,C03DA,Aldosterone antagonists,65+,F,645.89,0.2,2.8,"7,948",78
10,Alberta,L03AB,Interferons,65+,F,638.38,0.2,0,34,79
10,Alberta,A04AD,Other antiemetics,65+,F,617.53,0.2,0.4,"1,228",80
10,Alberta,J01FA,Macrolides,65+,F,612.64,0.2,8.6,"24,744",81
10,Alberta,J01MA,Fluoroquinolones,65+,F,604.23,0.2,9.7,"27,893",82
10,Alberta,L03AX,Other immunostimulants,65+,F,603.26,0.2,0,40,83
10,Alberta,J01CA,Penicillins with extended spectrum,65+,F,594.65,0.2,11.9,"34,390",84
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,F,588.22,0.2,2.4,"7,053",85
10,Alberta,P01BA,Aminoquinolines,65+,F,564.28,0.2,1.6,"4,662",86
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,557.28,0.2,0.3,960,87
10,Alberta,J01XE,Nitrofuran derivatives,65+,F,554.66,0.2,7.6,"22,002",88
10,Alberta,C03BA,"Sulfonamides, plain",65+,F,513.55,0.2,3.2,"9,329",89
10,Alberta,M01AE,Propionic acid derivatives,65+,F,484.44,0.2,5.3,"15,396",90
10,Alberta,S01BA,"Corticosteroids, plain",65+,F,484.32,0.2,4.4,"12,596",91
10,Alberta,C10AX,Other lipid-modifying agents,65+,F,484.12,0.2,1.4,"4,128",92
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,469.32,0.1,0.3,795,93
10,Alberta,A02BA,H2-receptor antagonists,65+,F,463.96,0.1,2.6,"7,576",94
10,Alberta,N04BC,Dopamine agonists,65+,F,447.48,0.1,1,"2,981",95
10,Alberta,A03FA,Propulsives,65+,F,446.18,0.1,3.1,"8,975",96
10,Alberta,N03AE,Benzodiazepine derivatives,65+,F,441.91,0.1,2.3,"6,593",97
10,Alberta,A05AA,Bile acids and derivatives,65+,F,439.91,0.1,0.3,787,98
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,F,429.06,0.1,1,"2,805",99
10,Alberta,J01DB,First-generation cephalosporins,65+,F,427.72,0.1,7.2,"20,846",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"127,532.39",40.1,5.5,"5,931",1
10,Alberta,L04AA,Selective immunosuppressants,<65,Total,"31,609.97",9.9,1.8,"1,877",2
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,Total,"21,032.10",6.6,0.4,411,3
10,Alberta,L04AC,Interleukin inhibitors,<65,Total,"14,385.94",4.5,0.9,974,4
10,Alberta,L04AX,Other immunosuppressants,<65,Total,"9,531.80",3,1.6,"1,750",5
10,Alberta,L03AX,Other immunostimulants,<65,Total,"7,285.73",2.3,0.6,600,6
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"5,300.40",1.7,0.3,311,7
10,Alberta,L03AB,Interferons,<65,Total,"4,900.07",1.5,0.3,304,8
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"4,251.67",1.3,4.4,"4,741",9
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"3,706.38",1.2,1.8,"1,905",10
10,Alberta,N02AA,Natural opium alkaloids,<65,Total,"3,434.83",1.1,3.9,"4,219",11
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"3,052.49",1,4.7,"5,063",12
10,Alberta,R07AX,Other respiratory system products,<65,Total,"2,854.39",0.9,0,13,13
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"2,788.08",0.9,0,10,14
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"2,568.46",0.8,3.4,"3,612",15
10,Alberta,N06AX,Other antidepressants,<65,Total,"2,380.38",0.7,13.8,"14,827",16
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,Total,"2,152.54",0.7,3.1,"3,276",17
10,Alberta,H01CB,Somatostatin and analogues,<65,Total,"1,867.14",0.6,0.1,105,18
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"1,823.25",0.6,2.1,"2,209",19
10,Alberta,A02BC,Proton pump inhibitors,<65,Total,"1,803.31",0.6,22.9,"24,541",20
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,787.29",0.6,23.8,"25,503",21
10,Alberta,B01AB,Heparin group,<65,Total,"1,762.19",0.6,1,"1,069",22
10,Alberta,A16AB,Enzymes,<65,Total,**,**,**,**,23
10,Alberta,N03AX,Other antiepileptics,<65,Total,"1,688.17",0.5,8.8,"9,476",24
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,622.67",0.5,3.1,"3,296",25
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,591.04",0.5,13.6,"14,576",26
10,Alberta,B03XA,Other antianemic preparations,<65,Total,"1,526.28",0.5,0.4,377,27
10,Alberta,N05AX,Other antipsychotics,<65,Total,"1,509.05",0.5,1.7,"1,844",28
10,Alberta,L01XC,Monoclonal antibodies,<65,Total,"1,492.19",0.5,0.1,120,29
10,Alberta,L03AA,Colony-stimulating factors,<65,Total,"1,455.56",0.5,0.2,223,30
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"1,433.72",0.5,7.3,"7,786",31
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,Total,"1,367.68",0.4,1.6,"1,671",32
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"1,365.02",0.4,1.6,"1,748",33
10,Alberta,H03AA,Thyroid hormones,<65,Total,"1,229.36",0.4,15.5,"16,604",34
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,Total,"1,042.55",0.3,1.6,"1,677",35
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"1,018.00",0.3,0.6,637,36
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,983.25,0.3,9.6,"10,333",37
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,Total,976.52,0.3,2.8,"2,952",38
10,Alberta,C09AA,"ACE inhibitors, plain",<65,Total,970.9,0.3,11.9,"12,809",39
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,899.14,0.3,3.8,"4,067",40
10,Alberta,N07BC,Drugs used in opioid dependence,<65,Total,**,**,**,**,41
10,Alberta,C08CA,Dihydropyridine derivatives,<65,Total,828.37,0.3,8.8,"9,460",42
10,Alberta,V03AC,Iron-chelating agents,<65,Total,788.27,0.2,0,38,43
10,Alberta,R03BA,Glucocorticoids,<65,Total,750.51,0.2,4.8,"5,107",44
10,Alberta,R03BB,Anticholinergics,<65,Total,743.24,0.2,2.5,"2,679",45
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,Total,741.88,0.2,2.6,"2,840",46
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,Total,706.16,0.2,10,"10,686",47
10,Alberta,A16AX,Various alimentary tract and metabolism products,<65,Total,700.84,0.2,0,6,48
10,Alberta,A09AA,Enzyme preparations,<65,Total,681.42,0.2,0.4,422,49
10,Alberta,G03DA,Pregnen (4) derivatives,<65,Total,625.12,0.2,2,"2,108",50
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,585.63,0.2,10.4,"11,156",51
10,Alberta,N05AE,Indole derivatives,<65,Total,563.31,0.2,0.4,467,52
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,519.61,0.2,5.5,"5,890",53
10,Alberta,A04AD,Other antiemetics,<65,Total,509.52,0.2,0.7,730,54
10,Alberta,J01DF,Monobactams,<65,Total,**,**,**,**,55
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,Total,500.76,0.2,8.6,"9,235",56
10,Alberta,A16AA,Amino acids and derivatives,<65,Total,499.81,0.2,0,9,57
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,482.58,0.2,4.1,"4,406",58
10,Alberta,J01GB,Other aminoglycosides,<65,Total,476.16,0.1,0.1,77,59
10,Alberta,A10BA,Biguanides,<65,Total,470.88,0.1,9.5,"10,148",60
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,Total,464.75,0.1,1.9,"2,029",61
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,462.01,0.1,4.5,"4,833",62
10,Alberta,L01BA,Folic acid analogues,<65,Total,459.06,0.1,2.4,"2,590",63
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,Total,434.31,0.1,7.1,"7,564",64
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,Total,429.93,0.1,0.1,65,65
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,Total,426.43,0.1,3.1,"3,305",66
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,420.61,0.1,11.7,"12,542",67
10,Alberta,M05BA,Bisphosphonates,<65,Total,372.17,0.1,3.1,"3,342",68
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,371.75,0.1,1.4,"1,504",69
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,362.02,0.1,0.6,649,70
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,Total,352.01,0.1,7.7,"8,302",71
10,Alberta,H02AB,Glucocorticoids,<65,Total,346.26,0.1,10.5,"11,274",72
10,Alberta,A07AA,Antibiotics,<65,Total,341.23,0.1,1.3,"1,378",73
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,Total,320.64,0.1,0.4,387,74
10,Alberta,L01XE,Protein kinase inhibitors,<65,Total,307.42,0.1,0,18,75
10,Alberta,C08DB,Benzothiazepine derivatives,<65,Total,304.74,0.1,1.1,"1,204",76
10,Alberta,N05BA,Benzodiazepine derivatives,<65,Total,298.18,0.1,7.3,"7,823",77
10,Alberta,M03BX,Other centrally acting agents,<65,Total,289.56,0.1,6.1,"6,528",78
10,Alberta,S01LA,Antineovascularization agents,<65,Total,279.82,0.1,0,35,79
10,Alberta,A05AA,Bile acids and derivatives,<65,Total,278.79,0.1,0.3,319,80
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,Total,254.76,0.1,1.7,"1,875",81
10,Alberta,J01FA,Macrolides,<65,Total,250.49,0.1,9.8,"10,485",82
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,246.26,0.1,0.1,115,83
10,Alberta,J01CA,Penicillins with extended spectrum,<65,Total,241.35,0.1,13.5,"14,444",84
10,Alberta,M01AE,Propionic acid derivatives,<65,Total,236.44,0.1,7.5,"8,004",85
10,Alberta,J02AC,Triazole derivatives,<65,Total,235.43,0.1,2.3,"2,507",86
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,Total,228.74,0.1,1,"1,023",87
10,Alberta,J01MA,Fluoroquinolones,<65,Total,227.45,0.1,6.4,"6,886",88
10,Alberta,C10AX,Other lipid-modifying agents,<65,Total,219.92,0.1,0.8,874,89
10,Alberta,R01AD,Corticosteroids,<65,Total,219.61,0.1,7,"7,530",90
10,Alberta,P01BA,Aminoquinolines,<65,Total,210.44,0.1,1.8,"1,967",91
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,Total,209.57,0.1,7.3,"7,833",92
10,Alberta,G02BA,Intrauterine contraceptives,<65,Total,207.09,0.1,0.6,637,93
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,202.33,0.1,2.3,"2,424",94
10,Alberta,A10BB,Sulfonylureas,<65,Total,200.25,0.1,2.9,"3,133",95
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,193.63,0.1,0.4,418,96
10,Alberta,V04CJ,Tests for thyreoidea function,<65,Total,186.36,0.1,0.1,86,97
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,Total,184.11,0.1,0.9,961,98
10,Alberta,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,**,**,**,**,99
10,Alberta,N03AF,Carboxamide derivatives,<65,Total,182.54,0.1,0.7,753,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"70,311.69",47.2,8.2,"2,993",1
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,M,"13,796.52",9.3,0.7,267,2
10,Alberta,L04AA,Selective immunosuppressants,<65,M,"10,229.82",6.9,1.5,531,3
10,Alberta,L04AC,Interleukin inhibitors,<65,M,"7,625.50",5.1,1.3,485,4
10,Alberta,L04AX,Other immunosuppressants,<65,M,"3,189.11",2.1,1.8,670,5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"2,299.59",1.5,6.6,"2,394",6
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"2,086.33",1.4,0.3,103,7
10,Alberta,L03AX,Other immunostimulants,<65,M,"1,959.95",1.3,0.5,165,8
10,Alberta,R07AX,Other respiratory system products,<65,M,"1,920.76",1.3,0,8,9
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,**,**,**,**,10
10,Alberta,N02AA,Natural opium alkaloids,<65,M,"1,519.56",1,4.2,"1,547",11
10,Alberta,L03AB,Interferons,<65,M,"1,351.85",0.9,0.2,80,12
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"1,312.21",0.9,5,"1,824",13
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,101.95",0.7,4.9,"1,774",14
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,M,"1,066.14",0.7,4.3,"1,576",15
10,Alberta,H01CB,Somatostatin and analogues,<65,M,"1,059.35",0.7,0.2,56,16
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,924.76,0.6,4.6,"1,679",17
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,904.8,0.6,3,"1,076",18
10,Alberta,N05AX,Other antipsychotics,<65,M,823.26,0.6,2.2,790,19
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,M,794.79,0.5,30.3,"11,021",20
10,Alberta,A16AB,Enzymes,<65,M,**,**,**,*,21
10,Alberta,B03XA,Other antianemic preparations,<65,M,741.92,0.5,0.5,200,22
10,Alberta,B01AB,Heparin group,<65,M,672.78,0.5,1,365,23
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,650.47,0.4,1.1,400,24
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,618.17,0.4,2.1,771,25
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,M,600.48,0.4,1.9,677,26
10,Alberta,N06AX,Other antidepressants,<65,M,586.82,0.4,10.4,"3,785",27
10,Alberta,A02BC,Proton pump inhibitors,<65,M,586.77,0.4,21.6,"7,849",28
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,M,556.43,0.4,2.2,797,29
10,Alberta,N03AX,Other antiepileptics,<65,M,514.08,0.3,7.6,"2,751",30
10,Alberta,A16AA,Amino acids and derivatives,<65,M,**,**,**,*,31
10,Alberta,N07BC,Drugs used in opioid dependence,<65,M,472.4,0.3,1.1,387,32
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,462.53,0.3,3.8,"1,372",33
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,455.31,0.3,0.7,251,34
10,Alberta,C09AA,"ACE inhibitors, plain",<65,M,448.25,0.3,16,"5,826",35
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,M,424.58,0.3,10.5,"3,838",36
10,Alberta,C08CA,Dihydropyridine derivatives,<65,M,371.53,0.2,11.1,"4,055",37
10,Alberta,A09AA,Enzyme preparations,<65,M,363.48,0.2,0.5,188,38
10,Alberta,V03AC,Iron-chelating agents,<65,M,338.75,0.2,0,17,39
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,333.27,0.2,9.6,"3,497",40
10,Alberta,L01XC,Monoclonal antibodies,<65,M,326.54,0.2,0.1,27,41
10,Alberta,R03BB,Anticholinergics,<65,M,283.06,0.2,2.7,972,42
10,Alberta,R03BA,Glucocorticoids,<65,M,275.99,0.2,4.8,"1,743",43
10,Alberta,J01GB,Other aminoglycosides,<65,M,271.79,0.2,0.1,42,44
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,254.94,0.2,2.5,904,45
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,M,232.7,0.2,2.1,753,46
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,M,224.04,0.2,10.1,"3,664",47
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,M,224.04,0.2,0.1,29,48
10,Alberta,J01DF,Monobactams,<65,M,**,**,**,**,49
10,Alberta,A10BA,Biguanides,<65,M,204.48,0.1,11.7,"4,266",50
10,Alberta,L03AA,Colony-stimulating factors,<65,M,201.12,0.1,0.1,38,51
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,197.36,0.1,10.2,"3,703",52
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,M,190,0.1,4,"1,457",53
10,Alberta,L01XE,Protein kinase inhibitors,<65,M,**,**,**,**,54
10,Alberta,N05AE,Indole derivatives,<65,M,177.35,0.1,0.4,138,55
10,Alberta,A07AA,Antibiotics,<65,M,174.72,0.1,1.1,390,56
10,Alberta,H03AA,Thyroid hormones,<65,M,172.97,0.1,6.8,"2,483",57
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,172.21,0.1,3.4,"1,222",58
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,171.22,0.1,0.2,85,59
10,Alberta,S01LA,Antineovascularization agents,<65,M,168.59,0.1,0.1,20,60
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,M,167.47,0.1,7.1,"2,602",61
10,Alberta,A04AD,Other antiemetics,<65,M,159.9,0.1,0.6,201,62
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,158.04,0.1,4.5,"1,651",63
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,154.55,0.1,0.7,265,64
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,152.13,0.1,11.5,"4,186",65
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,M,145.09,0.1,6.7,"2,440",66
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,<65,M,142.63,0.1,2,718,67
10,Alberta,L01BA,Folic acid analogues,<65,M,140.36,0.1,2.2,810,68
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,<65,M,139.13,0.1,6.2,"2,267",69
10,Alberta,C08DB,Benzothiazepine derivatives,<65,M,135.06,0.1,1.4,494,70
10,Alberta,H02AB,Glucocorticoids,<65,M,127.48,0.1,10.3,"3,762",71
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,M,121.8,0.1,7.8,"2,822",72
10,Alberta,C10AX,Other lipid-modifying agents,<65,M,116.55,0.1,1.3,466,73
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,M,116.31,0.1,0.4,146,74
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,112.45,0.1,2.6,961,75
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,M,110.54,0.1,1.1,397,76
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,M,110.03,0.1,0.9,341,77
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,M,101.91,0.1,1.4,527,78
10,Alberta,N04BA,Dopa and dopa derivatives,<65,M,97.92,0.1,0.4,135,79
10,Alberta,M04AA,Preparations inhibiting uric acid production,<65,M,95.51,0.1,3.9,"1,417",80
10,Alberta,A10BB,Sulfonylureas,<65,M,95.12,0.1,4.1,"1,493",81
10,Alberta,J02AC,Triazole derivatives,<65,M,89.98,0.1,0.9,331,82
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,M,89.96,0.1,1.6,596,83
10,Alberta,M03BX,Other centrally acting agents,<65,M,87.67,0.1,5,"1,817",84
10,Alberta,N05BA,Benzodiazepine derivatives,<65,M,85.24,0.1,5.2,"1,904",85
10,Alberta,N03AG,Fatty acid derivatives,<65,M,83.22,0.1,1,355,86
10,Alberta,V06C,Infant formulas,<65,M,80.01,0.1,0,17,87
10,Alberta,B01AE,Direct thrombin inhibitors,<65,M,78.89,0.1,0.3,99,88
10,Alberta,J01CA,Penicillins with extended spectrum,<65,M,78.33,0.1,12.8,"4,655",89
10,Alberta,H01BA,Vasopressin and analogues,<65,M,77.92,0.1,0.2,63,90
10,Alberta,J01FA,Macrolides,<65,M,75.79,0.1,8.4,"3,058",91
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,75.67,0.1,0.5,165,92
10,Alberta,M01AE,Propionic acid derivatives,<65,M,74.95,0.1,6.7,"2,438",93
10,Alberta,N03AF,Carboxamide derivatives,<65,M,72.87,0,0.7,266,94
10,Alberta,C10AB,Fibrates,<65,M,71.81,0,1.6,593,95
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,71.55,0,0.5,184,96
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,M,71.52,0,0.9,333,97
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,M,66.04,0,6.3,"2,286",98
10,Alberta,R01AD,Corticosteroids,<65,M,65.26,0,5.8,"2,123",99
10,Alberta,C03DA,Aldosterone antagonists,<65,M,64.88,0,1.8,663,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"57,220.70",33.8,4.1,"2,938",1
10,Alberta,L04AA,Selective immunosuppressants,<65,F,"21,380.15",12.6,1.9,"1,346",2
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,F,"7,235.58",4.3,0.2,144,3
10,Alberta,L04AC,Interleukin inhibitors,<65,F,"6,760.44",4,0.7,489,4
10,Alberta,L04AX,Other immunosuppressants,<65,F,"6,342.69",3.7,1.5,"1,080",5
10,Alberta,L03AX,Other immunostimulants,<65,F,"5,325.78",3.1,0.6,435,6
10,Alberta,L03AB,Interferons,<65,F,"3,548.22",2.1,0.3,224,7
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"3,251.07",1.9,2.3,"1,654",8
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"3,214.07",1.9,0.3,208,9
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,952.08",1.2,3.3,"2,347",10
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,950.54",1.2,4.6,"3,289",11
10,Alberta,N02AA,Natural opium alkaloids,<65,F,"1,915.27",1.1,3.8,"2,672",12
10,Alberta,N06AX,Other antidepressants,<65,F,"1,793.56",1.1,15.6,"11,042",13
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"1,424.64",0.8,10.9,"7,732",14
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"1,256.26",0.7,2.5,"1,788",15
10,Alberta,L03AA,Colony-stimulating factors,<65,F,"1,254.44",0.7,0.3,185,16
10,Alberta,A02BC,Proton pump inhibitors,<65,F,"1,216.55",0.7,23.6,"16,692",17
10,Alberta,N03AX,Other antiepileptics,<65,F,"1,174.09",0.7,9.5,"6,725",18
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,166.46",0.7,15.2,"10,738",19
10,Alberta,L01XC,Monoclonal antibodies,<65,F,"1,165.65",0.7,0.1,93,20
10,Alberta,B01AB,Heparin group,<65,F,"1,089.41",0.6,1,704,21
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,F,"1,086.39",0.6,2.4,"1,700",22
10,Alberta,H03AA,Thyroid hormones,<65,F,"1,056.39",0.6,19.9,"14,121",23
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,F,992.5,0.6,20.5,"14,482",24
10,Alberta,A16AB,Enzymes,<65,F,**,**,**,*,25
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,**,**,**,*,26
10,Alberta,R07AX,Other respiratory system products,<65,F,933.63,0.6,0,5,27
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,918.45,0.5,1.6,"1,133",28
10,Alberta,H01CB,Somatostatin and analogues,<65,F,807.79,0.5,0.1,49,29
10,Alberta,B03XA,Other antianemic preparations,<65,F,784.37,0.5,0.3,177,30
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,F,767.2,0.5,1.4,994,31
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,746.85,0.4,1.4,977,32
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,F,743.82,0.4,3.1,"2,199",33
10,Alberta,A16AX,Various alimentary tract and metabolism products,<65,F,700.84,0.4,0,6,34
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,697.91,0.4,2.3,"1,617",35
10,Alberta,N05AX,Other antipsychotics,<65,F,685.8,0.4,1.5,"1,054",36
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,649.99,0.4,9.7,"6,836",37
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,F,631.85,0.4,3.5,"2,499",38
10,Alberta,G03DA,Pregnen (4) derivatives,<65,F,621.38,0.4,3,"2,092",39
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,F,538.69,0.3,11.4,"8,084",40
10,Alberta,C09AA,"ACE inhibitors, plain",<65,F,522.65,0.3,9.9,"6,983",41
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,F,486.12,0.3,1.2,880,42
10,Alberta,R03BA,Glucocorticoids,<65,F,474.52,0.3,4.8,"3,364",43
10,Alberta,R03BB,Anticholinergics,<65,F,460.18,0.3,2.4,"1,707",44
10,Alberta,C08CA,Dihydropyridine derivatives,<65,F,456.83,0.3,7.6,"5,405",45
10,Alberta,V03AC,Iron-chelating agents,<65,F,449.52,0.3,0,21,46
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,436.61,0.3,3.8,"2,695",47
10,Alberta,N07BC,Drugs used in opioid dependence,<65,F,400.31,0.2,0.5,365,48
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,F,393.23,0.2,2.4,"1,696",49
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,388.27,0.2,10.5,"7,453",50
10,Alberta,N05AE,Indole derivatives,<65,F,385.96,0.2,0.5,329,51
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,370.13,0.2,4.9,"3,445",52
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,367.53,0.2,0.3,237,53
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,F,355.67,0.2,9.6,"6,795",54
10,Alberta,A04AD,Other antiemetics,<65,F,349.62,0.2,0.7,529,55
10,Alberta,M05BA,Bisphosphonates,<65,F,347.66,0.2,4.3,"3,073",56
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,347.4,0.2,6.6,"4,668",57
10,Alberta,L01BA,Folic acid analogues,<65,F,318.69,0.2,2.5,"1,780",58
10,Alberta,A09AA,Enzyme preparations,<65,F,317.94,0.2,0.3,234,59
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,F,303.97,0.2,4.5,"3,182",60
10,Alberta,J01DF,Monobactams,<65,F,**,**,**,**,61
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,268.49,0.2,11.8,"8,356",62
10,Alberta,A10BA,Biguanides,<65,F,266.4,0.2,8.3,"5,882",63
10,Alberta,A05AA,Bile acids and derivatives,<65,F,237.76,0.1,0.3,232,64
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,F,236.43,0.1,2.6,"1,848",65
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,F,230.21,0.1,7.7,"5,480",66
10,Alberta,H02AB,Glucocorticoids,<65,F,218.79,0.1,10.6,"7,512",67
10,Alberta,N05BA,Benzodiazepine derivatives,<65,F,212.94,0.1,8.4,"5,919",68
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,F,210.27,0.1,5.5,"3,900",69
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,207.47,0.1,0.5,384,70
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,F,205.89,0.1,0.1,36,71
10,Alberta,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,72
10,Alberta,J01GB,Other aminoglycosides,<65,F,204.36,0.1,0,35,73
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,F,204.33,0.1,0.3,241,74
10,Alberta,M03BX,Other centrally acting agents,<65,F,201.89,0.1,6.7,"4,711",75
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,76
10,Alberta,J01MA,Fluoroquinolones,<65,F,174.91,0.1,7,"4,991",77
10,Alberta,J01FA,Macrolides,<65,F,174.7,0.1,10.5,"7,427",78
10,Alberta,L02AE,Gonadotropin-releasing hormone analogues,<65,F,169.7,0.1,0.1,73,79
10,Alberta,C08DB,Benzothiazepine derivatives,<65,F,169.68,0.1,1,710,80
10,Alberta,P01BA,Aminoquinolines,<65,F,169.47,0.1,2.2,"1,589",81
10,Alberta,A07AA,Antibiotics,<65,F,166.51,0.1,1.4,988,82
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,F,164.8,0.1,1.8,"1,279",83
10,Alberta,J01CA,Penicillins with extended spectrum,<65,F,163.03,0.1,13.8,"9,789",84
10,Alberta,M01AE,Propionic acid derivatives,<65,F,161.49,0.1,7.9,"5,566",85
10,Alberta,R01AD,Corticosteroids,<65,F,154.35,0.1,7.6,"5,407",86
10,Alberta,J02AC,Triazole derivatives,<65,F,145.45,0.1,3.1,"2,176",87
10,Alberta,V04CJ,Tests for thyreoidea function,<65,F,145.42,0.1,0.1,66,88
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,F,143.53,0.1,7.8,"5,547",89
10,Alberta,N03AE,Benzodiazepine derivatives,<65,F,124.94,0.1,2.9,"2,031",90
10,Alberta,L01XE,Protein kinase inhibitors,<65,F,**,**,**,**,91
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,F,118.19,0.1,0.9,626,92
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,117.96,0.1,0.4,253,93
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,F,117.87,0.1,0,24,94
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,116.82,0.1,0.8,600,95
10,Alberta,G03EB,"Androgen, progestogen and estrogen in combination",<65,F,113.49,0.1,0.5,344,96
10,Alberta,S01LA,Antineovascularization agents,<65,F,111.23,0.1,0,15,97
10,Alberta,N03AF,Carboxamide derivatives,<65,F,109.67,0.1,0.7,487,98
10,Alberta,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,105.41,0.1,6,"4,278",99
10,Alberta,A10BB,Sulfonylureas,<65,F,105.13,0.1,2.3,"1,640",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"198,626.17",16.1,0.4,"12,465",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"155,424.60",12.6,0.1,"3,053",2
11,British Columbia,L04AA,Selective immunosuppressants,Total,Total,"59,653.85",4.8,0.3,"7,604",3
11,British Columbia,N05AX,Other antipsychotics,Total,Total,"51,027.98",4.1,1.3,"39,820",4
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,Total,"42,436.69",3.4,0.9,"27,755",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"33,303.49",2.7,3.4,"103,492",6
11,British Columbia,N02AA,Natural opium alkaloids,Total,Total,"26,458.42",2.1,3.4,"101,198",7
11,British Columbia,L04AC,Interleukin inhibitors,Total,Total,"25,685.37",2.1,0.1,"2,089",8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"22,792.59",1.8,11.3,"337,813",9
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"21,943.90",1.8,17.3,"520,056",10
11,British Columbia,N06AX,Other antidepressants,Total,Total,"21,671.66",1.8,7.8,"233,529",11
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,Total,"21,060.08",1.7,1.4,"41,471",12
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"18,517.86",1.5,1.8,"53,109",13
11,British Columbia,N03AX,Other antiepileptics,Total,Total,"18,234.95",1.5,5,"149,973",14
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,Total,"14,405.94",1.2,3.1,"93,267",15
11,British Columbia,A02BC,Proton pump inhibitors,Total,Total,"13,914.43",1.1,6.1,"181,654",16
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"13,209.61",1.1,0.9,"26,994",17
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,Total,"13,071.25",1.1,8.5,"255,478",18
11,British Columbia,L01XC,Monoclonal antibodies,Total,Total,"12,632.11",1,0,"1,112",19
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,Total,"12,532.50",1,12.1,"362,508",20
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,Total,"10,913.94",0.9,7.8,"234,802",21
11,British Columbia,H03AA,Thyroid hormones,Total,Total,"10,527.08",0.9,9.3,"278,448",22
11,British Columbia,L04AX,Other immunosuppressants,Total,Total,"10,488.95",0.9,0.2,"6,679",23
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,Total,"9,550.55",0.8,1.1,"34,269",24
11,British Columbia,B02AB,Proteinase inhibitors,Total,Total,"9,376.79",0.8,0,95,25
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"7,893.44",0.6,0.9,"28,347",26
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"7,613.57",0.6,0.5,"15,157",27
11,British Columbia,R03BB,Anticholinergics,Total,Total,"7,532.60",0.6,1.7,"50,935",28
11,British Columbia,A10BA,Biguanides,Total,Total,"7,335.03",0.6,6.8,"202,851",29
11,British Columbia,R03BA,Glucocorticoids,Total,Total,"7,268.37",0.6,4.1,"123,447",30
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"7,090.37",0.6,2.9,"85,934",31
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,Total,"5,953.61",0.5,0.7,"22,150",32
11,British Columbia,N03AG,Fatty acid derivatives,Total,Total,"5,819.84",0.5,0.6,"18,409",33
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"5,621.02",0.5,0,208,34
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"5,573.18",0.5,10,"300,434",35
11,British Columbia,B01AB,Heparin group,Total,Total,"5,554.41",0.5,0.3,"8,947",36
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,Total,"5,415.75",0.4,7,"208,633",37
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"5,381.38",0.4,0.2,"4,564",38
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"5,298.76",0.4,1.1,"34,242",39
11,British Columbia,L03AA,Colony-stimulating factors,Total,Total,"5,186.80",0.4,0.1,"2,075",40
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"5,061.97",0.4,10.3,"308,581",41
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"4,917.60",0.4,2.7,"81,015",42
11,British Columbia,C03CA,"Sulfonamides, plain",Total,Total,"4,614.19",0.4,2.9,"87,437",43
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,Total,"4,218.43",0.3,0.5,"14,182",44
11,British Columbia,A09AA,Enzyme preparations,Total,Total,"4,113.30",0.3,0.2,"5,984",45
11,British Columbia,L01XE,Protein kinase inhibitors,Total,Total,"3,940.64",0.3,0,213,46
11,British Columbia,A02BA,H2-receptor antagonists,Total,Total,"3,882.57",0.3,2.8,"84,257",47
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,Total,"3,706.28",0.3,1.7,"49,538",48
11,British Columbia,M01AE,Propionic acid derivatives,Total,Total,"3,664.24",0.3,6.5,"195,587",49
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"3,647.92",0.3,0.3,"9,111",50
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"3,623.12",0.3,3.4,"101,237",51
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"3,543.62",0.3,0.5,"15,367",52
11,British Columbia,V03AC,Iron-chelating agents,Total,Total,"3,527.67",0.3,0,179,53
11,British Columbia,S01ED,Beta-blocking agents,Total,Total,"3,511.37",0.3,1.5,"43,586",54
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,Total,"3,378.66",0.3,1.4,"42,043",55
11,British Columbia,A04AD,Other antiemetics,Total,Total,"3,340.60",0.3,0.3,"8,069",56
11,British Columbia,S01EE,Prostaglandin analogues,Total,Total,"3,311.48",0.3,1.4,"42,160",57
11,British Columbia,A10BB,Sulfonylureas,Total,Total,"3,229.01",0.3,1.3,"39,877",58
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,Total,"3,181.03",0.3,1.1,"34,027",59
11,British Columbia,L03AB,Interferons,Total,Total,"3,142.12",0.3,0,231,60
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"3,140.38",0.3,0.5,"14,790",61
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"3,097.68",0.3,0,152,62
11,British Columbia,N03AF,Carboxamide derivatives,Total,Total,"3,060.51",0.2,0.4,"12,342",63
11,British Columbia,M03BX,Other centrally acting agents,Total,Total,"2,973.84",0.2,4.2,"127,346",64
11,British Columbia,C03AA,"Thiazides, plain",Total,Total,"2,925.78",0.2,5.2,"156,778",65
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"2,859.90",0.2,0.1,"2,389",66
11,British Columbia,H02AB,Glucocorticoids,Total,Total,"2,844.94",0.2,8,"240,693",67
11,British Columbia,B01AA,Vitamin K antagonists,Total,Total,"2,502.37",0.2,1.2,"36,781",68
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"2,497.24",0.2,0.2,"6,872",69
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"2,449.97",0.2,1.4,"43,149",70
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,Total,"2,410.25",0.2,0.9,"25,672",71
11,British Columbia,L03AX,Other immunostimulants,Total,Total,"2,391.79",0.2,0,387,72
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"2,350.12",0.2,0.1,"3,789",73
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"2,335.44",0.2,0.1,"2,775",74
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,Total,"2,290.24",0.2,9.3,"279,656",75
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,274.05",0.2,4.5,"136,461",76
11,British Columbia,R05CB,Mucolytics,Total,Total,"2,223.70",0.2,0,569,77
11,British Columbia,N06DA,Anticholinesterases,Total,Total,"2,220.26",0.2,0.3,"9,037",78
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,Total,"2,218.28",0.2,2.1,"61,824",79
11,British Columbia,C01DA,Organic nitrates,Total,Total,"2,214.49",0.2,1.5,"45,467",80
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,Total,"2,198.90",0.2,0,244,81
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,Total,"2,004.24",0.2,1.2,"35,330",82
11,British Columbia,C03DA,Aldosterone antagonists,Total,Total,"1,908.77",0.2,1.5,"43,832",83
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"1,873.45",0.2,0.4,"13,137",84
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,Total,"1,870.88",0.2,0.1,"2,874",85
11,British Columbia,A03FA,Propulsives,Total,Total,"1,839.44",0.1,1.7,"49,519",86
11,British Columbia,N05AN,Lithium,Total,Total,"1,806.42",0.1,0.3,"9,633",87
11,British Columbia,L01BA,Folic acid analogues,Total,Total,"1,718.89",0.1,0.8,"24,896",88
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,Total,"1,692.82",0.1,0,473,89
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,Total,"1,691.75",0.1,0.1,"3,388",90
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"1,654.79",0.1,4,"121,416",91
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,Total,"1,624.58",0.1,15.9,"477,127",92
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,624.53",0.1,1.8,"54,196",93
11,British Columbia,M05BA,Bisphosphonates,Total,Total,"1,615.09",0.1,0.4,"12,731",94
11,British Columbia,N07BB,Drugs used in alcohol dependence,Total,Total,"1,535.57",0.1,0.2,"7,304",95
11,British Columbia,N05AF,Thioxanthene derivatives,Total,Total,"1,494.85",0.1,0.1,"2,377",96
11,British Columbia,A05AA,Bile acids and derivatives,Total,Total,"1,481.01",0.1,0.1,"3,520",97
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,Total,"1,474.12",0.1,0.5,"14,042",98
11,British Columbia,C07AG,Alpha- and beta-blocking agents,Total,Total,"1,399.67",0.1,0.3,"9,924",99
11,British Columbia,G02BA,Intrauterine contraceptives,Total,Total,"1,384.72",0.1,0.9,"27,445",100
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,M,"103,710.74",16.7,0.2,"2,036",1
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"100,273.66",16.1,0.4,"5,889",2
11,British Columbia,N05AX,Other antipsychotics,Total,M,"31,918.23",5.1,1.5,"20,781",3
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,M,"28,709.22",4.6,1.4,"18,389",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"20,562.73",3.3,3.6,"48,764",5
11,British Columbia,L04AA,Selective immunosuppressants,Total,M,"19,937.53",3.2,0.2,"2,335",6
11,British Columbia,N02AA,Natural opium alkaloids,Total,M,"15,126.64",2.4,3.4,"45,451",7
11,British Columbia,L04AC,Interleukin inhibitors,Total,M,"12,189.40",2,0.1,893,8
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,M,"10,512.67",1.7,22.6,"305,219",9
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,M,"9,595.48",1.5,1.6,"21,510",10
11,British Columbia,N06AX,Other antidepressants,Total,M,"9,225.12",1.5,6.6,"88,384",11
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"8,975.80",1.4,8.5,"115,217",12
11,British Columbia,N03AX,Other antiepileptics,Total,M,"8,193.39",1.3,4.5,"60,594",13
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,M,"7,983.54",1.3,3.8,"51,814",14
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"7,760.51",1.2,1.7,"22,891",15
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"6,931.91",1.1,1.1,"14,969",16
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,M,"6,204.76",1,15.5,"209,433",17
11,British Columbia,B02AB,Proteinase inhibitors,Total,M,"5,976.04",1,0,54,18
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,M,"5,725.37",0.9,1.5,"20,080",19
11,British Columbia,A02BC,Proton pump inhibitors,Total,M,"5,599.44",0.9,5.7,"76,999",20
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,M,"5,256.29",0.8,9.8,"131,849",21
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,M,"5,047.28",0.8,9.6,"129,953",22
11,British Columbia,L04AX,Other immunosuppressants,Total,M,"4,079.13",0.7,0.2,"2,657",23
11,British Columbia,R03BB,Anticholinergics,Total,M,"3,648.94",0.6,1.9,"25,190",24
11,British Columbia,A10BA,Biguanides,Total,M,"3,535.27",0.6,8.4,"113,511",25
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"3,496.02",0.6,0.6,"7,712",26
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"3,477.22",0.6,7.1,"96,432",27
11,British Columbia,L01XC,Monoclonal antibodies,Total,M,"3,457.61",0.6,0,312,28
11,British Columbia,N03AG,Fatty acid derivatives,Total,M,"3,399.98",0.5,0.7,"9,849",29
11,British Columbia,L01XE,Protein kinase inhibitors,Total,M,"3,182.12",0.5,0,163,30
11,British Columbia,R03BA,Glucocorticoids,Total,M,"3,005.53",0.5,4.1,"55,230",31
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,943.51",0.5,1.4,"18,895",32
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"2,709.55",0.4,1.3,"18,043",33
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,M,"2,702.77",0.4,0.7,"9,866",34
11,British Columbia,B01AB,Heparin group,Total,M,"2,668.95",0.4,0.3,"3,951",35
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"2,496.18",0.4,10.7,"144,634",36
11,British Columbia,H03AA,Thyroid hormones,Total,M,"2,481.26",0.4,4.6,"61,758",37
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,M,"2,412.98",0.4,0.6,"7,994",38
11,British Columbia,A09AA,Enzyme preparations,Total,M,"2,293.75",0.4,0.2,"2,730",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"2,274.86",0.4,10.2,"137,186",40
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"2,260.99",0.4,2.6,"34,662",41
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,M,"2,202.82",0.4,5.1,"69,163",42
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"2,198.02",0.4,0.1,"1,530",43
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"2,163.35",0.3,0.1,"1,880",44
11,British Columbia,M01AE,Propionic acid derivatives,Total,M,"2,049.20",0.3,6.7,"90,512",45
11,British Columbia,C03CA,"Sulfonamides, plain",Total,M,"1,930.59",0.3,3.1,"41,640",46
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"1,930.37",0.3,1.9,"26,068",47
11,British Columbia,A02BA,H2-receptor antagonists,Total,M,"1,922.51",0.3,2.6,"34,786",48
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"1,905.43",0.3,0.6,"8,130",49
11,British Columbia,V03AC,Iron-chelating agents,Total,M,"1,878.78",0.3,0,98,50
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"1,765.48",0.3,0.4,"5,113",51
11,British Columbia,N03AF,Carboxamide derivatives,Total,M,"1,692.63",0.3,0.4,"5,947",52
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"1,634.36",0.3,0.5,"7,301",53
11,British Columbia,A10BB,Sulfonylureas,Total,M,"1,553.11",0.3,1.7,"22,392",54
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,M,"1,499.89",0.2,1.2,"15,913",55
11,British Columbia,A04AD,Other antiemetics,Total,M,"1,495.17",0.2,0.2,"3,324",56
11,British Columbia,L03AA,Colony-stimulating factors,Total,M,"1,486.93",0.2,0,599,57
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"1,480.68",0.2,0,70,58
11,British Columbia,S01ED,Beta-blocking agents,Total,M,"1,462.11",0.2,1.6,"21,832",59
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,"1,461.65",0.2,0,52,60
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,M,"1,419.01",0.2,0,153,61
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,M,"1,386.73",0.2,1.3,"17,622",62
11,British Columbia,M03BX,Other centrally acting agents,Total,M,"1,370.62",0.2,4.2,"56,101",63
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"1,336.44",0.2,0.2,"2,264",64
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,M,"1,332.30",0.2,3.6,"48,555",65
11,British Columbia,S01EE,Prostaglandin analogues,Total,M,"1,279.52",0.2,1.5,"19,847",66
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"1,270.09",0.2,0.3,"3,830",67
11,British Columbia,B01AA,Vitamin K antagonists,Total,M,"1,266.63",0.2,1.6,"21,896",68
11,British Columbia,H02AB,Glucocorticoids,Total,M,"1,168.78",0.2,8,"108,140",69
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,M,"1,129.84",0.2,1.2,"15,518",70
11,British Columbia,R05CB,Mucolytics,Total,M,"1,099.66",0.2,0,294,71
11,British Columbia,C03AA,"Thiazides, plain",Total,M,"1,075.83",0.2,5,"67,430",72
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,M,"1,073.77",0.2,9.2,"124,256",73
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"1,024.10",0.2,0.7,"9,053",74
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"1,017.70",0.2,0.6,"8,176",75
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,M,"1,015.63",0.2,0.7,"9,049",76
11,British Columbia,N05AN,Lithium,Total,M,983.38,0.2,0.3,"4,516",77
11,British Columbia,N05AF,Thioxanthene derivatives,Total,M,977.16,0.2,0.1,"1,489",78
11,British Columbia,C01DA,Organic nitrates,Total,M,950.67,0.2,1.9,"26,121",79
11,British Columbia,C03DA,Aldosterone antagonists,Total,M,911.49,0.1,1.5,"19,614",80
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,M,900.53,0.1,0.1,"1,584",81
11,British Columbia,N07BB,Drugs used in alcohol dependence,Total,M,877.19,0.1,0.3,"4,240",82
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,M,865.66,0.1,1.1,"14,851",83
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,828.01,0.1,0,476,84
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,825.33,0.1,0.3,"3,671",85
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,Total,M,808.88,0.1,0.2,"3,304",86
11,British Columbia,C07AG,Alpha- and beta-blocking agents,Total,M,801.56,0.1,0.4,"5,006",87
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,M,778.86,0.1,0.4,"5,890",88
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,751.29,0.1,3.5,"46,753",89
11,British Columbia,L03AB,Interferons,Total,M,741.17,0.1,0,52,90
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,M,736.58,0.1,0.1,"1,399",91
11,British Columbia,N06DA,Anticholinesterases,Total,M,728.11,0.1,0.3,"3,691",92
11,British Columbia,J02AC,Triazole derivatives,Total,M,699.66,0.1,0.1,687,93
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,M,699.41,0.1,16.5,"222,341",94
11,British Columbia,A03FA,Propulsives,Total,M,697.52,0.1,1.1,"14,803",95
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,Total,M,612.49,0.1,0.3,"4,706",96
11,British Columbia,J01DB,First-generation cephalosporins,Total,M,609.52,0.1,7.5,"101,340",97
11,British Columbia,J01AA,Tetracyclines,Total,M,606.27,0.1,4.9,"65,882",98
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,M,573.8,0.1,0.6,"8,472",99
11,British Columbia,L03AX,Other immunostimulants,Total,M,561.4,0.1,0,85,100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"98,352.51",16.1,0.4,"6,576",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,F,"51,713.86",8.4,0.1,"1,017",2
11,British Columbia,L04AA,Selective immunosuppressants,Total,F,"39,716.32",6.5,0.3,"5,269",3
11,British Columbia,N05AX,Other antipsychotics,Total,F,"19,109.76",3.1,1.2,"19,039",4
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"13,816.79",2.3,13.5,"222,596",5
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,F,"13,727.47",2.2,0.6,"9,366",6
11,British Columbia,L04AC,Interleukin inhibitors,Total,F,"13,495.96",2.2,0.1,"1,196",7
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"12,740.76",2.1,3.3,"54,728",8
11,British Columbia,N06AX,Other antidepressants,Total,F,"12,446.54",2,8.8,"145,144",9
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,F,"11,464.60",1.9,1.2,"19,961",10
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,F,"11,431.23",1.9,13,"214,837",11
11,British Columbia,N02AA,Natural opium alkaloids,Total,F,"11,331.77",1.8,3.4,"55,744",12
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"10,757.36",1.8,1.8,"30,218",13
11,British Columbia,N03AX,Other antiepileptics,Total,F,"10,041.56",1.6,5.4,"89,379",14
11,British Columbia,L01XC,Monoclonal antibodies,Total,F,"9,174.50",1.5,0,800,15
11,British Columbia,A02BC,Proton pump inhibitors,Total,F,"8,314.99",1.4,6.3,"104,655",16
11,British Columbia,H03AA,Thyroid hormones,Total,F,"8,045.82",1.3,13.1,"216,690",17
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,F,"7,814.96",1.3,7.5,"123,629",18
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,F,"6,422.39",1,2.5,"41,453",19
11,British Columbia,L04AX,Other immunosuppressants,Total,F,"6,409.82",1,0.2,"4,022",20
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,F,"6,327.74",1,9.3,"153,075",21
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"6,277.70",1,0.7,"12,025",22
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,F,"5,866.66",1,6.3,"104,849",23
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"5,183.89",0.8,0.6,"10,304",24
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"4,829.38",0.8,3.1,"51,272",25
11,British Columbia,R03BA,Glucocorticoids,Total,F,"4,262.63",0.7,4.1,"68,215",26
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"4,159.37",0.7,0,156,27
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"4,117.55",0.7,0.5,"7,445",28
11,British Columbia,R03BB,Anticholinergics,Total,F,"3,883.67",0.6,1.6,"25,745",29
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,F,"3,825.18",0.6,0.9,"14,189",30
11,British Columbia,A10BA,Biguanides,Total,F,"3,799.77",0.6,5.4,"89,340",31
11,British Columbia,L03AA,Colony-stimulating factors,Total,F,"3,699.87",0.6,0.1,"1,476",32
11,British Columbia,B02AB,Proteinase inhibitors,Total,F,"3,400.75",0.6,0,41,33
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,F,"3,250.84",0.5,0.7,"12,284",34
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,F,"3,212.94",0.5,8.4,"139,467",35
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"3,183.36",0.5,0.2,"3,034",36
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"3,076.99",0.5,9.4,"155,799",37
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"2,987.23",0.5,3.3,"54,947",38
11,British Columbia,B01AB,Heparin group,Total,F,"2,885.47",0.5,0.3,"4,996",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"2,787.04",0.5,10.4,"171,390",40
11,British Columbia,C03CA,"Sulfonamides, plain",Total,F,"2,683.60",0.4,2.8,"45,797",41
11,British Columbia,N03AG,Fatty acid derivatives,Total,F,"2,419.86",0.4,0.5,"8,560",42
11,British Columbia,L03AB,Interferons,Total,F,"2,400.96",0.4,0,179,43
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,355.24",0.4,0.9,"15,347",44
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,F,"2,319.55",0.4,1.9,"31,916",45
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,F,"2,051.19",0.3,1.1,"18,509",46
11,British Columbia,S01ED,Beta-blocking agents,Total,F,"2,049.26",0.3,1.3,"21,754",47
11,British Columbia,S01EE,Prostaglandin analogues,Total,F,"2,031.97",0.3,1.4,"22,313",48
11,British Columbia,A02BA,H2-receptor antagonists,Total,F,"1,960.06",0.3,3,"49,470",49
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"1,882.44",0.3,0.2,"3,998",50
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,F,"1,878.77",0.3,1.6,"26,130",51
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,876.17",0.3,2.1,"34,677",52
11,British Columbia,C03AA,"Thiazides, plain",Total,F,"1,849.95",0.3,5.4,"89,348",53
11,British Columbia,A04AD,Other antiemetics,Total,F,"1,845.43",0.3,0.3,"4,745",54
11,British Columbia,L03AX,Other immunostimulants,Total,F,"1,830.39",0.3,0,302,55
11,British Columbia,A09AA,Enzyme preparations,Total,F,"1,819.55",0.3,0.2,"3,254",56
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,F,"1,805.45",0.3,0.4,"6,188",57
11,British Columbia,H02AB,Glucocorticoids,Total,F,"1,676.16",0.3,8,"132,552",58
11,British Columbia,A10BB,Sulfonylureas,Total,F,"1,675.90",0.3,1.1,"17,485",59
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"1,654.36",0.3,7.3,"121,381",60
11,British Columbia,V03AC,Iron-chelating agents,Total,F,"1,648.89",0.3,0,81,61
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"1,638.19",0.3,0.4,"7,237",62
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,617.00",0.3,0,82,63
11,British Columbia,M01AE,Propionic acid derivatives,Total,F,"1,615.04",0.3,6.4,"105,075",64
11,British Columbia,M03BX,Other centrally acting agents,Total,F,"1,603.22",0.3,4.3,"71,245",65
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,522.76",0.2,5.4,"89,708",66
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"1,507.42",0.2,0.1,"2,299",67
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,506.01",0.2,0.5,"7,489",68
11,British Columbia,N06DA,Anticholinesterases,Total,F,"1,492.15",0.2,0.3,"5,346",69
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,460.16",0.2,3.2,"53,074",70
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,F,"1,394.62",0.2,1,"16,623",71
11,British Columbia,G02BA,Intrauterine contraceptives,Total,F,"1,384.20",0.2,1.7,"27,436",72
11,British Columbia,N03AF,Carboxamide derivatives,Total,F,"1,367.88",0.2,0.4,"6,395",73
11,British Columbia,C01DA,Organic nitrates,Total,F,"1,263.81",0.2,1.2,"19,346",74
11,British Columbia,B01AA,Vitamin K antagonists,Total,F,"1,235.73",0.2,0.9,"14,885",75
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"1,227.15",0.2,0.2,"3,042",76
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,F,"1,217.02",0.2,0,245,77
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,F,"1,216.47",0.2,9.4,"155,400",78
11,British Columbia,M05BA,Bisphosphonates,Total,F,"1,200.34",0.2,0.6,"10,487",79
11,British Columbia,L01BA,Folic acid analogues,Total,F,"1,180.88",0.2,1,"15,780",80
11,British Columbia,A05AA,Bile acids and derivatives,Total,F,"1,166.37",0.2,0.2,"2,520",81
11,British Columbia,A03FA,Propulsives,Total,F,"1,141.92",0.2,2.1,"34,716",82
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,F,"1,138.57",0.2,1.2,"20,479",83
11,British Columbia,R05CB,Mucolytics,Total,F,"1,124.04",0.2,0,275,84
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"1,013.68",0.2,0.1,"1,525",85
11,British Columbia,C03DA,Aldosterone antagonists,Total,F,997.29,0.2,1.5,"24,218",86
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,F,970.35,0.2,0.1,"1,290",87
11,British Columbia,C05BA,Heparins or heparinoids for topical use,Total,F,965.72,0.2,0.1,"1,167",88
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,F,955.17,0.2,0.1,"1,989",89
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,F,925.17,0.2,15.4,"254,784",90
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,F,885.97,0.1,0.8,"13,269",91
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,F,861.09,0.1,0.3,"5,444",92
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,855.74,0.1,0.3,"4,961",93
11,British Columbia,J01XE,Nitrofuran derivatives,Total,F,833.11,0.1,8,"132,695",94
11,British Columbia,N05AN,Lithium,Total,F,823.04,0.1,0.3,"5,117",95
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,F,779.88,0.1,0,91,96
11,British Columbia,L01XE,Protein kinase inhibitors,Total,F,758.53,0.1,0,50,97
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,Total,F,738.09,0.1,1.5,"24,213",98
11,British Columbia,J01FA,Macrolides,Total,F,730.31,0.1,7.2,"118,222",99
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,696.55,0.1,0,509,100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"44,685.95",10.1,0.4,"2,980",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,Total,"33,376.88",7.6,0.1,653,2
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,Total,"18,914.64",4.3,4.2,"35,137",3
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"16,425.30",3.7,39.9,"333,905",4
11,British Columbia,L04AA,Selective immunosuppressants,65+,Total,"14,217.61",3.2,0.3,"2,596",5
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"12,457.37",2.8,3.5,"29,215",6
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,Total,"10,582.03",2.4,20.4,"170,863",7
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,Total,"8,848.88",2,26.3,"220,144",8
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,Total,"8,693.55",2,20.1,"168,569",9
11,British Columbia,A02BC,Proton pump inhibitors,65+,Total,"8,266.60",1.9,12.9,"107,750",10
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"7,514.90",1.7,1.7,"13,989",11
11,British Columbia,L04AC,Interleukin inhibitors,65+,Total,"7,025.62",1.6,0.1,562,12
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"6,734.23",1.5,10,"83,533",13
11,British Columbia,N06AX,Other antidepressants,65+,Total,"6,460.87",1.5,9.7,"81,209",14
11,British Columbia,H03AA,Thyroid hormones,65+,Total,"6,372.37",1.4,16.8,"140,586",15
11,British Columbia,N02AA,Natural opium alkaloids,65+,Total,"6,295.61",1.4,5.8,"48,609",16
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"6,071.44",1.4,7.9,"66,235",17
11,British Columbia,N05AX,Other antipsychotics,65+,Total,"5,685.81",1.3,1.3,"10,895",18
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"5,627.11",1.3,1.3,"10,553",19
11,British Columbia,R03BB,Anticholinergics,65+,Total,"5,559.10",1.3,4.1,"34,401",20
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"5,424.65",1.2,3.9,"32,325",21
11,British Columbia,N03AX,Other antiepileptics,65+,Total,"5,247.79",1.2,7.3,"61,191",22
11,British Columbia,L01XC,Monoclonal antibodies,65+,Total,"5,083.33",1.2,0.1,426,23
11,British Columbia,A10BA,Biguanides,65+,Total,"4,791.68",1.1,13.4,"111,820",24
11,British Columbia,C03CA,"Sulfonamides, plain",65+,Total,"3,819.49",0.9,8.5,"71,385",25
11,British Columbia,B02AB,Proteinase inhibitors,65+,Total,"3,815.85",0.9,0,36,26
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"3,768.00",0.9,2.5,"21,164",27
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,Total,"3,699.50",0.8,1.4,"11,647",28
11,British Columbia,L01XE,Protein kinase inhibitors,65+,Total,"3,477.27",0.8,0,188,29
11,British Columbia,R03BA,Glucocorticoids,65+,Total,"3,402.22",0.8,3.5,"28,979",30
11,British Columbia,S01ED,Beta-blocking agents,65+,Total,"3,099.88",0.7,4,"33,726",31
11,British Columbia,B01AB,Heparin group,65+,Total,"3,004.76",0.7,0.7,"5,464",32
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"2,985.84",0.7,8.9,"74,338",33
11,British Columbia,S01EE,Prostaglandin analogues,65+,Total,"2,955.34",0.7,4.1,"34,207",34
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,Total,"2,650.67",0.6,3,"25,319",35
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"2,641.54",0.6,1.3,"10,817",36
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,538.06",0.6,10.5,"88,183",37
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,Total,"2,461.34",0.6,1.8,"14,950",38
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,Total,"2,456.36",0.6,0.9,"7,645",39
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"2,454.24",0.6,0.6,"5,239",40
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"2,319.32",0.5,10.8,"90,815",41
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,Total,"2,297.89",0.5,3.4,"28,226",42
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,Total,"2,224.85",0.5,8.7,"72,567",43
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,Total,"2,215.76",0.5,0.3,"2,110",44
11,British Columbia,A10BB,Sulfonylureas,65+,Total,"2,188.67",0.5,2.9,"24,639",45
11,British Columbia,L04AX,Other immunosuppressants,65+,Total,"2,166.79",0.5,0.3,"2,098",46
11,British Columbia,N06DA,Anticholinesterases,65+,Total,"2,154.81",0.5,1,"8,738",47
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"2,154.77",0.5,0,90,48
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,147.87",0.5,1.6,"13,455",49
11,British Columbia,C03AA,"Thiazides, plain",65+,Total,"2,109.39",0.5,11.9,"99,544",50
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"2,072.95",0.5,0.2,"1,620",51
11,British Columbia,B01AA,Vitamin K antagonists,65+,Total,"2,041.97",0.5,3.5,"29,416",52
11,British Columbia,C01DA,Organic nitrates,65+,Total,"1,999.19",0.5,4.1,"33,994",53
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,880.76",0.4,0.9,"7,532",54
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"1,877.07",0.4,0.3,"2,316",55
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,864.66",0.4,3.5,"29,352",56
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"1,790.32",0.4,0.6,"4,890",57
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,Total,"1,789.29",0.4,4.7,"39,196",58
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"1,773.36",0.4,0.2,"1,791",59
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,Total,"1,741.41",0.4,0.3,"2,638",60
11,British Columbia,L03AA,Colony-stimulating factors,65+,Total,"1,698.95",0.4,0.1,694,61
11,British Columbia,H02AB,Glucocorticoids,65+,Total,"1,647.30",0.4,11.1,"93,292",62
11,British Columbia,A02BA,H2-receptor antagonists,65+,Total,"1,568.12",0.4,4.1,"34,379",63
11,British Columbia,M05BA,Bisphosphonates,65+,Total,"1,329.14",0.3,1.3,"10,763",64
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,228.48",0.3,10.4,"86,702",65
11,British Columbia,C03DA,Aldosterone antagonists,65+,Total,"1,169.24",0.3,3,"25,296",66
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"1,148.60",0.3,0,58,67
11,British Columbia,V03AC,Iron-chelating agents,65+,Total,"1,104.56",0.3,0,88,68
11,British Columbia,A03FA,Propulsives,65+,Total,"1,100.90",0.2,2.4,"20,059",69
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"1,095.76",0.2,0.8,"6,517",70
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"1,078.38",0.2,0.5,"4,453",71
11,British Columbia,N03AG,Fatty acid derivatives,65+,Total,"1,052.62",0.2,0.5,"3,846",72
11,British Columbia,A09AA,Enzyme preparations,65+,Total,"1,034.38",0.2,0.4,"3,043",73
11,British Columbia,A04AD,Other antiemetics,65+,Total,958.77,0.2,0.3,"2,844",74
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,952.72,0.2,0.1,"1,204",75
11,British Columbia,L01BA,Folic acid analogues,65+,Total,942.25,0.2,1.4,"11,695",76
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,Total,933.19,0.2,1.7,"14,386",77
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,926.27,0.2,1,"8,183",78
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,Total,924.67,0.2,1.4,"11,638",79
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,Total,922.63,0.2,1.7,"14,087",80
11,British Columbia,C01AA,Digitalis glycosides,65+,Total,913.63,0.2,1.2,"9,685",81
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,Total,912.49,0.2,0.6,"5,250",82
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,Total,862.82,0.2,1.6,"13,002",83
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,Total,822.11,0.2,0.2,"1,961",84
11,British Columbia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,775.12,0.2,1.5,"12,312",85
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,726.65,0.2,3.5,"29,534",86
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,Total,724.15,0.2,0,199,87
11,British Columbia,S01BA,"Corticosteroids, plain",65+,Total,719.18,0.2,5,"42,225",88
11,British Columbia,A12BA,Potassium,65+,Total,697.66,0.2,2,"16,969",89
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,Total,696.28,0.2,0.9,"7,701",90
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,655.19,0.1,2.8,"23,637",91
11,British Columbia,J01MA,Fluoroquinolones,65+,Total,646.52,0.1,8.2,"68,610",92
11,British Columbia,A05AA,Bile acids and derivatives,65+,Total,632.2,0.1,0.2,"1,373",93
11,British Columbia,A11CC,Vitamin D and analogues,65+,Total,612.18,0.1,0.7,"5,537",94
11,British Columbia,M03BX,Other centrally acting agents,65+,Total,608.15,0.1,3,"25,035",95
11,British Columbia,J01FA,Macrolides,65+,Total,562.53,0.1,5.8,"48,330",96
11,British Columbia,C10AC,Bile acid sequestrants,65+,Total,543.38,0.1,0.6,"4,686",97
11,British Columbia,J01XE,Nitrofuran derivatives,65+,Total,538.64,0.1,5.6,"46,613",98
11,British Columbia,C05BA,Heparins or heparinoids for topical use,65+,Total,520.28,0.1,0.1,480,99
11,British Columbia,M01AE,Propionic acid derivatives,65+,Total,509.28,0.1,3.8,"32,134",100
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,M,"22,971.48",11.5,0.1,445,1
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"19,860.46",10,0.3,"1,258",2
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,M,"8,247.28",4.1,4.5,"17,665",3
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,M,"7,355.49",3.7,47.9,"186,898",4
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"5,126.01",2.6,3.3,"12,733",5
11,British Columbia,L04AA,Selective immunosuppressants,65+,M,"4,361.16",2.2,0.2,780,6
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,M,"3,980.41",2,31.3,"122,046",7
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,872.60",1.9,2,"7,672",8
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,M,"3,863.31",1.9,21,"82,153",9
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,M,"3,664.65",1.8,23,"89,665",10
11,British Columbia,N02AA,Natural opium alkaloids,65+,M,"3,020.57",1.5,5.3,"20,535",11
11,British Columbia,A02BC,Proton pump inhibitors,65+,M,"2,896.34",1.5,11.3,"43,936",12
11,British Columbia,L04AC,Interleukin inhibitors,65+,M,"2,890.36",1.5,0.1,208,13
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"2,872.58",1.4,18.6,"72,458",14
11,British Columbia,L01XE,Protein kinase inhibitors,65+,M,**,**,**,**,15
11,British Columbia,R03BB,Anticholinergics,65+,M,"2,609.80",1.3,4.4,"17,074",16
11,British Columbia,B02AB,Proteinase inhibitors,65+,M,"2,510.45",1.3,0,21,17
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"2,496.55",1.3,3.7,"14,354",18
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"2,488.72",1.2,1.3,"5,245",19
11,British Columbia,N05AX,Other antipsychotics,65+,M,"2,384.73",1.2,1.1,"4,382",20
11,British Columbia,A10BA,Biguanides,65+,M,"2,208.30",1.1,16.1,"62,982",21
11,British Columbia,N06AX,Other antidepressants,65+,M,"2,193.77",1.1,7.6,"29,823",22
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,M,"2,106.18",1.1,1.7,"6,652",23
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,082.95",1,7,"27,185",24
11,British Columbia,N03AX,Other antiepileptics,65+,M,"2,026.64",1,6.2,"24,277",25
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"1,839.26",0.9,6.6,"25,684",26
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,M,"1,608.99",0.8,0.4,"1,378",27
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"1,533.44",0.8,0.3,"1,266",28
11,British Columbia,L04AX,Other immunosuppressants,65+,M,"1,519.12",0.8,0.2,906,29
11,British Columbia,B01AB,Heparin group,65+,M,"1,518.38",0.8,0.6,"2,507",30
11,British Columbia,C03CA,"Sulfonamides, plain",65+,M,"1,516.57",0.8,8.6,"33,713",31
11,British Columbia,L01XC,Monoclonal antibodies,65+,M,"1,512.60",0.8,0,127,32
11,British Columbia,H03AA,Thyroid hormones,65+,M,"1,440.16",0.7,9.1,"35,434",33
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"1,424.84",0.7,3.2,"12,683",34
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"1,367.09",0.7,1.5,"5,714",35
11,British Columbia,R03BA,Glucocorticoids,65+,M,"1,349.57",0.7,3,"11,534",36
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,M,"1,292.18",0.6,2,"7,898",37
11,British Columbia,S01ED,Beta-blocking agents,65+,M,"1,233.20",0.6,4.2,"16,324",38
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,225.29",0.6,2,"7,716",39
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"1,173.70",0.6,0.7,"2,902",40
11,British Columbia,S01EE,Prostaglandin analogues,65+,M,"1,111.15",0.6,4,"15,789",41
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,109.35",0.6,9.7,"37,820",42
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,M,"1,038.74",0.5,0.9,"3,436",43
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,M,"1,012.69",0.5,7.4,"28,761",44
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,998.53,0.5,1.1,"4,279",45
11,British Columbia,A10BB,Sulfonylureas,65+,M,996.57,0.5,3.5,"13,531",46
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,989.86,0.5,11.2,"43,852",47
11,British Columbia,B01AA,Vitamin K antagonists,65+,M,984.34,0.5,4.4,"17,194",48
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,49
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,899.03,0.5,0.7,"2,670",50
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,M,861.07,0.4,3.1,"12,258",51
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,M,859.49,0.4,2.8,"10,783",52
11,British Columbia,C01DA,Organic nitrates,65+,M,818.05,0.4,4.8,"18,724",53
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,M,804.99,0.4,0.4,"1,403",54
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,M,740.47,0.4,6.2,"24,181",55
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,722.7,0.4,0.1,382,56
11,British Columbia,C03AA,"Thiazides, plain",65+,M,704.56,0.4,10.5,"41,116",57
11,British Columbia,N06DA,Anticholinesterases,65+,M,690.25,0.3,0.9,"3,527",58
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,658.12,0.3,0.7,"2,738",59
11,British Columbia,L03AA,Colony-stimulating factors,65+,M,657.99,0.3,0.1,260,60
11,British Columbia,H02AB,Glucocorticoids,65+,M,655.22,0.3,10.8,"42,341",61
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,628.31,0.3,0,30,62
11,British Columbia,V03AC,Iron-chelating agents,65+,M,616.68,0.3,0,51,63
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,609.08,0.3,1.1,"4,128",64
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,594.22,0.3,0.1,573,65
11,British Columbia,A02BA,H2-receptor antagonists,65+,M,592.24,0.3,3.7,"14,375",66
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,M,571.21,0.3,10.3,"40,305",67
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,557.39,0.3,2.3,"9,115",68
11,British Columbia,C03DA,Aldosterone antagonists,65+,M,537.41,0.3,3.3,"13,069",69
11,British Columbia,N03AG,Fatty acid derivatives,65+,M,505.9,0.3,0.5,"1,799",70
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,504.3,0.3,0.2,703,71
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,M,488.27,0.2,0.8,"3,205",72
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,473.31,0.2,0,21,73
11,British Columbia,A03FA,Propulsives,65+,M,418.56,0.2,2,"7,627",74
11,British Columbia,A04AD,Other antiemetics,65+,M,416.94,0.2,0.3,"1,228",75
11,British Columbia,A09AA,Enzyme preparations,65+,M,410.13,0.2,0.3,"1,326",76
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,M,366.03,0.2,1.4,"5,615",77
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,M,362.78,0.2,0.2,842,78
11,British Columbia,C01AA,Digitalis glycosides,65+,M,351.23,0.2,1.2,"4,515",79
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,M,343.55,0.2,1.6,"6,299",80
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,M,317.93,0.2,1.2,"4,713",81
11,British Columbia,M05BA,Bisphosphonates,65+,M,312.9,0.2,0.4,"1,716",82
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,M,293.27,0.1,1.2,"4,692",83
11,British Columbia,A11CC,Vitamin D and analogues,65+,M,283.88,0.1,0.7,"2,645",84
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,279.08,0.1,2.8,"11,083",85
11,British Columbia,L01BA,Folic acid analogues,65+,M,277.65,0.1,1.1,"4,254",86
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,M,274.31,0.1,1,"3,728",87
11,British Columbia,J01MA,Fluoroquinolones,65+,M,272.45,0.1,8.2,"31,889",88
11,British Columbia,S01BA,"Corticosteroids, plain",65+,M,269.28,0.1,4.8,"18,554",89
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,65+,M,**,**,**,*,90
11,British Columbia,M03BX,Other centrally acting agents,65+,M,249.19,0.1,2.8,"10,780",91
11,British Columbia,M01AE,Propionic acid derivatives,65+,M,243.86,0.1,3.9,"15,033",92
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,65+,M,240.7,0.1,0.7,"2,834",93
11,British Columbia,B02BX,Other systemic hemostatics,65+,M,**,**,**,**,94
11,British Columbia,J01FA,Macrolides,65+,M,227.24,0.1,5.3,"20,729",95
11,British Columbia,J01AA,Tetracyclines,65+,M,225.88,0.1,5.4,"21,179",96
11,British Columbia,C01BD,"Antiarrhythmics, class III",65+,M,220.45,0.1,0.9,"3,409",97
11,British Columbia,J02AC,Triazole derivatives,65+,M,216.44,0.1,0.1,259,98
11,British Columbia,A12BA,Potassium,65+,M,215.48,0.1,1.6,"6,363",99
11,British Columbia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,213.58,0.1,1.2,"4,534",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"24,825.49",10.3,0.4,"1,722",1
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,F,"10,667.35",4.4,3.9,"17,472",2
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,F,"10,405.40",4.3,0,208,3
11,British Columbia,L04AA,Selective immunosuppressants,65+,F,"9,856.44",4.1,0.4,"1,816",4
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,F,"9,069.81",3.7,32.9,"147,007",5
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"7,331.36",3,3.7,"16,482",6
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,F,"6,718.73",2.8,19.8,"88,710",7
11,British Columbia,A02BC,Proton pump inhibitors,65+,F,"5,370.26",2.2,14.3,"63,814",8
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,F,"5,028.90",2.1,17.6,"78,904",9
11,British Columbia,H03AA,Thyroid hormones,65+,F,"4,932.21",2,23.5,"105,152",10
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,F,"4,868.46",2,21.9,"98,098",11
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"4,651.28",1.9,12.6,"56,348",12
11,British Columbia,N06AX,Other antidepressants,65+,F,"4,267.10",1.8,11.5,"51,385",13
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"4,232.18",1.7,9.1,"40,551",14
11,British Columbia,L04AC,Interleukin inhibitors,65+,F,"4,135.26",1.7,0.1,354,15
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"3,642.30",1.5,1.4,"6,317",16
11,British Columbia,L01XC,Monoclonal antibodies,65+,F,"3,570.73",1.5,0.1,299,17
11,British Columbia,N05AX,Other antipsychotics,65+,F,"3,301.09",1.4,1.5,"6,513",18
11,British Columbia,N02AA,Natural opium alkaloids,65+,F,"3,275.04",1.4,6.3,"28,074",19
11,British Columbia,N03AX,Other antiepileptics,65+,F,"3,221.15",1.3,8.3,"36,914",20
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"3,138.38",1.3,1.2,"5,308",21
11,British Columbia,R03BB,Anticholinergics,65+,F,"2,949.30",1.2,3.9,"17,327",22
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"2,928.10",1.2,4,"17,971",23
11,British Columbia,A10BA,Biguanides,65+,F,"2,583.38",1.1,10.9,"48,838",24
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"2,343.16",1,1.9,"8,481",25
11,British Columbia,C03CA,"Sulfonamides, plain",65+,F,"2,302.92",1,8.4,"37,672",26
11,British Columbia,R03BA,Glucocorticoids,65+,F,"2,052.65",0.8,3.9,"17,445",27
11,British Columbia,S01ED,Beta-blocking agents,65+,F,"1,866.67",0.8,3.9,"17,402",28
11,British Columbia,S01EE,Prostaglandin analogues,65+,F,"1,844.20",0.8,4.1,"18,418",29
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,F,"1,791.18",0.7,3.3,"14,536",30
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"1,681.46",0.7,0,69,31
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,F,"1,593.31",0.7,1.1,"4,995",32
11,British Columbia,B01AB,Heparin group,65+,F,"1,486.38",0.6,0.7,"2,957",33
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,F,"1,484.38",0.6,10.8,"48,386",34
11,British Columbia,N06DA,Anticholinesterases,65+,F,"1,464.56",0.6,1.2,"5,211",35
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,F,"1,436.82",0.6,3.6,"15,968",36
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,428.71",0.6,11.3,"50,363",37
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,417.62",0.6,0.9,"4,209",38
11,British Columbia,C03AA,"Thiazides, plain",65+,F,"1,404.83",0.6,13.1,"58,428",39
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,329.46",0.5,10.5,"46,963",40
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,307.27",0.5,4.5,"20,237",41
11,British Columbia,B02AB,Proteinase inhibitors,65+,F,"1,305.39",0.5,0,15,42
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"1,280.54",0.5,0.5,"2,337",43
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"1,274.44",0.5,1.1,"5,103",44
11,British Columbia,A10BB,Sulfonylureas,65+,F,"1,192.10",0.5,2.5,"11,108",45
11,British Columbia,C01DA,Organic nitrates,65+,F,"1,181.14",0.5,3.4,"15,270",46
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"1,179.13",0.5,0.3,"1,218",47
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,F,"1,169.16",0.5,1.6,"7,052",48
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"1,154.37",0.5,0.4,"1,934",49
11,British Columbia,B01AA,Vitamin K antagonists,65+,F,"1,057.63",0.4,2.7,"12,222",50
11,British Columbia,L03AA,Colony-stimulating factors,65+,F,"1,040.96",0.4,0.1,434,51
11,British Columbia,M05BA,Bisphosphonates,65+,F,"1,016.24",0.4,2,"9,047",52
11,British Columbia,H02AB,Glucocorticoids,65+,F,992.07,0.4,11.4,"50,951",53
11,British Columbia,A02BA,H2-receptor antagonists,65+,F,975.88,0.4,4.5,"20,004",54
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,F,936.42,0.4,0.3,"1,235",55
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,922.58,0.4,1.3,"5,739",56
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,891.29,0.4,0.5,"2,220",57
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,882.23,0.4,0.7,"3,253",58
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,F,776.6,0.3,2.3,"10,435",59
11,British Columbia,A03FA,Propulsives,65+,F,682.34,0.3,2.8,"12,432",60
11,British Columbia,L01XE,Protein kinase inhibitors,65+,F,**,**,**,**,61
11,British Columbia,L01BA,Folic acid analogues,65+,F,664.6,0.3,1.7,"7,441",62
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,F,657.27,0.3,10.4,"46,397",63
11,British Columbia,L04AX,Other immunosuppressants,65+,F,647.67,0.3,0.3,"1,192",64
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,646.6,0.3,5.3,"23,547",65
11,British Columbia,C03DA,Aldosterone antagonists,65+,F,631.83,0.3,2.7,"12,227",66
11,British Columbia,A09AA,Enzyme preparations,65+,F,624.26,0.3,0.4,"1,717",67
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,F,615.26,0.3,2.2,"9,673",68
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,F,606.76,0.3,0.2,732,69
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,F,579.07,0.2,1.7,"7,788",70
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,F,569.56,0.2,1.9,"8,310",71
11,British Columbia,C01AA,Digitalis glycosides,65+,F,562.39,0.2,1.2,"5,170",72
11,British Columbia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,561.54,0.2,1.7,"7,778",73
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,F,558.64,0.2,1.3,"6,023",74
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,F,546.92,0.2,0,97,75
11,British Columbia,N03AG,Fatty acid derivatives,65+,F,546.71,0.2,0.5,"2,047",76
11,British Columbia,A04AD,Other antiemetics,65+,F,541.83,0.2,0.4,"1,616",77
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,539.51,0.2,0.1,354,78
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,520.29,0.2,0,28,79
11,British Columbia,A05AA,Bile acids and derivatives,65+,F,492.84,0.2,0.2,"1,033",80
11,British Columbia,V03AC,Iron-chelating agents,65+,F,487.88,0.2,0,37,81
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,486.69,0.2,0.5,"2,389",82
11,British Columbia,A12BA,Potassium,65+,F,482.18,0.2,2.4,"10,606",83
11,British Columbia,J01XE,Nitrofuran derivatives,65+,F,469.56,0.2,9,"40,315",84
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,F,459.34,0.2,0.3,"1,119",85
11,British Columbia,S01BA,"Corticosteroids, plain",65+,F,449.9,0.2,5.3,"23,671",86
11,British Columbia,C05BA,Heparins or heparinoids for topical use,65+,F,449.48,0.2,0.1,409,87
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,448.42,0.2,0.1,501,88
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,447.56,0.2,4.1,"18,451",89
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,F,424.22,0.2,0.5,"2,045",90
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,F,421.97,0.2,0.9,"3,973",91
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,420.25,0.2,0.4,"1,715",92
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,65+,F,392.94,0.2,1.1,"4,784",93
11,British Columbia,J01MA,Fluoroquinolones,65+,F,374.07,0.2,8.2,"36,721",94
11,British Columbia,M03BX,Other centrally acting agents,65+,F,358.97,0.1,3.2,"14,255",95
11,British Columbia,C10AC,Bile acid sequestrants,65+,F,350.77,0.1,0.7,"3,102",96
11,British Columbia,P01BA,Aminoquinolines,65+,F,349.26,0.1,1.5,"6,629",97
11,British Columbia,J01FA,Macrolides,65+,F,335.29,0.1,6.2,"27,601",98
11,British Columbia,A11CC,Vitamin D and analogues,65+,F,328.3,0.1,0.6,"2,892",99
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,F,301.04,0.1,0.5,"2,381",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"153,940.22",19.4,0.4,"9,485",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"122,047.72",15.4,0.1,"2,400",2
11,British Columbia,L04AA,Selective immunosuppressants,<65,Total,"45,436.24",5.7,0.2,"5,008",3
11,British Columbia,N05AX,Other antipsychotics,<65,Total,"45,342.17",5.7,1.3,"28,925",4
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,Total,"40,220.94",5.1,1.2,"25,645",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"27,878.84",3.5,3.3,"71,167",6
11,British Columbia,N02AA,Natural opium alkaloids,<65,Total,"20,162.81",2.5,2.4,"52,586",7
11,British Columbia,L04AC,Interleukin inhibitors,<65,Total,"18,659.75",2.4,0.1,"1,527",8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"16,058.36",2,11.8,"254,280",9
11,British Columbia,N06AX,Other antidepressants,<65,Total,"15,210.79",1.9,7,"152,320",10
11,British Columbia,N03AX,Other antiepileptics,<65,Total,"12,987.16",1.6,4.1,"88,782",11
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,Total,"11,944.60",1.5,3.6,"78,317",12
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,Total,"9,164.94",1.2,1.5,"32,402",13
11,British Columbia,L04AX,Other immunosuppressants,<65,Total,"8,322.16",1.1,0.2,"4,581",14
11,British Columbia,L01XC,Monoclonal antibodies,<65,Total,"7,548.77",1,0,686,15
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"6,060.49",0.8,1.1,"23,894",16
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"5,694.72",0.7,0.6,"13,005",17
11,British Columbia,A02BC,Proton pump inhibitors,<65,Total,"5,647.83",0.7,3.4,"73,904",18
11,British Columbia,B02AB,Proteinase inhibitors,<65,Total,"5,560.94",0.7,0,59,19
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,Total,"5,518.60",0.7,8.6,"186,151",20
11,British Columbia,N03AG,Fatty acid derivatives,<65,Total,"4,767.22",0.6,0.7,"14,563",21
11,British Columbia,H03AA,Thyroid hormones,<65,Total,"4,154.71",0.5,6.4,"137,862",22
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"4,125.44",0.5,0.3,"7,183",23
11,British Columbia,R03BA,Glucocorticoids,<65,Total,"3,866.15",0.5,4.4,"94,468",24
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,Total,"3,683.62",0.5,6.6,"142,364",25
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"3,608.02",0.5,0.1,"2,773",26
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,Total,"3,497.26",0.4,0.7,"14,505",27
11,British Columbia,L03AA,Colony-stimulating factors,<65,Total,"3,487.85",0.4,0.1,"1,381",28
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"3,466.25",0.4,0,118,29
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"3,253.85",0.4,9.7,"209,618",30
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,Total,"3,190.90",0.4,6.3,"136,063",31
11,British Columbia,M01AE,Propionic acid derivatives,<65,Total,"3,154.96",0.4,7.6,"163,453",32
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"3,150.89",0.4,1,"20,787",33
11,British Columbia,A09AA,Enzyme preparations,<65,Total,"3,078.92",0.4,0.1,"2,941",34
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"3,052.94",0.4,2.4,"51,663",35
11,British Columbia,L03AB,Interferons,<65,Total,"2,881.22",0.4,0,207,36
11,British Columbia,N03AF,Carboxamide derivatives,<65,Total,"2,626.05",0.3,0.4,"8,471",37
11,British Columbia,B01AB,Heparin group,<65,Total,"2,549.66",0.3,0.2,"3,483",38
11,British Columbia,A10BA,Biguanides,<65,Total,"2,543.35",0.3,4.2,"91,031",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"2,523.92",0.3,10.2,"220,395",40
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,Total,"2,515.84",0.3,1.3,"29,041",41
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,Total,"2,489.22",0.3,3.9,"84,615",42
11,British Columbia,V03AC,Iron-chelating agents,<65,Total,"2,423.11",0.3,0,91,43
11,British Columbia,A04AD,Other antiemetics,<65,Total,"2,381.83",0.3,0.2,"5,225",44
11,British Columbia,M03BX,Other centrally acting agents,<65,Total,"2,365.68",0.3,4.7,"102,311",45
11,British Columbia,A02BA,H2-receptor antagonists,<65,Total,"2,314.45",0.3,2.3,"49,877",46
11,British Columbia,L03AX,Other immunostimulants,<65,Total,"2,256.95",0.3,0,366,47
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,Total,"2,220.39",0.3,3.1,"66,233",48
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,**,49
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,Total,"2,145.45",0.3,0.3,"6,334",50
11,British Columbia,R05CB,Mucolytics,<65,Total,"2,074.08",0.3,0,304,51
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"1,986.46",0.3,0.2,"4,604",52
11,British Columbia,R03BB,Anticholinergics,<65,Total,"1,973.50",0.2,0.8,"16,534",53
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,949.08",0.2,0,94,54
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"1,944.53",0.2,1.7,"37,192",55
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"1,653.77",0.2,5.6,"121,398",56
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"1,547.40",0.2,4.9,"106,927",57
11,British Columbia,N05AN,Lithium,<65,Total,"1,530.46",0.2,0.4,"7,730",58
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,Total,"1,477.05",0.2,0.5,"11,286",59
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,Total,"1,408.39",0.2,1,"21,312",60
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"1,397.40",0.2,0.1,"2,585",61
11,British Columbia,G02BA,Intrauterine contraceptives,<65,Total,"1,380.02",0.2,1.3,"27,410",62
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,Total,"1,344.15",0.2,0.3,"6,366",63
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,Total,"1,305.66",0.2,0.5,"11,460",64
11,British Columbia,N05AF,Thioxanthene derivatives,<65,Total,"1,280.70",0.2,0.1,"1,942",65
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"1,259.62",0.2,0.3,"7,258",66
11,British Columbia,H02AB,Glucocorticoids,<65,Total,"1,197.65",0.2,6.8,"147,400",67
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"1,193.68",0.2,0.2,"3,872",68
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,Total,"1,151.04",0.1,0.2,"4,659",69
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,Total,"1,118.66",0.1,17.7,"382,814",70
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,Total,"1,081.61",0.1,1,"21,243",71
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,Total,"1,067.90",0.1,0,63,72
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,Total,"1,061.75",0.1,8.9,"192,954",73
11,British Columbia,A10BB,Sulfonylureas,<65,Total,"1,040.34",0.1,0.7,"15,238",74
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"1,018.93",0.1,0.9,"19,699",75
11,British Columbia,N05AE,Indole derivatives,<65,Total,970.18,0.1,0,709,76
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,969.35,0.1,1.4,"30,559",77
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,Total,968.67,0.1,0,274,78
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,Total,941.65,0.1,1.7,"37,294",79
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,Total,911.71,0.1,0.3,"7,050",80
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,902.08,0.1,0.2,"4,550",81
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,Total,869.64,0.1,0.1,"1,427",82
11,British Columbia,J01DB,First-generation cephalosporins,<65,Total,850.84,0.1,7,"151,986",83
11,British Columbia,A05AA,Bile acids and derivatives,<65,Total,848.81,0.1,0.1,"2,147",84
11,British Columbia,J02AC,Triazole derivatives,<65,Total,848.69,0.1,0,908,85
11,British Columbia,C03AA,"Thiazides, plain",<65,Total,816.4,0.1,2.6,"57,234",86
11,British Columbia,J01DF,Monobactams,<65,Total,**,**,**,**,87
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,Total,805.7,0.1,0.2,"4,940",88
11,British Columbia,C03CA,"Sulfonamides, plain",<65,Total,794.7,0.1,0.7,"16,052",89
11,British Columbia,J01AA,Tetracyclines,<65,Total,792.53,0.1,4.8,"102,757",90
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,786.95,0.1,0,769,91
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,777.68,0.1,0.3,"6,620",92
11,British Columbia,L01BA,Folic acid analogues,<65,Total,776.63,0.1,0.6,"13,201",93
11,British Columbia,J01GB,Other aminoglycosides,<65,Total,751.13,0.1,0,193,94
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,**,**,**,**,95
11,British Columbia,C03DA,Aldosterone antagonists,<65,Total,739.53,0.1,0.9,"18,536",96
11,British Columbia,A03FA,Propulsives,<65,Total,738.54,0.1,1.4,"29,460",97
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,706.92,0.1,0.1,"1,982",98
11,British Columbia,J01FA,Macrolides,<65,Total,681.02,0.1,7.4,"160,653",99
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,678.54,0.1,0.2,"3,777",100
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,M,"80,739.26",19.1,0.2,"1,591",1
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"80,413.20",19.1,0.5,"4,631",2
11,British Columbia,N05AX,Other antipsychotics,<65,M,"29,533.50",7,1.7,"16,399",3
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,M,"27,100.23",6.4,1.8,"17,011",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"18,066.18",4.3,3.6,"34,410",5
11,British Columbia,L04AA,Selective immunosuppressants,<65,M,"15,576.37",3.7,0.2,"1,555",6
11,British Columbia,N02AA,Natural opium alkaloids,<65,M,"12,106.07",2.9,2.6,"24,916",7
11,British Columbia,L04AC,Interleukin inhibitors,<65,M,"9,299.05",2.2,0.1,685,8
11,British Columbia,N06AX,Other antidepressants,<65,M,"7,031.36",1.7,6.1,"58,561",9
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,M,"6,892.85",1.6,9.2,"88,032",10
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,M,"6,691.36",1.6,4.6,"43,916",11
11,British Columbia,N03AX,Other antiepileptics,<65,M,"6,166.75",1.5,3.8,"36,317",12
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,M,"5,557.21",1.3,2,"19,184",13
11,British Columbia,B02AB,Proteinase inhibitors,<65,M,"3,465.58",0.8,0,33,14
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,M,"3,157.18",0.7,12.3,"118,321",15
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"3,059.32",0.7,0.8,"7,297",16
11,British Columbia,N03AG,Fatty acid derivatives,<65,M,"2,894.08",0.7,0.8,"8,050",17
11,British Columbia,A02BC,Proton pump inhibitors,<65,M,"2,703.10",0.6,3.4,"33,063",18
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"2,634.50",0.6,1.1,"10,158",19
11,British Columbia,L04AX,Other immunosuppressants,<65,M,"2,560.01",0.6,0.2,"1,751",20
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,M,"2,224.35",0.5,9.1,"87,387",21
11,British Columbia,L01XC,Monoclonal antibodies,<65,M,"1,945.01",0.5,0,185,22
11,British Columbia,A09AA,Enzyme preparations,<65,M,"1,883.62",0.4,0.1,"1,404",23
11,British Columbia,M01AE,Propionic acid derivatives,<65,M,"1,805.33",0.4,7.9,"75,479",24
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,718.22",0.4,1.2,"11,179",25
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,M,"1,664.03",0.4,0.7,"6,430",26
11,British Columbia,R03BA,Glucocorticoids,<65,M,"1,655.96",0.4,4.6,"43,696",27
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"1,603.80",0.4,0.1,957,28
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"1,506.32",0.4,10.5,"100,782",29
11,British Columbia,N03AF,Carboxamide derivatives,<65,M,"1,499.42",0.4,0.4,"4,180",30
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,M,"1,462.34",0.3,4.7,"44,982",31
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,32
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,M,"1,392.99",0.3,5.2,"49,696",33
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,M,"1,382.63",0.3,4.2,"40,288",34
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,372.97",0.3,1.8,"16,953",35
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,M,"1,348.20",0.3,0.4,"3,845",36
11,British Columbia,A02BA,H2-receptor antagonists,<65,M,"1,330.27",0.3,2.1,"20,411",37
11,British Columbia,A10BA,Biguanides,<65,M,"1,326.96",0.3,5.3,"50,529",38
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"1,284.71",0.3,0.6,"5,360",39
11,British Columbia,V03AC,Iron-chelating agents,<65,M,"1,262.10",0.3,0,47,40
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,M,"1,206.62",0.3,1.2,"11,221",41
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"1,165.51",0.3,10.4,"99,366",42
11,British Columbia,B01AB,Heparin group,<65,M,"1,150.57",0.3,0.2,"1,444",43
11,British Columbia,M03BX,Other centrally acting agents,<65,M,"1,121.43",0.3,4.7,"45,321",44
11,British Columbia,A04AD,Other antiemetics,<65,M,"1,078.22",0.3,0.2,"2,096",45
11,British Columbia,H03AA,Thyroid hormones,<65,M,"1,041.10",0.2,2.7,"26,324",46
11,British Columbia,R03BB,Anticholinergics,<65,M,"1,039.13",0.2,0.8,"8,116",47
11,British Columbia,R05CB,Mucolytics,<65,M,"1,014.58",0.2,0,153,48
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"1,007.30",0.2,0.3,"2,467",49
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,988.34,0.2,0,31,50
11,British Columbia,N05AN,Lithium,<65,M,871.64,0.2,0.4,"3,686",51
11,British Columbia,N05AF,Thioxanthene derivatives,<65,M,866.26,0.2,0.1,"1,287",52
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,852.36,0.2,0,40,53
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,832.14,0.2,0.2,"1,561",54
11,British Columbia,L03AA,Colony-stimulating factors,<65,M,828.95,0.2,0,339,55
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,M,751.1,0.2,0.4,"3,663",56
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,M,733.49,0.2,0.5,"5,178",57
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,M,708.74,0.2,0.3,"2,759",58
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,M,697.69,0.2,0.5,"4,336",59
11,British Columbia,L03AB,Interferons,<65,M,671.75,0.2,0,47,60
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,635.83,0.2,0.3,"3,022",61
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,629.91,0.1,0.1,614,62
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,604.64,0.1,2.5,"23,974",63
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,591.78,0.1,0.2,"2,211",64
11,British Columbia,A10BB,Sulfonylureas,<65,M,556.54,0.1,0.9,"8,861",65
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,538.34,0.1,0.3,"2,416",66
11,British Columbia,L03AX,Other immunostimulants,<65,M,536.31,0.1,0,80,67
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,M,525.66,0.1,0.6,"5,364",68
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,M,522.11,0.1,0.9,"8,552",69
11,British Columbia,H02AB,Glucocorticoids,<65,M,513.56,0.1,6.9,"65,799",70
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,M,502.56,0.1,8.8,"83,951",71
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,M,492.45,0.1,18.5,"177,526",72
11,British Columbia,J02AC,Triazole derivatives,<65,M,483.21,0.1,0,428,73
11,British Columbia,J01GB,Other aminoglycosides,<65,M,481.48,0.1,0,110,74
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,472.21,0.1,3.7,"35,670",75
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,M,461.3,0.1,0.8,"7,299",76
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,M,453.17,0.1,0,20,77
11,British Columbia,G03BA,3-oxoandrosten (4) derivatives,<65,M,**,**,**,**,78
11,British Columbia,J01DB,First-generation cephalosporins,<65,M,436.46,0.1,7.7,"73,618",79
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,421.74,0.1,0.9,"8,978",80
11,British Columbia,J01DF,Monobactams,<65,M,**,**,**,**,81
11,British Columbia,C03CA,"Sulfonamides, plain",<65,M,414.02,0.1,0.8,"7,927",82
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,M,410.21,0.1,0.3,"2,618",83
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,408.63,0.1,0.4,"4,048",84
11,British Columbia,N05AE,Indole derivatives,<65,M,392.53,0.1,0,280,85
11,British Columbia,J01AA,Tetracyclines,<65,M,380.4,0.1,4.7,"44,703",86
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,M,375.11,0.1,1.7,"16,635",87
11,British Columbia,C03DA,Aldosterone antagonists,<65,M,374.07,0.1,0.7,"6,545",88
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,M,373.8,0.1,0.1,557,89
11,British Columbia,L01XE,Protein kinase inhibitors,<65,M,**,**,**,**,90
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,371.79,0.1,0.2,"1,872",91
11,British Columbia,C03AA,"Thiazides, plain",<65,M,371.27,0.1,2.7,"26,314",92
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,371.06,0.1,0.1,"1,160",93
11,British Columbia,N03AB,Hydantoin derivatives,<65,M,352.47,0.1,0.3,"2,538",94
11,British Columbia,M04AA,Preparations inhibiting uric acid production,<65,M,319.61,0.1,2.1,"19,794",95
11,British Columbia,C07AG,Alpha- and beta-blocking agents,<65,M,313.29,0.1,0.2,"1,801",96
11,British Columbia,N04BA,Dopa and dopa derivatives,<65,M,306.79,0.1,0.1,"1,342",97
11,British Columbia,D06AX,Other antibiotics for topical use,<65,M,303.54,0.1,2.9,"27,904",98
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,M,298.58,0.1,0,126,99
11,British Columbia,J01FA,Macrolides,<65,M,286,0.1,7.3,"70,032",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"73,527.02",19.8,0.4,"4,854",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,F,"41,308.46",11.1,0.1,809,2
11,British Columbia,L04AA,Selective immunosuppressants,<65,F,"29,859.88",8.1,0.3,"3,453",3
11,British Columbia,N05AX,Other antipsychotics,<65,F,"15,808.67",4.3,1,"12,526",4
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,F,"13,120.71",3.5,0.7,"8,634",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"9,812.66",2.6,3.1,"36,757",6
11,British Columbia,L04AC,Interleukin inhibitors,<65,F,"9,360.70",2.5,0.1,842,7
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,F,"9,165.51",2.5,13.8,"166,248",8
11,British Columbia,N06AX,Other antidepressants,<65,F,"8,179.44",2.2,7.8,"93,759",9
11,British Columbia,N02AA,Natural opium alkaloids,<65,F,"8,056.74",2.2,2.3,"27,670",10
11,British Columbia,N03AX,Other antiepileptics,<65,F,"6,820.41",1.8,4.4,"52,465",11
11,British Columbia,L04AX,Other immunosuppressants,<65,F,"5,762.15",1.6,0.2,"2,830",12
11,British Columbia,L01XC,Monoclonal antibodies,<65,F,"5,603.76",1.5,0,501,13
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,F,"5,253.23",1.4,2.9,"34,401",14
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,F,"3,607.73",1,1.1,"13,218",15
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"3,426.00",0.9,1.1,"13,736",16
11,British Columbia,H03AA,Thyroid hormones,<65,F,"3,113.61",0.8,9.3,"111,538",17
11,British Columbia,A02BC,Proton pump inhibitors,<65,F,"2,944.73",0.8,3.4,"40,841",18
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"2,840.73",0.8,0.2,"1,823",19
11,British Columbia,L03AA,Colony-stimulating factors,<65,F,"2,658.90",0.7,0.1,"1,042",20
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"2,635.40",0.7,0.5,"5,708",21
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,477.91",0.7,0,87,22
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,F,"2,361.43",0.6,5.6,"67,830",23
11,British Columbia,R03BA,Glucocorticoids,<65,F,"2,209.98",0.6,4.2,"50,770",24
11,British Columbia,L03AB,Interferons,<65,F,"2,209.47",0.6,0,160,25
11,British Columbia,B02AB,Proteinase inhibitors,<65,F,"2,095.36",0.6,0,26,26
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"2,004.22",0.5,0.2,"1,816",27
11,British Columbia,N03AG,Fatty acid derivatives,<65,F,"1,873.15",0.5,0.5,"6,513",28
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,F,"1,833.23",0.5,0.7,"8,075",29
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"1,747.54",0.5,9,"108,836",30
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,F,"1,728.56",0.5,7.6,"91,081",31
11,British Columbia,L03AX,Other immunostimulants,<65,F,"1,720.64",0.5,0,286,32
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"1,679.97",0.5,2.9,"34,710",33
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,34
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,F,"1,483.23",0.4,2.5,"29,893",35
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,F,"1,459.27",0.4,4.6,"54,977",36
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"1,432.66",0.4,0.8,"9,608",37
11,British Columbia,B01AB,Heparin group,<65,F,"1,399.09",0.4,0.2,"2,039",38
11,British Columbia,G02BA,Intrauterine contraceptives,<65,F,"1,379.49",0.4,2.3,"27,401",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"1,358.33",0.4,10,"121,027",40
11,British Columbia,M01AE,Propionic acid derivatives,<65,F,"1,349.63",0.4,7.3,"87,974",41
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,F,"1,309.22",0.4,1.5,"17,820",42
11,British Columbia,A04AD,Other antiemetics,<65,F,"1,303.61",0.4,0.3,"3,129",43
11,British Columbia,M03BX,Other centrally acting agents,<65,F,"1,244.25",0.3,4.7,"56,990",44
11,British Columbia,A10BA,Biguanides,<65,F,"1,216.39",0.3,3.4,"40,502",45
11,British Columbia,A09AA,Enzyme preparations,<65,F,"1,195.30",0.3,0.1,"1,537",46
11,British Columbia,V03AC,Iron-chelating agents,<65,F,"1,161.01",0.3,0,44,47
11,British Columbia,N03AF,Carboxamide derivatives,<65,F,"1,126.62",0.3,0.4,"4,291",48
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"1,096.71",0.3,0,54,49
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,F,"1,096.23",0.3,2.9,"34,919",50
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"1,075.19",0.3,5.9,"71,257",51
11,British Columbia,R05CB,Mucolytics,<65,F,"1,059.50",0.3,0,151,52
11,British Columbia,A02BA,H2-receptor antagonists,<65,F,984.18,0.3,2.4,"29,466",53
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,979.16,0.3,0.2,"2,137",54
11,British Columbia,R03BB,Anticholinergics,<65,F,934.37,0.3,0.7,"8,418",55
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,F,882.73,0.2,1.3,"15,948",56
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,F,837.75,0.2,2.2,"25,945",57
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,813.55,0.2,2.5,"29,527",58
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,F,797.25,0.2,0.2,"2,489",59
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,60
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,F,779.36,0.2,0.6,"6,950",61
11,British Columbia,H02AB,Glucocorticoids,<65,F,684.09,0.2,6.8,"81,601",62
11,British Columbia,A05AA,Bile acids and derivatives,<65,F,673.53,0.2,0.1,"1,487",63
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,F,670.1,0.2,0,148,64
11,British Columbia,N05AN,Lithium,<65,F,658.82,0.2,0.3,"4,044",65
11,British Columbia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,66
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,F,626.21,0.2,17,"205,288",67
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,623.78,0.2,0.4,"4,236",68
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,F,614.73,0.2,0,43,69
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,601.9,0.2,0.1,"1,661",70
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,597.19,0.2,0.9,"10,721",71
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,F,593.05,0.2,0.2,"2,703",72
11,British Columbia,N05AE,Indole derivatives,<65,F,577.65,0.2,0,429,73
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,F,572.18,0.2,0.5,"6,282",74
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,F,566.24,0.2,1.7,"20,658",75
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,565.26,0.2,0.1,"1,024",76
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,F,560.06,0.2,0.3,"3,063",77
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,F,559.5,0.2,1.1,"12,691",78
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,F,559.2,0.2,9.1,"109,003",79
11,British Columbia,G03AC,Progestogens,<65,F,**,**,**,**,80
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,81
11,British Columbia,L01BA,Folic acid analogues,<65,F,516.28,0.1,0.7,"8,339",82
11,British Columbia,C05BA,Heparins or heparinoids for topical use,<65,F,516.24,0.1,0.1,758,83
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,F,501.5,0.1,0.4,"4,432",84
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,F,495.84,0.1,0.1,870,85
11,British Columbia,A10BB,Sulfonylureas,<65,F,483.8,0.1,0.5,"6,377",86
11,British Columbia,A03FA,Propulsives,<65,F,459.58,0.1,1.9,"22,284",87
11,British Columbia,C03AA,"Thiazides, plain",<65,F,445.12,0.1,2.6,"30,920",88
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,F,442.3,0.1,0.2,"1,900",89
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,<65,F,**,**,**,**,90
11,British Columbia,N05AF,Thioxanthene derivatives,<65,F,414.44,0.1,0.1,655,91
11,British Columbia,J01DB,First-generation cephalosporins,<65,F,414.38,0.1,6.5,"78,368",92
11,British Columbia,J01AA,Tetracyclines,<65,F,412.13,0.1,4.8,"58,054",93
11,British Columbia,J01FA,Macrolides,<65,F,395.02,0.1,7.5,"90,621",94
11,British Columbia,J01DF,Monobactams,<65,F,**,**,**,**,95
11,British Columbia,C03CA,"Sulfonamides, plain",<65,F,380.68,0.1,0.7,"8,125",96
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,369.06,0.1,0.2,"2,572",97
11,British Columbia,J02AC,Triazole derivatives,<65,F,365.47,0.1,0,480,98
11,British Columbia,C03DA,Aldosterone antagonists,<65,F,365.46,0.1,1,"11,991",99
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,363.74,0.1,0.2,"2,134",100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,Total,"1,714.71",15.4,0.5,30,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"1,357.54",12.2,1.5,82,2
12,Yukon,L04AA,Selective immunosuppressants,Total,Total,353.53,3.2,1.1,59,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,289.65,2.6,0.4,21,4
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,282.21,2.5,5,277,5
12,Yukon,R07AX,Other respiratory system products,Total,Total,**,**,**,*,6
12,Yukon,L04AX,Other immunosuppressants,Total,Total,277.85,2.5,0.7,41,7
12,Yukon,L01XE,Protein kinase inhibitors,Total,Total,260.91,2.3,0.2,10,8
12,Yukon,S01LA,Antineovascularization agents,Total,Total,218.64,2,0.5,25,9
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,Total,203.86,1.8,30.8,"1,693",10
12,Yukon,L04AC,Interleukin inhibitors,Total,Total,194.18,1.7,0.3,16,11
12,Yukon,C09AA,"ACE inhibitors, plain",Total,Total,170.84,1.5,27.2,"1,499",12
12,Yukon,R03BB,Anticholinergics,Total,Total,163.84,1.5,8.9,488,13
12,Yukon,L02BB,Antiandrogens,Total,Total,**,**,**,**,14
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,145.28,1.3,3.6,197,15
12,Yukon,A02BC,Proton pump inhibitors,Total,Total,130.15,1.2,21.9,"1,205",16
12,Yukon,N03AX,Other antiepileptics,Total,Total,116.04,1,8.8,485,17
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,113.39,1,0.6,34,18
12,Yukon,B01AB,Heparin group,Total,Total,106.23,1,0.9,52,19
12,Yukon,L01XC,Monoclonal antibodies,Total,Total,96.82,0.9,0.4,21,20
12,Yukon,C08CA,Dihydropyridine derivatives,Total,Total,95.47,0.9,16,883,21
12,Yukon,R03BA,Glucocorticoids,Total,Total,93.87,0.8,6.1,333,22
12,Yukon,N02AA,Natural opium alkaloids,Total,Total,92.97,0.8,5.9,326,23
12,Yukon,N06AX,Other antidepressants,Total,Total,92.71,0.8,9.9,547,24
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,Total,92.52,0.8,1.8,98,25
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,Total,88.77,0.8,10,550,26
12,Yukon,N04BA,Dopa and dopa derivatives,Total,Total,86.21,0.8,0.8,43,27
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,83.08,0.7,11.1,609,28
12,Yukon,N05AX,Other antipsychotics,Total,Total,81.85,0.7,1,53,29
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,81.78,0.7,3.2,175,30
12,Yukon,H03AA,Thyroid hormones,Total,Total,79.14,0.7,16.4,901,31
12,Yukon,A16AX,Various alimentary tract and metabolism products,Total,Total,**,**,**,*,32
12,Yukon,L01XX,Other antineoplastic agents,Total,Total,75.04,0.7,0.2,10,33
12,Yukon,L04AD,Calcineurin inhibitors,Total,Total,74.98,0.7,0.5,27,34
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,Total,74.44,0.7,1.5,83,35
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,Total,71.71,0.6,14.6,803,36
12,Yukon,B03XA,Other antianemic preparations,Total,Total,70.84,0.6,0.2,11,37
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,60.69,0.5,15.4,849,38
12,Yukon,A10BA,Biguanides,Total,Total,59.23,0.5,14.1,778,39
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,Total,54.28,0.5,1.5,82,40
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,53.98,0.5,2,111,41
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,49,0.4,2.9,160,42
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,48.65,0.4,8.1,443,43
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,46.8,0.4,0.4,21,44
12,Yukon,S01ED,Beta-blocking agents,Total,Total,44.62,0.4,2.8,152,45
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,39.75,0.4,11.3,623,46
12,Yukon,R05CB,Mucolytics,Total,Total,**,**,**,**,47
12,Yukon,A09AA,Enzyme preparations,Total,Total,37.83,0.3,0.3,19,48
12,Yukon,L01BC,Pyrimidine analogues,Total,Total,35.89,0.3,0.8,42,49
12,Yukon,L03AB,Interferons,Total,Total,**,**,**,*,50
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,33.71,0.3,0.3,16,51
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,33.64,0.3,4,219,52
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,33.41,0.3,15.1,831,53
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,32.2,0.3,4.2,230,54
12,Yukon,L03AA,Colony-stimulating factors,Total,Total,**,**,**,**,55
12,Yukon,C03AA,"Thiazides, plain",Total,Total,31.42,0.3,12,658,56
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,30.28,0.3,0.6,34,57
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,Total,30.01,0.3,2.3,126,58
12,Yukon,C03CA,"Sulfonamides, plain",Total,Total,27.91,0.3,6.1,333,59
12,Yukon,L02BG,Aromatase inhibitors,Total,Total,27.57,0.2,0.8,42,60
12,Yukon,A10BB,Sulfonylureas,Total,Total,27.38,0.2,5,274,61
12,Yukon,S01EE,Prostaglandin analogues,Total,Total,26.82,0.2,2.6,143,62
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,Total,26.44,0.2,1.9,104,63
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,Total,25.67,0.2,7.3,404,64
12,Yukon,H02AB,Glucocorticoids,Total,Total,25.37,0.2,12.3,675,65
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,24.66,0.2,3.2,175,66
12,Yukon,A16AB,Enzymes,Total,Total,**,**,**,*,67
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,**,**,**,*,68
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,24.28,0.2,0.6,33,69
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,Total,23.62,0.2,4.9,272,70
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,22.82,0.2,2.7,149,71
12,Yukon,C01DA,Organic nitrates,Total,Total,22.16,0.2,4.2,231,72
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,Total,22.05,0.2,3.4,186,73
12,Yukon,R01AD,Corticosteroids,Total,Total,21.68,0.2,6.9,377,74
12,Yukon,L03AX,Other immunostimulants,Total,Total,21.39,0.2,0.1,5,75
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,**,**,**,*,76
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,Total,**,**,**,*,77
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,Total,20.64,0.2,0.6,33,78
12,Yukon,M05BA,Bisphosphonates,Total,Total,20.52,0.2,2.5,139,79
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,Total,20.38,0.2,0.1,6,80
12,Yukon,N03AF,Carboxamide derivatives,Total,Total,20.37,0.2,0.5,28,81
12,Yukon,N03AE,Benzodiazepine derivatives,Total,Total,19.78,0.2,2.4,133,82
12,Yukon,C08DB,Benzothiazepine derivatives,Total,Total,19.36,0.2,1.9,107,83
12,Yukon,B01AA,Vitamin K antagonists,Total,Total,19.15,0.2,2.8,155,84
12,Yukon,C03DA,Aldosterone antagonists,Total,Total,19.02,0.2,3.1,171,85
12,Yukon,L01BA,Folic acid analogues,Total,Total,18.52,0.2,1.6,90,86
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,Total,18.22,0.2,1.2,64,87
12,Yukon,L01AX,Other alkylating agents,Total,Total,**,**,**,*,88
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,Total,17.51,0.2,1.9,102,89
12,Yukon,L01XB,Methylhydrazines,Total,Total,**,**,**,*,90
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,16.43,0.1,0.4,20,91
12,Yukon,S01BA,"Corticosteroids, plain",Total,Total,16.04,0.1,4.9,272,92
12,Yukon,N07BA,Drugs used in nicotine dependence,Total,Total,15.73,0.1,1.1,58,93
12,Yukon,H01CB,Somatostatin and analogues,Total,Total,**,**,**,*,94
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,Total,15.21,0.1,0.7,36,95
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,Total,15.06,0.1,8.1,445,96
12,Yukon,A04AD,Other antiemetics,Total,Total,13.79,0.1,0.4,20,97
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,Total,13.57,0.1,1.3,70,98
12,Yukon,M01AE,Propionic acid derivatives,Total,Total,13.56,0.1,6.3,346,99
12,Yukon,N05BA,Benzodiazepine derivatives,Total,Total,12.74,0.1,5.8,321,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,M,"1,331.21",21,0.8,23,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,656.23,10.4,1.3,37,2
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,236.9,3.7,0.5,15,3
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,164.71,2.6,5.5,156,4
12,Yukon,L04AX,Other immunosuppressants,Total,M,161.88,2.6,0.7,20,5
12,Yukon,L02BB,Antiandrogens,Total,M,161.32,2.5,0.5,13,6
12,Yukon,S01LA,Antineovascularization agents,Total,M,**,**,**,**,7
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,M,127.54,2,37.4,"1,068",8
12,Yukon,L04AC,Interleukin inhibitors,Total,M,125.26,2,0.3,8,9
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,M,**,**,**,**,10
12,Yukon,C09AA,"ACE inhibitors, plain",Total,M,108.46,1.7,32.5,928,11
12,Yukon,R03BB,Anticholinergics,Total,M,99.92,1.6,9.5,272,12
12,Yukon,L01XE,Protein kinase inhibitors,Total,M,88.15,1.4,0.2,5,13
12,Yukon,N04BA,Dopa and dopa derivatives,Total,M,83.1,1.3,1.1,30,14
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,M,80.36,1.3,3.9,111,15
12,Yukon,A16AX,Various alimentary tract and metabolism products,Total,M,**,**,**,*,16
12,Yukon,L04AA,Selective immunosuppressants,Total,M,69.24,1.1,0.7,19,17
12,Yukon,B01AB,Heparin group,Total,M,67.23,1.1,1.1,30,18
12,Yukon,A02BC,Proton pump inhibitors,Total,M,63.73,1,20.2,577,19
12,Yukon,L04AD,Calcineurin inhibitors,Total,M,59.51,0.9,0.6,16,20
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,M,58.06,0.9,2.1,60,21
12,Yukon,C08CA,Dihydropyridine derivatives,Total,M,56.82,0.9,17.7,504,22
12,Yukon,L01XC,Monoclonal antibodies,Total,M,**,**,**,**,23
12,Yukon,N05AX,Other antipsychotics,Total,M,53.26,0.8,1.1,31,24
12,Yukon,N03AX,Other antiepileptics,Total,M,49.04,0.8,7.4,211,25
12,Yukon,B03XA,Other antianemic preparations,Total,M,48.91,0.8,0.2,5,26
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,47.39,0.7,3.4,97,27
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,M,46.89,0.7,15.1,431,28
12,Yukon,R03BA,Glucocorticoids,Total,M,46.11,0.7,4.7,135,29
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,M,44.69,0.7,18.1,515,30
12,Yukon,N02AA,Natural opium alkaloids,Total,M,42.6,0.7,5.6,160,31
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,39.44,0.6,10.2,291,32
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,M,38.08,0.6,1.5,43,33
12,Yukon,A10BA,Biguanides,Total,M,37.52,0.6,16.8,478,34
12,Yukon,N06AX,Other antidepressants,Total,M,33.41,0.5,7.3,209,35
12,Yukon,L01BC,Pyrimidine analogues,Total,M,32.77,0.5,1.3,36,36
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,32.75,0.5,14.5,414,37
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,31.37,0.5,2.2,62,38
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,M,30.51,0.5,6.9,198,39
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,29.11,0.5,2.8,80,40
12,Yukon,S01ED,Beta-blocking agents,Total,M,26.11,0.4,3.2,90,41
12,Yukon,A09AA,Enzyme preparations,Total,M,25.3,0.4,0.3,8,42
12,Yukon,A16AB,Enzymes,Total,M,**,**,**,*,43
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,**,**,**,*,44
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,24.07,0.4,18.7,533,45
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,22.82,0.4,5.2,149,46
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,21.84,0.3,12,342,47
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,21.05,0.3,0.8,22,48
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,**,**,**,*,49
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,M,20.79,0.3,1.1,30,50
12,Yukon,H03AA,Thyroid hormones,Total,M,20.41,0.3,8.8,251,51
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,M,20.38,0.3,0.2,6,52
12,Yukon,A10BB,Sulfonylureas,Total,M,18.89,0.3,6.6,187,53
12,Yukon,R05CB,Mucolytics,Total,M,**,**,**,*,54
12,Yukon,C03CA,"Sulfonamides, plain",Total,M,17.6,0.3,6.6,189,55
12,Yukon,L01XB,Methylhydrazines,Total,M,**,**,**,*,56
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,16.65,0.3,0.3,9,57
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,M,16.59,0.3,5.1,146,58
12,Yukon,C03AA,"Thiazides, plain",Total,M,15.96,0.3,11.9,339,59
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,15.54,0.2,0.7,21,60
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,15.44,0.2,2.9,83,61
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,M,14.28,0.2,1.9,55,62
12,Yukon,C01DA,Organic nitrates,Total,M,13.57,0.2,5.4,154,63
12,Yukon,H01CB,Somatostatin and analogues,Total,M,**,**,**,*,64
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,M,12.67,0.2,0.7,21,65
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,M,12.65,0.2,5.6,161,66
12,Yukon,C03DA,Aldosterone antagonists,Total,M,12.62,0.2,3.9,111,67
12,Yukon,B01AA,Vitamin K antagonists,Total,M,12.62,0.2,3.6,102,68
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,12.42,0.2,0.3,8,69
12,Yukon,H02AB,Glucocorticoids,Total,M,12.1,0.2,11.8,336,70
12,Yukon,S01EE,Prostaglandin analogues,Total,M,11.47,0.2,2.4,69,71
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,M,11.38,0.2,5.7,164,72
12,Yukon,H01AC,Somatropin and somatropin agonists,Total,M,**,**,**,*,73
12,Yukon,R01AD,Corticosteroids,Total,M,10.85,0.2,6,172,74
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,**,**,**,*,75
12,Yukon,N07BA,Drugs used in nicotine dependence,Total,M,10.71,0.2,1.1,32,76
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,M,10.44,0.2,1.2,34,77
12,Yukon,L03AA,Colony-stimulating factors,Total,M,**,**,**,*,78
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,9.77,0.2,2.2,63,79
12,Yukon,N07BB,Drugs used in alcohol dependence,Total,M,9.28,0.1,0.3,9,80
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,M,8.71,0.1,8.1,232,81
12,Yukon,N03AE,Benzodiazepine derivatives,Total,M,8.59,0.1,2,57,82
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,**,**,**,**,83
12,Yukon,C08DB,Benzothiazepine derivatives,Total,M,8.28,0.1,1.7,48,84
12,Yukon,S01BA,"Corticosteroids, plain",Total,M,8.19,0.1,5.1,145,85
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,M,8,0.1,1.6,46,86
12,Yukon,C07AG,Alpha- and beta-blocking agents,Total,M,7.48,0.1,1.1,32,87
12,Yukon,A04AD,Other antiemetics,Total,M,**,**,**,**,88
12,Yukon,L01BA,Folic acid analogues,Total,M,7.04,0.1,1.1,32,89
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,M,6.92,0.1,0.7,20,90
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,Total,M,6.81,0.1,0.8,23,91
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,6.66,0.1,0.3,9,92
12,Yukon,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,M,**,**,**,*,93
12,Yukon,M01AE,Propionic acid derivatives,Total,M,6.44,0.1,6,170,94
12,Yukon,H01BA,Vasopressin and analogues,Total,M,**,**,**,*,95
12,Yukon,J05AE,Protease inhibitors,Total,M,**,**,**,*,96
12,Yukon,M03BX,Other centrally acting agents,Total,M,6.07,0.1,3.6,102,97
12,Yukon,N03AG,Fatty acid derivatives,Total,M,5.86,0.1,0.8,23,98
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,M,5.74,0.1,1.5,43,99
12,Yukon,B01AD,Enzymes,Total,M,**,**,**,*,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,701.31,14.6,1.7,45,1
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,F,383.5,8,0.3,7,2
12,Yukon,L04AA,Selective immunosuppressants,Total,F,284.29,5.9,1.5,40,3
12,Yukon,R07AX,Other respiratory system products,Total,F,**,**,**,*,4
12,Yukon,L01XE,Protein kinase inhibitors,Total,F,172.76,3.6,0.2,5,5
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,117.5,2.4,4.6,121,6
12,Yukon,L04AX,Other immunosuppressants,Total,F,115.97,2.4,0.8,21,7
12,Yukon,S01LA,Antineovascularization agents,Total,F,**,**,**,**,8
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,F,76.32,1.6,23.6,625,9
12,Yukon,L01XX,Other antineoplastic agents,Total,F,71.62,1.5,0.2,5,10
12,Yukon,L04AC,Interleukin inhibitors,Total,F,68.92,1.4,0.3,8,11
12,Yukon,N03AX,Other antiepileptics,Total,F,67,1.4,10.3,274,12
12,Yukon,A02BC,Proton pump inhibitors,Total,F,66.42,1.4,23.7,628,13
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,F,64.92,1.3,3.2,86,14
12,Yukon,R03BB,Anticholinergics,Total,F,63.93,1.3,8.2,216,15
12,Yukon,C09AA,"ACE inhibitors, plain",Total,F,62.38,1.3,21.6,571,16
12,Yukon,N06AX,Other antidepressants,Total,F,59.3,1.2,12.8,338,17
12,Yukon,H03AA,Thyroid hormones,Total,F,58.72,1.2,24.5,650,18
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,F,58.26,1.2,13.3,352,19
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,52.75,1.1,0.2,6,20
12,Yukon,N02AA,Natural opium alkaloids,Total,F,50.37,1,6.3,166,21
12,Yukon,R03BA,Glucocorticoids,Total,F,47.76,1,7.5,198,22
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,43.64,0.9,12,318,23
12,Yukon,L01XC,Monoclonal antibodies,Total,F,**,**,**,**,24
12,Yukon,B01AB,Heparin group,Total,F,39,0.8,0.8,22,25
12,Yukon,C08CA,Dihydropyridine derivatives,Total,F,38.66,0.8,14.3,379,26
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,F,36.36,0.8,1.5,40,27
12,Yukon,L03AB,Interferons,Total,F,**,**,**,*,28
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,F,34.46,0.7,1.4,38,29
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,34.4,0.7,2.9,78,30
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,F,**,**,**,**,31
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,F,33.5,0.7,2,52,32
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,32.2,0.7,8.7,230,33
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,30.15,0.6,0.5,12,34
12,Yukon,N05AX,Other antipsychotics,Total,F,28.58,0.6,0.8,22,35
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,27.94,0.6,16.4,435,36
12,Yukon,L02BG,Aromatase inhibitors,Total,F,27.57,0.6,1.6,42,37
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,F,27.02,0.6,10.9,288,38
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,22.61,0.5,1.8,49,39
12,Yukon,B03XA,Other antianemic preparations,Total,F,21.93,0.5,0.2,6,40
12,Yukon,A10BA,Biguanides,Total,F,21.71,0.5,11.3,300,41
12,Yukon,L03AA,Colony-stimulating factors,Total,F,**,**,**,**,42
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,F,21.39,0.4,2.8,74,43
12,Yukon,R05CB,Mucolytics,Total,F,**,**,**,*,44
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,19.89,0.4,3,80,45
12,Yukon,S01ED,Beta-blocking agents,Total,F,18.51,0.4,2.3,62,46
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,18.19,0.4,5.1,136,47
12,Yukon,L01AX,Other alkylating agents,Total,F,**,**,**,*,48
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,17.91,0.4,10.6,281,49
12,Yukon,L03AX,Other immunostimulants,Total,F,**,**,**,*,50
12,Yukon,M05BA,Bisphosphonates,Total,F,16.97,0.4,4.4,117,51
12,Yukon,N03AF,Carboxamide derivatives,Total,F,15.84,0.3,0.4,10,52
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,F,15.73,0.3,2.7,71,53
12,Yukon,L04AD,Calcineurin inhibitors,Total,F,15.48,0.3,0.4,11,54
12,Yukon,C03AA,"Thiazides, plain",Total,F,15.47,0.3,12,319,55
12,Yukon,S01EE,Prostaglandin analogues,Total,F,15.35,0.3,2.8,74,56
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,14.89,0.3,4.2,112,57
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,F,14.29,0.3,9.1,240,58
12,Yukon,H02AB,Glucocorticoids,Total,F,13.27,0.3,12.8,339,59
12,Yukon,A09AA,Enzyme preparations,Total,F,12.53,0.3,0.4,11,60
12,Yukon,L01BA,Folic acid analogues,Total,F,11.48,0.2,2.2,58,61
12,Yukon,N03AE,Benzodiazepine derivatives,Total,F,11.19,0.2,2.9,76,62
12,Yukon,C08DB,Benzothiazepine derivatives,Total,F,11.08,0.2,2.2,59,63
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,F,10.98,0.2,4.2,111,64
12,Yukon,R01AD,Corticosteroids,Total,F,10.83,0.2,7.7,205,65
12,Yukon,C03CA,"Sulfonamides, plain",Total,F,10.31,0.2,5.4,144,66
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,*,67
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,9.77,0.2,0.4,11,68
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,F,9.51,0.2,2.1,56,69
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,9.35,0.2,11.2,298,70
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,9.22,0.2,0.5,12,71
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,8.74,0.2,0.5,12,72
12,Yukon,C01DA,Organic nitrates,Total,F,8.59,0.2,2.9,77,73
12,Yukon,A10BB,Sulfonylureas,Total,F,8.49,0.2,3.3,87,74
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,F,8.29,0.2,0.6,16,75
12,Yukon,N05BA,Benzodiazepine derivatives,Total,F,8.07,0.2,8,212,76
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,F,8,0.2,1.4,37,77
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,F,7.97,0.2,0.5,12,78
12,Yukon,S01BA,"Corticosteroids, plain",Total,F,7.85,0.2,4.8,127,79
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,F,7.77,0.2,1.1,30,80
12,Yukon,M01AE,Propionic acid derivatives,Total,F,7.12,0.1,6.6,176,81
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,Total,F,6.88,0.1,1.1,29,82
12,Yukon,D06BB,Antivirals,Total,F,**,**,**,**,83
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,F,6.64,0.1,1.2,32,84
12,Yukon,B01AA,Vitamin K antagonists,Total,F,6.53,0.1,2,53,85
12,Yukon,A04AD,Other antiemetics,Total,F,**,**,**,**,86
12,Yukon,C03DA,Aldosterone antagonists,Total,F,6.39,0.1,2.3,60,87
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,F,6.35,0.1,8,213,88
12,Yukon,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,6.18,0.1,2.3,60,89
12,Yukon,S01GX,Other antiallergics,Total,F,6.18,0.1,2,54,90
12,Yukon,M01AH,Coxibs,Total,F,6,0.1,2.5,65,91
12,Yukon,J01XE,Nitrofuran derivatives,Total,F,5.61,0.1,5.8,153,92
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,F,5.46,0.1,1.5,40,93
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,Total,F,**,**,**,*,94
12,Yukon,R03DC,Leukotriene receptor antagonists,Total,F,5.09,0.1,1.2,32,95
12,Yukon,N07BA,Drugs used in nicotine dependence,Total,F,5.02,0.1,1,26,96
12,Yukon,A07EA,Corticosteroids acting locally,Total,F,4.82,0.1,0.3,7,97
12,Yukon,A11CC,Vitamin D and analogues,Total,F,4.73,0.1,11.1,295,98
12,Yukon,A05AA,Bile acids and derivatives,Total,F,4.59,0.1,0.3,7,99
12,Yukon,P01BA,Aminoquinolines,Total,F,4.44,0.1,1.4,36,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,394.33,7.3,0.5,22,1
12,Yukon,L01XE,Protein kinase inhibitors,65+,Total,**,**,**,**,2
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,207.31,3.8,4.8,196,3
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,Total,**,**,**,*,4
12,Yukon,S01LA,Antineovascularization agents,65+,Total,181.09,3.4,0.5,19,5
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,Total,167.08,3.1,34.4,"1,398",6
12,Yukon,L02BB,Antiandrogens,65+,Total,**,**,**,**,7
12,Yukon,C09AA,"ACE inhibitors, plain",65+,Total,142.14,2.6,30.4,"1,233",8
12,Yukon,R03BB,Anticholinergics,65+,Total,131.39,2.4,9.7,395,9
12,Yukon,A02BC,Proton pump inhibitors,65+,Total,119.03,2.2,26.9,"1,093",10
12,Yukon,L04AX,Other immunosuppressants,65+,Total,102.88,1.9,0.4,17,11
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,94.25,1.7,0.7,27,12
12,Yukon,N04BA,Dopa and dopa derivatives,65+,Total,**,**,**,**,13
12,Yukon,C08CA,Dihydropyridine derivatives,65+,Total,82.15,1.5,18.2,739,14
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,Total,81.82,1.5,2,83,15
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,**,**,**,**,16
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,69.15,1.3,12.2,496,17
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,68.95,1.3,2.4,96,18
12,Yukon,R03BA,Glucocorticoids,65+,Total,64.04,1.2,6,242,19
12,Yukon,H03AA,Thyroid hormones,65+,Total,63.29,1.2,18,732,20
12,Yukon,L04AC,Interleukin inhibitors,65+,Total,63.04,1.2,0.1,6,21
12,Yukon,B01AB,Heparin group,65+,Total,62.11,1.2,1,39,22
12,Yukon,N02AA,Natural opium alkaloids,65+,Total,61.91,1.1,6.4,260,23
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,Total,61.39,1.1,17,689,24
12,Yukon,N03AX,Other antiepileptics,65+,Total,59.26,1.1,7.9,319,25
12,Yukon,L04AA,Selective immunosuppressants,65+,Total,58.79,1.1,0.4,17,26
12,Yukon,N06AX,Other antidepressants,65+,Total,46.85,0.9,8.3,338,27
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,46.67,0.9,10.7,433,28
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,Total,46.64,0.9,8.4,340,29
12,Yukon,A10BA,Biguanides,65+,Total,43.82,0.8,14.2,578,30
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,43.31,0.8,15.5,630,31
12,Yukon,B03XA,Other antianemic preparations,65+,Total,**,**,**,**,32
12,Yukon,S01ED,Beta-blocking agents,65+,Total,41.33,0.8,3.5,141,33
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,39.55,0.7,1.8,73,34
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,Total,33.02,0.6,1,42,35
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,32.33,0.6,1.7,71,36
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,31.23,0.6,13.5,549,37
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,28.26,0.5,19.8,803,38
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,28.11,0.5,4.9,201,39
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,27.1,0.5,0.3,11,40
12,Yukon,C03AA,"Thiazides, plain",65+,Total,26.26,0.5,13.6,551,41
12,Yukon,S01EE,Prostaglandin analogues,65+,Total,25.96,0.5,3.4,137,42
12,Yukon,C03CA,"Sulfonamides, plain",65+,Total,25.56,0.5,7.2,293,43
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,25.19,0.5,0.6,24,44
12,Yukon,L01BC,Pyrimidine analogues,65+,Total,**,**,**,**,45
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,**,**,**,*,46
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,Total,23.52,0.4,9.3,376,47
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,**,**,**,**,48
12,Yukon,A10BB,Sulfonylureas,65+,Total,22.07,0.4,4.9,198,49
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,Total,21.44,0.4,2.4,96,50
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**,**,**,*,51
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,20.98,0.4,4.1,168,52
12,Yukon,L04AD,Calcineurin inhibitors,65+,Total,20.83,0.4,0.2,7,53
12,Yukon,R01AD,Corticosteroids,65+,Total,20.64,0.4,8.7,352,54
12,Yukon,L02BX,Other hormone antagonists and related agents,65+,Total,20.38,0.4,0.1,6,55
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,20,0.4,3.7,151,56
12,Yukon,C01DA,Organic nitrates,65+,Total,19.45,0.4,4.9,200,57
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,Total,19.33,0.4,4.1,167,58
12,Yukon,H02AB,Glucocorticoids,65+,Total,19.25,0.4,13.1,532,59
12,Yukon,L02BG,Aromatase inhibitors,65+,Total,18.95,0.4,0.6,25,60
12,Yukon,M05BA,Bisphosphonates,65+,Total,18.66,0.3,3.1,126,61
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,Total,18.05,0.3,2.7,110,62
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,Total,17.56,0.3,5.9,238,63
12,Yukon,C08DB,Benzothiazepine derivatives,65+,Total,17.12,0.3,2.4,96,64
12,Yukon,B01AA,Vitamin K antagonists,65+,Total,16.31,0.3,3.4,138,65
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,Total,16.26,0.3,1.4,57,66
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,15.77,0.3,0.6,23,67
12,Yukon,S01BA,"Corticosteroids, plain",65+,Total,15.73,0.3,6.5,265,68
12,Yukon,H01CB,Somatostatin and analogues,65+,Total,**,**,**,*,69
12,Yukon,C03DA,Aldosterone antagonists,65+,Total,15.49,0.3,3.3,134,70
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,Total,14.15,0.3,0.6,24,71
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,Total,14.11,0.3,1.9,79,72
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,Total,**,**,**,**,73
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,Total,13.39,0.2,10,408,74
12,Yukon,L01XC,Monoclonal antibodies,65+,Total,**,**,**,**,75
12,Yukon,L01BA,Folic acid analogues,65+,Total,12.43,0.2,1.3,53,76
12,Yukon,N05BA,Benzodiazepine derivatives,65+,Total,11.35,0.2,7.1,289,77
12,Yukon,M01AE,Propionic acid derivatives,65+,Total,11.24,0.2,7.2,293,78
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,Total,10.36,0.2,1.5,61,79
12,Yukon,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,9.81,0.2,2.4,98,80
12,Yukon,N07BB,Drugs used in alcohol dependence,65+,Total,**,**,**,**,81
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,Total,**,**,**,**,82
12,Yukon,A04AD,Other antiemetics,65+,Total,**,**,**,**,83
12,Yukon,M01AH,Coxibs,65+,Total,8.96,0.2,2.4,97,84
12,Yukon,S01GX,Other antiallergics,65+,Total,**,**,**,**,85
12,Yukon,D06BB,Antivirals,65+,Total,**,**,**,**,86
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,**,**,**,*,87
12,Yukon,S01AE,Fluoroquinolones,65+,Total,7.99,0.1,6,243,88
12,Yukon,L03AA,Colony-stimulating factors,65+,Total,**,**,**,*,89
12,Yukon,J01MA,Fluoroquinolones,65+,Total,7.84,0.1,7.5,305,90
12,Yukon,J01FA,Macrolides,65+,Total,7.68,0.1,6.1,249,91
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,7.57,0.1,0.2,9,92
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,Total,7.56,0.1,0.8,31,93
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,7.48,0.1,1.5,59,94
12,Yukon,A12BA,Potassium,65+,Total,7.46,0.1,2.8,114,95
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,Total,**,**,**,*,96
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,**,**,**,*,97
12,Yukon,J01CA,Penicillins with extended spectrum,65+,Total,7.02,0.1,8.8,359,98
12,Yukon,N06BA,Centrally acting sympathomimetics,65+,Total,6.96,0.1,0.2,9,99
12,Yukon,N03AE,Benzodiazepine derivatives,65+,Total,6.84,0.1,1.4,56,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,234.95,7.4,0.5,10,1
12,Yukon,L02BB,Antiandrogens,65+,M,**,**,**,**,2
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,*,3
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,119.24,3.8,4.9,108,4
12,Yukon,S01LA,Antineovascularization agents,65+,M,**,**,**,**,5
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,M,106.66,3.4,41.5,906,6
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,7
12,Yukon,C09AA,"ACE inhibitors, plain",65+,M,90.22,2.9,35.2,768,8
12,Yukon,N04BA,Dopa and dopa derivatives,65+,M,**,**,**,**,9
12,Yukon,R03BB,Anticholinergics,65+,M,80.66,2.6,10.1,220,10
12,Yukon,L04AX,Other immunosuppressants,65+,M,78.81,2.5,0.4,9,11
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,12
12,Yukon,A02BC,Proton pump inhibitors,65+,M,60.06,1.9,24.6,538,13
12,Yukon,L01XE,Protein kinase inhibitors,65+,M,**,**,**,*,14
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,M,**,**,**,**,15
12,Yukon,C08CA,Dihydropyridine derivatives,65+,M,49.21,1.6,19.2,420,16
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,M,**,**,**,**,17
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,M,42.63,1.3,2.7,59,18
12,Yukon,B01AB,Heparin group,65+,M,**,**,**,**,19
12,Yukon,B03XA,Other antianemic preparations,65+,M,**,**,**,*,20
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,M,38.24,1.2,20.2,442,21
12,Yukon,L04AC,Interleukin inhibitors,65+,M,**,**,**,*,22
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,31.22,1,10.4,228,23
12,Yukon,R03BA,Glucocorticoids,65+,M,30.71,1,4.8,105,24
12,Yukon,A10BA,Biguanides,65+,M,28.55,0.9,16.8,366,25
12,Yukon,N02AA,Natural opium alkaloids,65+,M,28.4,0.9,6,130,26
12,Yukon,N03AX,Other antiepileptics,65+,M,25.33,0.8,6.6,144,27
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,*,28
12,Yukon,S01ED,Beta-blocking agents,65+,M,24.08,0.8,3.8,84,29
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,22.83,0.7,14.5,317,30
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,22.59,0.7,1.9,41,31
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,32
12,Yukon,L01BC,Pyrimidine analogues,65+,M,**,**,**,**,33
12,Yukon,L02BX,Other hormone antagonists and related agents,65+,M,20.38,0.6,0.3,6,34
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,19.61,0.6,23.5,513,35
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,**,**,**,**,36
12,Yukon,L04AD,Calcineurin inhibitors,65+,M,**,**,**,**,37
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,18.03,0.6,14.4,315,38
12,Yukon,H03AA,Thyroid hormones,65+,M,16.79,0.5,9.6,210,39
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,16.06,0.5,1.6,36,40
12,Yukon,N06AX,Other antidepressants,65+,M,15.94,0.5,6.4,139,41
12,Yukon,C03CA,"Sulfonamides, plain",65+,M,15.51,0.5,7.2,158,42
12,Yukon,A10BB,Sulfonylureas,65+,M,15.49,0.5,6.6,143,43
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,M,15.36,0.5,5.5,121,44
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,M,**,**,**,**,45
12,Yukon,C03AA,"Thiazides, plain",65+,M,13.33,0.4,13,283,46
12,Yukon,H01CB,Somatostatin and analogues,65+,M,**,**,**,*,47
12,Yukon,C01DA,Organic nitrates,65+,M,12.11,0.4,6,132,48
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,M,11.69,0.4,6.8,148,49
12,Yukon,L01XC,Monoclonal antibodies,65+,M,**,**,**,**,50
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,M,**,**,**,**,51
12,Yukon,B01AA,Vitamin K antagonists,65+,M,11.08,0.4,4.2,91,52
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,M,10.91,0.3,0.7,15,53
12,Yukon,S01EE,Prostaglandin analogues,65+,M,**,**,**,**,54
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,**,**,**,*,55
12,Yukon,R01AD,Corticosteroids,65+,M,**,**,**,**,56
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,M,10.58,0.3,7.2,158,57
12,Yukon,C03DA,Aldosterone antagonists,65+,M,10.21,0.3,3.9,85,58
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,M,**,**,**,**,59
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,M,**,**,**,**,60
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,M,**,**,**,**,61
12,Yukon,H02AB,Glucocorticoids,65+,M,9.09,0.3,12.6,274,62
12,Yukon,N07BB,Drugs used in alcohol dependence,65+,M,**,**,**,**,63
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,8.66,0.3,2.7,58,64
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,M,8.47,0.3,10.3,224,65
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,8.4,0.3,2.7,60,66
12,Yukon,S01BA,"Corticosteroids, plain",65+,M,**,**,**,**,67
12,Yukon,L04AA,Selective immunosuppressants,65+,M,7.95,0.3,0.2,5,68
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**,**,**,**,69
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,M,**,**,**,*,70
12,Yukon,C08DB,Benzothiazepine derivatives,65+,M,**,**,**,**,71
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,*,72
12,Yukon,L03AA,Colony-stimulating factors,65+,M,**,**,**,*,73
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,M,6.1,0.2,1.6,34,74
12,Yukon,B01AD,Enzymes,65+,M,**,**,**,*,75
12,Yukon,M01AE,Propionic acid derivatives,65+,M,5.41,0.2,7.1,154,76
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,65+,M,**,**,**,**,77
12,Yukon,N06BA,Centrally acting sympathomimetics,65+,M,**,**,**,**,78
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,M,**,**,**,**,79
12,Yukon,D05AX,Other antipsoriatics for topical use,65+,M,**,**,**,**,80
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,M,**,**,**,**,81
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,M,4.89,0.2,1.6,36,82
12,Yukon,J01MA,Fluoroquinolones,65+,M,4.81,0.2,7.8,170,83
12,Yukon,A12BA,Potassium,65+,M,**,**,**,**,84
12,Yukon,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,4.41,0.1,2.3,50,85
12,Yukon,J01FA,Macrolides,65+,M,4.26,0.1,5.9,129,86
12,Yukon,S01AE,Fluoroquinolones,65+,M,**,**,**,**,87
12,Yukon,L01BA,Folic acid analogues,65+,M,4.24,0.1,1,22,88
12,Yukon,N03AE,Benzodiazepine derivatives,65+,M,4.22,0.1,1.3,29,89
12,Yukon,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,**,**,**,**,90
12,Yukon,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,**,**,**,*,91
12,Yukon,J01CA,Penicillins with extended spectrum,65+,M,3.93,0.1,9,197,92
12,Yukon,A04AD,Other antiemetics,65+,M,**,**,**,**,93
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,M,**,**,**,**,94
12,Yukon,J01DB,First-generation cephalosporins,65+,M,**,**,**,**,95
12,Yukon,N05BA,Benzodiazepine derivatives,65+,M,3.7,0.1,4.4,97,96
12,Yukon,M01AH,Coxibs,65+,M,3.69,0.1,2,43,97
12,Yukon,N03AF,Carboxamide derivatives,65+,M,**,**,**,**,98
12,Yukon,N07BC,Drugs used in opioid dependence,65+,M,**,**,**,**,99
12,Yukon,H01BA,Vasopressin and analogues,65+,M,**,**,**,*,100
12,Yukon,L01XE,Protein kinase inhibitors,65+,F,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,159.37,7.2,0.6,12,2
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,88.07,4,4.7,88,3
12,Yukon,S01LA,Antineovascularization agents,65+,F,**,**,**,**,4
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,F,60.42,2.7,26.2,492,5
12,Yukon,A02BC,Proton pump inhibitors,65+,F,58.97,2.6,29.5,555,6
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,F,**,**,**,*,7
12,Yukon,C09AA,"ACE inhibitors, plain",65+,F,51.92,2.3,24.7,465,8
12,Yukon,L04AA,Selective immunosuppressants,65+,F,50.84,2.3,0.6,12,9
12,Yukon,R03BB,Anticholinergics,65+,F,50.72,2.3,9.3,175,10
12,Yukon,H03AA,Thyroid hormones,65+,F,46.5,2.1,27.8,522,11
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,37.93,1.7,14.3,268,12
12,Yukon,N03AX,Other antiepileptics,65+,F,33.93,1.5,9.3,175,13
12,Yukon,N02AA,Natural opium alkaloids,65+,F,33.51,1.5,6.9,130,14
12,Yukon,R03BA,Glucocorticoids,65+,F,33.33,1.5,7.3,137,15
12,Yukon,C08CA,Dihydropyridine derivatives,65+,F,32.94,1.5,17,319,16
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,F,31.28,1.4,11.7,219,17
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,F,**,**,**,**,18
12,Yukon,N06AX,Other antidepressants,65+,F,30.91,1.4,10.6,199,19
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,28.11,1.3,10.7,201,20
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,21
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,F,26.32,1.2,2,37,22
12,Yukon,L04AC,Interleukin inhibitors,65+,F,**,**,**,*,23
12,Yukon,L04AX,Other immunosuppressants,65+,F,24.06,1.1,0.4,8,24
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,F,23.14,1,13.1,247,25
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,F,22.11,1,1.4,27,26
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,20.48,0.9,16.7,313,27
12,Yukon,B01AB,Heparin group,65+,F,**,**,**,**,28
12,Yukon,L02BG,Aromatase inhibitors,65+,F,18.95,0.9,1.3,25,29
12,Yukon,S01ED,Beta-blocking agents,65+,F,17.26,0.8,3,57,30
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,16.95,0.8,1.7,32,31
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,F,**,**,**,**,32
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,16.27,0.7,1.9,35,33
12,Yukon,M05BA,Bisphosphonates,65+,F,**,**,**,**,34
12,Yukon,A10BA,Biguanides,65+,F,15.27,0.7,11.3,212,35
12,Yukon,S01EE,Prostaglandin analogues,65+,F,**,**,**,**,36
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,13.2,0.6,12.5,234,37
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,F,12.94,0.6,11.6,218,38
12,Yukon,C03AA,"Thiazides, plain",65+,F,12.93,0.6,14.3,268,39
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,12.58,0.6,5.7,108,40
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,11.34,0.5,4.9,93,41
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,*,42
12,Yukon,H02AB,Glucocorticoids,65+,F,10.16,0.5,13.7,258,43
12,Yukon,C03CA,"Sulfonamides, plain",65+,F,10.05,0.5,7.2,135,44
12,Yukon,C08DB,Benzothiazepine derivatives,65+,F,**,**,**,**,45
12,Yukon,R01AD,Corticosteroids,65+,F,**,**,**,**,46
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,8.65,0.4,15.4,290,47
12,Yukon,L01BA,Folic acid analogues,65+,F,8.19,0.4,1.6,31,48
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,F,8.01,0.4,2.4,45,49
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**,**,**,**,50
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,*,51
12,Yukon,S01BA,"Corticosteroids, plain",65+,F,**,**,**,**,52
12,Yukon,N05BA,Benzodiazepine derivatives,65+,F,7.65,0.3,10.2,192,53
12,Yukon,C01DA,Organic nitrates,65+,F,7.34,0.3,3.6,68,54
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,F,**,**,**,**,55
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,F,**,**,**,**,56
12,Yukon,A10BB,Sulfonylureas,65+,F,6.57,0.3,2.9,55,57
12,Yukon,S01GX,Other antiallergics,65+,F,**,**,**,**,58
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,**,**,**,**,59
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,F,5.87,0.3,4.8,90,60
12,Yukon,M01AE,Propionic acid derivatives,65+,F,5.82,0.3,7.4,139,61
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,F,**,**,**,**,62
12,Yukon,D06BB,Antivirals,65+,F,5.63,0.3,1.9,35,63
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,F,5.47,0.2,1.3,25,64
12,Yukon,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,5.4,0.2,2.6,48,65
12,Yukon,A04AD,Other antiemetics,65+,F,**,**,**,*,66
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,F,**,**,**,**,67
12,Yukon,C03DA,Aldosterone antagonists,65+,F,5.29,0.2,2.6,49,68
12,Yukon,M01AH,Coxibs,65+,F,5.27,0.2,2.9,54,69
12,Yukon,B01AA,Vitamin K antagonists,65+,F,5.23,0.2,2.5,47,70
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,65+,F,**,**,**,*,71
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,F,4.92,0.2,9.8,184,72
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,F,**,**,**,**,73
12,Yukon,J01XE,Nitrofuran derivatives,65+,F,**,**,**,**,74
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,4.57,0.2,1.8,33,75
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,**,**,**,*,76
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,F,**,**,**,**,77
12,Yukon,N05AX,Other antipsychotics,65+,F,**,**,**,**,78
12,Yukon,R03DC,Leukotriene receptor antagonists,65+,F,4.07,0.2,1.2,23,79
12,Yukon,S01AE,Fluoroquinolones,65+,F,**,**,**,**,80
12,Yukon,J01FA,Macrolides,65+,F,3.41,0.2,6.4,120,81
12,Yukon,L01AX,Other alkylating agents,65+,F,**,**,**,*,82
12,Yukon,C03BA,"Sulfonamides, plain",65+,F,3.18,0.1,3.2,61,83
12,Yukon,C01CA,Adrenergic and dopaminergic agents,65+,F,**,**,**,**,84
12,Yukon,B03XA,Other antianemic preparations,65+,F,**,**,**,*,85
12,Yukon,N04BC,Dopamine agonists,65+,F,**,**,**,**,86
12,Yukon,L01BC,Pyrimidine analogues,65+,F,**,**,**,**,87
12,Yukon,N04BA,Dopa and dopa derivatives,65+,F,**,**,**,**,88
12,Yukon,J01CA,Penicillins with extended spectrum,65+,F,3.09,0.1,8.6,162,89
12,Yukon,A12BA,Potassium,65+,F,**,**,**,**,90
12,Yukon,C08DA,Phenylalkylamine derivatives,65+,F,**,**,**,**,91
12,Yukon,J01MA,Fluoroquinolones,65+,F,3.03,0.1,7.2,135,92
12,Yukon,A11CC,Vitamin D and analogues,65+,F,**,**,**,**,93
12,Yukon,A09AA,Enzyme preparations,65+,F,**,**,**,**,94
12,Yukon,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,**,**,**,*,95
12,Yukon,M03BX,Other centrally acting agents,65+,F,2.84,0.1,4,76,96
12,Yukon,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",65+,F,**,**,**,**,97
12,Yukon,J01AA,Tetracyclines,65+,F,2.71,0.1,5.3,100,98
12,Yukon,J01DB,First-generation cephalosporins,65+,F,**,**,**,**,99
12,Yukon,D07AD,"Corticosteroids, very potent (group IV)",65+,F,**,**,**,**,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,Total,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,963.22,16.7,4.2,60,2
12,Yukon,L04AA,Selective immunosuppressants,<65,Total,294.75,5.1,2.9,42,3
12,Yukon,R07AX,Other respiratory system products,<65,Total,**,**,**,*,4
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,**,**,**,**,5
12,Yukon,L04AX,Other immunosuppressants,<65,Total,174.98,3,1.7,24,6
12,Yukon,L04AC,Interleukin inhibitors,<65,Total,131.14,2.3,0.7,10,7
12,Yukon,L01XC,Monoclonal antibodies,<65,Total,**,**,**,**,8
12,Yukon,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,9
12,Yukon,N05AX,Other antipsychotics,<65,Total,76.99,1.3,2.7,39,10
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,76.33,1.3,7,101,11
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,74.9,1.3,5.6,81,12
12,Yukon,L01XX,Other antineoplastic agents,<65,Total,**,**,**,*,13
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,Total,67.47,1.2,5.1,74,14
12,Yukon,N03AX,Other antiepileptics,<65,Total,56.78,1,11.5,166,15
12,Yukon,L04AD,Calcineurin inhibitors,<65,Total,54.15,0.9,1.4,20,16
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,49.45,0.9,7.2,104,17
12,Yukon,N06AX,Other antidepressants,<65,Total,45.86,0.8,14.5,209,18
12,Yukon,B01AB,Heparin group,<65,Total,44.12,0.8,0.9,13,19
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,Total,42.13,0.7,14.6,210,20
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,41.52,0.7,7,101,21
12,Yukon,R05CB,Mucolytics,<65,Total,**,**,**,*,22
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,**,**,**,**,23
12,Yukon,S01LA,Antineovascularization agents,<65,Total,37.55,0.7,0.4,6,24
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,Total,36.78,0.6,20.5,295,25
12,Yukon,L03AB,Interferons,<65,Total,**,**,**,*,26
12,Yukon,A09AA,Enzyme preparations,<65,Total,33.23,0.6,0.8,12,27
12,Yukon,R03BB,Anticholinergics,<65,Total,32.46,0.6,6.5,93,28
12,Yukon,N02AA,Natural opium alkaloids,<65,Total,31.06,0.5,4.6,66,29
12,Yukon,R03BA,Glucocorticoids,<65,Total,29.82,0.5,6.3,91,30
12,Yukon,C09AA,"ACE inhibitors, plain",<65,Total,28.7,0.5,18.5,266,31
12,Yukon,L01XE,Protein kinase inhibitors,<65,Total,**,**,**,*,32
12,Yukon,B03XA,Other antianemic preparations,<65,Total,**,**,**,**,33
12,Yukon,A16AB,Enzymes,<65,Total,**,**,**,*,34
12,Yukon,L03AA,Colony-stimulating factors,<65,Total,**,**,**,**,35
12,Yukon,L03AX,Other immunostimulants,<65,Total,21.39,0.4,0.3,5,36
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,Total,21.26,0.4,2.8,40,37
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,19.15,0.3,0.5,7,38
12,Yukon,L01XB,Methylhydrazines,<65,Total,**,**,**,*,39
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,17.38,0.3,15.2,219,40
12,Yukon,N03AF,Carboxamide derivatives,<65,Total,16.72,0.3,0.8,12,41
12,Yukon,H03AA,Thyroid hormones,<65,Total,15.85,0.3,11.7,169,42
12,Yukon,A10BA,Biguanides,<65,Total,15.41,0.3,13.9,200,43
12,Yukon,L01AX,Other alkylating agents,<65,Total,**,**,**,*,44
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,14.43,0.3,2.6,38,45
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,13.93,0.2,7.8,113,46
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,**,**,**,*,47
12,Yukon,C08CA,Dihydropyridine derivatives,<65,Total,13.32,0.2,10,144,48
12,Yukon,N03AE,Benzodiazepine derivatives,<65,Total,12.95,0.2,5.3,77,49
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,12.65,0.2,3.5,51,50
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,Total,11.96,0.2,1.1,16,51
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,*,52
12,Yukon,A02BC,Proton pump inhibitors,<65,Total,11.13,0.2,7.8,112,53
12,Yukon,L01BC,Pyrimidine analogues,<65,Total,**,**,**,*,54
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,Total,10.7,0.2,1,15,55
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,Total,10.33,0.2,7.9,114,56
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,10.05,0.2,3.1,44,57
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,8.86,0.2,0.8,11,58
12,Yukon,L02BG,Aromatase inhibitors,<65,Total,8.63,0.1,1.2,17,59
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,Total,8.62,0.1,0.8,11,60
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,8.52,0.1,5.1,74,61
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,8.51,0.1,0.7,10,62
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,**,**,**,*,63
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,**,**,**,**,64
12,Yukon,J05AE,Protease inhibitors,<65,Total,**,**,**,*,65
12,Yukon,N03AG,Fatty acid derivatives,<65,Total,6.84,0.1,1.5,22,66
12,Yukon,A05AA,Bile acids and derivatives,<65,Total,**,**,**,**,67
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,<65,Total,6.61,0.1,0.3,5,68
12,Yukon,N05AE,Indole derivatives,<65,Total,**,**,**,*,69
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,Total,6.5,0.1,0.6,9,70
12,Yukon,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,**,**,**,*,71
12,Yukon,H02AB,Glucocorticoids,<65,Total,6.12,0.1,9.9,143,72
12,Yukon,L01BA,Folic acid analogues,<65,Total,6.08,0.1,2.6,37,73
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,Total,6.06,0.1,2.4,34,74
12,Yukon,A07EA,Corticosteroids acting locally,<65,Total,**,**,**,**,75
12,Yukon,A10BB,Sulfonylureas,<65,Total,5.32,0.1,5.3,76,76
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,**,**,**,*,77
12,Yukon,N05AF,Thioxanthene derivatives,<65,Total,5.26,0.1,0.3,5,78
12,Yukon,C03AA,"Thiazides, plain",<65,Total,5.16,0.1,7.4,107,79
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,5.15,0.1,1.9,28,80
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,5.09,0.1,0.7,10,81
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,Total,5,0.1,0.6,8,82
12,Yukon,J02AA,Antibiotics,<65,Total,**,**,**,*,83
12,Yukon,A04AD,Other antiemetics,<65,Total,**,**,**,**,84
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,4.66,0.1,1.7,24,85
12,Yukon,M03BX,Other centrally acting agents,<65,Total,4.54,0.1,2.4,35,86
12,Yukon,N05AN,Lithium,<65,Total,4.33,0.1,1.7,25,87
12,Yukon,H01BA,Vasopressin and analogues,<65,Total,**,**,**,**,88
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,4.09,0.1,2,29,89
12,Yukon,C03DA,Aldosterone antagonists,<65,Total,3.52,0.1,2.6,37,90
12,Yukon,N05AB,Phenothiazines with piperazine structure,<65,Total,3.4,0.1,0.7,10,91
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,Total,3.4,0.1,1.6,23,92
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,**,**,**,*,93
12,Yukon,S01ED,Beta-blocking agents,<65,Total,3.28,0.1,0.8,11,94
12,Yukon,N07BC,Drugs used in opioid dependence,<65,Total,**,**,**,*,95
12,Yukon,B01AA,Vitamin K antagonists,<65,Total,2.83,0,1.2,17,96
12,Yukon,N05AD,Butyrophenone derivatives,<65,Total,2.73,0,0.9,13,97
12,Yukon,M04AA,Preparations inhibiting uric acid production,<65,Total,2.72,0,1.3,19,98
12,Yukon,C01DA,Organic nitrates,<65,Total,2.71,0,2.2,31,99
12,Yukon,C07AG,Alpha- and beta-blocking agents,<65,Total,2.61,0,1,14,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,421.28,13.3,4,27,2
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,3
12,Yukon,L04AC,Interleukin inhibitors,<65,M,**,**,**,**,4
12,Yukon,L04AX,Other immunosuppressants,<65,M,83.07,2.6,1.6,11,5
12,Yukon,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,*,6
12,Yukon,L04AA,Selective immunosuppressants,<65,M,61.29,1.9,2.1,14,7
12,Yukon,N05AX,Other antipsychotics,<65,M,**,**,**,**,8
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,45.47,1.4,7.2,48,9
12,Yukon,L01XC,Monoclonal antibodies,<65,M,**,**,**,*,10
12,Yukon,L04AD,Calcineurin inhibitors,<65,M,**,**,**,**,11
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,M,37.73,1.2,7.8,52,12
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,M,**,**,**,**,13
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,31.32,1,9.1,61,14
12,Yukon,S01LA,Antineovascularization agents,<65,M,**,**,**,*,15
12,Yukon,L01XE,Protein kinase inhibitors,<65,M,**,**,**,*,16
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,26.2,0.8,8.1,54,17
12,Yukon,B01AB,Heparin group,<65,M,**,**,**,**,18
12,Yukon,A16AB,Enzymes,<65,M,**,**,**,*,19
12,Yukon,N03AX,Other antiepileptics,<65,M,23.71,0.7,10,67,20
12,Yukon,A09AA,Enzyme preparations,<65,M,**,**,**,**,21
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,M,20.89,0.7,24.2,162,22
12,Yukon,R03BB,Anticholinergics,<65,M,19.25,0.6,7.8,52,23
12,Yukon,C09AA,"ACE inhibitors, plain",<65,M,18.25,0.6,23.9,160,24
12,Yukon,R05CB,Mucolytics,<65,M,**,**,**,*,25
12,Yukon,N06AX,Other antidepressants,<65,M,17.47,0.6,10.4,70,26
12,Yukon,L01XB,Methylhydrazines,<65,M,**,**,**,*,27
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**,**,**,**,28
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,29
12,Yukon,R03BA,Glucocorticoids,<65,M,15.4,0.5,4.5,30,30
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,M,15.15,0.5,11.5,77,31
12,Yukon,N02AA,Natural opium alkaloids,<65,M,14.2,0.4,4.5,30,32
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,*,33
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,*,34
12,Yukon,L01BC,Pyrimidine analogues,<65,M,**,**,**,*,35
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,9.92,0.3,14.5,97,36
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,M,9.87,0.3,2.2,15,37
12,Yukon,B03XA,Other antianemic preparations,<65,M,**,**,**,*,38
12,Yukon,A10BA,Biguanides,<65,M,8.97,0.3,16.7,112,39
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,8.78,0.3,3.1,21,40
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,8.21,0.3,9.4,63,41
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,**,**,**,**,42
12,Yukon,C08CA,Dihydropyridine derivatives,<65,M,7.61,0.2,12.5,84,43
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,M,**,**,**,**,44
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,7.04,0.2,3.4,23,45
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,M,6.45,0.2,10.9,73,46
12,Yukon,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,**,**,**,*,47
12,Yukon,J05AE,Protease inhibitors,<65,M,**,**,**,*,48
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,**,**,**,**,49
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,**,**,**,*,50
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,**,**,**,*,51
12,Yukon,N05AF,Thioxanthene derivatives,<65,M,**,**,**,*,52
12,Yukon,N03AG,Fatty acid derivatives,<65,M,5,0.2,2.2,15,53
12,Yukon,J02AA,Antibiotics,<65,M,**,**,**,*,54
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,4.45,0.1,3,20,55
12,Yukon,N03AE,Benzodiazepine derivatives,<65,M,4.37,0.1,4.2,28,56
12,Yukon,N05AE,Indole derivatives,<65,M,**,**,**,*,57
12,Yukon,L03AX,Other immunostimulants,<65,M,**,**,**,*,58
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,3.81,0.1,4,27,59
12,Yukon,A02BC,Proton pump inhibitors,<65,M,3.68,0.1,5.8,39,60
12,Yukon,A05AA,Bile acids and derivatives,<65,M,**,**,**,**,61
12,Yukon,H03AA,Thyroid hormones,<65,M,3.63,0.1,6.1,41,62
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,**,**,**,*,63
12,Yukon,A04AD,Other antiemetics,<65,M,**,**,**,*,64
12,Yukon,A10BB,Sulfonylureas,<65,M,3.4,0.1,6.6,44,65
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,M,**,**,**,**,66
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,**,**,**,*,67
12,Yukon,H01BA,Vasopressin and analogues,<65,M,**,**,**,*,68
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,M,**,**,**,*,69
12,Yukon,M03BX,Other centrally acting agents,<65,M,3.05,0.1,2.2,15,70
12,Yukon,H02AB,Glucocorticoids,<65,M,3.01,0.1,9.3,62,71
12,Yukon,L03AA,Colony-stimulating factors,<65,M,**,**,**,*,72
12,Yukon,L01BA,Folic acid analogues,<65,M,2.8,0.1,1.5,10,73
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,M,2.79,0.1,2.4,16,74
12,Yukon,C03AA,"Thiazides, plain",<65,M,2.62,0.1,8.4,56,75
12,Yukon,M04AA,Preparations inhibiting uric acid production,<65,M,**,**,**,**,76
12,Yukon,C03DA,Aldosterone antagonists,<65,M,2.41,0.1,3.9,26,77
12,Yukon,L01XX,Other antineoplastic agents,<65,M,**,**,**,*,78
12,Yukon,C07AG,Alpha- and beta-blocking agents,<65,M,**,**,**,**,79
12,Yukon,C03CA,"Sulfonamides, plain",<65,M,2.09,0.1,4.6,31,80
12,Yukon,A16AA,Amino acids and derivatives,<65,M,**,**,**,*,81
12,Yukon,S01ED,Beta-blocking agents,<65,M,2.03,0.1,0.9,6,82
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,<65,M,**,**,**,**,83
12,Yukon,N05AD,Butyrophenone derivatives,<65,M,**,**,**,**,84
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,M,1.89,0.1,1.8,12,85
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,M,**,**,**,*,86
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,**,**,**,*,87
12,Yukon,A07AA,Antibiotics,<65,M,**,**,**,*,88
12,Yukon,N05AN,Lithium,<65,M,**,**,**,**,89
12,Yukon,N04AC,Ethers of tropine or tropine derivatives,<65,M,**,**,**,**,90
12,Yukon,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,**,**,**,*,91
12,Yukon,B01AA,Vitamin K antagonists,<65,M,1.54,0,1.6,11,92
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,<65,M,**,**,**,*,93
12,Yukon,C01DA,Organic nitrates,<65,M,1.46,0,3.3,22,94
12,Yukon,H04AA,Glycogenolytic hormones,<65,M,**,**,**,**,95
12,Yukon,A07EA,Corticosteroids acting locally,<65,M,**,**,**,**,96
12,Yukon,N03AF,Carboxamide derivatives,<65,M,**,**,**,**,97
12,Yukon,C08DB,Benzothiazepine derivatives,<65,M,**,**,**,**,98
12,Yukon,C03BA,"Sulfonamides, plain",<65,M,1.12,0,2.7,18,99
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,1.11,0,0.7,5,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,541.94,21,4.3,33,1
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,F,**,**,**,**,2
12,Yukon,R07AX,Other respiratory system products,<65,F,**,**,**,*,3
12,Yukon,L04AA,Selective immunosuppressants,<65,F,233.45,9,3.6,28,4
12,Yukon,L04AX,Other immunosuppressants,<65,F,91.91,3.6,1.7,13,5
12,Yukon,L01XX,Other antineoplastic agents,<65,F,**,**,**,*,6
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,7
12,Yukon,L04AC,Interleukin inhibitors,<65,F,**,**,**,**,8
12,Yukon,L01XC,Monoclonal antibodies,<65,F,**,**,**,*,9
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,F,38.6,1.5,6.4,49,10
12,Yukon,L03AB,Interferons,<65,F,**,**,**,*,11
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,F,**,**,**,**,12
12,Yukon,N03AX,Other antiepileptics,<65,F,33.07,1.3,12.9,99,13
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,29.43,1.1,4.3,33,14
12,Yukon,N06AX,Other antidepressants,<65,F,28.39,1.1,18.1,139,15
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,F,26.98,1,17.3,133,16
12,Yukon,N05AX,Other antipsychotics,<65,F,**,**,**,**,17
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,18
12,Yukon,R05CB,Mucolytics,<65,F,**,**,**,*,19
12,Yukon,L03AA,Colony-stimulating factors,<65,F,**,**,**,*,20
12,Yukon,B01AB,Heparin group,<65,F,**,**,**,*,21
12,Yukon,B03XA,Other antianemic preparations,<65,F,**,**,**,**,22
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,18.13,0.7,5.6,43,23
12,Yukon,L03AX,Other immunostimulants,<65,F,**,**,**,*,24
12,Yukon,N02AA,Natural opium alkaloids,<65,F,16.86,0.7,4.7,36,25
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,F,15.89,0.6,17.3,133,26
12,Yukon,N03AF,Carboxamide derivatives,<65,F,**,**,**,**,27
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,15.32,0.6,6.1,47,28
12,Yukon,L01AX,Other alkylating agents,<65,F,**,**,**,*,29
12,Yukon,R03BA,Glucocorticoids,<65,F,14.42,0.6,7.9,61,30
12,Yukon,L04AD,Calcineurin inhibitors,<65,F,**,**,**,**,31
12,Yukon,R03BB,Anticholinergics,<65,F,13.2,0.5,5.3,41,32
12,Yukon,H03AA,Thyroid hormones,<65,F,12.22,0.5,16.6,128,33
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,F,11.39,0.4,3.2,25,34
12,Yukon,C09AA,"ACE inhibitors, plain",<65,F,10.45,0.4,13.8,106,35
12,Yukon,A09AA,Enzyme preparations,<65,F,**,**,**,**,36
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,F,**,**,**,**,37
12,Yukon,L02BG,Aromatase inhibitors,<65,F,8.63,0.3,2.2,17,38
12,Yukon,N03AE,Benzodiazepine derivatives,<65,F,8.58,0.3,6.4,49,39
12,Yukon,S01LA,Antineovascularization agents,<65,F,**,**,**,*,40
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,7.46,0.3,15.8,122,41
12,Yukon,A02BC,Proton pump inhibitors,<65,F,7.45,0.3,9.5,73,42
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,F,7.26,0.3,3.6,28,43
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,F,**,**,**,**,44
12,Yukon,A10BA,Biguanides,<65,F,6.44,0.2,11.4,88,45
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,<65,F,**,**,**,*,46
12,Yukon,C08CA,Dihydropyridine derivatives,<65,F,5.72,0.2,7.8,60,47
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,5.72,0.2,6.5,50,48
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,5.66,0.2,2.2,17,49
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,5.61,0.2,3.6,28,50
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,**,**,**,**,51
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,F,5.11,0.2,2.7,21,52
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,F,**,**,**,**,53
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,4.72,0.2,6.1,47,54
12,Yukon,A07EA,Corticosteroids acting locally,<65,F,**,**,**,*,55
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,4.09,0.2,3.8,29,56
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,F,3.88,0.2,5.3,41,57
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,3.55,0.1,2.5,19,58
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,F,**,**,**,*,59
12,Yukon,L01BA,Folic acid analogues,<65,F,3.29,0.1,3.5,27,60
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,**,**,**,**,61
12,Yukon,A05AA,Bile acids and derivatives,<65,F,**,**,**,**,62
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,F,**,**,**,*,63
12,Yukon,H02AB,Glucocorticoids,<65,F,3.11,0.1,10.5,81,64
12,Yukon,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,*,65
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,**,**,**,*,66
12,Yukon,N05AN,Lithium,<65,F,**,**,**,**,67
12,Yukon,C03AA,"Thiazides, plain",<65,F,2.53,0.1,6.6,51,68
12,Yukon,N05AE,Indole derivatives,<65,F,**,**,**,*,69
12,Yukon,N05AB,Phenothiazines with piperazine structure,<65,F,**,**,**,**,70
12,Yukon,J02AC,Triazole derivatives,<65,F,**,**,**,**,71
12,Yukon,A10BB,Sulfonylureas,<65,F,1.92,0.1,4.2,32,72
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,*,73
12,Yukon,N03AG,Fatty acid derivatives,<65,F,1.84,0.1,0.9,7,74
12,Yukon,P01BA,Aminoquinolines,<65,F,**,**,**,**,75
12,Yukon,A11CC,Vitamin D and analogues,<65,F,**,**,**,**,76
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,**,**,**,*,77
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,F,1.51,0.1,1.4,11,78
12,Yukon,C02AC,Imidazoline receptor agonists,<65,F,**,**,**,**,79
12,Yukon,M03BX,Other centrally acting agents,<65,F,1.48,0.1,2.6,20,80
12,Yukon,D07AC,"Corticosteroids, potent (group III)",<65,F,1.42,0.1,3.8,29,81
12,Yukon,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",<65,F,**,**,**,*,82
12,Yukon,N05CF,Benzodiazepine-related drugs,<65,F,1.35,0.1,2.9,22,83
12,Yukon,M05BA,Bisphosphonates,<65,F,**,**,**,**,84
12,Yukon,B01AA,Vitamin K antagonists,<65,F,1.3,0.1,0.8,6,85
12,Yukon,M01AE,Propionic acid derivatives,<65,F,1.29,0.1,4.8,37,86
12,Yukon,S01ED,Beta-blocking agents,<65,F,1.25,0,0.6,5,87
12,Yukon,C01DA,Organic nitrates,<65,F,1.25,0,1.2,9,88
12,Yukon,S01EC,Carbonic anhydrase inhibitors,<65,F,**,**,**,**,89
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,<65,F,**,**,**,*,90
12,Yukon,C09BA,ACE inhibitors and diuretics,<65,F,1.17,0,0.9,7,91
12,Yukon,A04AD,Other antiemetics,<65,F,**,**,**,**,92
12,Yukon,N03AA,Barbiturates and derivatives,<65,F,**,**,**,*,93
12,Yukon,C03DA,Aldosterone antagonists,<65,F,1.11,0,1.4,11,94
12,Yukon,C08DB,Benzothiazepine derivatives,<65,F,**,**,**,*,95
12,Yukon,J05AE,Protease inhibitors,<65,F,**,**,**,*,96
12,Yukon,H01BA,Vasopressin and analogues,<65,F,**,**,**,*,97
12,Yukon,D06BB,Antivirals,<65,F,1.02,0,0.9,7,98
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,F,1.02,0,1.2,9,99
12,Yukon,C01CA,Adrenergic and dopaminergic agents,<65,F,**,**,**,**,100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,Total,Total,"58,654.72",9.2,0.2,"1,181",1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,Total,Total,"36,773.17",5.8,2.6,"15,350",2
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"24,812.29",3.9,0.3,"1,581",3
13,Indigenous Services Canada,N05AX,Other antipsychotics,Total,Total,"17,529.79",2.8,2.1,"12,006",4
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"15,100.73",2.4,0.4,"2,341",5
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"15,045.35",2.4,3.6,"20,963",6
13,Indigenous Services Canada,N03AX,Other antiepileptics,Total,Total,"12,804.30",2,6.7,"39,161",7
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,Total,Total,"10,727.23",1.7,17.2,"100,799",8
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,Total,Total,"10,268.70",1.6,2.5,"14,706",9
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"10,022.58",1.6,2.6,"14,969",10
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,Total,Total,"9,915.75",1.6,12.3,"71,836",11
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"9,134.57",1.4,2.1,"12,076",12
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"9,101.09",1.4,10.3,"60,082",13
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",Total,Total,"8,621.07",1.4,10.4,"60,986",14
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"8,403.68",1.3,13.9,"81,473",15
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,Total,Total,"8,292.94",1.3,0.3,"2,014",16
13,Indigenous Services Canada,N06AX,Other antidepressants,Total,Total,"8,215.98",1.3,8.2,"47,646",17
13,Indigenous Services Canada,R03BA,Glucocorticoids,Total,Total,"7,923.79",1.2,7.1,"41,292",18
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"7,456.36",1.2,4.1,"23,965",19
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"7,079.60",1.1,1.9,"11,178",20
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"6,360.84",1,1.4,"8,240",21
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"5,999.03",0.9,2.2,"12,846",22
13,Indigenous Services Canada,A10BA,Biguanides,Total,Total,"5,562.92",0.9,9.5,"55,789",23
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,Total,Total,"5,547.43",0.9,3.9,"22,749",24
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,396.94",0.8,8,"46,985",25
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,Total,Total,"5,394.69",0.8,5.8,"33,920",26
13,Indigenous Services Canada,S01LA,Antineovascularization agents,Total,Total,"4,980.12",0.8,0.1,669,27
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"4,677.99",0.7,15.2,"88,796",28
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,Total,Total,"4,529.25",0.7,26.5,"154,617",29
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,Total,Total,"4,062.39",0.6,0,157,30
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,Total,Total,"4,031.54",0.6,4.2,"24,446",31
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,Total,Total,"3,685.21",0.6,10.4,"60,807",32
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,Total,Total,"3,557.32",0.6,0.9,"5,295",33
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",Total,Total,"3,555.34",0.6,4.9,"28,673",34
13,Indigenous Services Canada,A10BB,Sulfonylureas,Total,Total,"3,437.75",0.5,4.6,"27,079",35
13,Indigenous Services Canada,B03XA,Other antianemic preparations,Total,Total,"3,398.40",0.5,0.2,"1,035",36
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,Total,Total,"3,388.49",0.5,6.9,"40,436",37
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,Total,Total,"3,369.39",0.5,0,284,38
13,Indigenous Services Canada,L04AX,Other immunosuppressants,Total,Total,"3,319.59",0.5,0.2,"1,284",39
13,Indigenous Services Canada,A16AB,Enzymes,Total,Total,"3,104.81",0.5,0,6,40
13,Indigenous Services Canada,H03AA,Thyroid hormones,Total,Total,"3,099.90",0.5,4.7,"27,734",41
13,Indigenous Services Canada,R03BB,Anticholinergics,Total,Total,"3,079.80",0.5,2.3,"13,353",42
13,Indigenous Services Canada,R06AE,Piperazine derivatives,Total,Total,"3,070.73",0.5,5.4,"31,685",43
13,Indigenous Services Canada,J05AE,Protease inhibitors,Total,Total,"3,065.14",0.5,0.1,461,44
13,Indigenous Services Canada,N02BE,Anilides,Total,Total,"3,063.04",0.5,23.2,"135,655",45
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,Total,Total,"3,041.76",0.5,20.7,"120,866",46
13,Indigenous Services Canada,J05AX,Other antivirals,Total,Total,"3,038.77",0.5,0.1,774,47
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"2,887.42",0.5,3.5,"20,606",48
13,Indigenous Services Canada,G02BA,Intrauterine contraceptives,Total,Total,"2,882.25",0.5,1.4,"7,917",49
13,Indigenous Services Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"2,799.19",0.4,4.1,"23,766",50
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,Total,Total,"2,675.99",0.4,10.4,"60,849",51
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",Total,Total,"2,574.11",0.4,7.5,"43,899",52
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,Total,Total,"2,442.36",0.4,0,258,53
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"2,296.33",0.4,3,"17,756",54
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,Total,Total,"2,173.61",0.3,0.1,671,55
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"2,084.34",0.3,0.3,"1,813",56
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",Total,Total,"2,081.48",0.3,7.5,"43,568",57
13,Indigenous Services Canada,R01AD,Corticosteroids,Total,Total,"2,022.26",0.3,7,"40,977",58
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,891.51",0.3,1.3,"7,510",59
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,Total,Total,"1,810.76",0.3,1.7,"9,798",60
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,Total,Total,"1,744.67",0.3,8.6,"50,356",61
13,Indigenous Services Canada,M03BX,Other centrally acting agents,Total,Total,"1,731.85",0.3,5.4,"31,383",62
13,Indigenous Services Canada,J01FA,Macrolides,Total,Total,"1,683.63",0.3,9.5,"55,382",63
13,Indigenous Services Canada,G03AC,Progestogens,Total,Total,"1,631.70",0.3,2.8,"16,340",64
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,Total,Total,"1,600.12",0.3,4.1,"23,872",65
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,Total,Total,"1,583.46",0.2,1.5,"8,599",66
13,Indigenous Services Canada,A12AA,Calcium,Total,Total,"1,534.27",0.2,4.2,"24,796",67
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,508.54",0.2,0.4,"2,568",68
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,Total,Total,"1,506.68",0.2,1.9,"11,017",69
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,Total,Total,"1,502.84",0.2,5.4,"31,708",70
13,Indigenous Services Canada,R06AA,Aminoalkyl ethers,Total,Total,"1,495.71",0.2,6.8,"39,610",71
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",Total,Total,"1,491.27",0.2,5.3,"30,695",72
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,483.06",0.2,1.1,"6,161",73
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,Total,Total,"1,477.54",0.2,1.6,"9,305",74
13,Indigenous Services Canada,C03AA,"Thiazides, plain",Total,Total,"1,437.21",0.2,3.1,"18,138",75
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,Total,Total,"1,407.09",0.2,3.5,"20,503",76
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,401.61",0.2,0.4,"2,330",77
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,"1,380.69",0.2,6.9,"40,542",78
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"1,377.02",0.2,2.6,"15,444",79
13,Indigenous Services Canada,H02AB,Glucocorticoids,Total,Total,"1,370.37",0.2,7.2,"42,234",80
13,Indigenous Services Canada,V03AB,Antidotes,Total,Total,"1,365.90",0.2,0.7,"4,066",81
13,Indigenous Services Canada,V06C,Infant formulas,Total,Total,"1,344.03",0.2,0.2,"1,392",82
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"1,318.22",0.2,0.3,"2,009",83
13,Indigenous Services Canada,B01AB,Heparin group,Total,Total,"1,306.40",0.2,0.3,"1,801",84
13,Indigenous Services Canada,C02AC,Imidazoline receptor agonists,Total,Total,"1,302.92",0.2,1.2,"6,930",85
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"1,297.98",0.2,0.2,"1,266",86
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"1,285.13",0.2,0,97,87
13,Indigenous Services Canada,L03AX,Other immunostimulants,Total,Total,"1,278.70",0.2,0,49,88
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",Total,Total,"1,239.13",0.2,2.1,"12,200",89
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,211.20",0.2,0.6,"3,394",90
13,Indigenous Services Canada,G03AB,"Progestogens and estrogens, sequential preparations",Total,Total,"1,181.76",0.2,1.2,"6,948",91
13,Indigenous Services Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,167.32",0.2,1.3,"7,538",92
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,Total,Total,"1,153.49",0.2,0,251,93
13,Indigenous Services Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"1,131.58",0.2,1.6,"9,073",94
13,Indigenous Services Canada,D05AX,Other antipsoriatics for topical use,Total,Total,"1,125.55",0.2,0.6,"3,491",95
13,Indigenous Services Canada,N03AG,Fatty acid derivatives,Total,Total,"1,117.62",0.2,0.5,"3,109",96
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,Total,Total,"1,085.94",0.2,3.6,"20,765",97
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"1,057.21",0.2,0.1,499,98
13,Indigenous Services Canada,R06AX,Other antihistamines for systemic use,Total,Total,"1,037.61",0.2,2.2,"12,729",99
13,Indigenous Services Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"1,021.32",0.2,0,68,100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,Total,M,"33,929.25",12.1,0.3,662,1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,Total,M,"17,001.05",6.1,2.9,"7,047",2
13,Indigenous Services Canada,N05AX,Other antipsychotics,Total,M,"11,275.35",4,2.5,"6,298",3
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"8,785.83",3.1,0.2,523,4
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"8,618.50",3.1,0.5,"1,258",5
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,Total,M,"6,480.48",2.3,3.6,"8,945",6
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"6,330.06",2.3,3.6,"8,836",7
13,Indigenous Services Canada,N03AX,Other antiepileptics,Total,M,"5,419.59",1.9,6.5,"16,053",8
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,Total,M,"4,974.34",1.8,14.6,"36,008",9
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"4,798.51",1.7,2.9,"7,158",10
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"4,284.82",1.5,4.4,"10,806",11
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",Total,M,"4,251.90",1.5,12.4,"30,534",12
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,Total,M,"4,208.36",1.5,16,"39,579",13
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"3,942.11",1.4,2.1,"5,200",14
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"3,715.76",1.3,14.8,"36,556",15
13,Indigenous Services Canada,R03BA,Glucocorticoids,Total,M,"3,078.36",1.1,6.6,"16,201",16
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"3,004.96",1.1,1.6,"3,899",17
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,Total,M,"2,892.94",1,7.4,"18,268",18
13,Indigenous Services Canada,N06AX,Other antidepressants,Total,M,"2,766.08",1,6.6,"16,414",19
13,Indigenous Services Canada,S01LA,Antineovascularization agents,Total,M,"2,661.48",0.9,0.1,344,20
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,640.48",0.9,1.7,"4,105",21
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"2,600.05",0.9,9.5,"23,470",22
13,Indigenous Services Canada,A10BA,Biguanides,Total,M,"2,572.32",0.9,10.2,"25,252",23
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,Total,M,"2,538.30",0.9,6.5,"15,970",24
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,Total,M,"2,474.69",0.9,0.2,559,25
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,450.41",0.9,2,"5,044",26
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,Total,M,"2,329.14",0.8,3.7,"9,064",27
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,Total,M,"2,185.08",0.8,0,80,28
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,Total,M,"2,006.23",0.7,1.1,"2,796",29
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",Total,M,"1,905.29",0.7,6.2,"15,240",30
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"1,871.82",0.7,13.9,"34,305",31
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,Total,M,"1,836.85",0.7,25.9,"64,013",32
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,Total,M,"1,814.35",0.6,4.2,"10,444",33
13,Indigenous Services Canada,A16AB,Enzymes,Total,M,**,**,**,*,34
13,Indigenous Services Canada,A10BB,Sulfonylureas,Total,M,"1,627.77",0.6,5.2,"12,863",35
13,Indigenous Services Canada,J05AX,Other antivirals,Total,M,"1,463.49",0.5,0.1,318,36
13,Indigenous Services Canada,J05AE,Protease inhibitors,Total,M,"1,428.99",0.5,0.1,222,37
13,Indigenous Services Canada,B03XA,Other antianemic preparations,Total,M,"1,405.32",0.5,0.2,429,38
13,Indigenous Services Canada,R03BB,Anticholinergics,Total,M,"1,314.57",0.5,2.2,"5,353",39
13,Indigenous Services Canada,L04AX,Other immunosuppressants,Total,M,"1,310.96",0.5,0.2,390,40
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,Total,M,"1,273.20",0.5,5.7,"14,079",41
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,Total,M,"1,221.69",0.4,19.6,"48,311",42
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,Total,M,"1,196.35",0.4,10.7,"26,455",43
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"1,174.08",0.4,3.4,"8,458",44
13,Indigenous Services Canada,N02BE,Anilides,Total,M,"1,141.84",0.4,21.3,"52,667",45
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,Total,M,"1,111.61",0.4,6.5,"16,094",46
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,Total,M,"1,088.86",0.4,0.1,348,47
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,Total,M,"1,072.65",0.4,0,85,48
13,Indigenous Services Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"1,057.11",0.4,3.3,"8,141",49
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"1,023.43",0.4,0.4,895,50
13,Indigenous Services Canada,R06AE,Piperazine derivatives,Total,M,930.09,0.3,4.1,"10,111",51
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,Total,M,927.59,0.3,2,"4,978",52
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",Total,M,885.11,0.3,6.9,"17,012",53
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,782.35,0.3,2.4,"5,893",54
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,Total,M,752.53,0.3,8.8,"21,674",55
13,Indigenous Services Canada,M03BX,Other centrally acting agents,Total,M,735.73,0.3,5.1,"12,651",56
13,Indigenous Services Canada,H03AA,Thyroid hormones,Total,M,708.08,0.3,2.4,"5,947",57
13,Indigenous Services Canada,C02AC,Imidazoline receptor agonists,Total,M,706.01,0.3,1.2,"2,937",58
13,Indigenous Services Canada,R01AD,Corticosteroids,Total,M,705.57,0.3,5.6,"13,758",59
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,672.92,0.2,0.3,622,60
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,Total,M,670.2,0.2,1.6,"4,037",61
13,Indigenous Services Canada,N03AG,Fatty acid derivatives,Total,M,665.71,0.2,0.7,"1,720",62
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,Total,M,660.85,0.2,1.4,"3,473",63
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,Total,M,656.4,0.2,3.7,"9,216",64
13,Indigenous Services Canada,J01FA,Macrolides,Total,M,631.3,0.2,8.2,"20,373",65
13,Indigenous Services Canada,C03AA,"Thiazides, plain",Total,M,618.87,0.2,3.1,"7,648",66
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",Total,M,612.28,0.2,3.1,"7,760",67
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,Total,M,602.3,0.2,1.6,"3,930",68
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,Total,M,597.09,0.2,0.4,899,69
13,Indigenous Services Canada,D05AX,Other antipsoriatics for topical use,Total,M,586.76,0.2,0.7,"1,641",70
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,Total,M,578.97,0.2,3.2,"7,950",71
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,Total,M,578.6,0.2,0.9,"2,221",72
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,573.47,0.2,0.4,918,73
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,563.14,0.2,6.6,"16,334",74
13,Indigenous Services Canada,N07BB,Drugs used in alcohol dependence,Total,M,553.67,0.2,0.5,"1,329",75
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,Total,M,553.23,0.2,4.4,"10,871",76
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",Total,M,546.53,0.2,2.1,"5,225",77
13,Indigenous Services Canada,B01AB,Heparin group,Total,M,538.31,0.2,0.3,678,78
13,Indigenous Services Canada,V03AB,Antidotes,Total,M,513.53,0.2,0.7,"1,624",79
13,Indigenous Services Canada,H02AB,Glucocorticoids,Total,M,504.52,0.2,6.5,"16,077",80
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,497.9,0.2,1.9,"4,750",81
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,493.22,0.2,0.3,734,82
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",Total,M,491.49,0.2,4.3,"10,600",83
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,470.76,0.2,0.5,"1,183",84
13,Indigenous Services Canada,N03AF,Carboxamide derivatives,Total,M,465.89,0.2,0.4,"1,052",85
13,Indigenous Services Canada,L02BB,Antiandrogens,Total,M,**,**,**,**,86
13,Indigenous Services Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,M,447.22,0.2,0.1,259,87
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,444.01,0.2,0,30,88
13,Indigenous Services Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,433.16,0.2,0.1,242,89
13,Indigenous Services Canada,J01AA,Tetracyclines,Total,M,429.46,0.2,3.9,"9,741",90
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,Total,M,422.09,0.2,3.2,"7,932",91
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,Total,M,421.4,0.2,0,68,92
13,Indigenous Services Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,M,408.24,0.1,0.2,588,93
13,Indigenous Services Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,400.83,0.1,1.2,"2,925",94
13,Indigenous Services Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,393.28,0.1,1,"2,358",95
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,391.32,0.1,0.1,163,96
13,Indigenous Services Canada,J01FF,Lincosamides,Total,M,385.49,0.1,4,"9,826",97
13,Indigenous Services Canada,H01CB,Somatostatin and analogues,Total,M,379.45,0.1,0,20,98
13,Indigenous Services Canada,A12AA,Calcium,Total,M,368.29,0.1,2.3,"5,572",99
13,Indigenous Services Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,353.74,0.1,0.5,"1,163",100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,Total,F,"24,725.47",7,0.2,519,1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,Total,F,"19,772.12",5.6,2.6,"8,303",2
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"16,026.46",4.5,0.3,"1,058",3
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"8,715.29",2.5,3.7,"12,127",4
13,Indigenous Services Canada,N03AX,Other antiepileptics,Total,F,"7,377.61",2.1,7.1,"23,065",5
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,Total,F,"6,494.82",1.8,18.8,"60,970",6
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"6,478.31",1.8,0.3,"1,078",7
13,Indigenous Services Canada,N05AX,Other antipsychotics,Total,F,"6,254.44",1.8,1.8,"5,708",8
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,Total,F,"6,208.15",1.8,12.9,"41,814",9
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,Total,F,"5,818.06",1.6,0.4,"1,454",10
13,Indigenous Services Canada,N06AX,Other antidepressants,Total,F,"5,449.90",1.5,9.6,"31,232",11
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"5,224.07",1.5,2.4,"7,811",12
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"5,192.46",1.5,2.1,"6,876",13
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,Total,F,"4,941.41",1.4,11,"35,828",14
13,Indigenous Services Canada,R03BA,Glucocorticoids,Total,F,"4,808.28",1.4,7.5,"24,410",15
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"4,687.92",1.3,13.8,"44,917",16
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"4,438.86",1.3,2.2,"7,072",17
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",Total,F,"4,368.79",1.2,9.4,"30,445",18
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,Total,F,"3,788.21",1.1,1.8,"5,761",19
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"3,548.62",1,2.4,"7,802",20
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"3,355.87",0.9,1.3,"4,341",21
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,Total,F,"3,216.50",0.9,4.2,"13,619",22
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"3,171.55",0.9,4.1,"13,159",23
13,Indigenous Services Canada,A10BA,Biguanides,Total,F,"2,990.60",0.8,9.4,"30,537",24
13,Indigenous Services Canada,G02BA,Intrauterine contraceptives,Total,F,**,**,**,**,25
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,Total,F,"2,855.13",0.8,5.5,"17,944",26
13,Indigenous Services Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"2,796.84",0.8,7.3,"23,734",27
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"2,796.84",0.8,7.2,"23,512",28
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"2,767.31",0.8,16.3,"52,873",29
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,Total,F,"2,660.91",0.8,27.4,"88,932",30
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,Total,F,"2,485.70",0.7,12.7,"41,220",31
13,Indigenous Services Canada,H03AA,Thyroid hormones,Total,F,"2,390.76",0.7,6.7,"21,765",32
13,Indigenous Services Canada,S01LA,Antineovascularization agents,Total,F,"2,318.63",0.7,0.1,325,33
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,Total,F,"2,296.74",0.7,0.1,199,34
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,Total,F,"2,217.19",0.6,4.3,"14,002",35
13,Indigenous Services Canada,R06AE,Piperazine derivatives,Total,F,"2,139.19",0.6,6.6,"21,485",36
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,Total,F,"2,113.91",0.6,8.1,"26,338",37
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,Total,F,"2,020.96",0.6,0.1,190,38
13,Indigenous Services Canada,L04AX,Other immunosuppressants,Total,F,"2,008.63",0.6,0.3,894,39
13,Indigenous Services Canada,B03XA,Other antianemic preparations,Total,F,"1,992.77",0.6,0.2,604,40
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",Total,F,"1,951.08",0.6,11,"35,801",41
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,Total,F,"1,877.31",0.5,0,77,42
13,Indigenous Services Canada,A10BB,Sulfonylureas,Total,F,"1,809.98",0.5,4.4,"14,216",43
13,Indigenous Services Canada,N02BE,Anilides,Total,F,"1,802.99",0.5,24.1,"78,065",44
13,Indigenous Services Canada,R03BB,Anticholinergics,Total,F,"1,763.81",0.5,2.5,"7,973",45
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,Total,F,"1,731.15",0.5,21.3,"69,044",46
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,713.34",0.5,3.7,"12,148",47
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",Total,F,"1,650.05",0.5,4.1,"13,433",48
13,Indigenous Services Canada,J05AE,Protease inhibitors,Total,F,"1,636.16",0.5,0.1,239,49
13,Indigenous Services Canada,G03AC,Progestogens,Total,F,"1,606.00",0.5,5,"16,280",50
13,Indigenous Services Canada,J05AX,Other antivirals,Total,F,"1,575.28",0.4,0.1,456,51
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,Total,F,"1,551.09",0.4,0.8,"2,499",52
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"1,513.98",0.4,3.7,"11,863",53
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,Total,F,"1,412.99",0.4,10.3,"33,554",54
13,Indigenous Services Canada,A16AB,Enzymes,Total,F,**,**,**,*,55
13,Indigenous Services Canada,R01AD,Corticosteroids,Total,F,"1,316.12",0.4,8.4,"27,195",56
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,310.27",0.4,1.6,"5,234",57
13,Indigenous Services Canada,R06AA,Aminoalkyl ethers,Total,F,"1,238.97",0.4,8.6,"28,064",58
13,Indigenous Services Canada,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,"1,180.42",0.3,2.1,"6,941",59
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",Total,F,"1,178.01",0.3,8,"26,065",60
13,Indigenous Services Canada,A12AA,Calcium,Total,F,"1,165.66",0.3,5.9,"19,217",61
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,145.29",0.3,1.5,"4,851",62
13,Indigenous Services Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,108.54",0.3,2.3,"7,319",63
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,Total,F,"1,084.75",0.3,0.1,323,64
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,"1,060.81",0.3,0.3,917,65
13,Indigenous Services Canada,J01FA,Macrolides,Total,F,"1,031.75",0.3,10.5,"34,186",66
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,Total,F,"1,014.85",0.3,4.9,"15,762",67
13,Indigenous Services Canada,M03BX,Other centrally acting agents,Total,F,995.93,0.3,5.8,"18,730",68
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",Total,F,991.38,0.3,6.1,"19,909",69
13,Indigenous Services Canada,L03AX,Other immunostimulants,Total,F,956,0.3,0,33,70
13,Indigenous Services Canada,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,946.19,0.3,0,60,71
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,Total,F,945.14,0.3,6.3,"20,566",72
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,Total,F,943.77,0.3,8.4,"27,303",73
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,Total,F,914.39,0.3,1.6,"5,078",74
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,Total,F,912.11,0.3,0.1,184,75
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,Total,F,911.45,0.3,0.5,"1,669",76
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,Total,F,904.17,0.3,2.2,"7,085",77
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,Total,F,883.16,0.2,1.5,"4,820",78
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,870.09,0.2,3.3,"10,641",79
13,Indigenous Services Canada,H02AB,Glucocorticoids,Total,F,855.51,0.2,7.9,"25,661",80
13,Indigenous Services Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,854.34,0.2,0,49,81
13,Indigenous Services Canada,N02CC,Selective serotonin (5HT1) agonists,Total,F,854.24,0.2,1.6,"5,141",82
13,Indigenous Services Canada,V03AB,Antidotes,Total,F,852.37,0.2,0.8,"2,442",83
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,841.12,0.2,0,67,84
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,828.15,0.2,0.4,"1,412",85
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,825,0.2,0.4,"1,275",86
13,Indigenous Services Canada,C03AA,"Thiazides, plain",Total,F,817.85,0.2,3.2,"10,484",87
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,Total,F,807.34,0.2,1.6,"5,268",88
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,798.35,0.2,7.3,"23,769",89
13,Indigenous Services Canada,B01AB,Heparin group,Total,F,758.72,0.2,0.3,"1,096",90
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,Total,F,750.7,0.2,3.5,"11,287",91
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,740.44,0.2,0.7,"2,211",92
13,Indigenous Services Canada,R06AX,Other antihistamines for systemic use,Total,F,735.11,0.2,2.6,"8,527",93
13,Indigenous Services Canada,L01BA,Folic acid analogues,Total,F,719.92,0.2,0.9,"2,923",94
13,Indigenous Services Canada,J01XE,Nitrofuran derivatives,Total,F,708.37,0.2,7.9,"25,677",95
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",Total,F,689.67,0.2,2.1,"6,913",96
13,Indigenous Services Canada,M05BA,Bisphosphonates,Total,F,674.21,0.2,1.4,"4,550",97
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,665.89,0.2,0.1,336,98
13,Indigenous Services Canada,J02AC,Triazole derivatives,Total,F,654.09,0.2,4.7,"15,382",99
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,Total,F,639.99,0.2,3.8,"12,373",100
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,897.26",3.4,48,"27,175",1
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"3,172.79",2.8,10.1,"5,691",2
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,65+,Total,"3,141.88",2.8,40.3,"22,836",3
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",65+,Total,"2,912.98",2.6,33.6,"19,044",4
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"2,707.48",2.4,0.3,196,5
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"2,510.76",2.2,7.1,"4,034",6
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,65+,Total,"2,240.43",2,23.9,"13,538",7
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"2,185.94",1.9,36.4,"20,594",8
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,65+,Total,"2,040.28",1.8,5.1,"2,863",9
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"2,021.89",1.8,6.6,"3,741",10
13,Indigenous Services Canada,S01LA,Antineovascularization agents,65+,Total,"1,924.75",1.7,0.5,290,11
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"1,842.53",1.6,5.4,"3,038",12
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",65+,Total,"1,713.28",1.5,23.1,"13,097",13
13,Indigenous Services Canada,A10BA,Biguanides,65+,Total,"1,657.01",1.5,26,"14,707",14
13,Indigenous Services Canada,L04AX,Other immunosuppressants,65+,Total,"1,551.85",1.4,0.5,263,15
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,65+,Total,"1,519.07",1.3,0.7,390,16
13,Indigenous Services Canada,N03AX,Other antiepileptics,65+,Total,"1,490.09",1.3,11.4,"6,476",17
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,65+,Total,"1,471.09",1.3,0.1,60,18
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,381.86",1.2,4,"2,253",19
13,Indigenous Services Canada,R03BB,Anticholinergics,65+,Total,"1,359.40",1.2,10.1,"5,704",20
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,65+,Total,"1,314.61",1.2,28,"15,881",21
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,65+,Total,"1,310.07",1.2,0,26,22
13,Indigenous Services Canada,N06AX,Other antidepressants,65+,Total,"1,198.95",1.1,11.1,"6,271",23
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"1,165.05",1,17.2,"9,726",24
13,Indigenous Services Canada,H03AA,Thyroid hormones,65+,Total,"1,163.17",1,16.6,"9,406",25
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,146.53",1,14.1,"7,985",26
13,Indigenous Services Canada,R03BA,Glucocorticoids,65+,Total,"1,105.16",1,8.6,"4,858",27
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,095.94",1,5.5,"3,133",28
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,65+,Total,999.54,0.9,9.9,"5,622",29
13,Indigenous Services Canada,B03XA,Other antianemic preparations,65+,Total,974.32,0.9,0.6,327,30
13,Indigenous Services Canada,A10BB,Sulfonylureas,65+,Total,969.37,0.9,12.6,"7,119",31
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,831.85,0.7,22.4,"12,656",32
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,65+,Total,831.38,0.7,7.9,"4,466",33
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",65+,Total,725.32,0.6,13.4,"7,569",34
13,Indigenous Services Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,719.37,0.6,8.9,"5,018",35
13,Indigenous Services Canada,A12AA,Calcium,65+,Total,682.6,0.6,15.8,"8,918",36
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",65+,Total,677.04,0.6,11,"6,207",37
13,Indigenous Services Canada,N02BE,Anilides,65+,Total,623.56,0.5,26.4,"14,929",38
13,Indigenous Services Canada,C03AA,"Thiazides, plain",65+,Total,551.12,0.5,11.5,"6,495",39
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,65+,Total,526.27,0.5,3.7,"2,091",40
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,65+,Total,512.91,0.5,9.8,"5,568",41
13,Indigenous Services Canada,R06AE,Piperazine derivatives,65+,Total,511.38,0.4,6.8,"3,862",42
13,Indigenous Services Canada,M05BA,Bisphosphonates,65+,Total,503.73,0.4,6,"3,381",43
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,65+,Total,494.05,0.4,4.8,"2,691",44
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,488.05,0.4,1,585,45
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,472.63,0.4,5.7,"3,255",46
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,406.2,0.4,1.3,750,47
13,Indigenous Services Canada,N05AX,Other antipsychotics,65+,Total,392.78,0.3,1.3,759,48
13,Indigenous Services Canada,L02BB,Antiandrogens,65+,Total,382.09,0.3,0.2,140,49
13,Indigenous Services Canada,S01EE,Prostaglandin analogues,65+,Total,377.75,0.3,3.6,"2,034",50
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,65+,Total,367.21,0.3,11.9,"6,756",51
13,Indigenous Services Canada,R01AD,Corticosteroids,65+,Total,364.2,0.3,10.1,"5,713",52
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,359.42,0.3,3.2,"1,796",53
13,Indigenous Services Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,355.5,0.3,4.4,"2,480",54
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,65+,Total,354.45,0.3,7.1,"4,005",55
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,65+,Total,347,0.3,3.7,"2,069",56
13,Indigenous Services Canada,S01ED,Beta-blocking agents,65+,Total,346.52,0.3,3,"1,694",57
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,65+,Total,341.32,0.3,0.1,30,58
13,Indigenous Services Canada,C01DA,Organic nitrates,65+,Total,340.91,0.3,6.5,"3,657",59
13,Indigenous Services Canada,C08DB,Benzothiazepine derivatives,65+,Total,333.9,0.3,2.7,"1,506",60
13,Indigenous Services Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,332.27,0.3,2.1,"1,192",61
13,Indigenous Services Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,322.87,0.3,9.2,"5,222",62
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,306.54,0.3,1.4,815,63
13,Indigenous Services Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,301.06,0.3,3,"1,725",64
13,Indigenous Services Canada,A06AB,Contact laxatives,65+,Total,299.76,0.3,11.2,"6,337",65
13,Indigenous Services Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,294.31,0.3,3.8,"2,126",66
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,65+,Total,291.26,0.3,0.2,118,67
13,Indigenous Services Canada,B01AB,Heparin group,65+,Total,288.27,0.3,0.8,472,68
13,Indigenous Services Canada,H02AB,Glucocorticoids,65+,Total,287.24,0.3,13.5,"7,638",69
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,65+,Total,281.55,0.2,0.1,42,70
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,65+,Total,272.01,0.2,0.8,476,71
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,270.07,0.2,0.7,395,72
13,Indigenous Services Canada,N04BA,Dopa and dopa derivatives,65+,Total,270.02,0.2,1.1,645,73
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,65+,Total,268.69,0.2,12.9,"7,305",74
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",65+,Total,266.74,0.2,9.9,"5,581",75
13,Indigenous Services Canada,A11HA,Other plain vitamin preparations,65+,Total,247.4,0.2,6,"3,418",76
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,65+,Total,242.73,0.2,0.2,139,77
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,241.31,0.2,0.1,41,78
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,65+,Total,241.05,0.2,1.6,890,79
13,Indigenous Services Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,236.8,0.2,0.3,144,80
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,65+,Total,234.25,0.2,0.1,68,81
13,Indigenous Services Canada,A12CC,Magnesium,65+,Total,233.82,0.2,4.4,"2,500",82
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,65+,Total,229.22,0.2,4.4,"2,469",83
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,65+,Total,229.1,0.2,2.6,"1,491",84
13,Indigenous Services Canada,A12BA,Potassium,65+,Total,228,0.2,3.9,"2,204",85
13,Indigenous Services Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,225.03,0.2,0.3,173,86
13,Indigenous Services Canada,L01BA,Folic acid analogues,65+,Total,223.4,0.2,1.6,896,87
13,Indigenous Services Canada,J01MA,Fluoroquinolones,65+,Total,204.62,0.2,12.2,"6,890",88
13,Indigenous Services Canada,R06AX,Other antihistamines for systemic use,65+,Total,199.38,0.2,2.8,"1,612",89
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,196.09,0.2,0.7,372,90
13,Indigenous Services Canada,C10AX,Other lipid-modifying agents,65+,Total,191.58,0.2,2.6,"1,477",91
13,Indigenous Services Canada,J01FA,Macrolides,65+,Total,189.43,0.2,10.4,"5,893",92
13,Indigenous Services Canada,B01AA,Vitamin K antagonists,65+,Total,186.18,0.2,2,"1,129",93
13,Indigenous Services Canada,C03DA,Aldosterone antagonists,65+,Total,184.66,0.2,2.9,"1,657",94
13,Indigenous Services Canada,S01XA,Other ophthalmologicals,65+,Total,179.45,0.2,5.6,"3,193",95
13,Indigenous Services Canada,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,96
13,Indigenous Services Canada,B01AE,Direct thrombin inhibitors,65+,Total,**,**,**,**,97
13,Indigenous Services Canada,H01CB,Somatostatin and analogues,65+,Total,176.43,0.2,0,15,98
13,Indigenous Services Canada,C07AG,Alpha- and beta-blocking agents,65+,Total,174.11,0.2,1.3,711,99
13,Indigenous Services Canada,M03BX,Other centrally acting agents,65+,Total,164.85,0.1,5.2,"2,968",100
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,823.56",3.8,54.3,"12,608",1
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"1,408.70",3,10.7,"2,478",2
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",65+,M,"1,310.85",2.8,38.1,"8,833",3
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,65+,M,"1,176.22",2.5,37,"8,581",4
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,65+,M,"1,085.75",2.3,6.2,"1,440",5
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"1,079.16",2.3,7.5,"1,737",6
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"1,073.24",2.3,41.6,"9,661",7
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"1,060.73",2.2,8.3,"1,919",8
13,Indigenous Services Canada,S01LA,Antineovascularization agents,65+,M,"1,047.74",2.2,0.6,140,9
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,65+,M,979.44,2.1,0.1,19,10
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,65+,M,913.39,1.9,23.6,"5,478",11
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",65+,M,835.28,1.8,27.4,"6,367",12
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,65+,M,806.58,1.7,0.2,35,13
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,753.27,1.6,0.2,52,14
13,Indigenous Services Canada,A10BA,Biguanides,65+,M,750.31,1.6,28.9,"6,711",15
13,Indigenous Services Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,M,683.4,1.4,20.4,"4,743",16
13,Indigenous Services Canada,L04AX,Other immunosuppressants,65+,M,677.81,1.4,0.4,86,17
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,675.94,1.4,4.8,"1,106",18
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,674.6,1.4,4.7,"1,079",19
13,Indigenous Services Canada,N03AX,Other antiepileptics,65+,M,581.07,1.2,10.7,"2,486",20
13,Indigenous Services Canada,R03BB,Anticholinergics,65+,M,572.73,1.2,10,"2,314",21
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,483.45,1,17.7,"4,101",22
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,476.47,1,5.6,"1,301",23
13,Indigenous Services Canada,A10BB,Sulfonylureas,65+,M,456.91,1,14.5,"3,372",24
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,410.71,0.9,12.4,"2,868",25
13,Indigenous Services Canada,L02BB,Antiandrogens,65+,M,**,**,**,**,26
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,65+,M,379.16,0.8,18.5,"4,297",27
13,Indigenous Services Canada,B03XA,Other antianemic preparations,65+,M,378.29,0.8,0.5,123,28
13,Indigenous Services Canada,R03BA,Glucocorticoids,65+,M,367.6,0.8,6.6,"1,541",29
13,Indigenous Services Canada,N06AX,Other antidepressants,65+,M,335.22,0.7,8.3,"1,914",30
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,65+,M,330,0.7,7.4,"1,707",31
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,310.14,0.7,19.2,"4,448",32
13,Indigenous Services Canada,H03AA,Thyroid hormones,65+,M,303.91,0.6,10.1,"2,352",33
13,Indigenous Services Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,300.51,0.6,7.4,"1,719",34
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",65+,M,281.66,0.6,11.3,"2,613",35
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,65+,M,265.04,0.6,6.6,"1,521",36
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",65+,M,263.6,0.6,11.6,"2,702",37
13,Indigenous Services Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,38
13,Indigenous Services Canada,C03AA,"Thiazides, plain",65+,M,219.34,0.5,10.8,"2,513",39
13,Indigenous Services Canada,N02BE,Anilides,65+,M,217.61,0.5,23.9,"5,542",40
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,65+,M,212.54,0.4,5,"1,157",41
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,205.17,0.4,1.1,253,42
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,198.99,0.4,0.1,28,43
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,65+,M,191.14,0.4,0.4,100,44
13,Indigenous Services Canada,L02BX,Other hormone antagonists and related agents,65+,M,178.1,0.4,0.1,15,45
13,Indigenous Services Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,173.15,0.4,0.5,105,46
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,164.28,0.3,1.2,283,47
13,Indigenous Services Canada,C01DA,Organic nitrates,65+,M,160.09,0.3,7.9,"1,834",48
13,Indigenous Services Canada,S01EE,Prostaglandin analogues,65+,M,151.23,0.3,3.5,812,49
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,65+,M,151.14,0.3,7.1,"1,645",50
13,Indigenous Services Canada,S01ED,Beta-blocking agents,65+,M,151.06,0.3,3.1,725,51
13,Indigenous Services Canada,R06AE,Piperazine derivatives,65+,M,150.11,0.3,5,"1,162",52
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,65+,M,148.84,0.3,0.3,58,53
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,65+,M,148.04,0.3,11.2,"2,593",54
13,Indigenous Services Canada,A12AA,Calcium,65+,M,141.5,0.3,7.9,"1,824",55
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,65+,M,141.34,0.3,0.3,75,56
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,138.09,0.3,4.2,977,57
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,65+,M,135.38,0.3,3.4,799,58
13,Indigenous Services Canada,N05AX,Other antipsychotics,65+,M,134.54,0.3,1.2,276,59
13,Indigenous Services Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,134.38,0.3,2.1,487,60
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,65+,M,131.1,0.3,6.2,"1,428",61
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",65+,M,129.85,0.3,10.2,"2,358",62
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,128.75,0.3,1.5,342,63
13,Indigenous Services Canada,N04BA,Dopa and dopa derivatives,65+,M,128.4,0.3,1.4,320,64
13,Indigenous Services Canada,R01AD,Corticosteroids,65+,M,128.12,0.3,8,"1,865",65
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,126.68,0.3,0.8,179,66
13,Indigenous Services Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,126.03,0.3,4,918,67
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,65+,M,120.95,0.3,0.8,181,68
13,Indigenous Services Canada,C08DB,Benzothiazepine derivatives,65+,M,119.7,0.3,2.4,555,69
13,Indigenous Services Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,119.27,0.3,8,"1,848",70
13,Indigenous Services Canada,A06AB,Contact laxatives,65+,M,117.29,0.2,10.7,"2,479",71
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,116.56,0.2,2.7,621,72
13,Indigenous Services Canada,B01AB,Heparin group,65+,M,115.01,0.2,0.8,180,73
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,65+,M,108.04,0.2,12.2,"2,841",74
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,65+,M,106.11,0.2,1.8,427,75
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,65+,M,104.6,0.2,0,8,76
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,65+,M,103.93,0.2,4.7,"1,095",77
13,Indigenous Services Canada,H02AB,Glucocorticoids,65+,M,101.78,0.2,11.9,"2,760",78
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,65+,M,100.48,0.2,2.8,642,79
13,Indigenous Services Canada,B01AE,Direct thrombin inhibitors,65+,M,99.15,0.2,0.5,113,80
13,Indigenous Services Canada,C10AX,Other lipid-modifying agents,65+,M,98.24,0.2,3.1,719,81
13,Indigenous Services Canada,B01AA,Vitamin K antagonists,65+,M,96.51,0.2,2.6,601,82
13,Indigenous Services Canada,C03DA,Aldosterone antagonists,65+,M,95.14,0.2,3.5,803,83
13,Indigenous Services Canada,A11HA,Other plain vitamin preparations,65+,M,94.37,0.2,5.5,"1,268",84
13,Indigenous Services Canada,M04AA,Preparations inhibiting uric acid production,65+,M,**,**,**,**,85
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,**,**,**,**,86
13,Indigenous Services Canada,C07AG,Alpha- and beta-blocking agents,65+,M,84.78,0.2,1.6,360,87
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,65+,M,83.74,0.2,1.1,256,88
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,65+,M,82.33,0.2,0.1,26,89
13,Indigenous Services Canada,A12CC,Magnesium,65+,M,78.1,0.2,3.5,807,90
13,Indigenous Services Canada,A12BA,Potassium,65+,M,75.68,0.2,3.2,737,91
13,Indigenous Services Canada,D01AC,Imidazole and triazole derivatives,65+,M,75.1,0.2,5.5,"1,283",92
13,Indigenous Services Canada,J01MA,Fluoroquinolones,65+,M,74.68,0.2,10.5,"2,427",93
13,Indigenous Services Canada,D05AX,Other antipsoriatics for topical use,65+,M,73.64,0.2,1.2,267,94
13,Indigenous Services Canada,C10AB,Fibrates,65+,M,73.22,0.2,1.4,328,95
13,Indigenous Services Canada,D09AA,Medicated dressings with antiinfectives,65+,M,69.29,0.1,0.6,128,96
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,65+,M,68.85,0.1,0.1,15,97
13,Indigenous Services Canada,M05BA,Bisphosphonates,65+,M,63.63,0.1,1.8,406,98
13,Indigenous Services Canada,C03BA,"Sulfonamides, plain",65+,M,62.23,0.1,3.1,720,99
13,Indigenous Services Canada,J01FA,Macrolides,65+,M,61.79,0.1,8.6,"1,985",100
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,65+,F,"2,073.70",3.1,43.6,"14,567",1
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,65+,F,"1,965.66",3,42.7,"14,255",2
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"1,954.21",2.9,0.4,144,3
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,764.09",2.7,9.6,"3,213",4
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",65+,F,"1,602.14",2.4,30.6,"10,211",5
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"1,431.59",2.2,6.9,"2,297",6
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,65+,F,"1,327.93",2,0.9,290,7
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,65+,F,"1,327.04",2,24.1,"8,060",8
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"1,167.93",1.8,5.9,"1,959",9
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,112.70",1.7,32.7,"10,933",10
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,961.17,1.4,5.5,"1,822",11
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,65+,F,954.54,1.4,4.3,"1,423",12
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,65+,F,935.45,1.4,34.7,"11,584",13
13,Indigenous Services Canada,N03AX,Other antiepileptics,65+,F,909.02,1.4,11.9,"3,990",14
13,Indigenous Services Canada,A10BA,Biguanides,65+,F,906.7,1.4,23.9,"7,996",15
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",65+,F,878,1.3,20.1,"6,730",16
13,Indigenous Services Canada,S01LA,Antineovascularization agents,65+,F,877.02,1.3,0.4,150,17
13,Indigenous Services Canada,L04AX,Other immunosuppressants,65+,F,874.04,1.3,0.5,177,18
13,Indigenous Services Canada,N06AX,Other antidepressants,65+,F,863.73,1.3,13,"4,357",19
13,Indigenous Services Canada,H03AA,Thyroid hormones,65+,F,859.25,1.3,21.1,"7,054",20
13,Indigenous Services Canada,R03BB,Anticholinergics,65+,F,786.67,1.2,10.1,"3,390",21
13,Indigenous Services Canada,R03BA,Glucocorticoids,65+,F,737.56,1.1,9.9,"3,317",22
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,735.82,1.1,15.3,"5,117",23
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,65+,F,734.51,1.1,12.3,"4,101",24
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,705.92,1.1,3.4,"1,147",25
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,681.6,1,16.8,"5,625",26
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,65+,F,664.51,1,0.1,25,27
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,619.47,0.9,5.5,"1,832",28
13,Indigenous Services Canada,B03XA,Other antianemic preparations,65+,F,596.02,0.9,0.6,204,29
13,Indigenous Services Canada,A12AA,Calcium,65+,F,541.11,0.8,21.2,"7,094",30
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,521.71,0.8,24.6,"8,208",31
13,Indigenous Services Canada,A10BB,Sulfonylureas,65+,F,512.47,0.8,11.2,"3,747",32
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,65+,F,501.37,0.8,8.3,"2,759",33
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",65+,F,461.73,0.7,14.6,"4,867",34
13,Indigenous Services Canada,M05BA,Bisphosphonates,65+,F,440.1,0.7,8.9,"2,975",35
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,65+,F,420.15,0.6,5,"1,664",36
13,Indigenous Services Canada,N02BE,Anilides,65+,F,405.95,0.6,28.1,"9,387",37
13,Indigenous Services Canada,C03CA,"Sulfonamides, plain",65+,F,395.38,0.6,10.8,"3,594",38
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,65+,F,361.78,0.5,11.7,"3,923",39
13,Indigenous Services Canada,R06AE,Piperazine derivatives,65+,F,361.27,0.5,8.1,"2,700",40
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,334.54,0.5,6.8,"2,278",41
13,Indigenous Services Canada,C03AA,"Thiazides, plain",65+,F,331.78,0.5,11.9,"3,982",42
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,65+,F,330.63,0.5,0,7,43
13,Indigenous Services Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,**,**,**,**,44
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,282.89,0.4,1,332,45
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,65+,F,281.51,0.4,4.6,"1,534",46
13,Indigenous Services Canada,N05AX,Other antipsychotics,65+,F,258.25,0.4,1.4,483,47
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,242.86,0.4,3.5,"1,175",48
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,241.92,0.4,1.4,467,49
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,65+,F,236.72,0.4,0.1,22,50
13,Indigenous Services Canada,R01AD,Corticosteroids,65+,F,236.08,0.4,11.5,"3,848",51
13,Indigenous Services Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,229.47,0.3,4.7,"1,562",52
13,Indigenous Services Canada,S01EE,Prostaglandin analogues,65+,F,226.52,0.3,3.7,"1,222",53
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,65+,F,223.35,0.3,7.7,"2,577",54
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,65+,F,219.18,0.3,12.5,"4,163",55
13,Indigenous Services Canada,C08DB,Benzothiazepine derivatives,65+,F,214.19,0.3,2.8,951,56
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,65+,F,212.7,0.3,0.1,27,57
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,65+,F,211.62,0.3,3.8,"1,270",58
13,Indigenous Services Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,203.6,0.3,10.1,"3,374",59
13,Indigenous Services Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,197.89,0.3,2.1,705,60
13,Indigenous Services Canada,S01ED,Beta-blocking agents,65+,F,195.46,0.3,2.9,969,61
13,Indigenous Services Canada,H02AB,Glucocorticoids,65+,F,185.46,0.3,14.6,"4,878",62
13,Indigenous Services Canada,A06AB,Contact laxatives,65+,F,182.47,0.3,11.5,"3,858",63
13,Indigenous Services Canada,C01DA,Organic nitrates,65+,F,180.82,0.3,5.5,"1,823",64
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,177.79,0.3,1.4,473,65
13,Indigenous Services Canada,B01AB,Heparin group,65+,F,173.26,0.3,0.9,292,66
13,Indigenous Services Canada,L01BA,Folic acid analogues,65+,F,163.9,0.2,2,653,67
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,65+,F,160.65,0.2,13.4,"4,464",68
13,Indigenous Services Canada,H01CB,Somatostatin and analogues,65+,F,**,**,**,**,69
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,65+,F,157.3,0.2,1.9,634,70
13,Indigenous Services Canada,A12CC,Magnesium,65+,F,155.73,0.2,5.1,"1,693",71
13,Indigenous Services Canada,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,72
13,Indigenous Services Canada,A11HA,Other plain vitamin preparations,65+,F,153.03,0.2,6.4,"2,150",73
13,Indigenous Services Canada,A12BA,Potassium,65+,F,152.31,0.2,4.4,"1,467",74
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,65+,F,151.91,0.2,0.1,42,75
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,65+,F,151.05,0.2,0.9,295,76
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,143.39,0.2,0.6,216,77
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,65+,F,142.41,0.2,0.2,60,78
13,Indigenous Services Canada,R06AX,Other antihistamines for systemic use,65+,F,142.01,0.2,3.4,"1,128",79
13,Indigenous Services Canada,N04BA,Dopa and dopa derivatives,65+,F,141.62,0.2,1,325,80
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",65+,F,136.89,0.2,9.6,"3,223",81
13,Indigenous Services Canada,J01XE,Nitrofuran derivatives,65+,F,130.15,0.2,11.1,"3,711",82
13,Indigenous Services Canada,J01MA,Fluoroquinolones,65+,F,129.94,0.2,13.4,"4,463",83
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,65+,F,128.62,0.2,2.5,849,84
13,Indigenous Services Canada,J01FA,Macrolides,65+,F,127.64,0.2,11.7,"3,908",85
13,Indigenous Services Canada,S01XA,Other ophthalmologicals,65+,F,125.41,0.2,6.4,"2,135",86
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,65+,F,125.29,0.2,4.1,"1,374",87
13,Indigenous Services Canada,A05AA,Bile acids and derivatives,65+,F,119.66,0.2,0.4,139,88
13,Indigenous Services Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,118.89,0.2,2.1,716,89
13,Indigenous Services Canada,N07CA,Antivertigo preparations,65+,F,108.07,0.2,3.7,"1,230",90
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,F,**,**,**,**,91
13,Indigenous Services Canada,P01BA,Aminoquinolines,65+,F,105.5,0.2,1.9,646,92
13,Indigenous Services Canada,B03BB,Folic acid and derivatives,65+,F,105.1,0.2,3.5,"1,170",93
13,Indigenous Services Canada,M03BX,Other centrally acting agents,65+,F,104.02,0.2,5.5,"1,843",94
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,65+,F,103.99,0.2,2.7,901,95
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,65+,F,101.39,0.2,0.2,64,96
13,Indigenous Services Canada,A07AA,Antibiotics,65+,F,99.12,0.1,1.6,545,97
13,Indigenous Services Canada,C03BA,"Sulfonamides, plain",65+,F,97.34,0.1,3.3,"1,103",98
13,Indigenous Services Canada,A03FA,Propulsives,65+,F,94.83,0.1,4,"1,322",99
13,Indigenous Services Canada,N06DA,Anticholinesterases,65+,F,94.32,0.1,1.1,364,100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,<65,Total,"57,344.65",11,0.2,"1,155",1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,<65,Total,"36,530.45",7,2.9,"15,211",2
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"22,104.81",4.2,0.3,"1,385",3
13,Indigenous Services Canada,N05AX,Other antipsychotics,<65,Total,"17,137.00",3.3,2.1,"11,247",4
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"14,859.42",2.8,0.4,"2,300",5
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"11,872.56",2.3,2.9,"15,272",6
13,Indigenous Services Canada,N03AX,Other antiepileptics,<65,Total,"11,314.21",2.2,6.2,"32,685",7
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,<65,Total,"10,242.36",2,2.8,"14,628",8
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"8,101.55",1.5,10.3,"54,460",9
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"8,000.68",1.5,2.1,"11,228",10
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,<65,Total,"7,585.35",1.5,14.8,"77,963",11
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"7,238.63",1.4,13.6,"71,747",12
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"7,096.94",1.4,4.2,"22,169",13
13,Indigenous Services Canada,N06AX,Other antidepressants,<65,Total,"7,017.03",1.3,7.8,"41,375",14
13,Indigenous Services Canada,R03BA,Glucocorticoids,<65,Total,"6,818.63",1.3,6.9,"36,434",15
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,<65,Total,"6,773.87",1.3,0.3,"1,624",16
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"6,623.82",1.3,1.5,"8,042",17
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,<65,Total,"6,018.49",1.2,8.5,"44,661",18
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",<65,Total,"5,708.09",1.1,7.9,"41,942",19
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"5,237.07",1,1.5,"8,140",20
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"4,978.97",1,1.1,"5,987",21
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"4,903.09",0.9,1.8,"9,713",22
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,<65,Total,"4,716.05",0.9,3.5,"18,283",23
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,<65,Total,"4,260.55",0.8,27.9,"147,312",24
13,Indigenous Services Canada,A10BA,Biguanides,<65,Total,"3,905.91",0.7,7.8,"41,082",25
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"3,846.14",0.7,14.4,"76,140",26
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,<65,Total,"3,684.54",0.7,4.2,"22,377",27
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"3,211.00",0.6,5,"26,391",28
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,<65,Total,"3,154.26",0.6,3.9,"20,382",29
13,Indigenous Services Canada,A16AB,Enzymes,<65,Total,"3,104.81",0.6,0,6,30
13,Indigenous Services Canada,S01LA,Antineovascularization agents,<65,Total,"3,055.36",0.6,0.1,379,31
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,<65,Total,"3,028.06",0.6,0,254,32
13,Indigenous Services Canada,J05AE,Protease inhibitors,<65,Total,"3,017.47",0.6,0.1,450,33
13,Indigenous Services Canada,J05AX,Other antivirals,<65,Total,"2,929.83",0.6,0.1,752,34
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,<65,Total,"2,893.70",0.6,21.6,"113,894",35
13,Indigenous Services Canada,G02BA,Intrauterine contraceptives,<65,Total,**,**,**,**,36
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,<65,Total,"2,875.57",0.5,6.6,"34,868",37
13,Indigenous Services Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,**,**,**,**,38
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,<65,Total,"2,591.30",0.5,0,97,39
13,Indigenous Services Canada,R06AE,Piperazine derivatives,<65,Total,"2,559.35",0.5,5.3,"27,823",40
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,<65,Total,"2,553.82",0.5,10.6,"56,003",41
13,Indigenous Services Canada,A10BB,Sulfonylureas,<65,Total,"2,468.38",0.5,3.8,"19,960",42
13,Indigenous Services Canada,N02BE,Anilides,<65,Total,"2,439.48",0.5,22.9,"120,726",43
13,Indigenous Services Canada,B03XA,Other antianemic preparations,<65,Total,"2,424.08",0.5,0.1,708,44
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,<65,Total,"2,370.61",0.5,8.5,"44,926",45
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,<65,Total,"2,160.81",0.4,0,216,46
13,Indigenous Services Canada,H03AA,Thyroid hormones,<65,Total,"1,936.73",0.4,3.5,"18,328",47
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,<65,Total,"1,882.36",0.4,0.1,553,48
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",<65,Total,"1,848.78",0.4,6.9,"36,330",49
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",<65,Total,"1,842.06",0.4,3,"15,576",50
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"1,823.69",0.3,2.7,"14,501",51
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",<65,Total,"1,814.74",0.3,7.2,"37,987",52
13,Indigenous Services Canada,L04AX,Other immunosuppressants,<65,Total,"1,767.74",0.3,0.2,"1,021",53
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"1,740.88",0.3,2.4,"12,621",54
13,Indigenous Services Canada,R03BB,Anticholinergics,<65,Total,"1,720.39",0.3,1.4,"7,649",55
13,Indigenous Services Canada,R01AD,Corticosteroids,<65,Total,"1,658.06",0.3,6.7,"35,264",56
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,<65,Total,"1,650.46",0.3,1.3,"6,620",57
13,Indigenous Services Canada,G03AC,Progestogens,<65,Total,**,**,**,**,58
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,<65,Total,"1,611.02",0.3,8.8,"46,397",59
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"1,596.29",0.3,0.2,"1,228",60
13,Indigenous Services Canada,M03BX,Other centrally acting agents,<65,Total,"1,567.00",0.3,5.4,"28,415",61
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,<65,Total,"1,517.04",0.3,0.5,"2,432",62
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,<65,Total,"1,512.62",0.3,1.5,"8,131",63
13,Indigenous Services Canada,J01FA,Macrolides,<65,Total,"1,494.20",0.3,9.4,"49,489",64
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",<65,Total,"1,457.77",0.3,5.7,"29,982",65
13,Indigenous Services Canada,R06AA,Aminoalkyl ethers,<65,Total,"1,413.47",0.3,6.9,"36,664",66
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,<65,Total,"1,365.83",0.3,1.8,"9,764",67
13,Indigenous Services Canada,V06C,Infant formulas,<65,Total,"1,341.36",0.3,0.3,"1,367",68
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,<65,Total,"1,316.71",0.3,1.3,"7,107",69
13,Indigenous Services Canada,V03AB,Antidotes,<65,Total,"1,295.84",0.2,0.7,"3,847",70
13,Indigenous Services Canada,L03AX,Other immunostimulants,<65,Total,"1,278.70",0.2,0,49,71
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,<65,Total,"1,248.44",0.2,1.5,"7,814",72
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,<65,Total,"1,245.67",0.2,3.8,"19,867",73
13,Indigenous Services Canada,C02AC,Imidazoline receptor agonists,<65,Total,"1,242.76",0.2,1.2,"6,553",74
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,"1,241.85",0.2,6.8,"35,856",75
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"1,236.59",0.2,2.6,"13,942",76
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,<65,Total,"1,236.53",0.2,0.4,"2,092",77
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,198.81",0.2,0,88,78
13,Indigenous Services Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,"1,181.76",0.2,1.3,"6,948",79
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,<65,Total,"1,177.87",0.2,3.4,"18,034",80
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,<65,Total,"1,135.63",0.2,4.7,"24,952",81
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"1,101.89",0.2,0.2,894,82
13,Indigenous Services Canada,H02AB,Glucocorticoids,<65,Total,"1,083.13",0.2,6.6,"34,596",83
13,Indigenous Services Canada,N03AG,Fatty acid derivatives,<65,Total,"1,055.12",0.2,0.6,"2,925",84
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"1,048.16",0.2,0.3,"1,614",85
13,Indigenous Services Canada,B01AB,Heparin group,<65,Total,"1,018.13",0.2,0.3,"1,329",86
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,995.41,0.2,0.3,"1,580",87
13,Indigenous Services Canada,D05AX,Other antipsoriatics for topical use,<65,Total,994.66,0.2,0.6,"2,961",88
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,<65,Total,986.92,0.2,3.6,"18,967",89
13,Indigenous Services Canada,N07BB,Drugs used in alcohol dependence,<65,Total,971.78,0.2,0.5,"2,508",90
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,<65,Total,956.8,0.2,0.8,"4,070",91
13,Indigenous Services Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,953.75,0.2,0,70,92
13,Indigenous Services Canada,N02CC,Selective serotonin (5HT1) agonists,<65,Total,941.86,0.2,1.1,"5,835",93
13,Indigenous Services Canada,J02AC,Triazole derivatives,<65,Total,931.66,0.2,3,"15,655",94
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,921.8,0.2,0.1,388,95
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,<65,Total,919.25,0.2,0,183,96
13,Indigenous Services Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,913.91,0.2,0,62,97
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,904.67,0.2,0.5,"2,579",98
13,Indigenous Services Canada,C03AA,"Thiazides, plain",<65,Total,886.1,0.2,2.2,"11,643",99
13,Indigenous Services Canada,J01AA,Tetracyclines,<65,Total,880.83,0.2,4.1,"21,612",100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,<65,M,"32,949.80",14.1,0.3,643,1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,<65,M,"16,859.72",7.2,3.1,"6,972",2
13,Indigenous Services Canada,N05AX,Other antipsychotics,<65,M,"11,140.81",4.8,2.7,"6,022",3
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"8,419.52",3.6,0.5,"1,230",4
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"8,032.56",3.4,0.2,471,5
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,<65,M,"6,473.55",2.8,4,"8,918",6
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"4,921.36",2.1,2.8,"6,358",7
13,Indigenous Services Canada,N03AX,Other antiepileptics,<65,M,"4,838.53",2.1,6.1,"13,567",8
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"4,168.26",1.8,4.5,"10,185",9
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"3,737.78",1.6,2.3,"5,239",10
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"3,232.31",1.4,14.5,"32,455",11
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,<65,M,"3,150.78",1.4,10.5,"23,400",12
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,<65,M,"3,032.15",1.3,13.8,"30,998",13
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",<65,M,"2,941.05",1.3,9.7,"21,701",14
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"2,862.94",1.2,1.5,"3,463",15
13,Indigenous Services Canada,R03BA,Glucocorticoids,<65,M,"2,710.76",1.2,6.5,"14,660",16
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,<65,M,"2,627.90",1.1,7.5,"16,747",17
13,Indigenous Services Canada,N06AX,Other antidepressants,<65,M,"2,430.86",1,6.5,"14,500",18
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"2,329.02",1,1.2,"2,793",19
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,<65,M,"2,283.55",1,0.2,459,20
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,<65,M,"1,999.13",0.9,3.3,"7,357",21
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,973.94",0.8,1.7,"3,743",22
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,965.88",0.8,1.4,"3,026",23
13,Indigenous Services Canada,A10BA,Biguanides,<65,M,"1,822.01",0.8,8.3,"18,541",24
13,Indigenous Services Canada,A16AB,Enzymes,<65,M,**,**,**,*,25
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,<65,M,"1,728.80",0.7,27.3,"61,172",26
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,<65,M,"1,678.97",0.7,4.3,"9,645",27
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,<65,M,"1,624.92",0.7,4.7,"10,492",28
13,Indigenous Services Canada,S01LA,Antineovascularization agents,<65,M,"1,613.74",0.7,0.1,204,29
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"1,561.69",0.7,13.3,"29,857",30
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"1,526.81",0.7,6.2,"13,809",31
13,Indigenous Services Canada,J05AX,Other antivirals,<65,M,"1,416.00",0.6,0.1,307,32
13,Indigenous Services Canada,J05AE,Protease inhibitors,<65,M,**,**,**,**,33
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,<65,M,"1,378.50",0.6,0,45,34
13,Indigenous Services Canada,A10BB,Sulfonylureas,<65,M,"1,170.86",0.5,4.2,"9,491",35
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,<65,M,"1,166.74",0.5,20.4,"45,726",36
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,<65,M,"1,145.19",0.5,10.9,"24,503",37
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,<65,M,"1,122.06",0.5,5.6,"12,434",38
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",<65,M,"1,070.01",0.5,4,"8,873",39
13,Indigenous Services Canada,B03XA,Other antianemic preparations,<65,M,"1,027.03",0.4,0.1,306,40
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,<65,M,968.05,0.4,0,77,41
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,<65,M,940.02,0.4,0.1,290,42
13,Indigenous Services Canada,N02BE,Anilides,<65,M,924.23,0.4,21,"47,125",43
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,<65,M,920.48,0.4,0.6,"1,356",44
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,818.26,0.4,0.3,642,45
13,Indigenous Services Canada,R06AE,Piperazine derivatives,<65,M,779.98,0.3,4,"8,949",46
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,763.37,0.3,2.5,"5,590",47
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",<65,M,755.26,0.3,6.5,"14,654",48
13,Indigenous Services Canada,R03BB,Anticholinergics,<65,M,741.84,0.3,1.4,"3,039",49
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,<65,M,732.45,0.3,5.3,"11,797",50
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,<65,M,715.05,0.3,1.7,"3,821",51
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,<65,M,696,0.3,8.9,"20,018",52
13,Indigenous Services Canada,C02AC,Imidazoline receptor agonists,<65,M,692.47,0.3,1.3,"2,844",53
13,Indigenous Services Canada,M03BX,Other centrally acting agents,<65,M,674.9,0.3,5.1,"11,526",54
13,Indigenous Services Canada,N03AG,Fatty acid derivatives,<65,M,646.87,0.3,0.7,"1,650",55
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,644.26,0.3,2.2,"4,916",56
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,<65,M,633.67,0.3,1.5,"3,326",57
13,Indigenous Services Canada,L04AX,Other immunosuppressants,<65,M,633.16,0.3,0.1,304,58
13,Indigenous Services Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,**,**,**,**,59
13,Indigenous Services Canada,R01AD,Corticosteroids,<65,M,577.45,0.2,5.3,"11,893",60
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,<65,M,569.72,0.2,1.5,"3,395",61
13,Indigenous Services Canada,J01FA,Macrolides,<65,M,569.5,0.2,8.2,"18,388",62
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,<65,M,565.44,0.2,1.6,"3,578",63
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,<65,M,552.47,0.2,3.6,"8,121",64
13,Indigenous Services Canada,N07BB,Drugs used in alcohol dependence,<65,M,535.73,0.2,0.6,"1,279",65
13,Indigenous Services Canada,D05AX,Other antipsoriatics for topical use,<65,M,513.12,0.2,0.6,"1,374",66
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,508.03,0.2,6.5,"14,451",67
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,<65,M,494.86,0.2,0.9,"1,965",68
13,Indigenous Services Canada,V03AB,Antidotes,<65,M,**,**,**,**,69
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",<65,M,479.68,0.2,4.6,"10,354",70
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,<65,M,476.14,0.2,0.3,718,71
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,<65,M,447.88,0.2,2.9,"6,522",72
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,447.62,0.2,1.9,"4,207",73
13,Indigenous Services Canada,N03AF,Carboxamide derivatives,<65,M,439.08,0.2,0.4,937,74
13,Indigenous Services Canada,B01AB,Heparin group,<65,M,423.3,0.2,0.2,498,75
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,409.18,0.2,0.3,635,76
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,<65,M,405.19,0.2,3.7,"8,278",77
13,Indigenous Services Canada,H03AA,Thyroid hormones,<65,M,404.17,0.2,1.6,"3,595",78
13,Indigenous Services Canada,H02AB,Glucocorticoids,<65,M,402.74,0.2,5.9,"13,317",79
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,**,80
13,Indigenous Services Canada,C03AA,"Thiazides, plain",<65,M,399.54,0.2,2.3,"5,135",81
13,Indigenous Services Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,389.71,0.2,0.2,541,82
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,<65,M,382.01,0.2,3.2,"7,260",83
13,Indigenous Services Canada,J01AA,Tetracyclines,<65,M,376.23,0.2,3.7,"8,285",84
13,Indigenous Services Canada,G04CA,Alpha-adrenoreceptor antagonists,<65,M,373.71,0.2,1.5,"3,398",85
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,366.55,0.2,0.2,555,86
13,Indigenous Services Canada,J01FF,Lincosamides,<65,M,365.96,0.2,4.1,"9,187",87
13,Indigenous Services Canada,H01CB,Somatostatin and analogues,<65,M,**,**,**,**,88
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,<65,M,352.55,0.2,0,53,89
13,Indigenous Services Canada,V06C,Infant formulas,<65,M,**,**,**,**,90
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",<65,M,348.68,0.1,2.3,"5,058",91
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,345.54,0.1,0.1,131,92
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,342.01,0.1,0.4,841,93
13,Indigenous Services Canada,J02AC,Triazole derivatives,<65,M,321.17,0.1,0.6,"1,335",94
13,Indigenous Services Canada,N03AB,Hydantoin derivatives,<65,M,289.22,0.1,0.6,"1,386",95
13,Indigenous Services Canada,N05AF,Thioxanthene derivatives,<65,M,**,**,**,**,96
13,Indigenous Services Canada,D01AC,Imidazole and triazole derivatives,<65,M,277.83,0.1,3,"6,766",97
13,Indigenous Services Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,274.8,0.1,0.9,"2,007",98
13,Indigenous Services Canada,J01EE,"Combinations of sulfonamides and trimethoprim, including derivatives",<65,M,272.9,0.1,3.7,"8,256",99
13,Indigenous Services Canada,D09AA,Medicated dressings with antiinfectives,<65,M,270.3,0.1,0.2,410,100
13,Indigenous Services Canada,J05AP,Antivirals for treatment of HCV infections,<65,F,"24,394.84",8.5,0.2,512,1
13,Indigenous Services Canada,N07BC,Drugs used in opioid dependence,<65,F,"19,670.73",6.9,2.8,"8,239",2
13,Indigenous Services Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"14,072.25",4.9,0.3,914,3
13,Indigenous Services Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"6,951.20",2.4,3.1,"8,914",4
13,Indigenous Services Canada,N03AX,Other antiepileptics,<65,F,"6,468.59",2.3,6.6,"19,075",5
13,Indigenous Services Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"6,435.98",2.2,0.4,"1,065",6
13,Indigenous Services Canada,N05AX,Other antipsychotics,<65,F,"5,996.19",2.1,1.8,"5,225",7
13,Indigenous Services Canada,N06AB,Selective serotonin reuptake inhibitors,<65,F,"5,473.65",1.9,13,"37,713",8
13,Indigenous Services Canada,N06AX,Other antidepressants,<65,F,"4,586.16",1.6,9.2,"26,875",9
13,Indigenous Services Canada,A02BC,Proton pump inhibitors,<65,F,"4,529.16",1.6,16,"46,715",10
13,Indigenous Services Canada,L04AA,Selective immunosuppressants,<65,F,"4,490.12",1.6,0.4,"1,164",11
13,Indigenous Services Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"4,262.90",1.5,2.1,"5,989",12
13,Indigenous Services Canada,R03BA,Glucocorticoids,<65,F,"4,070.72",1.4,7.2,"21,093",13
13,Indigenous Services Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"4,006.32",1.4,13.5,"39,292",14
13,Indigenous Services Canada,N06BA,Centrally acting sympathomimetics,<65,F,"3,768.81",1.3,2,"5,710",15
13,Indigenous Services Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"3,760.87",1.3,1.6,"4,579",16
13,Indigenous Services Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"3,270.93",1.1,1.8,"5,113",17
13,Indigenous Services Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"2,929.15",1,2.1,"5,970",18
13,Indigenous Services Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"2,928.69",1,4.1,"11,984",19
13,Indigenous Services Canada,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,20
13,Indigenous Services Canada,C10AA,HMG-CoA reductase inhibitors,<65,F,"2,867.71",1,7.3,"21,261",21
13,Indigenous Services Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,22
13,Indigenous Services Canada,C09AA,"ACE inhibitors, plain",<65,F,"2,766.65",1,7,"20,234",23
13,Indigenous Services Canada,N02AA,Natural opium alkaloids,<65,F,"2,715.13",0.9,3.7,"10,860",24
13,Indigenous Services Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"2,649.95",0.9,1.1,"3,194",25
13,Indigenous Services Canada,M01AE,Propionic acid derivatives,<65,F,"2,500.27",0.9,29,"84,468",26
13,Indigenous Services Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"2,245.59",0.8,15.3,"44,665",27
13,Indigenous Services Canada,A10BA,Biguanides,<65,F,"2,083.90",0.7,7.7,"22,541",28
13,Indigenous Services Canada,L04AC,Interleukin inhibitors,<65,F,"2,060.02",0.7,0.1,177,29
13,Indigenous Services Canada,N07BA,Drugs used in nicotine dependence,<65,F,"2,005.57",0.7,4.4,"12,732",30
13,Indigenous Services Canada,L01XC,Monoclonal antibodies,<65,F,"1,808.26",0.6,0.1,163,31
13,Indigenous Services Canada,R06AE,Piperazine derivatives,<65,F,"1,777.92",0.6,6.5,"18,785",32
13,Indigenous Services Canada,N05BA,Benzodiazepine derivatives,<65,F,"1,752.13",0.6,7.7,"22,415",33
13,Indigenous Services Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,684.14",0.6,4.3,"12,579",34
13,Indigenous Services Canada,J01CA,Penicillins with extended spectrum,<65,F,"1,638.03",0.6,22.2,"64,657",35
13,Indigenous Services Canada,J05AE,Protease inhibitors,<65,F,**,**,**,**,36
13,Indigenous Services Canada,G03AC,Progestogens,<65,F,**,**,**,**,37
13,Indigenous Services Canada,A11CC,Vitamin D and analogues,<65,F,"1,550.25",0.5,10.2,"29,636",38
13,Indigenous Services Canada,H03AA,Thyroid hormones,<65,F,"1,531.51",0.5,5.1,"14,711",39
13,Indigenous Services Canada,C08CA,Dihydropyridine derivatives,<65,F,"1,528.08",0.5,3.4,"9,884",40
13,Indigenous Services Canada,J05AX,Other antivirals,<65,F,"1,513.83",0.5,0.2,445,41
13,Indigenous Services Canada,B03AA,"Iron bivalent, oral preparations",<65,F,"1,489.36",0.5,10.6,"30,934",42
13,Indigenous Services Canada,S01LA,Antineovascularization agents,<65,F,"1,441.62",0.5,0.1,175,43
13,Indigenous Services Canada,N02BE,Anilides,<65,F,"1,397.04",0.5,23.6,"68,678",44
13,Indigenous Services Canada,B03XA,Other antianemic preparations,<65,F,"1,396.75",0.5,0.1,400,45
13,Indigenous Services Canada,J01DB,First-generation cephalosporins,<65,F,"1,341.96",0.5,10.5,"30,660",46
13,Indigenous Services Canada,A16AB,Enzymes,<65,F,**,**,**,*,47
13,Indigenous Services Canada,A10BB,Sulfonylureas,<65,F,"1,297.51",0.5,3.6,"10,469",48
13,Indigenous Services Canada,L01XE,Protein kinase inhibitors,<65,F,"1,212.80",0.4,0,52,49
13,Indigenous Services Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"1,180.42",0.4,2.4,"6,941",50
13,Indigenous Services Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"1,179.43",0.4,3.3,"9,585",51
13,Indigenous Services Canada,R06AA,Aminoalkyl ethers,<65,F,"1,178.36",0.4,8.9,"25,960",52
13,Indigenous Services Canada,A04AA,Serotonin (5HT3) antagonists,<65,F,"1,152.97",0.4,1.6,"4,600",53
13,Indigenous Services Canada,L04AX,Other immunosuppressants,<65,F,"1,134.58",0.4,0.2,717,54
13,Indigenous Services Canada,R01AD,Corticosteroids,<65,F,"1,080.04",0.4,8,"23,347",55
13,Indigenous Services Canada,D07AC,"Corticosteroids, potent (group III)",<65,F,"1,041.12",0.4,7.8,"22,842",56
13,Indigenous Services Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,977.51,0.3,2.4,"7,031",57
13,Indigenous Services Canada,R03BB,Anticholinergics,<65,F,977.14,0.3,1.6,"4,583",58
13,Indigenous Services Canada,P03AC,"Pyrethrines, including synthetic compounds",<65,F,969.69,0.3,6.7,"19,442",59
13,Indigenous Services Canada,L03AX,Other immunostimulants,<65,F,956,0.3,0,33,60
13,Indigenous Services Canada,L04AD,Calcineurin inhibitors,<65,F,942.34,0.3,0.1,263,61
13,Indigenous Services Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,933.08,0.3,0,39,62
13,Indigenous Services Canada,J01FA,Macrolides,<65,F,904.11,0.3,10.4,"30,278",63
13,Indigenous Services Canada,M03BX,Other centrally acting agents,<65,F,891.91,0.3,5.8,"16,887",64
13,Indigenous Services Canada,C01CA,Adrenergic and dopaminergic agents,<65,F,870.73,0.3,1.6,"4,757",65
13,Indigenous Services Canada,D06AX,Other antibiotics for topical use,<65,F,866.66,0.3,8.6,"25,000",66
13,Indigenous Services Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,**,**,**,**,67
13,Indigenous Services Canada,V03AB,Antidotes,<65,F,**,**,**,**,68
13,Indigenous Services Canada,N03AE,Benzodiazepine derivatives,<65,F,800.18,0.3,2.1,"6,184",69
13,Indigenous Services Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,70
13,Indigenous Services Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,71
13,Indigenous Services Canada,N02CC,Selective serotonin (5HT1) agonists,<65,F,795.77,0.3,1.7,"4,858",72
13,Indigenous Services Canada,A02BA,H2-receptor antagonists,<65,F,791.49,0.3,4.5,"13,185",73
13,Indigenous Services Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,779.94,0.3,3.3,"9,682",74
13,Indigenous Services Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,777.92,0.3,0.2,585,75
13,Indigenous Services Canada,C07AB,"Beta-blocking agents, selective",<65,F,772.05,0.3,2.3,"6,703",76
13,Indigenous Services Canada,A07EC,Aminosalicylic acid and similar agents,<65,F,760.4,0.3,0.5,"1,374",77
13,Indigenous Services Canada,L03AA,Colony-stimulating factors,<65,F,760.2,0.3,0,142,78
13,Indigenous Services Canada,A06AD,Osmotically acting laxatives,<65,F,725.96,0.3,5.6,"16,403",79
13,Indigenous Services Canada,G04BD,Drugs for urinary frequency and incontinence,<65,F,725.13,0.3,1.1,"3,187",80
13,Indigenous Services Canada,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,714.62,0.2,7.2,"20,966",81
13,Indigenous Services Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,681.61,0.2,0.4,"1,059",82
13,Indigenous Services Canada,N05CD,Benzodiazepine derivatives,<65,F,678.72,0.2,1.5,"4,419",83
13,Indigenous Services Canada,H02AB,Glucocorticoids,<65,F,670.05,0.2,7.1,"20,783",84
13,Indigenous Services Canada,M01AB,Acetic acid derivatives and related substances,<65,F,625.41,0.2,3.4,"9,913",85
13,Indigenous Services Canada,A12AA,Calcium,<65,F,624.55,0.2,4.2,"12,123",86
13,Indigenous Services Canada,J02AC,Triazole derivatives,<65,F,605.82,0.2,4.9,"14,257",87
13,Indigenous Services Canada,C09BA,ACE inhibitors and diuretics,<65,F,601.65,0.2,1.1,"3,286",88
13,Indigenous Services Canada,B01AF,Direct factor Xa inhibitors,<65,F,596.56,0.2,0.4,"1,076",89
13,Indigenous Services Canada,R06AX,Other antihistamines for systemic use,<65,F,593.1,0.2,2.5,"7,399",90
13,Indigenous Services Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,586.23,0.2,0.3,945,91
13,Indigenous Services Canada,B01AB,Heparin group,<65,F,585.46,0.2,0.3,804,92
13,Indigenous Services Canada,S02CA,Corticosteroids and antiinfectives in combination,<65,F,581.04,0.2,3.9,"11,247",93
13,Indigenous Services Canada,J01XE,Nitrofuran derivatives,<65,F,578.21,0.2,7.5,"21,966",94
13,Indigenous Services Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,576.26,0.2,0.1,257,95
13,Indigenous Services Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,562.65,0.2,0.6,"1,738",96
13,Indigenous Services Canada,L01BA,Folic acid analogues,<65,F,556.02,0.2,0.8,"2,270",97
13,Indigenous Services Canada,C02AC,Imidazoline receptor agonists,<65,F,550.29,0.2,1.3,"3,709",98
13,Indigenous Services Canada,P03AX,"Other ectoparasiticides, including scabicides",<65,F,543.25,0.2,3.8,"10,945",99
13,Indigenous Services Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,100